"","language_a","language_b","a_text","b_text","sentence_length_b","sentence_length_a"
"1","fr","en","À administrer en fonction de l’ évaluation par le vétérinaire responsable du rapport bénéfice-risque.","Use only according to the risk-benefit assessment by the responsible veterinarian.",11,14
"2","fr","en","À administrer mélangé à l’ alimentation.","To be administered mixed with food.",6,6
"3","fr","en","A chaque début d’ administration de dose, IONSYS émettra un bip sonore.","You will hear IONSYS beep once each time you start a dose.",12,12
"4","fr","en","A chaque injection d'insuline, vous devez changer de point de piqûre au sein d'une zone cutanée donnée.","With each injection, change the puncture site within the particular area of skin that you are using.",17,17
"5","fr","en","A compléter si besoin","To be completed as appropriate.",5,4
"6","fr","en","A conserver et transporter réfrigéré (entre 2°C et 8°C).","Store and transport refrigerated (2°C – 8°C).",7,9
"7","fr","en","A conserver réfrigéré (entre + 2°C et + 8°C).","Store refrigerated (2°C to 8°C).",5,9
"8","fr","en","A d o p t é e n a v r il 1998","Adopted in April 1998",4,13
"9","fr","en","A diluer avant utilisation intraveineuse.","Dilute prior to intravenous use.",5,5
"10","fr","en","À doses plus élevées, il permet de contrôler un système immunitaire anormal et de moduler la réponse immunitaire.","At higher doses, it can help to adjust an abnormal immune system and modulate the immune response.",17,18
"11","fr","en","A l’ inclusion, 87% des patients avaient des fistules périanales, 14% des fistules abdominales, 9% des fistules rectovaginales.","At baseline, 87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had rectovaginal fistulae.",17,18
"12","fr","en","A l’aide d’une main, pincez un pli de peau molle.","With one hand, pinch a fold of loose skin.",9,10
"13","fr","en","A la fin de la perfusion, les Cmax du régio-isomère BPD-MAD obtenues étaient supérieures à celles du BPD-MAC.","Cmax values obtained at the end of infusion were higher for BPD-MAD than for BPD-MAC.",15,18
"14","fr","en","A la suite de ce diagnostic, Tasmar doit être immédiatement arrêté et le patient étroitement surveillé.","Under such a diagnosis Tasmar should be immediately discontinued and the patient should be followed up closely.",17,16
"15","fr","en","A noter que les données ci-dessous concernant les interactions avec l’ amprénavir ont été obtenues chez l’ adulte.","Of note, the following interaction data was obtained in adults.",10,18
"16","fr","en","A partir de 3 semaines d’ âge:","Chickens 3 weeks of age or older:",7,7
"17","fr","en","A prendre en compte en cas de régime pauvre en sel.","To be taken into consideration by patients on a controlled sodium diet.",12,11
"18","fr","en","A protéger de la lumière.","Do not freeze Protect from light.",6,5
"19","fr","en","À quel stade en était l’ évaluation lors du retrait de la demande?","How far into the evaluation was the application when it was withdrawn?",12,13
"20","fr","en","A quoi ressemble DaTSCAN et contenu de l’emballage extérieur","What DaTSCAN looks like and contents of the pack",9,9
"21","fr","en","A quoi ressemble Irbesartan Hydrochlorothiazide Winthrop et contenu de l'emballage extérieur","What Irbesartan Hydrochlorothiazide Winthrop looks like and contents of the pack",11,11
"22","fr","en","A quoi ressemble MabCampath et contenu de l’emballage extérieure","What MabCampath looks like and contents of the pack",9,9
"23","fr","en","A tenir hors de la portée et de la vue des enfants.","Keep out of the reach and sight of children.",9,12
"24","fr","en","A TITULAIRE DE L’ AUTORISATION DE FABRICATION RESPONSABLE DE LA LIBÉRATION DES LOTS","MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE",7,13
"25","fr","en","A usage unique seulement.","For single use only.",4,4
"26","fr","en","À usage vétérinaire - à ne délivrer que sur ordonnance vétérinaire.","For animal treatment only - to be supplied only on veterinary prescription.",12,11
"27","fr","en","a) Gélule b) 200mg c) 1 Présentation","C apsule 200mg 1 Presentation",5,7
"28","fr","en","a) VO9IB03 b) Diagnostic de l'Adino-","VO9IB03 Diagnosis of Ovarian",4,6
"29","fr","en","Abbott OY Pihatörmä 1A/Gårdsbrinken 1B FIN-02240 Espoo/Esbo","Suomi/Finland Abbott OY Pihatörmä 1A/Gårdsbrinken 1B",6,7
"30","fr","en","Abonnements aux journaux et périodiques","Subscriptions to newspapers and periodicals",5,5
"31","fr","en","Abraxane vous sera administré par un médecin ou un personnel infirmier par perfusion intraveineuse.","Abraxane will be given to you by a doctor or nurse into a vein from an intravenous drip.",18,14
"32","fr","en","Abseamed 10 000 UI/ 1 ml, solution injectable en seringue pré-remplie","Abseamed 10 000 IU/ 1 ml solution for injection in a pre-filled syringe",13,11
"33","fr","en","Abseamed 5 000 UI/ 0,5 ml, solution injectable en seringue pré-remplie","Abseamed 5000 IU/ 0.5 ml solution for injection in a pre-filled syringe",12,11
"34","fr","en","Abseamed contient une hormone appelée époétine alfa qui stimule la production des globules rouges.","Abseamed contains a hormone called epoetin alfa, which stimulates the production of red blood cells.",15,14
"35","fr","en","Absorption Après administration sous-cutanée, le fondaparinux est entièrement et rapidement absorbé (biodisponibilité absolue 100%).","ho Absorption After subcutaneous dosing, fondaparinux is completely and rapidly absorbed (absolute bioavailability 100%).",14,14
"36","fr","en","Absorption L’ absorption de la rispéridone est complète après administration de RISPERDAL CONSTA.","Absorption The absorption of risperidone from RISPERDAL CONSTA is complete.",10,13
"37","fr","en","Absorption L’ absorption de la rivastigmine libérée par les dispositifs transdermiques de Prometax est lente.","Absorption Absorption of rivastigmine from Prometax transdermal patches is slow.",10,15
"38","fr","en","Ac Helcor S. R. L.","Ac Helcor S. R. L.",5,5
"39","fr","en","accélération du pouls malaise sueurs froides","nervousness or shakiness • feel",5,6
"40","fr","en","Accords de reconnaissance mutuelle avec des pays tiers","Mutual recognition agreements with third countries",6,8
"41","fr","en","Achats compulsifs, Idées délirantes, hypersexualité, troubles de la libido, paranoïa, jeu pathologique","compulsive shopping, delusion, hypersexuality, libido disorder, paranoia, pathological gambling",9,12
"42","fr","en","Acide édétique 3 Hydroxide de potassium 4 Propylène glycol 5","Edetic acid3 Potassium Hydroxide4 Propylene glycol5",6,10
"43","fr","en","Acide lactique (E 270) Chlorure de sodium Acide chlorhydrique (E 507) pour l’ ajustement du pH Eau ppi","Lactic acid (E 270) Sodium chloride Hydrochloric acid (E 507) for pH adjustment Water for injections",16,18
"44","fr","en","Acide tartrique (E 334), mannitol (E 421), acide chlorhydrique (E 507), hydroxyde de sodium.","tartaric acid (E334), mannitol (E421), hydrochloric acid (E507), sodium hydroxide.",10,14
"45","fr","en","Acide tartrique Gomme arabique Hypromellose Diméticone 350 Talc Hydroxypropylcellulose","Capsule fill • Tartaric acid • Acacia • Hypromellose • Dimeticone 350 • Talc • Hydroxypropylcellulose",16,9
"46","fr","en","Acidose hyperchlorémique (voir section 4.2).","Hyperchloraemic acidosis (see section 4.2).",5,5
"47","fr","en","Aclasta est administré en une seule perfusion intraveineuse par un médecin ou une infirmière.","Aclasta is given as a single infusion into a vein by a doctor or nurse.",15,14
"48","fr","en","Acquisition de nouveau matériel nécessaire à des projets spécifiques","Purchases of new hardware for specified projects",7,9
"49","fr","en","Actelion Registration Ltd BSI Building 13th Floor 389 Chiswick High Road Londres W4 4AL Royaume-Uni","Actelion Registration Ltd BSI Building 13th Floor 389 Chiswick High Road London W4 4AL United Kingdom",16,15
"50","fr","en","Activités et initiatives européennes","The sector undertook the development and",6,4
"51","fr","en","Activités spéciales à affecter 20%","Special activities to be earmarked 20%",6,5
"52","fr","en","Actraphane 10 NovoLet 100 UI/ ml suspension injectable en stylo prérempli","Actraphane 10 NovoLet 100 IU/ ml suspension for injection in a pre-filled pen.",13,11
"53","fr","en","Actraphane 30 40 UI/ ml suspension injectable en flacon Insuline humaine (ADNr)","Actraphane 30 40 IU/ ml suspension for injection in a vial Insulin human (rDNA)",14,12
"54","fr","en","Actraphane 30 Penfill et FlexPen:","Actraphane 30 Penfill and FlexPen:",5,5
"55","fr","en","Actraphane 50 Penfill 100 UI/ ml suspension injectable Insuline humaine, (ADNr) Voie SC","Actraphane 50 Penfill 100 IU/ ml suspension for injection Insulin human (rDNA) SC use",14,13
"56","fr","en","ActraphaneFlexPen non utilisé est à conserver au réfrigérateur (entre 2°C et 8°C).","The FlexPen that is not being used is to be stored in a refrigerator (2°C - 8°C).",17,12
"57","fr","en","Actrapid 100 UI/ ml solution injectable en flacon Insuline humaine, (ADNr)","Actrapid 100 IU/ ml solution for injection in a vial Insulin human (rDNA)",13,11
"58","fr","en","Actrapid est une insuline de substitution, identique à l’ insuline fabriquée par le pancréas.","Actrapid is a replacement insulin that is identical to the insulin made by the pancreas.",15,14
"59","fr","en","Actrapid Penfill 100 UI/ ml solution injectable en cartouche","Actrapid Penfill 100 IU/ ml solution for injection in a cartridge",11,9
"60","fr","en","Adaptation de la posologie en cas d'effets indésirables:","Dose adjustment for undesirable effects:",5,8
"61","fr","en","Adaptez la pompe doseuse sur le flacon Sortez la pompe de son emballage.","Fit the metering pump onto the bottle Take the pump out of its bag.",14,13
"62","fr","en","Addition du solvant dans la poudre f.","Adding solvent to the powder f.",6,7
"63","fr","en","ADENURIC 120 mg est présenté en boîtes de 28 et 84 comprimés pelliculés.","ADENURIC 120 mg is available in pack sizes of 28 and 84 film-coated tablets.",14,13
"64","fr","en","adéquate de la plaie, puis thérapie de","therapy for at least another 7 days.",7,7
"65","fr","en","Administration concomitante de Levviax et de la simvastatine, de l’ atorvastatine et de la lovastatine.","Levviax should not be used concomitantly with simvastatin, atorvastatin and lovastastin.",11,15
"66","fr","en","Administration dans l’ alimentation","Application period of medicated feed as the sole daily ration",10,4
"67","fr","en","Administration par injection sous-cutanée, de préférence au niveau de l'abdomen.","Administration is by subcutaneous injection, preferably at an abdominal site.",10,10
"68","fr","en","Administration Par voie sous-cutanée Les suspensions d'insuline ne doivent jamais être administrées par voie intraveineuse.","Insulin suspensions are never to be administered intravenously.",8,15
"69","fr","en","Administration simultanée d'anti-TNFα et d' anakinra","Concurrent administration of TNF-antagonists and anakinra",6,6
"70","fr","en","Administrer 0,1 mg de firocoxib par kg de poids vif, une fois par jour.","Administer 0.1 mg firocoxib per kg bodyweight, once daily.",9,14
"71","fr","en","Administrer la quantité requise.","Administer the amount required.",4,4
"72","fr","en","Administrer par voie intramusculaire.","Immunisation should be carried out by intramuscular injection.",8,4
"73","fr","en","Adolescents (âgés de 13 à 17 ans) et adultes:","Adolescents (13 to 17 years of age) and adults:",9,9
"74","fr","en","Adopté en février 1998","Status Adopted in February 1998",5,4
"75","fr","en","Adoptée en juillet 1997","Adopted in July 1997",4,4
"76","fr","en","Adoptée en juillet 1997 EMEA/CVMP/183/96","EMEA/ CVMP/ 183/ 96",4,5
"77","fr","en","Adoptée en novembre 1997","Adopted in November 1997",4,4
"78","fr","en","ADROVANCE 70 mg 5600 UI","ADROVANCE 70 mg 5600 IU",5,5
"79","fr","en","Adultes (y compris sujets âgés ≥ 65 ans)","Adults (including the elderly ≥ 65 years of age)",9,8
"80","fr","en","Adultes et adolescents âgés de 13 ans et plus:","Adults and adolescents 13 years of age and older:",9,9
"81","fr","en","Adultes et enfants âgés de plus de 12 ans","Adults and children above the age of 12",8,9
"82","fr","en","Adultes La dose sera individualisée selon le profil du patient (voir rubrique 4.4) et le contrôle tensionnel.","Adults The dose should be individualised according to the patient profile (see section 4.4) and blood pressure control.",18,17
"83","fr","en","Advagraf 1 mg gélules à libération prolongée (Boîte de 30, 50, 60, 100)","Advagraf 1 mg Prolonged-Release Capsules (30, 50, 60, 100 Box)",10,13
"84","fr","en","Advagraf a été aussi efficace que les deux médicaments auxquels il a été comparé.","Advagraf was as effective as both comparator medicines.",8,14
"85","fr","en","Advasure est une émulsion injectable.","What is Advasure? ng Advasure is an emulsion for injection.",10,5
"86","fr","en","ADVATE 250 UI poudre et solvant pour solution injectable.","ADVATE 250 IU powder and solvent for solution for injection",10,9
"87","fr","en","Advocate pour chiens contient 100 mg/ ml d’ imidaclopride et 25 mg/ ml de moxidectine.","Advocate for dogs contains 100 mg/ ml imidacloprid and 25 mg/ ml moxidectin.",13,15
"88","fr","en","Advocate solution pour spot -on pour grands chats","Advocate spot-on solution for large cats",6,8
"89","fr","en","Aerinaze est un médicament contenant les substances actives desloratadine (2,5 mg) et pseudoéphédrine (120 mg).","Aerinaze is a medicine containing the active substances desloratadine (2.5 mg) and pseudoephedrine (120 mg).",15,15
"90","fr","en","Aerius 5 mg comprimés orodispersibles est indiqué chez les adultes et les adolescents (12 ans et plus).","Aerius 5 mg orodispersible tablet is indicated for adults and adolescents (12 years of age and older).",17,17
"91","fr","en","Aerius doit être utilisé avec précaution en cas d’ insuffisance rénale sévère.","In the case of severe renal insufficiency, Aerius should be used with caution.",13,12
"92","fr","en","Aesica Queenborough Limited Queenborough Kent ME11 5EL Royaume-Uni","Aesica Queenborough Limited Queenborough Kent ME11 5EL United Kingdom",9,8
"93","fr","en","Affaires réglementaires et pharmacovigilance","Head of Unit Regulatory affairs and pharmacovigilance",7,4
"94","fr","en","Affections cardiaques Peu fréquent: bradycardie","Cardiac disorders Uncommon: bradycardia",4,5
"95","fr","en","Affections de l'oreille et du conduit auditif:","Ear and labyrinth disorders:",4,7
"96","fr","en","Affections de l'oreille et du labyrinthe","Ear and labyrinth disorders",4,6
"97","fr","en","Affections de la peau et du tissu sous-cutané","Ear and labyrinth disorders Rare Hypoacusis, tinnitus",7,8
"98","fr","en","Affections de la peau et du tissu sous-cutané Alopécie, rash Très fréquent:","Chest pain, asthenia, oedema, injection site pain",7,12
"99","fr","en","Affections de la peau et du tissus sous-cutané Affections musculo- squelettiques et systémiques","Skin and subcutaneous tissue disorders Musculoskeletal and connective tissue disorders Vascular disorders",12,13
"100","fr","en","Affections de la peau et du tissus sous-cutané Très fréquent: alopécie.","Skin and subcutaneous tissue disorders Very common: alopecia.",8,11
"101","fr","en","Affections de votre organe transplanté Fréquent:","If any of the side",5,6
"102","fr","en","Affections des organes de la","Reproductive system and breast disorders:",5,5
"103","fr","en","Affections des organes de reproduction et du sein","Reproductive system and breast disorders",5,8
"104","fr","en","Affections des organes de reproduction et du sein Femme: aménorrhée, ménorragie, trouble menstruel, troubles Fréquent: vaginaux dic","Female: amenorrhea, menorrhagia, menstrual disorder, vaginal disorder Male: testicular pain",10,17
"105","fr","en","Affections des organes de reproduction et du sein Symptômes ménopausiques Hémorragie gynécologique Affections psychiatriques","Reproductive System and Breast Disorders Menopausal symptoms Gynaecological haemorrhage Psychiatric Disorders 11",12,14
"106","fr","en","Affections des organes de reproduction et Fréquent:","Micturition frequency, polyuria Renal failure*, renal insufficiency* Nephrotic syndrome*",9,7
"107","fr","en","Affections du métabolisme et de la nutrition Très fréquents Fréquents","Metabolism and Nutrition Disorders Very common Common",7,10
"108","fr","en","Affections du rein et des voies urinaires","Renal and urinary disorders Skin and subcutaneous tissue disorders",9,7
"109","fr","en","Affections du rein et des voies urinaires Fréquent Peu fréquent Rare","Renal and urinary disorders Common Uncommon Rare",7,11
"110","fr","en","Affections du rein et des voies urinaires nt","Renal and urinary disorders",4,8
"111","fr","en","Affections du rein et des voies urinaires Peu fréquents: insuffisance rénale aigue","Renal insufficiency, including renal impairment and renal failure",8,12
"112","fr","en","Affections du rein et des voies urinaires Rétention","Urine flow decreased Polyuria",4,8
"113","fr","en","Affections du rein et des voies urinaires:","Renal and urinary disorders:",4,7
"114","fr","en","Affections du système immunitaire","Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e. g.",13,4
"115","fr","en","Affections du système immunitaire Fréquent Peu fréquent","Immune system disorders Common Uncommon",5,7
"116","fr","en","Affections du système immunitaire Très rare:","Immune system disorders Very rare:",5,6
"117","fr","en","Affections du système nerveux (périphérique et central)","Nervous system disorders (Peripheral and Central)",6,7
"118","fr","en","Affections du système nerveux Fréquents:","Nervous system disorders Common:",4,5
"119","fr","en","Affections du système nerveux Peu fréquent:","Nervous system disorders Uncommon:",4,6
"120","fr","en","Affections du système nerveux sensations vertigineuses *","Nervous system disorders dizziness* headache*",5,7
"121","fr","en","Affections du système nerveux Très fréquent: céphalée Peu fréquent: paresthésie, somnolence, sensations vertigineuses","Nervous system disorders Very common: headache Uncommon: paraesthesia, somnolence, dizziness",10,13
"122","fr","en","Affections endocriniennes Hypothyroïdie: fréquent","Endocrine disorders Hypothyroidism: common",4,4
"123","fr","en","Affections gastro-intestinales Très fréquent","Gastrointestinal disorders Very common Skin and subcutaneous Very common",9,4
"124","fr","en","Affections hématologiques et du système lymphatique","Blood and lymphatic system disorders",5,6
"125","fr","en","Affections hématologiques et du système lymphatique Fréquent: lymphadénopathie","Blood and lymphatic system disorders Common: lymphadenopathy",7,8
"126","fr","en","Affections hématologiques et du système lymphatique Fréquents:","anaemia, leukopenia, thrombocytopenia, leukocytosis, red blood cell analyses abnormal",9,7
"127","fr","en","Affections hématologiques et du système lymphatique:","Blood and the lymphatic system disorders:",6,6
"128","fr","en","Affections hépatobiliaires Fréquent: hyperbilirubinémie","Hepato-biliary disorders Uncommon: hyperbilirubinaemia.",4,4
"129","fr","en","Affections hépatobiliaires Peu fréquent: hépatite, cholestase Rare: cholécystite","Hepatobiliary disorders Uncommon: hepatitis, cholestasis Rare: cholecystitis",7,8
"130","fr","en","Affections malignes Le risque de développement d’ une affection maligne est augmenté chez les patients atteints de PR.","Malignancy The risk of malignancy is increased in patients with RA.",11,18
"131","fr","en","Affections musculo-squelettiques et systémiques","Musculoskeletal and connective tissue disorders",5,4
"132","fr","en","Affections musculo-squelettiques et systémiques Affections endocriniennes","Muscoskeletal and connective tissue disorders Endocrine disorders Metabolism and Nutrition Disorders",11,6
"133","fr","en","Affections musculo-squelettiques et systémiques fractures osseuses4 myalgie*","Musculoskeletal and connective tissue disorders bone fractures4 myalgia*",8,7
"134","fr","en","Affections musculo-squelettiques et systémiques Fréquents: myalgies","Musculoskeletal, connective tissue and bone disorders Common: myalgia",8,6
"135","fr","en","Affections musculo-squelettiques et systémiques:","Musculoskeletal and connective tissue disorders:",5,4
"136","fr","en","Affections psychiatriques Peu fréquent: insomnie","Psychiatric disorders Uncommon: insomnia",4,5
"137","fr","en","Affections respiratoires, thoraciques et médiastinales","Respiratory, thoracic and mediastinal disorders",5,5
"138","fr","en","Affections respiratoires, thoraciques et médiastinales:","Respiratory, thoracic and mediastinal disorder:",5,5
"139","fr","en","Affections respiratoires, thoraciques et médiastinales: asthme","Respiratory, thoracic and mediastinal disorders: asthma",6,6
"140","fr","en","Affections sous-cutanées et de la peau Rares: prurit, rash et urticaire","Pruritus, rash and urticaria.",4,11
"141","fr","en","Afin d’ optimiser l’ absorption du ténofovir, il est recommandé de prendre Truvada avec de la nourriture.","In order to optimise the absorption of tenofovir, it is recommended that Truvada should be taken with food.",18,17
"142","fr","en","Afin d’obtenir une dose précise, vous devez:","To obtain an accurate dose you must:",7,7
"143","fr","en","Age médian en années (extrêmes) Sexe: hommes / femmes","Median age in years (range) Gender: male/ female",8,9
"144","fr","en","Agenerase 150 mg, capsules molles","Agenerase 150 mg soft capsules.",5,5
"145","fr","en","Agent chélateur du phosphate dans l’ hyperphosphatémie.","Phosphate binder in hyperphosphataemia.",4,7
"146","fr","en","Agglomérat/ poudre blanche à presque blanche.","White to off-white cake/ powder.",5,6
"147","fr","en","Aggressivité persistante dans la démence","Persistent aggression in dementia",4,5
"148","fr","en","Agiter doucement le vaccin avant emploi.","Shake the vaccine gently before use.",6,6
"149","fr","en","Agiter doucement pour faciliter la dissolution de la poudre.","Agitate gently to complete dissolution of powder.",7,9
"150","fr","en","Agitez le flacon pendant 20 secondes avant la première utilisation.","Shake the bottle for 20 seconds before the first use.",10,10
"151","fr","en","Agranulocytose Anémie aplasique Leucocytose Leucopénie Lymphadénopathie Pancytopénie Thrombocytopénie","Pneumonia Urinary tract infection",4,8
"152","fr","en","Ainsi l’ incidence globale des infections peut augmenter (notamment les rhinites, bronchites et pneumonies).","Thus, the overall incidence of infections can increase (in particular of rhinitis, bronchitis and pneumonia).",15,14
"153","fr","en","Ainsi, le vaccin induit un statut immunitaire contre le virus de la leucose féline.","As a consequence, the vaccine induces an immune status against feline leukaemia virus.",13,14
"154","fr","en","Ainsi, les signes d’ augmentation des enzymes hépatiques peuvent être détectés le plus tôt possible.","This is so that signs of increased liver enzymes can be detected as early as possible.",16,15
"155","fr","en","Ainsi, Silgard peut être administré chez les femmes qui allaitent.","Therefore Silgard can be given to breastfeeding women.",8,10
"156","fr","en","Ajouter doucement la solution tampon en la faisant couler le long d'une face du flacon à réaction.","Gently add the formulation buffer down the side of the reaction vial.",12,17
"157","fr","en","Ajouter environ 15 ml d’ eau distillée dans le flacon, le boucher, et agiter pour dissoudre le solide.","Add approximately 15 ml of distilled water to the flask, stopper, and swirl to dissolve the solid.",17,18
"158","fr","en","Ajuster la seringue à la dose nécessaire.","Bring the syringe to the correct dose needed.",8,7
"159","fr","en","ALAT/ASAT > 3x LSN","ALT/ AST > 3xULN",4,4
"160","fr","en","Alcaloïdes de l’ ergot de seigle (substrats du CYP3A4):","Ergot alkaloids (CYP3A4 substrates):",4,9
"161","fr","en","Alcon d.o.o. + 386 1 422 5280","Slovenija Alcon d.o.o. + 386 1 422 5280",8,7
"162","fr","en","Alcon Romania S.R.L.: + 40 21 203 93 24","Alcon Romania S.R.L.: + 40 21 203 93 24",9,9
"163","fr","en","Alcool benzylique Acétate de sodium (trihydraté) Acide acétique glacial Chlorhydrate de sodium Acide chlorhydrique 4N Eau pour injection","Benzyl alcohol Sodium acetate (tri-hydrate) Acetic acid, glacial Sodium chloride / Hydrochloric acid 4N (for pH adjustment)",17,18
"164","fr","en","Alcool Evitez de boire trop d’ alcool pendant que vous prenez ce médicament.","Alcohol Avoid drinking too much alcohol while taking this medicine.",10,13
"165","fr","en","Aldurazyme/ Aldurazyme A 208 semaines","Aldurazyme/ Aldurazyme At 208 weeks",5,5
"166","fr","en","Aliments et boissons FORSTEO peut être administré avec ou sans nourriture.","Using FORSTEO with food and drink Forsteo can be given with or without food.",14,11
"167","fr","en","Aliments et boissons Il est important que vous preniez INTELENCE après un repas.","Taking INTELENCE with food and drink It is important that you take INTELENCE following a meal.",16,13
"168","fr","en","Aliments et boissons La prise alimentaire n'affecte pas significativement l'absorption de la cétirizine.","Taking Zyrtec with food and drink Food does not affect noticeabily the absorbtion of cetirizine.",15,13
"169","fr","en","Aliments et boissons Limitez la consommation de jus de pamplemousse pendant le traitement par Corlentor.","Limit your consumption of grapefruit juice during treatment with Corlentor.",10,15
"170","fr","en","ALIMTA 100 mg poudre pour solution à diluer pour perfusion pemetrexed Pour voie intraveineuse après reconstitution et dilution.","ALIMTA 100 mg powder for concentrate for solution for infusion pemetrexed For intravenous use after reconstitution and dilution.",18,18
"171","fr","en","Allaitement Il est recommandé aux femmes traitées par Trizivir de NE PAS allaiter leur enfant.","Breast-feeding You are recommended NOT to breast-feed your baby while taking Trizivir.",12,15
"172","fr","en","Allaitement Le passage du folinate de calcium dans le lait maternel n’a pas été évalué.","Lactation It is not known whether calcium folinate is excreted into human breast milk.",14,15
"173","fr","en","Allaitement On ignore si le tocilizumab est excrété dans le lait maternel.","Lactation It is unknown whether tocilizumab is excreted in human breast milk.",12,12
"174","fr","en","Almac Pharma Services 22 Seagoe Industrial Estate Craigavon BT63 5QD Royaume Uni","Almac Pharma Services 22 Seagoe Industrial Estate Craigavon BT63 5QD United Kingdom",12,12
"175","fr","en","Alpharma-ISIS GmbH & Co KG","Aliud Pharma GmbH & Co KG Gottlieb-Daimler Str 19 D-89150 Laichingen Germany",12,5
"176","fr","en","Alterner les sites d’ injection afin d’ éviter une gêne au point d’ injection.","ed Rotate the injection sites to avoid discomfort at the site of injection.",13,14
"177","fr","en","Aluminium/ blister en aluminium (Alu/ OPA/ PVC/ PE)","Aluminium/ Aluminium blister (Alu/ OPA/ PVC/ PE)",7,8
"178","fr","en","Am Euro Platz 2 A-1120 Wien Tel: +43-(0) 1 813 12 31","Am Euro Platz 2 A-1120 Wien Tel: + 43-(0) 1 813 12 31",13,12
"179","fr","en","Ambirix ne doit pas être administré:","Ambirix should not be given:",5,6
"180","fr","en","Amélioration ≥ 90% selon l’ évaluation globale du médecin","Decrease (Primary Endpoint)§ Improvement ≥ 90% in Physician’ s Global Evaluation",11,9
"181","fr","en","Amener la seringue à température ambiante avant l’ injection.","Allow the pre-filled syringe to reach room temperature before injecting.",10,9
"182","fr","en","Amgen Europe B. V.","Amgen Europe B. V.",4,4
"183","fr","en","Amines vasopressives (par exemple noradrénaline): l’ effet des amines vasopressives peut être diminué.","The effect of pressor amines may be decreased.",8,13
"184","fr","en","Analogue de l'insuline humaine à action Intermédiaire.","Intermediate acting human insulin analogue.",5,7
"185","fr","en","Analogues de l’ acide folique, code ATC:","Folic acid analogues, ATC code:",5,7
"186","fr","en","Analyse de toute la population (en intention de traiter) 2 Médiane de survie estimée","Docetaxel Winthrop in combination with capecitabine",6,14
"187","fr","en","Analyse per protocole des essais POWER et DUET.","As treated analysis of the POWER and DUET trials.",9,8
"188","fr","en","Analyses basées sur un test de résistance phénotypique","Analyses based on phenotypic resistance testing.",6,8
"189","fr","en","anaphylaxie, lupus érythémateux aigu disséminé, polyarthrite rhumatoïde","Anaphylaxis, systemic lupus erythematosus, rheumatoid arthritis",6,7
"190","fr","en","Anémie et épistaxis ont aussi été rapportées.","Anaemia and epistaxis have also been reported.",7,7
"191","fr","en","Angiox est uniquement administré à l’ hôpital.","Angiox is only given when a patient is in hospital.",10,7
"192","fr","en","Annexe 2 - Résumé du budget de l’ EMEA pour 1997-1999 (en Ecus)","Annex 2 - EMEA budget summaries 1997 - 1999",9,13
"193","fr","en","Anorexie Perte de poids Hyperglycémie, prise de poids","Anorexia Weight decreased Hyperglycaemia, weight increased",6,8
"194","fr","en","Anti-HBs (10 mUI/ ml) †","Anti-HBs (10 mIU/ ml) †",5,5
"195","fr","en","Anti-tétanique (0,1 UI/ ml) †","Anti-tetanus (0.1 IU/ ml) †",5,5
"196","fr","en","anticoagulants (médicaments fluidifiant le sang) ou si vous avez des problèmes de saignements.","medicines) or you have bleeding problems.",6,13
"197","fr","en","Antigène de surface de l'hépatite B 2 3 1","Adsorbed on aluminium hydroxide, hydrated",5,9
"198","fr","en","Antigène de surface de l’ hépatite B recombinant (protéine S)* adsorbé 20 microgrammes pour 1 ml","Hepatitis B virus surface antigen recombinant (S protein)* adsorbed 20 micrograms per 1 ml",14,16
"199","fr","en","Antiviral à usage systémique, code ATC:","Antiviral for systemic use, ATC code:",6,6
"200","fr","en","Apathie, Hallucinations, Myoclonies, Agitation, Troubles de la coordination et de l’ équilibre","Apathy, Hallucinations, Myoclonus, Agitation, Impaired coordination and balance",8,12
"201","fr","en","Apidra est injecté sous la peau (par voie sous-cutanée).","Apidra is injected under the skin (subcutaneously).",7,9
"202","fr","en","apparaît dans la fenêtre de lecture.","is in the dose window.",5,6
"203","fr","en","Applicateur translucide ou blanc en PEBD et étui.","White opaque HDPE bottle with a white LDPE cap, a natural or white LDPE applicator and a sheath.",18,8
"204","fr","en","Appliquer immédiatement après ouverture du sachet-dose.","Apply immediately upon removal from sachet.",6,6
"205","fr","en","Appliquer le médicament directement sur la peau, à la base du cou, en avant des omoplates.","Apply topically to the skin at the base of the neck in front of the shoulder blades.",17,16
"206","fr","en","Appliquer si possible sur une peau saine.","Wherever possible apply to undamaged skin.",6,7
"207","fr","en","Appliquez la crème deux fois par jour, à au moins 8 heures d'intervalle.","Use it twice a day, at least 8 hours apart.",10,13
"208","fr","en","Apposer une étiquette avec une date de péremption d’ un mois.","Label the solution with a one month expiration date.",9,11
"209","fr","en","appropriée peut ensuite être prélevée à l’ aide d’ une seringue stérile et injectée.","The appropriate dose can then be withdrawn with a sterile injection syringe and injected.",14,14
"210","fr","en","Approximativement 27% de la","Approximately 27% of the dose is eliminated in the urine during the first 24 hours.",15,4
"211","fr","en","Appuyez à fond sur le bouton d’injection.","Press the injection button all the way in.",8,7
"212","fr","en","Appuyez sur le bouton blanc de réarmement.","Press the white reset button.",5,7
"213","fr","en","Après 18 mois de traitement, une atrophie rétinienne a été observée.","After 18 months of treatment retinal atrophy was observed.",9,11
"214","fr","en","Après administration de Telzir, la demi-vie d’ élimination plasmatique de l'amprénavir est de 7,7 heures.","Following administration of Telzir, the half-life of amprenavir is 7.7 hours.",11,15
"215","fr","en","Après administration orale chez le chien, peu d’ effets systémiques ont été observés.","After oral administration in dogs few systemic effects were observed.",10,13
"216","fr","en","Après administration orale, l'urée marquée atteint la muqueuse gastrique.","After oral ingestion the labelled urea reaches the gastric mucosa.",10,9
"217","fr","en","Après administration orale, l’ olopatadine a été détectée dans le lait de rates allaitant.","Olopatadine has been detected in the milk of nursing rats following oral administration.",13,14
"218","fr","en","Après administration orale, la demi-vie d’ élimination du ténofovir est de 12 à 18 heures environ.","Following oral administration, the elimination half-life of tenofovir is approximately 12 to 18 hours.",14,16
"219","fr","en","Après application, attendre que le site d’application soit sec pour caresser ou toiletter l’animal.","After application do not stroke or groom animals until the application site is dry.",14,14
"220","fr","en","Après avoir sélectionné la dose, retirez le capuchon pour injecter l’insuline.","Go straight on to Injecting the insulin.",7,11
"221","fr","en","Après avoir utilisé le collyre, attendez 15 minutes avant de remettre vos lentilles sur vos yeux.","Wait 15 minutes after using the eye drops before putting your lenses back into your eyes.",16,16
"222","fr","en","Après chaque utillisation, laver la cuillère avec de l’ eau puis la laisser sécher à l’ air libre.","After each use, rinse the spoon with water and allow it to air dry.",14,18
"223","fr","en","Après dilution, la stabilité chimique et physique a été démontrée pendant 30 heures jusqu’ à 25ºC.","After dilution, chemical and physical stability has been demonstrated for 30 hours up to 25ºC.",15,16
"224","fr","en","Après dissolution dans l’ eau pour préparations injectables fournie, le produit doit être limpide.","After it has been dissolved in the supplied water for injections, the product should be clear.",16,14
"225","fr","en","Après environ 8 semaines, votre médecin peut décider d'augmenter la dose.","After about 8 weeks your doctor may need to increase your dose.",12,11
"226","fr","en","Après initiation du traitement, votre médecin maintiendra votre taux d’hémoglobine entre 10 et 12 g/dl.","After initiation of therapy, your doctor will maintain your haemoglobin level between 10 and 12 g/dl",16,15
"227","fr","en","Après injection, ne pas masser le point d'injection.","After injection, the site of injection should not be massaged.",10,8
"228","fr","en","Après mélange, la suspension doit avoir un aspect blanc laiteux uniforme.","After mixing, the suspension must have a uniform milky white appearance.",11,11
"229","fr","en","Après ouverture du flacon, ce médicament doit être utilisé immédiatement.","Once the vial has been opened, the dilution must be performed immediately.",12,10
"230","fr","en","Après ouverture du flacon:","After first opening the container:",5,4
"231","fr","en","Après ouverture, la solution peut être utilisée pendant 2 mois.","Do not use after 2 months of first opening the bottle.",11,10
"232","fr","en","Après ouverture, la solution reconstituée peut être conservée pendant maximum un mois entre 2°C et 8°C.","Once opened, the reconstituted solution may be stored for maximum of one month at 2°C - 8°C.",17,16
"233","fr","en","Après ouverture, utiliser dans les 8 heures.","Once broached, use within 8 hours",6,7
"234","fr","en","Après ouverture: conserver 28 jours maximum","Discard 28 days after first opening",6,6
"235","fr","en","Après prélèvement de la dose, tout produit non utilisé doit être éliminé.","Any unused product must be discarded after withdrawal of the dose.",11,12
"236","fr","en","Après prélèvement de la dose, toute solution restante doit être éliminée.","After withdrawal of the dose, any remaining solution must be discarded.",11,11
"237","fr","en","Après reconstitution avec 10 ml d’eau pour préparations injectables, chaque ml contient 2 mg de Drotrécogine alfa (activée).","After reconstitution with 10 ml of Water for Injection each ml contains 2 mg of Drotrecogin alfa (activated).",18,18
"238","fr","en","Après reconstitution, 1 ml contient 18 millions d’ UI d’ interféron alfa-2b.","After reconstitution, 1 ml contains 18 million IU of interferon alfa-2b.",11,12
"239","fr","en","Après reconstitution, chaque ml de solution contient approximativement 62,5 UI de moroctocog alfa.","After reconstitution, each ml of solution contains approximately 62.5 IU moroctocog alfa.",12,13
"240","fr","en","Après reconstitution, il est recommandé d’ injecter le vaccin rapidement.","After reconstitution, it is recommended to inject the vaccine promptly.",10,10
"241","fr","en","Après reconstitution, la concentration finale en parécoxib est de 20 mg/ ml.","After reconstitution, the final concentration of parecoxib is 20 mg/ ml.",11,12
"242","fr","en","Après reconstitution, le produit doit être utilisé immédiatement.","After reconstitution the product should be used immediately.",8,8
"243","fr","en","Après reconstitution, le vaccin doit être injecté rapidement ou conservé au réfrigérateur (2°C-8°C).","After reconstitution, the vaccine should be administered promptly or kept in the refrigerator (2°C – 8°C).",16,13
"244","fr","en","Après reconstitution, un volume injectable de 1 ml de solution contient 500 microgrammes de romiplostim (500 microgrammes/ ml).","After reconstitution, a deliverable volume of 1 ml solution contains 500 micrograms of romiplostim (500 micrograms/ ml).",17,18
"245","fr","en","Après reconstitution, une utilisation immédiate est recommandée.","After reconstitution an immediate use is recommended.",7,7
"246","fr","en","Après une administration multiple, il y a une accumulation d’ interférons immunoréactifs.","Upon multiple dosing, there is an accumulation of immunoreactive interferons.",10,12
"247","fr","en","Après une administration orale, environ 0,6% de la dose est retrouvé dans les urines.","Approximately 0.6% of the dose is recovered in urine following oral administration.",12,14
"248","fr","en","Après une injection intraveineuse, la naloxone est distribuée rapidement (demi-vie de distribution d’ environ 4 minutes).","Following intravenous administration, naloxone is rapidly distributed (distribution half-life ~ 4 minutes).",12,16
"249","fr","en","Aprovel 150 mg comprimés.","Aprovel 150 mg tablets.",4,4
"250","fr","en","APTIVUS peut réduire l’ efficacité des contraceptifs oraux (voir dans la rubrique 2.","APTIVUS can affect oral contraceptives (see 2.",7,13
"251","fr","en","Aranesp 130 microgrammes, solution injectable en seringue préremplie.","Aranesp 130 micrograms solution for injection in a pre-filled syringe.",10,8
"252","fr","en","Aranesp 20 microgrammes, solution injectable en seringue préremplie.","Aranesp 20 micrograms solution for injection in a pre-filled syringe.",10,8
"253","fr","en","Aranesp 40 microgrammes, solution injectable en seringue préremplie.","Aranesp 40 micrograms solution for injection in a pre-filled syringe.",10,8
"254","fr","en","Aranesp 60 microgrammes, solution injectable en seringue préremplie.","Aranesp 60 micrograms solution for injection in a pre-filled syringe.",10,8
"255","fr","en","Aranesp doit être injecté par voie intraveineuse (dans une veine) ou sous-cutanée (sous la peau).","Aranesp is injected intravenously (into a vein) or subcutaneously (under the skin).",12,15
"256","fr","en","Arava est contre-indiqué chez les patients présentant une hypoprotéinémie sévère ou une insuffisance hépatique (voir rubrique 4.3).","Arava is contraindicated in patients with severe hypoproteinaemia or impairment of liver function (see section 4.3).",16,17
"257","fr","en","ARICLAIM 20 mg, gélule gastro-résistante Duloxétine","ARICLAIM 20 mg hard gastro-resistant capsules Duloxetine",7,6
"258","fr","en","ARICLAIM est contre-indiqué chez la femme enceinte (voir rubrique 4.3).","ARICLAIM should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.",18,10
"259","fr","en","Arixtra 2,5 mg/0,5 ml solution injectable fondaparinux sodique","Arixtra 2.5 mg/ 0.5 ml solution for injection fondaparinux sodium",10,8
"260","fr","en","Arrêter Glivec jusqu'à ce que PN ≥ 1,5 x 109/ l et plaquettes ≥ 75 x 109/ l.","Stop Glivec until ANC ≥ 1.5 x 109/ l and",10,18
"261","fr","en","Arthralgies Myalgies Raideur musculaire Affections de la peau","Myalgia Musculoskeletal stiffness Skin disorders",5,8
"262","fr","en","Article 15 Directive 75/ 319/ CEE du Conseil","Article 15 Council Directive 75/ 319/ EEC",7,8
"263","fr","en","Article 4 -Experts européens","Article 4 - European experts",5,4
"264","fr","en","ASC: ↑ 37% (↑ 25 à ↑ 51) Cmax: ↔ Efavirenz:","AUC: ↑ 37% (↑ 25 to ↑ 51) Cmax: ↔ Efavirenz:",11,11
"265","fr","en","ASC: ↓ 26% (↓ 15 to ↓ 36)","Mean percent change in AUC, Cmax, Cmin with confidence intervals if availablea (mechanism)",13,8
"266","fr","en","ASC: ↓ 77% Cmax: ↓ 61% Efavirenz:","Effects on drug levels",4,7
"267","fr","en","ASC: ↔ Cmax: ↔ Cmin: ↔","AUC: ↔ Cmax: ↔ Cmin: ↔",6,6
"268","fr","en","Ascpect du solvant: solution incolore limpide.","Appearance of the solvent: clear colourless solution.",7,6
"269","fr","en","Aspartame Les comprimés orodispersibles de ZALASTA contiennent de l’ aspartame.","Aspartame Zalasta orodispersible tablets contain aspartame, a source of phenylalanine.",10,10
"270","fr","en","Aspect de Kineret et contenu de l’ emballage extérieur","What Kineret looks like and contents of the pack",9,9
"271","fr","en","Aspirez lentement toute la solution dans la seringue.","Slowly draw back all the solution through the vial adapter into the syringe.",13,8
"272","fr","en","Association à d’ autres inhibiteurs de la protéase du VIH (IP):","Co-administration with other HIV protease inhibitors (PIs):",7,11
"273","fr","en","Association aux Inhibiteurs de la Mono-Amine Oxydase non sélectifs, irréversibles (IMAO) (voir rubrique 4.5).","Concomitant use of ARICLAIM with nonselective, irreversible Monoamine Oxidase Inhibitors (MAOIs) is contraindicated (see section 4.5).",16,14
"274","fr","en","association avec l'indinavir ou","No dosage adjustment is necessary for efavirenz when given with indinavir or indinavir/ ritonavir.",14,4
"275","fr","en","association avec l'indinavir ou avec l'indinavir/ ritonavir.","necessary for efavirenz when given with indinavir or indinavir/ ritonavir.",10,7
"276","fr","en","Association de NovoMix 30 avec la pioglitazone:","Combination of NovoMix 30 with pioglitazone:",6,7
"277","fr","en","associée à différents types de cancers fréquents, traités par érythropoïétine humaine recombinante, par rapport aux groupes contrôles.","associated with various common cancers who received recombinant human erythropoietin compared ed",12,17
"278","fr","en","Assurez -vous également de lire le paragraphe « Faites attention » de la notice de l’ interféron alfa-2b.","Also, be sure to read the “Take special care” section of the Package Leaflet for interferon alfa-2b.",17,18
"279","fr","en","Assurez -vous que l’ extrémité de l’ aiguille se trouve dans la solution reconstituée de PegIntron.","Be sure the tip of needle is in the PegIntron reconstituted solution.",12,16
"280","fr","en","Assurez- vous de choisir la présentation et le dosage appropriés.","Please make sure to select an appropriate dosage form and strength. na",12,10
"281","fr","en","Assurez-vous que vous avez la forme de Liprolog Mix50 KwikPen 100 UI/ml prescrite par votre médecin.","Make sure you get the Liprolog Mix50 KwikPen that your doctor has told you to use.",16,16
"282","fr","en","Astellas Pharma a/s C","Naverland 4 DK-2600 Glostrup M",5,4
"283","fr","en","Astellas Pharma GmbH Neumarkter Str.","Astellas Pharma GmbH Neumarkter Str.",5,5
"284","fr","en","Asthénie, bouffées vasomotrices, bouffées de chaleur, aggravation de l’ état, raideur, décoloration de la langue, parosmie, soif","Asthenia, flushing, hot flushes, condition aggravated, rigors, tongue discolouration, parosmia, thirst",11,17
"285","fr","en","AstraZeneca Produtos Farmacêuticos, Lda.","AstraZeneca Produtos Farmacêuticos, Lda.",4,4
"286","fr","en","AstraZeneca UK Limited Alderley Park Macclesfield Cheshire SK10 4TG Royaume-Uni","MARKETING AUTHORISATION HOLDER AstraZeneca UK Limited Alderley Park Macclesfield Cheshire SK10 4TG United Kingdom 8.",15,10
"287","fr","en","Atazanavir 400 mg une fois par jour (maraviroc 300 mg deux","Atazanavir 400 mg QD (maraviroc 300 mg BID)",8,11
"288","fr","en","Atriance est conditionné par boîte de 6 flacons.","Atriance is supplied in packs of 6 vials.",8,8
"289","fr","en","Atripla peut avoir un effet sur vos reins.","Atripla may affect your kidneys.",5,8
"290","fr","en","atteintes hépatiques cytolytiques, cholestatiques ou mixtes)","Hepatitis (including hepatocellular, cholestatic or mixed liver injury)",8,6
"291","fr","en","atteintes hépatiques sévères notamment insuffisance hépatique aiguë et nécrose hépatique aiguë pouvant être d’ évolution fatale","severe liver injury such as hepatic failure and acute hepatic necrosis that may be fatal",15,16
"292","fr","en","Attendez que la surface soit sèche.","Wait for the area to dry.",6,6
"293","fr","en","au (également comprise dans l’ EPAR) ou contacter votre médecin ou votre pharmacien.","If you want more",4,13
"294","fr","en","Au 4ème jour, l'effet suppresseur est d'environ 70%.","On day 4 the suppression was approximately 70%.",8,8
"295","fr","en","au Abbott Laboratories Ltd.","ed Abbott Laboratories Ltd Queenborough",5,4
"296","fr","en","au calcitonine de saumon), administrée par voie hypodermique ou intramusculaire.","au calcitonin) once daily by subcutaneous or intramuscular injection.",9,10
"297","fr","en","Au cours d’ études cliniques contrôlées, l’ utilisation de Nespo et d’ autres agents stimulant","au In controlled clinical studies, use of Nespo and other erythropoiesis-stimulating agents (ESAs) have shown:",15,15
"298","fr","en","Au cours des essais cliniques, l’ étoricoxib a été administré sans tenir compte de la prise d’ aliments.","In clinical trials, etoricoxib was administered without regard to food intake.",11,18
"299","fr","en","Au cours du traitement, ces patients doivent éviter si possible toute intervention dentaire invasive.","While on treatment, these patients should avoid invasive dental procedures if possible.",12,14
"300","fr","en","Au début du traitement, les sujets étaient âgés de 6 mois à 3,5 ans.","Subjects ranged in age from 6 months to 3.5 years at initiation of treatment.",14,14
"301","fr","en","au discussion scientifique (également comprise dans l’ EPAR).","au of the EPAR).",4,8
"302","fr","en","au Edétate de sodium, Chlorure disodique, Métacrésol, Polysorbate 80,","M-cresol, Polysorbate 80, Water for injections. rod",7,9
"303","fr","en","au Informations sur les essais cliniques","Use of inhaled human insulin is associated with an increase in frequency, and levels of insulin M",17,6
"304","fr","en","au Ireland EXUBERA Customer Care Centre Tel:","ed Ireland EXUBERA Customer Care Centre",6,7
"305","fr","en","Au jour 14, l'ASC du 5-FU était augmentée de 30 à 35%.","The AUC of 5-FU was 30%-35% higher on day 14.",10,12
"306","fr","en","au L’ expérience chez les sujets âgés de plus de 75 ans avec EXUBERA est limitée.","There is little experience with EXUBERA in patients older than 75 years.",12,16
"307","fr","en","au Lietuva Abbott Laboratories Baltics Vienibas 87h LV-1004 Rīga","Lietuva Abbott Laboratories Baltics Vienibas 87h LV-1004 Rīga Latvia Tel: + 371 7605580",13,9
"308","fr","en","au lus tp s n'e nt e am dic mé Ce","lp i na dic Me",5,11
"309","fr","en","au moins une étude clinique)","least one clinical trial)",4,5
"310","fr","en","Au moment de l’injection, la température de la suspension doit atteindre environ 20°C-25°C.","The temperature of the suspension at the time of injection should be approximately 20ºC-25ºC.",14,13
"311","fr","en","au oedème angioneurotique, difficultés respiratoires, palpitations et baisse de la pression artérielle.","rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.",16,12
"312","fr","en","au Phosphate disodique anhydre Chlorure de sodium Polysorbate 80 Eau pour préparations injectables","au Sodium chloride Polysorbate 80",5,13
"313","fr","en","au remplies EU/ 1/ 02/ 207/ 008","n EU/ 1/ 02/ 207/ 008",6,7
"314","fr","en","Au sein de chaque fréquence de groupe, les effets indésirables sont présentés suivant un ordre décroissant de gravité.","Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.",13,18
"315","fr","en","Au sein de chaque groupe de fréquence, les effets indésirables sont présentés suivant un ordre décroissant de gravité.","Within each frequency grouping, undesirable effects are presented in order of decreasing seriouness",13,18
"316","fr","en","au Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham, Basingstoke","th Hampshire International Business Park Chineham, Basingstoke",7,11
"317","fr","en","Au total, 161 réunions sont prévues en 1997, couvrant environ 300 jours de réunion.","For 1997 a total of 161 meetings is expected over some 300 meeting days.",14,14
"318","fr","en","Au total, 20 procédures de sélection internes et externes ont été traitées en 2001.","Sylvie BÉNÉFICE Head of Sector for project management Tim BUXTON (acting)",11,14
"319","fr","en","Au total, des réactions indésirables sont survenues, chez 32,2% des patients.","Overall 32.2% of the patients experienced adverse drug reactions.",9,11
"320","fr","en","Au-dessous de 68, 1 kg","Below 68.1 kg 68.1 kg to 74.7 kg 74.8 kg to 83.9 kg 84.0 kg and over",17,5
"321","fr","en","Aucun ajustement posologique de CHAMPIX ou des médicaments cités ci-dessous administrés de façon concomitante n'est nécessaire.","No dosage adjustment of CHAMPIX or co-administered medicinal products listed below is recommended.",13,16
"322","fr","en","Aucun ajustement posologique n’ est nécessaire chez les patients âgés de plus de 65 ans.","No dose adjustment is required in patients aged 65 years and older.",12,15
"323","fr","en","Aucun ajustement posologique n’ est nécessaire pour ces médicaments.","No dosage adjustment is necessary for either medicinal product.",9,9
"324","fr","en","Aucun ajustement posologique n’ est nécessaire pour le raltegravir.","No dosage adjustment is necessary for raltegravir.",7,9
"325","fr","en","Aucun cas de surdosage avec le raloxifène n’ a été reporté durant les essais cliniques.","No cases of raloxifene overdose were reported during clinical trials.",10,15
"326","fr","en","Aucun cas de surdosage n’ a été rapporté.","No case of overdose has been reported.",7,8
"327","fr","en","Aucun des composants contenus dans le vaccin n'est contaminant.","None of the components in the vaccine are infectious.",9,9
"328","fr","en","Aucun effet indésirable n’ a été observé avec Rabigen SAG2.","No undesirable effects have been shown for Rabigen SAG2.",9,10
"329","fr","en","Aucun effet n’ a cependant été noté chez les descendants.","No effect on the offspring was noted.",7,10
"330","fr","en","Aucun effet significatif sur les concentrations d’ atazanavir n’ a été","No significant effect on atazanavir concentrations was observed.",8,11
"331","fr","en","Aucun effet tératogène n’ a été constaté chez le rat ou le lapin.","No teratogenic effects were observed in the rat or rabbit.",10,13
"332","fr","en","Aucun potentiel génotoxique n’ a été observé sur la télithromycine et ses métabolites.","Telithromycin, and its principal human metabolites, were negative in tests on genotoxic potential in vitro and in vivo.",18,13
"333","fr","en","Aucun problème sérieux n’ est attendu lors d’ un surdosage accidentel.","No serious problems are expected with accidental overdose.",8,11
"334","fr","en","Aucun signe de surdosage avec le facteur VIII recombinant de coagulation n’ a été rapporté.","No symptoms of overdosage with recombinant coagulation factor VIII have been reported.",12,15
"335","fr","en","Aucune action cytotoxique de l'époétine alfa sur les cellules de moelle osseuse humaine n'a été détectée.","Cytotoxic actions of epoetin alfa on bone marrow cells could not be detected.",13,16
"336","fr","en","Aucune adaptation de la dose de FABLYN n’ est nécessaire chez les patientes âgées.","No dose adjustment for FABLYN is necessary in elderly patients.",10,14
"337","fr","en","Aucune adaptation posologique n’ est nécessaire chez les patients ayant une atteinte rénale.","No dose adjustment is necessary for patients with renal impairment.",10,13
"338","fr","en","Aucune adaptation posologique n’ est nécessaire.","No dosage adjustment is necessary.",5,6
"339","fr","en","Aucune adaptation posologique n’est recommandée mais la prudence est conseillée chez les patients présentant une insuffisance hépatique modérée.","No dose adjustment is suggested but caution is adviced in patients with moderate hepatic impairment.",15,18
"340","fr","en","Aucune adaptation posologique n’est requise.","No dose adjustment required.",4,5
"341","fr","en","Aucune altération macroscopique fœ tale des tissus mous ou squelettiques n’ a été observée.","There were no gross foetal alterations of soft or skeletal tissues.",11,14
"342","fr","en","Aucune autre enzyme n’ a été identifiée comme étant impliquée dans le métabolisme du lacosamide.","No other enzymes have been identified to be involved in the metabolism of lacosamide.",14,15
"343","fr","en","Aucune différence de risque entre les AHNS évalués n’ été relevée.","There was no evidence of a difference in risk between the NSAHs evaluated.",13,11
"344","fr","en","Aucune différence sur le plan statistique n’ a été constatée entre les deux groupes de traitement.","No statistical differences were found between both treatment groups.",9,16
"345","fr","en","Aucune donnée clinique n'est disponible chez les sujets âgés de moins de 18 ans.","No clinical data have been generated in subjects below 18 years of age.",13,14
"346","fr","en","Aucune donnée clinique n’ est disponible chez la femme enceinte. en","For Nespo no clinical data on exposed pregnancies are available.",10,11
"347","fr","en","Aucune donnée de tolérance sur IDflu n'existe après commercialisation.","There is no safety data from post-marketing experience with IDflu.",10,9
"348","fr","en","Aucune donnée n’ est disponible chez les patients nécessitant une dialyse.","No data is available in patients requiring dialysis.",8,11
"349","fr","en","Aucune donnée n’ est disponible pour faire une recommandation posologique.","No data are available to make a dose recommendation.",9,10
"350","fr","en","Aucune donnée n’ est disponible sur l'administration quotidienne de tadalafil chez les patients atteints d’ insuffisance hépatique.","There are no available data about the administration of once-a-day dosing of tadalafil to patients with hepatic impairment.",18,17
"351","fr","en","Aucune donnée n’ est disponible sur l’ utilisation de Kepivance chez la femme enceinte.","There are no adequate data from the use of Kepivance in pregnant women.",13,14
"352","fr","en","Aucune donnée n’ est disponible sur les effets indésirables sur les nourrissons allaités.","There are no data available on adverse effects in breast-feeding infants.",11,13
"353","fr","en","Aucune donnée pharmacocinétique n’ est disponible en cas de rejet de greffe hépatique.","No pharmacokinetic data are available during hepatic transplant rejection.",9,13
"354","fr","en","Aucune estimation n’ était disponible dans la dernière étude.","No point estimate was available for the remaining study.",9,9
"355","fr","en","Aucune étude animale n'a été réalisée avec AVAGLIM.","No animal studies have been conducted with the combined products in AVAGLIM.",12,8
"356","fr","en","Aucune étude clinique n'a été conduite chez la femme enceinte ou allaitante.","No clinical study has been conducted in pregnant or lactating women.",11,12
"357","fr","en","Aucune étude clinique ni pharmacocinétique n’ a été réalisée chez l’ enfant ou l’ adolescent.","Paediatric use No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents.",16,15
"358","fr","en","Aucune étude d’ interaction n’ a été réalisée chez l’ homme avec l’ interféron bêta-1a.","No interaction studies have been performed with Iinterferon beta-1a in humans.",11,15
"359","fr","en","Aucune étude d’ interaction n’ a été réalisée.","No interaction studies have been performed.",6,8
"360","fr","en","Aucune étude de carcinogénèse n’ a été réalisée avec RELISTOR.","Carcinogenicity studies have not been conducted with RELISTOR.",8,10
"361","fr","en","Aucune étude de carcinogénicité n’ a été réalisée avec Ceplene.","No carcinogenicity studies have been performed on Ceplene.",8,10
"362","fr","en","Aucune étude de génotoxicité, de carcinogénicité, de développement pré- et post-natal n’ a été conduite avec Xeomin.","No genotoxicity, carcinogenicity and pre- and postnatal development studies have been conducted with Xeomin.",14,17
"363","fr","en","Aucune étude de reproduction n’ a été effectuée chez l’ animal.","Animal reproduction studies have not been conducted.",7,11
"364","fr","en","Aucune étude formelle d’ interaction n’ a été réalisée.","No formal interaction studies have been performed.",7,9
"365","fr","en","Aucune étude n'a été fournie pour étayer l'indication à la suite d’ une transplantation hépatique.","No study was provided to support the indication after liver transplantation.",11,15
"366","fr","en","Aucune étude n'a été menée chez des animaux allaitants avec les substances actives de Janumet associées.","No studies in lactating animals have been conducted with the combined active substances of Janumet.",15,16
"367","fr","en","Aucune étude sur le potentiel carcinogène ou la toxicité sur la reproduction n’ a été menée.","No investigations on carcinogenic potential or toxicity to reproduction have been conducted.",12,16
"368","fr","en","Aucune génotoxicité ni potentiel carcinogène n'ont été observés avec le zonisamide.","Zonisamide was not genotoxic and has no carcinogenic potential.",9,11
"369","fr","en","Aucune information concernant une éventuelle résistance croisée avec d’autres produits cytostatiques n’est disponible.","No information relating to potential cross-resistance with other cytostatic products is available.",12,13
"370","fr","en","Aucune information n’ est disponible sur la compatibilité de ce vaccin avec un autre vaccin.","No information is available on the compatibility of this vaccine with any other.",13,15
"371","fr","en","Aucune information spécifique n’ est disponible sur le traitement en cas de surdosage par Irbesartan Hydrochlorothiazide Winthrop.","No specific information is available on the treatment of overdose with Irbesartan Hydrochlorothiazide Winthrop.",14,17
"372","fr","en","Aucune interaction n’ a été mise en évidence avec la supplémentation orale en vitamine D.","No interaction was observed with oral supplementation of vitamin D.",10,15
"373","fr","en","Aucune interaction pharmacocinétique cliniquement siginificative.","No clinically significant pharmacokinetic interaction",5,5
"374","fr","en","Aucune malformation liée au traitement n’ a été observée chez le rat.","There were no treatment-related malformations in rats.",7,12
"375","fr","en","Aucune modification de posologie liée à l’ âge n’ est nécessaire.","Dosage adjustment based on age is not required.",8,11
"376","fr","en","Aucune modification marquée n'a été observée au niveau individuel.","No marked changes were observed on an individual level.",9,9
"377","fr","en","Aucune précaution particulière n’ est nécessaire dans un tel cas.","No action needs to be taken if this is observed.",10,10
"378","fr","en","Aucune preuve n’ indique que le traitement par érythropoïétine altère le métabolisme d’ autres médicaments.","There is no evidence to indicate that treatment with erythropoietin alters the metabolism of other medicinal products.",17,15
"379","fr","en","Aucune source d’ eau ne doit être accessible durant la période de traitement.","No other source of drinking water should be available during the medication period.",13,13
"380","fr","en","Aucune supplémentation par antipsychotique oral n’ était autorisée.","No oral antipsychotic supplementation was allowed.",6,8
"381","fr","en","Aucune toxicité additionnelle n’ a été observée après administration concomitante des deux produits.","There is no evidence of added toxicity following concurrent administration of the two compounds.",14,13
"382","fr","en","Aucune toxicité liée à la dose n'a été observée dans les essais cliniques.","No dose-limiting toxicity was observed during clinical trials.",8,13
"383","fr","en","Aucune toxicité sur la reproduction n’a été observée lors des études réalisées chez les rats et les lapins.","No reproductive toxicity was observed in studies performed in rats and rabbits.",12,18
"384","fr","en","Augmentation de la cholestérolémie 11 Affections du systeme nerveux Très fréquent:","Elevated cholesterol levels11 Nervous system disorders Very common:",8,11
"385","fr","en","Augmentation des enzymes hépatiques","Dabigatran etexilate 150 mg",4,4
"386","fr","en","Augmentation des triglycérides, augmentation du cholestérol total, augmentation des γ GT","Increased triglycerides, increased total cholesterol, increased GGT",7,11
"387","fr","en","augmentation du temps de prothrombine Hyperuricémie","Weight increased, prothrombin time prolonged",5,6
"388","fr","en","AUTRE(S) MISE EN GARDE(S) SPECIALE(S), SI NECESSAIRE","OTHER SPECIAL WARNING(S), IF NECESSARY",5,7
"389","fr","en","Autres antagonistes d’ hormone et agents apparentés, code ATC:","Other hormone antagonists and related agents, ATC code:",8,9
"390","fr","en","Autres antipsychotiques: code ATC:","Other antipsychotics, ATC code:",4,4
"391","fr","en","Autres cytokines et immunomodulateurs, code ATC:","Other Cytokines and Immunomodulators, ATC code:",6,6
"392","fr","en","Autres dépenses en capital Frais de port et communications","Rent/charges Expenditure on data processing Other capital expenditure Postage and communications Other administrative expenditure",14,9
"393","fr","en","Autres effets secondaires possibles: tumeur, anémie, œ dème au fond de l’ oeil, vision double (diplopie).","Other possible side effects: neoplasm, anaemia, papilloedema, diplopia.",8,16
"394","fr","en","Autres informations sur les interactions de l’ irbésartan:","Additional information on irbesartan interactions:",5,8
"395","fr","en","Autres médicaments utilisés pour l’ infection par le VIH:","Other medicines used for HIV infection:",6,9
"396","fr","en","Avaglim contient deux principes actifs aux mécanismes d’ action différents.","Avaglim contains two active substances, which have different modes of action.",11,10
"397","fr","en","Avalez le comprimé avec un verre d’ eau.","Swallow one tablet with a glass of water",8,8
"398","fr","en","Avalez les comprimés avec une quantité suffisante de liquide (ex un verre d’ eau).","Swallow the tablets with a sufficient amount of fluid (e. g. one glass of water).",15,14
"399","fr","en","Avamys 27,5 microgrammes/ pulverisation Suspension pour pulvérisation nasale","AVAMYS 27.5 micrograms/ spray nasal spray suspension",7,8
"400","fr","en","AVANDAMET n'a aucun effet notable sur l’ aptitude à conduire des véhicules et à utiliser des machines.","AVANDAMET has no or negligible influence on the ability to drive and use machines.",14,17
"401","fr","en","Avant administration, le vaccin reconstitué doit être vigoureusement agité.","Before administration, the reconstituted vaccine should be shaken vigorously.",9,9
"402","fr","en","Avant agitation, Gardasil peut apparaître comme un liquide clair avec un précipité blanc.","Prior to agitation, Gardasil may appear as a clear liquid with a white precipitate.",14,13
"403","fr","en","Avant chaque injection, chassez les bulles d'air.","Before every injection, clear any air bubbles.",7,7
"404","fr","en","Avant d’ insérer la cartouche dans un système d’ administration d’ insuline:","Before you put the cartridge into the insulin delivery system:",10,12
"405","fr","en","Avant d’ instaurer le traitement, il est préférable de réaliser des tests de sensibilité microbienne.","Prior to initiation of therapy, bacteriological sensitivity tests should be conducted.",11,15
"406","fr","en","Avant de partir en voyage, consultez votre médecin p our vous informer sur les points suivants:","You may need to talk about",6,16
"407","fr","en","Avant de prendre OSSEOR demandez à votre médecin:","Before taking OSSEOR talk to your doctor:",7,8
"408","fr","en","AVANT DE PRENDRE TRUDEXA","BEFORE YOU USE TRUDEXA",4,4
"409","fr","en","Avant de vous prescrire ISENTRESS, votre médecin évaluera la gravité de votre maladie hépatique.","Your doctor may evaluate how severe your liver disease is before deciding if you can take ISENTRESS.",17,14
"410","fr","en","Avant l’apparition des lésions vasculaires, on n’observe habituellement aucun symptôme de l’hypertension artérielle.","There are usually no symptoms of high blood pressure before damage occurs.",12,13
"411","fr","en","Avant le premier prélèvement d'insuline, vous devez retirer le couvercle de sécurité.","Before the first withdrawal of insulin you must remove the safety tear-off cap on the vial.",16,12
"412","fr","en","Avant utilisation d’une aiguille, lisez attentivement les « instructions d’utilisation » accompagnant les aiguilles.","Before use of needle, carefully read the “Instructions for Use” accompanying the needles.",13,14
"413","fr","en","Avant-propos du président du Conseil d’ administration Introduction du directeur exécutif","Introduction by the Executive Director",5,11
"414","fr","en","Avda de la Industria 30 E-28108 Alcobendas (Madrid) Espagne","Avda de la Industria 30 E-28108 Alcobendas (Madrid) Spain",9,9
"415","fr","en","Avec l’autre main, tenez et maintenez le stylo comme vous le feriez avec un crayon.","With your other hand, pick up the pen and hold it as you would a i",16,15
"416","fr","en","avec le CYP450 UInteractions","Inducers of P-gp (St.",4,4
"417","fr","en","Avenida de Burgos, 91 E-28050 Madrid","Avenida de Burgos, 91",4,6
"418","fr","en","AVENTIS PHARMA LTD 50 Kings Hill Avenue Kings Hill West Malling Kent ME19 4AH","AVENTIS PHARMA LTD 50 Kings Hill Avenue Kings Hill West Malling Kent ME19 4AH",14,14
"419","fr","en","Avenue de la Métrologie 5","Avenue de la Métrologie 5",5,5
"420","fr","en","Avis sur les limites maximales de résidus pour les anciennes substances 2000-2002","Opinions for maximum residue limtis for old substances 2000-2002",9,12
"421","fr","en","Avonex et réactions allergiques.","Avonex and allergic reactions.",4,4
"422","fr","en","Axcan Pharma S. A.","Axcan Pharma S. A.",4,4
"423","fr","en","Axura agit sur ces récepteurs NMDA, ce qui permet d’améliorer la transmission des signaux nerveux et la mémoire.","Axura acts on these NMDA-receptors improving the transmission of nerve signals and the memory.",14,18
"424","fr","en","Azarga contient deux principes actifs, le brinzolamide et le timolol.","Azarga contains two active substances, brinzolamide and timolol.",8,10
"425","fr","en","Azomyr 0,5 mg/ ml sirop","Azomyr 0.5 mg/ ml syrup",5,5
"426","fr","en","Azomyr a correctement contrôlé les symptômes durant tout le nycthémère.","Azomyr effectively controlled symptoms for 24 hours.",7,10
"427","fr","en","AZOPT est un sulfonamide inhibiteur de 1’ anhydrase carbonique absorbé par voie systémique.","AZOPT is a sulphonamide inhibitor of carbonic anhydrase with systemic absorption.",11,13
"428","fr","en","B CONDITIONS RELATIVES A L’ AUTORISATION DE MISE SUR LE MARCHE","B CONDITIONS OF THE MARKETING AUTHORISATION",6,11
"429","fr","en","B-1070 Brüssel/Bruxelles Tél/Tel: +32 (0)2 5580737","Tél/ Tel: +32 (0)2 5580737",5,6
"430","fr","en","b) METHODE SANS l’ADAPTATEUR POUR FLACON","b) NON VIAL ADAPTER METHOD",5,6
"431","fr","en","B02BD02 Contrôle et prévention des épisodes hémorragiques","B02BD02 Control and prevention of haemorrhagic episodes",7,7
"432","fr","en","Baisse de Déshydratation l’ appétit Infections et infestations Laryngite Affections vasculaires","Hyperglycemia (reported especially in diabetic patients) SIADH Hyponatremia",8,11
"433","fr","en","Balmes, 84-4-2a 08008 Barcelona Spain","Balmes, 84-4-2a 08008 Barcelona Spain",5,5
"434","fr","en","Baraclude ne doit pas être utilisé pendant la grossesse, à moins d'une nécessité absolue.","Baraclude should not be used during pregnancy unless clearly necessary.",10,14
"435","fr","en","Baxter AG Industriestrasse 131 1221 Vienna Austria","Baxter AG Industriestrasse 131 1221 Vienna Austria",7,7
"436","fr","en","Baxter Oncology GmbH Kantstrasse 2 33790 Halle/Westfalen Allemagne","Baxter Oncology GmbH Kantstrasse 2 33790 Halle/Westfalen Germany",8,8
"437","fr","en","Bayer AG D-51368 Leverkusen Allemagne","Bayer AG, D-51368 Leverkusen, Germany",5,5
"438","fr","en","Bayer Austria GmbH Geschäftsbereich Tiergesundheit Herbststraße 6 – 10 A-1160 Wien Tel: +43 1 71146 2850","Österreich Bayer Austria GmbH Geschäftsbereich Tiergesundheit Herbststraße 6 – 10 A-1160 Wien Tel: +43 1 71146 2850",17,16
"439","fr","en","Bayer BV Energieweg 1 3641 RT Mijdrecht Pays-Bas","Bayer BV Energieweg 1 3641 RT Mijdrecht Nederland",8,8
"440","fr","en","Bayer Healthcare AG 51368 Leverkusen Allemagne","Iceland Bayer HealthCare AG 51368 Leverkusen Germany",7,6
"441","fr","en","Bayer Healthcare AG 51368 Leverkusen, Allemagne","Bayer Healthcare AG Ciproxin 51368 Leverkusen, Ciproxin Germany Ciproxin Ciproxin Ciproxin",11,6
"442","fr","en","Bayer HealthCare Manufacturing S. r. l.","Bayer HealthCare Manufacturing S. r. l.",6,6
"443","fr","en","Bayer Plc Animal Health Division Bayer House Strawberry Hill Newbury Berkshire RG14 1JA Royaume-Uni","Bayer Plc Animal Health Division Bayer House Strawberry Hill Newbury Berkshire RG14 1JA United Kingdom",15,14
"444","fr","en","Bayer SA-NV Health Care Animal Health Louizalaan 143 Avenue Louise 1050 Brussel Belgique","Bayer SA-NV Health Care Animal Health Louizalaan 143 Avenue Louise 1050 Brussel Belgium",13,13
"445","fr","en","Bayer Schering Pharma AG ,13342 Berlin, Allemagne","Bayer Schering Pharma AG, 13342 Berlin, Germany",7,7
"446","fr","en","België / Belgique / Belgien Pfizer S. A. / N. V.","België / Belgique / Belgien Pfizer S. A. / N. V.",11,11
"447","fr","en","België / Belgique/ Belgien sanofi-aventis Belgium Tél/ Tel: +32 (0)2 710 54 00","België/ Belgique/ Belgien sanofi-aventis Belgium Tél/ Tel: +32 (0)2 710 54 00",12,13
"448","fr","en","België/ Belgique/ Belgien Eisai Ltd.","België/ Belgique/ Belgien Eisai Ltd.",5,5
"449","fr","en","België/ Belgique/ Belgien KRKA, d. d., Novo mesto Tél/ Tel.: +32 (0)3 321 63 52 (BE)","België/ Belgique/ Belgien KRKA, d. d., Novo mesto Tél/ Tel.: +32 (0)3 321 63 52",15,16
"450","fr","en","België/Belgique/ Belgien sanofi-aventis Belgium Tél/Tel: +32 (0)2 710 54 00","België/Belgique/Belgien sanofi-aventis Belgium Tél/ Tel: +32 (0)2 710 54 00",10,10
"451","fr","en","België/Belgique/Belgien Abbott SA Parc Scientifique Rue du Bosquet, 2 B-1348 Ottignies/Louvain-la-Neuve Tél/Tel: + 32 10 475311","België/Belgique/Belgien Abbott SA Parc Scientifique Rue du Bosquet, 2 B-1348 Ottignies/Louvain-la-Neuve Tél/Tel: + 32 10 475311",16,16
"452","fr","en","Belgique /België Pr Paul-Pierre PASTORET Mme Françoise FALIZE","Paul-Pierre PASTORET Mrs Françoise FALIZE",5,8
"453","fr","en","Belgique/ Belgien Tél/ Tel: + 32 (0)2 656 21 11","Belgique/Belgien Tél/ Tel: + 32 (0)2 656 21 11",9,10
"454","fr","en","Belgique/ Belgien Tél/ Tel: + 32 (0)2 656 21 11 Tél/ Tel: + 32 (0)2 656 21 11","Belgique/ Belgien Tél/ Tel: + 32 (0)2 656 21 11",10,18
"455","fr","en","Belgique/België/Belgien Eli Lilly Benelux S.A./N.V.","Belgique/ België/ Belgien Eli Lilly Benelux S. A. / N. V.",11,5
"456","fr","en","BeneFIX 500 UI, poudre et solvant pour solution injectable Nonacog alfa (Facteur IX de coagulation recombinant)","BeneFIX 1000 IU powder and solvent for solution for injection Nonacog alfa (recombinant coagulation factor IX)",16,16
"457","fr","en","BeneFIX contient du facteur IX de coagulation recombinant (nonacog alfa).","BeneFIX contains recombinant coagulation factor IX, (nonacog alfa).",8,10
"458","fr","en","Beromun est réservé à un usage unique.","Beromun is for single use only.",6,7
"459","fr","en","Betaferon est une poudre stérile pour solution injectable de couleur blanche à blanc cassé.","Betaferon is a sterile white to off-white powder for solution for injection.",12,14
"460","fr","en","Bien agiter pour dissoudre.","Shake well to dissolve.",4,4
"461","fr","en","Bien lire la notice pour la destruction des médicaments inutilisés","Please read the package leaflet for disposal of medicines no longer required",12,10
"462","fr","en","Bien que moins fréquentes, les augmentations de la bilirubine semblaient plus persistantes.","Although less common, elevations in bilirubin appeared to be more persistent.",11,12
"463","fr","en","Binocrit 2 000 UI/ 1 ml","Binocrit 2000 IU/ 1 ml",5,6
"464","fr","en","Binocrit 6 000 UI/ 0,6 ml, solution injectable en seringue pré-remplie","Binocrit 6000 IU/ 0.6 ml solution for injection in a pre-filled syringe",12,11
"465","fr","en","Binocrit doit être administrée par injection intraveineuse (dans une veine).","Binocrit is given by injection into a vein (intravenously).",9,10
"466","fr","en","Biogal-Teva Pharma Rákóczi U.","Biogal-Teva Pharma Rákóczi U.",4,4
"467","fr","en","Biologicals: testing of residual fomaldehyde VICH:","Biologicals: testing of residual fomaldehyde",5,6
"468","fr","en","biologiques à usage vétérinaire","Impurities Residual Solvents 6.",4,4
"469","fr","en","Biotransformation Etant un cation divalent, le strontium n’ est pas métabolisé.","Biotransformation As a divalent cation, strontium is not metabolised.",9,11
"470","fr","en","Bleomicin Teva 15 U (USP), praš ek za raztopino za injiciranje","Bleomicin Teva 15 U (USP), praš ek za raztopino za injiciranje",11,11
"471","fr","en","Blessure accidentelle, mauvaise cicatrisation.","accidental injury, impaired healing",4,4
"472","fr","en","blessure ou s’il vous semble que vous êtes sujet à de très nombreuses infections;","catching a lot of infections.",5,14
"473","fr","en","Blister – Pramipexole Teva 0,18 mg, comprimé","Blister – Pramipexole Teva 0.18 mg tablets",7,7
"474","fr","en","Blister (PVC/ PVDC/ Al)","Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat Vimpat",13,4
"475","fr","en","Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein","Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein Germany",12,11
"476","fr","en","Boehringer Ingelheim International GmbH, Binger Str.","Boehringer Ingelheim International GmbH, Binger Str.",6,6
"477","fr","en","Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/ Rhein Allemagne","Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/ Rhein Germany",8,8
"478","fr","en","Boire immédiatement la solution ainsi préparée.","The patient should drink this test solution immediately.",8,6
"479","fr","en","Boîte de 1 blister","Box containing N/ a 1 blister",6,4
"480","fr","en","Boîte de 1 ou 12.","Pack sizes of 1 or 12.",6,5
"481","fr","en","Boite de 20 flacons.","Box of 20 x 1 bottles",6,4
"482","fr","en","BOITE EN CARTON {flacons de 50 ml, 100 ml et de 200 ml}","OUTER CARTON {50 ml vial, 100 ml and 200 ml vial}",11,13
"483","fr","en","BOITE EN CARTON / Comprimés","CARDBOARD CARTON / Tablets",4,5
"484","fr","en","Boite en carton contenant un blister / Boite en carton contenant deux blisters","Carton box for 1 blister card - Carton box for 2 blister cards",13,13
"485","fr","en","BOITE EXTERIEURE EN CARTON ET ETIQUETTE DU FLACON (Wilzin 25 mg gélules)","OUTER CARTON BOX AND BOTTLE LABEL (Wilzin 25 mg hard capsules)",11,12
"486","fr","en","Boîte: seringue avec aiguille","Box: syringe with needle",4,4
"487","fr","en","Boîte/ Plaquettes thermoformées pour délivrance à l’ unité (60, 90, 180, 270)","Carton/Unit dose blisters (60, 90, 180, 270)",7,12
"488","fr","en","Boîtes contenant 1 flacon à usage unique.","Pack containing 1 single-use vial.",5,7
"489","fr","en","Boîtes de 1 flacon de 60, 75, 100, 125, 150 ou 200 ml de solution.","Pack with a bottle of 60, 75, 100, 125, 150, or 200 mL solution.",14,15
"490","fr","en","Boîtes de 1, 10 et 25 avec ou sans seringue.","Pack of 1, 10, 25.",5,10
"491","fr","en","Boîtes de 1, 4 ou 10 flacons.","Pack sizes of 1, 4 or 10 vials.",8,7
"492","fr","en","Boîtes de 2 ou 12 comprimés.","Packs of 2 or 12 tablets.",6,6
"493","fr","en","Boîtes de 30 x 1 gélules en plaquettes thermoformées unidoses (aluminium).","Packs of 30 x 1 film-coated tablets in aluminium perforated unit dose blisters.",13,11
"494","fr","en","Boîtes de 7, 14, 28, 56 et 98 gélules sous plaquettes thermoformées.","These gastro-resistant capsules are available in blister packs containing 7, 14, 28, 56 or 98 capsules.",16,12
"495","fr","en","Boîtes de 84 (3x28), 90 (3x30), 98 (2x49) ou 280 (20x14) comprimés en conditionnements multiples.","Packs containing 84 (3x28), 90 (3x30), 98 (2x49) or 280 (20x14) tablets are multi-packs.",14,15
"496","fr","en","Bondenza IV 3 mg tous les 3 mois","Bondenza 3 mg injection every 3 months",7,8
"497","fr","en","Bondronat 50 mg comprimés pelliculés acide ibandronique","Bondronat 50 mg film-coated tablets ibandronic acid",7,7
"498","fr","en","Bondronat ne doit pas être utilisé chez les enfants.","Bondronat should not be used in children.",7,9
"499","fr","en","Bonnes pratiques cliniques: ligne directrice consolidée","responsible for methodological guidelines on both general clinical aspects and on specific therapeutic",13,6
"500","fr","en","Bonviva peut être administré soit par voie orale sous forme de comprimés, soit par injection intraveineuse.","Bonviva can be given either by mouth as a tablet or as an injection into a vein.",17,16
"501","fr","en","bouche sèche Constipation Diarrhée Nausées Douleurs abdominales Dyspepsie Gêne abdominale Troubles musculo-squelettiques","Dry Mouth Constipation Diarrhea Nausea Abdominal Pain Dyspepsia Abdominal Discomfort Musculoskeletal disorders",12,12
"502","fr","en","Bouchon en butyl avec joint de couleur pourpre.","Butyl stopper with purple seal.",5,8
"503","fr","en","Bouffée vasomotrice Hypertension Bouffée de chaleur","Flushing Hypertension Hot flush",4,6
"504","fr","en","Boundary Way Hemel Hempstead Herts.,HP2 7UD Royaume Uni","Boundary Way Hemel Hempstead Herts HP2 7UD United Kingdom",9,8
"505","fr","en","Bovins (veaux et jeunes bovins) et porcins.","Cattle (calves and young cattle) and pigs",7,7
"506","fr","en","Bovins: viande et abats:","Cattle: meat and offal:",4,4
"507","fr","en","Box 20 NL-5340 BH Oss Pays-Bas","Box 20 NL-5340 BH Oss The Netherlands",7,6
"508","fr","en","Box 217, mg enterokapsler","Box 217, 3640 AE Mijdrecht The Netherlands",7,4
"509","fr","en","Box 4220 Nydalen NO-0401 OSLO, Norvège","Box 4220 Nydalen NO-0401 OSLO, Norway",6,6
"510","fr","en","Box 581, 2003 PC Haarlem Pays-Bas","Box 581, 2003 PC Haarlem The Netherlands",7,6
"511","fr","en","Box 6185 S-102 33 Stockholm Tel: + 46-(0)8 522 21 500","Tel: + 46-(0)8 522 21 500",6,11
"512","fr","en","Bretland Tel: +44 (0)28 7086 8733","Bretland Tel: +44 (0)28 7086 8733",6,6
"513","fr","en","Bristol-Myers Squibb B. V.","Bristol-Myers Squibb B. V.",4,4
"514","fr","en","Bristol-Myers Squibb Pharma EEIG F","Bristol-Myers Squibb Pharma EEIG F",5,5
"515","fr","en","Bristol-Myers Squibb Pharmaceuticals Ltd Watery Lane IRL-Swords, Co.","Bristol-Myers Squibb Pharmaceuticals Ltd Watery Lane IRL-Swords, Co.",8,8
"516","fr","en","Bristol-Myers Squibb, S. r. l.","Bristol-Myers Squibb, S. p. A.",5,5
"517","fr","en","bronchospasme (0,2% vs 0%), dyspnée d'effort (0,5% vs 0,5%)","bronchospasm (0.2% vs 0%), exertional dyspnoea (0.5% vs 0.5%)",9,9
"518","fr","en","Bucureş ti-Ploieş ti, nr.","Bucureş ti-Ploieş ti, nr.",4,4
"519","fr","en","Buvez la dose prescrite de Remeron dans un verre ou une tasse mélangée à un peu d’ eau.","Drink your prescribed dose of Remeron oral solution in a glass or cup mixed with some water.",17,18
"520","fr","en","BYETTA est disponible en stylo prérempli contenant 5 µg ou 10 µg/ dose.","BYETTA is available as either a 5 µg or a 10 µg exenatide per dose pre-filled pen.",17,13
"521","fr","en","Č eská republika Boehringer Ingelheim spol. s r. o.","Č eská republika Boehringer Ingelheim spol. s r. o.",9,9
"522","fr","en","Č eská republika ELI LILLY Č R, s. r. o.","Česká republika Eli Lilly ČR, s.r.o.",6,10
"523","fr","en","Č eská republika GlaxoSmithKline s. r. o.","Č eská republika GlaxoSmithKline s. r. o.",7,7
"524","fr","en","Č eská republika Orion Corporation Tel: +358 10 4261","Č eská republika Orion Corporation Tel: +358 10 4261",9,9
"525","fr","en","Č eská republika Sandoz s. r. o.","Č eská republika Sandoz s. r. o.",7,7
"526","fr","en","C EU/ 1/ 01/ 184/ 042","ro EU/ 1/ 01/ 184/ 042",6,6
"527","fr","en","C'est notamment le cas au début du traitement et après chaque augmentation de la dose.","This is especially true at the beginning of the treatment and after increase in dose.",15,15
"528","fr","en","C’ est pourquoi les réponses anti -anticorps humains semblent être sans aucune significativité clinique.","Therefore, HAHA responses appear to be of no clinical relevance.",10,14
"529","fr","en","C’est pourquoi votre fonction cardiaque sera surveillée avant et pendant le traitement par Herceptin.","Therefore, your heart function will be checked before and during the treatment with Herceptin.",14,14
"530","fr","en","c) 208 Jours d) 180 Jours","c) 208 days d) 180 days",6,6
"531","fr","en","c) Nombre de Présent ations","Presentation a) Form b) Dose c) Number of Presentations",9,5
"532","fr","en","c/ o Icepharma hf Tel: +354 540 8000","ori Roche a/s c/o Icepharma hf Tel: +354 540 8000",10,8
"533","fr","en","C09DA Treatment of essential hypertension in patients whose blood pressure is","C09DA Treatment of essential hypertension in patients whose blood pressure is not adequately",13,11
"534","fr","en","Caelyx est aussi utilisé pour traiter le cancer de l’ ovaire.","Caelyx is also used to treat cancer of the ovary.",10,11
"535","fr","en","calcémie (mg/ dl) + 0,8 x [4 - albumine (g/ dl)]","Serum calcium (mg/ dl) + 0.8 x [4 - albumin (g/ dl)]",12,11
"536","fr","en","Calcichew-D3 et dénominations associées (voir annexe 1) 500 mg/ 10 µg comprimés à croquer","Calcichew-D3 and associated names (see Annex I) 500 mg / 10 µg chewable tablets",14,14
"537","fr","en","Calcium ""Sandoz"" forte - Brausetabletten","Calcium ""Sandoz"" forte - Brausetabletten",5,5
"538","fr","en","CALCIUM-SANDOZ 500mg compresse effervescenti","CALCIUM-SANDOZ 500mg compresse effervescenti",4,4
"539","fr","en","Can Guasch, 2 - Parets del Vallès 08150 Barcelone - Espagne","Can Guasch, 2 - Parets del Vallès 08150 Barcelona - Spain",11,11
"540","fr","en","Cancer bronchopulmonaire non à petites cellules","Non-small cell lung cancer",4,6
"541","fr","en","Cancer de la parathyroïde et hyperparathyroïdie primaire","Parathyroid carcinoma and Primary Hyperparathyroidism",5,7
"542","fr","en","Cancer du pancréas (Tarceva associé à la gemcitabine dans l’ étude PA.3):","Pancreatic cancer (Tarceva administered concurrently with gemcitabine in study PA.3):",10,12
"543","fr","en","Cancer du sein métastatique: administration hebdomadaire","Weekly dosing in MBC",4,6
"544","fr","en","Cancidas est un médicament antifongique.","Cancidas is an antifungal medicine.",5,5
"545","fr","en","Carbamazépine: risque d’ hyponatrémie en raison d’ un effet additif avec l’ hydrochlorothiazide.","Carbamazepine: risk of hyponatraemia due to additive effect with hydrochlorothiazide.",10,13
"546","fr","en","Cardace Comp 2,5 mg / 12,5 mg tabletit","Cardace Comp 2.5 mg/12.5 mg tabletit",6,8
"547","fr","en","cardiaque, notamment hypertension, hyperlipidémie (taux élevés de cholestérol), diabète et tabagisme.","hyperlipidaemia (high cholesterol levels), diabetes and smoking.",7,11
"548","fr","en","Carmellose poudre pour solution pour implantation pour Opgenra Utilisation intra-osseuse.","Carmellose powder for suspension for implantation for Opgenra Intraosseous use",10,10
"549","fr","en","CARTON EXTERIEUR POUR CONDITIONNEMENTS MULTIPLES CONTENANT DES PLAQUETTES THERMOFORMEES DE TYPE PA/ ALU/ PVC (INCLUANT LA BLUE BOX)","OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING PA/ ALU/ PVC BLISTERS",12,18
"550","fr","en","Carton pour plaquettes thermoformées contenant des comprimés pelliculés de maraviroc à 300 mg","Carton for blister pack containing 300 mg maraviroc film-coated tablets",10,13
"551","fr","en","Cartouche (verre) Cartouche (verre) Cartouche (verre) en stylo prérempli","cartridge (glass) in pre-filled pen",5,9
"552","fr","en","cartouche (verre) dans stylo prérempli (FlexPen)","Subcutaneous use Subcutaneous use Subcutaneous use Subcutaneous use Subcutaneous use Subcutaneous use Subcutaneous use Subcutaneous use Subcutaneous use",18,6
"553","fr","en","Ce crédit est destiné à couvrir d'autres dépenses de fonctionnement non spécialement prévues aux autres postes.","This appropriation is intended to cover other administrative expenditure not separately provided for in other items.",16,16
"554","fr","en","Ce cycle est répété trois fois et suivi de cinq cycles d'une injection hebdomadaire.","This cycle is repeated three more times, followed by five cycles of once-weekly injections.",14,14
"555","fr","en","Ce document est un résumé du rapport européen public d'évaluation (EPAR).","This document is a summary of the European Public Assessment Report (EPAR).",12,11
"556","fr","en","Ce groupe de travail (PhVWP) s’est réuni deux fois sous la présidence du Pr A.","This working party (PhVWP) met twice under the chairmanship of Professor A.",12,15
"557","fr","en","Ce groupe s’ est réuni 11 fois en 2002.","The Group met 11 times in 2002.",7,9
"558","fr","en","Ce groupe se réunira pour la première fois en 2003.","This group will meet for the first time in 2003.",10,10
"559","fr","en","Ce liquide est constamment évacué de l 'œ il et du nouveau liquide est produit pour le remplacer.","Liquid is constantly being drained out of the eye and new liquid is made to replace this.",17,18
"560","fr","en","Ce médicament apparaît dans la liste de 2007 des médicaments identifiés en vue d’ une harmonisation des RCP.","This medicinal product belongs to the list of products identified in 2007 for SPC harmonisation.",15,18
"561","fr","en","Ce médicament contient environ 17 mg de sodium par flacon.","This medicinal product contains approximately 17 mg sodium per vial.",10,10
"562","fr","en","Ce médicament est à usage diagnostique uniquement.","This medicinal product is for diagnostic use only.",8,7
"563","fr","en","Ce médicament est autorisé dans les Etats membres de l'Espace Economique Européen sous les noms suivants:","This medicinal product is authorised in the Member States of the EEA under the following names:",16,16
"564","fr","en","Ce médicament est autorisé dans les États membres de l'Espace Économique Européen sous les noms suivants:","This medicinal product is authorised in the Member States of the EEA under following names:",15,16
"565","fr","en","Ce médicament est contre-indiqué chez les patients présentant une allergie au blé (autre que la maladie cœ liaque).","Patients with wheat allergy (different from coeliac disease) should not take this medicine.",13,18
"566","fr","en","Ce médicament est habituellement injecté par une infirmière ou un médecin.","This medicine is usually injected by a nurse or a doctor.",11,11
"567","fr","en","Ce médicament est strictement réservé à la voie intraveineuse.","For intravenous use only.",4,9
"568","fr","en","Ce médicament est TERATOGENE","This medicinal product is TERATOGENIC",5,4
"569","fr","en","Ce médicament ne doit pas être mélangé à d’ autres médicaments ou fluides intraveineux.","This medicinal product must not be mixed with other medicinal products or intravenous fluids.",14,14
"570","fr","en","Ce médicament ne nécessite aucune précaution de conservation particulière.","This medicinal product does not require any special storage conditions.",10,9
"571","fr","en","Ce médicament ne nécessite pas de précautions particulières de conservation.","This medicine does not require any special storage conditions.",9,10
"572","fr","en","Ce médicament vous a été personnellement prescrit.","This medicine has been prescribed for you personally and you should not pass it on to others.",17,7
"573","fr","en","Ce paragraphe présente les instructions permettant de vous administrer vous -même une injection de Neulasta.","This section contains information on how to give yourself an injection of Neulasta.",13,15
"574","fr","en","Ce phénomène est appelé démyélinisation.","This is called demyelination.",4,5
"575","fr","en","Ce pourcentage peut varier en fonction de l’ origine ethnique.","This percentage may vary according to ethnic background.",8,10
"576","fr","en","Ce produit contient 1,4 mg de phenylalanine par comprimé orodispersible de Neoclarityn 2,5 mg.","This product contains 1.4 mg of phenylalanine per 2.5 mg dose of Neoclarityn orodispersible tablet.",15,14
"577","fr","en","Ce rapport devra aussi comporter les détails des effets indésirables comme précisé ci-dessous.","This report shall also provide the details of the ADRs as specified above.",13,13
"578","fr","en","Ce risque persiste jusqu’ à obtention d’ une rémission significative.","This risk persists until significant remission occurs.",7,10
"579","fr","en","Ce sont des substances naturelles qui transmettent des messages d’ une cellule à l’ autre.","These are natural substances that transmit messages between cells.",9,15
"580","fr","en","Ce syndrome est caractérisé par de volumineux kystes ovariens.","This syndrome is characterized by large ovarian cysts.",8,9
"581","fr","en","Ce traitement est contre-indiqué au cours du 2ème et 3ème trimestre de la grossesse ou durant l’ allaitement.","The product should not be used during the 2nd and 3rd trimester of pregnancy, or while breast-feeding.",17,18
"582","fr","en","Ce traitement n’est pas recommandé pour les enfants et les adolescents.","The treatment with this medicine is not recommended for children and adolescents.",12,11
"583","fr","en","Ce vaccin contient de l’ huile minérale.","This product contains mineral oil.",5,7
"584","fr","en","Ce vaccin peut uniquement être obtenu sur prescription.","The vaccine can only be obtained with a prescription.",9,8
"585","fr","en","Ce volume sera administré à l’ aide d’ un dispositif de mesure précis gradué de façon appropriée.","An accurate measuring device with suitable graduations should be used for this purpose.",13,17
"586","fr","en","Ceci complète le cycle de traitement de 28 jours.","This adds up to a 28-day treatment cycle.",8,9
"587","fr","en","Ceci comprend l'anorexie, les vomissements, ou la diarrhée.","These include anorexia, vomiting, and diarrhea.",6,8
"588","fr","en","Ceci contribue à réduire les effets de l’ intoxication au cyanure.","This helps to reduce the effects of cyanide poisoning.",9,11
"589","fr","en","Ceci correspond aux observations des études animales.","This was consistent with the observations in animal studies.",9,7
"590","fr","en","Ceci devrait vous aider à mieux comprendre comment noter les sites et les dates d’injection.","This should give you an idea of how you can keep track of your injection sites and dates.",18,15
"591","fr","en","Ceci est normal et ne diminue pas l’ effet du vaccin.","This is normal and does not impair the performance of the vaccine.",12,11
"592","fr","en","Ceci est plus fréquent chez les patients dont les reins ne fonctionnent pas correctement.","This is more common in people whose kidneys are not working properly.",12,14
"593","fr","en","Ceci est typique des antimycosiques azolés.","This is typical of azole antimycotics.",6,6
"594","fr","en","Ceci est un récipient multidose..","This is a multidose container.",5,5
"595","fr","en","Ceci ne constitue pas un signe de détérioration.","This does not constitute a sign of deterioration.",8,8
"596","fr","en","Ceci permet de mesurer la relation 13C/12C de toutes les concentrations de CO2 supérieures à 1%.","This enables measurement of the 13C/12C ratio at any CO2 concentration above 1%.",13,16
"597","fr","en","Ceci peut avoir lieu en particulier au début du traitement, ou lors du remplacement d’ autres préparations.","This can happen especially at the start of treatment, or when changing over from other preparations.",16,17
"598","fr","en","Ceci peut également concerner tout autre médicament, y compris les médicaments obtenus sans ordonnance.","This includes any other medicines including medicines obtained without a prescription.",11,14
"599","fr","en","Ceci peut être dû à une réaction allergique (hypersensibilité).","This may be due to an allergic (hypersensitivity) reaction.",9,9
"600","fr","en","Ceci pourrait endommager le mécanisme.","This may damage the mechanism.",5,5
"601","fr","en","Ceci pourrait entraîner une perte partielle du produit.","This may cause partial loss of product.",7,8
"602","fr","en","Ceci provoque une paralysie flasque des parasites exposés suivie par leur mort ou leur expulsion.","The result is flaccid paralysis of affected parasites, followed by their death and/ or expulsion.",15,15
"603","fr","en","Ceci s’applique également aux virus inconnus ou émergents ou à d’autres types d’infections.","This also applies to any unknown or emerging viruses or other types of infections.",14,13
"604","fr","en","Cefuroxim Sandoz 250 mg filmomhulde tabletten","Cefuroxim Sandoz 250 mg filmomhulde tabletten",6,6
"605","fr","en","Céfuroximaxétil 500 contient 601,44 mg de céfuroxime axétil, équivalents à 500 mg de céfuroxime par comprimé","Cefuroximaxetil 500 contain 601.44 mg cefuroxime axetil which is equivalent to 500 mg cefuroxime per tablet",16,16
"606","fr","en","Cefuroxime axetil Sandoz 250 mg Cefuroxime axetil Sandoz 500 mg","Cefuroxime axetil Sandoz 250 mg Cefuroxime axetil Sandoz 500 mg",10,10
"607","fr","en","Celà a été confirmé dans une étude de maintien d’ efficacité sur 36 semaines.","This was supported by a 36 week maintenance study.",9,14
"608","fr","en","Cela correspond à 4 mg de kétoprofène / kg.","This corresponds to 4 mg ketoprofen / kg.",8,9
"609","fr","en","Cela entraîne des effets nocifs tels que gonflement et lésions des tissus.","This results in harmful effects such as swelling and tissue damage.",11,12
"610","fr","en","Cela est dû à l’ induction par le millepertuis d’ enzymes métabolisantes.","This is due to induction of metabolising enzymes by St John’ s Wort.",13,12
"611","fr","en","Cela facilite la remise en suspension.","This makes it easier to resuspend.",6,6
"612","fr","en","Cela libère des ressources","as a whole, to perform better",6,4
"613","fr","en","Cela peut entraîner une perte grave de vision et même une cécité.","This can result in serious vision loss and even blindness.",10,12
"614","fr","en","Cela peut être dû à une perte d’ efficacité partielle de cette insuline.","This is because the insulin may have lost some of its effectiveness.",12,13
"615","fr","en","Cela peut modifier ou augmenter les effets des autres médicaments.","It may modify or increase the effects of other medicines.",10,10
"616","fr","en","Cela peut prendre 5 à 10 minutes.","This may take 5-10 minutes.",5,7
"617","fr","en","Cela pourrait être des symptômes de réactions allergiques sévères aux insulines qui peuvent mettre la vie en danger.","These could be symptoms of severe allergic reactions to insulins and may become life- threatening.",15,18
"618","fr","en","Cela pourrait signifier la présence d’une infection.","This may mean there is an infection.",7,7
"619","fr","en","Cela pourrait signifier la présence d’une infection. mé","Wipe the injection site with the enclosed alcohol pad, using a circular motion. rod",14,8
"620","fr","en","Cela signifie qu’ il aide à empêcher la formation de caillots sanguins.","This means that it helps to prevent blood clots from forming.",11,12
"621","fr","en","Cela signifie que des données complémentaires concernant ce médicament devront être déposées.","This means that there is more evidence to come about this medicine.",12,12
"622","fr","en","Cela souligne l'importance de respecter attentivement les contre-indications et mises en garde mentionnées ci-dessus.","This underlines the importance of careful adherence to the above mentioned contra-indications and safeguards.",14,14
"623","fr","en","Cela vaut même pour les dispositifs transdermiques déjà utilisés.","This is also the case with used transdermal patches.",9,9
"624","fr","en","Celgene Europe Ltd., Riverside House, Riverside Walk, Windsor, SL4 1NA, Royaume Uni","Celgene Europe Ltd., Riverside House, Riverside Walk, Windsor, SL4 1NA, United Kingdom",12,12
"625","fr","en","CellCept 500 mg poudre pour solution à diluer pour perfusion Mycophénolate mofétil","CellCept 500 mg powder for concentrate for solution for infusion mycophenolate mofetil",12,12
"626","fr","en","CellCept ne doit pas vous être administré:","CellCept should not be given to you:",7,7
"627","fr","en","Cellulose microcristalline Croscarmellose sodique Silice colloïdale anhydre Stéarate de magnésium","Microcrystalline cellulose Croscarmellose sodium Colloidal anhydrous silica Magnesium stearate",9,10
"628","fr","en","Cellulose microcristalline, carboxyméthylamidon sodique, stéarate de","The other ingredients are microcrystalline cellulose, sodium starch glycollate and magnesium stearate in the core of the tablet.",18,6
"629","fr","en","CELSENTRI 300 mg deux fois par jour et les statines peuvent être co- administrés sans adaptation posologique.","CELSENTRI 300 mg twice daily and statins can be coadministered without dose adjustment.",13,17
"630","fr","en","Celvapan est un vaccin « prototype ».","Celvapan is a ‘ mock-up’ vaccine.",6,7
"631","fr","en","Centocor Biologics, LLC 4777 LeBourget Drive St.","Centocor Biologics, LLC 4777 LeBourget Drive St.",7,7
"632","fr","en","Cependant ceci n’ a pas conduit à une augmentation de la mortalité dans l’ étude.","However, this did not lead to an increase in mortality in this study.",13,15
"633","fr","en","Cependant certains peuvent être sérieux et nécessiter un traitement.","However, some may be serious and require treatment.",8,9
"634","fr","en","Cependant des cas d’ exacerbations sévères, pouvant être fatals, ont été rapportés après l’ arrêt du traitement.","Nonetheless, there have also been reports of severe – and sometimes fatal – post-treatment disease exacerbations.",16,17
"635","fr","en","Cependant on ne sait pas si l'association de lopinavir/ ritonavir entraîne une augmentation similaire de l'exposition à la","However, it is unknown whether the combination of lopinavir/ ritonavir causes a similar increase in trazodone exposure.",17,18
"636","fr","en","Cependant, {Nom de fantaisie} ne doit pas être utilisé au cours de la grossesse.","However, < Invented Name > should not be used during pregnancy.",11,14
"637","fr","en","Cependant, à ce jour, aucun effet particulier de malformation n’ a été rapporté.","However, to date, no particular malformative effect has been reported.",10,13
"638","fr","en","Cependant, aucun bénéfice net n’ a été démontré en termes de survie.","Androgen ablation is considered to be a palliative treatment.",9,12
"639","fr","en","Cependant, ces troubles biologiques ont rarement été observés au cours des essais cliniques.","These events were seen infrequently in clinical studies.",8,13
"640","fr","en","Cependant, dans de très rares cas, des patients ont rapporté une somnolence ou des étourdissements.","However, in very rare cases, individuals have reported drowsiness or dizziness.",11,15
"641","fr","en","Cependant, des vertiges et de la fatigue peuvent survenir occasionnellement lors du traitement de l'hypertension artérielle.","However, occasionally dizziness or weariness may occur during treatment of high blood pressure.",13,16
"642","fr","en","Cependant, il pourra être nécessaire de modifier la posologie d’ Insulatard.","However, the Insulatard dosage may need to be adjusted.",9,11
"643","fr","en","Cependant, il pourra être nécessaire de modifier la posologie de Protaphane.","However, the Protaphane dosage may need to be adjusted.",9,11
"644","fr","en","Cependant, l'incidence a été rare.","However, the occurrence was rare.",5,5
"645","fr","en","Cependant, l’ injection de plus de 5.0 unités par site ne semble apporter aucun bénéfice supplémentaire.","However, there appears to be no additional benefit obtainable from injecting more than 5.0 U per site.",17,16
"646","fr","en","Cependant, la plupart des événements indésirables hépatiques dans le Programme MEDAL n'étaient pas graves.","However, most hepatic adverse experiences in the MEDAL Program were non-serious.",11,14
"647","fr","en","Cependant, la TEP n’ est pas suffisamment disponible en Europe.","However PET is not widely available throughout Europe.",8,10
"648","fr","en","Cependant, le basiliximab étant une IgG1, son excrétion dans le lait maternel est prévisible.","However, based on the IgG1 nature of basiliximab, excretion into milk should be expected.",14,14
"649","fr","en","Cependant, les raisons de cette différence ne sont pas connues et peuvent être liées à d’ autres facteurs.","However the reasons for this difference are unknown and could be related to other factors.",15,18
"650","fr","en","Cependant, on ne sait pas si l'éfavirenz est excrété dans le lait maternel humain.","It is not known whether efavirenz is excreted in human milk.",11,14
"651","fr","en","Cependant, pour les infections telles l’ otite externe maligne (OEM), le scénario est différent.","However, for infections such as malignant external otitis (MEO), the scenario is different.",13,14
"652","fr","en","Céphalée, syncope Symptômes extrapyramidaux","Headache, syncope Extrapyramidal symptoms",4,4
"653","fr","en","Céphalées Λ Vertiges Insomnie Migraine Paresthésie Affections oculaires","Headache Λ Dizziness Insomnia Migraine Paraesthesia Eye disorders",8,8
"654","fr","en","Ceplene doit être injecté 1 à 3 minutes après l’ IL-2.","Ceplene must be injected 1 to 3 minutes after IL-2.",10,11
"655","fr","en","cérébrale et communication interventriculaire.","embolism and ventricular septal defect",5,4
"656","fr","en","Cerepro a été désigné médicament orphelin le 6 février 2002.","Cerepro was designated an orphan medicinal product on 6 February 2002.",11,10
"657","fr","en","Certaines camptothécines sont utilisées en médecine comme anticancéreux.","Certain camptothecins are used in medicine as anti-cancer agents.",9,8
"658","fr","en","Certaines études ont également étudié des associations composées de Glustin et d’ autres antidiabétiques (sulphonylurées, insuline ou metformine).","Some studies also looked at combining Glustin with other anti-diabetes medicines (sulphonylureas, insulin or metformin).",15,18
"659","fr","en","Certaines personnes ressentent des vertiges ou une fatigue lors du traitement d’ une hypertension artérielle.","Some people feel dizzy or tired when they are treated for high blood pressure.",14,15
"660","fr","en","Certaines procédures retirées ont été analysées en 1998.","Some of the withdrawn procedures were analysed in 1998.",9,8
"661","fr","en","Certaines recommandations ont été introduites pour les patients présentant une insuffisance rénale légère à modérée.","Some recommendations were introduced for patients with patients with mild to moderate renal impairment.",14,15
"662","fr","en","Certains cas peuvent nécessiter un traitement plus long.","Some cases may require longer treatment.",6,8
"663","fr","en","Certains effets secondaires associés à la perfusion sont susceptibles de s’ aggraver.","Some of these infusion related side effects became serious.",9,12
"664","fr","en","Certificats d'études supérieures en médecine tropicale, recherche clinique et épidémiologie.","Post-graduate degrees in tropical medicine, clinical research and epidemiology.",9,10
"665","fr","en","Cervarix Suspension injectable en seringue préremplie","Cervarix Suspension for injection in pre-filled syringe",7,6
"666","fr","en","Ces associations doivent être évitées chez les métaboliseurs lents avérés du CYP2C9 (voir rubriques 4.2 et 5.2).","Such combinations should be avoided in known CYP2C9 poor metabolisers (see sections 4.2 and 5.2).",15,17
"667","fr","en","Ces associations doivent être utilisées avec prudence.","This combination should be used with caution.",7,7
"668","fr","en","Ces augmentations sont habituellement mineures et transitoires, et ne requièrent pas l'interruption du traitement.","These changes were usually mild, transient, and did not require interruption of treatment.",13,14
"669","fr","en","Ces changements sont généralement légers et disparaissent avec le temps. 'e","These changes are usually mild and go away with time.",10,11
"670","fr","en","Ces composants peuvent causer des réactions allergiques (parfois retardées).","These ingredients may cause allergic reactions (sometimes delayed).",8,9
"671","fr","en","Ces deux effets sont attendus pour cette classe de composés.","Both of these effects are expected for this class of compound.",11,10
"672","fr","en","Ces effets indésirables ont disparu d'eux -mêmes sans traitement après un ou deux jours.","These adverse reactions were self-limiting within one or two days and did not require additional treatment.",16,14
"673","fr","en","Ces effets indésirables peuvent apparaître lors de l’ utilisation de Zenapax.","These side effects may occur when using Zenapax.",8,11
"674","fr","en","Ces effets indésirables très sérieux sont très rares.","These very serious side effects are very rare.",8,8
"675","fr","en","Ces effets n’ ont pas été observés à des doses ≤ 30 mg/ kg.","These effects were not seen at doses ≤ 30 mg/ kg.",11,14
"676","fr","en","Ces effets ont été","These effects have been seen",5,4
"677","fr","en","Ces effets peuvent être majorés si Advagraf est administré en association avec de l’ alcool.","This effect may be enhanced if Advagraf is administered in association with alcohol.",13,15
"678","fr","en","Ces effets sont normalement d’ intensité légère à modérée et disparaissent souvent après quelques semaines.","These effects are normally mild to moderate and often disappear after a few weeks.",14,15
"679","fr","en","Ces effets sont présentés par système classe-organe et par ordre de fréquence.","These reactions are presented by system organ class and by frequency.",11,12
"680","fr","en","Ces études ont mesuré le taux de guérison de ces infections.","The studies measured the rate at which the infections were cured.",11,11
"681","fr","en","Ces évènements sont qualitativement similaires à ceux rapportés après les 5 injections initiales.","These events are similar in character to those after the initial five doses.",13,13
"682","fr","en","Ces interférons ont des activités biologiques qui se chevauchent tout en étant clairement identifiables.","These interferons have overlapping but clearly distinguishable biological activities.",9,14
"683","fr","en","Ces lésions cutanées étaient associées à des vergetures et des lésions osseuses découvertes lors d’ un examen radiologique.","These skin lesions were associated with skin striae and bone lesions first seen during an X-ray examination.",17,18
"684","fr","en","Ces médicaments doivent être arrêtés AU MOINS 7 jours avant le traitement par VISTIDE.","These medicines must be stopped AT LEAST 7 days before taking VISTIDE.",12,14
"685","fr","en","Ces médicaments sont contre-indiqués avec Invirase/ritonavir (voir rubrique 4.3).","These medicinal products are contraindicated for use with Invirase/ritonavir (see section 4.3).",12,9
"686","fr","en","Ces médicaments sont utilisés pour traiter diverses infections dues à des champignons (infections fongiques).","Uncommon side effects (occurring in at least 1 in 1,000 patients) are:",12,14
"687","fr","en","Ces mesures contribuent à préserver l'environnement.","These measures should help to protect the environment.",8,6
"688","fr","en","Ces mesures contribuent à protéger l’ environnement.","These measures will help to protect the environment.",8,7
"689","fr","en","Ces mesures permettront de protéger l’ environnement.","This will help to protect the environment.",7,7
"690","fr","en","Ces mesures permettront de protéger l’environnement. st 'e tn en am ic éd m e C","These measures will help to protect the environment",8,16
"691","fr","en","Ces observations pourraient traduire une clairance métabolique plus efficace chez les sujets jeunes.","These observations may be a reflection of more efficient metabolic clearance in younger subjects.",14,13
"692","fr","en","Ces patients doivent être surveillés étroitement et des précautions appropriées doivent être prises.","These patients should be monitored closely and appropriate precautions taken.",10,13
"693","fr","en","Ces patients présentaient une infection VIH stable et un nombre moyen de CD4 de 500/μl.","These patients had stable HIV disease and mean CD4 T-cell count was about 500 cells/ µL.",16,15
"694","fr","en","Ces réactions peuvent être évitées en interrompant temporairement le traitement par l’ IEC avant chaque aphérèse.","These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.",14,16
"695","fr","en","Ces réactions peuvent particulièrement survenir si la durée de la perfusion est inférieure ou égale à 30 minutes.","These reactions may occcur particularly when the infusion time is 30 minutes or less.",14,18
"696","fr","en","Ces récepteurs sont hyper- exprimés par les tumeurs malignes.","These receptors are hyper-expressed by malignant tumours.",7,9
"697","fr","en","Ces recommandations posologiques reposent actuellement sur un faible nombre d’ enfants (voir rubriques 5.1 et 5.2).","The dose recommendation is currently based on a small number of paediatric patients (see sections 5.1 and 5.2).",18,16
"698","fr","en","Ces résultats ont été corroborés de façon indépendante et en insu par un ensemble de radiologues.","These results were independently corroborated by a radiology panel blinded to treatment.",12,16
"699","fr","en","Ces signes peuvent indiquer que votre foie ne fonctionne pas bien.","These may be signs that your liver is not working properly.",11,11
"700","fr","en","Ces substances peuvent causer des réactions allergiques chez certains patients.","These products may cause an allergic reaction in some individuals.",10,10
"701","fr","en","Ces substances sont ajoutées à Fendrix pour accélérer, augmenter et prolonger l’ effet protecteur du vaccin.","These substances are included in Fendrix to accelerate, improve and prolong the protective effect of the vaccine.",17,16
"702","fr","en","Ces symptômes répondent généralement bien au traitement par anti- histaminiques et/ ou par corticoïdes.","These symptoms generally respond to treatment with antihistamines and/ or corticosteroids.",11,14
"703","fr","en","Ces symptômes sont énumérés ultérieurement.","Warning signs are listed later in this leaflet.",8,5
"704","fr","en","Ces symptômes sont habituellement transitoires.","These symptoms are usually of transitory nature.",7,5
"705","fr","en","Ces textes sont également disponi bles sur le site EudraLex Internet 83 http://dg3.eudra.org/eudralex/index.htm","The texts are also available on the EudraLex Internet site at http://dg3.eudra.org/eudralex/index.htm 81 (b) EMEA documents",16,13
"706","fr","en","Česká republika Na Příkopě 25 CZ-110 00 Praha 1 Tel: +420 221771250 mé","ed Na Příkopě 25 CZ-110 00 P raha 1 Tel: + 420 221771250",13,13
"707","fr","en","Česká Republika Wyeth Whitehall Czech s.r.o.","Č eská Republika Wyeth Whitehall Czech s. r. o.",9,6
"708","fr","en","Cet élément devra être pris en compte lors d’ une administration en perfusion continue.","This should be considered for a continuous infusion administration.",9,14
"709","fr","en","cet événement a eu une issue fatale. *voir rubrique 4.4.: pancréatites et lipides","See section 4.4: pancreatitis and lipids",6,13
"710","fr","en","Cet impact limité ne devrait pas avoir de conséquences cliniquement pertinentes.","This limited impact is not expected to be clinically significant.",10,11
"711","fr","en","Cetirizine-UCB, Zyrtec, Virlix Bulgarie:","Reactine, Cetirizine-UCB, Zyrtec Bulgaria:",4,4
"712","fr","en","Cetrotide 3 mg poudre pour solution injectable cétrorélix Voie sous-cutanée","Cetrotide 3 mg powder for solution for injection cetrorelix Subcutaneous use.",11,10
"713","fr","en","Cette apparence est normale","This appearance is normal",4,4
"714","fr","en","Cette augmentation du risque de fracture a été retrouvée pendant toute la durée de l’ étude.","This increased risk remained during the course of the study.",10,16
"715","fr","en","Cette bactérie a été inactivée (traitée pour la rendre incapable de provoquer une maladie).","The bacterium has been inactivated (treated to make it unable to cause an illness).",14,14
"716","fr","en","Cette cartouche doit être utilisée avec OptiClik uniquement..","This cartridge is for use with OptiClik only.",8,8
"717","fr","en","Cette différence d'exposition ne nécessite pas d’ ajustement posologique.","This difference in exposure does not warrant a dose adjustment.",10,9
"718","fr","en","Cette dose doit être considérée comme la dose maximale pour tous les patients.","This dose should be considered as a maximal dose for all patients.",12,13
"719","fr","en","Cette étude a montré que le ViraferonPeg était supérieur à l’ interféron alfa-2b (Tableau 5).","This study showed that Viraferon Peg was superior to interferon alfa-2b (Table 5).",13,15
"720","fr","en","Cette faible augmentation de la Cmax du sildénafil n’ est pas considérée comme cliniquement significative (voir rubrique 4.5).","This slight increase in sildenafil Cmax is not considered clinically relevant (see section 4.5).",14,18
"721","fr","en","Cette maladie entraine la fonte musculaire","This disease leads to a wasting of muscle tissue.",9,6
"722","fr","en","Cette manifestation n'apparaît pas cliniquement pertinente pour l'homme.","This finding is not clinically relevant to man.",8,8
"723","fr","en","Cette méthode de contraception permet de plus de réduire le risque de transmission du VIH.","For this reason, and to reduce the risk of HIV transmission, barrier contraception (e. g., condoms) is recommended.",18,15
"724","fr","en","Cette modification des paramètres biologiques n'est pas considérée comme cliniquement pertinente.","This change in laboratory parameters is not considered to be clinically relevant.",12,11
"725","fr","en","Cette opération permet de maintenir Liprolog Mix50 stérile et empêche les fuites.","This will keep the Liprolog Mix50 sterile and prevent leaking.",10,12
"726","fr","en","Cette présentation de NeoRecormon contient un lyophilisat blanc et un solvant.","This NeoRecormon presentation contains white lyophilisate and solvent.",8,11
"727","fr","en","Cette pression peut conduire à une maladie appelée glaucome.","This pressure can lead to an illness called glaucoma.",9,9
"728","fr","en","Cette proportion tend à rester stable sur les périodes prolongées de suivi.","This proportion tends to remain stable over prolonged periods of follow– up.",12,12
"729","fr","en","Cette réaction s’accompagne souvent d’une hausse du taux de certaines graisses (triglycérides) dans le sang.","This is often associated with an increase of certain blood fats (triglycerides).",12,15
"730","fr","en","Cette rougeur devrait disparaître dans les heures suivant le retrait du dispositif.","This redness should disappear within several hours after removal of the patch.",12,12
"731","fr","en","Cette solution injectable ne doit pas être mélangée avec un autre médicament.","This injection should not be mixed with any other medicine.",10,12
"732","fr","en","Cette substance de substitution fonctionne de la même manière que le G-CSF produit naturellement.","The replacement acts in same way as naturally produced G-CSF.",10,14
"733","fr","en","Cette surveillance aura lieu tous les 6 à 12 mois.","This might be every 6 to 12 months.",8,10
"734","fr","en","Cette suspension a été levée le 31 août 2004.","The suspension was lifted on 31 August 2004.",8,9
"735","fr","en","CEVA SANTE ANIMALE ZI Très le Bois 22600 LOUDEAC France","Très le Bois 22600 Loudéac France",6,10
"736","fr","en","Cf rubrique 6.6 pour des instructions plus détaillées.","See section 6.6 for more detailed instructions.",7,8
"737","fr","en","Changer à chaque fois de site d’injection afin d'éviter les irritations dans la même zone.","Change the place that you inject each time so you don’t become sore in one area.",16,15
"738","fr","en","Changer le site d'injection quotidiennement.","The injection site should be varied daily.",7,5
"739","fr","en","Changez l'endroit où vous l’ appliquez à chaque nouvelle application.","Rotate application sites with each new application.",7,10
"740","fr","en","Chaque ampoule de 2 ml contient 10 mg d’ ibuprofène.","Each 2 ml ampoule contains 10 mg ibuprofen.",8,10
"741","fr","en","Chaque boîte contient des plaquettes de 14, 21, 30, 42, 50, 56 ou 100 comprimés.","Each pack contains blisters of 14, 21, 30, 42, 50, 56 or 100 tablets.",14,15
"742","fr","en","Chaque capsule molle contient 150 mg d’ amprénavir.","Each capsule contains 150 mg amprenavir",6,8
"743","fr","en","Chaque capsule molle contient: lopinavir 133,3 mg et ritonavir 33,3 mg (potentialisateur de la pharmacocinétique du lopinavir).","Each soft capsule contains: lopinavir 133.3 mg and ritonavir 33.3 mg (pharmacokinetic enhancer).",13,17
"744","fr","en","Chaque cartouche comporte trois petites billes de métal qui facilitent le mélange rapide et efficace du contenu.","Each cartridge contains three small metal balls to facilitate quick and thorough mixing of the contents.",16,17
"745","fr","en","Chaque cartouche contient 14 doses.","Each cartridge contains 14 doses.",5,5
"746","fr","en","Chaque comprimé à libération prolongée d’ INVEGA 6 mg contient 6 mg de palipéridone.","Each INVEGA 6 mg prolonged-release tablet contains 6 mg of paliperidone.",11,14
"747","fr","en","Chaque comprimé contient 0,18 mg de pramipexole base (correspondant à 0,25 mg de dichlorhydrate de pramipexole monohydraté.","Each tablet contains 0.18 mg pramipexole base (as 0.25 mg pramipexole dihydrochloride monohydrate).",13,17
"748","fr","en","Chaque comprimé contient 1 mg de rasagiline (sous forme","Each tablet contains 1 mg rasagiline (as mesilate).",8,9
"749","fr","en","Chaque comprimé contient 10 mg d’ aripiprazole.","Each tablet contains 10 mg of aripiprazole.",7,7
"750","fr","en","Chaque comprimé contient 100 mg d’ urée 13C.","Each tablet contains 100 mg of 13C-urea",7,8
"751","fr","en","Chaque comprimé contient 125 mg, 250 mg ou 500 mg de déférasirox.","Each tablet contains 125 mg, 250 mg or 500 mg of deferasirox.",12,12
"752","fr","en","Chaque comprimé contient 15 mg de pioglitazone (sous forme de chlorhydrate).","Each tablet contains 15mg of pioglitazone (as hydrochloride).",8,11
"753","fr","en","Chaque comprimé contient 2,5 mg de tadalafil.","Each tablet contains 2.5 mg tadalafil.",6,7
"754","fr","en","Chaque comprimé contient 20 mg de telmisartan.","Each tablet contains 20 mg telmisartan.",6,7
"755","fr","en","Chaque comprimé contient 25 mg de losartan potassique.","Each tablet contains 25 mg losartan potassium.",7,8
"756","fr","en","Chaque comprimé contient 30 mg de pioglitazone (sous forme de chlorhydrate).","Each tablet contains 30 mg pioglitazone (as hydrochloride).",8,11
"757","fr","en","Chaque comprimé contient 40 mg de telmisartan.","Each tablet contains 40 mg telmisartan.",6,7
"758","fr","en","Chaque comprimé contient 5 mg de tadalafil.","Each tablet contains 5 mg tadalafil.",6,7
"759","fr","en","Chaque comprimé contient 500 mg de mitotane.","Each tablet contains 500 mg of mitotane.",7,7
"760","fr","en","Chaque comprimé contient 8 mg de rosiglitazone sous forme de maléate de rosiglitazone et 4 mg de glimépiride","Each tablet contains rosiglitazone maleate corresponding to 8 mg rosiglitazone and 4 mg glimepiride.",14,18
"761","fr","en","Chaque comprimé contient: de la silice colloïdale anhydre de l’ acide stéarique","Silica, colloidal anhydrous Stearic acid",5,12
"762","fr","en","Chaque comprimé d’EXJADE 250 mg contient 250 mg de déférasirox.","Each tablet of EXJADE 250 mg contains 250 mg deferasirox.",10,10
"763","fr","en","Chaque comprimé de Cozaar 12,5 mg contient 12,5 mg de losartan (sous forme de sel de potassium).","Each Cozaar 12.5 mg Tablet contains 12.5 mg of losartan (as potassium salt).",13,17
"764","fr","en","Chaque comprimé enrobé contient 20 mg d’ olanzapine.","Each coated tablet contains 20 mg olanzapine.",7,8
"765","fr","en","Chaque comprimé orodispersible contient 10 mg d’ olanzapine.","Each orodispersible tablet contains 10 mg olanzapine.",7,8
"766","fr","en","Chaque comprimé orodispersible contient 7,5 mg d’ olanzapine.","Each orodispersible tablet contains 7.5 mg olanzapine.",7,8
"767","fr","en","Chaque comprimé orodispersible de ZYPREXA","What ZYPREXA VELOTAB contains • The active substance is olanzapine.",10,5
"768","fr","en","Chaque comprimé pelliculé contient 0,34 mg de lécithine de soja.","Each film-coated tablet contains 0.34 mg soya-lecithin.",7,10
"769","fr","en","Chaque comprimé pelliculé contient 10 mg de chlorhydrate de mémantine (équivalent à 8,31 mg de mémantine base).","Each film-coated tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine.",14,17
"770","fr","en","Chaque comprimé pelliculé contient 150 mg d’ aliskiren (sous forme d’ hémifumarate) et 12,5 mg d’ hydrochlorothiazide.","Each film-coated tablet contains 150 mg aliskiren (as hemifumarate) and 12.5 mg hydrochlorothiazide.",13,17
"771","fr","en","Chaque comprimé pelliculé contient 180 mg de natéglinide.","Each film-coated tablet contains 180 mg nateglinide.",7,8
"772","fr","en","Chaque comprimé pelliculé contient 200 mg de tolcapone.","Each film-coated tablet contains 200 mg tolcapone.",7,8
"773","fr","en","Chaque comprimé pelliculé contient 300 mg d’ abacavir (sulfate), 150 mg de lamivudine et 300 mg de zidovudine.","Each film-coated tablet contains 300 mg of abacavir (as sulfate), 150 mg lamivudine and 300 mg zidovudine.",17,18
"774","fr","en","Chaque comprimé pelliculé contient 5 mg d'amlodipine (sous forme de bésylate d'amlodipine) et 80 mg de valsartan.","Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate) and 80 mg of valsartan.",16,17
"775","fr","en","Chaque comprimé pelliculé contient 600 mg d’ éfavirenz.","Each film-coated tablet contains 600 mg of efavirenz.",8,8
"776","fr","en","Chaque comprimé pelliculé contient 600 mg ou 800 mg de gabapentine.","Each film-coated tablet contains either 600 mg or 800 mg gabapentin.",11,11
"777","fr","en","Chaque comprimé pelliculé contient 80 mg ou 120 mg de fébuxostat.","Each tablet contains 80 mg or 120 mg of febuxostat.",10,11
"778","fr","en","Chaque comprimé pelliculé d’ Olanzapine Teva 5 mg contient 5 mg de substance active.","Each Olanzapine Teva 5 mg film-coated tablet contains 5 mg of the active substance.",14,14
"779","fr","en","Chaque conditionnement contient un dosage différent de Vimpat, donc vous augmenterez votre dose progressivement.","Each package contains a different dosage strength of Vimpat, so you will increase your dose gradually.",16,14
"780","fr","en","Chaque de dose de 1 ml de vaccin contient:","Each dose of 1ml of vaccine contains:",7,9
"781","fr","en","Chaque dispositif de 15 cm2 contient 8,25 mg de fentanyl.","Each patch of 15 cm2 contains 8.25 mg fentanyl.",9,10
"782","fr","en","Chaque dispositif transdermique de 5 cm2 contient 2,25 mg de rotigotine.","Each patch of 5 cm2 contains 2.25 mg of rotigotine.",10,11
"783","fr","en","Chaque dispositif transdermique est conditionné dans un sachet séparé.","Each transdermal patch is packed in a separate sachet.",9,9
"784","fr","en","Chaque dose du vaccin est fournie avec un sachet-dose de granulés effervescents.","Each dose of vaccine is supplied with one sachet of effervescent granules.",12,12
"785","fr","en","Chaque emballage contient 1 flacon.","Each carton contains 1 bottle.",5,5
"786","fr","en","Chaque flacon contient 0,25 mg de trabectédine Yondelis 1 mg:","Each vial contains 0.25 mg of trabectedin Yondelis 1 mg:",10,10
"787","fr","en","Chaque flacon contient 10 mg d'olanzapine.","Each vial contains 10 mg olanzapine.",6,6
"788","fr","en","Chaque flacon contient 100 mg de paclitaxel.","Each vial contains 100 mg paclitaxel.",6,7
"789","fr","en","Chaque flacon contient 15 microgrammes de darbepoetin alfa dans 1 ml (15 µg/ ml).","Each vial contains 15 micrograms of darbepoetin alfa in 1 ml (15 µg/ ml).",14,14
"790","fr","en","Chaque flacon contient 200 ou 1 000 mg de gemcitabine.","Each vial contains 200 or 1000 mg of gemcitabine.",9,10
"791","fr","en","Chaque flacon contient 250 ml de sévoflurane (à 100%).","Each bottle contains 250 ml sevoflurane (100%).",7,9
"792","fr","en","Chaque flacon contient 300 microgrammes (9,6 millions d’UI) d’interféron bêta-1b.","Each vial contains 300 microgram (9.6 million IU) interferon beta-1b per vial.",12,10
"793","fr","en","Chaque flacon contient 45 mg d’ ustekinumab dans 0,5 ml.","Each vial contains 45 mg ustekinumab in 0.5 ml of solution for injection.",13,10
"794","fr","en","Chaque flacon contient 500 mg de daptomycine.","Each vial contains 500 mg daptomycin.",6,7
"795","fr","en","Chaque flacon contient nominalement 1000 UI de nonacog alfa (Facteur IX de coagulation recombinant).","Each vial contains nominally 250 IU nonacog alfa (recombinant coagulation factor IX).",12,14
"796","fr","en","Chaque flacon de 1 ml contient 90 mg d’ ustkinumab.","Each vial contains 90 mg of ustekinumab in 1 ml.",10,10
"797","fr","en","Chaque flacon de 100 ml contient 200 mg de ciprofloxacine.","Each vial with 100 ml contains 200 mg ciprofloxacin.",9,10
"798","fr","en","Chaque flacon de 3,5 ml de solution à diluer pour perfusion contient 3,5 mg d'agalsidase alpha.","Each vial of 3.5 ml of concentrate contains 3.5 mg of agalsidase alfa.",13,16
"799","fr","en","Chaque flacon de Fabrazyme contient une valeur nominale de 5 mg d'agalsidase bêta.","Each vial of Fabrazyme contains a nominal value of 5 mg of agalsidase beta.",14,13
"800","fr","en","Chaque flacon est placé dans un sachet.","Each bottle is placed in a pouch.",7,7
"801","fr","en","Chaque flacon possède une capsule de protection inviolable en plastique.","Each vial has a protective, tamper-proof plastic cap.",8,10
"802","fr","en","Chaque gélule à libération prolongée contient 536,4 mg de lactose monohydraté","Each prolonged-release capsule contains 536.4 mg of lactose monohydrate",9,11
"803","fr","en","Chaque gélule contient 10 mg de lénalidomide.","Each capsule contains 10 mg of lenalidomide.",7,7
"804","fr","en","Chaque gélule contient 100 mg de prégabaline","Each hard capsule contains 100 mg pregabalin",7,7
"805","fr","en","Chaque gélule contient 182,2 mg de lactose anhydre.","Each hard capsule contains 182.2 mg of anhydrous lactose.",9,8
"806","fr","en","Chaque gélule contient 200 mg de ribavirine.","Each capsule contains 200 mg of ribavirin.",7,7
"807","fr","en","Chaque gélule contient 300 mg d'atazanavir (sous forme de sulfate).","Each capsule contains 300 mg of atazanavir (as sulphate)",9,10
"808","fr","en","Chaque gélule contient 300 mg de prégabaline.","Each hard capsule contains 300 mg of pregabalin.",8,7
"809","fr","en","Chaque gélule contient 50 mg d’ imatinib (sous forme de mésilate).","Each capsule contains 50 mg of imatinib (as mesilate).",9,11
"810","fr","en","Chaque gélule contient du malate de sunitinib, équivalant à 50,0 mg de sunitinib","Each capsule contains sunitinib malate, equivalent to 50.0 mg of sunitinib",11,13
"811","fr","en","Chaque gélule de 400 mg contient 54 mg de lactose (sous forme monohydraté).","Each 400 mg hard capsule contains 54 mg lactose (as monohydrate).",11,13
"812","fr","en","Chaque gélule de Prometax 6,0 mg contient 6,0 mg de rivastigmine.","Each Prometax 6.0 mg capsule contains 6.0 mg of rivastigmine.",10,11
"813","fr","en","Chaque gramme de poudre orale contient du mésylate de nelfinavir équivalent à 50 mg de nelfinavir.","What VIRACEPT contains Each gram of oral powder contains nelfinavir mesilate corresponding to 50 mg of nelfinavir.",17,16
"814","fr","en","Chaque marque (0,1, 0,2, 0,3, etc.) représente un dixième de millilitre (0,1 ml).","Each mark (0.1, 0.2, 0.3, etc.) represents one-tenth of a millilitre (0.1 ml).",13,13
"815","fr","en","Chaque millilitre de solution contient 10 mg de lacosamide.","Each ml of solution contains 10 mg lacosamide.",8,9
"816","fr","en","Chaque ml contient 100 UI (équivalent à 3,15 mg) d’ insuline humaine.","Each ml contains 100 IU insulin human (equivalent to 3.5 mg).",11,12
"817","fr","en","Chaque ml contient 25 mg d'abatacept, après reconstitution.","Each ml contains 25 mg of abatacept, after reconstitution.",9,8
"818","fr","en","Chaque ml contient de la rivastigmine sous forme d’ hydrogénotartrate correspondant à 2,0 mg de rivastigmine base.","Each ml contains rivastigmine hydrogen tartrate corresponding to rivastigmine base 2.0 mg.",12,17
"819","fr","en","Chaque ml de sirop contient 15 mg de lacosamide.","Each ml of syrup contains 15 mg lacosamide.",8,9
"820","fr","en","Chaque ml de solution buvable contient 0,5 mg de desloratadine.","Each ml of oral solution contains 0.5 mg desloratadine.",9,10
"821","fr","en","Chaque paquet contient 10 ampoules. mé","Each pack contains 10 ampoules. lp",6,6
"822","fr","en","Chaque poche de 50 ml contient 100 mg de ciprofloxacine.","Each bag with 50 ml contains 100 mg ciprofloxacin.",9,10
"823","fr","en","Chaque sachet contient 2g de ranélate de strontium.","Each sachet contains 2 g of strontium ranelate.",8,8
"824","fr","en","Chaque seringue pré-remplie (5ml) contient 250 mg de","Each pre-filled syringe (5 ml) contains 250 mg fulvestrant.",9,8
"825","fr","en","Chaque seringue pré-remplie d’ Enbrel 50 mg contient 1,0 ml de solution, soit 50 mg d’etanercept.","Each pre-filled syringe contains 1.0 ml of solution, providing 50 mg of etanercept.",13,16
"826","fr","en","Chaque seringue préremplie contient 6 mg de pegfilgrastim dans 0,6 ml (10 mg/ ml) de solution injectable.","Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml (10 mg/ ml) solution for injection.",17,17
"827","fr","en","Chaque seringue préremplie de 0,4 ml contient 80 microgrammes de darbepoetin alfa (200 microgrammes/ ml).","Each 0.4 ml pre-filled syringe contains 80 micrograms darbepoetin alfa (200 micrograms/ ml).",13,15
"828","fr","en","Chaque stylo contient 28 doses de 20 microgrammes (par 80 microlitres).","Each pen contains 28 doses of 20 micrograms (per 80 microliters).",11,11
"829","fr","en","Chaque stylo est prévu pour une période d’utilisation de quatre semaines et doit ensuite être jeté.","Each pen is intended for a maximum four-week use period and must then be discarded.",15,16
"830","fr","en","Chaque stylo prérempli contient 15 microgrammes de darbepoetin alfa dans 0.375 ml (40 µg/ ml).","Each pre-filled pen contains 15 micrograms of darbepoetin alfa in 0.375 ml (40 µg/ ml).",15,15
"831","fr","en","Chaque stylo prérempli ne doit être utilisé que par un seul patient.","Individual pre-filled pens should be for single patient use only.",10,12
"832","fr","en","Charge virale < 400 copies/ ml**","HIV RNA < 400 copies/ ml**",6,6
"833","fr","en","Chemical works of Gedeon Richter","Chemical works of Gedeon Richter Ltd, Gyömröi út 19-21, 1103 Budapest, Hungary",12,5
"834","fr","en","Chez 18% des patients","Skin rash was considered treatment related in 18% of patients treated with efavirenz.",13,4
"835","fr","en","Chez celles- ci, une amélioration significative (p < 0,001) a été apportée par le traitement versus l'excipient.","Significant improvement (p < 0.001) versus vehicle was seen in postmenopausal women.",12,17
"836","fr","en","Chez certains d’entre eux, l'hyperglycémie a été sévère et, dans certains cas, associée à une acidocétose.","In some of these patients the hyperglycaemia was severe and in some cases also associated with ketoacidosis.",17,16
"837","fr","en","Chez ces patientes, la production de LH était rapidement supprimée à la 1ère administration d’ Orgalutran.","In these patients LH production was rapidly suppressed after the first Orgalutran administration.",13,16
"838","fr","en","Chez ces patients, le traitement par somatropine normalise la concentration sérique des taux d’ IGF-1.","Metabolic alterations in these patients include normalisation of IGF-1 serum levels.",11,15
"839","fr","en","Chez ces sujets, la fonction rénale sera surveillée.","Monitoring of renal function in such patients should be considered.",10,8
"840","fr","en","Chez des patients traités conjointement par warfarine, des hémorragies graves ont été rapportées.","In patients on concurrent therapy with warfarin, serious bleeding events have been reported.",13,13
"841","fr","en","Chez l 'homme: • Déficience de la spermatogenèse due à un hypogonadisme hypogonadotrope.","In the male: • Deficient spermatogenesis due to hypogonadotrophic hypogonadism.",10,13
"842","fr","en","Chez l'enfant et l'adolescent:","Use in children and adolescents:",5,4
"843","fr","en","Chez l’ adulte, le traitement par l’ isotrétinoïne doit débuter à une dose de 0,5 mg/ kg/ jour.","In adults, isotretinoin therapy should be started at a dose of 0.5 mg/ kg daily.",15,18
"844","fr","en","Chez l’ enfant pesant entre 14 et 30 kg, la dose dépend du poids corporel.","In children weighing between 14 and 30 kg, the dose depends on body weight.",14,15
"845","fr","en","Chez l’ homme, l'effet de Volibris sur la fonction testiculaire et sur la fertilité masculine n'est pas connu.","The effect of Volibris on human testicular function and male fertility is not known.",14,18
"846","fr","en","Chez la femme, la clairance systémique est inférieure d'environ 25% à celle observée chez l'homme.","In female patients the systemic clearance is about 25% lower as compared to male patients.",15,15
"847","fr","en","Chez le chat, dans de très rares cas, le produit peut provoquer de la salivation et des vomissements.","In cats, in very rare cases, the cat might salivate or vomit after treatment.",14,18
"848","fr","en","Chez le chien, l'administration répétée du peptide retéplase d'origine humaine a entraîné des réactions immuno- allergiques.","In dogs repeated dosing of the human peptide reteplase led to immunologic-allergic reactions.",13,16
"849","fr","en","Chez le lapin, aucune toxicité du développement n’ a été observée à des doses maternelles toxiques.","No developmental toxicity was observed in rabbits at maternally toxic doses.",11,16
"850","fr","en","Chez le patient atteint d’ insuffisance hépatique:","Patients with hepatic impairment:",4,7
"851","fr","en","Chez le rat, le gain de poids de la génération F1 a été ralenti.","Body weight gain was decreased in F1 offspring in rats.",10,14
"852","fr","en","Chez les animaux, l'atosiban n'a pas eu d'effet cardio-vasculaire.","In animals atosiban did not exhibit cardiovascular effects.",8,9
"853","fr","en","Chez les dindes, le produit est utilisé chez des animaux âgés de 5-6 semaines.","In turkeys the product is used in animals of 5-6 weeks of age.",13,14
"854","fr","en","Chez les enfants, la pharmacocinétique de l'éfavirenz est similaire à celle des adultes.","The pharmacokinetics of efavirenz in paediatric patients were similar to adults.",11,13
"855","fr","en","Chez les femmes en âge de procréer, une contraception efficace doit être conseillée pendant le traitement.","Women of childbearing potential must be advised to use effective contraception during treatment.",13,16
"856","fr","en","Chez les hommes, la FSH est nécessaire pour la production de spermatozoïdes","In men, FSH is needed for the production of sperm.",10,12
"857","fr","en","Chez les patients atteints d'insuffisance rénale sévère, la dose maximale recommandée est 10 mg.","For patients with severe renal impairment 10 mg is the maximum recommended dose.",13,14
"858","fr","en","Chez les patients atteints de cancer, les érythropoïétines peuvent agir comme un facteur de croissance.","If you are a cancer patient be aware that erythropoietins may act as growth factor.",15,15
"859","fr","en","Chez les patients ayant une insuffisance hépatique sévère, le fondaparinux doit être utilisé avec précaution (voir rubrique 4.4).","In patients with severe hepatic impairment, fondaparinux should be used with care (see section 4.4).",15,18
"860","fr","en","Chez les patients co-infectés VHC-VIH, la durée de traitement est de 48 semaines.","For HCV/HIV co-infected patients, the duration of treatment is 48 weeks.",11,13
"861","fr","en","Chez les patients hypertendus, le telmisartan diminue la pression artérielle systolique et diastolique sans modifier la fréquence cardiaque.","The antihypertensive efficacy of telmisartan is comparable to that of agents",11,18
"862","fr","en","Chez les patients insuffisants rénaux chroniques, Retacrit ne doit pas être administré par voie sous- cutanée.","In chronic renal failure patients Retacrit has not to be administered subcutaneously.",12,16
"863","fr","en","Chez les patients pédiatriques, de tels effets indésirables ne sont pas fréquents.","In paediatric patients such undesirable effects are uncommon.",8,12
"864","fr","en","Chez les patients présentant une insuffisance hépatique modérée, la posologie ne devrait pas excéder 15 mg par jour.","In patients with moderately impaired hepatic function, the dose should be restricted to 15 mg daily.",16,18
"865","fr","en","Chez les patients présentant une réponse inappropriée au traitement par Dynepo malgré un taux de fer m","In the iron-replete patient with an inadequate response to Dynepo therapy, the following conditions in",15,17
"866","fr","en","Chez les patients traités à un stade précoce de la maladie, les effets indésirables hématologiques sont peu fréquents.","In patients with early HIV disease haematological adverse reactions are infrequent.",11,18
"867","fr","en","Chez les patients VIH, les concentrations d’ enfuvirtide dans le liquide céphalo-rachidien ont été rapportées comme étant négligeables.","In HIV patients, enfuvirtide levels in the cerebrospinal fluid have been reported to be negligible.",15,18
"868","fr","en","Chez les rats, l’ éfavirenz a induit des résorptions fœ tales.","Efavirenz induced foetal resorptions in rats.",6,11
"869","fr","en","Chez tous les patients évalués, la clairance rénale du bexarotène était estimée inférieure à 1 ml / minute.","In all evaluated patients, the estimated renal clearance of bexarotene was less than 1 ml/ minute.",16,18
"870","fr","en","Chez tous les patients, un dosage des enzymes hépatiques devra être effectué avant l'instauration du traitement par Tandemact.","Liver enzymes should be checked prior to the initiation of therapy with Tandemact in all patients.",16,18
"871","fr","en","Chiens moyens Grands chiens","Small dog Medium dog Large dog",6,4
"872","fr","en","Chiens: le produit reconstitué est injecté par voie intraveineuse une fois par jour pendant 3 jours consécutifs.","The reconstituted product should be injected intravenously once daily for 3 consecutive days.",13,17
"873","fr","en","Chiens: toute vaccination pendant et après traitement avec VIRBAGEN OMEGA est contre-indiquée jusqu’ au rétablissement complet du chien.","Vaccination during and after VIRBAGEN OMEGA treatment is contra-indicated, until the dog appears to have recovered.",16,18
"874","fr","en","Chiens: voie intraveineuse ou intramusculaire Chats: voie intramusculaire","Dogs: intravenous or intramuscular use Cats: intramuscular use",8,8
"875","fr","en","Chlorure de sodium Phosphate monosodique monohydraté Phosphate disodique heptahydraté Polysorbate 80 Eau pour préparations injectables","Sodium chloride Sodium phosphate monobasic, monohydrate Sodium phosphate dibasic, heptahydrate Polysorbate 80 Water for injections",15,15
"876","fr","en","Chlorure de sodium pour perfusion à 9 mg/ml (0,9%) ou du glucose pour perfusion à 50 mg/ml (5%).","Either 9 mg/ ml (0.9%) sodium chloride for infusion or 50 mg/ ml (5%) glucose for infusion.",17,18
"877","fr","en","Choisir au moins 4 sites d'injection différents, utilisés tour à tour.","Injections should be rotated between at least four different sites.",10,11
"878","fr","en","Choisir le point d’ injection et désinfecter la peau au moyen d’ un antiseptique.","Determine the point of injection and prepare antiseptically 14.",9,14
"879","fr","en","Choisissez le degré qui correspond le plus à vos activités quotidiennes.","If you’re unsure which level you are, choose Low Activity.",10,11
"880","fr","en","Choisissez une heure qui vous convient bien et prenez vos comprimés chaque jour à cette même heure.","Choose a time that is convenient for you and take your tablets at this time each day.",17,17
"881","fr","en","Choisissez une surface de travail plane, propre et bien éclairée.","Select a clean, well-lit, flat working surface.",7,10
"882","fr","en","Chugai Pharma Manufacturing Co., Ltd.","Chugai Pharma Manufacturing Co., Ltd.",5,5
"883","fr","en","CIALIS 5 mg comprimés pelliculés tadalafil","CIALIS 5 mg film-coated tablets tadalafil",6,6
"884","fr","en","Ciclosporine A: aucune modification de la pharmacocinétique de la ciclosporine A par le mycophénolate mofétil n'a été observée.","Ciclosporin A: ciclosporin A (CsA) pharmacokinetics were unaffected by mycophenolate mofetil.",11,18
"885","fr","en","Cimétidine Une étude d'interaction entre {PRODUCT NAME} et la cimétidine a été conduite et n'a montré aucune interaction.","Mortality and morbidity studies with atorvastatin have not yet completed.",10,18
"886","fr","en","CIN 3 associés aux","HPV 16/ 18- related CIN 3",6,4
"887","fr","en","Cipla (Uk) Limited 53a High Street Esher Surrey Kt10 9qr Royaume-Uni","Cipla (Uk) Limited 53a High Street Esher Surrey Kt10 9qr United Kingdom",12,11
"888","fr","en","Ciprofloxacin Kabi 400 2 mg/ ml mg/ 200 ml, solution pour perfusion","Ciprofloxacin Kabi 400 mg/ 200 ml,",6,12
"889","fr","en","ciprofloxacine ou de l’ enoxacine utilisées pour traiter certaines infections.","enoxacine which are used to treat some infections.",8,10
"890","fr","en","CIS bio international Boîte Postale 32 91192 GIF SUR YVETTE Cedex FRANCE","CIS bio international BP 32 F-91192 GIF-SUR-YVETTE Cedex France",9,12
"891","fr","en","Clairance de la créatinine","Creatinine clearance ml/ min",4,4
"892","fr","en","Clairance La clairance a diminué inversement à la dose.","Clearance Clearance decreased with increased dose level.",7,9
"893","fr","en","Classe pharmaco-thérapeutique: médicaments ophtalmologiques; décongestionnants et antiallergiques; autres antiallergiques.","Pharmacotherapeutic Group: ophthalmologicals; decongestant and antiallergics; other antiallergics.",8,9
"894","fr","en","Classe pharmacothérapeutique: anti gonadotrophin releasing hormone, code ATC:","Pharmacotherapeutic group: anti-gonadotrophin-releasing hormones, ATC code:",6,8
"895","fr","en","Classe pharmacothérapeutique: antisérums et immunoglobulines: immunoglobulines humaines normales, pour administration intravasculaire.","Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration, ATC code:",14,11
"896","fr","en","Classe pharmacothérapeutique: autres produits alimentaires et du métabolisme.","Other alimentary and metabolism products.",5,8
"897","fr","en","Classe pharmacothérapeutique: inhibiteur de protéase, code ATC:","Pharmacotherapeutic group: protease inhibitor, ATC code:",6,7
"898","fr","en","Classe pharmacothérapeutique: vaccin grippal, code ATC:","Influenza vaccines, ATC code:",4,6
"899","fr","en","ClCr est calculée selon la formule de Cockcroft-Gault à partir de la créatininémie.","CrCl is calculated from serum creatinine using the Cockcroft-Gault formula.",10,13
"900","fr","en","Clinicoimmunologic aspects of botulinum toxin type B treatment of cervical dystonia.","Clinicoimmunologic aspects of botulinum toxin type B treatment of cervical dystonia.",11,11
"901","fr","en","Clomicalm sera administré sous prescription vétérinaire.","Clomicalm should be used under veterinary supervision.",7,6
"902","fr","en","Clopidogrel BMS s’ est avéré plus efficace que l’ aspirine en matière de prévention de nouveaux événements ischémiques.","Clopidogrel BMS was more effective than aspirin at preventing new ischaemic events.",12,18
"903","fr","en","Clopidogrel Winthrop s’ est avéré plus efficace que l’ aspirine en matière de prévention de nouveaux événements ischémiques.","Clopidogrel Winthrop was more effective than aspirin at preventing new ischaemic events.",12,18
"904","fr","en","CoAprovel 300 mg/ 12,5 mg comprimés.","CoAprovel 300 mg/ 12.5 mg tablets.",6,6
"905","fr","en","Cohérence des évaluations et des avis grâce au développement de la base de données ""mémoire scientifique"".","EMEA/ MB/ 049/ 01-EN-Final Work progamme for 2002",8,16
"906","fr","en","Collyre en suspension 1 x 5 ml","Eye drops, suspension 1 x 5 ml",7,7
"907","fr","en","Combivir peut être pris au cours ou en dehors des repas.","Combivir can be taken with or without food.",8,11
"908","fr","en","COMITE DES MEDICAMENTS A USAGE HUMAIN (CHMP)","COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)",8,7
"909","fr","en","COMITE DES MEDICAMENTS A USAGE VETERINAIRE (CVMP)","COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)",8,7
"910","fr","en","Comme avec les autres céphalosporines, la couleur de la solution reconstituée peut brunir pendant cette période.","As with other cephalosporins, the colour of the reconstituted solution may darken during this period.",15,16
"911","fr","en","Comme avec les autres vaccins, une réponse immunitaire satisfaisante peut ne pas être obtenue chez ces sujets.","As with other vaccines, an adequate immune response may not be elicited in these individuals.",15,17
"912","fr","en","Comme avec toutes les protéines, il existe un risque d’ immunogénicité.","As with all proteins there is a potential for immunogenicity.",10,11
"913","fr","en","Comme les autres tétracyclines, la doxycycline forme un complexe stable avec le calcium dans les tissus ostéogéniques.","As for other tetracyclines, doxycycline forms a stable calcium complex in any bone- forming tissue.",15,17
"914","fr","en","COMME NT CONSERVER MABCAMPATH?","HOW TO STORE MABCAMPATH",4,4
"915","fr","en","Comme pour d’ autres agents ophtalmiques à usage local, GANFORT peut passer dans la circulation générale.","Like other topically applied ophthalmic agents, GANFORT may be absorbed systemically.",11,16
"916","fr","en","Comme pour d’ autres anti-thrombotiques, l’ effet indésirable le plus couramment observé sous Quixidar est le saignement.","The European Commission granted a marketing authorisation valid throughout the European Union for Quixidar on 21 March 2002.",18,17
"917","fr","en","Comme pour tout produit d’ origine protéique, des réactions allergiques d'hypersensibilité sont possibles.","As with any protein product, allergic type hypersensitivity reactions are possible.",11,13
"918","fr","en","Comme tous les médicaments, Carbaglu est susceptible d'avoir des effets indésirables.","Like all medicines, Carbaglu can have side effects.",8,11
"919","fr","en","Comme tous les médicaments, Myfenax est susceptible d'avoir des effets indésirables, bien que tous n’y soient pas sujets.","Like all medicines, Myfenax can have side effects, although not everybody gets them.",13,18
"920","fr","en","Comme tout médicament, Trudexa peut entraîner des effets indésirables, mais tout le monde ne les a pas.","Like all medicines, Trudexa can have side effects, although not everybody gets them.",13,17
"921","fr","en","Comment Abilify est -il utilisé?","How is Abilify used?",4,5
"922","fr","en","Comment Actraphane fonctionne -t-il?","How does Actraphane work?",4,4
"923","fr","en","Comment Ammonaps est -il utilisé?","How is Ammonaps used?",4,5
"924","fr","en","Comment Avaglim agit -il?","How does Avaglim work?",4,4
"925","fr","en","Comment BeneFIX est -il utilisé?","How is BeneFIX used?",4,5
"926","fr","en","Comment Caelyx agit -il?","How does Caelyx work?",4,4
"927","fr","en","Comment Cetrotide est -il utilisé?","How is Cetrotide used?",4,5
"928","fr","en","COMMENT CONSERVER {Nom de fantaisie}","STORING < INVENTED NAME > CREAM",6,5
"929","fr","en","COMMENT CONSERVER ALENDRONAT HEXAL","HOW TO STORE ALENDRONATE HEXAL",5,4
"930","fr","en","Comment conserver ARICLAIM 6.","Possible side effects 5 How to store ARICLAIM 6.",9,4
"931","fr","en","Comment conserver Azomyr lyophilisat oral 6.","How to store Azomyr oral lyophilisate 6.",7,6
"932","fr","en","Comment conserver Cerezyme 6.","How to store Cerezyme.",4,4
"933","fr","en","Comment conserver Cyanokit 6.","How to store Cyanokit 6.",5,4
"934","fr","en","Comment conserver Emselex 6.","How to store Emselex 6.",5,4
"935","fr","en","Comment conserver Filgrastim HEXAL 6.","How to store Filgrastim HEXAL 6.",6,5
"936","fr","en","Comment conserver HBVAXPRO 40 microgrammes/ml 6.","How to store HBVAXPRO 40 micrograms/ ml 6.",8,6
"937","fr","en","Comment conserver Helicobacter Test INFAI pour les enfants agés de 3 à 11 ans 6.","Possible side effects 5 How to store Helicobacter Test INFAI for children of the age 3-11 6.",17,15
"938","fr","en","Comment conserver Humalog KwikPen 6.","How to store Humalog KwikPen 6.",6,5
"939","fr","en","Comment conserver Infanrix Penta 6.","How to store Infanrix Penta 6.",6,5
"940","fr","en","COMMENT CONSERVER INSUMAN COMB 50","HOW TO STORE INSUMAN COMB 50",6,5
"941","fr","en","COMMENT CONSERVER IRBESARTAN HYDROCHLOROTHIAZIDE WINTHROP","HOW TO STORE IRBESARTAN HYDROCHLOROTHIAZIDE WINTHROP",6,5
"942","fr","en","Comment conserver KOGENATE Bayer 2000 UI 6.","How to store KOGENATE Bayer 2000 IU 6.",8,7
"943","fr","en","COMMENT CONSERVER LIPROLOG MIX25","HOW TO STORE LIPROLOG MIX25",5,4
"944","fr","en","Comment conserver NeuroBloc 6.","How to store NeuroBloc 6.",5,4
"945","fr","en","COMMENT CONSERVER OLANZAPINE TEVA","HOW TO STORE OLANZAPINE TEVA",5,4
"946","fr","en","Comment conserver PegIntron 6.","How to store PegIntron 6.",5,4
"947","fr","en","Comment conserver Puregon 6.","How to store Puregon 6.",5,4
"948","fr","en","Comment conserver REYATAZ 6.","How to store REYATAZ 6.",5,4
"949","fr","en","Comment conserver Sonata 6.","How to store Sonata 6.",5,4
"950","fr","en","Comment conserver Tadalafil Lilly 6.","Possible side effects 5 How to store Tadalafil Lilly 6.",10,5
"951","fr","en","Comment conserver TESAVEL 6.","How to store TESAVEL 6.",5,4
"952","fr","en","COMMENT CONSERVER TWINRIX ENF ANT","HOW TO STORE TWINRIX PAEDIATRIC",5,5
"953","fr","en","Comment conserver Xeloda 6.","How to store Xeloda 6.",5,4
"954","fr","en","Comment Crixivan agit -il?","How does Crixivan work?",4,4
"955","fr","en","Comment DaTSCAN est -il utilisé 4.","How DaTSCAN is used 4.",5,6
"956","fr","en","Comment DepoCyte est -il utilisé?","How is DepoCyte used?",4,5
"957","fr","en","Comment EMSELEX fonctionne -t-il?","How does EMSELEX work?",4,4
"958","fr","en","COMMENT EST ADMINISTRE PANDEMRIX","HOW PANDEMRIX IS GIVEN",4,4
"959","fr","en","Comment Eucreas est -il utilisé?","How is Eucreas used?",4,5
"960","fr","en","Comment Faslodex agit -il?","How does Faslodex work?",4,4
"961","fr","en","Comment Flebogammadif est -il utilisé?","How is Flebogammadif used?",4,5
"962","fr","en","Comment Glustin agit -il?","How does Glustin work?",4,4
"963","fr","en","Comment IDflu est -il utilisé?","How is IDflu used?",4,5
"964","fr","en","Comment Insuman fonctionne -t-il?","How does Insuman work?",4,4
"965","fr","en","Comment Irbesartan Winthrop est -il utilisé?","How is Irbesartan Winthrop used?",5,6
"966","fr","en","Comment Kineret agit -il?","How does Kineret work?",4,4
"967","fr","en","Comment l’ efficacité d’ Ibraxion a -t-elle été étudiée?","How has the effectiveness of Ibraxion been studied?",8,9
"968","fr","en","Comment Levemir est -il utilisé?","How is Levemir used?",4,5
"969","fr","en","Comment manipuler les cartouches pour OptiClik","How to handle the cartridges for OptiClik",7,6
"970","fr","en","Comment mesurer la quantité correcte de suspension:","How to measure the correct amount of suspension:",8,7
"971","fr","en","Comment Métalyse fonctionne -t-il?","How does Metalyse work?",4,4
"972","fr","en","Comment Monotard est -il utilisé? am","How is Monotard used?",4,6
"973","fr","en","Comment Nobilis Influenza H5N6 fonctionne -t-il?","How does Nobilis Influenza H5N6 work?",6,6
"974","fr","en","Comment NovoSeven est -il utilisé?","How is NovoSeven used?",4,5
"975","fr","en","Comment Omnitrope agit -il?","Reproduction is authorised provided the source is acknowledged. carbohydrates.",9,4
"976","fr","en","Comment Optruma agit -il?","How does Optruma work?",4,4
"977","fr","en","Comment Ovitrelle est -il utilisé?","How is Ovitrelle used?",4,5
"978","fr","en","Comment Prac-tic agit -il?","How does Prac-tic work?",4,4
"979","fr","en","Comment prendre {NOM DU PRODUIT} 10 mg 4.","How to take {PRODUCT NAME}10 mg 4.",7,8
"980","fr","en","Comment prendre < Nom (de fantaisie) du médicament > 4.","How to take< Invented name > 4.",7,10
"981","fr","en","Comment prendre Atriance 4.","How Atriance is used 4.",5,4
"982","fr","en","Comment prendre AVANDAMET 4.","How to take Avandamet 4.",5,4
"983","fr","en","COMMENT PRENDRE DULOXETINE BOEHRINGER INGELHEIM","HOW TO TAKE DULOXETINE BOEHRINGER INGELHEIM",6,5
"984","fr","en","Comment prendre Glivec 4.","How to take Glivec 4.",5,4
"985","fr","en","Comment prendre Irbesartan Hydrochlorothiazide Winthrop 4.","How to take Irbesartan Hydrochlorothiazide Winthrop 4.",7,6
"986","fr","en","COMMENT PRENDRE LA CIPROFLOXACINE BAYER?","HOW TO TAKE CIPROFLOXACIN BAYER",5,5
"987","fr","en","COMMENT PRENDRE MIRAPEXIN COMPRIMES","HOW TO TAKE MIRAPEXIN",4,4
"988","fr","en","Comment prendre OPTRUMA 4.","How to take OPTRUMA 4.",5,4
"989","fr","en","COMMENT PRENDRE OU DONNER LANSOPRAZOLE RATIOPHARM 15 MG, GELULE GASTRO-RESISTANTE?","Always take Lansoprazol-ratiopharm exactly as your doctor has told you.",10,10
"990","fr","en","COMMENT PRENDRE RASILEZ HCT","HOW TO TAKE RASILEZ HCT",5,4
"991","fr","en","Comment prendre STOCRIN 4.","How to take STOCRIN 4.",5,4
"992","fr","en","COMMENT PRENDRE TEMODAL 198 Posologie et durée de traitement","Dosage and duration of treatment",5,9
"993","fr","en","Comment prendre TOVIAZ 4.","How to take TOVIAZ 4.",5,4
"994","fr","en","Comment prendre Vectibix 4.","How to use Vectibix 4.",5,4
"995","fr","en","Comment prendre Xenical 4.","How to take Xenical 4.",5,4
"996","fr","en","Comment préparer l’injection de Neupopeg?","How do I prepare my Neupopeg injection?",7,5
"997","fr","en","Comment Procoralan est -il utilisé?","How is Procoralan used?",4,5
"998","fr","en","Comment Protopy fonctionne -t-il?","How does Protopy work?",4,4
"999","fr","en","Comment Remicade est -il utilisé?","How is Remicade used?",4,5
"1000","fr","en","Comment Replagal agit -il?","How does Replagal work?",4,4
"1001","fr","en","Comment Simulect vous est -il administré 4.","How Simulect is given to you 4.",7,7
"1002","fr","en","Comment SOMAVERT est -il utilisé?","How is SOMAVERT used?",4,5
"1003","fr","en","Comment Stelara agit -il?","How does Stelara work?",4,4
"1004","fr","en","Comment Tekturna est -il utilisé?","How is Tekturna used?",4,5
"1005","fr","en","Comment Tracleer agit -il?","How does Tracleer work?",4,4
"1006","fr","en","Comment Twinrix Adulte est -il utilisé?","How is Twinrix Adult used?",5,6
"1007","fr","en","Comment utiliser Bonviva 4.","How to use Bonviva 4.",5,4
"1008","fr","en","Comment utiliser cette insuline Actraphane doit être injecté sous la peau (voie sous-cutanée).","Actraphane is for injection under the skin (subcutaneously).",8,13
"1009","fr","en","Comment utiliser Doribax 4.","How to use Doribax 4.",5,4
"1010","fr","en","Comment utiliser Flebogammadif 4.","How to use Flebogammadif 4.",5,4
"1011","fr","en","COMMENT UTILISER Helixate NexGen 250 UI","HOW TO USE Helixate NexGen 250 IU",7,6
"1012","fr","en","COMMENT UTILISER HUMALOG MIX50 KWIKPEN","HOW TO USE HUMALOG MIX50 KWIKPEN",6,5
"1013","fr","en","Comment utiliser INOmax 4.","How your baby is treated with INOmax 4.",8,4
"1014","fr","en","COMMENT UTILISER INSULIN HUMAN WINTHROP RAPID","HOW TO USE INSULIN HUMAN WINTHROP RAPID",7,6
"1015","fr","en","COMMENT UTILISER KOGENATE Bayer 1000 UI","HOW TO USE KOGENATE Bayer 1000 IU",7,6
"1016","fr","en","Comment utiliser Liprolog Mix25 Pen 4.","How to use Liprolog Mix25 Pen 4.",7,6
"1017","fr","en","Comment utiliser Nespo Effets indésirables éventuels Comment conserver Nespo 'e","Possible side effects lo 5.",5,10
"1018","fr","en","COMMENT UTILISER NEUPOPEG (SURECLICK) ic","HOW TO USE NEUPOPEG od",5,5
"1019","fr","en","Comment utiliser Panretin 4.","How to use Panretin 4.",5,4
"1020","fr","en","COMMENT UTILISER REFACTO AF","HOW TO USE REFACTO AF",5,4
"1021","fr","en","Comment utiliser ZOSTAVAX 4.","How to use ZOSTAVAX 4.",5,4
"1022","fr","en","Comment Vimpat agit -il?","How does Vimpat work?",4,4
"1023","fr","en","Comment ViraferonPeg est -il utilisé?","How is ViraferonPeg used?",4,5
"1024","fr","en","Comment Zavesca est -il utilisé?","How is Zavesca used?",4,5
"1025","fr","en","Comment Zeffix agit -il?","How does Zeffix work?",4,4
"1026","fr","en","Commission a) Avis reçu le b) Décision c) Notification d) JO n°","Commission (a) Opinion (b) Decision (c) Notification (d) Official Journal",10,12
"1027","fr","en","Commission européenne Stefano MICOSSI Joaquim HEINE","Mr José Félix OLLALA MARAÑÓN Prof.",6,6
"1028","fr","en","Committee for Committee for","Committee for Committee for",4,4
"1029","fr","en","Competact comprimé est un antidiabétique utilisé dans le traitement du diabète sucré de type II (non insulino-dépendant).","Competact tablets are an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus.",15,17
"1030","fr","en","Complications GI graves Identification des sujets à risque L’ incidence des complications GI graves augmente avec l’ âge.","Serious GI Complications Identification of at-risk subjects The risk for developing serious GI complications increases with age.",17,18
"1031","fr","en","Complications liées au diabète","Hospitalisation for heart failure Complications related to diabetes",8,4
"1032","fr","en","COMPOSITION EN SUBSTANCE ACTIVE","STATEMENT OF ACTIVE SUBSTANCE",4,4
"1033","fr","en","COMPOSITION EN SUBSTANCES ACTIVES","STATEMENT OF ACTIVE SUBSTANCE(S)",4,4
"1034","fr","en","COMPOSITION QUALITATIVE ET QUANTITATIVE","QUALITATIVE AND QUANTITATIVE COMPOSITION",4,4
"1035","fr","en","Comprimé ovale de couleur orangée qui porte les inscriptions ""300MG"" sur une face et ""TMC114"" sur l’ autre.","Orange oval shaped tablet, debossed with “ 300MG” on one side and “ TMC114” on the other side.",18,18
"1036","fr","en","Comprimé pâle, brun jaunâtre, multi-facette, superelliptique, marqué “ GSEC7” sur une face et “ 25” sur l’ autre.","Pale, yellowish-brown, multifaceted, super-elliptical tablet, marked “ GSEC7” on one side and “ 25” on the other.",17,18
"1037","fr","en","Comprimé pelliculé 25 mg, 50 mg, 100 mg 12 Présentations","Film-coated tablet 25 mg, 50 mg, 100 mg 12 presentations",10,10
"1038","fr","en","Comprimé pelliculé ovale, blanc à légèrement jaunâtre et portant l’ inscription « LDT » sur une face.","White to slightly yellowish, oval film-coated tablet, imprinted with “ LDT” on one side.",14,17
"1039","fr","en","Comprimé: crospovidone, lactose monohydraté, stéarate de magnésium, cellulose microcristalline et povidone.","Tablet core: crospovidone, lactose monohydrate, magnesium stearate, cellulose microcrystalline and povidone.",11,11
"1040","fr","en","Comprimés Patients de 40 kg ou plus Patients de moins de 40 kg","NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER",8,13
"1041","fr","en","Comprimés pelliculés Comprimés pelliculés Comprimés pelliculés Solution pour perfusion","film-coated tablet film-coated tablet film-coated tablet solution for infusion solution for infusion solution for infusion",15,9
"1042","fr","en","Comprimés roses en forme de gélules, constitués de trois couches portant l’ inscription « PAL 9 ».","Trilayer capsule-shaped pink tablets printed with “ PAL 9”",9,17
"1043","fr","en","Compte tenu de la nature du produit (cytotoxique et mutagène), un effet sur la reproduction est probable.","Considering the nature of the compound (cytotoxic and mutagenic), it is likely to affect the reproductive capacity.",17,17
"1044","fr","en","Compter chaque section de bandelette dans un appareil de comptage de dose et interpréter les résultats comme suit:","Count each strip section in a dose calibrator and interpret the results as follows:",14,18
"1045","fr","en","Comtan n’ a aucun effet sur la maladie de Parkinson sans lévodopa.","Comtan has no antiparkinsonian activity without levodopa.",7,12
"1046","fr","en","Comtess a été plus efficace que le placebo dans les deux études.","Comtess was more effective than placebo in both studies.",9,12
"1047","fr","en","Concentration radioactive au moment de l'utilisation","Radioactivity concentration at time of use",6,6
"1048","fr","en","Concentrations du lopinavir: similaires à lopinavir/ ritonavir 400/ 100 mg deux fois par jour sans efavirenz.","Lopinavir concentrations: similar to lopinavir/ ritonavir 400/ 100 mg twice daily without efavirenz",13,16
"1049","fr","en","Concentré pour perfusion 375mg 1 Présentation","infusion 375mg 1 Present ation",5,6
"1050","fr","en","CONCLUSIONS SCIENTIFIQUES ET MOTIFS DE LA MODIFICATION DU RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT PRÉSENTÉS PAR L’ EMEA","SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS PRESENTED BY THE EMEA",16,17
"1051","fr","en","Conditionné en sachets (polyéthylène/ aluminium/ polyester), boîte de 7, 20, 28 et 30 sachets.","Cartons of 7, 20, 28 and 30 sachets.",8,14
"1052","fr","en","Conditionnement en strip Alu/ Alu Conditionnement en plaquettes thermoformées Alu/ Alu","Al/ Al strip packaging Al/ Al blister packaging",8,11
"1053","fr","en","Conditionnement multiple de 10 boîtes contenant chacune 98 comprimés pelliculés.","Multipack comprising 10 packs, each containing 98 film-coated tablets.",9,10
"1054","fr","en","CONDITIONNEMENTS MULTIPLES UNIQUEMENT EMBALLAGE EXTERIEUR - ETUI BLISTER (SANS LE CADRE BLEU) 30 COMPRIMES","MULTIPACKS ONLY OUTER CARTON BLISTER PACK (WITHOUT BLUE BOX) 30 TABLETS",11,14
"1055","fr","en","CONDITIONS DE PRESCRIPTION ET DE DELIVRANCE","GENERAL CLASSIFICATION FOR SUPPLY",4,6
"1056","fr","en","CONDITIONS DE PRESCRIPTION ET DE DELIVRANCE Médicament soumis à prescription médicale","Medicinal product subject to medical prescription.",6,11
"1057","fr","en","CONDITIONS OU RESTRICTIONS EN VUE D'UNE UTILISATION SURE ET EFFICACE DU MEDICAMENT","CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT",15,12
"1058","fr","en","CONDITIONS OU RESTRICTIONS RELATIVES A L’ AUTORISATION DE MISE SUR LE MARCHE CONCERNANT LA DELIVRANCE ET L’ UTILISATION","CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE",11,18
"1059","fr","en","CONDITIONS OU RESTRICTIONS RELATIVES À L’ AUTORISATION DE MISE SUR LE MARCHÉ POUR UNE UTILISATION SÛRE ET EFFICACE","AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE",8,18
"1060","fr","en","CONDITIONS RELATIVES À L'AUTORISATION DE MISE SUR LE MARCHÉ","CONDITIONS OF THE MARKETING AUTHORISATION",5,9
"1061","fr","en","Conduite de véhicules et utilisation de machines","Driving and using machines",4,7
"1062","fr","en","Conduite de véhicules et utilisation de machines Le traitement par ZALASTA comporte un risque de somnolence.","Driving and using machines There is a risk of feeling drowsy when you are given Zalasta.",16,16
"1063","fr","en","Conduite de véhicules et utilisation de machines:","Driving and using machines:",4,7
"1064","fr","en","Congestion nasale Toux Diarrhée","Nasal congestion Cough Diarrhoea",4,4
"1065","fr","en","Connectez l’ applicateur pour administration orale sur l’ adaptateur de transfert en le poussant fermement sur le dispositif.","Connect the oral applicator into the transfer adapter by pushing it firmly on this device.",15,18
"1066","fr","en","CONSEIL POUR UNE ADMINISTRATION CORRECTE","ADVICE ON CORRECT ADMINISTRATION",4,5
"1067","fr","en","Conservation de longue durée À conserver au congélateur à une température de -18°C ou inférieure.","Long term storage Store in a freezer at -18°C or colder.",11,15
"1068","fr","en","CONSERVE HORS DE PORTEE ET DE VUE DES ENFANTS","SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN na",18,9
"1069","fr","en","CONSERVÉ HORS DE PORTÉE ET DE VUE DES ENFANTS","OF THE REACH AND SIGHT OF CHILDREN",7,9
"1070","fr","en","Conserver au réfrigérateur (entre +2°C et +8°C).","Store in a refrigerator (2°C - 8°C).",7,7
"1071","fr","en","Conserver dans le conditionnement original afin de protéger de la lumière.","Store in the original package, in order to protect from light.",11,11
"1072","fr","en","Conserver la bouteille soigneusement fermée.","Keep the bottle tightly closed.",5,5
"1073","fr","en","Conserver la cartouche dans l'emballage extérieur à l’abri de la lumière.","Keep the cartridge in the outer carton in order to protect from light.",13,11
"1074","fr","en","Conserver la cartouche dans l’ emballage extérieur.","Keep the cartridge in the outer carton.",7,7
"1075","fr","en","Conserver la seringue dans l’ emballage extérieur à l’ abri de la lumière.","Keep the syringe in the outer carton in order to protect from light.",13,13
"1076","fr","en","Conserver la seringue préremplie dans l’emballage extérieur à l’abri de la lumière.","Keep the pre-filled syringe in the outer carton in order to protect from light.",14,12
"1077","fr","en","Conserver la seringue préremplie dans son emballage d’ origine pour la protéger de la lumière. tn","Keep the container in the outer carton, in order to protect from light. a",14,16
"1078","fr","en","Conserver le conditionnement primaire dans l'emballage extérieur à l’ abri de la lumière.","Keep the container in the outer carton in order to protect from light.",13,13
"1079","fr","en","Conserver le dispositif transdermique dans le sachet jusqu’ à son utilisation.","Keep the patch in the sachet until use.",8,11
"1080","fr","en","Conserver le flacon dans l'emballage extérieur à l’ abri de la lumière.","Keep the vial in the outer carton in order to protect from light.",13,12
"1081","fr","en","Conserver le flacon soigneusement fermé à l’abri de l'humidité.","Keep the container tightly closed in order to protect from moisture.",11,9
"1082","fr","en","Conserver le flacon soigneusement fermé afin de le protéger de l’ humidité.","Keep the bottle tightly closed in order to protect from moisture.",11,12
"1083","fr","en","Conserver le stylo prérempli dans l'emballage extérieur à l’abri de la lumière.","Keep the pre-filled pen in the outer carton in order to protect from light.",14,12
"1084","fr","en","Conserver les flacons dans l'emballage extérieur à l'abri de la lumière.","Keep the vials in the outer carton in order to protect from light.",13,11
"1085","fr","en","Conserver les plaquettes thermoformées dans l’ emballage extérieur, à l’ abri de la lumière.","Keep the blister packs in the outer carton in order to protect from light.",14,14
"1086","fr","en","Conservez le flacon de comprimés pour pouvoir décrire facilement ce que vous avez pris.","Keep the tablet bottle with you so that you can easily describe what you have taken.",16,14
"1087","fr","en","Considérations générales pour les essais cliniques","General considerations for clinical trials",5,6
"1088","fr","en","Consulter la notice pour des informations supplémentaires.","Contains lactose monohydrate, see leaflet for further information.",8,7
"1089","fr","en","Consulter la rubrique 6.4 pour connaître les conditions de conservation de SoloStar.","Please check section 6.4 for instructions on how to store SoloStar.",11,12
"1090","fr","en","Consultez le dos de cette notice pour savoir comment utiliser votre FlexPen.","Now turn over for information on how to use your FlexPen.",11,12
"1091","fr","en","Consultez votre médecin ou celui de votre enfant en cas de prise excessive.","Consult your doctor if you or your child have taken an overdose.",12,13
"1092","fr","en","Contactez immédiatement un médecin et dites -lui combien de gélules vous avez pris.","Contact a doctor immediately and say how many capsules you have taken.",12,13
"1093","fr","en","Contactez immédiatement un service médical d’ urgences si vous pensez présenter un syndrome sérotoninergique.","Get medical care right away if you think serotonin syndrome is happening to you.",14,14
"1094","fr","en","Contactez immédiatement votre médecin ou votre pharmacien.","Contact your doctor or pharmacist immediately.",6,7
"1095","fr","en","Contactez immédiatement votre médecin si vous suspectez une réaction d’ hypersensibilité à Trizivir.","You should immediately contact your doctor if you think you are having a hypersensitivity reaction to Trizivir.",17,13
"1096","fr","en","Contactez immédiatement votre médecin.","Contact your doctor immediately.",4,4
"1097","fr","en","contactez un médecin immédiatement, car ce sont des signes d’un possible problème hépatique.","Call a doctor immediately as they may be signs of a possible liver problem.",14,13
"1098","fr","en","Contactez votre médecin si votre dose adéquate d’ Effentora ne soulage pas votre accès douloureux paroxystique.","Contact your doctor if your right dose of Effentora does not relieve your breakthrough pain.",15,16
"1099","fr","en","Contenu de la gélule Sucrose Cellulose microcristalline (E 460) Hydroxypropylcellulose (E 463) Laurilsulfate de sodium","Capsule content Sucrose Microcrystalline cellulose (E 460) Hydroxypropyl cellulose (E 463) Sodium laurilsulfate",13,15
"1100","fr","en","CONTENU EN POIDS, EN VOLUME OU EN NOMBRE DE DOSES","CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES",10,10
"1101","fr","en","CONTENU EN POIDS, VOLUME OU UNITÉ","CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT",8,6
"1102","fr","en","CONTENU EN POIDS, VOLUME OU UNITE en am ic éd m e C","CONTENTS BY WEIGHT, BY VOLUME",5,13
"1103","fr","en","contenus dans Aerius lyophilisat oral, ou à la loratadine.","oral lyophilisate, or to loratadine.",5,9
"1104","fr","en","contenus dans Azomyr comprimés orodispersibles, ou à la loratadine.","orodispersible tablet, or to loratadine.",5,9
"1105","fr","en","contenus dans ce médicaments (voir « informations supplémentaires »),","medicine (See “ Further Information”).",5,9
"1106","fr","en","contient 60 millions d’ unités internationales [MUI] (600 microgrammes) de filgrastim Biograstim 30 MUI/ 0,5 ml:","Biograstim 30 MIU/ 0.5 ml:",5,16
"1107","fr","en","Contient du jaune orangé S (E110), voir notice pour de plus amples informations.","Contains Sunset Yellow (E110); see leaflet for further information.",9,13
"1108","fr","en","Contient également: chlorure de sodium, acide acétique glacial, acétate de sodium trihydraté, eau pour préparations injectables.","Also contains sodium chloride, glacial acetic acid, sodium acetate trihydrate, water for injections.",13,16
"1109","fr","en","Contient également: chlorure de sodium, eau pour préparations injectables, acide chlorhydrique, hydroxyde de sodium.","Also contains: sodium chloride, water for injections, hydrochloric acid, sodium hydroxide.",11,14
"1110","fr","en","Contient une source de phénylalanine.","Contains a source of phenylalanine.",5,5
"1111","fr","en","Continuez jusqu'à ce qu'une goutte d'Humalog Mix25 s'échappe de l'aiguille.","Do this until a drop of Humalog Mix25 comes out of the needle.",13,10
"1112","fr","en","Contraceptifs hormonaux Ethinyl estradiol","Hormonal contraceptive Ethinyl estradiol",4,4
"1113","fr","en","Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italie","Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy",8,8
"1114","fr","en","Contribuer à la protection et à la promotion de la santé humaine et animale par:","To contribute to the protection and promotion of public and animal health by:",13,15
"1115","fr","en","Contrôlez l’ étiquette pour vous assurer que votre FlexPen contient le type d’ insuline correct.","Check the label to make sure that your FlexPen contains the correct type of insulin.",15,15
"1116","fr","en","convulsives (voir rubrique 2:","seizures (see Section 2:",4,4
"1117","fr","en","Coordination des inspections pour les procédures centralisées","Coordination of inspections for centralised procedures",6,7
"1118","fr","en","Corlentor 5 mg comprimés pelliculés","Corlentor 5 mg film-coated tablets",5,5
"1119","fr","en","CORTAVANCE 0.584 mg/ ml solution cutanée en spray pour chiens","CORTAVANCE 0.584 mg/ ml cutaneous spray solution for dogs",9,10
"1120","fr","en","Cozaar 12,5 mg Comprimé pelliculé ovale, de couleur bleue portant, sur une seule face, l’ inscription ""11"".","Cozaar 12,5 mg tablet Blue, oval film-coated tablets marked 11 on one side and plain on the other.",18,17
"1121","fr","en","Cozaar Comp 50 mg/ 12,5 mg","Cozaar Comp 50 mg/ 12.5 mg",6,6
"1122","fr","en","CPMP Groupes de travail (permanents) Autres réunions Réunions sur les médicaments orphelins (désignation et assistance","CPMP Working parties (permanent) Other meetings Meetings on orphan medicinal products (designation and",13,15
"1123","fr","en","CPMP/ EWP/ 570/ 98","CPMP/ EWP/ 570/ 98",4,4
"1124","fr","en","Crampes et spasmes musculaires, douleurs musculosquelettiques incluant les myalgies, arthralgies, douleurs osseuses6","Muscle spasm and cramps, musculoskeletal pain including myalgia, arthralgia, bone pain6",11,12
"1125","fr","en","Critères principaux combinés Infarctus du myocarde Décès de causes cardiovasculaires Accident vasculaire cérébral","Primary combined events Myocardial infarction Death from cardiovascular causes Stroke",10,13
"1126","fr","en","CRIXIVAN 200 mg, gélules","CRIXIVAN 200 mg hard capsules",5,4
"1127","fr","en","croscarmellose de sodium, stéarate de magnésium.","microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate,",10,6
"1128","fr","en","Croscarmellose sodique Lactose monohydraté Stéarate de magnésium (E572) Cellulose microcristalline (E460) Amidon prégélatinisé (sans gluten)","Croscarmellose sodium Lactose monohydrate Magnesium stearate (E572) Microcrystalline cellulose (E460) Pregelatinised starch (gluten free)",14,15
"1129","fr","en","Croscarmellose sodique Macrogol 6000 silice colloïdale anhydre,","Sodium croscarmellose Macrogol 6000 Colloidal anhydrous silica Magnesium stearate",9,7
"1130","fr","en","croscarmellose sodique, la povidone et le stéarate de magnésium.","povidone and magnesium stearate.",4,9
"1131","fr","en","CSL Behring GmbH Emil-von-Behring-Straße 76 35041 Marburg Allemagne","CSL Behring GmbH Emil-von-Behring-Straße 76 35041 Marburg Germany",8,8
"1132","fr","en","Cubicin 350 mg poudre pour solution à diluer pour perfusion daptomycine","Cubicin 350 mg powder for concentrate for solution for infusion daptomycin",11,11
"1133","fr","en","cutanée maligne (tumeur) ou si vous avez un système immunitaire affaibli (immunodépression) quelle qu’ en soit la cause.","if you have a weakened immune system (immuno-compromised) whatever the cause.",11,18
"1134","fr","en","cutanée maligne (tumeur) ou si vous avez un système immunitaire affaibli (immunodépression) quelle qu’en soit la cause.","Talk to your doctor before using Protopy.",7,17
"1135","fr","en","CVMP/ 431317/ 06 1/ 1 ©EMEA 2006","CVMP/ 431317/ 06 1/ 1 ©EMEA 2006",7,7
"1136","fr","en","Cyathostomum spp, Cylicocyclus spp., Cylicodontophorus spp., Cylicostephanus spp., Gyalocephalus spp., aux ascarides:","Cyathostomum spp, Cylicocyclus spp., Cylicodontophorus spp., Cylicostephanus spp., Gyalocephalus spp., Ascarids:",11,12
"1137","fr","en","CYMBALTA 30 mg est disponible en boîtes de 7, 28 et 98 gélules.","CYMBALTA 30 mg is available in packs of 7, 28 and 98 capsules.",13,13
"1138","fr","en","CYSTAGON est prescrit dans la prise en charge de cette maladie rare héréditaire.","CYSTAGON is prescribed to manage this rare inherited disorder.",9,13
"1139","fr","en","Cytogénétique classique [t(15; 17)]","Conventional Cytogenetics [t(15; 17)]",4,4
"1140","fr","en","D torony V. em.","D torony V. em.",4,4
"1141","fr","en","d'atorvastatine et assurer un suivi attentif.","Use the lowest possible dose of atorvastatin with careful monitoring.",10,6
"1142","fr","en","D'autres effets indésirables moins fréquents ont été rapportés suite à l'administration de ProQuad dont certains étaient graves.","Other less common side effects have been reported following administration of ProQuad and some of these were serious.",18,17
"1143","fr","en","D'autres traitements ne devraient pas être associés à REYATAZ.","There are other medicines that may not mix with REYATAZ.",10,9
"1144","fr","en","d'hépatite C chronique traités par interféron.","Cases of Vogt-Koyanagi-Harada (VKH) syndrome have been reported in patients with chronic hepatitis C treated with interferon.",17,6
"1145","fr","en","D'un point de vue microbiologique, le produit doit être utilisé immédiatement.","From a microbiological point of view, the product should be used immediately.",12,11
"1146","fr","en","D’ autres manifestations hémorragiques (telles que les EMEA/ CHMP/ 46089/ 2006/ FR","EMEA/ CHMP/ 46089/ 2006/ EN",5,12
"1147","fr","en","D’ autres présentent de signes pseudo-grippaux légers tandis que certains peuvent devenir très malades.","Others have signs of mild flu, but some people can become very ill.",13,14
"1148","fr","en","d’ autres troubles (voir les produits listés dans la rubrique « Prise d’ autres médicaments »),","conditions (see the products listed in “ Taking other medicines”),",10,16
"1149","fr","en","D’ un point de vue microbiologique, le produit doit être utilisé immédiatement après reconstitution.","From a microbiological point of view, the product should be used immediately after reconstitution.",14,14
"1150","fr","en","D’ un point de vue microbiologique, le produit doit être utilisé immédiatement.","From a microbiological point of view the product should be used immediately.",12,12
"1151","fr","en","D’ une façon caractéristique, la toux est non productive, persistante et disparaît à l’ arrêt du traitement.","Characteristically, the cough is non- productive, persistent and resolves after discontinuation of therapy.",13,17
"1152","fr","en","d’ une monothérapie orale par metformine ne permet pas d’ obtenir un contrôle glycémique suffisant","control despite maximal tolerated dose of monotherapy with metformin",9,15
"1153","fr","en","Dafiro 5 mg/ 160 mg comprimés pelliculés","Dafiro 5 mg/ 160 mg film-coated tablets",7,7
"1154","fr","en","Damastown, Mulhuddart, Dublin 15 Irlande","Damastown, Mulhuddart, Dublin 15 Republic of Ireland",7,5
"1155","fr","en","Danmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88","Danmark Boehringer Ingelheim Danmark A/ S Tlf: +45 39 15 88 49",12,11
"1156","fr","en","Danmark GE Healthcare A/ S Huginsvej 8 DK-3400 Hillerød Tlf: + 45 70 22 22 03","Danmark GE Healthcare A/ S Huginsvej 8 DK-3400 Hillerød Tlf: + 45 70 22 22 03",16,16
"1157","fr","en","Danmark Ib VALSBORG Mogens BJØRNBACK-HANSEN (2)","Danmark Ib VALSBORG Mogens BJØRNBACK-HANSEN (2)",6,6
"1158","fr","en","Danmark Merck Sharp & Dohme Tlf: +45 43 28 77 66 dkmail@merck. com","Danmark Merck Sharp & Dohme Tlf: +45 43 28 77 66 dkmail@merck. com",13,13
"1159","fr","en","Danmark ScanVet Animal Health A/ S Tlf: + 45 48 48 43 17","Danmark ScanVet Animal Health A/ S Tlf: + 45 48 48 43 17",13,13
"1160","fr","en","Dans ce cas, ces patients devront être évalués de façon approfondie et une surveillance appropriée sera effectuée individuellement.","If this occurs, they should be evaluated fully, and appropriate intervention considered on an individual basis.",16,18
"1161","fr","en","Dans ce cas, contacter immédiatement l'hôpital ou votre médecin.","If this happens, consult your doctor or hospital immediately.",9,9
"1162","fr","en","Dans ce cas, il est recommandé d’ utiliser AMMONAPS granulés.","It is recommended to use AMMONAPS granules instead.",8,10
"1163","fr","en","Dans ce cas, la dose de lévodopa doit être réduite.","If they occur, the dose of levodopa should be decreased.",10,10
"1164","fr","en","Dans ce cas, la prise de ciprofloxacine doit être immédiatement interrompue et un traitement approprié doit être instauré.","In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated.",13,18
"1165","fr","en","Dans ce cas, Privigen régularise les dysfonctions du système immunitaire.","In these cases Privigen is regulating the malfunctioning immune system.",10,10
"1166","fr","en","Dans ce cas, une augmentation de la dose peut être nécessaire.","In this case dose increases may be necessary.",8,11
"1167","fr","en","Dans ce cas, votre médecin peut avoir besoin de réajuster la posologie de vos autres traitements antiparkinsoniens.","In such case, your doctor may need to re- adjust the dosage of your other antiparkinsonian medicines.",17,17
"1168","fr","en","Dans ce cas, vous devez en parler immédiatement à votre médecin.","If this is the case, you should speak to your doctor without delay.",13,11
"1169","fr","en","Dans ce sous-groupe, une réponse virologique prolongée a été obtenue chez 56% des patients (463/ 823).","In this subgroup, there was a 56% (463/823) sustained virological response rate.",12,16
"1170","fr","en","Dans certains cas, d'autres facteurs concomitants peuvent avoir contribué au développement","In some cases concomitant factors may have contributed to the development of these effects.",14,11
"1171","fr","en","Dans certains cas, leur utilisation avec VIRACEPT n’est h abituellement pas recommandée.","In some cases, their use with VIRACEPT is not usually recommended.",11,12
"1172","fr","en","Dans certains cas, votre médecin pourra effectuer certaines analyses, modifier la posologie ou vous surveiller régulièrement.","In some cases your doctor may need to perform certain tests, change the dose or monitor you regularly.",18,16
"1173","fr","en","Dans ces conditions, l’ utilisation de Xeomin pendant l’ allaitement n’ est pas recommandée.","Therefore, the use of Xeomin in breast-feeding women is not recommended.",11,14
"1174","fr","en","Dans ces études, le diagnostic d’ insomnie (psychophysiologique) primaire avait été posé pour tous les patients.","In these studies, patients were diagnosed with primary (psychophysiological) insomnia.",10,16
"1175","fr","en","Dans cette étude, 34 patients ont reçu de l’ anagrélide pendant une période allant jusqu’ à 5 ans.","In this study 34 patients received anagrelide for up to 5 years.",12,18
"1176","fr","en","Dans cette notice, le patient est désigné par le pronom « vous ».","In this leaflet the patient is addressed as ‘ you’.",10,13
"1177","fr","en","Dans de rares cas, ces troubles musculaires se sont révélés graves (rhabdomyolyse).","On rare occasions these muscle disorders have been serious (rhabdomyolysis).",10,12
"1178","fr","en","Dans de rares cas, des réactions anaphylactoïdes retardées (de quelques heures à plusieurs jours) ont été observées.","In rare cases delayed anaphylactoid reactions (after hours to days) have been observed.",13,17
"1179","fr","en","Dans de telles circonstances, la capacité à conduire doit être évaluée.","The advisability of driving should be considered in these circumstances.",10,11
"1180","fr","en","Dans des cas rares, des irritations temporaires peuvent apparaître au site d’ application.","In rare cases, temporary irritation may occur at the site of application.",12,13
"1181","fr","en","Dans des cas très rares, si nécessaire, une transfusion sanguine peut être réalisée.","In very rare cases, if necessary, a blood transfusion could be given.",12,13
"1182","fr","en","Dans l’ étude où NovoSeven était utilisé à la maison, 90% des épisodes hémorragiques ont été arrêtés.","In the study where NovoSeven was given in the home setting, 90% of the bleeding episodes were stopped.",18,17
"1183","fr","en","Dans l’ un de ces essais, les femmes avaient subi une hystérectomie.","In one of these trials the women had previously undergone hysterectomy.",11,12
"1184","fr","en","Dans la plupart des cas, un traitement de 10 jours sera suffisant.","In most cases, a 10 day-treatment course will be sufficient.",10,12
"1185","fr","en","Dans la tranche de population prédéfinie pour comparer le fondaparinux au placebo [c’ est-à-dire des patients traités par","In the predefined stratum comparing fondaparinux to placebo (i. e patients treated with non-",14,18
"1186","fr","en","Dans le cadre d’ une étude clinique, ont été observées:","In a field study conducted, it was observed that there was:",11,10
"1187","fr","en","Dans le cas contraire, votre médecin pourra interrompre le traitement ou l’ arrêter complètement.","If not, your doctor may interrupt treatment or stop it altogether.",11,14
"1188","fr","en","Dans le cas où l’ extrémité détachable serait poussée accidentellement dans le tube, jetez le vaccin.","In the event that the tip seal is accidentally pushed into the tube, discard the vaccine.",16,16
"1189","fr","en","Dans le groupe 2, 95 patients ont poursuivi à 5 mg/ kg toutes les 6 semaines.","There were 95 subjects from group 2 who continued on 5 mg/ kg every 6 weeks.",16,16
"1190","fr","en","Dans le groupe atorvastatine (n = 253), aucune progression de l’ athérosclérose n’ a été observée.","In the atorvastatin group (n=253), there was no progression of atherosclerosis.",11,16
"1191","fr","en","Dans le traitement de la schizophrénie","For the treatment of schizophrenia",5,6
"1192","fr","en","Dans les deux études, la dose d’ époétine reçue était la même pour les deux médicaments.","In both studies, the dose of epoetin received was similar with both medicines.",13,16
"1193","fr","en","Dans les études chez l’animal en gestation, les interférons ont quelquefois entraîné des avortements spontanés.","In studies in pregnant animals, interferons have sometimes caused miscarriage.",10,15
"1194","fr","en","Dans les études cliniques avec l’ aripiprazole, l’ incidence de l’ allongement du QT était comparable au placebo.","In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo.",14,18
"1195","fr","en","Dans les études cliniques, les anticorps anti-romiplostim ont été étudiés.","In clinical studies, antibodies to romiplostim were examined.",8,10
"1196","fr","en","Dans les études cliniques, les doses étaient réduites par paliers de 50 mg.","In the clinical studies doses were reduced by 50 mg steps.",11,13
"1197","fr","en","Dans les études dans le trouble panique, la posologie initiale était de 37,5 mg/ jour pendant 7 jours.","The initial dose in panic disorder studies was 37.5 mg/ day for 7 days.",14,18
"1198","fr","en","Dans les études de prévention primaire, la dose était de 10 mg/ jour.","In the primary prevention trials, the dose was 10 mg/ day.",11,13
"1199","fr","en","Dans les études effectuées chez le rat, le passage transplacentaire du pegfilgrastim a été mis en évidence.","In rat studies, it was shown that pegfilgrastim may cross the placenta.",12,17
"1200","fr","en","Dans les études par administration réitérée, le nimésulide a montré une toxicité gastro-intestinale, rénale et hépatique.","In repeated dose toxicity studies, nimesulide showed gastrointestinal, renal and hepatic toxicity.",12,16
"1201","fr","en","Dans les études précliniques et cliniques, aucun anticorps anti-romiplostim n’ a interagi avec la TPO endogène.","In pre-clinical and clinical studies no anti-romiplostim antibodies cross reacted with endogenous TPO.",13,16
"1202","fr","en","Dans les trois études, la principale mesure d’ efficacité a été la durée de survie des patients.","In all three studies, the main measure of effectiveness was how long the patients survived.",15,17
"1203","fr","en","Dans quel cas Betaferon est -il utilisé?","What is Betaferon used for?",5,7
"1204","fr","en","Dans quel cas Cholestagel est -il utilisé?","What is Cholestagel used for?",5,7
"1205","fr","en","Dans quel cas Dafiro est -il utilisé?","What is Dafiro used for?",5,7
"1206","fr","en","Dans quel cas EXULETT devait -il être utilisé?","What was EXULETT expected to be used for?",8,8
"1207","fr","en","Dans quel cas Firmagon est -il utilisé?","What is Firmagon used for?",5,7
"1208","fr","en","Dans quel cas Infanrix Hexa est -il utilisé?","What is Infanrix Hexa used for?",6,8
"1209","fr","en","Dans quel cas Kivexa est -il utilisé?","What is Kivexa used for?",5,7
"1210","fr","en","Dans quel cas Masivet est -il utilisé?","What is Masivet used for?",5,7
"1211","fr","en","Dans quel cas Posaconazole SP est -il utilisé?","What is Posaconazole SP used for?",6,8
"1212","fr","en","Dans quel cas Purevax RCPCh est -il utilisé?","What is Purevax RCPCh used for?",6,8
"1213","fr","en","Dans quel cas Remicade est -il utilisé?","What is Remicade used for?",5,7
"1214","fr","en","Dans quel cas Simulect est -il utilisé?","What is Simulect used for?",5,7
"1215","fr","en","Dans quel cas Tamiflu est -il utilisé?","What is Tamiflu used for?",5,7
"1216","fr","en","Dans quel cas Thalidomide Celgene est-il utilisé:","What Thalidomide Celgene is used for:",6,7
"1217","fr","en","Dans quel cas Tredaptive est -il utilisé?","What is Tredaptive used for?",5,7
"1218","fr","en","Dans quel cas Valdoxan est -il utilisé?","What is Valdoxan used for?",5,7
"1219","fr","en","Dans quel cas Vistide est -il utilisé?","What is Vistide used for?",5,7
"1220","fr","en","Dans quel cas Zavesca est -il utilisé?","What is Zavesca used for?",5,7
"1221","fr","en","Dans quels cas Aranesp est -il utilisé?","What is Aranesp used for?",5,7
"1222","fr","en","Dans quels cas Efficib est -il utilisé?","What is Efficib used for?",5,7
"1223","fr","en","Dans quels cas Nespo est -il utilisé?","What is Nespo used for? no",6,7
"1224","fr","en","Dans quels cas Novem est -il utilisé?","What is Novem used for?",5,7
"1225","fr","en","Dans quels cas Optruma est -il utilisé?","What is Optruma used for?",5,7
"1226","fr","en","Dans tous les cas, le bolus d'attaque doit être réduit à 0,2 mg/ kg de poids corporel.","In any case, the bolus dose must be reduced to 0.2 mg / kg body weight.",16,17
"1227","fr","en","Dans tous les cas, les jours de remplacement du dispositif seront maintenus.","In either case, the original treatment regimen should be maintained.",10,12
"1228","fr","en","Dans une étude chez des femmes non malades allaitant, l’ olanzapine a été retrouvée dans le lait maternel.","In a study in lactating, healthy women, olanzapine was excreted in breast milk.",13,18
"1229","fr","en","Dans ViraferonPeg, l’ interféron alfa-2b a été « pégylé » (conjugué à une substance appelée polyéthylène glycol).","In ViraferonPeg, the interferon alfa-2b has been ‘ pegylated’ (coated with a chemical called polyethylene glycol).",16,17
"1230","fr","en","Daronrix ne doit pas être administré en même temps que d'autres vaccins.","Daronrix should not be given at the same time as other vaccines.",12,12
"1231","fr","en","Dasatinib est fortement métabolisé chez l'homme par de multiples enzymes impliquées dans la production de métabolites.","Dasatinib is extensively metabolized in humans with multiple enzymes involved in the generation of the metabolites.",16,16
"1232","fr","en","date d’ expiration fait référence au dernier jour du mois.","The expiry date refers to the last day of that month.",11,10
"1233","fr","en","DATE DE LA DERNIERE NOTICE APPROUVEE","DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED",9,6
"1234","fr","en","DATE DE LA PREMIERE AUTORISATION / DE RENOUVELLEMENT DE L' AUTORISATION","DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION",8,11
"1235","fr","en","Date de la première autorisation:","Date of first authorization:",4,5
"1236","fr","en","Date de mise à jour du texte","Date of revision of the text",6,7
"1237","fr","en","DATE DE PREMIERE AUTORISATION","DATE OF FIRST AUTHORISATION",4,4
"1238","fr","en","Date de première autorisation:","Date of first authorisation:",4,4
"1239","fr","en","DATE DE PREMIÈRE AUTORISATION/ DE RENOUVELLEMENT DE L' AUTORISATION","DATE OF FIRST AUTHORISATION/ RENEWAL OF AUTHORISATION",7,9
"1240","fr","en","DATE DE PREMIERE AUTORISATION/ DE RENOUVELLEMENT DE L’ AUTORISATION","DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION",9,9
"1241","fr","en","DATE DE PREMIERE AUTORISATION/ DE RENOUVELLEMENT DE L’ AUTORISATION 29 novembre 2004","DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION 29 November 2004",11,12
"1242","fr","en","Date de renouvellement de l’ autorisation: le 18 mars 2007 ic","DATE OF REVISION OF THE TEXT lo",7,11
"1243","fr","en","DaTSCAN 74 MBq/ml, solution injectable Ioflupane (123I) 74 MBq/ml","Ioflupane (123I) 74 MBq/ ml",5,9
"1244","fr","en","DaTSCAN est administré par injection, généralement dans une veine du bras.","DaTSCAN is given to you as an injection, usually into a vein in your arm.",15,11
"1245","fr","en","de 7 jours et l’ expérience clinique au-delà de 10 jours est limitée. e","trials was 7 days and the clinical experience from treatment beyond 10 days is limited.",15,14
"1246","fr","en","De ce fait, il existe un risque élevé de cancer de la peau.","Because of this, there is an increased risk of skin cancer.",11,13
"1247","fr","en","De ce fait, l’ allaitement doit être arrêté lors de traitement par Cubicin.","Therefore, breastfeeding should be discontinued during treatment with Cubicin.",9,13
"1248","fr","en","De ce fait, l’ utilisation chez l’ enfant n’ est pas recommandée.","Therefore, use in children is not recommended.",7,12
"1249","fr","en","De ce fait, PROTELOS ne doit pas être pris pendant une grossesse.","Therefore, PROTELOS should not be taken during pregnancy.",8,12
"1250","fr","en","de contamination et d’obstruction de l’aiguille.","This helps prevent contamination, and potential needle blocks.",8,6
"1251","fr","en","de documents Beatrice FAYL Chef de secteur Services","Inspections Stephen FAIRCHILD Head of Sector Document management and publishing",10,8
"1252","fr","en","de gestion électronique des","EMEA/ MB/ 049/ 01-EN-Final Work progamme for 2002 European initiatives and activities",12,4
"1253","fr","en","DE L’ AUTORISATION DE MISE SUR LE MARCHE en","NAME OF THE MARKETING AUTHORISATION HOLDER a",7,9
"1254","fr","en","de l’information Autres dépenses d’investissement Courrier et communications Autres frais de fonctionnement","The evaluation of the EC and US legislation and GMP guidelines and compliance systems continued in 2000.",17,12
"1255","fr","en","de la maladie d’ Aujeszky, souche NIA3-783 ≥ 105.2 DICC50* par dose","Aujeszky’ s Disease Virus, strain NIA3- 783: ≥ 105.2 CCID50* per dose.",12,12
"1256","fr","en","De plus, Azomyr comprimés orodispersibles a été bien toléré dans un essai de doses multiples.","In addition, Azomyr orodispersible tablets were well tolerated in a multiple dose trial.",13,15
"1257","fr","en","De plus, certains patients peuvent vomir.","In addition some patients may experience vomiting.",7,6
"1258","fr","en","De plus, ces troubles peuvent être associés à un épisode dépressif majeur.","In addition, these conditions may be co-morbid with major depressive disorder.",11,12
"1259","fr","en","De plus, le processus de fabrication du médicament final n’ avait pas été convenablement validé.","Also, the process used for making the finished medicine had not been adequately validated.",14,15
"1260","fr","en","De plus, le risque global d’ éruptions semble être fortement lié à:","Additionally the overall risk of rash appears to be strongly associated with:",12,12
"1261","fr","en","De plus, un PGR mis à jour devra être soumis:","In addition, an updated RMP should be submitted",8,10
"1262","fr","en","De rares cas d’hypokaliémie et d’insuffisance rénale (dont certains d’évolution fatale) ont été rapportés.","There have been rare reports of hypokalaemia and renal failure (including fatalities).",12,14
"1263","fr","en","De rares cas de cardiomyopathie ont été rapportés.","Rare cases of cardiomyopathy have been reported.",7,8
"1264","fr","en","De rares cas de pancytopénie y compris d'anémie aplasique ont été rapportés avec les anti-TNF.","Rare reports of pancytopenia including aplastic anaemia have been reported with TNFantagonists.",12,15
"1265","fr","en","De rares cas de pneumopathie radique ont été rapportés chez les patients recevant une radiothérapie concomitante.","Rare cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.",13,16
"1266","fr","en","de sodium, acide chlorhydrique et eau pour préparations injectables.","hydrochloric acid and water for injections.",6,9
"1267","fr","en","De telles contributions devraient se poursuivre en 1998 et 1999.","It is anticipated that such contributions will continue in 1998-99.",10,10
"1268","fr","en","De telles réactions ont particulièrement été rapportées chez les patients âgés et chez les patients traités par corticostéroïdes.","Such reactions have particularly been noted in older patients and those on corticosteroids.",13,18
"1269","fr","en","De tels facteurs pourraient contribuer à l’ observation de la moyenne d’ exposition plus élevée chez les adolescents.","Such factors possibly contribute to the higher average exposure observed in adolescents.",12,18
"1270","fr","en","de Valeur de base","Summary of outcome in Trial 4",6,4
"1271","fr","en","Déconnecter la seringue du dispositif de reconstitution.","Disconnect the syringe from the reconstitution spike.",7,7
"1272","fr","en","Degré de l'hémorragie / type d'intervention chirurgicale Hémorragie","Degree of haemorrhage/type of surgical procedure Haemorrhage",7,8
"1273","fr","en","Délai médian jusqu’ à événement (jours) (IC95%)","Median Time to Event (Days)",5,7
"1274","fr","en","Délais de réponse 43 RC+RP (jours) a","Days (months) Time to response",5,7
"1275","fr","en","Demander au patient de bien agiter le flacon avant utilisation.","Instruct patients to shake the bottle well before use.",9,10
"1276","fr","en","Demander conseil à votre vétérinaire comment éliminer les médicaments non utilisés.","Ask your veterinary surgeon how to dispose of medicines no longer required.",12,11
"1277","fr","en","Demandes d’informations Services internes","Requests for information • Internal services",6,4
"1278","fr","en","Demandez à votre médecin ou votre pharmacien plus d'informations sur les effets indésirables.","Ask your doctor or pharmacist for more information about side effects.",11,13
"1279","fr","en","Demandez à votre pharmacien ce qu'il faut faire des médicaments inutilisés.","Ask your pharmacist how to dispose of medicines no longer required.",11,11
"1280","fr","en","Demandez à votre pharmacien comment manipuler les patchs qui ne sont pas utilisés.","Ask your pharmacist how to dispose of any patches no longer required.",12,13
"1281","fr","en","Demandez conseil à votre médecin avant de prendre tout médicament si vous êtes enceinte ou allaitez.","Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.",15,16
"1282","fr","en","Demandez conseil à votre médecin ou à votre pharmacien avant de prendre tout médicament.","Ask your doctor or pharmacist for advice before taking any medicine.",11,14
"1283","fr","en","Demandez conseil à votre médecin.","Ask your doctor for advice.",5,5
"1284","fr","en","Demandez immédiatement de l’ aide si vous souffrez de l’ un des effets indésirables mentionnés ci- dessous.","You should seek help immediately if you suffer from any of the below mentioned side effects.",16,17
"1285","fr","en","Demandez-vous quel poids vous souhaitez perdre puis fixez vous un objectif de perte de poids.","Think about how much weight you want to lose and then set a target weight.",15,15
"1286","fr","en","Démence associée à la maladie de Parkinson Population ITT + RDO","Dementia associated with Parkinson’ s Disease",6,11
"1287","fr","en","Dénomination commune internationale (DCI): cytarabine","International Non-proprietary Name (INN): cytarabine",5,5
"1288","fr","en","Dénomination commune internationale (DCI): moxifloxacine","International non-proprietary name (INN): moxifloxacin",5,5
"1289","fr","en","DÉNOMINATION DU MÉDICAMENT ADARTREL 0,25 mg, comprimés pelliculés Ropinirole","ADARTREL 0.25 mg film-coated tablets Ropinirole",6,9
"1290","fr","en","DENOMINATION DU MEDICAMENT ET VOIE D’ ADMINISTRATION","NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION",9,7
"1291","fr","en","DÉNOMINATION DU MÉDICAMENT ET VOIE(S) D' ADMINISTRATION","NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION",9,7
"1292","fr","en","DENOMINATION DU MEDICAMENT Olanzapine Teva 2,5 mg, comprimés pelliculés.","Olanzapine Teva 2.5 mg film-coated tablets",6,9
"1293","fr","en","DENOMINATION DU MEDICAMENT tn","Nespo 150 µg injection ro",5,4
"1294","fr","en","DENOMINATION DU MEDICAMENT VETERINAIRE","NAME OF THE VETERINARY MEDICINAL PRODUCT",6,4
"1295","fr","en","Département européen pour la qualité des médicaments (EDQM)/ Pharmacopée européenne","European Department for the Quality of Medicines/ European Pharmacopoeia",9,10
"1296","fr","en","DepoCyte aide à contrôler les symptomes de la maladie.","DepoCyte helps control the symptoms of the disease.",8,9
"1297","fr","en","dépourvu de tout effet sédatif ou cognitif.","d any significant cognitive or sedative effect.",7,7
"1298","fr","en","Dermapharm GmbH Lochhamer Schlag 10 D-82166 Gräfelfing","Dermapharm GmbH Arzneimittel Lochhamer Schlag 10 D-82166 Gräfelfing",8,7
"1299","fr","en","Dermatite exfoliative, œ dème angioneurotique","Exfoliative dermatitis, angioneurotic oedema",4,5
"1300","fr","en","Dernière mise à jour du présent résumé 02-2008.","This summary was last updated in 02-2008.",7,8
"1301","fr","en","Dernière mise à jour du présent résumé:","This summary was last updated in May 2008.",8,7
"1302","fr","en","Dernière mise à jour du présent résumé: décembre 2005.","This summary was last updated in 12-2005",7,9
"1303","fr","en","Des analyses peuvent également montrer:","Tests may also show:",4,5
"1304","fr","en","Des angioedèmes sont survenus durant le traitement par Riprazo.","Angioedema has occurred during treatment with Riprazo.",7,9
"1305","fr","en","Des anomalies congénitales ont été rapportées dans 14,5% des grossesses exposées.","Congenital anomalies were reported in 14.5% of exposed pregnancies.",9,11
"1306","fr","en","des autres composants contenus dans MIRCERA (voir paragraphe 6)","other ingredients of MIRCERA (see section 6)",7,9
"1307","fr","en","Des calculs rénaux ont été signalés, ainsi que les douleurs et hypertrophies rénales associées.","Kidney stones have been reported, as well as associated pain and kidney swelling.",13,14
"1308","fr","en","Des cas d'hypopigmentation et d'hyperpigmentation localisées ont été rapportés après utilisation de la crème imiquimod.","Reports have been received of localised hypopigmentation and hyperpigmentation following imiquimod cream use.",13,15
"1309","fr","en","Des cas d’ érections prolongées parfois douloureuses ont été rapportés après la prise de VIAGRA.","Prolonged and sometimes painful erections have been reported after taking VIAGRA.",11,15
"1310","fr","en","Des cas d’ événements hépatobiliaires, dont certains d’ issue fatale, ont été rapportés.","Cases of hepatobiliary events, some with fatal outcome, have been reported.",11,13
"1311","fr","en","Des cas d’ hémorragie rectale ont été rapportés chez des patients prenant l’ orlistat.","Cases of rectal bleeding have been reported in patients taking orlistat.",11,14
"1312","fr","en","Des cas d’ insuffisance rénale aiguë ont été observés chez des patients sévères traités par VFEND.","Caution should be used in prescribing VFEND to patients with hypersensitivity to other azoles (see also section 4.8).",18,16
"1313","fr","en","Des cas de diabète et de pneumonie ont été rarement rapportés.","Diabetes and pneumonia have been reported rarely.",7,11
"1314","fr","en","Des cas de diarrhée, parfois sévère, ont été rapportés sous traitement par lapatinib (voir rubrique 4.8).","Diarrhoea, including severe diarrhoea, has been reported with lapatinib treatment (see section 4.8).",13,16
"1315","fr","en","Des cas plus rares de peau morte et tissu mort autour du site d’injection (nécrose) ont été signalés.","Dead skin and tissue around the injection site (necrosis) are reported less frequently.",13,18
"1316","fr","en","Des combinaisons de mutations ont été observées chez 9 des 12 patients étudiés.","Combinations of mutations were found in nine of the 12 patients observed.",12,13
"1317","fr","en","Des comptes rendus actualisés sur le recrutement et l’ avancement des travaux seront fournis conjointement aux PSUR standard.","Progress and recruitment updates will be provided alongside the standard PSURs.",11,18
"1318","fr","en","Des conditionnements de 1, 3, 4, 5, 6, 8, 9 et 10 cartouches sont disponibles.","Packs of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges are available.",14,15
"1319","fr","en","Des conditionnements de 56x1 comprimés présentés en plaquettes thermoformées unitaires sont également disponibles pour les hôpitaux.","Unit dose blister packs of 56 x 1 tablets for delivery in hospitals are also available.",16,16
"1320","fr","en","Des conditions aseptiques (assurant propreté et absence de germes) sont nécessaires pendant la reconstitution et l’ administration.","Aseptic conditions (meaning clean and germ free) are required during reconstitution and administration.",13,17
"1321","fr","en","Des convulsions ont été rapportées chez des patients traités par Aranesp.","Convulsions have been reported in patients receiving Aranesp.",8,11
"1322","fr","en","Des cycles de traitements ultérieurs TRACTOCILE peuvent être utilisés si les contractions recommencent.","Further treatment cycles of TRACTOCILE can be used should contractions recur.",11,13
"1323","fr","en","Des différences pharmacocinétiques dues à l’ origine ethnique n’ ont pas été identifiées.","Pharmacokinetic differences due to race have not been identified.",9,13
"1324","fr","en","des difficultés de déglutition ou de respiration (œdème de Quincke) • Difficultés respiratoires (dyspnées) éd","th • Shortness of breath (dyspnoea) • Skin rash",9,15
"1325","fr","en","Des diminutions significatives moyennes du score DAS28 par rapport à la","The proportion of patients achieving a DAS28 clinical remission (DAS28 < 2.6) was significantly higher in patients receiving",18,11
"1326","fr","en","Des discussions préliminaires on débuté en 1996 pour rédiger des propositions de lignes directrices sur les sujets suivants:","Preliminary discussions have begun on drafting guidelines for the following topics in 1996:",13,18
"1327","fr","en","Des données complémentaires liées à cette problématique sont attendues.","Further data addressing this issue are currently awaited.",8,9
"1328","fr","en","Des données concernant la vitesse de croissance avant le traitement étaient disponibles pour 59 patients.","Pre- treatment height velocity data were available for 59 subjects.",10,15
"1329","fr","en","Des données limitées sur 169 prématurés indiquent qu’ Infanrix hexa peut leur être administré.","Limited data in 169 premature infants indicate that Infanrix hexa can be given to premature children.",16,14
"1330","fr","en","Des données longitudinales seront ensuite collectées sur la cohorte de patients pendant 2 ans.","Longitudinal data will then be gathered on the patient cohort over a 2-year period.",14,14
"1331","fr","en","Des données suggèrent qu’ une instillation le soir pourrait avoir quelques avantages sur la baisse moyenne de PIO.","Existing data suggest that evening dosing might have some advantages in the mean IOP reduction.",15,18
"1332","fr","en","des doses (heures) / durée du traitement (jours)","Frequency of doses (hours)/duration of therapy (days)",7,8
"1333","fr","en","Des doses élevées de kétoconazole et d'itraconazole (> 200 mg/ jour) ne sont pas recommandées.","itraconazole (> 200 mg/ day) are not recommended.",8,15
"1334","fr","en","Des échantillons pour le dosage des anticorps anti-IgG seront recueillis à intervalles précis.","Samples for IgG antibody will be collected at specific intervals.",10,13
"1335","fr","en","Des effets cardiovasculaires et des anomalies hématologiques ont été observés chez certaines espèces.","Cardiovascular effects and haematological changes were observed in some species.",10,13
"1336","fr","en","Des effets indésirables de grade 3 ou 4 sont prévisibles chez environ 40% des patients.","Around 40% of patients are expected to have adverse reactions of grade 3 or 4 severity.",16,15
"1337","fr","en","Des effets indésirables dose-dépendants sont probables.","Dose- dependent side effects are likely to occur.",8,6
"1338","fr","en","Des effets plus importants sont attendus lorsque le propionate de fluticasone est inhalé.","Greater effects may be expected when fluticasone propionate is inhaled.",10,13
"1339","fr","en","Des effets sévères peuvent apparaître, y compris des réactions allergiques et anaphylactiques.","Severe effects may occur, including allergic and anaphylactic reactions.",9,12
"1340","fr","en","Des effets sur l'ossification sternale ont été observés à 1,5 et 3,0 mg/ kg/ jour.","Effects on sternal ossification were seen at 1.5 and 3.0 mg/ kg/ day.",13,15
"1341","fr","en","Des effets thrombo-emboliques veineux ont rarement été rapportés.","Vascular disorders Venous thromboembolic events have rarely been reported.",9,8
"1342","fr","en","Des élévations de l’ ALAT sont survenues rarement et en général ont disparu à l’ arrêt du traitement.","Elevations of ALT occurred rarely and usually resolved upon discontinuation of therapy.",12,18
"1343","fr","en","Des éruptions cutanées érythémateuses ou maculopapuleuses, avec ou sans prurit, peuvent survenir pendant le traitement.","Rash / cutaneous reactions: erythematous or maculopapular cutaneous eruptions, with or without pruritus, may occur during therapy.",17,15
"1344","fr","en","Des études chez le rat montrent que le lisinopril traverse peu la barrière hémato-encéphalique.","Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly.",11,14
"1345","fr","en","Des études chez les rates allaitantes ont montré que la stavudine était excrétée dans le lait.","Studies in lactating rats showed that stavudine is excreted in breast milk.",12,16
"1346","fr","en","Des études de toxicité à doses répétées de voriconazole ont montré que le foie est l’ organe cible.","General pharmacokinetic characteristics The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients.",17,18
"1347","fr","en","Des études effectuées chez l’ animal font penser que la varénicline est excrétée dans le lait maternel.","Animal studies suggest that varenicline is excreted in breast milk.",10,17
"1348","fr","en","Des études effectuées chez l’ animal ont mis en évidence une toxicité sur la reproduction (voir rubrique 5.3).","Studies in animals have shown reproductive toxicity (see section 5.3).",10,18
"1349","fr","en","Des études in vitro n'ont montré aucune inhibition d'un sous- type du cytochrome P450.","In vitro studies have shown no inhibition of any subtype of cytochrome P450.",13,14
"1350","fr","en","Des études pharmacocinétiques ont été effectuées après l'administration intraveineuse du produit.","Pharmacokinetic studies were performed after the intravenous administration of the product.",11,11
"1351","fr","en","Des évaluations de tolérance à long terme sont en cours.","Long-term safety evaluations are ongoing.",5,10
"1352","fr","en","Des évanouissements, parfois accompagnés de tremblements ou raideurs importantes, ont été rapportés.","Fainting, sometimes accompanied by shaking or stiffening, has been reported.",10,12
"1353","fr","en","Des gants, des lunettes et des vêtements de protection doivent être utilisés.","Gloves, goggles and protective clothing should be used.",8,12
"1354","fr","en","Des idées et des comportements suicidaires ont été rapportés pendant le traitement par aripiprazole.","Suicidal thoughts and behaviours have been reported during aripiprazole treatment.",10,14
"1355","fr","en","Des informations détaillées sur ce médicament sont disponibles sur le site internet de l’ Agence 'e","Detailed information on this medicinal product is available on the website of the European Medicines ed",16,16
"1356","fr","en","Des informations sur les modalités de prescription de ce produit sont disponibles sur l’ étiquette/ l’ emballage.","Information on the prescription status of this product may be found on the label/ outer package.",16,17
"1357","fr","en","Des interactions significatives sur le plan clinique impliquant le cytochrome CYP2C9 paraissent donc improbables.","Therefore, clinically relevant interactions involving cytochrome CYP2C9 appear unlikely.",9,14
"1358","fr","en","Des interférences avec l’ évaluation des niveaux de glucose sanguins sont peu probables.","Interferences with determination of blood glucose levels are not expected.",10,13
"1359","fr","en","Dès lors, les inhibiteurs de ces enzymes peuvent augmenter l’ exposition à la darifénacine.","Therefore, inhibitors of these enzymes may increase darifenacin exposure.",9,14
"1360","fr","en","Des mesures appropriées de désinfection doivent être prises après l'utilisation de ce vaccin bactérien vivant.","Appropriate disinfection procedures should be used following use of this live bacterial vaccine.",13,15
"1361","fr","en","Des mises à jour annuelles devront être fournies au moment des Réévaluations Annuelles.","Annual updates will be provided at the time of the annual reassessments.",12,13
"1362","fr","en","Des nausées, vomissements, diarrhées et dyspnée ont été signalés en association avec l’ inhalation de Ventavis.","Vomiting, nausea, diarrhoea and dyspnoea have been reported in association with Ventavis inhalation.",13,16
"1363","fr","en","Des observations similaires sont attendues avec la dose approuvée de","Similar findings are expected with the approved darunavir/ ritonavir",9,10
"1364","fr","en","Des œ dèmes périphériques ont été observés avec les AREs, y compris avec l’ ambrisentan.","Peripheral oedema has been observed with ERAs including ambrisentan.",9,15
"1365","fr","en","Des papules ont pu été observées plus rarement (chez moins de 1% des chiens traités).","Papules were observed uncommonly (less than 1% of treated dogs).",10,15
"1366","fr","en","Des précautions particulières seront prises chez les femmes présentant une allergie active ou ayant un terrain allergique connu.","Special care should be taken in women with an active allergic condition or a known history of allergy.",18,18
"1367","fr","en","Des réactions cutanées d’ hypersensibilité ont été observées.","Cutaneous hypersensitivity reactions have been reported.",6,8
"1368","fr","en","Des réactions d’ hypersensibilité incluant rash, urticaire, angio-oedème et réactions anaphylactiques ont été rarement rapportées.","Hypersensitivity reactions including rash, urticaria, angioedema and anaphylactic reactions have been reported rarely.",13,15
"1369","fr","en","Des réactions de photosensibilité ont été signalées, en particulier lors des traitements à long-terme (voir aussi rubrique 4.4).","Sinusitis Anaphylactoid reaction, hypersensitivity",4,18
"1370","fr","en","Des récepteurs à l’ érythropoïétine seraient exprimés à la surface de différents types de cellules","Two of the studies recruited patients who were being treated with chemotherapy.",12,15
"1371","fr","en","Des récepteurs à l’ érythropoïétine seraient exprimés à la surface de différents types de cellules tumorales.","is receptors may be expressed on the surface of a variety of tumour cells.",14,16
"1372","fr","en","Des récepteurs de l’ érythropoïétine peuvent également être présents à la surface de certaines cellules tumorales.","Erythropoietin receptors may be expressed on the surface of a variety of tumour cells.",14,16
"1373","fr","en","Des résultats complémentaires d'efficacité sont présentés dans le Tableau 5.","Further efficacy results are reported in Table 5.",8,10
"1374","fr","en","Des résultats similaires ont été observés dans les deux autres études à court terme.","Similar results were seen in the other two short- term studies.",11,14
"1375","fr","en","Des surdosages allant jusqu’ à 19,2 MBq/ kg de [90Y]-Zevalin se sont produits au cours des essais cliniques.","Overdose as high as 19.2 MBq/ kg of [90Y]-radiolabelled Zevalin occurred in clinical trials.",14,18
"1376","fr","en","Des traitements alternatifs faiblement inducteurs du CYP3A4 doivent être envisagés chaque fois que possible.","Alternate treatments lacking potent CYP3A4 inducing activity should be considered when possible.",12,14
"1377","fr","en","Des traitements répétés par MabThera sont possibles.","Repeated courses of treatment with MabThera are possible.",8,7
"1378","fr","en","Désinfecter le bouchon en caoutchouc du dispositif avec de l'alcool.","Disinfect the rubber seal of the device with alcohol.",9,10
"1379","fr","en","Désinfectez la peau à l’aide d’un désinfectant approprié.","For skin disinfection use an appropriate disinfectant.",7,8
"1380","fr","en","Desquamation, sécheresse cutanée Tuméfaction, inflammation Sensation de picotements, fourmillements Saignement Décoloration de la peau Ulcère cutané","Flaking, peeling, dry skin Swelling, inflammation Stinging, tingling Bleeding Skin discoloration Skin ulcer",13,16
"1381","fr","en","détresse respiratoire, dyspnée, toux","respiratory distress, dyspnoea, cough",4,4
"1382","fr","en","Deutschland Astellas Pharma GmbH Georg-Brauchle-Ring 64 – 66 D-80992 München Tel: + 49 (0)89 454401","Deutschland Astellas Pharma GmbH Georg-Brauchle-Ring 64 – 66 D-80992 München Tel: + 49 (0)89 454401",15,15
"1383","fr","en","Deutschland BioPartners GmbH Eisenstrasse 3 D-65428 Rüsselsheim Tel: +49 (0) 6142 70 8000","Deutschland BioPartners GmbH Eisenstrasse 3 D-65428 Rüsselsheim Tel: + 49(0) 6142 70 8000",13,13
"1384","fr","en","Deutschland GlaxoSmithKline GmbH & Co.","Deutschland GlaxoSmithKline GmbH & Co.",5,5
"1385","fr","en","Deutschland MEDA Pharma GmbH & Co.","Deutschland MEDA Pharma GmbH & Co.",6,6
"1386","fr","en","Deutschland Pfizer GmbH, Tel: +49 30 550 055 01","Deutschland Pfizer GmbH, Tel: +49 (0) 30 5500 5501",9,9
"1387","fr","en","Deutschland Takeda Pharma GmbH Tel. + 49 (0) 241 941-0","Deutschland Takeda Pharma GmbH Tel. + 49 (0) 241 941-0",10,10
"1388","fr","en","Deux études ont été réalisées afin d'évaluer l'efficacité et la tolérance de Januvia en monothérapie.","Two studies were conducted to evaluate the efficacy and safety of Januvia monotherapy.",13,15
"1389","fr","en","Deux inhalations deux fois par jour","This medicine if not recommended",5,6
"1390","fr","en","Deux isoformes, la COX-1 et la COX-2 ont été identifiées.","Two isoforms, COX-1 and COX-2, have been identified.",8,10
"1391","fr","en","Deuxième et troisième trimestres de la grossesse (voir rubriques 4.4 et 4.6).","Second and third trimester of pregnancy (see sections 4.4 and 4.6).",11,12
"1392","fr","en","Dévisser la seringue de l’ adaptateur.","Unscrew the syringe from the vial access device.",8,6
"1393","fr","en","Dévissez complètement l’aiguille en tournant dans le sens contraire des aiguilles d’une montre, comme am","ge Completely unscrew the injection needle assembly using an anti-clockwise turning motion as shown in Diagram R.",17,15
"1394","fr","en","Dévissez l'aiguille protégée par son capuchon, puis jetez-la conformément","Insert needle into skin using injection technique recommended by your healthcare professional.",12,9
"1395","fr","en","Diabète, Troubles du métabolisme et de la nutrition","Metabolism and nutrition disorders",4,8
"1396","fr","en","Diacomit est un médicament qui contient le principe actif stiripentol.","Diacomit is a medicine that contains the active substance stiripentol.",10,10
"1397","fr","en","Diagnostic L'acidose lactique est caractérisée par une dyspnée acidosique, des douleurs abdominales, et une hypothermie suivie d'un coma.","Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain and hypothermia followed by coma.",14,18
"1398","fr","en","Diarrhée Reflux gastro-intestinal Douleur abdominale Constipation Atteintes cutanées et sous-cutanées","Diarrhoea Gastrointestinal reflux disease Abdominal pain Constipation Skin and subcutaneous tissue disorders",12,10
"1399","fr","en","Dicural comprimés enrobés doit être utilisé seulement après vérification de la sensibilité des souches.","Dicural Coated Tablets should only be used based on susceptibility testing.",11,14
"1400","fr","en","diffusé pour consultation en mars 2001 diffusé pour consultation en septembre 2001","Released for consultation September 2001",5,12
"1401","fr","en","Digoxine 0,4 mg en dose 600/100 deux fois par Digoxine","Digoxin 0.4 mg single dose 600/100 b.i.d.",7,10
"1402","fr","en","Diminution de TMZ d’ un niveau de dosea","See footnote b See footnote b",6,8
"1403","fr","en","Diminution du taux de prothrombine et augmentation de l’ INR (voir rubriques 4.3 et 4.5)","Decreased prothrombin and increased INR (see sections 4.3 and 4.5)",10,15
"1404","fr","en","Dioxyde de titane (E171) Gélatine","Titanium dioxide (E171) Gelatin",4,5
"1405","fr","en","Diplôme de chimiste et de pharmacienne de l'université libre de Berlin.","Qualified chemist and pharmacist from the Free University of Berlin.",10,11
"1406","fr","en","Diplôme de pharmacien de l’université libre de Bruxelles.","Qualified Pharmacist from the Free University of Brussels.",8,8
"1407","fr","en","Diplôme en sciences vétérinaires de l’université de Milan.","Veterinary medicine degree from the University of Milan.",8,8
"1408","fr","en","Discutez avec votre médecin, infirmière ou pharmacien si vous avez un doute.","Discuss with your doctor, nurse or pharmacist if you are unsure about anything.",13,12
"1409","fr","en","Disposer la barquette sur la surface de travail.","Lay the tray down on it.",6,8
"1410","fr","en","Distribution Acide nicotinique La fixation de l’ acide nicotinique aux protéines plasmatiques est de moins de 20%.","Distribution Nicotinic acid Nicotinic acid is less than 20% bound to serum proteins.",13,17
"1411","fr","en","Distribution L’ aprépitant se lie fortement aux protéines, avec une moyenne de 97%.","Distribution Aprepitant is highly protein bound, with a mean of 97%.",11,13
"1412","fr","en","Distribution Le zaleplon est lipophile avec un volume de distribution d'environ 1,4±0,3 l/ kg après administration intraveineuse.","Distribution Zaleplon is lipophilic with a volume of distribution of about 1.4±0.3 l/ kg following intravenous administration.",17,17
"1413","fr","en","Dix-huit patients ont participé à l’ étude jusqu’ à son terme.","Eighteen patients completed the study.",5,11
"1414","fr","en","DMO lombaire – évolution moyenne entre le début de l’ étude et la 3ème année","BMD – mean change relative to baseline total hip at year 3",12,15
"1415","fr","en","docétaxel toutes les 3 docétaxel toutes les semaines semaines","Docetaxel every Docetaxel every 3 weeks week",7,9
"1416","fr","en","Doctorat en santé publique de l'université de Bordeaux.","PhD in public health from the University of Bordeaux.",9,8
"1417","fr","en","dodécahydraté, le phosphate monosodique dihydraté et l’eau pour préparations injectables.","dihydrogen phosphate dihydrate and water for injections.",7,10
"1418","fr","en","doivent être faites selon les schémas de vaccination recommandés.","given as in the recommended immunisation schedule.",7,9
"1419","fr","en","doivent être utilisés avec précaution avec l'atazanavir/ ritona","REYATAZ/ ritonavir is co-administered with",5,8
"1420","fr","en","Dolovet vet 2,4 g poudre orale","Dolovet vet 2.4 g oral powder.",6,6
"1421","fr","en","Données post - commercialisation: insuffisance hépatique, hépatite, anomalies des tests de la fonction hépatique","Post-marketing experience: hepatic failure, hepatitis, liver function test abnormal",9,14
"1422","fr","en","Doribax doit être utilisé avec prudence chez les patients présentant de tels antécédents.","Doribax should be used with caution in patients with such a history.",12,13
"1423","fr","en","dorsales, douleurs thoraciques, par ex.) Arthralgie Dysfonctionn","Musculoskeletal pain (e.g. extremity pain, back pain, chest pain) Arthralgia",10,7
"1424","fr","en","Dosage 100 Unités/ ml","Strength 100 Units/ ml 100 Units/ ml 100 Units/ ml 100 Units/ ml 100 Units/ ml",16,4
"1425","fr","en","dose d’ atazanavir et de ritonavir respectivement à 400 mg et à","Co-administration of efavirenz with atazanavir/ ritonavir is not recommended.",9,12
"1426","fr","en","Dose d’ entretien compris entre 17 et 33 UI/ kg, 3 fois par semaine, par voie intraveineuse.","Maintenance dose between 17 and 33 IU/ kg 3 times per week by the intravenous route.",16,17
"1427","fr","en","Dose de cisplatine (mg/ m²)","Dose for cisplatin (mg/ m2)",5,5
"1428","fr","en","dose recommandée est de 6 mg/ kg administrée une fois toutes les 24 heures.","recommended dose is 6 mg/ kg administered once every 24 hours.",11,14
"1429","fr","en","Douleur abdominale Diarrhée Constipation Nausée","Skin and subcutaneous tissue disorders",5,5
"1430","fr","en","Douleurs dorsales, douleurs de la nuque, douleurs dans les extrémités, rigidité musculo-squelettique","Back pain, neck pain, pain in extremity, musculoskeletal stiffness",9,12
"1431","fr","en","Down, BT35 6JP Northern Ireland","Down, BT35 6JP United Kingdom",5,5
"1432","fr","en","Dr Alexander JENTZSCH Ministerialrat Bundesministerium für Arbeit, Gesundheit und Soziales Stubenring 1 A-1010 Wien Tel: +43.1.71172-4673 Fax: +43.1.714.9222","Dr Alexander JENTZSCH Ministerialrat Bundesministerium für Arbeit, Gesundheit und Soziales Stubenring 1 A-1010 Vienna Tel: +43.1.71172.4673 Fax: +43.1.714.9222",18,18
"1433","fr","en","Du fait du nt","Due to the lack of data in children with severe progression of the disease, and i",16,4
"1434","fr","en","Duchnicka 3 PL-01-796 Warszawa Tel.: +48 22 663 43 10","Duchnicka 3 PL-01-796 Warszawa Tel.: +48 22 663 43 10",10,10
"1435","fr","en","Duloxetine Boehringer Ingelheim peut être pris au moment ou en dehors des repas.","Duloxetine Boehringer Ingelheim can be taken with or without food.",10,13
"1436","fr","en","Durant 1996, l’utilisation des technologies de l’information existantes a été optimisée pour parvenir au meilleur fonctionnement possible.","During 1996 the use of existing information technology systems was consolidated and optimised for best possible operation.",17,17
"1437","fr","en","Durant le stockage, un dépôt blanc avec un surnageant limpide peut être observé pour le composant","Upon storage, a white deposit and clear supernatant may be observed for the DTPw-HBV component.",15,16
"1438","fr","en","Durascan Medical Products AS Svendborgvej 243 DK-5260 Odense S","Durascan Medical Products AS Svendborgvej 243 DK-5260 Odense S",9,9
"1439","fr","en","Durée de conservation après ouverture du récipient:","Shelf-life after first use of the product:",7,7
"1440","fr","en","Durée de conservation après première ouverture du conditionnement:","Shelf-life after first opening the container:",6,8
"1441","fr","en","Durée de conservation du médicament vétérinaire tel que conditionné pour la vente:","Shelf life of the product as packaged for sale:",9,12
"1442","fr","en","Durée du traitement Un nombre limité de patients (50 patients) a reçu une seconde perfusion pour hypercalcémie.","Duration of treatment A limited number of patients (50 patients) have received a second infusion for hypercalcaemia.",17,17
"1443","fr","en","Durk Stellingwerf Tel: +31 35 6993 372 Fax: +31 35 6993380 Email: stellid@fdah. com","Durk Stellingwerf Tel: +31 35 6993 372 Fax: +31 35 6993380 Email: stellid@fdah. com",14,14
"1444","fr","en","Dynastat doit être administré dans les 24 heures suivant sa reconstitution (voir rubrique 6.3.) sinon il sera jeté.","Dynastat should be administered within 24 hours of reconstitution (see section 6.3), or discarded.",14,18
"1445","fr","en","Dynepo 4000 UI/ 0,4ml","Dynepo 4,000 IU/ 0.4ml Injection Epoetin delta",7,4
"1446","fr","en","Dysgueusie Somnolence Léthargie Céphalée Tremblement Sédation","Dysgeusia Somnolence Lethargy Headache Tremor Sedation",6,6
"1447","fr","en","Dysphagie Chéilite Saignement gingival Hémorroïdes Proctalgie Aphte buccal Gêne gastrique Hémorragie rectale Erythrodysesthésie","Dysphagia Cheilitis Gingival bleeding Haemorrhoids Proctalgia Mouth ulceration Stomach discomfort Rectal haemorrhage Palmar-plantar erythrodysaesthesia syndrome",15,13
"1448","fr","en","Dyspnée, Epistaxis, Toux, Rhinorrhée","Dyspnoea, Epistaxis, Cough, Rhinorrhea",4,4
"1449","fr","en","é Alignez la ligne bleue se trouvant sur la partie","ut with one hand, turn the top counter-clockwise as far as it will go.",14,10
"1450","fr","en","é Chaque flacon de 1ml contient 25 microgrammes de darbepoetin alfa.","Each 1 ml vial 25 micrograms darbepoetin alfa.",8,11
"1451","fr","en","é Dompé Biotec S. p. A.","or Dompé Biotec S. p. A.",6,6
"1452","fr","en","é L’ élimination du fondaparinux est essentiellement rénale.","Fondaparinux is known to be mainly excreted by the kidney. lP",11,8
"1453","fr","en","é Le titulaire de l'autorisation de mise sur le marché est Pfizer Limited, Ramsgate Road, Sandwich, Kent","The marketing authorisation holder is Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom.",15,17
"1454","fr","en","é ris Principe(s) actif(s) Glycoprotéine E2 du virus de la peste porcine classique (PPC), minimum 32µg","au E2 glycoprotein of Classical Swine Fever (CSF) virus minimum 32 µg",12,16
"1455","fr","en","E-post: btjeu-pub@btj.se URL: http://www.btj.se","Guidelines/Status Conduct of pharmacokinetic studies in animals Adopted March 2000",10,4
"1456","fr","en","e) Effet sur les fonctions cognitives","e) Effects on cognitive function",5,6
"1457","fr","en","Easotic, suspension pour instillation auriculaire, pour chien","Easotic, ear drops suspension for dogs",6,7
"1458","fr","en","Eau pour préparations injectables Alcool benzylique","Water for Injections Benzyl alcohol",5,6
"1459","fr","en","Eau purifiée Acide malique pour l’ ajustement du pH Hydroxyde de sodium pour l’ ajustement du pH","Purified water Malic acid for pH adjustment Sodium Hydroxide for pH adjustment",12,17
"1460","fr","en","Ebixa 10 mg/ g solution buvable en gouttes.","Ebixa 10 mg/ g oral drops, solution.",7,8
"1461","fr","en","ECALTA 100 mg poudre et solvant pour solution à diluer pour perfusion","ECALTA 100 mg powder and solvent for concentrate for solution for infusion Anidulafungin",13,12
"1462","fr","en","échographie en mode B des cavités cardiaques, au repos ou de stress:","B-mode imaging of cardiac chambers, at rest or with stress:",10,12
"1463","fr","en","Econor 0,5% Prémélange médicamenteux pour porcs.","Econor 0.5% premix for medicated feed for pigs",8,6
"1464","fr","en","Econor 50% Prémélange médicamenteux pour porcs.","Econor 50% premix for medicated feed for pigs",8,6
"1465","fr","en","Eesti filiaal Tel: +3726441100","Eesti filiaal Tel: +372 6441100",5,4
"1466","fr","en","Eesti GE Healthcare Estonia OÜ Mustamäe tee 46 EE – 10621 Tallinn Tel: + 372 6260 061","Eesti Österreich GE Healthcare Estonia OÜ Mustamäe tee 46 EE – 10621 Tallinn Tel: + 372 6260 061",18,17
"1467","fr","en","Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk .com","Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk. com",10,10
"1468","fr","en","Eesti Norge Pfizer Animal Health Tel: +370 5 269 17 96","Eesti Pfizer Animal Health Tel: +370 5 269 17 96",10,11
"1469","fr","en","Eesti Österreich Cephalon Sp. zo. o.","Eesti Cephalon Sp. zo. o.",5,6
"1470","fr","en","Eesti Österreich Novartis Pharma GmbH Novartis Pharma Services Inc.","Eesti Österreich Novartis Pharma Services Inc.",6,9
"1471","fr","en","Eesti Österreich Roche Eesti OÜ Tel: + 372 - 6 177 380","Eesti Roche Eesti OÜ Tel: + 372 - 6 177 380",11,12
"1472","fr","en","Eesti Portugal Alcon Eesti + 372 6 313 214","Eesti Alcon Eesti + 372 6 313 214",8,9
"1473","fr","en","Eesti UAB Bayer Eesti filiaal Tel. +372 6 55 85 65","Eesti UAB Bayer Eesti filiaal Tel. +372 6 55 85 65",11,11
"1474","fr","en","Efavirenz (inducteur du CYP450; inhibiteur et substrat du CYP3A4):","Efavirenz (CYP450 inducer; CYP3A4 inhibitor and substrate):",7,9
"1475","fr","en","Efexor 126, Kyprou & 25th Martiou str., 164 52 Argyroupolis-Athens, Greece","Efexor 126, Kyprou & 25th Martiou str., 164 52 Argyroupolis-Athens, Greece",11,11
"1476","fr","en","Efexor doit être pris au cours d’ un repas.","Efexor should be taken with food.",6,9
"1477","fr","en","Effectuez l'injection suivante le jour normal prévu.","Take your next injection on the regularly scheduled day.",9,7
"1478","fr","en","Effectuez toujours un test de sécurité avant chaque injection.","Always perform the safety test before each injection.",8,9
"1479","fr","en","Effectuez un test de sécurité.","Perform the safety test.",4,5
"1480","fr","en","Effentora est un médicament contenant le principe actif fentanyl.","Effentora is a medicine containing the active substance fentanyl.",9,9
"1481","fr","en","Effet sur la croissance tumorale ic","ed Effect on tumour growth",5,6
"1482","fr","en","Effets d’ autres médicaments sur la pharmacocinétique de l’ étoricoxib","Effects of other drugs on the pharmacokinetics of etoricoxib",9,10
"1483","fr","en","Effets de l’ âge, du poids corporel et de la surface corporelle","Effects of age, body weight, and body surface area",9,12
"1484","fr","en","Effets de la ranolazine sur d’ autres médicaments","Effects of ranolazine on other medicinal products",7,8
"1485","fr","en","Effets des aliments La biodisponibilité du nilotinib est augmentée par la prise alimentaire.","Food effect The bioavailability of nilotinib is increased by food.",10,13
"1486","fr","en","Effets indésirables au point d'injection:","Injection site side effects:",4,5
"1487","fr","en","Effets indésirables Augmentation de la créatine phosphokinase","Table 1 Undesirable Effects in Clinical Studies",7,7
"1488","fr","en","Effets indésirables fréquents (Peuvent affecter jusqu’à 10 patients sur 100)","Common side effects (These can affect up to 10 in every 100 patients)",13,10
"1489","fr","en","Effets indésirables lors des essais cliniques contrôlés versus placebo","Undesirable Effects in Placebo-Controlled Trials",5,9
"1490","fr","en","Effets indésirables peu fréquemment rapportés","Side effects reported uncommonly",4,5
"1491","fr","en","Effets indésirables Pharyngite*, infection virale* Bronchite, sinusite, herpes simplex (résistance), rhinite Infection bactérienne Pneumonie§, sepsis","Pharyngitis*, infection viral* Bronchitis, sinusitis, herpes simplex (resistance), rhinitis",9,15
"1492","fr","en","Effets indésirables rapportés chez des sujets traités par le voriconazole Classe organe Investigations","Oral contraceptives containing doses other than 1 mg norethisterone and 0.035 mg ethinylestradiol have not been studied.",17,13
"1493","fr","en","Effets indésirables rapportés chez les adultes au cours des essais cliniques et après commercialisation","Undesirable Effects in Clinical Studies and Post-marketing in Adult Patients Immune system disorders",13,14
"1494","fr","en","Effets indésirables rapportés depuis la commercialisation d’ EXJADE.","P P Adverse reactions reported during postmarketing experience.",8,8
"1495","fr","en","Effets indésirables rares • Réactions allergiques sévères d’ apparition soudaine.","Rare side effects • Sudden severe allergic reactions.",8,10
"1496","fr","en","Effets indésirables très fréquents","Very common side effects",4,4
"1497","fr","en","Effets indésirables très fréquents (Peuvent affecter plus de 10 patients sur 100 traités par Hepsera)","Very common side effects (These can affect more than 10 in every 100 people taking Hepsera)",16,15
"1498","fr","en","Effets sur toutes les fractures cliniques Toutes les fractures cliniques ont été vérifiées par radiographie.","Effect on all clinical fractures All clinical fractures were verified based on the radiographic and/ or clinical evidence.",18,15
"1499","fr","en","Efficacité à 3 semaines","Efficacy at week 3",4,4
"1500","fr","en","Efficib est contre-indiqué chez les patients avec:","Efficib is contraindicated in patients with:",6,7
"1501","fr","en","Efungumab est produit par une méthode appelée « technique de l’ ADN recombinant ».","Efungumab is produced by a method known as ‘ recombinant DNA technology’.",12,14
"1502","fr","en","également été observée chez les patients traités par pravastatine;","observed among patients treated with pravastatin;",6,9
"1503","fr","en","Elévation de la kaliémie due","Blood potassium increased due",4,5
"1504","fr","en","Élévation des phosphatases alcalines et du taux de LDH (transitoire, mineure)","Blood alkaline phosphatase and LDH increased (transient, minor)",8,11
"1505","fr","en","Eli Lilly Benelux S. A. rue de l'Etuve 52 Stoofstraat 1000 Brussels Belgium","Eli Lilly Benelux S. A. rue de l'Etuve 52 Stoofstraat 1000 Brussels Belgium",13,13
"1506","fr","en","Eli Lilly Italia S. p. A., Via Gramsci 731/ 733, 50019 Sesto Fiorentino (Fi), ITALY","Eli Lilly Italia S. p. A., Via Gramsci 731/ 733, 50019 Sesto Fiorentino (Fi), ITALY",15,15
"1507","fr","en","Eli Lilly Nederland B. V., Grootslag 1-5, Nl-3991 RA, Houten, Pays Bas","Eli Lilly Nederland B. V., Grootslag 1-5, NL-3991 RA, Houten, The Netherlands",12,12
"1508","fr","en","Eli Lilly Nederland BV, Grootslag 1-5, NL-3991 RA Houten, Pays-Bas.","Eli Lilly Nederland BV, Grootslag 1-5, NL-3991 RA Houten, The Netherlands",11,10
"1509","fr","en","Elidel et dénominations associées (voir annexe I)","Elidel and associated names (See Annex 1)",7,7
"1510","fr","en","Elimination Acide nicotinique L’ acide nicotinique est excrété essentiellement dans les urines sous forme de métabolites.","Elimination Nicotinic acid Nicotinic acid is predominantly excreted in the urine as metabolites.",13,16
"1511","fr","en","Elimination La gabapentine est éliminée sous forme inchangée uniquement par voie rénale.","Gabapentin is eliminated unchanged solely by renal excretion.",8,12
"1512","fr","en","Elimination: la vitamine D3 est excrétée via les faeces et l’urine.","Vitamin D is excreted in faeces and urine.",8,11
"1513","fr","en","Eliminer de façon appropriée les produits non utilisés.","Discard unused contents appropriately.",4,8
"1514","fr","en","Eliminer les déchets conformément aux exigences locales.","Dispose of waste material in accordance with local requirements.",9,7
"1515","fr","en","Eliminez votre Mixtard 30 NovoLet usagé prudemment, sans l’ aiguille attachée.","Dispose of your used Mixtard 30 NovoLet carefully without the needle attached.",12,11
"1516","fr","en","Elle a travaillé pour l’industrie pharmaceutique de 1992 à 1995 avant de rejoindre l’EMEA en juillet 1995.","She worked for the pharmaceutical industry from 1992 to 1995 before joining the EMEA in July 1995.",17,17
"1517","fr","en","Elle a une forte affinité pour les récepteurs sérotoninergiques 5-HT2 et dopaminergiques D2.","It has a high affinity for serotoninergic 5-HT2 and dopaminergic D2 receptors.",12,13
"1518","fr","en","Elle agit comme un facteur stimulant la mitose et comme une hormone de différenciation.","It acts as a mitosis stimulating factor and differentiation hormone.",10,14
"1519","fr","en","Elle correspond à l'endomètre anormal et il est donc difficile de la distinguer de l'hyperplasie.","It corresponds to abnormal endometrium and distinction from hyperplasia is not so clear.",13,15
"1520","fr","en","Elle doit être administrée par voie intraveineuse par un professionnel de santé.","It will be admin istered into a vein by a health care professional.",13,12
"1521","fr","en","Elle est aussi efficace sur les bactéries à Gram positif, tels les staphylocoques et les streptocoques.","It is also effective against Gram-positive organisms, such as staphylococci and streptococci.",12,16
"1522","fr","en","Elle est particulièrement fréquente chez les femmes après la ménopause.","It is especially common in women after the menopause.",9,10
"1523","fr","en","Elle n’est pas absorbée après administration orale.","Ceftriaxone is not absorbed after oral application.",7,7
"1524","fr","en","Elle ne stimule pas la sécrétion d'insuline, et par conséquent ne provoque pas d’ hypoglycémie.","It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.",12,15
"1525","fr","en","Elle recueillera ensuite des informations","Other information about Pandemrix:",4,5
"1526","fr","en","Elle se caractérise par un déficit en α -galactosidase.","It is characterised by the deficiency of α -galactosidase.",9,9
"1527","fr","en","Elles incluaient au total 2.349 patients ayant reçu soit Tredaptive, soit de l’ acide nicotinique.","They included a total of 2,349 patients who were taking either Tredaptive or nicotinic acid.",15,15
"1528","fr","en","Ellesfield Avenue Bracknell, Berkshire RG12 8YS-UK Tel: +44 1344 424 600","Ellesfield Avenue Bracknell, Berkshire RG12 8YS-UK Tel: +44 1344 424 600",11,11
"1529","fr","en","Emballage / Emballage extérieur","Carton / Outer Package",4,4
"1530","fr","en","Emédastine 0,5 mg/ ml sous forme de difumarate.","Emedastine 0.5 mg/ml as difumarate.",5,8
"1531","fr","en","EMEND 80 mg gélules aprépitant","EMEND 80 mg hard capsules aprepitant",6,5
"1532","fr","en","EMEND doit être utilisé avec précaution chez ces patients (voir rubrique 5.2).","EMEND should be used with caution in these patients (see section 5.2).",12,12
"1533","fr","en","Emulsion devant être exclusivement mélangée avec la suspension avant administration","Emulsion to be exclusively mixed with suspension before administration",9,10
"1534","fr","en","En 2001, nous avons engagé un nouveau directeur exécutif, Thomas Lönngren.","In 2001 we start with the new executive director, Thomas Lönngren.",11,11
"1535","fr","en","En accord avec les recommandations officielles de votre pays, un schéma alternatif peut être utilisé par votre médecin.","According to official recommendations in your country, an alternative schedule may be used by your health-care provider.",17,18
"1536","fr","en","En bithérapie orale, en association avec","As dual oral therapy in combination with",7,6
"1537","fr","en","En bloquant l’ intégrine, le natalizumab empêche les leucocytes de passer du sang dans le cerveau.","By blocking the integrin, natalizumab stops the leucocytes from going from the blood into the brain.",16,16
"1538","fr","en","En cas d'élévation du taux sérique des transaminases, une surveillance s'impose jusqu'à normalisation.","Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve.",13,13
"1539","fr","en","En cas d'infection, une antibiothérapie doit être instaurée si elle est cliniquement nécessaire.","In case of infections, antibiotic treatment should be initiated as required.",11,13
"1540","fr","en","En cas d'oubli d'une dose de Januvia, le patient doit prendre cette dose dès qu'il s'en rend compte.","If a dose of Januvia is missed, it should be taken as soon as the patient remembers.",17,18
"1541","fr","en","En cas d'utilisation avec une pompe à insuline, Liprolog ne doit pas être mélangé avec une autre insuline.","When used with an insulin infusion pump, Liprolog should not be mixed with any other insulin.",16,18
"1542","fr","en","En cas d’ hypersensibilité, ne pas manipuler le produit.","Do not handle this product if you know you are hypersensitive.",11,9
"1543","fr","en","En cas d’ hypoglycémie, la dose d’ insuline devra être diminuée.","If patients report hypoglycaemia, the dose of insulin should be decreased.",11,11
"1544","fr","en","En cas d’ incertitude, consultez votre médecin ou votre pharmacien.","You should check with your doctor or pharmacist if you are not sure.",13,10
"1545","fr","en","En cas d’ infarctus du myocarde, des caillots se sont formés dans les artères menant au cœ ur.","In myocardial infarction, clots have formed in the arteries to the heart.",12,18
"1546","fr","en","En cas d’ insuffisance hépatique sévère, les patients doivent être surveillés attentivement afin de détecter les événements indésirables.","Patients with severe hepatic organ impairment should be carefully monitored for adverse",12,18
"1547","fr","en","En cas d’ oubli d’ une dose, prenez la dose suivante normalement, ne doublez pas la dose.","If you miss a dose, take the next dose as usual - do not double the dose.",17,17
"1548","fr","en","En cas d’ urgence","This medicine is prescribed for you personally and you should not pass it on to others.",16,4
"1549","fr","en","En cas d’aggravation, votre médecin décidera si votre traitement par ribavirine doit être modifié ou interrompu.","If it does get worse, then your doctor may decide to alter or stop your ribavirin treatment.",17,16
"1550","fr","en","En cas d’incertitude, consultez votre médecin ou votre pharmacien.","Check with your doctor or pharmacist if you are not sure.",11,9
"1551","fr","en","En cas d’incertitude, consultez votre médecin.","You should check with your doctor if you are not sure.",11,6
"1552","fr","en","En cas de choc, un traitement médical standard devra être instauré.","In case of shock, standard medical treatment for shock should be implemented.",12,11
"1553","fr","en","En cas de contact accidentel avec la peau, rincer abondamment à l’ eau la région affectée.","In case of accidental contact with the skin, wash affected area with abundant water.",14,16
"1554","fr","en","En cas de contact accidentel, bien laver au savon et à l'eau; rincer les yeux à l'eau courante.","If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.",15,18
"1555","fr","en","En cas de contact avec la peau, laver immédiatement avec de l’eau et du savon.","If Abraxane suspension contacts the skin, the skin should be washed immediately and thoroughly with soap and water.",18,15
"1556","fr","en","En cas de contact cutané accidentel, il est recommandé de laver soigneusement avec de l’ eau.","In case of accidental skin contact, it is recommended to wash thoroughly with water.",14,16
"1557","fr","en","En cas de crise convulsive, le traitement doit être interrompu.","Treatment should be discontinued in any patient who develops seizures.",10,10
"1558","fr","en","En cas de difficulté pour isoler ces muscles, les injections doivent être faites avec un guidage électromyographique.","In case of any difficulty in isolating the individual muscles, injections should be made under electromyographic assistance.",17,17
"1559","fr","en","En cas de doute parlez -en à votre médecin.","If you are unsure, please talk to your doctor.",9,9
"1560","fr","en","En cas de doute sur une des instructions, consultez votre médecin ou votre pharmacien.","You should check with your doctor or pharmacist if you are not sure about any of the instructions.",18,14
"1561","fr","en","En cas de grossesse survenue sous Xeloda, les risques potentiels pour le fœ tus doivent être expliqués.","If the patient becomes pregnant while receiving Xeloda, the potential hazard to the foetus must be explained.",17,17
"1562","fr","en","En cas de modifications cliniquement significatives de ces paramètres, des ajustements du traitement immunosuppresseur doivent être envisagés.","Herbal preparations containing St.",4,17
"1563","fr","en","En cas de réaction allergique, le traitement doit être immédiatement arrêté.","In case of the occurrence of allergic reaction, the treatment should be immediately withdrawn.",14,11
"1564","fr","en","En cas de signes cliniques, le traitement doit être interrompu et un traitement symptomatique doit être administré.","If clinical signs occur, treatment should be discontinued and symptomatic treatment initiated.",12,17
"1565","fr","en","En cas de somnolence, il est déconseillé de conduire ou d’ utiliser certains outils ou machines.","If this happens do not drive or operate any tools or machines.",12,16
"1566","fr","en","En cas de surdosage aigu, un lavage gastrique doit être effectué.","In the event of acute overdose the stomach should be emptied.",11,11
"1567","fr","en","En cas de surdosage instaurer un traitement symptomatique.","In the case of overdosage symptomatic treatment should be initiated.",10,8
"1568","fr","en","En cas de surdosage par FOSAVANCE, du lait ou des antiacides seront administrés afin de chélater l’ alendronate.","In case of overdose with FOSAVANCE, milk or antacids should be given to bind alendronate.",15,18
"1569","fr","en","En cas de surdosage, il convient d’ assurer une assistance cardio-vasculaire et respiratoire appropriée.","Should overdosage occur, the respiratory and cardiovascular systems should be supported appropriately.",12,14
"1570","fr","en","En cas de surdosage, traitement symptomatique et surveillance sont préconisés.","In the event of overdose, symptomatic and supportive measures should be employed.",12,10
"1571","fr","en","En cas de suspicion d’ atteinte hépatique, un bilan biologique et étiologique approfondi doit être pratiqué.","When a hepatic event is suspected, further biological and etiological evaluation is required.",13,16
"1572","fr","en","En cas de traitement prophylactique, une durée maximale de 7 jours de traitement est suffisante.","In case of prophylactic treatment, a maximum duration of treatment of 7 consecutive days is sufficient.",16,15
"1573","fr","en","En clinique, le risque potentiel en clinique n’ est pas connu.","These differences were not considered to be clinically significant.",9,11
"1574","fr","en","En conséquence, l'utilisation de Irbesartan Hydrochlorothiazide BMS n’ est pas recommandée.","Therefore, the use of Irbesartan Hydrochlorothiazide BMS is not recommended.",10,11
"1575","fr","en","En conséquence, les concentrations plasmatiques des substances métabolisées par ces isoenzymes peuvent être diminuées quand Tracleer est associé.","Consequently, plasma concentrations of substances metabolised by these isoenzymes will be decreased when Tracleer is co-administered.",16,18
"1576","fr","en","En conséquence, Luminity ne sera administré qu’ avec prudence chez la femme qui allaite.","Therefore, caution should be exercised when Luminity is administered to breast-feeding women.",12,14
"1577","fr","en","En conséquence, pour l’ initiation du traitement le premier jour, il faudra administrer deux fois la dose d'entretien.","Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.",17,18
"1578","fr","en","En conséquence, signalez à votre médecin toute douleur à l'injection.","Therefore, be sure to tell the medical staff if you experience pain during the injection.",15,10
"1579","fr","en","En conséquence, un effet direct (légère toxicité) ou indirect (goût peu agréable) ne peut être exclu.","Consequently, a direct effect (slight toxicity), or an indirect effect (low palatability) cannot be excluded.",15,16
"1580","fr","en","En de rares occasions, les troubles musculaires étaient graves (rhabdomyolyse).","On rare occasions, these muscle disorders have been serious (rhabdomyolysis).",10,10
"1581","fr","en","En fonction de la sévérité des symptômes, l’ arrêt du traitement pourra être envisagé (voir rubrique 4.8).","Depending on the severity of symptoms, consideration should be given to stopping treatment (see section 4.8).",16,17
"1582","fr","en","En général, la pharmacocinétique de la lamivudine chez les enfants est comparable à celle observée chez les adultes.","In general, lamivudine pharmacokinetics in paediatric patients are similar to adults.",11,18
"1583","fr","en","En général, le traitement doit être débuté à une dose faible de 0,25 ml (62,5 microgrammes).","In general, treatment should be started at a low dose of 0.25 ml (62.5 micrograms).",15,16
"1584","fr","en","En général, les cas rapportés ont été plus fréquents après une administration par voie intraveineuse.","Overall, reports were more common after IV administration.",8,15
"1585","fr","en","En général, les chiens se réveillent et se tiennent sur leurs pattes au bout de 15 minutes.","Within 15 minutes dogs are normally awake and standing.",9,17
"1586","fr","en","en juillet 2002 Diffusé pour consultation","Released for consultation July 2002",5,6
"1587","fr","en","En l’ absence d’ études de compatibilité, ce médicament ne doit pas être mélangé avec d'autres médicaments.","In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.",17,17
"1588","fr","en","En l’absence d’expérience, l’utilisation répétée d’InductOs n’est pas recommandée.","In the absence of any experience, the repeated use of the medicinal product is not recommended.",16,9
"1589","fr","en","En l’état actuel des connaissances, on ne sait pas combien de temps doit durer le traitement par Extavia.","At present it is not known how long treatment with Extavia should last.",13,18
"1590","fr","en","En outre, aux deux dates, la dose de 30 mg semblait pré- senter une efficacité supérieure.","Furthermore, at both timepoints, there was a trend for better efficacy of the 30 mg dose.",16,16
"1591","fr","en","En outre, il ne semble pas y avoir de corrélation entre les taux plasmatiques et le résultat clinique.","Furthermore, there does not appear to be a correlation between plasma levels and clinical outcome.",15,18
"1592","fr","en","En outre, la tolérance nasale du produit a été étudiée chez le chien et le singe.","In addition, nasal tolerance was investigated in dogs and monkeys.",10,16
"1593","fr","en","En outre, une hypertension artérielle pulmonaire est également caractérisée par une activité réduite du monoxyde d’ azote.","Additionally, pulmonary arterial hypertension also is characterized by reduced nitric oxide activity.",12,17
"1594","fr","en","En particulier, ils sont apparus moins favorables chez les femmes et chez les patients non-blancs (voir rubrique 5.1).","In particular, they appeared less favourable in women and non-white subjects (see section 5.1).",14,18
"1595","fr","en","En particulier, prévenez votre médecin si vous prenez un traitement pour la maladie de Parkinson.","Especially tell your doctor if you are taking medicines for Parkinson’ s disease.",13,15
"1596","fr","en","En plus, des cas de maux de tête, fatigue, éruption cutanée, prurit et bouffée congestive ont été rapportés.","In addition, headache, tiredness, rash, itching, and flushing have been reported.",11,18
"1597","fr","en","en plusieurs doses pendant 2 à 5 jours en association avec de l'acide acétylsalicylique","in several doses for 2 – 5 days in association with acetylsalicylic acid",13,14
"1598","fr","en","En présence de particules dans le liquide, il ne faut pas l’utiliser.","If there are particles in it, you must not use it. od",12,12
"1599","fr","en","En raison du profil de la cétirizine, aucune interaction avec d'autres médicaments n'est attendue.","Due to the profile of cetirizine, no interactions with other drugs are expected.",13,14
"1600","fr","en","En stoppant cette « substance P », Cerenia permet d’ éviter les vomissements.","By stopping “ Substance P”, Cerenia acts as an anti-emetic.",10,13
"1601","fr","en","En tant qu’ ammonium quaternaire, la capacité de la méthylnaltrexone à franchir la barrière hémato- encéphalique est limitée.","As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted.",15,18
"1602","fr","en","En terme de bonne pratique clinique, injecter seulement un vaccin qui a atteint la température ambiante.","It is good clinical practice to only inject a vaccine when it has reached room temperature.",16,16
"1603","fr","en","Enbrel 25 mg/ml poudre et solvant pour solution injectable pour usage pédiatrique Etanercept","Enbrel 25 mg/ ml powder and solvent for solution for injection for paediatric use Etanercept",15,13
"1604","fr","en","Enbrel n'a pas été étudié chez l'enfant de moins de 4 ans.","Enbrel has not been studied in children aged less than 4 years.",12,12
"1605","fr","en","Enbrel peut augmenter le risque d’ avoir des infections, qui pourraient être graves.","Enbrel may increase your risk of getting infections, which could be serious.",12,13
"1606","fr","en","Enfant âgé de 4 à 11 ans et adolescent (12 à 17 ans) pesant moins de 50 kg","Children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg",17,18
"1607","fr","en","Enfants (3 mois à 12 ans):","Children (3 months to 12 years of age):",8,6
"1608","fr","en","Enfants (âgés de 2 à 17 ans):","Paediatric patients (2 to 17 years of age) U",9,7
"1609","fr","en","Enfants âgés de 3 ans et plus et adolescents:","Children 3 years of age or older and adolescents:",9,9
"1610","fr","en","Enfants âgés de moins de 6 ans:","Children less than 6 years of age:",7,7
"1611","fr","en","Enfants atteints de psoriasis en plaques","Paediatric patients with plaque psoriasis",5,6
"1612","fr","en","Enfants et adolescents (âgés de 21 ans ou moins)","Children and adolescents (aged 21 years and younger)",8,9
"1613","fr","en","ENGERIX B 10 microgrammes/ 0,5 ml Suspension injectable Vaccin de l’ hépatite B recombinant adsorbé","ENGERIX B 10 micrograms/ 0.5 ml Suspension for injection Hepatitis B recombinant vaccine, adsorbed",14,15
"1614","fr","en","Enlevez et jetez le perforateur-filtre.","Remove and discard the filter spike.",6,5
"1615","fr","en","Enlevez le film protecteur de l’ aiguille neuve.","Remove the protective seal from a new needle.",8,8
"1616","fr","en","Ensuite, enfoncez le piston pour injecter toute la solution à un rythme lent, régulier (voir Schéma 19).","Then push the plunger to inject all of the solution at a slow, steady rate (see Diagram 19).",18,17
"1617","fr","en","Ensuite, la clairance de la créatinine est ajustée à la surface corporelle comme suit:","Then CLcr is adjusted for body surface area (BSA) as follows:",11,14
"1618","fr","en","Entérocolite pseudomembraneuse (voir rubrique 4.4).","Pseudomembranous enterocolitis (see section 4.4).",5,5
"1619","fr","en","entraîne un risque accru","indinavir/ 100 mg ritonavir twice daily results in increased risk of adverse events.",13,4
"1620","fr","en","Entre 1 patient sur 10 et 1 patient sur 100","Between 1 in 10 and 1 in 100 patients experience",10,10
"1621","fr","en","Enurace 50 a reçu sa première autorisation de mise sur le marché le 15 septembre 2000 aux Pays-Bas.","Enurace 50 was first authorised in The Netherlands on 15 September 2000.",12,18
"1622","fr","en","Enviage peut être utilisé seul ou en association avec d’ autres antihypertenseurs (voir rubriques 4.4 et 5.1).","Enviage may be used alone or in combination with other antihypertensive agents (see sections 4.4 and 5.1).",17,17
"1623","fr","en","Environ 3% de la dose administrée sont excrétés sous forme inchangée dans les urines.","About 3% of the administered dose is excreted in urine as unchanged drug.",13,14
"1624","fr","en","Environ un tiers (PHOENIX 1) et un quart (PHOENIX 2) des sujets présentaient un rhumatisme psoriasique (Rhum Pso).","Approximately one third (PHOENIX 1) and one quarter (PHOENIX 2) of subjects had Psoriatic Arthritis (PsA).",16,18
"1625","fr","en","Envisager une réduction de la dose de melphalan de 25% lors du cycle suivant.","Consider reduction of the melphalan dose by 25% in the next cycle.",12,14
"1626","fr","en","Epanchements péricardiques (comprenant des épanchements hémodynamiqueme nt significatifs chez les enfants et les adultes)","Common ( 1/ 100 to < 1/ 10)",8,14
"1627","fr","en","EpiCept GmbH Goethestrasse 4 D-80336 München Allemagne","EpiCept GmbH Goethestrasse 4 D-80336 München Germany",7,7
"1628","fr","en","Episodes maniaques dans les troubles bipolaires de type I:","Manic episodes in Bipolar I Disorder:",6,9
"1629","fr","en","Epistaxis; Douleurs pharyngo- laryngée; Rhinopharyngite; Dyspnée; Toux; Rhinorrhée","Epistaxis; Pharyngolaryngeal pain; Nasopharyngitis; Dyspnoea; Cough; Rhinorrhoea",7,8
"1630","fr","en","Epoetin alfa HEXAL 2 000 UI/ 1 ml, solution injectable en seringue pré-remplie","Epoetin alfa HEXAL 2000 IU/ 1 ml solution for injection in a pre-filled syringe",14,13
"1631","fr","en","Epoetin alfa HEXAL 7 000 UI/ 0,7 ml, solution injectable en seringue pré-remplie","Epoetin alfa HEXAL 7000 IU/ 0.7 ml solution for injection in a pre-filled syringe",14,13
"1632","fr","en","Époétine alfa IV/ SC","Epoetin alfa IV/ SC",4,4
"1633","fr","en","eptacog alfa (activé) 1 mg/ flacon (50 KUI/ flacon), 1 mg/ ml après reconstitution","eptacog alfa (activated) 1 mg/ vial (50 KIU/ vial), 1 mg/ ml after reconstitution",14,14
"1634","fr","en","Equilis Prequenza, suspension injectable pour chevaux","Equilis Prequenza, suspension for injection, for horses",7,6
"1635","fr","en","EQUIOXX ne doit pas être administré avec des corticostéroïdes ou d’ autres AINS.","EQUIOXX must not be administered with corticosteroids or other NSAIDs.",10,13
"1636","fr","en","équipe de secrétariat PIQ, a été établie","European Technical Office for Medicinal Products (ETOMEP)",7,7
"1637","fr","en","Erbitux 5 mg/ ml solution pour perfusion","Erbitux 5 mg/ ml solution for infusion",7,7
"1638","fr","en","éruption généralisée sur tout le corps • difficultés de respiration • accélération respiration sifflante de type asthmatique","rash over the whole body • difficulty in breathing • wheezing • sweating.",13,17
"1639","fr","en","España Actelion Pharmaceuticals España S.L.","España Actelion Pharmaceuticals España S.L.",5,5
"1640","fr","en","España Ferrer Internacional, S.A.","España Ferrer Internacional, S. A.",5,4
"1641","fr","en","España INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Tel: +49 234 971130","España INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Tel: +49 234 971130",17,17
"1642","fr","en","España Lilly, S. A.","España Lilly, S. A.",4,4
"1643","fr","en","España Novartis Farmacéutica, S. A.","España Novartis Farmacéutica, S.A.",4,5
"1644","fr","en","España Roche Farma S.A.","España Roche Farma S.A.",4,4
"1645","fr","en","España UCB Pharma, S. A.","España UCB Pharma, S. A.",5,5
"1646","fr","en","Essayez de prendre Competact comprimé tous les jours selon la prescription.","Try to take Competact tablets daily as prescribed.",8,11
"1647","fr","en","essoufflement constrictions thoraciques et","During the infusion at the hospital, you may have an allergic reaction and notice any of the following:",18,4
"1648","fr","en","est souvent dure, douloureuse au toucher et rouge","hard strand covered with red skin",6,8
"1649","fr","en","Estrada Consiglieri Pedroso, 69 A Queluz de Baixo P-2734-503 Barcarena Tel: +351 21 43 68 835","Estrada Consiglieri Pedroso, 69 A Queluz de Baixo P-2734-503 Barcarena Tel: +351 21 43 68 835",16,16
"1650","fr","en","Estradiol (sous forme hémihydratée) 0,5 mg + acétate de noréthisthérone 0,1 mg","Activelle Estradiol (as hemihydrate) 0.5 mg Film-coated tablets Oral use + Norethisterone acetate 0.1 mg",15,12
"1651","fr","en","et à celle du module 3 (qualité) de la documentation pharmaceutique;","and harmonisation of the pharmaceutical documentation – module 3 (quality)",10,11
"1652","fr","en","et de la nutrition","Metabolism and nutrition disorders hypercholesterolaemia1 hypertriglyceridaemia",6,4
"1653","fr","en","et des installations Chef du secteur de la comptabilité","Specific recommendations for poultry (CVMP/ VICH/ 546/ 00) • Efficacy of anthelmintics:",12,9
"1654","fr","en","et des produits immunologiques.","Vicari met on 9 occasions in 1996.",7,4
"1655","fr","en","et les inspections"" de la Commission européenne, qui se réunit à Bruxelles.","Certification of medicinal products At the request of the European",10,12
"1656","fr","en","et/ ou plaquettes < 50 x 109/ l","platelets < 50 x 109/ l",6,8
"1657","fr","en","Etanercept, le composant actif d’ Enbrel, est un médicament biologique fabriqué à partir de deux protéines humaines.","Etanercept, the active ingredient in Enbrel, is a biologic medicine that is made from two human proteins.",17,17
"1658","fr","en","ETIQUETAGE DE LA SERINGUE PREREMPLIE NON CONDITIONNEE SOUS PLAQUETTE THERMOFORMEE tn","UNBLISTERED PRE-FILLED SYRINGE LABEL ct",5,11
"1659","fr","en","ETIQUETAGE DU BLISTER – EU/ 1/ 99/ 126/ 006, 007 et 008 (50 mg Flacon seul)","TEXT FOR TRAY BACKING – EU/ 1/ 99/ 126/ 006-008 (50 mg Vial only)",14,16
"1660","fr","en","ETIQUETAGE stp lus au tor isé MENTIONS DEVANT FIGURER SUR L’ EMBALLAGE EXTERIEUR","LABELLING lon ge ra uth ori sed PARTICULARS TO APPEAR ON THE OUTER PACKAGING",14,13
"1661","fr","en","ÉTIQUETTE DE LA BOÎTE (PANNEAU SUPÉRIEUR)","TRAY TOP LID LABEL",4,6
"1662","fr","en","ETIQUETTE DU FLACON (45 mg)","VIAL LABEL TEXT (45 mg)",5,5
"1663","fr","en","ÉTIQUETTE FLACON DE VERRE AMBRÉ DE 120 et de 210 ml","LABEL AMBER GLASS BOTTLE 120 and 210 ml",8,11
"1664","fr","en","Etiquette flacon pour Cozaar Comp 50 mg/ 12,5 mg, comprimé pelliculé en flacon HDPE","Bottle label for Cozaar Comp 50 mg/ 12.5 mg film-coated tablets HDPE Bottle",13,14
"1665","fr","en","être prises en cas de surdosage.","or the general measures employed in the management of overdoses, such as keeping airways",14,6
"1666","fr","en","Etude ACTG 364 48 semaines","Study ACTG 364 48 weeks",5,5
"1667","fr","en","Etudes cliniques Lors des études cliniques, 2 011 sujets ont reçu Cubicin.","Clinical Studies In clinical studies, 2,011 subjects received Cubicin.",9,12
"1668","fr","en","ETUI - 4 × 135 µg seringues pré-remplies","OUTER CARTON – 4 x 135 μ g PRE-FILLED SYRINGES",10,8
"1669","fr","en","ETUI CONTENANT 5 OU 20 GELULES DE TEMODAL 180 mg INDIVIDUELLEMENT SCELLEES DANS DES SACHETS","CARTON CONTAINING 5 OR 20 HARD CAPSULES OF TEMODAL 180 mg INDIVIDUALLY SEALED IN SACHETS",15,15
"1670","fr","en","ETUI DES COMPRIMES DE ZALASTA 10 mg","CARTON FOR ZALASTA 10 mg TABLETS",6,7
"1671","fr","en","ETUI DES COMPRIMES ENROBES SOUS PLAQUETTE THERMOFORMEE","CARTON OF COATED TABLETS IN BLISTERS",6,7
"1672","fr","en","Etui extérieur pour Janumet 50 mg/ 1000 mg, comprimés pelliculés","Outer carton for Janumet 50 mg/ 1,000 mg film-coated tablets",10,10
"1673","fr","en","Eucreas ne doit pas être utilisé pendant la grossesse.","Eucreas should not be used during pregnancy.",7,9
"1674","fr","en","European Medicines Agency Evaluation of Medicines for Human Use","European Medicines Agency Evaluation of Medicines for Human Use",9,9
"1675","fr","en","European Medicines Agency Veterinary Medicines","European Medicines Agency Veterinary Medicines",5,5
"1676","fr","en","European Medicines Agency Veterinary Medicines and Inspections","European Medicines Agency Veterinary Medicines and Inspections",7,7
"1677","fr","en","européenne du médicament (EMEA) http: / /www. emea. europa. eu","or Agency (EMEA) http: / /www. emea. europa. eu",9,10
"1678","fr","en","Évaluation des médicaments à usage humain Noël WATHION Chef d'unité Affaires réglementaires et pharmacovigilance","Evaluation of Medicines for Human Use",6,14
"1679","fr","en","Evaluation Préclinique des médicaments anticancereux","Preclinical evaluation of anti-cancer medicinal products",6,5
"1680","fr","en","Evénements indésirables de fréquence non connue:","Adverse events with unknown frequency:",5,6
"1681","fr","en","Evénements indésirables graves cardiovasculaires thrombotiques confirmés Per-protocole En intention de traiter","Confirmed Thrombotic Cardiovascular Serious Adverse Events",6,11
"1682","fr","en","EVISTA 60 mg comprimés pelliculés Chlorhydrate de raloxifène","EVISTA 60 mg film coated tablets raloxifene hydrochloride",8,8
"1683","fr","en","Eviter l’ introduction d’ une contamination.","Avoid introduction of contamination.",4,6
"1684","fr","en","Éviter l’ introduction de toute contamination au cours de l’ utilisation.","Avoid introduction of contamination during use.",6,11
"1685","fr","en","Éviter le contact avec les yeux et la peau.","Avoid contact with eyes and skin.",6,9
"1686","fr","en","Eviter le mélange avec des boissons acides telles que le jus d’ orange.","Do not add to acidic drinks e. g. orange juice.",10,13
"1687","fr","en","Éviter tout stress chez les oiseaux avant, pendant et après la vaccination.","Avoid stress in the birds around the time of vaccination.",10,12
"1688","fr","en","Evitez la lumière solaire directe ou une lumière d'intérieur intense.","Avoid direct sunlight or strong indoor lighting.",7,10
"1689","fr","en","Évitez tout effort inutile car ceci pourrait augmenter les risques de rupture des tendons.","Avoid any unnecessary exercise as this might increase the risk of a tendon rupture.",14,14
"1690","fr","en","Evoltra 1 mg/ ml, solution à diluer pour perfusion devra être dilué avant son administration (voir rubrique 6.6).","Evoltra 1 mg/ ml concentrate for solution for infusion must be diluted prior to administration (see section 6.6).",18,18
"1691","fr","en","EVRA n’ est pas indiqué pendant la grossesse (voir section 4.6)","EVRA is not indicated during pregnancy (see section 4.6).",9,11
"1692","fr","en","ex: thrombocytopénie, leucopénie) ont été peu souvent observés avec Trudexa.","thrombocytopaenia, leucopaenia) have been infrequently reported with Trudexa.",8,10
"1693","fr","en","Examinez la solution avant l’administration: elle doit être limpide et incolore.","Examine the solution prior to administration: it should be clear and colourless.",12,11
"1694","fr","en","Examinez la solution de Liprolog Pen.","Inspect the Liprolog Pen solution.",5,6
"1695","fr","en","Excipient Tredaptive contient du lactose.","Excipient Tredaptive contains lactose.",4,5
"1696","fr","en","Excipients ayant un effet notoire: sorbitol E420, acétate de sodium (voir rubrique 4.4)","is or Excipients known to have a recognised action: sorbitol E420, sodium acetate (see section 4.4).",16,13
"1697","fr","en","Excipients Pour la liste complète des excipients, voir rubrique 6.1.","For a full list of excipients, see section 6.1.",9,10
"1698","fr","en","Excipients: acide citrique monohydraté, hydroxyde de sodium, eau pour préparations injectables.","Excipients: citric acid monohydrate, sodium hydroxide, water for injections.",9,11
"1699","fr","en","Excipients: citrate de sodium, chlorure de sodium, édétate disodique, polysorbate 80, hydroxyde de sodium, eau pour préparations injectables.","Excipients: sodium citrate, sodium chloride, disodium edetate, polysorbate 80, sodium hydroxide, water for injections.",14,18
"1700","fr","en","Excipients: un comprimé contient 99 mg de lactose monohydraté et 338 mg de sorbitol (E420).","Each tablet contains 99 mg of lactose monohydrate and 338 mg sorbitol (E420).",13,15
"1701","fr","en","Excrétion La méthylnaltrexone est principalement éliminée sous forme active inchangée.","Excretion Methylnaltrexone is eliminated primarily as the unchanged active substance.",10,10
"1702","fr","en","Exelon 1,5 mg gélules Rivastigmine","Exelon 1.5 mg hard capsules Rivastigmine",6,5
"1703","fr","en","Exelon 9,5 mg/ 24 h dispositif transdermique rivastigmine","Exelon 9.5 mg/ 24 h transdermal patch rivastigmine",8,8
"1704","fr","en","Exfoliation cutanée Ampoule Lésion cutanée Douleurs des extrémités / des membres","Arthralgia Myalgia Muscle spasm Back pain Muscular weakness",8,11
"1705","fr","en","EXIGENCES PARTICULIÈRES DEVANT ÊTRE RESPECTÉS PAR LE TITULAIRE DE L’ AUTORISATION DE MISE SUR LE MARCHÉ","SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING AUTHORISATION HOLDER",10,16
"1706","fr","en","EXP {JJ/ MM/ AAAA} (12 h CET)","EXP {DD/ MM/ YYYY} (12h CET)",6,7
"1707","fr","en","EXP Après reconstitution, utiliser sous 24 heures.","EXP After reconstitution, use within 24 hours.",7,7
"1708","fr","en","EXP Une fois utilisées, les cartouches peuvent être conservées jusqu'à 4 semaines.","Once in-use, cartridges may be kept for up to 4 weeks.",11,12
"1709","fr","en","EXP Utiliser dans les 3 heures après reconstitution.","EXP {month/ year} Use within 3 hours after mixing.",9,8
"1710","fr","en","Exp: xx/ xxxx Jeter 4 semaines après la première ouverture.","Exp: xx/ xxxx Discard four weeks after first opening.",9,10
"1711","fr","en","Expérience acquise chez les patients montrant une réplication virale persistante:","Experience in patients with persistent viral replication:",7,10
"1712","fr","en","Expérience acquise dans la polyarthrite rhumatoïde","Experience from rheumatoid arthritis",4,6
"1713","fr","en","Expérience professionnelle: de 1976 à 1978, chargé de cours à l'université d'Uppsala.","From 1976 to 1978, lecturer at University of Uppsala.",9,12
"1714","fr","en","EXPO 2000, east wing, sectors B1 & B2, 1st fl.","EXPO 2000, east wing, sectors B1 & B2, 1st fl.",10,10
"1715","fr","en","Extavia n’a pas en lui -même d’effet direct sur le cœur.","Extavia itself does not affect the heart directly.",8,11
"1716","fr","en","EXUBERA est une insuline d’ action rapide.","EXUBERA is a fast-acting insulin.",5,7
"1717","fr","en","Eλλάδα BIANEΞ Α.Ε Τηλ: +3 0210 80091 11 Mailbox@vianex.gr.","Eλλάδα BIANEΞ Α.Ε Τηλ: +3 0210 80091 11 Mailbox@vianex.gr.",9,9
"1718","fr","en","F4 Charge Virale Initiale","F4 Baseline Viral Load",4,4
"1719","fr","en","Fablyn est conçu pour un traitement à long terme.","Fablyn is intended for long-term use.",6,9
"1720","fr","en","Fabrazyme peut passer dans le lait maternel.","Fabrazyme may get into breast milk.",6,7
"1721","fr","en","Fabricant Biogen Idec B. V.","Manufacturer Biogen Idec B. V.",5,5
"1722","fr","en","Fabricant Janssen-Cilag SpA Via C.","Manufacturer Janssen-Cilag SpA Via C.",5,5
"1723","fr","en","Fabricant Novartis Pharma GmbH Roonstraβ e 25 D-90429 Nuremberg Allemagne","Manufacturer Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany",9,10
"1724","fr","en","Fabricant responsable de la libération des lots:","Manufacturer for batch release:",4,7
"1725","fr","en","Fabricant Teva Pharmaceuticals Europe B. V.","Manufacturer Teva Pharmaceuticals Europe B. V.",6,6
"1726","fr","en","FABRICANT(S) DU(ES) PRINCIPE(S) ACTIF(S) D’ ORIGINE BIOLOGIQUE","MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE",14,7
"1727","fr","en","Faiblesse ou engour dissement soudain du visage, du bras ou de la jambe, particulièrement","Sudden numbness or weakness of the arm, leg or face, especially if only on one side of",17,14
"1728","fr","en","Fait partie d’ un conditionnement multiple de 10 boîtes contenant chacune 98 comprimés pelliculés.","Component of a multipack comprising 10 packs, each containing 98 film-coated tablets.",12,14
"1729","fr","en","Faites attention à ne pas tordre le capuchon durant la manipulation pour ne pas endommager l’aiguille.","Be careful not to bend or twist the cover during removal to avoid damage to the needle.",17,16
"1730","fr","en","Fareston peut être pris avec ou sans nourriture.","Fareston can be taken with or without food.",8,8
"1731","fr","en","Faslodex 250 mg solution injectable. fulvestrant","Faslodex 250 mg solution for injection. fulvestrant",7,6
"1732","fr","en","Fasturtec se présente en boîte de:","Fasturtec is supplied as a pack of:",7,6
"1733","fr","en","Fatigue et asthénie Malaise Chute accidentelle","Fatigue and asthenia Malaise Accidental fall",6,6
"1734","fr","en","Fax (82-2) 22 53-5635/6 E-mail: eucck@eucck.org URL: http://www.eucck.org","Joint CPMP/CVMP Quality Working Party",5,8
"1735","fr","en","Feldene Dispersable Tablets 10mg","Feldene Dispersable Tablets 10mg",4,4
"1736","fr","en","Fendrix, suspension injectable IM","Fendrix suspension for injection IM",5,4
"1737","fr","en","Fentanyl- ratiopharm 50 µg/ h TTS","Fentanyl- ratiopharm 50 µg/ h TTS",6,6
"1738","fr","en","Fentanyl-ratiopharm a une influence considérable sur l’ aptitude à conduire et à utiliser des machines.","Driving and using machines Fentanyl-ratiopharm has major influence on the ability to drive and use machines.",16,15
"1739","fr","en","Fentanyl– ratiopharm ne doit pas être utilisé dans cette population.","Fentanyl-ratiopharm should not be used in this population.",8,10
"1740","fr","en","Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 DK-2300 Copenhague S Danemark Tel: +45 88 33 88 34","Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 DK-2300 Copenhagen S Denmark Tel: +45 88 33 88 34",18,18
"1741","fr","en","Fertavid 150 UI/ 0,18 ml solution injectable follitropine bêta","Fertavid 150 IU/ 0.18 ml solution for injection follitropin beta",10,9
"1742","fr","en","Fertavid 75 UI/ 0,5 ml solution injectable follitropine bêta","Fertavid 75 IU/ 0.5 ml solution for injection follitropin beta",10,9
"1743","fr","en","fibrillation auriculaire, tachycardie, + troubles","fibrillation, tachycardia, + cardiac disorder",5,5
"1744","fr","en","Fièvre ≥ 40,0°C, dans les 48 heures, sans autre cause identifiable.","Temperature of ≥ 40.0°C within 48 hours, not due to another identifiable cause.",13,11
"1745","fr","en","fièvre, éruption cutanée, oedème et parfois chute de tension","include fever, rash, swelling and sometimes a fall in blood pressure",11,9
"1746","fr","en","Filgrastim ratiopharm est une solution injectable ou pour perfusion (goutte-à-goutte dans une veine).","Filgrastim ratiopharm is a solution for injection or for infusion (drip into a vein).",14,13
"1747","fr","en","Firazyr est conçu pour être administré par injection sous-cutanée (sous la peau).","Firazyr is intended for subcutaneous injection (under the skin).",9,12
"1748","fr","en","Firocoxib 57 mg Firocoxib 227 mg Oxydes de fer (E172) Caramel (E150d)","Firocoxib 57 mg Firocoxib 227 mg",6,12
"1749","fr","en","Fixation extracellulaire de la toxine sur des récepteurs spécifiques situés sur les terminaisons de nerfs moteurs 2.","Extracellular binding of the toxin to specific acceptors on motor nerve terminals 2.",13,17
"1750","fr","en","Fixer fermement, de manière aseptique, l’ aiguille pour injection (fournie dans la boîte) sur la seringue.","Aseptically and firmly assemble the injection needle (provided) onto the syringe.",11,16
"1751","fr","en","Fixez toujours une aiguille neuve avant chaque utilisation.","Important information for use of OptiSet:",6,8
"1752","fr","en","Fixez une nouvelle aiguille.","Attach a new needle.",4,4
"1753","fr","en","Flacon (verre ambré) Flacon (verre ambré) Flacon (verre ambré) Flacon (verre ambré) Flacon (verre ambré)","Packaging Vial (amber glass) Vial (amber glass) Vial (amber glass) Vial (amber glass) Vial (amber glass)",16,15
"1754","fr","en","Flacon (verre) Flacon (verre) Flacon (verre) Flacon (verre)","Bottle (glass) Bottle (glass) Bottle (glass) Bottle (glass)",8,8
"1755","fr","en","Flacon (verre), bouchon en","Vial (glass), rubber stopper and flip-off cap",7,4
"1756","fr","en","Flacon contenant 76 ml de solution.","Bottle containing 76 ml of solution.",6,6
"1757","fr","en","Flacon de solution à diluer (verre) Flacon de solvant (verre)","Concentrate: vial (glass) Solvent: vial (glass)",6,10
"1758","fr","en","Flacon de solvant: éthanol à 95% dans eau pour préparations injectables.","Solvent vial: ethanol 95%, water for injections.",7,11
"1759","fr","en","Flacon en HDPE Présentation:","HDPE tablet container 13/ 25 Pack sizes:",7,4
"1760","fr","en","Flacon en polyéthylène (de haute densité)","bottle Polyethylene (PEHD) bottle Polyethylene (PEHD) bottle",7,6
"1761","fr","en","Flacon en verre (type 1) muni d’ un bouchon en caoutchouc bromobutyl/ polyisoprène et d’ un capuchon","Glass vial (type 1) closed with a bromobutyl/ polyisoprene rubber stopper and a protective tamperproof plastic cap.",17,17
"1762","fr","en","Flacon en verre de Type I avec un bouchon en caoutchouc fermé par une capsule aluminium.","Type I glass vial with butyl rubber stopper sealed with an aluminium flip-off seal.",14,16
"1763","fr","en","Flacon portable en polyéthylène haute densité de 1000 ml contenant 980 ml de solution buvable.","High-density polyethylene portable bottle of 1000 ml containing 980 ml of the oral solution.",14,15
"1764","fr","en","FLACON/ SOLVANT pour TAXOTERE 80 mg","VIAL/ SOLVENT FOR TAXOTERE 80 mg",6,6
"1765","fr","en","Flacons en PEHD qui contiennent 250 ou 500 comprimés.","HDPE bottles containing 250 or 500 tablets.",7,9
"1766","fr","en","Flacons réservés à l’ usage unique.","Vials are for single use only.",6,6
"1767","fr","en","Fleming, 2 37135 Verona - Italie","Fleming, 2 37135 Verona Italy",5,6
"1768","fr","en","Fluconazole: l’ utilisation concomitante de Tracleer avec le fluconazole n’ est pas recommandée (voir rubrique 4.5).","Fluconazole: concomitant use of Tracleer with fluconazole is not recommended (see section 4.5).",13,16
"1769","fr","en","Fluticasone furoate GSK appartient à un groupe de médicaments appelés corticoïdes.","Fluticasone furoate GSK belongs to a group of medicines called glucocorticoids.",11,11
"1770","fr","en","Focetria est un vaccin contre la grippe pandémique.","Focetria is a vaccine against a pandemic influenza (flu).",9,8
"1771","fr","en","Formation: diplôme de pharmacien de l'université d'Heriot-Watt à Edimbourg.","John Purves, Head of Sector for quality of medicines, b.",10,9
"1772","fr","en","forme d’ hémifumarate) et 12,5 mg d’ hydrocholorothiazide.","hemifumarate) and 12.5 mg hydrocholorothiazide.",5,8
"1773","fr","en","FORME PHARMACEUTIQUE ET CONTENU","PHARMACEUTICAL FORM AND CONTENTS",4,4
"1774","fr","en","FORME PHARMACEUTIQUE ET CONTENU st Poudre pour inhalation en récipient unidose 'e","PHARMACEUTICAL FORM AND CONTENTS Inhalation powder pre-dispensed",7,12
"1775","fr","en","Forme pharmaceutique Solution injectable","Pharmaceutical Form Solution for injection",5,4
"1776","fr","en","Forme pharmaceutique Voie d’ administration Conditionnement","Route of administration Packaging",4,6
"1777","fr","en","FORSTEO ne doit pas être utilisé chez les patients ayant une insuffisance rénale sévère (voir rubrique 4.3).","FORSTEO should not be used in patients with severe renal impairment (see 4.3.).",13,17
"1778","fr","en","Fort Dodge Animal Health Limited Flanders Road, Hedge End, Southampton S030 4QH, UK","Fort Dodge Animal Health Limited Flanders Road, Hedge End, Southampton S030 4QH, UK",13,13
"1779","fr","en","Fort Dodge Veterinaria S. p. A.","Fort Dodge Veterinaria S. p. A.",6,6
"1780","fr","en","Fosavance est un médicament contenant deux principes actifs: l’ alendronate monosodique trihydraté et le colécalciférol (vitamine D3).","Fosavance is a medicine containing two active substances: alendronate sodium trihydrate and colecalciferol (vitamin D3).",15,17
"1781","fr","en","Foscan solution injectable est une solution de couleur violet foncé présenté dans un flacon en verre ambré.","Foscan solution for injection is a dark purple solution in an amber glass vial.",14,17
"1782","fr","en","Fourniture d'assistance à l'élaboration de","Scientific advice and protocol assistance given (including follow-up advice) 2000-2002",10,5
"1783","fr","en","Frais généraux - tous secteurs 13% Évaluation initiale 23% Activités spéciales à affecter 4%","Initial evaluation 23% Special activities to be earmarked 4%",9,14
"1784","fr","en","France Biogen Idec France +33 (0)1 41 37 95 95","France Biogen Idec France +33 (0)1 41 37 9595",9,10
"1785","fr","en","France JANSSEN-CILAG 1, rue Camille Desmoulins TSA 91003 F-92787 Issy Les Moulineaux Cedex 9 Tél:","France JANSSEN-CILAG 1, rue Camille Desmoulins TSA 91003 F-92787 Issy Les Moulineaux Cedex 9",14,15
"1786","fr","en","France Laboratoire GlaxoSmithKline Tél: + 33 (0)1 39 17 84 44 diam@gsk.com","France Laboratoire GlaxoSmithKline Tél: + 33 (0)1 39 17 84 44 diam@gsk. com",13,12
"1787","fr","en","France Laboratoires Merck Sharp & Dohme – Chibret Tél: +33 (0) 1 47 54 87 00 contact@msd-france.com","France Laboratoires Merck Sharp & Dohme – Chibret Tél: +33 (0)1 47 54 87 00 Contact@msd-france. com",17,17
"1788","fr","en","France Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Allemagne Tél: +49 (0)69 1503 – 1","France Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt",9,16
"1789","fr","en","France Pfizer Téléphone: +33 (0)1 58 07 46 00","France Pfizer Téléphone: +33 (0)1 58 07 46 00",9,9
"1790","fr","en","France sanofi-aventis France Tél:","France sanofi-aventis France Tél:",4,4
"1791","fr","en","France Wyeth Pharmaceuticals France Tél:+33 1 41 02 70 00 Fax:+33 1 41 02 70 10","France Wyeth Pharmaceuticals France Tél: +33 1 41 02 70 00 Fax: +33 1 41 02 70 10",18,16
"1792","fr","en","Frances NUTTALL Gerard O’MALLEY","Genotoxicity studies (CVMP/ VICH/ 526/ 00)",6,4
"1793","fr","en","Fréquence des épisodes infectieux:","Incidence of infectious episodes:",4,4
"1794","fr","en","Fréquence inconnue Affection de l’oreille et du labyrinthe","Not known Ear and labyrinth system disorders",7,8
"1795","fr","en","Fréquence indéterminée: érythème noueux, ulcérations cutanées, pétéchies, photosensibilité.","Not known: erythema nodosum, skin ulcer, petechiae, photosensitivity.",8,8
"1796","fr","en","Fréquent (> 1% et < 10%)","Common (> 1% to < 10%)",6,6
"1797","fr","en","fréquent (≥ 1/ 10)","common (> 1/ 10)",4,4
"1798","fr","en","Fréquent (≥ 1/ 100 à < 1/ 10)","Common (≥ 1/ 100 to < 1/ 10)",8,8
"1799","fr","en","Fréquent (survenant chez moins de 1 patient sur 10):","Common (affecting less than 1 in 10 patients):",8,9
"1800","fr","en","Fréquent ≥ 1 à < 10% des patients","Common adverse reactions ≥ 1 to < 10% of patients",10,8
"1801","fr","en","Fréquent Fréquent Très fréquent","Very common Common Common Common Common",6,4
"1802","fr","en","Fréquent: • léthargie • étourdissements • frissons ou tremblements • nausées","Very common: • increase in appetite and weight gain • drowsiness or sleepiness • headache • dry mouth",18,11
"1803","fr","en","Fréquent: céphalées, sensation vertigineuse Peu fréquent: somnolence, dysesthésie","Common: headache, dizziness Uncommon: somnolence, dysaesthesia,",6,8
"1804","fr","en","Fréquent: gonflement des tissus (œ dème), malaise, douleurs (douleurs musculaires, douleurs articulaires et douleurs osseuses).","Swelling in tissues (oedema), not feeling well, pain (muscle pain, joint pain, and bone pain).",15,15
"1805","fr","en","Fréquent: insomnie, dépression, anxiété","Adverse reactions reported with Abraxane at any dose in clinical trials.",11,4
"1806","fr","en","Fréquent: tachycardie, souffle cardiaque, hypotension artérielle, épistaxis, ischémie myocardique *","Common: tachycardia, heart murmur, hypotension, epistaxis, myocardial ischemia *",9,10
"1807","fr","en","Fréquents Peu fréquents Fréquence indéterminée Affections visuelles","Common Uncommon Not known Eye disorders",6,7
"1808","fr","en","Fréquents: augmentation des taux d'azote uréique, augmentation de la créatinine et de la créatine kinase.","Common: blood urea nitrogen increased, creatinine increased and creatine kinase increased.",11,15
"1809","fr","en","Fréquents: crampes musculaires, fatigue, malaise, céphalées, somnolence Peu fréquents: tremblements, raideur musculaire Rares: paresthésie","Common: muscle cramps, fatigue, malaise, headache, somnolence Uncommon: tremor, muscular stiffness Rare: paraesthesia",13,14
"1810","fr","en","Fréquents: palpitations, douleurs thoraciques Peu fréquents: arythmie, angine de poitrine, bradycardie, tachycardie, infarctus du myocarde","Common: palpitations, chest pain Uncommon: arrhythmia, angina pectoris, bradycardia, tachycardia, myocardial infarction",12,15
"1811","fr","en","Fresenius Kabi Limited Cestrian Court, Eastgate Way Manor Park, Runcorn Cheshire WA7 1NT, Royaume-Uni Tel-No.:","Fresenius Kabi Limited Cestrian Court, Eastgate",6,15
"1812","fr","en","From data to labelling","From data to labelling",4,4
"1813","fr","en","Gadovist est une solution limpide, incolore à jaune pâle.","Gadovist is a clear, colourless to pale yellow solution.",9,9
"1814","fr","en","Galvus 50 mg comprimés","Galvus 50 mg tablets",4,4
"1815","fr","en","GANFORT contient deux principes actifs: le bimatoprost (0,3 mg/ ml) et le timolol (5 mg/ ml).","GANFORT contains two active substances: bimatoprost (0.3 mg/ ml) and timolol (5 mg/ ml).",14,16
"1816","fr","en","Gardasil peut être administré à des femmes qui allaitent ou qui en ont l'intention.","Gardasil may be given to women who are breast-feeding or intend to breast-feed.",13,14
"1817","fr","en","Garder le flacon dans l’ emballage extérieur.","Keep the vial in the outer carton.",7,7
"1818","fr","en","Gastrite Diarrhées Douleurs abdominales","Gastritis Diarrhoea Abdominal pain Dyspepsia Nausea Constipation Musculoskeletal disorders",9,4
"1819","fr","en","gastrite, vomissement, nausée, constipation, flatulence","duodenal ulcer, haemorrhage gastritis, vomiting, nausea, constipation, flatulence",8,5
"1820","fr","en","gastro-résistantes) en dose unique (300 mg d’ atazanavir","capsules) 400 mg single dose (atazanavir 300 mg QD with",10,8
"1821","fr","en","GE Healthcare AS NO-0401 Oslo","GE Healthcare AS NO-0401 Oslo",5,5
"1822","fr","en","Gélatine Dioxyde de titane (E 171)","Gelatin Titanium dioxide (E 171)",5,6
"1823","fr","en","gélule gélule gélule gélule gélule gélule","Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard",12,6
"1824","fr","en","Gemcitabine ne s’accumule pas quand elle est administrée une fois par semaine.","Gemcitabine does not accumulate when administered once weekly.",8,12
"1825","fr","en","Gemini House Flex Meadow, Harlow Essex CM19 5TY","Gemini House Flex Meadow, Harlow Essex CM19 5TY",8,8
"1826","fr","en","GEMZAR 200 mg poudre pour solution pour perfusion GEMZAR 1 000 mg poudre pour solution pour perfusion Gemcitabine","Gemzar 200 mg powder for solution for infusion Gemzar 1000 mg powder for solution for infusion Gemcitabine",17,18
"1827","fr","en","Généralement l'action complète du vaccin est obtenue de 2 à 3 semaines après la vaccination.","Full effect of the vaccine is generally achieved 2-3 weeks after the vaccination.",13,15
"1828","fr","en","Généralement, l’ augmentation a été modeste et insuffisante pour nécessiter un ajustement de la posologie.","Generally the increase was modest and not large enough to warrant dosage adjustment.",13,15
"1829","fr","en","Generics (UK) Limited Station Close Potters Bar Hertfordshire EN6 1TL UK","Generics (UK) Limited Station Close Potters Bar Hertfordshire EN6 1TL UK",11,11
"1830","fr","en","Génotype 2, 44 3","Genotype 2, 44% (35/80) 3",5,4
"1831","fr","en","Genzyme Europe B. V.","Genzyme Europe B. V.",4,4
"1832","fr","en","Gilead Sciences Limited IDA Business & Technology Park Carrigtohill Co.","Gilead Sciences Limited IDA Business & Technology Park Carrigtohill Co.",10,10
"1833","fr","en","Glaxo Group Ltd Greenford Road Greenford Middlesex UB6 0NN Royaume-Uni","Glaxo Group Ltd Greenf ord Road Greenford Middlesex UB6 0NN United Kingdom",12,10
"1834","fr","en","Glaxo Group Ltd UK","Glaxo Group Ltd UK",4,4
"1835","fr","en","Glaxo Smith Kline Kft.","Glaxo Smith Kline Kft.",4,4
"1836","fr","en","Glaxo Wellcome Production Z. I.","Glaxo Wellcome Production Z. I.",5,5
"1837","fr","en","GlaxoSmithKline – Produtos Farmacêuticos, Lda Tel: + 351 21 412 95 00","Tel: + 351 21 412 95 00 FI.PT@gsk.com",8,12
"1838","fr","en","GlaxoSmithKline ehf Thverholt 14, 105 Reykjavik, Islande","GlaxoSmithKline ehf Thverholt 14, 105 Reykjavik Iceland",7,7
"1839","fr","en","GlaxoSmithKline Pharmaceuticals S. A. ul.","GlaxoSmithKline Pharmaceuticals S. A. ul.",5,5
"1840","fr","en","GlaxoSmithKline Piispansilta 9 A, 02230 Espoo, Suomi","Laboratoire GlaxoSmithKline, 100 Route de Versailles, 78163 Marly-le-Roi Cedex, France",10,7
"1841","fr","en","GlaxoSmithKline SA Parque Tecnologico de Madrid, Calle Severo Ochoa 2, 28760, Tres Cantos, Madrid, Espagne","Estrada Marco do Grilo Zemouto, 2830 Coina Portugal",8,15
"1842","fr","en","GlaxoSmithKline UK Tel: + 44 (0)800 221441","GlaxoSmithKline UK Tel: + 44 (0)800 221441",7,7
"1843","fr","en","Gliolan contient une substance appelée chlorhydrate d’ acide aminolévulinique (5-ALA).","Gliolan contains a substance called aminolevulinic acid hydrochloride (5-ALA).",9,10
"1844","fr","en","Glivec inhibe la croissance de ces cellules dans un certain sous-groupe de ces maladies.","Glivec inhibits the growth of these cells in a certain subtype of these diseases.",14,14
"1845","fr","en","globale = 6,4 mois","Median OS = 6.4 months",5,4
"1846","fr","en","GLUCOPHAGE peut être utilisé en monothérapie ou en association avec d'autres antidiabétiques oraux ou avec l’ insuline.","GLUCOPHAGE may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.",17,17
"1847","fr","en","Glustin 30 mg comprimés Pioglitazone (sous forme de chlorhydrate)","Glustin 30 mg tablets Pioglitazone (as HCl)",7,9
"1848","fr","en","GONA L-f, en général, n’est pas efficace dans ce cas.","GONAL-f is usually not effective in such cases.",8,10
"1849","fr","en","GONAL-f 300 UI/ 0,50 ml (22 microgrammes/ 0,50 ml) poudre et solvant pour solution injectable follitropine alfa","GONAL-f 300 IU/ 0.50 ml (22 micrograms/ 0.50 ml) powder and solvent for solution for injection Follitropin alfa",18,17
"1850","fr","en","Gonazon implant présente une forme rectangulaire, de couleur blanchâtre, de 14x3x1 mm.","Gonazon implant is rectangular in shape, off white, with dimensions of 14x3x1 mm.",13,12
"1851","fr","en","Gonflement localisé, sérome, migration du produit lors de l’utilisation concomittante d’un produit synthétique de comblement osseux.","Uncommon: localised swelling, seroma, product migration when mixed with synthetic bone void filler",13,16
"1852","fr","en","gonflement sont des effets secondaires fréquents.","are common side effects.",4,6
"1853","fr","en","Gostauto 40 a LT-01112 Vilnius Lituanie","Gostauto 40 a LT-01112 Vilnius Lithuania",6,6
"1854","fr","en","Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italie.","Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy.",7,7
"1855","fr","en","Grand-Duché de Luxembourg Dr Jean-Louis ROBERT Mme Jacqueline GENOUX-HAMES","Luxembourg Mr Marc WIRTOR Dr Albert HUBERTY",7,9
"1856","fr","en","Granules 7 x 1 sachet 20 x 1 sachet 28 x 1 sachet 30 x 1 sachet","Granules 7 x 1 sachet 20 x 1 sachet 28 x 1 sachet 30 x 1 sachet",17,17
"1857","fr","en","Grossesse et allaitement Avant de prendre Doribax, informez votre médecin ou pharmacien si:","Pregnancy and breast -feeding Tell your doctor or pharmacist before using Doribax if:",13,13
"1858","fr","en","Grossesse et allaitement Demandez conseil à votre médecin ou à votre pharmacien avant de prendre tout médicament.","Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine.",14,17
"1859","fr","en","Grossesse et allaitement Il est préférable de ne pas utiliser ce médicament pendant la grossesse ou pendant l’allaitement.","It is preferable not to use this product during pregnancy and breast-feeding.",12,18
"1860","fr","en","Grossesse et allaitement Ne prenez pas Comtess pendant la grossesse ou si vous allaitez.","Pregnancy and breast-feeding Do not use Comtess during pregnancy or if you are breast-feeding.",14,14
"1861","fr","en","Grossesse et allaitement On ne dispose d’aucune donnée clinique sur l’utilisation du gadoversétamide au cours de la grossesse.","Pregnancy and Lactation There is no clinical experience with the use of gadoversetamide during pregnancy.",15,18
"1862","fr","en","Grossesse et allaitement Targretin peut être nocif pour un fœ tus en développement.","Pregnancy and breast-feeding Targretin may be harmful to a developing foetus.",11,13
"1863","fr","en","Grossesse et allaitement Vous devez informer votre médecin si vous pensez être (ou prévoyez d’ être) enceinte.","Pregnancy and breast-feeding You must tell your doctor if you think you are (or might become) pregnant.",17,17
"1864","fr","en","Grossesse Il n'existe pas de données pertinentes concernant l'utilisation du raltégravir chez la femme enceinte.","Pregnancy There are no adequate data from the use of raltegravir in pregnant women.",14,15
"1865","fr","en","Grossesse Les radionucléides utilisés chez la femme enceinte délivrent également des doses de radiation au foetus.","Pregnancy Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus.",15,16
"1866","fr","en","Grossesse: les données sur l'utilisation de l'éfavirenz chez les femmes enceintes sont limitées.","Pregnancy: there are limited amount of data from the use of efavirenz in pregnant women.",15,13
"1867","fr","en","Groupe Affaires organisationnelles Ce groupe s’ est réuni 8 fois et a abordé divers aspects organisationnels.","The Pharmacovigilance Working Party met 8 times in 2002.",9,16
"1868","fr","en","Groupe d’âges Nouveau-nés (0 à 14 jours)","Age group Newborn infants (age 0 – 14 days)",9,7
"1869","fr","en","Groupe de travail «Immunologie» (BWP)","s Very dissatisfied s Satisfied",5,5
"1870","fr","en","Groupe de travail Efficacité","In support of the CVMP risk",6,4
"1871","fr","en","Groupe de travail Produits sanguins Groupe de travail Efficacité (y compris les groupes thérapeutiques)","Blood Products Working Group Efficacy Working Party (including therapeutic groups)",10,14
"1872","fr","en","Groupe de travail sur les médicaments à base de plantes","The Working Party on Herbal Medicinal Products met three times in 2001.",12,10
"1873","fr","en","Groupe pharmaco-thérapeutique: facteur VIII de coagulation sanguine (Code ATC B02B D02).","Pharmacotherapeutic group: blood coagulation factor VIII (ATC-Code B02B D02).",9,11
"1874","fr","en","Groupes ad hoc du CPMP","Ad hoc CPMP Groups",4,5
"1875","fr","en","Groupes de travail et groupes ad hoc","Safety Working Party Christian FRIIS",5,7
"1876","fr","en","H-1113 Budapest Tel: +36-1-463-8100","H-1113 Budapest Tel: +36-1-463-8100",4,4
"1877","fr","en","H-1139 Budapest Tel.: +36 1 465 2100","H-1139 Budapest Tel.: +36 1 465 2100",7,7
"1878","fr","en","Hadovka Office Park Evropská 2590/33d CZ-160 00 Praha 6 Tel: + 420 267 292 111","Hadovka Office Park Evropská 2590/33d CZ-160 00 Praha 6 Tel: + 420 267 292 111",15,15
"1879","fr","en","Hälsa Pharma GmbH Immermannstraße 9 33619 Bielefeld Allemagne","Hälsa Pharma GmbH Immermannstraße 9 33619 Bielefeld GERMANY",8,8
"1880","fr","en","Hausse des concentrations sanguines en phosphatase alcaline, transaminases, bilirubine, acide urique, chlorure, phosphate et sodium.","Increased blood alkaline phosphatase, transaminases, bilirubin, uric acid, chloride, phosphate and sodium.",12,15
"1881","fr","en","Hazard ratio (IC 95%)","Difference in response rate (95% CI)",6,4
"1882","fr","en","Hazard ratio (IC 95%) nombre total de patients traités.","Hazard ratio (95% CI) total number of patients treated.",9,9
"1883","fr","en","HBVAXPRO 10 microgrammes/ml Suspension injectable en seringue préremplie Vaccin de l’hépatite B (ADNr)","HBVAXPRO 10 micrograms/ ml Suspension for injection in pre-filled syringe Hepatitis B vaccine (rDNA)",14,13
"1884","fr","en","Heinrich Mack Strasse 35","Heinrich Mack Strasse 35",4,4
"1885","fr","en","Helixate NexGen 500 UI Poudre et solvant pour solution injectable","Helixate NexGen 500 IU Powder and solvent for solution for injection",11,10
"1886","fr","en","hématologiques et du système lymphatique","Blood and the lymphatic system disorders",6,5
"1887","fr","en","héparine + inhibiteur de la","REPLACE-2; bleeding site frequency data (bivalirudin versus heparin + GPIIb/ IIIa inhibitor).",12,5
"1888","fr","en","Hepsera 10 mg comprimés","Hepsera 10 mg tablets",4,4
"1889","fr","en","Hermal Kurt Herrmann GmbH & Co OHG Scholtzstrasse 3 D-21465 Reinbek Allemagne","Hermal Kurt Herrmann GmbH & Co OHG Scholtzstrasse 3 D-21465 Reinbek Germany",12,12
"1890","fr","en","Herpèsvirus de la rhinotrachéite féline inactivé (souche 605)","Inactivated Feline Rhinotracheitis Virus (605 strain)",6,8
"1891","fr","en","Hertfordshire AL7 1TW - UK Tel: + 44-(0)1 707 363 636","Hertfordshire AL7 1TW - UK Tel: + 44-(0)1 707 363 636",11,11
"1892","fr","en","Hertfordshire AL7 3AY, UK","Welwyn Garden City Hertfordshire AL7 3AY, UK",7,4
"1893","fr","en","HEXAL AG Industriestraße 25","HEXAL AG Industriestraße 25",4,4
"1894","fr","en","Hexal Pharma Nederland B. V.","Hexal Pharma Nederland B. V.",5,5
"1895","fr","en","HI titre ≥ 6.0 log2 par dose","HI titre ≥ Emulsion for 6.0 log2 injection per dose",10,7
"1896","fr","en","Hoechst Marion Roussel Broadwater Park Denham, Uxbridge Middlesex UB9 5HP Royaume-Uni","Hoechst Marion Roussel Broadwater Park Denham, Uxbridge Middlesex UB9 5HP UK",11,11
"1897","fr","en","Hörgatún 2 IS-210 Garðabær","Hörgatún 2 IS-210 Garðabær",4,4
"1898","fr","en","hormone surges in conteolled ovarian hyperstimulation","Room 3D – meeting room (18 people)",7,6
"1899","fr","en","http: / /www. pheur. org","International Conference on Harmonisation http: / /www. ich. org",9,5
"1900","fr","en","humaine ou à l’un des autres composants contenus dans Betaferon.","any of the other ingredients of Betaferon.",7,10
"1901","fr","en","Humalog BASAL 100 UI/ ml, suspension injectable en cartouche Insuline lispro protamine en suspension Voie sous-cutanée.","Humalog BASAL 100 U/ ml suspension for injection in cartridge Insulin lispro protamine suspension Subcutaneous use",16,16
"1902","fr","en","Humalog Mix25 100 UI/ml suspension injectable en flacon (insuline lispro)","Humalog Mix25 100 U/ml suspension for injection in vial (insulin lispro)",11,10
"1903","fr","en","Humalog Mix50 100 UI/ml suspension injectable en flacon est conditionné par boîte de 1 flacon.","Humalog Mix50 100 U/ml suspension for injection in vial comes in a pack of 1 vial.",16,15
"1904","fr","en","Humalog Pen 100 UI/ml, solution injectable (insuline lispro)","Humalog Pen 100 U/ml solution for injection (insulin lispro)",9,8
"1905","fr","en","Humalog peut, si votre médecin vous l'a indiqué, être injecté en intramusculaire.","You should only inject it into a muscle if your doctor has told you to.",15,12
"1906","fr","en","Humalog remplace votre propre insuline et assure un contrôle du glucose à long terme.","Humalog is a substitute for your own insulin and is used to control glucose in the long term.",18,14
"1907","fr","en","Human measles immunoglobulin i. m.","Human measles immunoglobulin i. m.",5,5
"1908","fr","en","Humira 40 mg, solution injectable en seringue préremplie avec protège-aiguille.","Humira 40 mg solution for injection in pre-filled syringe with needleguard",11,10
"1909","fr","en","Humira peut avoir un effet mineur sur l’ aptitude à conduire et à utiliser des machines.","Humira may have a minor influence on the ability to drive and use machines.",14,16
"1910","fr","en","Huntercombe Lane South Taplow Maidenhead Berkshire, SL6 0PH","Huntercombe Lane South Taplow, Maidenhead Berkshire, SL6 0PH United Kingdom",10,8
"1911","fr","en","Hycamtin affecte également les cellules non cancéreuses, ce qui entraîne des effets indésirables.","Hycamtin also affects non-cancer cells, which causes side effects.",9,13
"1912","fr","en","Hyperglycémie (rapportée particulièrement chez les patients diabétiques)","Feeling abnormal Feeling cold Thirst",5,7
"1913","fr","en","hyperhidrose, sueurs nocturnes, prurit, rash acné, dermatite acnéiforme, peau sèche,","hepatitis† hyperhidrosis, night sweats, pruritus, rash",6,10
"1914","fr","en","Hypersensibilité à l’ un des excipients.","Hypersensitivity to any of the excipients.",6,6
"1915","fr","en","Hypersensibilité à la substance active ou à l'un des excipients.","Hypersensitivity to the active substance or to any of the excipients.",11,10
"1916","fr","en","Hypersensibilité à la substance active, aux macrolides ou à l’ un des excipients.","Hypersensitivity to the active substance, to any of the macrolide antibacterial agents, or to any of the excipients.",18,13
"1917","fr","en","Hypersensibilité au gemfibrozil ou à l'un des excipients.","Hypersensitivity to gemfibrozil or any of the excipients.",8,8
"1918","fr","en","Hypersensibilité au principe actif ou à l’ un des excipients.","Hypersensitivity to the active substance or to any of the excipients",11,10
"1919","fr","en","Hypersensibilité connue à la substance active ou à l'un des excipients ou aux protéines murines.","Hypersensitivity to the active substance or to any of the excipients or to murine proteins.",15,15
"1920","fr","en","Hypersensibilité connue au principe actif ou à l'un des excipients.","Known hypersensitivity to the active substance or to any of the excipients.",12,10
"1921","fr","en","Hypersensibilité connue aux substances actives ou à l'un des excipients.","Hypersensitivity to the active substances or to any of the excipients.",11,10
"1922","fr","en","Hypertension intracrânienne (augmentation de la pression dans le cerveau):","Intracranial hypertension (increased pressure in the brain):",7,9
"1923","fr","en","Hypertension pulmonaire avec une pression artérielle pulmonaire systolique > 90 mm Hg.","Pulmonary hypertension with a systolic pulmonary artery pressure > 90 mm Hg.",12,12
"1924","fr","en","Hypertension, aggravation de l’ hypertension","Hypertension, hypertension aggravate d",4,5
"1925","fr","en","Hypertriglycéridémie§, hyperuricémie, augmentation de l’ appétit, Fréquent: § Affections psychiatriques Dépression, instabilité émotionnelle, insomnie Très fréquent:","Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour",10,16
"1926","fr","en","Hypophosphatémie Augmentation de la créatinémie et de","Hypophosphataemia Blood creatinine and blood urea increased, hypocalcaemia",8,7
"1927","fr","en","Hypromellose Dioxyde de titane (E171) Macrogols Triacétine","Hypromellose Titanium Dioxide (E171) Macrogols Triacetin",6,7
"1928","fr","en","Hypromellose, Mélange de couleur bleu (polydextrose, hypromellose, diacétate de glycérol, macrogol 8000, dioxyde de titane E171, indigotine E132)","Hypromellose Colour mixture blue (polydextrose, hypromellose, glycerol diacetate, macrogol 8000, titanium dioxide E171, indigo carmine E132)",16,18
"1929","fr","en","I-04010 Campoverde di Aprilia (Latina) Tel: + 39 06 928921","I-04010 Campoverde di Aprilia (Latina) Tel: + 39 06 928921",10,10
"1930","fr","en","i) Précautions particulières d’ emploi chez l’ animal","Special precautions for use in animals Do not administer in conjunction with other medicinal products.",15,8
"1931","fr","en","Ibaflin 7,5% gel oral.","Ibaflin 7.5% oral gel",4,4
"1932","fr","en","Ibaflin gel ne doit être utilisé qu’ après avoir réalisé un antibiogramme.","Ibaflin gel should only be used based on susceptibility testing.",10,12
"1933","fr","en","IDNT est une étude de morbi-mortalité en double aveugle, contrôlée, comparant Irbesartan BMS, amlodipine et un placebo.","IDNT was a double blind, controlled, morbidity and mortality trial comparing Irbesartan BMS, amlodipine and placebo.",16,17
"1934","fr","en","Ifidesa Aristegue Alameda de Urquijo, 27 48008 Bilbao","Ifidesa Aristegue Alameda de Urquijo, 27 48008 Bilbao",8,8
"1935","fr","en","II. E.2 Identification et essai des principes actifs","Identification and assay of active ingredients",6,8
"1936","fr","en","II. F.2 Stabilité du produit fini","II. F.1 Stability of the final product",7,6
"1937","fr","en","Il a été convenu que l'indication ne devait mentionner que «reflux gas- tro-œsophagien pathologique».","It was agreed that the indication should only mention “symptomatic gastroesophageal reflux disease”.",13,14
"1938","fr","en","Il a été nommé directeur exécutif en 1992.","He was appointed Executive Director in 1992.",7,8
"1939","fr","en","Il a été rapporté au moins un effet indésirables chez environ 71,4% des patientes recevant l’ hormone parathyroïde.","Approximately 71.4% of the patients on parathyroid hormone reported at least one ADR.",13,18
"1940","fr","en","Il a recommandé que Forcaltonin reçoive une autorisation de mise sur le marché.","They recommended that Forcaltonin be given marketing authorisation.",8,13
"1941","fr","en","Il a recommandé que INCRELEX reçoive une autorisation de mise sur le marché.","The Committee recommended that INCRELEX be given marketing authorisation.",9,13
"1942","fr","en","Il a rejoint l'EMEA en mai 2000.","He joined the EMEA in May 2000.",7,7
"1943","fr","en","Il a rejoint l’EMEA en avril 1995.","He joined the EMEA in April 1995.",7,7
"1944","fr","en","Il a, dès lors, recommandé l’ octroi d’ une autorisation de mise sur le marché pour ZOSTAVAX.","They recommended that ZOSTAVAX be given marketing authorisation.",8,17
"1945","fr","en","Il a, dès lors, recommandé qu’ une autorisation de mise sur le marché soit délivrée pour Zarzio.","The Committee recommended that Zarzio be given marketing authorisation.",9,17
"1946","fr","en","Il agit en augmentant la quantité d’ urine que vous produisez.","It works by increasing the amount of water (urine) you produce.",11,11
"1947","fr","en","Il aide à contrôler votre réaction allergique et ses symptômes.","It helps control your allergic reaction and its symptoms.",9,10
"1948","fr","en","Il bloque une enzyme appelée protéase, qui joue un rôle dans la reproduction du VIH.","It blocks an enzyme called protease, which is involved in the reproduction of HIV.",14,15
"1949","fr","en","Il contient le principe actif anakinra (100 mg).","It contains the active substance anakinra (100 mg).",8,8
"1950","fr","en","Il contient le principe actif émédastine (0,5 mg/ ml).","It contains the active substance emedastine (0.5 mg/ ml).",9,9
"1951","fr","en","Il contient une protéine (antigène) du circovirus porcin de type 2 (PCV2).","It contains a protein (antigen) from the porcine circovirus type 2 virus (PCV2).",13,12
"1952","fr","en","Il conviendra d'être prudent en cas de co- administration de Kaletra et de rosuvastatine.","Caution should be exercised when Kaletra is co-administered with rosuvastatin.",10,14
"1953","fr","en","Il convient d'être prudent en cas de prescription chez le sujet âgé.","Caution must be exercised when prescribing to elderly patients.",9,12
"1954","fr","en","Il convient d’ appuyer fermement sur le patch jusqu’ à ce que les bordures adhèrent correctement.","The patch should be pressed down firmly until the edges stick well.",12,16
"1955","fr","en","Il convient d’ éviter un e","Haemoglobin variability should be addressed ed",6,6
"1956","fr","en","Il convient de diminuer progressivement les doses lors de l’ arrêt de l’ olanzapine.","Gradual tapering of the dose should be considered when discontinuing olanzapine.",11,14
"1957","fr","en","Il convient de porter des gants.","The use of gloves is required.",6,6
"1958","fr","en","Il convient de respecter les procédures correctes de manipulation et d’élimination.","Procedures for proper handling and disposal should be observed.",9,11
"1959","fr","en","Il convient de tenir compte des recommandations officielles concernant l’ utilisation appropriée des antibactériens.","Consideration should be given to official guidance on the appropriate use of antibacterial agents.",14,14
"1960","fr","en","Il couvre également l’achat d’annuaires.","It also covers the purchase of directories.",7,5
"1961","fr","en","Il doit être envisagé de remplacer la zidovudine dans un traitement par association d’ antirétroviraux pré-existant.","Consideration should be given to replacing zidovudine in a combination ART regimen if this is already established.",17,16
"1962","fr","en","Il doit être manipulé avec soin.","It must be handled with care.",6,6
"1963","fr","en","Il doit être utilisé avec grande prudence chez les patients présentant de graves problèmes de foie.","It should be used with great caution in patients with severe liver problems.",13,16
"1964","fr","en","Il doit être utilisé avec précaution chez les patients traités simultanément par d’ autres médicaments.","Caution is also needed by patients taking AZILECT at the same time as other medicines.",15,15
"1965","fr","en","Il en résulte un besoin d'augmentation du personnel et des ressources financières de l'EMEA.","users of medicines, the pharmaceutical industry, health care",8,14
"1966","fr","en","Il est administré sous forme de perfusion intraveineuse en 15 minutes.","It is given as an intravenous infusion over 15 minutes.",10,11
"1967","fr","en","Il est attendu une augmentation des concentrations plasmatiques de la warfarine avec INTELENCE.","INTELENCE is expected to increase plasma concentrations of warfarin.",9,13
"1968","fr","en","Il est conseillé d'effectuer l'injection immédiatement après le mélange.","It is advisable to inject immediately after mixing.",8,9
"1969","fr","en","Il est disponible en comprimés blancs en forme de capsule.","It is available as white capsule-shaped tablets.",7,10
"1970","fr","en","Il est disponible en comprimés orange de forme oblongue, contenant 400 mg de télithromycine.","It is available as orange, oblong tablets containing 400 mg telithromycin.",11,14
"1971","fr","en","Il est disponible sous forme de gélules (200 mg) et sous forme de solution buvable (40 mg/ ml).","It is available as capsules (200 mg) and as an oral solution (40 mg/ ml).",15,18
"1972","fr","en","Il est disponible sous la forme de comprimés ronds de couleur blanche (0,088, 0,18, 0,35 et 0,7 mg).","It is available as white, round tablets (0.088, 0.18, 0.35 and 0.7 mg).",13,18
"1973","fr","en","Il est donc important que vous continuiez à prendre Emselex correctement, comme décrit ci-dessus.","Therefore, it is important to keep taking Emselex correctly, as described above.",12,14
"1974","fr","en","Il est donc nécessaire de rechercher soigneusement tout signe de toxicité du fentanyl chez les personnes âgées.","Elderly patients should be observed carefully for signs of fentanyl toxicity.",11,17
"1975","fr","en","Il est écrit “ PFIZER” sur une face et “ VGR 50” sur l’ autre.","They are marked “ PFIZER” on one side and “ VGR 50” on the other side.",16,15
"1976","fr","en","Il est impératif de suivre le programme de prévention de la grossesse Thalidomide Celgene.","Patients must follow the Thalidomide Celgene Pregnancy Prevention Programme.",9,14
"1977","fr","en","Il est important de conserver Norvir dans son flacon d'origine.","It is important to keep Norvir in the bottle it came in.",12,10
"1978","fr","en","Il est important de continuer à prendre un comprimé de Bonviva chaque mois.","It’s important to keep taking Bonviva every month.",8,13
"1979","fr","en","Il est important de prendre les comprimés ou le liquide comme votre médecin vous l’indiquera.","It is important that you take the tablets or liquid as the doctor tells you.",15,15
"1980","fr","en","Il est important de signaler à votre médecin si vous êtes traité par l’ un de ces médicaments.","It is important to tell your doctor if you are taking either of these drugs.",15,18
"1981","fr","en","Il est important que vous preniez OLANZAPINE NEOPHARMA aussi longtemps que votre médecin vous l’ aura indiqué.","It is important that you carry on taking OLANZAPINE NEOPHARMA for as long as your doctor tells you.",18,17
"1982","fr","en","Il est peu probable que l'atosiban inhibe les isoformes hépatiques du cytochrome P450 chez l'homme (voir rubrique 4.5.).","It is unlikely that atosiban inhibits hepatic cytochrome P450 isoforms in humans (see section 4.5).",15,18
"1983","fr","en","Il est possible que vous ayez retiré trop rapidement l’aiguille de votre peau.","You may have removed the needle from your skin too quickly.",11,13
"1984","fr","en","Il est présenté en boîtes de un ou sept flacons.","It is available in packs of one or seven vials.",10,10
"1985","fr","en","Il est présenté en cartouche contenue dans un stylo prérempli jetable.","It is supplied in a cartridge contained in a prefilled disposable pen.",12,11
"1986","fr","en","Il est présenté en tubes contenant 10, 30 ou 60 grammes de pommade.","It is supplied in tubes containing 10, 30 or 60 grams of ointment.",13,13
"1987","fr","en","Il est recommandé d'inscrire la date de première utilisation du flacon sur l’ étiquette.","It is recommended that the date of the first use be noted on the label.",15,14
"1988","fr","en","Il est recommandé d’ administrer Rapamune 4 heures après la ciclosporine (microémulsion).","It is recommended that Rapamune be administered 4 hours after ciclosporin (microemulsion).",12,12
"1989","fr","en","Il est recommandé d’ utiliser Cerezyme immédiatement après l’ avoir mélangé à de l’ eau stérile.","It is recommended that Cerezyme is used immediately after it has been mixed with sterile water.",16,16
"1990","fr","en","Il est recommandé d’ utiliser la solution immédiatement après le radiomarquage.","After radiolabelling, an immediate use is recommended.",7,11
"1991","fr","en","Il est recommandé de contrôler régulièrement votre taux de sucre dans le sang.","It is recommended that you measure your blood glucose regularly.",10,13
"1992","fr","en","Il est recommandé de maintenir cette vitesse de perfusion réduite pour toutes les perfusions ultérieures.","It is recommended to maintain this lower infusion rate in all subsequent infusions.",13,15
"1993","fr","en","Il est recommandé de ne pas administrer la solution à un débit supérieur à 2 ml/ min.","It is recommended that the rate of administration should not exceed 2 ml/ min.",14,17
"1994","fr","en","Il est recommandé par la suite de poursuivre une surveillance régulière, par exemple tous les 3-6 mois.","Thereafter it is recommended to continue regular monitoring, e. g. every 3-6 months.",13,17
"1995","fr","en","Il est recommandé pour un usage à court ou long terme.","KOGENATE Bayer is intended for either short-term or long-term use.",10,11
"1996","fr","en","Il est utilisé dans les indications suivantes:","It is used in the following ways:",7,7
"1997","fr","en","Il est utilisé en association avec le cisplatine et le 5-fluorouracile.","It is used with cisplatin and 5-fluorouracil.",7,11
"1998","fr","en","Il existe aussi des liens à d’ autres sites concernant les maladies rares et les médicaments orphelins.","There are also links to other websites about rare diseases and treatments.",12,17
"1999","fr","en","Il existe quatre tailles différentes de conditionnements (flacons contenant 30, 60, 100 ou 175 comprimés).","There are four different pack sizes (bottles containing 30, 60, 100 or 175 tablets).",14,15
"2000","fr","en","Il faut au moins 4 semaines de traitement pour produire un effet maximum.","At least 4 weeks’ treatment is required to produce maximum effect.",11,13
"2001","fr","en","Il faut éviter de répéter l’ application au même endroit au cours des 14 jours qui suivent.","Reapplication to the same site within 14 days should be avoided.",11,17
"2002","fr","en","Il faut noter que les effets indésirables peuvent être intensifiés.","It should be noted that the adverse reactions may be intensified.",11,10
"2003","fr","en","Il faut veiller à ne pas introduire d'alcool ni d'autre produit désinfectant dans la suspension d'insuline.","Care must be taken to ensure that no alcohol or other disinfectants enter the insulin suspension.",16,16
"2004","fr","en","Il n'a pas été conduit d'études spécifiques d’ interactions médicamenteuses in vivo.","Specific in vivo drug interaction studies have not been performed.",10,12
"2005","fr","en","Il n'est pas recommandé de conduire un véhicule ou d'utiliser des machines dans ces circonstances.","It should be considered whether it is advisable to drive or operate machinery in these circumstances.",16,15
"2006","fr","en","Il n'existe aucune donnée disponible portant sur l’ utilisation du pegfilgrastim chez la femme enceinte.","There are no adequate data from the use of pegfilgrastim in pregnant women.",13,15
"2007","fr","en","Il n'existe pas d'antidote spécifique.","No specific antidotal therapy exists.",5,5
"2008","fr","en","Il n'existe pas de donnée sur l'utilisation de la duloxétine chez la femme enceinte.","Pregnancy There are no data on the use of duloxetine in pregnant women.",13,14
"2009","fr","en","Il n'existe pas de données suffisamment pertinentes concernant l'utilisation de CHAMPIX chez la femme enceinte.","There are no adequate data from the use of CHAMPIX in pregnant women.",13,15
"2010","fr","en","Il n'existe pas de données suffisamment pertinentes concernant l'utilisation de Zonegran chez la femme enceinte.","There are no adequate data from the use of Zonegran in pregnant women.",13,15
"2011","fr","en","Il n'existe pas de données sur l'utilisation simultanée par voie générale de stéroïdes ou de produits immunosuppresseurs.","There is no experience with concomitant use of systemic steroids or immunosuppressive agents.",13,17
"2012","fr","en","Il n'y a pas de données suffisantes pour recommander une dose chez l'enfant.","There is not enough information to recommend a dose in children.",11,13
"2013","fr","en","Il n'y a pas eu d'études cliniques évaluant les interactions du riluzole avec d'autres médicaments.","There have been no clinical studies to evaluate the interactions of riluzole with other medicinal products.",16,15
"2014","fr","en","Il n’ a pas été démontré que la réduction et le fractionnement des doses apportaient un bénéfice quelconque.","Dose reduction or splitting the daily dose has not been shown to provide benefit.",14,18
"2015","fr","en","Il n’ a pas été observé d’ événement évocateur d’ un effet rebond.","No evidence for acute rebound has been observed.",8,13
"2016","fr","en","Il n’ apparaît pas nécessaire d’ ajuster la posologie de Myfenax.","Dose adjustment of Myfenax does not appear to be necessary.",10,11
"2017","fr","en","Il n’ est pas nécessaire d’ éliminer la bulle avant l’ injection.","You do not have to remove the air bubble before injecting.",11,12
"2018","fr","en","Il n’ est pas recommandé de co-administrer INTELENCE avec le nelfinavir.","It is not recommended to co-administer INTELENCE with nelfinavir.",9,11
"2019","fr","en","Il n’ est utilisé que chez les veaux et les jeunes bovins.","It is only used in calves and young cattle.",9,12
"2020","fr","en","Il n’ existe pas d’ antidote spécifique au chlorhydrate de raloxifène.","There is no specific antidote for raloxifene hydrochloride.",8,11
"2021","fr","en","Il n’ existe pas d’ interaction pharmacocinétique entre Zenapax et l’ acide mycophénolique, le en","There is no pharmacokinetic interaction between Zenapax and mycophenolic acid, the active metabolite of mycophenolate mofetil (CellCept).",17,15
"2022","fr","en","Il n’ existe pas de données chez l’ enfant.","There is no experience in children.",6,9
"2023","fr","en","Il n’ existe pas de données concernant un éventuel passage de la bivalirudine dans le lait maternel.","It is not known whether bivalirudin is excreted in human milk.",11,17
"2024","fr","en","Il n’ existe pas de données sur l’ excrétion de la darifénacine dans le lait maternel.","Lactation Darifenacin is excreted into the milk of rats.",9,16
"2025","fr","en","Il n’ y a pas d’ antidote connu à APTIVUS en cas de surdosage.","There is no known antidote for APTIVUS overdose.",8,14
"2026","fr","en","Il n’ y a pas d’ études de toxicité de la reproduction chez le lapin.","There are no reproductive toxicity studies in rabbits.",8,15
"2027","fr","en","Il n’ y a pas d’ expérience clinique chez les patients atteints d’ insuffisance hépatique sévère.","There is no clinical experience in patients with severe hepatic impairment.",11,16
"2028","fr","en","Il n’ y a pas de données chez les enfants et adolescents ayant des antécédents de maladie cardiaque.","There are no data in children or adolescents with a history of cardiac disease.",14,18
"2029","fr","en","Il n’ y a pas de mise en garde ni de précaution supplémentaire spécifique à l’ association Trizivir.","There are no additional precautions or warnings relevant to the combination Trizivir.",12,18
"2030","fr","en","Il n’a pas été observé d’effet sur la fréquence des réhospitalisations pour angor instable.","There was no observed effect on the rate of rehospitalisation for unstable angina.",13,14
"2031","fr","en","Il n’existe aucune donnée sur la pharmacocinétique de la substance active chez l’homme.","There are no data on the pharmacokinetics of the active substance in man.",13,13
"2032","fr","en","Il n’y a pas d’expérience clinique concernant l’utilisation de Levemir chez les enfants de moins de 6 ans.","There is no clinical experience with Levemir in children below the age of 6 years.",15,18
"2033","fr","en","Il ne contient ni adjuvant, ni conservateur.","No adjuvant or preservative is included.",6,7
"2034","fr","en","Il ne doit en aucun cas être injecté dans un vaisseau sanguin.","Optaflu should under no circumstances be injected into a blood vessel.",11,12
"2035","fr","en","Il ne doit pas être mâché, cassé, ou écrasé.","It must not be chewed, broken, or crushed.",8,9
"2036","fr","en","Il ne doit pas être utilisé chez les femmes enceintes.","It should not be used in pregnant women.",8,10
"2037","fr","en","Il ne peut pas être administré à des femmes enceintes de plus de trois mois ou allaitantes.","It must not be used in women who are more than three months pregnant or who are breast-feeding.",18,17
"2038","fr","en","Il peut aussi aider à augmenter le nombre de cellules T appelées cellules CD4.","It may also help to increase the number of T cells called CD4 cells.",14,14
"2039","fr","en","Il peut être judicieux de prendre Atripla au coucher.","It can help to take Atripla at bedtime.",8,9
"2040","fr","en","Il peut être nécessaire d'ajuster la posologie du médicament, le régime ou l'activité physique.","Adjustments in dosage of the medicinal product, meal patterns, or physical activity may be needed.",15,14
"2041","fr","en","Il peut être nécessaire de reporter la vaccination jusqu’à la guérison complète.","It might be necessary to postpone the vaccination until recovery.",10,12
"2042","fr","en","Il peut être pris avec ou sans aliments et à tout moment de la journée.","It may be taken with or without food and without regard to the time of day.",16,15
"2043","fr","en","Il peut être pris avec ou sans aliments.","It can be taken with or without food.",8,8
"2044","fr","en","Il peut persister quelques petites bulles d'air dans le stylo.","There may still be some small air bubbles left in the pen.",12,10
"2045","fr","en","Il peut y avoir une goutte de sang au niveau du site d’injection.","There may be a little bleeding at the injection site.",10,13
"2046","fr","en","Il possède une longue chaîne latérale qui le lie à l'exo-site du récepteur.","In patients with asthma a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed.",17,13
"2047","fr","en","Il pourra être nécessaire d’effectuer régulièrement des analyses de sang pour contrôler votre fonction hépatique.","Regular blood tests may be required to check your liver is working properly.",13,15
"2048","fr","en","Il s’ agit d’ une solution pour injection (0,5 mg/ ml).","It is a solution for injection (0.5 mg/ ml).",9,11
"2049","fr","en","Il s’agit là du troisième mandat du Conseil et les membres sont nommés jusqu’à la fin 2002.","This is the third mandate of the Board and members are appointed until the end of 2002.",17,17
"2050","fr","en","Il se présente dans un flacon de 10 ml que vous utiliserez pour remplir une seringue.","It comes in a 10 ml vial that you use to fill a syringe.",14,16
"2051","fr","en","Il se présente en cartouches scellées dans un stylo injecteur jetable, OptiSet.","It comes in cartridges sealed in disposable pen injectors, OptiSet.",10,12
"2052","fr","en","Il se présente sous forme de comprimés ronds.","It is available as round tablets.",6,8
"2053","fr","en","Il surveillera votre réponse au traitement et votre état clinique.","He will monitor your response and condition.",7,10
"2054","fr","en","ILLUMINATION LASER DU SITE DE TRAITEMENT","LASER ILLUMINATION OF TREATMENT SITE",5,6
"2055","fr","en","Ils peuvent concerner jusqu'à 1 personne sur 10 traitées par Atriance.","These may affect up to 1 in 10 people treated with Atriance:",12,11
"2056","fr","en","Ils peuvent être aisément cassés en deux moitiés égales.","They can easily be broken into two equal halves.",9,9
"2057","fr","en","Ils peuvent être désagréables mais la plupart disparaissent rapidement.","These can be unpleasant, but most of them disappear quickly.",10,9
"2058","fr","en","Ils peuvent être pris pendant ou en dehors des repas.","The tablets may be taken with or without food.",9,10
"2059","fr","en","Ils sont fréquents chez l’ adulte mais peu fréquents chez le nourrisson, l’ enfant et l’ adolescent.","They are common in adult patients, but uncommon in infants, children and adolescents.",13,17
"2060","fr","en","Ils sont généralement légers à modérés.","These are usually mild to moderate.",6,6
"2061","fr","en","Ils sont généralement réversibles après l’arrêt du traitement par Intrinsa.","They are usually reversible if Intrinsa treatment is discontinued.",9,10
"2062","fr","en","Ils sont présentés dans une","What Clopidogrel Winthrop looks like and contents of the pack",10,5
"2063","fr","en","Immunogénicité A ce jour, la corrélation immunologique de protection n’ a pas été déterminée.","Immunogenicity No established immunological correlates of protection against cholera after oral vaccination have been identified.",15,14
"2064","fr","en","Immunostimulants, cytokines et immunomodulateurs, interférons, interféron alfa-2b, code ATC:","Immunostimulants, cytokines and immunomodulators, interferons, interferon alfa-2b, ATC code:",9,9
"2065","fr","en","IMPORTANT: ne jamais conserver un mélange granules/ nourriture pour une administration ultérieure.","Never store any granule/ food mixture for use at a later time.",12,12
"2066","fr","en","Imprida 5 mg/ 80 mg","Imprida 5 mg/ 80 mg",5,5
"2067","fr","en","impuissance, irritation de la prostate;","inflammation of the prostate",4,5
"2068","fr","en","In vitro, la glucosyl-céramide synthétase est inhibée par le miglustat avec une IC50 de 20-37µM.","In vitro, glucosylceramide synthase is inhibited by miglustat with an IC50 of 20-37 µM.",14,15
"2069","fr","en","Inclinez la tête légèrement en arrière et regardez en haut.","Tilt your head back and look at the ceiling.",9,10
"2070","fr","en","INCRELEX 10 mg/ml solution injectable Mécasermine SC","INCRELEX 10 mg/ml injection Mecasermin SC",6,7
"2071","fr","en","indésirables (% de patients)a","MedDRA Standard System Organ Class",5,4
"2072","fr","en","indésirables très fréquents (> 1/ 10)","Very Common Undesirable Effects (> 1/ 10)",7,6
"2073","fr","en","INDICATIONS D’ UTILISATION nt","INSTRUCTIONS ON USE rod",4,4
"2074","fr","en","Indinavir Cmin: ↓ 39% (Par rapport à indinavir 800 mg seul, trois fois/ jour)","Indinavir AUC ↓ 34% Indinavir Cmin: ↓ 39% (Relative to Indinavir 800 mg TID alone)",15,14
"2075","fr","en","InductOs est actif au site d'implantation.","InductOs is active at the site of implantation.",8,6
"2076","fr","en","Industriepark 30 B-2220 Heist-op-den-Berg","Industriepark 30 B-2220 Heist-op-den-Berg Belgium",5,4
"2077","fr","en","Industrieweg 23, P. O.","TEVA Pharma B. V., Industrieweg 23, P. O.",8,4
"2078","fr","en","Infanrix hexa doit être injecté par voie intramusculaire profonde, de préférence en des sites distincts à chaque injection.","Infanrix hexa is for deep intramuscular injection, preferably at alternating sites for subsequent injections.",14,18
"2079","fr","en","Infection des voies respiratoires basses (e. g. bronchite, pneumonie), infection des voies respiratoires hautes, sinusite, dyspnée","Lower respiratory tract infection (e. g. bronchitis, pneumonia), upper respiratory tract infection, sinusitis, dyspnoea Uncommon:",15,16
"2080","fr","en","Infection des voies urinaires, Cellulite, Amygdalite, Pharyngite, Candidose buccale, Grippe, Gastroentérite, Infection fongique, Infection, Abcès dentaire","Sepsis, Urinary tract infection, Cellulitis, Tonsillitis, Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Fungal infection, Infection, Tooth abscess",16,16
"2081","fr","en","Infection virale Infection respiratoire haute","Viral infection Upper respiratory infection",5,5
"2082","fr","en","Infections des voies respiratoires basses","Infections of the upper respiratory tract",6,5
"2083","fr","en","Infections des voies respiratoires supérieures","Upper respiratory tract infections",4,5
"2084","fr","en","Infections et infestations Laryngite Affections vasculaires","Infections and infestations Laryngitis Vascular Disorders",6,6
"2085","fr","en","Infections et infestations Très fréquent:","Infection s and infestations Very common:",6,5
"2086","fr","en","Infections réfractaires graves à Candida:","Visual disturbances In clinical trials, voriconazole treatment-related visual disturbances were very common.",12,5
"2087","fr","en","Inflammation muqueuse Vomissements Diarrhée Nausée Inconfort épigastrique","Mucositis Vomiting Diarrhoea Nausea Epigastric discomfort",6,7
"2088","fr","en","INFORMATION DE L' UTILISATEUR","INFORMATION FOR THE USER",4,4
"2089","fr","en","INFORMATION DE L'UTILISATEUR Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12,5 mg comprimés irbésartan/ hydrochlorothiazide","INFORMATION FOR THE USER Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg tablets irbesartan/ hydrochlorothiazide",14,13
"2090","fr","en","Information importante relative à certains excipients d’ ACTOS 45mg comprimés:","Important information about some of the ingredients of Actos 45mg tablets:",11,10
"2091","fr","en","INFORMATION POUR L’ UTILISATEUR CEPROTIN 500 UI, poudre et solvant pour solution injectable Protéine C Humaine","INFORMATION FOR THE USER CEPROTIN 500 IU powder and solvent for solution for injection Human Protein C",17,16
"2092","fr","en","Informations importantes concernant certains composants d’ Atripla","Important information about some of the ingredients of Atripla",9,7
"2093","fr","en","Informations importantes concernant certains composants d’Enbrel","Important information about some of the ingredients of Enbrel",9,6
"2094","fr","en","Informations importantes concernant certains composants de CEFUROXIME AXETIL","Important information about some of the ingredients of this medicine",10,8
"2095","fr","en","Informations importantes concernant certains composants de MicardisPlus","Important information about some of the ingredients of MicardisPlus",9,7
"2096","fr","en","Informations importantes concernant certains composants de PegIntron:","Important information about some of the ingredients of PegIntron:",9,7
"2097","fr","en","Informations importantes concernant certains composants de Revlimid Revlimid contient du lactose (un type de sucre).","Important information about some of the ingredients of Revlimid Revlimid contains lactose (a type of sugar).",16,15
"2098","fr","en","Informations importantes concernant certains composants de Visudyne Visudyne contient de petites quantités de butylhydroxytoluène (E321).","Important information about some of the ingredients of Visudyne Visudyne contains small amounts of butylated hydroxytoluene (E321).",17,15
"2099","fr","en","Informations importantes sur certains des constituants de CEPROTIN:","Important information about some of the ingredients of CEPROTIN",9,8
"2100","fr","en","Informations issues des essais cliniques","Information from clinical trials",4,5
"2101","fr","en","Informations supplémentaires concernant l’ auto-injection de Ceplene","Further information, instructions for self-injection of Ceplene",7,7
"2102","fr","en","Informations supplémentaires tp QU'EST-CE QUE ZIMULTI ET DANS QUEL CAS EST-IL UTILISE 1. 'es","WHAT ZIMULTI IS AND WHAT IT IS USED FOR on",10,14
"2103","fr","en","Informez votre médecin immédiatement si vous êtes enceinte ou prévoyez de l’ être.","Tell your doctor immediately if you are pregnant or intend to become pregnant.",13,13
"2104","fr","en","Informez votre médecin ou votre pharmacien.","Tell your doctor or pharmacist.",5,6
"2105","fr","en","Informez votre médecin si avez ou avez eu des problèmes rénaux.","Tell your doctor if you have, or have ever had, any kidney problems.",13,11
"2106","fr","en","Informez votre médecin si vous tombez enceinte pendant votre traitement par ORENCIA.","If you become pregnant while using ORENCIA, tell your doctor.",10,12
"2107","fr","en","Inhibiteurs de la dipeptidylpeptidase 4 (DPP-4), code ATC:","Dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code:",7,8
"2108","fr","en","Inhibiteurs de la pompe à protons, code ATC:","Proton pump inhibitors, ATC code:",5,8
"2109","fr","en","Inhibiteurs de la protéine kinase, code ATC:","Protein-kinase inhibitors, ATC code:",4,7
"2110","fr","en","injectable ou pour perfusion intraveineuse","Powder for solution for injection or infusion",7,5
"2111","fr","en","Injecter la solution intraveineuse sur plusieurs minutes tout en surveillant la position de l’ aiguille.","If no further dose is required, remove the venipuncture set and syringe.",12,15
"2112","fr","en","Injectez INCRELEX conformément aux instructions de votre médecin.","Inject INCRELEX as instructed by the doctor.",7,8
"2113","fr","en","injectez l’ insuline sous la peau.","Inject the insulin under the skin.",6,6
"2114","fr","en","Injectez la solution de Binocrit.","Inject the Binocrit solution.",4,5
"2115","fr","en","Injectez la solution en poussant le piston toujours lentement.","Inject the solution by pushing the plunger all the way down gently.",12,9
"2116","fr","en","Injectez toujours SOMAVERT exactement comme indiqué par votre médecin.","Always inject SOMAVERT exactly as your doctor has told you.",10,9
"2117","fr","en","Injectez ViraferonPeg une fois par semaine en une seule injection.","Inject ViraferonPeg once each week on the same day.",9,10
"2118","fr","en","Injection intramusculaire de 2 ml.","IM injection of 2 ml",5,5
"2119","fr","en","Injection unique sous-cutanée ou intraveineuse.","Single subcutaneous or intravenous injection.",5,5
"2120","fr","en","Inovelon 100 mg comprimés pelliculés Rufinamide","Inovelon 100 mg film-coated tablets Rufinamide",6,6
"2121","fr","en","Insérez l’aiguille dans le pli de la peau selon un angle d’environ 45°.","Insert the needle into the pinched skin at an angle of approximately 45°.",13,13
"2122","fr","en","Insérez la cartouche dans le stylo. • Réglez la dose à 1 ou 2 unités.","Put the cartridge into the pen. • You will set the dose to 1 or 2 units.",17,15
"2123","fr","en","Insomnie, hallucinations, confusion mentale, cauchemars, agitation","Insomnia, hallucinations, confusion, nightmares, agitation",5,6
"2124","fr","en","Instructions en cas d'omission d'une ou de plusieurs doses","If you forget to have Angiox",6,9
"2125","fr","en","INSTRUCTIONS ETAPE PAR ETAPE","STEP BY STEP INSTRUCTIONS",4,4
"2126","fr","en","Instructions particulières de manipulation Pour usage unique seulement","Special handling instructions For single use only.",7,8
"2127","fr","en","Instructions pour l’ élimination Jetez immédiatement la seringue usagée dans un collecteur pour objets tranchants.","Disposal instructions Dispose of the used syringe immediately in a sharps container.",12,15
"2128","fr","en","Instructions pour l’ utilisation BYETTA est à usage personnel uniquement.","Instructions for use BYETTA is for use by one person only.",11,10
"2129","fr","en","Instructions pour l’ utilisation et la manipulation","Any unused product or waste material should be disposed of in accordance with local requirements.",15,7
"2130","fr","en","INSTRUCTIONS POUR L’INJECTION DE NESPO EN STYLO PREREMPLI (SURECLICK)","INSTRUCTIONS FOR INJECTING WITH THE NESPO PRE-FILLED PEN (SURECLICK) ed",10,9
"2131","fr","en","Instructions pour la préparation et l’administration d’une injection d’Enbrel (voir au verso).","Instructions for preparing and giving an injection of Enbrel (See overleaf)",11,12
"2132","fr","en","Instructions pour la préparation et l’injection de Trudexa","Injecting Trudexa yourself rod",4,8
"2133","fr","en","Insuffisance cardiaque modérée à sévère (NYHA classes III/ IV) (voir rubrique 4.4). en","Moderate to severe heart failure (NYHA class III/ IV) (see section 4.4). no",13,13
"2134","fr","en","Insuffisance cortico-surrénalienne Hyperthyroïdie, hypothyroïdie","Torsades de pointes, ventricular tachycardia, atrioventricular complete block, bundle branch block, nodal rhythm",13,4
"2135","fr","en","Insuffisance hépatique - Aucune adaptation posologique n'est nécessaire.","Hepatic impairment - No dosing adjustment is necessary.",8,8
"2136","fr","en","Insuffisance hépatique Chez les patients atteints d'insuffisance hépatique, il faut administrer une dose réduite.","See 4.4 Special warning and precautions for use and 5.2 Pharmacokinetic properties.",12,14
"2137","fr","en","Insuffisance hépatique La clairance de la mirtazapine peut être diminuée chez les patients atteints d’ insuffisance hépatique.","Hepatic impairment The clearance of mirtazapine may be decreased in patients with hepatic impairment.",14,17
"2138","fr","en","Insuffisance hépatique sévère (Classe C Child-Pugh), notamment maladies hépatobiliaires obstructives sévères.","Severely reduced liver function (Child - Pugh class C), especially severe obstructive hepatobiliary disease.",14,11
"2139","fr","en","Insuffisance hépatique: voir rubrique 4.3.","Hepatic impairment: see section 4.3.",5,5
"2140","fr","en","Insuffisance rénale et hépatique","Renal and hepatic impairment",4,4
"2141","fr","en","Insuffisance rénale La clairance rénale du médicament inchangé est une voie mineure d'élimination.","Renal impairment Renal clearance of unchanged medicinal product is a minor pathway of elimination.",14,13
"2142","fr","en","Insuffisance rénale Oligurie Néphrite interstitielle","Renal failure Oliguria Interstitial nephritis",5,5
"2143","fr","en","Insuffisance rénale sévère (clairance de la créatinine < 30 ml/ min) (voir rubriques 4.2 et 5.2).","Severe renal impairment (creatinine clearance < 30 ml/ min) (see sections 4.2 and 5.2).",14,16
"2144","fr","en","Insuffisance rénale, insuffisance hépatique:","Renal impairment / hepatic impairment:",5,4
"2145","fr","en","Insuffisants hépatiques Aucune modification de la posologie n’ est nécessaire (voir rubrique 5.2).","Patients with renal impairment",4,13
"2146","fr","en","Insulatard 40 UI/ ml suspension injectable en flacon Insuline humaine (ADNr)","Insulatard 40 IU/ ml suspension for injection in a vial Insulin human (rDNA)",13,11
"2147","fr","en","Insulatard est une suspension d’ insuline isophane (NPH).","Insulatard is a suspension of isophane (NPH) insulin.",8,8
"2148","fr","en","Insulatard NovoLet 100 UI/ ml suspension injectable en stylo prérempli Insuline humaine (ADNr)","Insulatard NovoLet 100 IU/ ml suspension for injection in a pre-filled pen Insulin human (rDNA)",15,13
"2149","fr","en","Insulin Human Winthrop Basal 100 UI/ ml suspension injectable en cartouche","Insulin Human Winthrop Basal 100 IU/ ml suspension for injection in a cartridge",13,11
"2150","fr","en","Insulin Human Winthrop Basal en cartouches pour OptiClik est conçu pour être utilisé avec OptiClik uniquement.","Insulin Human Winthrop Basal in cartridges for OptiClik has been developed for use with OptiClik only.",16,16
"2151","fr","en","Insulin Human Winthrop Comb 15 40 UI/ ml","Insulin Human Winthrop Comb 15",5,8
"2152","fr","en","Insulin Human Winthrop Comb 15 contient 100 UI d'insuline par ml de suspension.","Insulin Human Winthrop Comb 15 contains 100 IU of insulin per ml suspension.",13,13
"2153","fr","en","Insulin Human Winthrop Comb 25 contient 40 UI d'insuline par ml.","Insulin Human Winthrop Comb 25 contains 40 IU insulin per ml.",11,11
"2154","fr","en","Insulin Human Winthrop Comb 50 100 UI/ ml suspension injectable en cartouche","Insulin Human Winthrop Comb 50 100 IU/ ml suspension for injection in a cartridge",14,12
"2155","fr","en","Insulin Human Winthrop Comb 50 contient 40 UI d'insuline par ml.","Insulin Human Winthrop Comb 50 contains 40 IU insulin per ml.",11,11
"2156","fr","en","Insulin Human Winthrop Comb 50 ne sera prescrit qu’ avec prudence chez la femme enceinte","Caution should be exercised when prescribing to pregnant women.",9,15
"2157","fr","en","Insulin Human Winthrop Infusat 100 UI/ ml solution injectable en flacon","Insulin Human Winthrop Infusat 100 IU/ ml solution for injection in a vial.",13,11
"2158","fr","en","Insulin Human Winthrop Rapid","Insulin Human Winthrop Rapid",4,4
"2159","fr","en","Insulin Human Winthrop Rapid 40 UI/ ml solution injectable en flacon","Insulin Human Winthrop Rapid 40 IU/ ml solution for injection in a vial.",13,11
"2160","fr","en","Insulin Human Winthrop Rapid est fourni en stylo prérempli, SoloStar, contenant 3 ml de solution (300 UI).","Insulin Human Winthrop Rapid is supplied in pre-filled pens, SoloStar, containing 3 ml solution (300 IU).",16,17
"2161","fr","en","Insuline asparte soluble*/ insuline asparte* protamine cristallisée...... ..100 U/ ml dans un rapport de 70/ 30","Soluble insulin aspart*/ protamine-crystallised insulin aspart*…… ..100 U/ ml in the ratio of 70/ 30",15,16
"2162","fr","en","Insuline lispro protamine en suspension (ADN d'origine recombinante) 100 UI/ ml (3,5 mg/ ml)","Insulin lispro protamine suspension (rDNA origin) 100 U/ ml (3.5 mg/ ml)",12,14
"2163","fr","en","Insuman Basal 40 UI/ ml suspension injectable en flacon","Insuman Basal 40 IU/ ml suspension for injection in a vial",11,9
"2164","fr","en","Insuman Basal est fourni en flacon contenant 10 ml de suspension (400 UI).","Insuman Basal is supplied in vials containing 10 ml suspension (400 IU).",12,13
"2165","fr","en","Insuman Basal est une suspension d'insuline isophane dont l'action est d'installation progressive et de longue durée.","Insuman Basal (an isophane insulin suspension) is an insulin with gradual onset and long duration of action.",17,16
"2166","fr","en","Insuman Comb 15 40 UI/ ml suspension injectable en flacon","Insuman Comb 15 40 IU/ ml suspension for injection in a vial",12,10
"2167","fr","en","Insuman Comb 15 est fourni en flacon contenant 5 ml de suspension (500 UI).","Insuman Comb 15 is supplied in vials containing 5 ml suspension (500 IU).",13,14
"2168","fr","en","Insuman Comb 25 40 UI/ ml suspension injectable en flacon","Insuman Comb 25 40 IU/ ml suspension for injection in a vial",12,10
"2169","fr","en","Insuman Comb 25 ne doit jamais être injecté par voie intraveineuse.","Insuman Comb 25 must never be injected intravenously.",8,11
"2170","fr","en","Insuman Comb 50 40 UI/ml suspension injectable en flacon Insuline humaine","Insuman Comb 50 40 IU/ml suspension for injection in a vial Insulin human",13,11
"2171","fr","en","Insuman Comb 50 ne doit pas être mélangé à d'autres insulines ou à des analogues de l'insuline.","Insuman Comb 50 must not be mixed with any other insulin or with insulin analogues.",15,17
"2172","fr","en","Insuman Infusat ne doit pas être utilisé dans des pompes péristaltiques à sondes en silicone.","Insuman Infusat must not be used in peristaltic pumps with silicone tubing.",12,15
"2173","fr","en","Insuman Rapid 40 UI/ ml solution injectable en flacon","Insuman Rapid 40 IU/ ml solution for injection in a vial",11,9
"2174","fr","en","Insuman Rapid est injecté sous la peau 15 à 20 minutes avant un repas.","Insuman Rapid is injected under the skin 15 to 20 minutes before a meal.",14,14
"2175","fr","en","INTELENCE 100 mg comprimé","INTELENCE 100 mg tablets",4,4
"2176","fr","en","Interactions avec le ténofovir:","Interactions relevant to tenofovir:",4,4
"2177","fr","en","Interactions communes à l'association Aucune étude d'interaction n'a été réalisée avec Exforge et d'autres médicaments.","Interactions common to the combination No drug interaction studies were performed with Exforge and other medicinal products.",17,15
"2178","fr","en","INTERDICTION DE VENTE, DE DELIVRANCE ET/ OU D’ UTILISATION","PROHIBITION OF SALE, SUPPLY AND/ OR USE",7,9
"2179","fr","en","Intervet Belgium Bedrijvenlaan 7 B-2800 Mechelen Belgique Tél.: +32 (15) 436 728 Fax: +32 (15) 436 733","Intervet Belgium Bedrijvenlaan 7 B-2800 Mechelen Belgium Tel: +32 (15) 436 728 Fax: +32 (15) 436 733",17,17
"2180","fr","en","Intervet International B. V.","Intervet International B. V.",4,4
"2181","fr","en","Intervet International bv Wim de Körverstraat 35 5831 AN Boxmeer Pays Bas","Intervet International Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands",11,12
"2182","fr","en","Intolérance aux lentilles de contact Affections oculaires","General disorders and administration site conditions",6,7
"2183","fr","en","Intrinsa 300 microgrammes/ 24 heures dispositif transdermique","Intrinsa 300 micrograms/ 24 hours transdermal patch",7,7
"2184","fr","en","Introduire la seringue dans le flacon.","Insert the syringe into the bottle 3.",7,6
"2185","fr","en","IntronA 18 millions d’UI solution injectable, stylo multidose Interféron alfa-2b","IntronA 18 million IU solution for injection, multidose pen Interferon alfa-2b",11,10
"2186","fr","en","IntronA 5 millions UI/ ml poudre pour solution injectable ou pour perfusion interféron alfa-2b SC/ IV","IntronA 3 million IU/ml powder for injection or infusion interferon alfa-2b SC/IV",12,16
"2187","fr","en","IntronA 60 millions d’UI solution injectable, stylo multidose Interféron alfa-2b","IntronA 60 million IU solution for injection, multidose pen Interferon alfa-2b",11,10
"2188","fr","en","IntronA se présente sous forme d’ une poudre à 18 millions d’ UI/ ml destinée à usage unique.","IntronA is supplied as a powder at strengths of 18 million IU/ml for single-dose use.",15,18
"2189","fr","en","INVEGA 6 mg comprimés à libération prolongée palipéridone","INVEGA 6 mg prolonged-release tablets paliperidone",6,8
"2190","fr","en","Investigations Affections du système sanguin et lymphatique","Investigations Blood and lymphatic system disorders Nervous system disorders",9,7
"2191","fr","en","Investigations Retard de croissance (diminution de la taille et/ ou du poids rapportée Très fréquent: à l'âge)§ Ce","Growth rate decrease (height and/ or weight decrease for age)§",10,18
"2192","fr","en","Investigations Très rare (< 1/ 10.000) Elévation des enzymes hépatiques","Investigations Very rare (< 1/ 10,000) Elevation of liver enzymes",10,10
"2193","fr","en","Invirase est prescrit en association avec le ritonavir et d’autres médicaments antirétroviraux.","Invirase is prescribed for use in combination with ritonavir and other antiretroviral medicines.",13,12
"2194","fr","en","IONSYS ne doit pas être placé sur des zones cutanées telles que cicatrices, brûlures, tatouages, etc.","IONSYS should not be placed on abnormal skin sites, such as scars, burns, tattoos, etc.",15,16
"2195","fr","en","IP ou INNTI) sont peu probables.","PIs or NNRTIs is unlikely.",5,6
"2196","fr","en","Irbesartan BMS 150 mg comprimés pelliculés.","Irbesartan BMS 150 mg film-coated tablets.",6,6
"2197","fr","en","Irbesartan Hydrochlorothiazide Winthrop est un médicament contenant deux principes actifs, l’ irbésartan et l’ hydrochlorothiazide.","Irbesartan Hydrochlorothiazide Winthrop is a medicine that contains two active substances, irbesartan and hydrochlorothiazide.",14,15
"2198","fr","en","Irbesartan Krka ne doit pas être donné aux enfants et aux adolescents (de moins de 18 ans).","Irbesartan Krka should not be given to children and adolescents (< 18 years)",13,17
"2199","fr","en","Ireland / United Kingdom","Ireland / United Kingdom",4,4
"2200","fr","en","Ireland BioMarin Europe Limited Tel:","Ireland BioMarin Europe Limited Tel:",5,5
"2201","fr","en","Ireland GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 4955000","Ireland GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 4955000",9,9
"2202","fr","en","Ireland Novartis Ireland Limited Tel: +353 1 260 12 55","Ireland Novartis Ireland Limited Tel: +353 1 260 12 55",10,10
"2203","fr","en","Irlande Meda Health Sales Ireland Ltd.","Ireland Meda Health Sales Ireland Ltd.",6,6
"2204","fr","en","Irlande VPA 10999/ 23/ 1","Ireland VPA 10999/ 23/ 1",5,5
"2205","fr","en","Iro MAVROPOULOS téléphone direct (44-20) 74 18 85 82 e-mail: subscriptions@emea. eu. int","above address or from Direct telephone (44-20) 74 18 85 E-mail: subscriptions@emea. eu. int",14,13
"2206","fr","en","Irritation, démangeaisons et rougeurs de la peau au niveau du site d’application.","Irritation, itching and reddening of the skin at the application site.",11,12
"2207","fr","en","Ischémie cérébrale: fréquence inconnue.","Cerebral ischemia: frequency unknown.",4,4
"2208","fr","en","Ischémie myocardique (G3/ 4:","Myocardial ischemia (G3/ 4:1.7%) Neutropenia (G3/ 4:",7,4
"2209","fr","en","Iscover n'est pas destiné aux enfants ou aux adolescents.","Iscover is not intended for use in children or adolescents.",10,9
"2210","fr","en","isé L’ EPAR complet relatif à Trudexa est disponible ici.","for Trudexa to Abbott Laboratories Ltd. on 1 September 2003.",10,10
"2211","fr","en","isé Le capuchon de la seringue contient du caoutchouc naturel (latex).","The needle cover of the syringe contains natural rubber (latex).",10,11
"2212","fr","en","isé médecin déterminera le schéma posologique exact en fonction de vos besoins.","Your doctor will determine the exact dosage schedule and regimen according to your needs.",14,12
"2213","fr","en","isé Rassemblez les éléments nécessaires avant de commencer:","ed Preparation Collect necessary items before you begin:",8,8
"2214","fr","en","isé Viraferon 5 millions UI/ ml poudre pour solution injectable interféron alfa-2b SC","ed Viraferon 5 million IU/ ml powder for injection interferon alfa-2b",11,13
"2215","fr","en","ISENTRESS 400 mg, comprimés raltégravir","ISENTRESS 400 mg tablets raltegravir",5,5
"2216","fr","en","Ísland Alexion Pharma France 56 avenue Hoche 75008 Paris Frakkland","Ísland Alexion Pharma France 56 avenue Hoche 75008 Paris Frakkland",10,10
"2217","fr","en","Ísland INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Sími: +49 234 971130","Ísland INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Sími: +49 234 971130",17,17
"2218","fr","en","Ísland Nycomed Langebjerg 1 DK-4000 Roskilde Danmörk Sími: + 45 46 77 11 11","Ísland Nycomed Langebjerg 1 DK-4000 Roskilde Danmörk Sími: + 45 46 77 11 11",14,14
"2219","fr","en","Ísland Vistor hf Sími: +354 535 7000","Ísland Vistor hf Sími: +354 535 7000",7,7
"2220","fr","en","Italia Biogen-Dompé s.r.l. +39 02 583 831","Italia Biogen-Dompé s.r.l. +39 02 583 831",7,7
"2221","fr","en","Italia Eli Lilly Italia S.p.A.","Italia Eli Lilly Italia S. p. A.",7,5
"2222","fr","en","Italia Hospira Italia Srl Tel: + 39 0812405912","Italia Hospira Italia Srl Tel: + 39 0812405912",8,8
"2223","fr","en","Italia Meda Pharma S .p .A.","Italia Meda Pharma S.p.A.",4,6
"2224","fr","en","Italia Nycomed Italia S.r.l.","Italia Nycomed Italia S. r. l.",6,4
"2225","fr","en","Italia Sandoz S. p. A.","Italia Sandoz S. p. A.",5,5
"2226","fr","en","Italia Teva Italia S. r. l.","Italia Teva Italia S.r.l.",4,6
"2227","fr","en","Italia Via fratelli Cervi snc, Centro Direzionale Milano Due Palazzo Borromini I-20090 Segrate (Milano) Tel: + 39-02 21018.1","Centro Direzionale Milano Palazzo Borromini I-20090 Segrate (Milano)",8,18
"2228","fr","en","Italia Wyeth Lederle S.p.A.","Italia Wyeth Lederle S. p. A.",6,4
"2229","fr","en","IV ibandronique 2,5 mg oral","System Organ Class/ Adverse reaction Gastrointestinal disorders",7,5
"2230","fr","en","IV/ SC 0,5 ml","MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS",9,4
"2231","fr","en","Ivax Pharmaceuticals 34, Avenue Franklin Roosevelt 92150 Suresnes France","Ivax Pharmaceuticals 34, Avenue Franklin Roosevelt 92150 Suresnes France",9,9
"2232","fr","en","IX nécessaire (%) ou (UI/ dl)","Factor IX level required (%) or (IU/ dl)",8,6
"2233","fr","en","J Gardez le bouton-poussoir totalement enfoncé après l’injection jusqu’à ce que l’aiguille ait été retirée de la peau.","J Keep the push-button fully depressed after the injection until the needle has been withdrawn from the skin.",18,18
"2234","fr","en","J05 Traite anticoagulant pour les trom bocytopénies associée à l'heparino thérapie","Tre atment of CMV renititis in patient with AIDS",9,11
"2235","fr","en","Jalra 50 mg comprimés Vildagliptine","Jalra 50 mg tablets Vildagliptin",5,5
"2236","fr","en","Janssen Cilag 1 rue Desmoulins TSA 91003 92787 Issy les Moulineaux Cedex 9 France","Janssen Cilag 1 rue Desmoulins TSA 91003 92787 Issy les Moulineaux Cedex 9 France",14,14
"2237","fr","en","Janssen Pharmaceutica N. V.","Janssen Pharmaceutica N. V.",4,4
"2238","fr","en","Janssen-Cilag AB, Box 7073 192 07 Sollentuna Suède","Janssen-Cilag AB, Box 7073 192 07 Sollentuna, Sverige",8,8
"2239","fr","en","Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse Belgique","Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse Belgium",8,8
"2240","fr","en","Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ Grande-Bretagne","Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ United Kingdom",10,9
"2241","fr","en","Janssen-Cilag s. r. o.","Janssen-Cilag s. r. o.",4,4
"2242","fr","en","Janumet est contre-indiqué chez les patients avec:","Janumet is contraindicated in patients with:",6,7
"2243","fr","en","Januvia appartient à une classe d'hypoglycémiants oraux appelés inhibiteurs de la dipeptidylpeptidase- 4 (DPP-4).","Januvia is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.",17,14
"2244","fr","en","Jerozolimskie 195a PL-02-222 Warszawa Tel.: + 48-(0)22 478 41 50","Jerozolimskie 195a PL-02-222 Warszawa Tel.: + 48-(0)22 478 41 50",10,10
"2245","fr","en","Jeter avec précaution toute solution de SOMAVERT non injectée.","Carefully dispose of any SOMAVERT solution that has not been injected.",11,9
"2246","fr","en","Jeter la solution si des particules étrangères ou un jaunissement sont observés.","Discard the solution if any particulate matter or discolouration is observed.",11,12
"2247","fr","en","Jeter quatre semaines après la première ouverture.","Discard four weeks after first opening.",6,7
"2248","fr","en","Jeter tout produit inutilisé conformément à la norme sur les agents cytotoxiques en vigueur.","Discard any unused contents according to standard practice for cytotoxic agents.",11,14
"2249","fr","en","Jetez cette dose et recommencez le réglage de dose correctement.","Discard the dose to waste and repeat the dose setting correctly.",11,10
"2250","fr","en","JO n° L272 du 25.10.96 JO n° L290 c h","All food-producing species All food-producing species",6,10
"2251","fr","en","JO No C 129/4 du 25.04.97","OJ No C 129/4 of 25.04.97",6,6
"2252","fr","en","Johnson & Johnson d. o. o., Š martinska 53, Ljubljana, Slovénie","Š martinska 53, Ljubljana, Slovenia",5,11
"2253","fr","en","juillet 2002 octobre 2002","March 2002 July 2002 October 2002",6,4
"2254","fr","en","Jungtin Karalyst Tel: +44 (0)28 7086 8733","Jungtin Karalyst Tel: +44 (0)28 7086 8733",7,7
"2255","fr","en","Jusqu’ à 0,05 mg/ kg de poids corporel par jour sous forme d’ injection sous-cutanée.","Up to 0.05 mg/ kg bodyweight given as a daily subcutaneous injection.",12,15
"2256","fr","en","Justification de ne pas inclure l’ information en Braille acceptée","Justification for not including Braille accepted",6,10
"2257","fr","en","Justification de ne pas inclure l’ information en Braille acceptée.","Justification for not including Braille accepted.",6,10
"2258","fr","en","Kaletra ne doit pas être administré aux patients présentant une insuffisance hépatique sévère.","Kaletra should not be taken by patients with severe liver disease.",11,13
"2259","fr","en","Kaletra solution buvable contient 42% v/ v d’ alcool.","Kaletra contains 42% v/v alcohol.",5,9
"2260","fr","en","Karvea 150 mg comprimés pelliculés irbésartan","Karvea 150 mg film-coated tablets irbesartan",6,6
"2261","fr","en","Karvezide 150 mg/ 12,5 mg comprimés pelliculés.","Karvezide 150 mg/ 12.5 mg film-coated tablets.",7,7
"2262","fr","en","Karvezide ne doit pas être donné aux enfants et aux adolescents (de moins de 18 ans).","Karvezide should not be given to children and adolescents (under 18 years).",12,16
"2263","fr","en","Kepivance 6,25 mg poudre pour solution injectable Palifermin","Kepivance 6.25 mg powder for injection Palifermin",7,8
"2264","fr","en","Keppra solution buvable est conditionné dans un flacon en verre de 300 ml dans un étui cartonné.","Keppra is packed in a 300 ml glass bottle in a cardboard box.",13,17
"2265","fr","en","Keppra100 mg/ ml, solution buvable Levetiracetam","Keppra 100 mg/ ml oral solution Levetiracetam",7,6
"2266","fr","en","Kereszturi Ut 30-38 H-1106, Budapest Hongrie","Kereszturi Ut 30-38 H-1106, Budapest Hungary",6,6
"2267","fr","en","Kétoconazole 400 mg, une fois/ jour (Indinavir 400 mg, trois fois/ jour)","Ketoconazole 400 mg QD (Indinavir 400 mg TID)",8,12
"2268","fr","en","KG D-55216 Ingelheim am Rhein Allemagne","KG D-55216 Ingelheim am Rhein Germany",6,6
"2269","fr","en","KG Max-Planck-Ring 2 D-65205 Wiesbaden Tel: + 49 (0) 6122 58-0","KG Max-Planck-Ring 2 D-65205 Wiesbaden Tel: + 49 (0) 6122 58-0",11,11
"2270","fr","en","KG Tel: + 49-(0)2371 937 0","KG Tel: + 49-(0)2371 937 0",6,6
"2271","fr","en","KG Tel.: + 48-(0)22 891 1678","KG Tel.: + 49-(0)2371 937 0",6,6
"2272","fr","en","KG, Theresienhöhe 11, 80339 München, Germany","KG, Theresienhöhe 11, 80339 München, Germany",6,6
"2273","fr","en","Kineret est une solution stérile sans conservateur.","Kineret is a sterile unpreserved solution.",6,7
"2274","fr","en","Kinzalkomb 80 mg/ 25 mg comprimés telmisartan/ hydrochlorothiazide","Kinzalkomb 80 mg/ 25 mg tablets telmisartan/ hydrochlorothiazide",8,8
"2275","fr","en","KIOVIG, 100 mg/ml, solution pour perfusion Immunoglobuline humaine normale","KIOVIG 100 mg/ml solution for infusion Human normal immunoglobulin",9,9
"2276","fr","en","KOGENATE Bayer 2000 UI poudre et solvant pour solution injectable.","KOGENATE Bayer 2000 IU Powder and solvent for solution for injection.",11,10
"2277","fr","en","Korinthou 12 New Psychiko 15451 Grèce","New Psychiko 15451 Greece Greece",5,6
"2278","fr","en","Kornelia GREIN Sheila KENNEDY (f. f.)","Melanie LEIVERS Kornelia GREIN Sheila KENNEDY (acting)",7,6
"2279","fr","en","KRKA Polska Sp. z o. o. ul.","KRKA Polska Sp. z o. o., ul.",7,7
"2280","fr","en","Kruczkowskiego, 8 00 - 380 Warszawa Pologne","Kruczkowskiego, 8 00 - 380 Warszawa Poland",7,7
"2281","fr","en","Kύπρος Amgen Ελλάς Φαρμακευτικά Ε .Π .Ε.","Kύπρος Amgen Ελλάς Φαρμακευτικά Ε .Π .Ε.",7,7
"2282","fr","en","Kύπρος Γ .Α .Σταμάτης & Σια Λτδ.","Kύπρος Γ .Α .Σταμάτης & Σια Λτδ.",7,7
"2283","fr","en","L 172 du 02.07.02 3 JO N°.","L 172 of 02.07.02 3 OJ No.",7,7
"2284","fr","en","L 290 du 5.12.95 JO No.","L 290 of 5.12.95 OJ No.",6,6
"2285","fr","en","L. le 17 mai 2001.","L. on 17 May 2001.",5,5
"2286","fr","en","L'acidose augmente la fraction libre de fentanyl.","The free fraction of fentanyl increases with acidosis.",8,7
"2287","fr","en","L'activité antimuscarinique tient essentiellement à l'isomère R.","Antimuscarinic activity resides predominantly in the R-isomer.",7,7
"2288","fr","en","L'activité pharmacologique est attribuée à la molécule mère.","Pharmacological activity resides in the parent substance.",7,8
"2289","fr","en","L'administration concomitante d'oméprazole (20 mg deux fois par jour) commençait au moins 2 jours avant l'injection de PhotoBarr.","Co-administration of omeprazole (20 mg BID) began at least 2 days before PhotoBarr injection.",14,18
"2290","fr","en","L'administration d'insuline peut provoquer la formation d'anticorps anti-insuline.","Insulin administration may cause insulin antibodies to form.",8,8
"2291","fr","en","L'administration de CHAMPIX doit débuter 1 à 2 semaines avant cette date.","CHAMPIX dosing should start 1-2 weeks before this date.",9,12
"2292","fr","en","L'administration des perfusions doit être progressive.","Infusions should be administered incrementally.",5,6
"2293","fr","en","L'administration intraveineuse de protéines, y compris MabThera, peut provoquer des réactions anaphylactiques ou d'autres réactions d'hypersensibilité.","Anaphylactic and other hypersensitivity reactions have been reported following the intravenous administration of proteins, including MabThera, to patients.",18,16
"2294","fr","en","L'administration quotidienne n'a pas été évaluée chez l'insuffisant hépatique.","Once-a-day administration has not been evaluated in patients with hepatic insufficiency.",11,9
"2295","fr","en","L'administration sous-cutanée doit être effectuée dans les bras, les cuisses, les fesses ou l'abdomen.","Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen.",12,14
"2296","fr","en","L'ADN polymérase epsilon est incapable d'éliminer la gemcitabine et de réparer les chaînes d'ADN en cours de formation.","DNA polymerase epsilon lacks the ability to eliminate gemcitabine and to repair the growing DNA strands.",16,18
"2297","fr","en","L'Agence européenne pour l'évaluation des médicaments","The European Agency for the Evaluation of Medicinal Products",9,6
"2298","fr","en","L'agomélatine ou ses métabolites passent dans le lait chez la rate.","Agomelatine or its metabolites are excreted in the milk of lactating rats.",12,11
"2299","fr","en","L'aire sous la courbe","Comparison of pharmacokinetic parameters did not suggest any change in pharmacokinetics over the 5 days of dosing.",17,4
"2300","fr","en","L'alcool peut intensifier et prolonger l'effet hypoglycémiant de l'insuline.","Alcohol may intensify and prolong the hypoglycaemic effect of insulin. uc",11,9
"2301","fr","en","L'allaitement doit donc être déconseillé aux patientes en cours de traitement parl’ aripiprazole.","Patients should be advised not to breast feed if they are taking aripiprazole.",13,13
"2302","fr","en","L'amlodipine n'altère pas la conduction AV et n'a pas d'effet inotrope négatif.","Amlodipine does not impair AV conduction and does not have a negative inotropic effect.",14,12
"2303","fr","en","l'appétit (y compris anorexie), hyperuricémie.","Hypokalaemia, lipids increased, appetite disorders (including anorexia), hyperuricaemia",8,5
"2304","fr","en","L'autorisation de mise sur le marché a été renouvelée le 6 mars 2008.","The marketing authorisation was renewed on 6 March 2008.",9,13
"2305","fr","en","L'effet de la prise de nourriture sur l'absorption du médicament est inconnu.","The effect of food on absorption is unknown.",8,12
"2306","fr","en","L'effet des injections apparaît dans un délai médian de quatre jours suivant l'injection.","The median first onset of effect is observed within four days after injection.",13,13
"2307","fr","en","L'effet inducteur peut persister jusqu'à 2 semaines après l'arrêt du traitement par le millepertuis.","The inducing effect may persist up to 2 weeks after cessation of treatment with St.",15,14
"2308","fr","en","L'efficacité de Karvea est indépendante de l'âge ou du sexe.","The efficacy of Karvea is not influenced by age or gender.",11,10
"2309","fr","en","L'efficacité de Karvezide est indépendante de l'âge et du sexe.","There is no difference in response to Karvezide, regardless of age or gender.",13,10
"2310","fr","en","L'efficacité de YENTREVE n'a pas été évaluée au-delà de 3 mois dans les études versus placebo.","The efficacy of YENTREVE has not been evaluated for longer than 3 months in placebo-controlled studies.",16,16
"2311","fr","en","L'élimination étant lente, les concentrations sériques à l'état d'équilibre sont atteintes en 4 à 6 semaines.","Owing to the slow elimination, steady-state concentrations in serum are reached in 4 to 6 weeks.",16,16
"2312","fr","en","L'élimination urinaire a été inférieure à 0,6% de la dose appliquée à la semaine 16 chez ces patients.","Urinary recovery was less than 0.6% of the applied dose at week 16 in these patients.",16,18
"2313","fr","en","L'entacapone est autorisée dans l’ Union européenne (UE) sous la dénomination Comtess/ Comtan depuis 1998.","Entacapone has been authorised in the European Union (EU) as Comtess/ Comtan since 1998.",14,15
"2314","fr","en","L'érythropoïétine est sécrétée et régulée principalement par le rein en réponse à des modifications de l'oxygénation tissulaire.","The production of erythropoietin primarily occurs in and is regulated by the M",13,17
"2315","fr","en","L'essai multicentrique comprenait 5 enfants (< 18 ans), dont 3 ont obtenu une RC.","The multicentre trial included 5 paediatric patients (< 18 years old), 3 of whom achieved CR.",16,14
"2316","fr","en","L'état d'équilibre est atteint en 3 à 4 jours, après quoi le produit ne s'accumule plus.","Steady state is reached after 3-4 days, after which there is no further accumulation.",14,16
"2317","fr","en","L'existence d’ erreurs de classification devrait être considérée comme un facteur contribuant à la puissance de l’ alerte.","The existence of misclassifications should be viewed as contributing to the strength of the signal.",15,18
"2318","fr","en","L'expérience avec les autres sulfonylurées montre que malgré des mesures initialement efficaces une hypoglycémie peut récidiver.","It is known from other sulphonylureas that, despite initially successful countermeasures, hypoglycaemia may recur.",14,16
"2319","fr","en","L'expérience clinique chez la femme enceinte est limitée, mais des anomalies congénitales et des avortements ont été rapportés.","Clinical experience in pregnant women is limited, but congenital anomalies and abortions have been reported.",15,18
"2320","fr","en","L'exposition au métabolite actif (ASC) augmente proportionnellement à la dose dans l’ intervalle de doses thérapeutiques.","The active metabolite’ s exposure (AUC) increases proportionally over the therapeutic dose range.",13,16
"2321","fr","en","L'exposition aux rayonnements ionisants résultant de l’ irradiation thérapeutique peut augmenter l’ incidence des cancers ou des mutations.","The radiation dose resulting from therapeutic exposure may result in higher incidence of cancer and mutations.",16,18
"2322","fr","en","L'extrapolation de ces résultats à l'utilisation clinique d'ORENCIA n'a pas été étudiée.","The relevance of these findings to the clinical use of ORENCIA is unknown.",13,12
"2323","fr","en","L'hydroxycarbamide est supposé être carcinogène pour les différentes espèces.","Hydroxycarbamide is presumed to be a transspecies carcinogen.",8,9
"2324","fr","en","L'hydroxyde de sodium ou l'acide chlorhydrique peuvent avoir été utilisés pour ajuster le pH","Sodium hydroxide or hydrochloric acid may have been used to adjust the acidity.",13,14
"2325","fr","en","L'hyperglycémie sévère et l'acidocétose doivent toujours être traitées par un médecin, généralement à l'hôpital.","Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.",15,14
"2326","fr","en","L'hypoglycémie non corrigée ou les réactions d'hyperglycémie peuvent entraîner une perte de connaissance, un coma ou la mort.","Uncorrected hypoglycaemic or hyperglycaemic reactions can cause loss of consciousness, coma, or death.",13,18
"2327","fr","en","L'incidence de l’ érythro-dysesthésie palmo-plantaire était similaire entre les bras lapatinib + capécitabine et capécitabine seule.","The incidence of PPE was similar in both lapatinib plus capecitabine and capecitabine alone treatment arms.",16,16
"2328","fr","en","L'information ci-dessous est destinée aux professionnels de santé uniquement:","The following information is intended for medical or healthcare professionals only:",11,9
"2329","fr","en","L'injection d'une autre substance au niveau du site d'extravasation ne présente aucun bénéfice connu.","There is no known benefit from injecting the extravasation site with another substance.",13,14
"2330","fr","en","L'injection ne doit pas être administrée, accidentellement, en dehors de la veine.","The injection must not be given mistakenly outside the vein.",10,12
"2331","fr","en","L'interruption du traitement peut être envisagée comme suit:","Treatment discontinuation may be considered as follows:",7,8
"2332","fr","en","L'irbésartan n'est pas épuré par hémodialyse.","Irbesartan is not removed by haemodialysis.",6,6
"2333","fr","en","L'irbésartan présente une pharmacocinétique linéaire et proportionnelle à la dose dans une fourchette de 10 à 600 mg.","Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.",16,18
"2334","fr","en","L'olanzapine se lie essentiellement à l'albumine et à l 'α 1-glycoprotéine acide.","Olanzapine is bound predominantly to albumin and α 1-acid-glycoprotein.",9,12
"2335","fr","en","L'utilisation de Jalra chez l'enfant et les adolescents n’ est pas recommandée.","The use of Jalra in children and adolescents is not recommended.",11,12
"2336","fr","en","L'utilisation de la sibutramine chez la femme enceinte n'a pas fait l'objet d'études.","Sibutramine’ s use in human pregnancy has not been investigated.",10,13
"2337","fr","en","L'utilisation de Tamiflu ne doit pas influer sur la décision de vaccination annuelle contre la grippe.","Use of Tamiflu must not affect the evaluation of individuals for annual influenza vaccination.",14,16
"2338","fr","en","L'utilisation de Ziagen n'est pas recommandée au cours de la grossesse.","Ziagen is not recommended during pregnancy.",6,11
"2339","fr","en","L’ absence de réponse au traitement par érythropoïétine doit mener à la recherche des facteurs causaux.","Non response to erythropoietin therapy should prompt a search for causative factors.",12,16
"2340","fr","en","L’ absorption est importante avec environ 10% de la dose marquée excrétée dans les fèces.","Absorption is extensive with approximately 10% of a radiolabelled dose excreted in the faeces.",14,15
"2341","fr","en","L’ absorption gastro-intestinale de Lisonorm n’ est pas influencée par la nourriture.","The gastrointestinal absorption of Lisonorm is not influenced by food.",10,12
"2342","fr","en","L’ acide ibandronique est éliminé uniquement par excrétion rénale et il ne subit aucune biotransformation.","Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation.",14,15
"2343","fr","en","L’ acide zolédronique n’ est pas métabolisé et est excrété sous forme inchangée par voie rénale.","Zoledronic acid is not metabolised and is excreted unchanged via the kidney.",12,16
"2344","fr","en","L’ action contraceptive de l’ Implanon repose principalement sur l’ inhibition de l’ ovulation.","The contraceptive action of Implanon is primarily achieved by inhibition of ovulation.",12,14
"2345","fr","en","L’ activité doit être mesurée immédiatement avant l’ administration à l’ aide d’ un activimètre.","The activity should be measured by a dose calibrator immediately before administration.",12,15
"2346","fr","en","L’ administration concomitante d’ inhibiteurs puissants du CYP3A4 est contre-indiquée (voir rubriques 4.3 et 4.5).","Concomitant administration of potent CYP3A4 inhibitors is contraindicated (see sections 4.3 and 4.5).",13,15
"2347","fr","en","L’ administration d’ autres azolés a été associée à une élévation des concentrations de digoxine.","Administration of other azoles has been associated with increases in digoxin levels.",12,15
"2348","fr","en","L’ administration de Avastin doit être définitivement arrêtée si vous développez:","The administration of Avastin should be permanently discontinued if you develop:",11,11
"2349","fr","en","L’ administration par voie intraveineuse doit être effectuée uniquement par des professionnels de santé.","Intravenous administration should only be carried out by health care professionals.",11,14
"2350","fr","en","L’ administration simultanée de tadalafil et de doxazosine n’ est donc pas recommandée.","The combination of tadalafil and doxazosin is not recommended.",9,13
"2351","fr","en","L’ âge initial de vaccination contre la FJ est donc de 9 mois.","The starting age for vaccination with YF vaccine is 9 months of age.",13,13
"2352","fr","en","L’ âge, le sexe ou la race n’ ont pas eu d’ influence sur la demi-vie d’ élimination.","Elimination half-life was not influenced by age, gender, or race.",10,18
"2353","fr","en","l’ albumine (mmol/ l) ou Calcémie corrigée en fonction de l’ albumine (mg/ dl)","Albumin-corrected serum calcium (mg/ dl)",5,14
"2354","fr","en","l’ aliment médicamenteux en","Incorporation of 75 mg active",5,4
"2355","fr","en","L’ allaitement doit être interrompu pendant le traitement par le pemetrexed (voir rubrique 4.6).","Breast-feeding must be discontinued during pemetrexed therapy (see section 4.6).",10,14
"2356","fr","en","L’ allaitement est déconseillé pendant le traitement par Neupro.","Breast-feeding is not recommended during treatment with Neupro.",8,9
"2357","fr","en","L’ amprénavir est métabolisé principalement par le cytochrome P450 3A4.","The primary route of metabolism is via the cytochrome P450 3A4 enzyme.",12,10
"2358","fr","en","L’ angiotensine-II est un puissant vasoconstricteur (une substance qui diminue le diamètre des vaisseaux sanguins).","Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels).",12,15
"2359","fr","en","L’ apparition de tout signe ou symptôme de troubles psychiatriques doit être attentivement surveillée 122 chez les patients.","Patients should be closely monitored for any signs or symptoms of psychiatric disorders.",13,18
"2360","fr","en","L’ application doit ensuite effectuée une fois par jour jusqu’ à ce que la peau soit propre.","Afterwards, application should be reduced to once a day until the skin is clear.",14,17
"2361","fr","en","L’ arrêt de votre traitement par Myfenax peut augmenter le risque de rejet de votre greffon.","Stopping your treatment with Myfenax may increase the chance of rejection of your transplanted organ.",15,16
"2362","fr","en","L’ ASC plasmatique de la sitagliptine a augmenté proportionnellement à la dose.","Plasma AUC of sitagliptin increased in a dose-proportional manner.",9,12
"2363","fr","en","L’ association d’ un diurétique tel que l’ hydrochlorothiazide diminuera encore davantage la pression artérielle chez ces patients.","The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.",17,18
"2364","fr","en","L’ association de ces médicaments chez un même patient doit être évitée.","The use of more than one of these products concomitantly should be avoided.",13,12
"2365","fr","en","l’ attention Nystagmus Paresthésies Troubles d’ élocution Tremblement","Bradyphrenia Disturbance in attention Nystagmus Paraesthesia Speech disorder Tremor",9,8
"2366","fr","en","L’ auto-injection accidentelle peut provoquer de fortes tin","If you are accidentally injected with this gA",8,8
"2367","fr","en","L’ autorisation de mise sur le marché a été renouvelée le 10 mars 2009.","The marketing authorisation was renewed on 10 March 2009.",9,14
"2368","fr","en","L’ autorisation de mise sur le marché a été renouvelée le 15 mai 2007.","The marketing authorisation was renewed on 15 May 2007.",9,14
"2369","fr","en","L’ autorisation de mise sur le marché a été renouvelée le 2 mars 2009.","The marketing authorisation was renewed on 2 March 2009.",9,14
"2370","fr","en","L’ autorisation de mise sur le marché a été renouvelée le 23 octobre 2005.","The marketing authorisation was renewed on 23 October 2005.",9,14
"2371","fr","en","L’ autorisation de mise sur le marché a été renouvelée le 28 janvier 2005.","The marketing authorisation was renewed on 28 January 2005.",9,14
"2372","fr","en","L’ autorisation de mise sur le marché a été renouvelée le 9 septembre 2007.","The marketing authorisation was renewed on 9 September 2007.",9,14
"2373","fr","en","L’ avis définitif est devenu décision de la Commission européenne en date du 17 octobre 2003.","The final opinion was converted into a Decision by the European Commission on 17 October 2003.",16,16
"2374","fr","en","L’ eau ou toute autre boisson n’ est pas nécessaire pour avaler la dose.","Water or other liquid is not needed to swallow the dose.",11,14
"2375","fr","en","L’ effet est vraisemblablement dépourvu de signification clinique.","The effect probably lacks clinical relevance.",6,8
"2376","fr","en","L’ effet était perceptible chez certains patients dès la 1ere semaine de traitement.","The effect in some patients was apparent in the first week of treatment.",13,13
"2377","fr","en","L’ effet indésirable le plus fréquent chez les patients insulino-traités est une fluctuation de la glycémie.","ed The most often seen undesirable effect in insulin-treated patients is a change in blood glucose levels.",17,16
"2378","fr","en","L’ effet indésirable le plus fréquent chez les patients sous insulinothérapie est une fluctuation de la","The most often seen undesirable effect in insulin-treated patients is a change in blood glucose levels.",16,16
"2379","fr","en","L’ effet indésirable le plus souvent rapporté a été une augmentation de la pression artérielle (fréquent).","The most frequent reported adverse reaction was hypertension (common).",9,16
"2380","fr","en","L’ effet sur la qualité de vie fut significatif et bénéfique (mesure avec l’ échelle PD-QUALIF).","There was a significant and beneficial effect in quality of life (as assessed by PD-QUALIF scale).",16,16
"2381","fr","en","L’ efficacité d’ Aerius solution buvable n’ a pas été évaluée par des études pédiatriques spécifiques.","Efficacy of Aerius oral solution has not been investigated in separate paediatric trials.",13,16
"2382","fr","en","L’ efficacité de Reyataz a été évaluée lors de quatre études principales.","The effectiveness of Reyataz has been assessed in four main studies.",11,12
"2383","fr","en","L’ efficacité et la tolérance de rimonabant n’ ont pas été évaluées au-delà de 2 ans.","The safety and efficacy of rimonabant have not been evaluated beyond 2 years.",13,16
"2384","fr","en","L’ efficacité maximale est atteinte dans les 48 heures.","Maximum efficacy is achieved within 48 hours.",7,9
"2385","fr","en","L’ elcatonine ne traverse pas la barrière placentaire.","Elcatonin does not cross the placental barrier.",7,8
"2386","fr","en","L’ élimination du ténofovir par dialyse péritonéale n’ a pas été étudiée.","The elimination of tenofovir by peritoneal dialysis has not been studied.",11,12
"2387","fr","en","L’ emballage contient une notice décrivant toutes les instructions d’ utilisation et de manipulation.","The carton contains a package leaflet with the full instructions for use and handling.",14,14
"2388","fr","en","L’ EMEA a désormais achevé avec succès sa quatrième année d’","By Fernand Sauer Executive Director",5,11
"2389","fr","en","L’ EMEA prévoit d’ examiner ses principaux processus afin de rationaliser leur fonctionnement.","The EMEA plans to review its key processes in order to rationalise their functioning.",14,13
"2390","fr","en","L’ emtricitabine est un analogue nucléosidique de la cytidine.","Emtricitabine is a nucleoside analogue of cytidine.",7,9
"2391","fr","en","L’ épaisseur endométriale des patientes sous raloxifène n’ était pas différente de celle des patientes sous placebo.","Raloxifene treated women consistently had an endometrial thickness which was indistinguishable from placebo.",13,17
"2392","fr","en","L’ épanchement péricardique et la péricardite ont été rapportés chez 8% (10/ 132) des patients.","Pericardial effusion and pericarditis were reported as an adverse event in 8% (10/ 132) of patients.",16,15
"2393","fr","en","L’ EPAR complet est disponible ici.","The full EPAR for Zeffix is available here.",8,6
"2394","fr","en","L’ EPAR complet est disponible: ici.","The full EPAR for Raptiva can be found here.",9,6
"2395","fr","en","L’ EPAR complet pour Caelyx est disponible ici.","The full EPAR for Caelyx can be found here.",9,8
"2396","fr","en","L’ EPAR complet pour Iscover est disponible ici.","The full EPAR for Iscover is available here.",8,8
"2397","fr","en","L’ EPAR complet pour Livensa est disponible à l’ adresse suivante: ici.","The full EPAR for Livensa can be found here.",9,12
"2398","fr","en","L’ EPAR complet relatif à Atripla est disponible ici.","The full EPAR for Atripla can be found here.",9,9
"2399","fr","en","L’ EPAR complet relatif à Crixivan est disponible ici.","The full EPAR for Crixivan can be found here.",9,9
"2400","fr","en","L’ EPAR complet relatif à Epoetin Alfa Hexal est disponible ici.","The full EPAR for Epoetin Alfa Hexal can be found here.",11,11
"2401","fr","en","L’ EPAR complet relatif à Fluticasone Furoate GSK est disponible ici.","The full EPAR for Fluticasone Furoate GSK can be found here.",11,11
"2402","fr","en","L’ EPAR complet relatif à Imprinda est disponible: ici.","The full EPAR for Imprida can be found here.",9,9
"2403","fr","en","L’ EPAR complet relatif à Neoclarityn est disponible: ici.","The full EPAR for Neoclarityn is available here.",8,9
"2404","fr","en","L’ EPAR complet relatif à Oprymea est disponible ici.","The full EPAR for Oprymea can be found here.",9,9
"2405","fr","en","L’ EPAR complet relatif à Pramipexole Teva est disponible ici.","The full EPAR for Pramipexole Teva can be found here.",10,10
"2406","fr","en","L’ EPAR complet relatif à Siklos est disponible ici.","The full EPAR for Siklos can be found here.",9,9
"2407","fr","en","L’ EPAR complet relatif à Tasigna est disponible ici.","The full EPAR for Tasigna can be found here.",9,9
"2408","fr","en","L’ EPAR complet relatif à Tractocile est disponible ici.","The full EPAR for Tractocile is available here.",8,9
"2409","fr","en","L’ EPAR complet relatif à Vimpat est disponible ici.","The full EPAR for Vimpat can be found here.",9,9
"2410","fr","en","L’ équivalent d’ une graduation est suffisante pour traiter 50 kg de poids corporel.","The equivalent of one marking is sufficient to treat 50 kg of bodyweight.",13,14
"2411","fr","en","L’ état d’ équilibre de la 9-hydroxy-rispéridone est atteint 4-5 jours après administration.","Steady-state of 9-hydroxy-risperidone is reached within 4-5 days of dosing.",10,13
"2412","fr","en","L’ étude a ensuite été étendue à quatre ans.","The study was then extended to four years.",8,9
"2413","fr","en","L’ étude du développement d’ une stratégie de gestion du risque de l’ EMEA a été lancée.","Some EMEA pharmacovigilance staff members began training in 2002",9,17
"2414","fr","en","L’ étude est toujours en cours.","The study is ongoing.",4,6
"2415","fr","en","L’ évaluation de ces effets indisérables est basée sur les fréquences suivants:","Evaluation of these side effects is based on the following frequencies:",11,12
"2416","fr","en","L’ examen d’ imagerie devra être réalisé dans l’ heure suivant l’ administration du produit de contraste.","The imaging procedure should be completed within 1 hour of administration of the contrast medium.",15,17
"2417","fr","en","L’ excrétion de l'acide zolédronique dans le lait maternel n’ est pas connue.","It is not known whether zoledronic acid is excreted into human breast milk.",13,13
"2418","fr","en","L’ excrétion de la dibotermine alpha da ns le l ait maternel n’est pas connue.","It is unknown whether dibotermin alfa is excreted in human breast milk.",12,15
"2419","fr","en","L’ excrétion fécale a représenté 6% de la dose administrée.","Faecal excretion accounted for 6% of the administered dose.",9,10
"2420","fr","en","L’ excrétion rénale n’ intervient pas dans la clairance du telmisartan.","Renal excretion does not contribute to the clearance of telmisartan.",10,11
"2421","fr","en","L’ expérience chez des patients recevant plus de 3 cycles thérapeutiques est actuellement limitée (voir rubrique 4.4).","There is currently limited experience of patients receiving more than 3 treatment cycles (see section 4.4).",16,17
"2422","fr","en","L’ exposition systémique augmente de façon linéaire avec l’ augmentation de la dose inhalée.","There is a linear increase in systemic exposure with increasing inhaled dose.",12,14
"2423","fr","en","L’ HCA est un glucocorticoïde de la classe des diesters.","HCA belongs to the diesters class of the glucocorticosteroids.",9,10
"2424","fr","en","L’ héparinothérapie associée peut contribuer à la survenue d’ hémorragies.","The concomitant use of heparin anticoagulation may contribute to bleeding.",10,10
"2425","fr","en","L’ histamine est une substance de l’ organisme à l’ origine des symptômes allergiques.","Histamine is a substance in the body that causes allergic symptoms.",11,14
"2426","fr","en","L’ hydrochlorothiazide circulant est lié aux protéines sériques (40% à 70%), essentiellement à l’ albumine sérique.","Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin.",11,16
"2427","fr","en","L’ hydrochlorothiazide est un diurétique, qui constitue un autre type de traitement contre l'hypertension artérielle.","Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension.",12,15
"2428","fr","en","L’ hyperhydratation doit être évitée chez les patients présentant un risque d’ insuffisance cardiaque.","Overhydration should be avoided in patients at risk of cardiac failure.",11,14
"2429","fr","en","L’ hypersensibilité aux pénicillines peut conduire à des réactions croisées avec les céphalosporines et réciproquement.","Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa.",13,15
"2430","fr","en","L’ impact à long terme d’ un traitement par Enbrel sur le développement de maladies auto-immunes est inconnu.","The impact of long-term treatment with Enbrel on the development of autoimmune diseases is unknown.",15,18
"2431","fr","en","L’ importance de l’ effet antihypertenseur doit être étroitement surveillée après administration de la dose initiale.","The magnitude of antihypertensive effect should be closely monitored after administering the initial dose.",14,16
"2432","fr","en","L’ incidence des ETV symptomatiques, incluant les EP, n’ était pas significativement différente entre les groupes.","The incidence of symptomatic VTE, including PE was not significantly different between treatment groups.",14,16
"2433","fr","en","L’ incidence des fractures vertébrales cliniques a été également significativement réduite de 49% (p=0,011).","The incidence of clinical vertebral fractures was also significantly reduced by 49% (p=0.011).",13,14
"2434","fr","en","L’ incidence des retards mentaux reste élevée dans ces formes néonatales.","Patients with neonatal-onset disease had a high incidence of mental retardation.",11,11
"2435","fr","en","L’ incidence des TVP proximales a été également significativement réduite.","ut but the incidence of proximal DVT was also significantly reduced.",11,10
"2436","fr","en","L’ influence sur la fertilité des mâles reproducteurs n’ a pas été étudiée.","The influence on fertility in male breeding animals has not been investigated.",12,13
"2437","fr","en","L’ initiation du traitement par Betaferon est contre-indiqué pendant la grossesse (voir rubrique 4.3).","Initiation of treatment is contraindicated during pregnancy (see section 4.3).",10,14
"2438","fr","en","L’ injection doit être faite immédiatement après le mélange.","Injection should be given immediately after mixing.",7,9
"2439","fr","en","L’ innocuité de la loratadine pendant la grossesse n’ a pas été établie.","The safe use of loratadine during pregnancy has not been established.",11,13
"2440","fr","en","L’ insuline en poudre est présentée sous plaquette thermoformée.","The insulin is contained as a powder in a blister.",10,9
"2441","fr","en","L’ insuline glargine est une insuline modifiée, tout à fait comparable à l'insuline humaine.","Insulin glargine is a modified insulin, very similar to human insulin.",11,14
"2442","fr","en","L’ interaction de Rebif avec des corticostéroïdes ou l’ hormone adrénocorticotrophique (ACTH) n’ a pas été étudiée systématiquement.","The interaction of Rebif with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically.",15,18
"2443","fr","en","L’ ionogramme sanguin (taux d’ électrolytes) doit être contrôlé.","Serum electrolytes should be monitored.",5,9
"2444","fr","en","L’ isomère (Z) et les autres métabolites retrouvés à l’ état de trace constituent les 5% restants.","The (Z)-isomer and traces of other metabolites account for the remaining 5%.",12,17
"2445","fr","en","L’ origine ethnique n'a pas affecté la pharmacocinétique du dabigatran de façon cliniquement significative.","Ethnic origin does not affect the pharmacokinetics of dabigatran in a clinically relevant manner.",14,14
"2446","fr","en","L’ ostéoporose peut être traitée et il n’ est jamais trop tard pour commencer le traitement.","Osteoporosis can be treated and it is never too late to begin treatment.",13,16
"2447","fr","en","L’ oubli d’ une dose peut favoriser la survenue de saignements et de spottings.","Forgetting a dose may increase the likelihood of breakthrough bleeding and spotting.",12,14
"2448","fr","en","L’ usage de contraceptifs efficaces est fortement recommandé.","The use of effective contraception is strongly recommended.",8,8
"2449","fr","en","L’ utilisation concomitante d’ imatinib avec des inducteurs puissants du CYP3A4 devra être évitée.","Concomitant use of rifampicin or other strong CYP3A4 inducers and imatinib should be avoided.",14,14
"2450","fr","en","L’ utilisation d’ Epivir en monothérapie n’ est pas recommandée.","Epivir is not recommended for use as monotherapy.",8,10
"2451","fr","en","L’ utilisation de charbon actif pourra être bénéfique.","The use of activated charcoal may be beneficial.",8,8
"2452","fr","en","L’ utilisation de Kivexa n’ est pas recommandée pendant la grossesse.","Kivexa is not recommended during pregnancy.",6,11
"2453","fr","en","L’ utilisation de techniques alternatives n’ utilisant pas de radiations ionisantes doit être considérée.","Alternative techniques, which do not involve ionising radiation, should be considered.",11,14
"2454","fr","en","L’ utilisation de YENTREVE n’ est pas recommandée pendant l’ allaitement.","The use of YENTREVE while breastfeeding is not recommended.",9,11
"2455","fr","en","L’ utilisation des ESA n’ est pas indiquée chez cette population de patients.","ESAs are not indicated for use in this patient population.",10,13
"2456","fr","en","L’ utilisation du LeukoScan n’ est pas recommandée chez l’ enfant.","LeukoScan is not recommended for use in children.",8,11
"2457","fr","en","L’absorption de kétoconazole et d’itraconazole au niveau du tractus gastro-intestinal est augmentée en présence d’acide gastrique.","The absorption of ketoconazole and itraconazole from the gastrointestinal tract is enhanced by the presence of gastric acid.",18,16
"2458","fr","en","L’administration d’antibiotiques peut provoquer l’ apparition d’agents pathogènes résistants à la substance active.","Each administration of antibiotics can lead to multiplication of pathogens resistant to the active substance used.",16,13
"2459","fr","en","L’administration doit être répétée une fois par semaine pendant 7 semaines consécutives suivies d’une semaine de repos.","This should be repeated once weekly for up to 7 weeks followed by a week of rest.",17,17
"2460","fr","en","L’administration simultanée de ciprofloxacine et de warfarine peut augmenter les effets anticoagulants de cette dernière.","Simultaneous administration of ciprofloxacin with warfarin may augment its anti-coagulant effects.",11,15
"2461","fr","en","L’allergie locale est fréquente (≥1/100 à < 1/10).","Local allergy is common (≥ 1/100 to < 1/10).",9,8
"2462","fr","en","L’arrêt brutal de votre traitement par Revatio peut entraîner une aggravation de vos symptômes.","If you stop taking Revatio Suddenly stopping your treatment with Revatio may lead to your symptoms getting worse.",18,14
"2463","fr","en","L’ASC plasmatique du midazolam a été augmentée de 1,5 fois.","The plasma AUC of midazolam was increased by 1.5-fold.",9,10
"2464","fr","en","L’augmentation de la digoxinémie peut s’atténuer au cours du temps (voir rubrique 4.5).","The increased digoxin levels may lessen over time (see section 4.5).",11,13
"2465","fr","en","L’échinococcose représente un danger pour l’homme.","Echinococcosis represents a hazard for humans.",6,6
"2466","fr","en","L’Emodepside est un substrat pour la glycoprotéine P.","Emodepside is a substrate for P-glycoprotein.",6,8
"2467","fr","en","L’excrétion rénale dépend de la filtration glomérulaire et de la réabsorption tubulaire du calcium.","Calcium is eliminated through faeces, urine and sweat. renal excretion depends on glomerular filtration and calcium tubular reabsorption.",18,14
"2468","fr","en","L’exposition et le profil pharmacocinétique étaient comparables, que les patients soient cirrhotiques (Child-Pugh grade A) ou non.","Comparable exposure and pharmacokinetic profiles were seen in cirrhotic (Child-Pugh Grade A) and non-cirrhotic patients.",15,17
"2469","fr","en","L’heure de la prise doit être notée.","The time of intake must be noted.",7,7
"2470","fr","en","L’huile de ricin hydrogénée est susceptible d’entraîner des maux d’estomac ou une diarrhée.","Hydrogenated castor oil may cause stomach upset or diarrhoea.",9,13
"2471","fr","en","L’information au patient doit contenir les informations suivantes:","The patient information shall contain the following information:",8,8
"2472","fr","en","L’inhibition de la glycoprotéine P (Pgp) en est une possible explication.","Inhibition of Pgp may be a likely explanation.",8,11
"2473","fr","en","L’interaction avec Invirase/ritonavir n’a pas été étudiée.","Interaction with Invirase/ritonavir not studied.",5,7
"2474","fr","en","L’interféron β-1b agit sur les récepteurs de l’interféron γ en diminuant leur affinité et en augmentant leur internalisation","Interferon beta-1b both decreases the binding affinity and enhances the internalisation and degradation of the interferon-gamma receptor.",17,18
"2475","fr","en","L’utilisation concomitante de voriconazole avec du darunavir co-administré avec 100 mg de ritonavir n’a pas été étudiée.","The combined use of voriconazole with darunavir co-administered with 100 mg ritonavir has not been studied.",16,17
"2476","fr","en","L’utilisation d’Agopton chez les enfants est déconseillée.","Agopton should not be given to children.",7,7
"2477","fr","en","L’utilisation de médicaments inhibant le péristaltisme est contre-indiquée dans cette situation.","Anti-peristaltic drugs are contraindicated in this situation.",7,11
"2478","fr","en","L’utilisation durant la grossesse n’est donc pas recommandée.","Use in pregnancy is, therefore, not recommended.",7,8
"2479","fr","en","La ½ vie d'élimination plasmatique est d’ environ 19 heures et n'augmente pas avec les fortes doses.","The elimination half-life does not increase at higher doses.",9,17
"2480","fr","en","La BH4 est un cofacteur de l'oxyde nitrique synthétase.","BH4 is a cofactor for nitric oxide synthetase.",8,9
"2481","fr","en","La biodisponibilité absolue d'une gélule à 300 mg est d'environ 60%.","Absolute bioavailability of a 300 mg capsule is approximately 60%.",10,11
"2482","fr","en","La biodisponibilité absolue de la sitagliptine est d'environ 87%.","The absolute bioavailability of sitagliptin is approximately 87%.",8,9
"2483","fr","en","La biodisponibilité absolue est réduite d'environ 16% en cas d'insuffisance cardiaque.","The absolute bioavailability is reduced approximately 16% in patients with heart failure.",12,11
"2484","fr","en","La biodisponibilité après injection sous-cutanée est de 88%.","After subcutaneous administration the bioavailability is 88% and the volume of distribution is 2.5 l/ kg.",16,8
"2485","fr","en","La biodisponibilité du ropinirole fait l’ objet d’ une large variabilité inter-individuelle.","The bioavailability of ropinirole varies greatly between individuals.",8,12
"2486","fr","en","La brochure d’ information doit contenir les éléments clés suivants:","Key elements to be included in the educational brochure",9,10
"2487","fr","en","La calcitonine de saumon ne traverse pas la barrière placentaire. am","Salmon calcitonin does not cross the placental barrier.",8,11
"2488","fr","en","La cartouche est scellée dans un stylo injecteur jetable.","The cartridge is sealed in a disposable pen injector.",9,9
"2489","fr","en","La cétirizine n'est pas éliminée efficacement par hémodialyse.","Cetirizine is not effectively removed by dialysis.",7,8
"2490","fr","en","La ciprofloxacine a un effet bactéricide rapide sur les bactéries en cours de multiplication ou quiescentes.","Ciprofloxacin has a rapid bactericidal effect, both in the growth phase and in the rest phase.",16,16
"2491","fr","en","La ciprofloxacine est excrétée dans le lait.","Ciprofloxacin is excreted in breast milk.",6,7
"2492","fr","en","La cladribine est contre- indiquée chez la femme enceinte.","Cladribine is contraindicated during pregnancy.",5,9
"2493","fr","en","La clairance de dialyse du perindoprilate est de 70 ml/ min.","Dialysis clearance of perindoprilat is equal to 70 ml/ min.",10,11
"2494","fr","en","La clairance extra-rénale diminue lorsque les doses mé","The non-renal clearance is decreased as the dose is increased.",10,8
"2495","fr","en","La clairance plasmatique totale du fentanyl est d’ environ 0,5 l/ h/ kg.","Total plasma clearance of fentanyl is about 0.5 l/ h/ kg.",11,13
"2496","fr","en","La clairance rénale semble participer pour 30% à la clairance totale de PegIntron.","Renal clearance appears to account for 30% of total clearance of Peg Intron.",13,13
"2497","fr","en","La clairance totale et la clairance rénale sont respectivement de 157-176 et 3-3,5 ml/ min.","The total body and renal clearance are 157-176 and 3.0-3.5 ml/ min, respectively.",13,15
"2498","fr","en","La Cmax plasmatique ne représentait que 1 à 2% de la dose appliquée.","At the Cmax, the plasma concentration represented only 1-2% of the applied dose.",13,13
"2499","fr","en","La co-administration d’EMEND et de préparations à base de plantes contenant du millepertuis (Hypericum perforatum) n’est pas recommandée.","John’ s Wort (Hypericum perforatum) is not recommended.",8,18
"2500","fr","en","La co-administration de REYATAZ/ ritonavir et de l'indinavir n'est pas recommandée (voir rubrique 4.4)","Coadministration of REYATAZ/ ritonavir and indinavir is not recommended (see section 4.4).",12,14
"2501","fr","en","La co-administration de sirolimus et de voriconazole n’ est pas recommandée (voir rubrique 4.4).","Co-administration of sirolimus and voriconazole is not recommended (see section 4.4).",11,14
"2502","fr","en","La coiffe est marquée avec « Temodal ».","The cap is imprinted with “Temodal”.",6,8
"2503","fr","en","La comparaison avec une précédente biopsie de moelle osseuse, si disponible, doit être effectuée.","If available, comparison to a prior bone marrow biopsy should be made.",12,14
"2504","fr","en","La concentration de la solution finale de bevacizumab doit être comprise entre 1,4 et 16,5 mg/ ml.","The concentration of the final bevacizumab solution should be kept within the range of 1.4-16.5 mg/ ml.",17,17
"2505","fr","en","La congélation détruit le vaccin.","Freezing destroys the vaccine.",4,5
"2506","fr","en","La consommation de jus de pamplemousse doit être évitée pendant le traitement par le lapatinib (voir rubrique 4.5)","Grapefruit juice should be avoided during treatment with lapatinib (see section 4.5).",12,18
"2507","fr","en","La contenance de chaque stylo est de 300 unités internationales (3 millilitres).","Each Humalog Mix50 KwikPen contains 300 units (3 millilitres).",9,12
"2508","fr","en","La couleur du stylo dans les illustrations est différente de celle de votre FlexPen.","The colour of the pen in the illustrations differs from your FlexPen.",12,14
"2509","fr","en","La crème imiquimod doit être éliminée par lavage de la peau avant toute activité sexuelle.","Imiquimod cream should be washed from the skin before sexual activity.",11,15
"2510","fr","en","La date d’ expiration fait référence au dernier jour du mois.","date refers to the last day of that month.",9,11
"2511","fr","en","La défériprone ne doit pas être utilisée par les femmes qui allaitent.","Deferiprone must not be used by breast-feeding mothers.",8,12
"2512","fr","en","La demi-vie d’ élimination est suffisante pour justifier une prise quotidienne unique.","The half-life of elimination is sufficient to justify once-a-day dosing.",10,12
"2513","fr","en","La demi-vie se situe entre 4.7 et 13.2 heures chez les patients.","The elimination half-life ranges from 4.7 to 13.2 hours in patients.",11,12
"2514","fr","en","La demi-vie terminale après une administration sous-cutanée est déterminée par la vitesse d’absorption à partir du tissu sous-cutané.","The terminal half-life after subcutaneous administration is determined by the rate of absorption from the subcutaneous tissue.",17,18
"2515","fr","en","La dernière date à laquelle cette notice a été approuvé est C","This leaflet was last approved in",6,12
"2516","fr","en","La dernière date à laquelle cette notice a été approuvée","This leaflet was last approved in:",6,10
"2517","fr","en","La dernière date à laquelle cette notice a été approuvée est (MM/ YYYY)","This leaflet was last approved in {MM/ YYYY}.",8,13
"2518","fr","en","La dernière date à laquelle cette notice a été approuvée est {date}","This leaflet was last approved on {date}",7,12
"2519","fr","en","La dernière date à laquelle cette notice a été approuvée est {MM/ AAAA}.","This leaflet was last approved in {MM/ YYYY}",8,13
"2520","fr","en","La dernière date à laquelle cette notice a été approuvée est {MM/AAAA}.","This leaflet was last approved in {MM/YYYY}.",7,12
"2521","fr","en","La dernière date à laquelle cette notice a été approuvée est le {date}","This leaflet was last approved on {MM/ YYYY}",8,13
"2522","fr","en","La desloratadine et la pseudoéphédrine sont toutes deux excrétées dans le lait maternel.","Desloratadine and pseudoephedrine are both excreted in breast milk.",9,13
"2523","fr","en","La diarrhée constitue l’ effet indésirable le plus fréquent.","The most common adverse drug reaction is diarrhoea.",8,9
"2524","fr","en","La dibotermine alpha se présente dans le kit sous la forme de poudre blanche.","Dibotermin alfa is supplied in the kit as a white powder.",11,14
"2525","fr","en","La didanosine doit être prise à jeun, 2 heures après REYATAZ/ ritonavir","Didanosine should be taken at the fasted state 2 hours after",11,12
"2526","fr","en","La différence n’ a pas été statistiquement significative:","The difference was not statistically significant:",6,8
"2527","fr","en","La diminution de la dose de lévodopa diminue la sévérité et la fréquence des réactions.","Reduction of levodopa dosage decreases the severity and frequency of the reactions.",12,15
"2528","fr","en","La diminution de la quantité de VIH dans le sang peut améliorer le fonctionnement de votre système immunitaire.","Reducing the amount of HIV in the blood may improve the functioning of your immune system.",16,18
"2529","fr","en","La direction assure également le secrétariat du conseil d’ administration.","The Directorate also provides the secretariat of the Management Board.",10,10
"2530","fr","en","La disparition complète (effet imiquimod moins effet excipient) dans les essais cumulés est de 46.1% (IC 39.0%,53.1%).","The complete clearance rate (imiquimod minus placebo) for the combined trials was 46.1% (CI 39.0%, 53.1%).",16,17
"2531","fr","en","La dissolution de la substance active est rapide après une légère agitation et produit une solution limpide.","The active substance is rapidly redispersed by shaking gently producing a clear solution.",13,17
"2532","fr","en","La distance entre chaque repère de l'échelle représente 20 unités environ.","The distance between each mark on the gauge is about 20 units.",12,11
"2533","fr","en","La dose à administrer sera calculée en fonction du poids de votre enfant.","The dose to be administered will be calculated from the weight of your baby.",14,13
"2534","fr","en","La dose de 40 mg est contre-indiquée en cas d’ association aux fibrates.","The 40 mg dose is contraindicated with concomitant use of a fibrate.",12,13
"2535","fr","en","La dose de départ recommandée est de 1 mg/ kg corporel/ jour divisé en 2 doses administrées oralement.","The recommended starting dose is 1 mg/ kg body weight/ day divided in 2 doses administered orally.",17,18
"2536","fr","en","La dose de dexaméthasone a été déterminée en tenant compte des interactions médicamenteuses.","The dose of dexamethasone was chosen to account for active substance interactions.",12,13
"2537","fr","en","La dose de méthadone a été augmentée de 22% en moyenne pour atténuer les symptômes de sevrage.","The methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.",14,17
"2538","fr","en","La dose de ribavirine à utiliser en association avec Pegasys est indiquée dans le tableau 1.","The dose of ribavirin to be used in combination with Pegasys s given in Table 1.",16,16
"2539","fr","en","La dose de votre anticoagulant peut nécessiter un ajustement.","anticoagulant may need adjustment.",4,9
"2540","fr","en","La dose est administrée toutes les 48 heures (un jour sur deux), en injection sous la peau.","The dose is given every 48 hours (every two days) as an injection under the skin.",16,17
"2541","fr","en","La dose est de 1 MU/ kg de poids vif.","The dose is 1 MU/ kg bodyweight.",7,10
"2542","fr","en","La dose habituelle est de 1 flacon de Pergoveris par jour pendant 3 semaines maximum.","The usual dose is one vial of Pergoveris used every day for up to three weeks.",16,15
"2543","fr","en","La dose habituelle est de 260 mg/ m2 de surface corporelle.","The usual dose is 260 mg/m2 of body surface area.",10,11
"2544","fr","en","La dose initiale recommandée de TOVIAZ est de 4 mg une fois par jour.","The recommended starting dose of TOVIAZ is 4 mg once a day.",12,14
"2545","fr","en","La dose initiale recommandée est de 300 mg/ m2/ jour.","The recommended initial dose is 300 mg/ m2/ day.",9,10
"2546","fr","en","La dose initiale sera de 150 mg/m2.","The first dose will be 150 mg/m2.",7,7
"2547","fr","en","La dose journalière de Olanzapine Teva se situe entre 5 et 20 mg.","The daily dose of Olanzapine Teva is between 5 and 20 mg.",12,13
"2548","fr","en","La dose maximale de {NOM DU PRODUIT} est de 80 mg une fois par jour.","The maximum dose of {PRODUCT NAME}is 80 mg once daily.",10,15
"2549","fr","en","La dose maximale journalière est de 1,6 ml.","The maximum total dose is 1.6 ml.",7,8
"2550","fr","en","La dose maximale quotidienne est de 1200 mg.","The maximum daily dose is 1200 mg.",7,8
"2551","fr","en","La dose maximale quotidienne recommandée est de 6 mg deux fois par jour.","The recommended maximum daily dose is 6 mg twice a day.",11,13
"2552","fr","en","La dose maximale recommandée est de 100 mg.","The maximum recommended dose is 100 mg.",7,8
"2553","fr","en","La dose maximum d’ InductOs est de 2 kits.","The maximum dosage of InductOs is limited to 2 kits.",10,9
"2554","fr","en","La dose peut alors être sélectionnée.","The dose can then be selected.",6,6
"2555","fr","en","La dose peut être réduite à 2,5 mg une fois par jour, en fonction de la tolérance individuelle.","The dose may be decreased to 2.5 mg once a day based on individual tolerability.",15,18
"2556","fr","en","La dose quotidienne de 5 mg est alors utilisée, après une dose de départ de 60 mg.","In this case, the 5-mg daily dose should be used following a 60-mg starting dose.",15,17
"2557","fr","en","La dose recommandée d’ INVEGA est de 6 mg une fois par jour, le matin.","The recommended dose of INVEGA is 6 mg once daily, administered in the morning.",14,15
"2558","fr","en","La dose recommandée de Viread est d’ un comprimé une fois par jour au cours d’ un repas.","The recommended dose of Viread is one tablet taken once a day with food.",14,18
"2559","fr","en","La dose recommandée est de 10 mg une fois par jour, au moment ou en dehors des repas.","The recommended dose is 10 mg once a day, taken with or without food.",14,18
"2560","fr","en","La dose recommandée est de 600 mg/ m2 prise deux fois par jour.","The recommended dose is 600 mg/ m2 taken twice a day.",11,13
"2561","fr","en","La dose thérapeutique initiale est de 500 mg deux fois par jour.","The initial therapeutic dose is 500 mg twice daily.",9,12
"2562","fr","en","La doxazosine est très largement métabolisée, moins de 5% du produit étant excrété sous forme inchangée.","Doxazosin is extensively metabolised with < 5% excreted as unchanged product.",11,16
"2563","fr","en","La doxorubicine appartient au groupe des médicaments anticancéreux appelés anthracyclines.","Doxorubicin belongs to a group of anti-tumour medicines called anthracyclines.",10,10
"2564","fr","en","La duloxétine est fortement métabolisée et ses métabolites sont éliminés principalement dans les urines.","Duloxetine is extensively metabolised and the metabolites are excreted principally in urine.",12,14
"2565","fr","en","La durée d’ action de la nifédipine peut être raccourcie.","The duration of action of nifedipine can be shortened.",9,10
"2566","fr","en","La durée d’ activité de la lévodopa est ainsi prolongée.","As a result, levodopa remains active for longer.",8,10
"2567","fr","en","La durée de l'efficacité dans l'angine de poitrine est d'au moins 24 heures.","The efficacy duration in angina pectoris is at least 24 hours.",11,13
"2568","fr","en","La durée de la protection est de 6 mois.","The duration of protection is 6 months. or",8,9
"2569","fr","en","La durée de traitement avec {NOM DU PRODUIT} 20 mg sera déterminée par votre médecin.","The duration of treatment with {PRODUCT NAME} 20 mg is determined by your doctor.",14,15
"2570","fr","en","La durée de traitement par l’ anidulafungine a été égale ou supérieure à 14 jours chez 119 patients.","One hundred and nineteen patients received ≥ 14 days of anidulafungin.",11,18
"2571","fr","en","La durée du traitement dépend de l’ état du patient.","The duration of treatment depends on the patient’ s condition.",10,10
"2572","fr","en","La durée recommandée du traitement est de 10 à 14 jours.","The recommended duration of treatment is 10 - 14 days.",10,11
"2573","fr","en","La durée totale de la fièvre a été réduite d'un jour dans les groupes traités par l'oseltamivir.","The total duration of fever was reduced by one day in the groups treated with oseltamivir.",16,17
"2574","fr","en","La fixation aux protéines plasmatiques humaines est d’ environ 25%.","The extent of eptifibatide binding to human plasma protein is about 25%.",12,10
"2575","fr","en","La formation de sténose œ sophagienne ne peut être diminuée ou prévenue par l’ utilisation de corticoïdes.","The formation of oesophageal stenosis cannot be reduced or eliminated by the use of steroids.",15,17
"2576","fr","en","La forme pharmaceutique est: poudre et solvant pour solution injectable.","The pharmaceutical form is: powder and solvent for solution for injection.",11,10
"2577","fr","en","La France considère que la posologie du produit n’ est pas correcte.","France considers that the dosing regime of the product is not correct.",12,12
"2578","fr","en","La fréquence de certains effets secondaires peut varier selon votre affection.","The frequency of some side effects may vary depending on your condition.",12,11
"2579","fr","en","La fréquence des doses initiales sera de toutes les deux heures jusqu'à l'obtention d'une amélioration clinique.","Dosing frequency should initially be every second hour until clinical improvement is observed.",13,16
"2580","fr","en","La fréquence des inhibiteurs FVIII détectés jusqu’ à présent se situe dans la plage attendue et antérieurement observée.","The frequency of FVIII inhibitors detected so far is within the expected and previously observed range.",16,18
"2581","fr","en","La fréquence des réactions indésirables est définie selon la convention suivante:","Adverse reactions frequency is defined using the following convention:",9,11
"2582","fr","en","La fréquence est définie comme: très fréquent (≥ 1/ 10); fréquent (≥ 1/ 100, < 1/ 10).","Frequency is defined as very common (≥ 1/ 10); common (≥ 1/ 100, < 1/ 10).",16,17
"2583","fr","en","La fréquence ou la sévérité des effets indésirables n’ augmentaient pas avec le nombre de doses.","No increase in the frequency or severity of adverse events was seen with subsequent doses.",15,16
"2584","fr","en","la glucuronisation de la","Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5):",13,4
"2585","fr","en","La goutte sera déposée à cet endroit (figure 1). • Rapprochez l’ embout du flacon de l’œ il.","The drop will go in here (picture 1). • Bring the bottle tip close to the eye.",17,18
"2586","fr","en","la GPIIb/ IIIa la GPIIb/ IIIa (N=2842) (N=2924)%%","Risk diff. alone inhibit or (95% CI) (95% CI) (N=2911) or (N=29% (N=28 24) 42)%%",15,8
"2587","fr","en","La kaliémie devra être dans les limites de la normale avant un début de traitement par sparfloxacine.","Potassium levels should be within the normal range before treatment with sparfloxacin is started.",14,17
"2588","fr","en","La lamivudine et la zidovudine sont des analogues nucléosidiques actifs sur le VIH.","Lamivudine and zidovudine are nucleoside analogues which have activity against HIV.",11,13
"2589","fr","en","La lépirudine est un inhibiteur direct et hautement spécifique de la thrombine.","Lepirudin is a highly specific direct inhibitor of thrombin.",9,12
"2590","fr","en","La lettre de la société notifiant à l’ EMEA le retrait de la demande est disponible ici.","The letter from the company notifying the EMEA of the withdrawal of the application is available here.",17,17
"2591","fr","en","La leucémie est un cancer des globules blancs du sang.","Leukaemia is a cancer of white blood cells.",8,10
"2592","fr","en","La liaison aux protéines plasmatiques est importante (98%).","Plasma protein binding is high (98%).",6,8
"2593","fr","en","La liaison aux protéines plasmatiques n'est pas modifiée en cas d’ insuffisance hépatique ou rénale.","Protein binding is not affected by renal or hepatic impairment.",10,15
"2594","fr","en","La liste des bactéries sensibles à INVANZ figure dans le résumé des caractéristiques du produit.","The list of bacteria against which INVANZ is active can be found in the Summary of Product Characteristics.",18,15
"2595","fr","en","La liste des dénominations concernées est fournie à l’ annexe I.","The list of product names concerned is given in Annex I.",11,11
"2596","fr","en","La loratadine n’ a pas d’ action significative au niveau des récepteurs H2.","Loratadine has no significant H2-receptor activity.",6,13
"2597","fr","en","La lyse tumorale peut également entraîner une hyperphosphorémie, une hyperkaliémie et une hypocalcémie.","Tumour lysis can also result in hyperphosphataemia, hyperkalaemia and hypocalcaemia.",10,13
"2598","fr","en","La majorité (> 95%) de ces évènements a été considérée comme légers à modérés.","The majority (> 95%) of these events was reported as mild to moderate.",13,14
"2599","fr","en","La majorité (57/ 61) n’ avait pas répondu aux traitements antifongiques administrés antérieurement.","Voriconazole has been infrequently associated with cases of serious hepatic toxicity in patients with other serious underlying conditions.",18,13
"2600","fr","en","La meilleure façon d’utiliser Pegasys chez les patients atteints d'hépatite chronique C est de l’associer à la ribavirine.","The optimal way to use Pegasys in patients with chronic hepatitis C is in combination with ribavirin.",17,18
"2601","fr","en","LA MENTION ""TENIR HORS DE LA PORTEE ET DE VUE DES ENFANTS""","THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”",12,12
"2602","fr","en","LA MENTION « À USAGE VÉTÉRINAIRE","THE WORDS “ FOR ANIMAL TREATMENT ONLY”",7,6
"2603","fr","en","LA MENTION « USAGE VETERINAIRE »","THE WORDS ""FOR ANIMAL TREATMENT ONLY""",6,6
"2604","fr","en","La métaflumizone est encore mesurable dans les poils 56 jours après traitement.","Metaflumizone was still measurable in the hair 56 days following treatment.",11,12
"2605","fr","en","La metformine agit principalement en diminuant la production endogène hépatique de glucose.","Metformin acts primarily by decreasing endogenous hepatic glucose production.",9,12
"2606","fr","en","La micafungine a hémolysé le sang de lapin in vitro.","Micafungin haemolysed rabbit blood in vitro.",6,10
"2607","fr","en","La mise en place de l’ immunité a été démontrée 3 semaines après vaccination.","Onset of immunity has been demonstrated 3 weeks after the primary vaccination course.",13,14
"2608","fr","en","La mousse pourrait gêner la mesure correcte de la dose.","Froth may interfere with the correct measurement of the dose.",10,10
"2609","fr","en","La moyenne géométrique de la clairance plasmatique est approximativement de 50 L/ heure (coefficient de variation de 21.7%).","The geometric mean plasma clearance is approximately 50 litres/ hour (coefficient of variation 21.7%).",14,18
"2610","fr","en","La mutation K65R était absente, et les mutations L74V et Y115F étaient peu fréquentes (≤ 3%).","K65R was absent and L74V and Y115F were uncommon (≤ 3%).",11,16
"2611","fr","en","La myéloablation s’ est produite chez tous les sujets adultes et enfants.","All adults and children achieved myeloablation.",6,12
"2612","fr","en","La myélosuppression a été l’ effet secondaire majeur dose-limitant de Paxene.","Bone marrow suppression was the major dose-limiting toxicity of Paxene.",10,11
"2613","fr","en","La nécessité d’ un traitement par AEs doit être réévaluée lorsqu’ une femme envisage une grossesse.","The need for treatment with AEDs should be reviewed when a woman is planning to become pregnant.",17,16
"2614","fr","en","La paroxétine inhibe le recaptage neuronal de la sérotonine et facilite ainsi la transmission sérotonergique.","Paroxetine inhibits the neuronal uptake of serotonin and thereby facilitates serotonergic transmission.",12,15
"2615","fr","en","La partie « Contre-indications » est restée inchangée.","Section on contraindications remained unchanged.",5,8
"2616","fr","en","La perfusion doit être effectuée selon les procédures médicales standards.","The infusion must be conducted according to standard medical practice.",10,10
"2617","fr","en","La perfusion dure 1 à 2 heures.","The infusion will last 1-2 hours.",6,7
"2618","fr","en","La période de latence est très courte, même pour un agent alkylant.","This latency period is very short even for an alkylating agent.",11,12
"2619","fr","en","La persistance des anticorps pour les vaccins prototypes varie.","The persistence of antibodies for the mock-up vaccines varies.",9,9
"2620","fr","en","La pertinence clinique de ces résultats n'est cependant pas bien définie.","The clinical relevance of such findings remains, however, not well defined.",11,11
"2621","fr","en","La pioglitazone peut provoquer une rétention hydrique susceptible d'aggraver ou d’ accélérer l’ évolution vers une insuffisance cardiaque.","Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure.",12,18
"2622","fr","en","La pirlimycine (sous forme de chlorhydrate) est un antibiotique semi-synthétique de la famille des lincosamides.","Pirlimycin hydrochloride is a semi-synthetic lincosamide antibiotic.",7,15
"2623","fr","en","La plupart de ces réactions locales sont modérées et transitoires.","The majority of these local reactions are mild and transient in nature.",12,10
"2624","fr","en","La plupart des cancers du sein se développent en réponse à l’ hormone œ strogène.","Most types of breast cancer grow in response to the hormone oestrogen.",12,15
"2625","fr","en","La plupart des échecs au traitement dans CAP-001 étaient dus à une tolérance faible.","Treatment failures caused by",4,14
"2626","fr","en","La plupart des effets indésirables observés étaient d’intensité légère à modérée.","Most ADRs observed were mild to moderate in nature.",9,11
"2627","fr","en","La plupart des effets indésirables rapportés avec Atriance ont été observés chez l'adulte, l'enfant et l'adolescent.","The majority of side effects reported with Atriance were seen in adults, children and adolescents.",15,16
"2628","fr","en","La plupart des patients atteints d’hyperplasie de la prostate sont contrôlés à la dose initiale.","Most of the patients with prostatic hyperplasia are controlled with the initial dose.",13,15
"2629","fr","en","La plupart des patients ont été traités dans le cadre d’ une étude « non contrôlée »:","Most patients received it as part of a ‘ uncontrolled’ study:",11,17
"2630","fr","en","La plupart des réactions mineures aux insulines disparaissent généralement en l'espace de quelques jours à quelques semaines.","Most minor reactions to insulins usually resolve in a few days to a few weeks.",15,17
"2631","fr","en","La pneumonie communautaire est généralement due à une infection bactérienne.","Community-acquired pneumonia is usually caused by infection with bacteria.",9,10
"2632","fr","en","La pommade doit être appliquée en fine couche sur les zones affectées de la peau.","The ointment should be applied as a thin layer to affected areas of the skin.",15,15
"2633","fr","en","La position déverrouillée est la position normale pour délivrer la solution buvable.","The unlocked position is the normal position for discharging the oral solution.",12,12
"2634","fr","en","La posologie doit être adaptée en fonction de la clairance de la créatinine (voir tableau 1 ci-dessous).","If required, diuretic therapy may be resumed (see section 4.4 and section 4.5).",13,17
"2635","fr","en","La posologie doit être adaptée en fonction de la réponse tensionnelle.","Dosage should be adjusted according to blood pressure response.",9,11
"2636","fr","en","La posologie doit être ajustée indi- viduellement et le traitement doit être poursuivi aussi longtemps que nécessaire.","The dose should be individually adjusted and the treatment should be continued for as long as necessary.",17,17
"2637","fr","en","La posologie doit être basée sur les résultats du dosage de l'activité en protéine C.","The dosage should be determined on the basis of laboratory measurements of the protein C activity.",16,15
"2638","fr","en","La posologie hebdomadaire peut aussi être divisée en doses quotidiennes.","The weekly dose can also be divided into daily doses.",10,10
"2639","fr","en","La posologie initiale habituelle est de 1,3 mg/ m2 de surface corporelle.","The usual starting dose is 1.3 mg/ m2 body surface area.",11,12
"2640","fr","en","La posologie n’ a pas été déterminée chez les enfants insuffisants rénaux et/ ou hépatiques.","The dosage in children with impaired renal and/ or hepatic function has not been investigated.",15,15
"2641","fr","en","La posologie recommandée est de 30 mg une fois par jour pendant 2 semaines.","The recommended dose is 30 mg once daily for 2 weeks.",11,14
"2642","fr","en","La posologie recommandée la plus faible ne devrait donc pas être dépassée chez ces patients.","Therefore, dosage should be restricted to the lower end of the dosage range.",13,15
"2643","fr","en","La posologie recommandée peut être augmentée ou diminuée.","The recommended dose may be increased or decreased.",8,8
"2644","fr","en","La posologie usuelle de MicardisPlus est d’un comprimé par jour.","The usual dose of MicardisPlus is one tablet a day.",10,10
"2645","fr","en","La poudre doit être reconstituée immédiatement avant l’ utilisation avec le solvant joint.","The powder should be reconstituted immediately prior to use with the solvent provided.",13,13
"2646","fr","en","La poudre est de couleur blanche ou presque blanche.","The powder is white to off-white.",6,9
"2647","fr","en","La poudre est jaune pâle, compacte et cristalline.","The powder is a light yellow compact crystalline cake.",9,8
"2648","fr","en","La prégabaline peut potentialiser les effets de l'éthanol et du lorazépam.","Pregabalin may potentiate the effects of ethanol and lorazepam.",9,11
"2649","fr","en","La première injection de Cetrotide doit être surveillée par votre médecin.","The first injection of Cetrotide should be supervised by your doctor.",11,11
"2650","fr","en","La première procédure d'arbitrage pour un médicament à usage vétérinaire a été entamée en 2001.","The first arbitration procedure for a veterinary medicinal product was initiated in 2001.",13,15
"2651","fr","en","La présence d’ une infection bénigne comme un rhume, ne constitue pas une contre-indication à la vaccination.","The presence of a minor infection such as a cold, is not a contraindication for immunisation.",16,17
"2652","fr","en","La prise alimentaire ralentit l’absorption du lansoprazole et réduit sa biodisponibilité d’environ 50%.","Intake of food slows the absorption rate of lansoprazole and reduces the bioavailabilty by about 50%.",16,13
"2653","fr","en","La prise d’ Axura par des patients atteints d’ insuffisance hépatique sévère n’ est pas recommandée.","Administration of Axura in patients with severe hepatic impairment is not recommended.",12,16
"2654","fr","en","La prise d’ EXJADE au cours de l’ allaitement n’ est pas recommandée.","Breast- feeding while taking EXJADE is not recommended.",8,13
"2655","fr","en","La prise en charge standard d'un surdosage peut être utilisée (lavage gastrique, administration de charbon activé).","Standard procedures for management of overdose may be indicated (i. e. gastric lavage, administration of activated charcoal).",17,16
"2656","fr","en","La prise simultanée d'alcool n’ est pas recommandée.","Concomitant intake with alcohol is not recommended.",7,8
"2657","fr","en","La probabilité que cela arrive est plus élevée chez les femmes prenant la rosiglitazone depuis plus d'un an.","The chances of this happening may be higher in women taking rosiglitazone for more than one year.",17,18
"2658","fr","en","La procédure de reconnaissance mutuelle a débuté le 25 mai 2005.","The Mutual Recognition Procedure started on 25 May 2005.",9,11
"2659","fr","en","La procédure de saisine a débuté le 17 mars 2005.","The referral procedure started on 17 March 2005.",8,10
"2660","fr","en","La procédure de saisine a débuté le 23 mars 2006.","The arbitration procedure started on 23 March 2006.",8,10
"2661","fr","en","La procédure opérationnelle standard récemment adoptée sur le conseil scientifique sera mis en oeuvre en 1997.","The recently adopted standard operating procedure (SOP) on scientific advice will be implemented in 1997.",15,16
"2662","fr","en","La protection contre l'hépatite A et contre l'hépatite B apparaît en 2 à 4 semaines.","Protection against hepatitis A and hepatitis B develops within 2-4 weeks.",11,15
"2663","fr","en","La protection débute 14 jours après la vaccination et persiste jusqu'à la 9ème semaine.","The onset of protection is from 2 weeks onwards and the protection extends to 9 weeks.",16,14
"2664","fr","en","La prudence est donc recommandée pour le traitement de ces patients.","Therefore these patients should be treated with caution.",8,11
"2665","fr","en","La prudence est justifiée et une surveillance clinique est recommandée, si la co-administration de clotrimazole est nécessaire.","Caution is warranted and clinical monitoring is recommended, when co-administration of clotrimazole is required.",14,17
"2666","fr","en","La prudence est recommandée en cas d’ administration concomitante à des substrats du CYP2B6 (ex. bupropion, efavirenz, cyclophosphamide).","Caution is advised during co-administration with CYP2B6 substrates (e. g. bupropion, efavirenz, cyclophosphamide).",13,18
"2667","fr","en","La prudence est recommmandée lorsque la palipéridone est utilisée chez ces patients.","Caution is recommended if paliperidone is used in such patients.",10,12
"2668","fr","en","La prudence s'impose lorsque le ziconotide est administré chez ce type de patients.","Caution should be exercised when ziconotide is administered to patients with impaired hepatic function.",14,13
"2669","fr","en","La prudence s’ impose chez les patientes recevant des glucosides cardiotoniques (voir rubrique 4.5).","Caution should be exercised in patients receiving cardiac glucosides (see section 4.5).",12,14
"2670","fr","en","La rasagiline est contre-indiquée chez les patients présentant une insuffisance hépatique sévère.","Rasagiline is contraindicated in patients with severe hepatic insufficiency.",9,12
"2671","fr","en","La réduction des niveaux de PTH entraîne également une diminution des taux de calcium sanguin.","The reduction in PTH levels also leads to a decrease in blood calcium levels.",14,15
"2672","fr","en","La relation de causalité entre le filgrastim et la survenue de ces troubles n'a pas été établie.","The causal association with filgrastim has not been established.",9,17
"2673","fr","en","La relation entre la concentration et l'effet n'a pas été évaluée après l'administration du fosaprépitant.","The relationship between concentration and effect has not been evaluated after administration of fosaprepitant.",14,15
"2674","fr","en","La remise en suspension est plus facile si l’ insuline a atteint la température ambiante.","Resuspending is easier if the insulin has reached room temperature 82 2.",12,15
"2675","fr","en","La réponse à un traitement à long terme doit être suivie à intervalles réguliers par un vétérinaire.","Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.",14,17
"2676","fr","en","La résistance aux sulfamidés potentialisés peut varier.","Resistance against potentiated sulphonamides may vary.",6,7
"2677","fr","en","La rivastigmine est métabolisée essentiellement par hydrolyse en son métabolite NAP226-90 par l’ acétylcholinestérase.","Metabolism is primarily via cholinesterase-mediated hydrolysis to the metabolite NAP226-90.",10,14
"2678","fr","en","La rosiglitazone est fortement liée aux protéines et n’ est pas éliminée par hémodialyse.","Rosiglitazone is highly protein bound and is not cleared by haemodialysis.",11,14
"2679","fr","en","La seringue encore reliée à l’adaptateur; faites tourner doucement le flacon jusqu’à ce que la poudre soit dissoute.","With the syringe still connected to the adapter, gently rotate the vial until the powder is dissolved.",17,18
"2680","fr","en","La seringue pré-remplie de Binocrit est prête à l'emploi.","The Binocrit pre-filled syringe is ready for use.",8,9
"2681","fr","en","La seringue pré-remplie ne doit pas être secouée.","The pre-filled syringe should not be shaken.",7,8
"2682","fr","en","La signification clinique de ces observations reste à confirmer.","The clinical relevance of these observations remains to be confirmed.",10,9
"2683","fr","en","La signification clinique de cette augmentation n’est pas connue, aussi, PREZISTA doit être utilisé avec prudence.","The clinical relevance of this increase is unknown therefore, PREZISTA should be used with caution.",15,16
"2684","fr","en","La signification clinique de cette donnée est peu claire.","The clinical significance of this finding is unclear.",8,9
"2685","fr","en","La signification clinique des augmentations asymptomatiques des taux d’ amylase sérique est inconnue.","The clinical significance of asymptomatic increases in serum amylase is unknown.",11,13
"2686","fr","en","La signification de cette observation pour l'homme n’est pas connue.","The significance for man is unknown.",6,10
"2687","fr","en","La société a également présenté des données issues de la littérature publiée concernant la lévodopa et la carbidopa.","The company also presented data from the published literature for levodopa and carbidopa.",13,18
"2688","fr","en","La société qui fabrique Eucreas a donné son accord pour que ses données scientifiques soient utilisées pour Icandra.","The company that makes Eucreas has agreed that its scientific data can be used for Icandra.",16,18
"2689","fr","en","La solubilité du lapatinib est pH-dépendante.","The solubility of lapatinib is pH-dependent.",6,6
"2690","fr","en","La solution buvable d’ Agenerase contient 15 mg/ ml d’ amprénavir.","Agenerase oral solution contains 15 mg/ ml of amprenavir.",9,11
"2691","fr","en","La solution buvable peut être utilisée pour obtenir la dose adaptée.","The oral solution can be used to achieve the appropriate dose.",11,11
"2692","fr","en","La solution contient 40 000 UI d’ époétine zêta par ml.","The solution contains 40000 IU Epoetin zeta per ml.",9,11
"2693","fr","en","La solution doit être jetée si des particules visibles ou une décoloration sont observées.","The solution is to be discarded if visible particulate matter or discolouration is observed.",14,14
"2694","fr","en","La solution doit être limpide et incolore à jaune pâle, sans amas, flocons ou particules visibles.","The solution should be clear and colourless to pale yellow, with no lumps, flakes, or particles.",16,16
"2695","fr","en","La solution doit être prise dans les 15 à 20 minutes.","The solution should be drunk within 15 to 20 minutes.",10,11
"2696","fr","en","La solution est claire ou légèrement opalescente et incolore ou jaune pâle.","The solution is clear or slightly opalescent and colourless or pale yellow.",12,12
"2697","fr","en","La solution est limpide, incolore, sans particules solides visibles.","It is a clear, colourless solution with no particles visible.",10,9
"2698","fr","en","La solution ne doit pas être administrée si elle contient des particules ou si elle est trouble.","The solution should not be administered if it contains particles or is not clear.",14,17
"2699","fr","en","La solution obtenue doit faire l’objet avant son administration d’une inspection visuelle pour détecter toute particule en suspension.","The final solution must be inspected visually for particulate matter before administration.",12,18
"2700","fr","en","La solution pour injection ou perfusion doit être une solution claire et jaunâtre.","The solution for injection or infusion should be a clear and yellowish solution.",13,13
"2701","fr","en","La solution reconstituée a une concentration de 100 microgrammes/ 0,5 ml.","The reconstituted solution has a concentration of 100 micrograms/0.5 ml.",10,11
"2702","fr","en","La solution reconstituée doit donc être immédiatement diluée dans des conditions aseptiques contrôlées et validées.","Therefore the reconstituted solution should be diluted under controlled and validated aseptic conditions.",13,15
"2703","fr","en","La solution reconstituée doit être utilisée immédiatement.","The reconstituted solution must be used immediately.",7,7
"2704","fr","en","La solution reconstituée est limpide et incolore.","The reconstituted solution is clear and colourless.",7,7
"2705","fr","en","La solution reconstituée ne doit pas être administrée si elle contient des particules ou si elle est trouble.","The reconstituted solution should not be administered if it contains particles or is not clear.",15,18
"2706","fr","en","La somatropine stimule le renouvellement osseux.","Somatropin stimulates the turnover of skeletal bone.",7,6
"2707","fr","en","La sparfloxacine, aminodifluoroquinolone, est un antibiotique de synthèse appartenant à la famille des quinolones.","Sparfloxacin, an aminodifluoroquinolone, is a synthetic antibiotic belonging to the quinolone family.",12,14
"2708","fr","en","La stabilité physicochimique du produit reconstitué a été démontrée pendant 24 heures entre 2°C-8°C.","Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8oC.",13,14
"2709","fr","en","La substance active de Glustin30 mg comprimés est la pioglitazone.","The active substance in Glustin 30 mg tablets is pioglitazone.",10,10
"2710","fr","en","La substance active de Lucentis est le ranibizumab.","The active substance in Lucentis is ranibizumab.",7,8
"2711","fr","en","La substance active du FORCALTONIN est la calcitonine de saumon recombinante.","The active substance of FORCALTONIN is recombinant salmon calcitonin.",9,11
"2712","fr","en","La substance active est l’interféron bêta 1-b, 250 microgrammes par millilitre après reconstitution.","The active substance is Interferon beta-1b, 250 microgram per millilitre when reconstituted.",12,13
"2713","fr","en","La substance active est la doxycycline.","The active substance is doxycycline.",5,6
"2714","fr","en","La substance active est la testostérone.","What Livensa contains The active substance is testosterone.",8,6
"2715","fr","en","La substance active est un conjugué covalent de l’ interféron alfa-2b recombinant* avec le monométhoxy polyéthylène glycol.","The active substance is a covalent conjugate of recombinant interferon alfa-2b* with monomethoxy polyethylene glycol.",15,17
"2716","fr","en","La succinylacétone inhibe la voie de synthèse des porphyrines, ce qui conduit à une accumulation de 5-aminolévulinate.","Succinylacetone inhibits the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate.",12,17
"2717","fr","en","La supplémentation orale en vitamine D n’ a pas d’ effet sur l’ exposition au strontium.","Oral supplementation with vitamin D has no effect on strontium exposure.",11,16
"2718","fr","en","La surface corporelle atteinte était de 10 à 92%.","The affected BSA ranged from 10-92%.",6,9
"2719","fr","en","La survenue d’ effets indésirables est principalement due aux propriétés pharmacologiques du médicament.","The occurrence of adverse reactions are mainly due to the pharmacological properties of the medicinal product.",16,13
"2720","fr","en","La suspension peut être administrée au moyen de la seringue-doseuse fournie dans le conditionnement.","The suspension can be given using the measuring syringe provided in the package.",13,14
"2721","fr","en","La taille de l’Agence nécessite désormais la mise en œuvre d’un système du personnel informatisé en 2000-2001.","The size of the Agency now requires a computerised personnel system to be implemented in 2000-2001.",16,17
"2722","fr","en","La tasonermine est produite par la technique de l’ ADN recombinant dans E. coli.","Tasonermin is produced by recombinat DNA technology in E. coli",10,14
"2723","fr","en","La tolérance à long terme d'Enbrel en association avec d'autres traitements de fond n'a pas été établie.","The long- term safety of Enbrel in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established.",18,17
"2724","fr","en","La tolerance de l’association n’a pas été établie.","Safety of combination not established; combination not recommended.",8,8
"2725","fr","en","La tolérance de Protopic pommade n'a pas été établie chez des patients présentant une érythrodermie généralisée.","The safety of Protopic ointment has not been established in patients with generalised erythroderma.",14,16
"2726","fr","en","La tolérance et l’ efficacité n’ ont pas été clairement établies dans cette tranche d’ âge.","Safety and efficacy in this group has not been well established.",11,16
"2727","fr","en","La totalité du contenu du flacon doit être utilisée dans les 2 heures suivant l’ ouverture.","The entire content of the bottle should be used within 2 hours after broaching the container.",16,16
"2728","fr","en","La toux est souvent accompagnée d'un son ""caverneux"" appelé communément ""chant du coq"".","The coughing is often accompanied by a “whooping” sound, hence the common name “whooping cough”.",15,13
"2729","fr","en","La toux induite par les IEC devra faire partie du diagnostic différentiel de la toux.","ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.",14,15
"2730","fr","en","La toxicité gastro-intestinale était dose-limitante chez le rat et le singe, l'intestin ayant été constamment un organe cible.","Gastrointestinal toxicity was dose-limiting in rats and monkeys, as the intestine was a consistent target organ.",16,18
"2731","fr","en","La troisième étude a porté sur une comparaison entre Hycamtin administré en perfusion et Hycamtin administré en gélules.","The third study compared Hycamtin given as an infusion and as capsules.",12,18
"2732","fr","en","La vaccination de chats FeLV-positifs n’ apporte aucun bénéfice.","Vaccination of FeLV positive cats is of no benefit.",9,9
"2733","fr","en","La variabilité de l’ exposition est augmentée avec une alimentation riche en graisses.","The variability is increased with high fat food.",8,13
"2734","fr","en","La venlafaxine est également un inhibiteur faible de la recapture de la dopamine.","Venlafaxine also weakly inhibits dopamine uptake.",6,13
"2735","fr","en","La vildagliptine n’ agit pas lorsque la glycémie est faible.","Vildagliptin does not work when the blood glucose is low.",10,10
"2736","fr","en","La vitesse d’ administration doit être déterminée en fonction du niveau de confort du patient.","The rate of administration should be determined by the patient’ s comfort level.",13,15
"2737","fr","en","La voie sous-cutanée doit être utilisée.","The subcutaneous route of administration should be used.",8,6
"2738","fr","en","La voie sublinguale constitue la seule voie d’ administration efficace pour ce produit.","Sublingual route is the only efficacious administration route for this product.",11,13
"2739","fr","en","La warfarine n’ a pas eu d’ effet sur le profil pharmacocinétique de la tigécycline.","Warfarin did not affect the pharmacokinetic profile of tigecycline.",9,15
"2740","fr","en","Laboratoire GlaxoSmithKline, 100 Route de Versailles, 78163 Marly-le-Roi Cedex, France","António Loureiro Borges, n. º 3, Arquiparque - Miraflores, 1495-131 Algés",11,10
"2741","fr","en","Laboratoire Rpg - Ranbaxy Pharmacie Generiques 4, Place Louis Armand, 75012 Paris France","Laboratoire Rpg - Ranbaxy Pharmacie Generiques 4, Place Louis Armand, 75012 Paris France",13,13
"2742","fr","en","Laboratori Prodotti Farmaceutici Boniscontro E Gazzone S. R. L.","Laboratori Prodotti Farmaceutici Boniscontro E Gazzone S. R. L.",9,9
"2743","fr","en","Laboratorios Davur S. L.","Laboratorios Davur S. L.",4,4
"2744","fr","en","Laboratórios Químico-Farmacêuticos Chibret, Lda.","Laboratórios Químico-Farmacêuticos Chibret, Lda.",4,4
"2745","fr","en","Lactose monohydraté Hydroxypropylcellulose Crospovidone type A Silice colloïdale anhydre Cellulose microcristalline Stéarate de magnésium","Lactose monohydrate Hydroxypropylcellulose Crospovidone type A Silica colloidal anhydrous Microcrystalline cellulose Magnesium stearate Tablet coating:",15,14
"2746","fr","en","Lactose monohydraté, dimyristoyl phosphatidylcholine, phosphatidylglycérol d'oeuf, ascorbyl palmitate, butylhydroxytoluène (E321).","Lactose monohydrate, dimyristoyl phosphatidylcholine, egg phosphatidylglycerol, ascorbyl palmitate, butylated hydroxytoluene (E321).",11,10
"2747","fr","en","Lactose Pour tous les excipients, cf. rubrique 6.1.","Lactose For a full list of excipients, see section 6.1.",10,8
"2748","fr","en","Lactose Voir la notice pour plus d’ information.","See leaflet for further information.",5,8
"2749","fr","en","Lage Mosten 33 NL-4822 NK Breda Pays-Bas","Lage Mosten 33 NL-4822 NK Breda Nederland",7,7
"2750","fr","en","Laisser incuber la solution de chlorure d'yttrium-90/acétate de sodium/ibritumomab tiuxétan à température ambiante pendant 5 minutes.","Incubate the yttrium-90 chloride/ acetate/ ibritumomab tiuxetan solution at room temperature for five minutes.",14,16
"2751","fr","en","Laisser le vaccin atteindre la température ambiante (15-25°C).","Allow the vaccine to reach a temperature of 15°C - 25°C.",11,8
"2752","fr","en","Lamictal et noms associés (voir Annexe 1) 25 mg comprimés dispersibles ou à croquer.","Lamictal and associated names (see Annex I) 25 mg dispersible/ chewable tablets.",12,14
"2753","fr","en","Lampugnani Farmaceutici Spa Bianca Maria Visconti, 33 20100 Milano Italie","Lampugnani Farmaceutici Spa Bianca Maria Visconti, 33 20100 Milano Italy",10,10
"2754","fr","en","Lansoprazol Teva, 15 15 mg mg enterokapseli, kova","Lansoprazol Teva, 15 mg 15 mg enterokapseli, kova",8,8
"2755","fr","en","Lantus 100 Unités/ ml solution injectable en cartouche est une solution limpide et incolore.","Lantus 100 Units/ ml solution for injection in a cartridge is a clear, colourless solution.",15,14
"2756","fr","en","Lantus 100 Unités/ ml solution injectable en cartouche Insuline glargine","INFORMATION FOR THE USER Lantus 100 Units/ ml solution for injection in a cartridge Insulin glargine",16,10
"2757","fr","en","Lantus ne doit pas être administré par voie intraveineuse.","Lantus should not be administered intravenously.",6,9
"2758","fr","en","Latvija AstraZeneca AB pārstāvniecība Latvijā","Latvija AstraZeneca AB pā rstā vniecī ba Latvijā",8,5
"2759","fr","en","Latvija BAXTER AG Latvijas filiā le Dzelzavas iela 117 Rī ga, LV 1021 Tel.: +371 67 784 784","Latvija BAXTER AG Latvijas filiāle Dzelzavas iela 117 Rīga, LV 1021 Tel.: +371 67 784 784",16,18
"2760","fr","en","Latvija GlaxoSmithKline Latvia SIA Tel: + 371 6 7312687 lv-epasts@gsk. com","Latvija GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk. com",10,11
"2761","fr","en","Latvija Instituto Grifols, S. A.","Latvija Instituto Grifols, S. A.",5,5
"2762","fr","en","Latvija Orion Corporation Orion Pharma pā rstā vniecī ba Bauskas iela 58-244 LV-1004 Rī ga Tel.: +371 67455563","Latvija Orion Corporation Orion Pharma pā rstā vniecī ba Bauskas iela 58-244 LV-1004 Rī ga Tel.: +371 67455563",18,18
"2763","fr","en","Latvija ratiopharm Latvijas pā rstā vniecī ba Tel: +371 67499110","Latvija ratiopharm Latvijas pā rstā vniecī ba Tel: +371 67499110",10,10
"2764","fr","en","Latvija SIA “Merck Sharp & Dohme Latvija” Tel: +371 67364 224 msd_lv@merck.com","Latvija SIA “ Merck Sharp & Dohme Latvija” Tel: +371 7364 224 msd_lv@merck. com",14,12
"2765","fr","en","Le 23 juin 2005, le CHMP a conclu que:","On 23 June 2005, the CHMP concluded that:",8,9
"2766","fr","en","Le bénéfice clinique en termes de symptômes thrombo-hémorragiques n’ a pas été démontré de façon convaincante.","Clinical benefit in terms of thrombohaemorrhagic events has not been convincingly demonstrated.",12,16
"2767","fr","en","Le bénéfice du traitement devra être réévalué à intervalles réguliers.","The benefit of treatment should be re-assessed at regular intervals.",10,10
"2768","fr","en","Le bimatoprost a déjà été approuvé dans l’ Union européenne sous le nom de Lumigan.","Bimatoprost on its own has already been approved in the European Union under the name Lumigan.",16,15
"2769","fr","en","Le bosentan possède trois métabolites dont un seul est pharmacologiquement actif.","Bosentan forms three metabolites and only one of these is pharmacologically active.",12,11
"2770","fr","en","Le bouchon du piston ne doit pas être retiré.","The plunger stopper should not be pulled back.",8,9
"2771","fr","en","Le bupropion est principalement métabolisé par le CYP2B6.","Bupropion is primarily metabolised by CYP2B6.",6,8
"2772","fr","en","Le caillot fibrineux est métabolisé de la même manière que la fibrine endogène par fibrinolyse et phagocytose.","The fibrin clot is metabolised in the same way as endogenous fibrin by fibrinolysis and phagocytosis.",16,17
"2773","fr","en","Le changement correspondant de la pression artérielle diastolique en position couchée était de 5,5 mmHg.","The corresponding change in supine diastolic blood pressure was 5.5 mmHg.",11,15
"2774","fr","en","Le changement de patch peut être effectué à tout moment du jour de changement prévu.","Patch changes may occur at any time on the scheduled Change Day.",12,15
"2775","fr","en","Le chlorure de benzalkonium (excipient) est un irritant et il peut provoquer une irritation de la muqueuse nasale.","The excipient benzalkonium chloride is an irritant and may cause irritation of the nasal mucosa (company-specific).",16,18
"2776","fr","en","Le CHMP a désigné le Dr.","The CHMP appointed Dr.",4,6
"2777","fr","en","Le CHMP a donc estimé que, comme pour EPREX/ ERYPO, le bénéfice est supérieur aux risques identifiés.","Therefore, the CHMP’ s view was that, as for EPREX/ ERYPO, the benefit outweighs the identified risks.",17,17
"2778","fr","en","Le CHMP a donc recommandé le refus de l’ autorisation de mise sur le marché pour Valdoxan/ Thymanax.","Hence, the CHMP recommended that Valdoxan/ Thymanax be refused marketing authorisation.",11,18
"2779","fr","en","Le CHMP a donc recommandé que ADROVANCE reçoive une autorisation de mise sur le marché.","The Committee recommended that ADROVANCE be given marketing authorisation.",9,15
"2780","fr","en","Le CHMP a par conséquent recommandé l’ octroi d’ une autorisation de mise sur le marché pour Panretin.","They recommended that Panretin be given marketing authorisation.",8,18
"2781","fr","en","Le CHMP a recommandé qu’ Avastin reçoive une autorisation de mise sur le marché.","The Committee recommended that Avastin be given marketing authorisation.",9,14
"2782","fr","en","Le CHMP a recommandé que VASOVIST reçoive une autorisation de mise sur le marché.","The committee recommended that VASOVIST be given marketing authorisation.",9,14
"2783","fr","en","Le CHMP a réexaminé les données constituant la demande de modification de type II.","The CHMP performed a re-evaluation of the type II variation application data.",12,14
"2784","fr","en","Le CHMP approuve la version modifiée du RCP.","The amended SPC is endorsed by the CHMP.",8,8
"2785","fr","en","Le cholestérol est une substance naturelle de l’ organisme et est nécessaire pour une croissance normale.","Cholesterol is a naturally occurring substance in the body necessary for normal growth.",13,16
"2786","fr","en","Le comité a recommandé l’ octroi d’ une autorisation de mise sur le marché pour Cervarix.","The Committee recommended that Cervarix be given marketing authorisation.",9,16
"2787","fr","en","Le comité a recommandé l’ octroi d’ une autorisation de mise sur le marché pour Fertavid.","The Committee recommended that Fertavid be given marketing authorisation.",9,16
"2788","fr","en","Le comité a recommandé l’ octroi d’ une autorisation de mise sur le marché pour Karvezide.","The Committee recommended that Karvezide be given marketing authorisation.",9,16
"2789","fr","en","Le comité a recommandé l’ octroi d’ une autorisation de mise sur le marché pour Mycamine.","The Committee recommended that Mycamine be given marketing authorisation.",9,16
"2790","fr","en","Le comité a recommandé l’ octroi d’ une autorisation de mise sur le marché pour ProteqFlu-Te.","The Committee recommended that ProteqFlu-Te be given a marketing authorisation.",10,16
"2791","fr","en","Le comité a recommandé l’ octroi d’ une autorisation de mise sur le marché pour Telzir.","The Committee recommended that Telzir be given marketing authorisation.",9,16
"2792","fr","en","Le comité a recommandé l’ octroi de l’ autorisation de mise sur le marché pour Emadine.","The Committee recommended that Emadine be given marketing authorisation.",9,16
"2793","fr","en","Le comité a, dès lors, recommandé l’ octroi d’ une autorisation de mise sur le marché pour Optaflu.","The Committee recommended that Optaflu be given marketing authorisation.",9,18
"2794","fr","en","Le comité a, dès lors, recommandé l’ octroi d’ une autorisation de mise sur le marché pour Siklos.","The Committee recommended that Siklos be given marketing authorisation.",9,18
"2795","fr","en","Le composant actif de NutropinAq, la somatropine, est identique à l’ hormone de croissance humaine.","The active ingredient in NutropinAq, somatropin, is identical to the human growth hormone.",13,15
"2796","fr","en","Le comprimé entier doit être avalé avec un peu d’ eau.","Swallow the tablet whole with some water.",7,11
"2797","fr","en","Le comprimé peut être administré avec la nourriture.","The product should be administered with food.",7,8
"2798","fr","en","Le comprimé peut être divisé en deux demi-doses égales.","The tablet can be divided into equal halves.",8,9
"2799","fr","en","Le comprimé peut être pris au cours ou en dehors des repas.","The tablet may be taken with or without food.",9,12
"2800","fr","en","Le Conseil de l’ Union européenne a fixé la date de l’ élargissement au 1er mai 2004.","Chapter 1 EMEA in the European system",7,17
"2801","fr","en","Le contenant ne doit pas être rerempli.","The container must not be refilled.",6,7
"2802","fr","en","Le contenu du flacon doit être utilisé immédiatement après avoir percé le bouchon en caoutchouc.","The contents of a vial should be used immediately after piercing of the rubber stopper.",15,15
"2803","fr","en","Le critère principal de l’étude était la survie globale.","The primary endpoint was overall survival.",6,9
"2804","fr","en","Le cuivre lié est ensuite éliminé dans les selles après desquamation des cellules intestinales.","The bound copper is then eliminated in the stool following desquamation of the intestinal cells.",15,14
"2805","fr","en","Le CVMP se réunira 11 fois en 2003.","Establishment of maximum residue limits for old substances",8,8
"2806","fr","en","Le dabigatran étant principalement excrété par voie rénale, une diurèse suffisante doit être maintenue.","Since dabigatran is excreted predominantly by the renal route adequate diuresis must be maintained.",14,14
"2807","fr","en","Le darunavir est métabolisé principalement par le CYP3A.","Darunavir is primarily metabolised by CYP3A.",6,8
"2808","fr","en","Le degré de résistance croisée entre la ciprofloxacine et les autres fluoroquinolones est variable.","The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable.",13,14
"2809","fr","en","Le demandeur a été invité à fournir les informations suivantes:","The applicant was requested to provide the following information:",9,10
"2810","fr","en","Le deuxième forum PERF II (Pan-European Regulatory Forum) se poursuivra jusqu'en juillet 2002.","The second Pan-European Regulatory Forum (PERF II) continues until July 2002.",11,13
"2811","fr","en","le développement de nouvelles activités en faveur des médicaments orphelins","support to the Mutual Recognition Facilitation Group,",7,10
"2812","fr","en","Le dispositif commencera à délivrer une dose de fentanyl pendant 10 minutes environ.","The device will start to deliver a dose of fentanyl over about 10 minutes.",14,13
"2813","fr","en","Le dosage et la posologie varient en fonction de l’ indication.","The dose and dosage regimen is dependent on the indication.",10,11
"2814","fr","en","Le dossier de désignation de Prialt comme médicament orphelin est disponible à l’ adresse suivante: ici.","The record of Prialt’ s designation as an orphan medicine is available here.",13,16
"2815","fr","en","Le fabricant est Shire Human Genetic Therapies AB, Åldermansgatan 2, P. O.","er The manufacturer is Shire Human Genetic Therapies AB, Åldermansgatan 2, P. O.",13,12
"2816","fr","en","Le facteur IX activé, associé au facteur VIII activé, active le facteur X.","Activated factor IX, in combination with activated factor VIII, activates factor X.",12,13
"2817","fr","en","Le fentanyl est métabolisé en métabolites inactifs au niveau du foie.","Fentanyl is metabolized into inactive metabolites in the liver.",9,11
"2818","fr","en","Le filgrastim pourrait affecter votre aptitude à être enceinte ou le bon déroulement de votre grossesse.","Filgrastim could affect your ability to become or stay pregnant.",10,16
"2819","fr","en","Le flacon contient 170 ml de solution buvable.","The bottle contains 170 ml of solution.",7,8
"2820","fr","en","Le flacon et le reste du matériel pour injection à usage unique doivent être éliminés.","Dispose of the syringe and needle",6,15
"2821","fr","en","Le flacon peut être remué délicatement et retourné de bas en haut pour la dissolution.","The vial contents may be swirled gently and inverted during dissolution.",11,15
"2822","fr","en","Le fondaparinux n'inhibe pas les cytochromes P450 (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 ou CYP3A4) in vitro.","Fondaparinux does not inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, ici",11,17
"2823","fr","en","Le glycérol peut provoquer des maux de tête, des troubles au niveau de l’estomac et des diarrhées.","Glycerol can cause headache, stomach upset and diarrhoea.",8,17
"2824","fr","en","Le groupe de travail mixte CPMP/ CVMP Qualité s'est réuni 4 fois en 2001.","The Joint CPMP/CVMP Quality Working Party met 4 times in 2001.",11,14
"2825","fr","en","Le lansoprazole est essentiellement métabolisé dans le foie.","Lansoprazole is mainly metabolised in the liver.",7,8
"2826","fr","en","Le losartan appartient à un groupe de médicaments appelés antagonistes des récepteurs de l’ angiotensine II.","Losartan belongs to a group of medicines known as angiotensin-II receptor antagonists.",12,16
"2827","fr","en","Le mandat de ce groupe a été limité à trois réunions en 1997.","The mandate for this working group was limited to three meetings in 1997.",13,13
"2828","fr","en","Le mécanisme à l’origine de ces anomalies n’est pas complètement élucidé.","Knowledge about the mechanism is incomplete.",6,11
"2829","fr","en","Le mécanisme de cette interaction n’est pas élucidé mais pourrait résulter d’une inhibition du transporteur.","The mechanism of this interaction is not clear, but may be the result of transporter inhibition.",16,15
"2830","fr","en","Le mécanisme de l’ effet antihypertenseur des diurétiques thiazidiques n’ est pas entièrement connu.","The mechanism of antihypertensive effect of thiazide diuretics is not fully known.",12,14
"2831","fr","en","Le médecin administrera Twinrix Adulte sous forme d’une injection dans la partie supérieure du bras.","The doctor will give Twinrix Adult as an injection into your upper arm muscle.",14,15
"2832","fr","en","Le médecin doit se référer aux recommandations nationales et/ou internationales concernant le traitement de la maladie du charbon.","Treating physicians should refer to national and /or international consensus documents regarding the treatment of anthrax.",16,18
"2833","fr","en","Le médecin peut également vous conseiller de prendre un complément de calcium et de vitamine D.","The doctor may also advise you to take calcium and vitamin D supplements.",13,16
"2834","fr","en","Le médecin pourra ensuite reprendre la diminution de la dose, mais à un rythme plus progressif.","Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.",14,16
"2835","fr","en","Le médicament est disponible en boîtes de 10 flacons.","The medicinal product is supplied in cartons containing 10 vials.",10,9
"2836","fr","en","Le médicament est indiqué dans le traitement des infections bactériennes équines, causées","The product is indicated in the treatment of bacterial infections in horses caused by sensitive micro-organisms including:",17,12
"2837","fr","en","Le médicament est uniquement délivré sur ordonnance.","The medicine can only be obtained with a prescription.",9,7
"2838","fr","en","Le médicament ne doit être administré qu’ aux patients pesant plus de 40 kg.","The medicine should only be given to patients who weigh over 40 kg.",13,14
"2839","fr","en","Le mélange de Liprolog BASAL avec des insulines autres que Liprolog n'a pas été étudié.","Mixing Liprolog Basal with insulins other than Liprolog has not been studied.",12,15
"2840","fr","en","Le méloxicam est métabolisé en un dérivé alcool, un dérivé acide et plusieurs métabolites polaires.","Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites.",14,15
"2841","fr","en","Le même site d’ application ne devrait pas être réutilisé dans un délai de 14 jours.","The same site should not be used within 14 days.",10,16
"2842","fr","en","Le métabolisme de l’alprazolam a été inhibé après l’introduction du ritonavir.","Alprazolam metabolism was inhibited following the introduction of ritonavir.",9,11
"2843","fr","en","Le métabolisme de la pravastatine et de la fluvastatine n'est pas dépendant du CYP3A4.","Interaction not studied Metabolism of pravastatin and fluvastatin is not dependent on CYP3A4.",13,14
"2844","fr","en","Le métabolisme de la rosuvastatine n’ est pas dépendant de l'isoforme CYP3A.","Rosuvastatin is not dependent on CYP3A.",6,12
"2845","fr","en","Le métabolisme du pegvisomant n’ a pas été étudié.","The metabolism of pegvisomant is not studied.",7,9
"2846","fr","en","Le métabolisme oxydatif du lumiracoxib est principalement médié par le CYP2C9.","The oxidative metabolism of lumiracoxib is mainly CYP2C9 mediated.",9,11
"2847","fr","en","Le méthotrexate, les AINS, les corticoïdes et les anti-TNF ne modifient pas la clairance d'abatacept.","Methotrexate, NSAIDs, corticosteroids, and TNF blocking agents were not found to influence abatacept clearance.",14,15
"2848","fr","en","Le mouvement doit être répété jusqu'à ce que le liquide soit uniformément blanc et opaque","Repeat this movement at least 10 times before each injection.",10,15
"2849","fr","en","Le mycophénolate mofétil est l'ester 2-morpholinoéthylique du MPA.","Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA).",10,8
"2850","fr","en","Le natéglinide est rapidement et presque totalement (≥ 90%) absorbé après administration sous forme de solution buvable.","Nateglinide is rapidly and almost completely (≥ 90%) absorbed from an oral solution.",13,17
"2851","fr","en","Le nelfinavir est principalement métabolisé par les isoenzymes du cytochrome P450 CYP3A et CYP2C19 (voir rubrique 5.2).","Nelfinavir is primarily metabolised via the cytochrome P450 isoenzymes CYP3A and CYP2C19 (see section 5.2).",15,17
"2852","fr","en","Le nom de vos comprimés est Velmetia.","The name of your tablet is Velmetia.",7,7
"2853","fr","en","Le nombre de documents explicatifs devrait augmenter de moitié en 2000 et d’un tiers en 2001.","The number of guidance documents is expected to increase by one-half in 2000 and one-third in 2001.",17,16
"2854","fr","en","Le nombre de globules blancs peut augmenter pendant une courte durée.","Your white blood cell count may become high for a short period of time.",14,11
"2855","fr","en","Le nombre de lymphocytes s'est normalisé après arrêt du traitement.","Lymphocyte count returned to baseline after therapy discontinuation.",8,10
"2856","fr","en","Le nombre de plaquettes peut diminuer et entraîner des ecchymoses.","platelet count may become low which might result in bruising.",10,10
"2857","fr","en","Le nouveau système européen ouvre deux nouvelles voies pour l’ autorisation des médicaments:","The new European system offers two routes for authorisation of medicinal products:",12,13
"2858","fr","en","Le patient doit prendre un comprimé pelliculé à 20 mg par jour.","The patient should take one 20 mg film-coated tablet per day.",11,12
"2859","fr","en","Le pelliculage de chaque comprimé dosé à 5 mg contient 0,12 mg de lécithine de soja.","The film-coating of each 5 mg tablet contains 0.12 mg soya lecithin",12,16
"2860","fr","en","Le pH peut avoir été ajusté avec de l’ hydroxyde de sodium et/ ou de l’ acide chlorhydrique.","The pH may have been adjusted with sodium hydroxide and/ or hydrochloric acid.",13,18
"2861","fr","en","Le pic de concentration plasmatique du périndoprilate est atteint en 3 à 4 heures.","The peak plasma concentration of perindoprilat is achieved within 3 to 4 hours.",13,14
"2862","fr","en","Le pic plasmatique est atteint environ 2,5 heures après l’ administration orale du produit.","Peak plasma concentrations occur approximately 2.5 hours after oral administration of lamotrigine.",12,14
"2863","fr","en","Le placer si possible par voie sous-cutanée.","Place it subcutaneously if possible.",5,7
"2864","fr","en","Le posaconazole n’ est pas génotoxique dans les études in vitro et in vivo.","Posaconazole was not genotoxic in in vitro and in vivo studies.",11,14
"2865","fr","en","Le potentiel carcinogène de l’ association lamivudine-zidovudine n’ a pas été testé.","The carcinogenic potential of a combination of lamivudine and zidovudine has not been tested.",14,12
"2866","fr","en","Le potentiel d’ inhibition du CYP2B6 n’ a pas été évalué.","The potential for inhibition of CYP2B6 has not been evaluated.",10,11
"2867","fr","en","Le premier rappel sera effectué au plus tard 17 mois après la primovaccination.","The first revaccination should be no later than 17 months after primary vaccination.",13,13
"2868","fr","en","Le présent document est un résumé du rapport européen public d’ évaluation.","This document is a summary of the European Public Assessment Report.",11,12
"2869","fr","en","Le principal critère d’ évaluation de l’ efficacité était le ralentissement de la progression du handicap.","The main measure of effectiveness was the delay to progression of disability.",12,16
"2870","fr","en","Le principal métabolite circulant est le 10-N-glucuronide; il ne franchit pas la barrière hémato-encéphalique.","The major circulating metabolite is the 10-N-glucuronide.",7,14
"2871","fr","en","Le principe actif d'ECALTA, l’ anidulafungine, est un antifongique qui appartient à la classe des « échinocandines ».","The active substance in ECALTA, anidulafungin, is an antifungal medicine, which belongs to the group ‘ echinocandins’.",17,18
"2872","fr","en","Le principe actif d’ Abraxane est le paclitaxel (à une concentration de5 mg/ ml).","It contains the active substance paclitaxel (5 mg/ ml).",9,14
"2873","fr","en","Le principe actif d’ INVANZ est l’ ertapénème.","INVANZ contains the active substance ertapenem.",6,8
"2874","fr","en","Le principe actif de Bondenza, l’ acide ibandronique, est un bisphosphonate.","The active substance in Bondenza, ibandronic acid, is a bisphosphonate.",10,11
"2875","fr","en","Le principe actif de GONAL-f est la follitropine alfa.","GONAL-f contains the active substance follitropin alfa.",7,9
"2876","fr","en","Le principe actif de NutropinAq, la somatropine, est identique à l’ hormone de croissance humaine.","NutropinAq replaces the natural hormone.",5,15
"2877","fr","en","Le principe actif de Parareg, le cinacalcet, est un agent calcimimétique.","The active substance in Parareg, cinacalcet, is a calcimimetic agent.",10,11
"2878","fr","en","Le principe actif de Procoralan est l’ ivabradine, dosée à 5 mg ou 7,5 mg.","Procoralan contains the active ingredient ivabradine at strengths of 5 mg or 7.5 mg.",14,15
"2879","fr","en","Le principe actif de Savene, la dexrazoxane, est un antidote des anthracyclines.","The active substance in Savene, dexrazoxane, is an antidote to anthracyclines.",11,12
"2880","fr","en","Le principe actif de Tygacil est la tigécycline.","Tygacil contains the active substance tigecycline.",6,8
"2881","fr","en","Le principe actif de Vimpat, la lacosamide, est un médicament antiépileptique.","The active substance in Vimpat, lacosamide, is an anti-epileptic medicine.",10,11
"2882","fr","en","Le produit a également révélé une activité immunomodulatrice significative in vitro.","These undesirable effects have also been reported with IntronA alone.",10,11
"2883","fr","en","Le produit ne peut être injecté que si le liquide est transparent, incolore et sans particules en suspension.","Only solutions which are clear, colourless and free of visible particles may be injected.",14,18
"2884","fr","en","Le produit reconstitué est stable pendant 3 heures à 2-8°C","In-use stability demonstrated for 3 hours at 2-8 °C.",9,10
"2885","fr","en","Le profil pharmacocinétique de la trabectédine est conforme à un modèle de distribution à compartiments multiples.","Trabectedin pharmacokinetic profile is consistent with a multiple-compartment disposition model.",10,16
"2886","fr","en","Le profil pharmacocinétique est linéaire, avec une faible variabilité intra- et inter-individuelle.","The pharmacokinetic profile is linear with low intra- and inter-subject variability.",11,12
"2887","fr","en","Le programme de travail pour les technologies de l'information figure au chapitre 5.","Achieve improved satisfaction of all parties in the benchmarking study, on the basis of the joint EMEA-",17,13
"2888","fr","en","Le pulvérisateur nasal doit être agité avant utilisation.","The intranasal device should be shaken before use.",8,8
"2889","fr","en","Le rapport bénéfice-risque figure dans le module 6 du présent EPAR.","The benefit-risk balance may be found in module 6 of this EPAR.",12,11
"2890","fr","en","Le rapporteur était le Dr Karl Broich et le co-rapporteur était le Dr Pierre Demolis.","The Rapporteur was Dr Karl Broich and Co-Rapporteur(s) was Dr Pierre Demolis.",12,15
"2891","fr","en","Le recours à la procédure en 1998 a été le suivant:","The use of the procedure in 1998 was:",8,11
"2892","fr","en","Le rejet de greffe de foie a également été rapporté.","Liver graft rejection has also been reported.",7,10
"2893","fr","en","Le résultat du test in vivo du micronoyau a été négatif.","The in vivo micronucleus test was negative.",7,11
"2894","fr","en","Le résumé de l’ avis du comité des médicaments orphelins pour Tasigna est disponible ici.","The summary of opinion of the Committee for Orphan Medicinal Products for Tasigna is available here.",16,15
"2895","fr","en","Le rimonabant doit être utilis é avec prudence dans cette population (voir rubrique 5.2).","Rimonabant should be used with caution in this population (see section 5.2).",12,14
"2896","fr","en","Le risque de morts in utero ou d’ anomalies congénitales graves, principalement la phocomélie, est extrêmement élevé.","The risk of intra-uterine death or severe birth defects, primarily phocomelia, is extremely high.",14,17
"2897","fr","en","Le risque peut augmenter avec l’ élévation des concentrations résiduelles de sirolimus.","The risk may be increased as the trough sirolimus level increases.",11,12
"2898","fr","en","Le risque peut être augmenté chez les patients prédisposés au développement de désordres auto-immuns.","Patients predisposed to the development of autoimmune disorders may be at increased risk.",13,14
"2899","fr","en","Le risque potentiel chez l’ homme est inconnu.","The potential risk for humans is unknown.",7,8
"2900","fr","en","Le ritonavir augmente les concentrations sériques du darunavir par inhibition du CYP3A.","Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition.",13,12
"2901","fr","en","Le ritonavir peut induire la glycuronidation de la zidovudine, entraînant une légère diminution des concentrations de zidovudine.","Ritonavir may induce the glucuronidation of zidovudine, resulting in slightly decreased levels of zidovudine.",14,17
"2902","fr","en","Le rituximab se fixe à la surface de certains globules blancs du sang, appelés lymphocytes B.","Rituximab binds to the surface of a type of white blood cell, the B lymphocyte.",15,16
"2903","fr","en","Le rôle des cellules CD4 est de maintenir un système immunitaire sain pour aider à combattre l’ infection.","CD4 cells play a role in maintaining a healthy immune system to help fight infection.",15,18
"2904","fr","en","Le rôle éventuel joué par ORENCIA dans l'apparition de tumeurs malignes, y compris de lymphome, n'est pas connu.","The potential role of ORENCIA in the development of malignancies, including lymphoma, in humans is unknown.",16,18
"2905","fr","en","Le rufinamide n’ a pas montré d’ effet génotoxique et n’ a pas eu d’ effet carcinogène.","Rufinamide was not genotoxic and had no carcinogenic potential.",9,17
"2906","fr","en","Le schéma de vaccination comporte 2 doses.","The vaccination course consists of two doses.",7,7
"2907","fr","en","Le schéma suivant montre le profil d'activité type, après injection sous-cutanée.","The typical activity profile following subcutaneous injection is illustrated below.",10,11
"2908","fr","en","Le score lombaire T moyen à l’ inclusion était d’ environ - 3,0 dans chaque groupe.","The mean baseline lumbar T score was approximately -3.0 in each treatment group.",13,16
"2909","fr","en","Le secrétariat de l’EMEA a toutefois trois objectifs globaux:","Nevertheless there are three main goals for the EMEA Secretariat:",10,9
"2910","fr","en","Le secteur Sécurité assure un soutien de secrétariat aux groupes de travail “sécurité” et “pharmacovigilance”.","The Safety Sector provides Secretariat support to the Safety and Pharmacovigilance Working Parties.",13,15
"2911","fr","en","Le sélecteur de Le sélecteur de dose ne tourne pas.","The dosage selector can only be turned forward.",8,10
"2912","fr","en","Le sévoflurane est susceptible de causer une légère élévation de la pression intracrânienne (PIC) en normocapnie.","Sevoflurane may cause a small increase in intracranial pressure (ICP) under conditions of normocapnia.",14,16
"2913","fr","en","Le sildénafil est rapidement absorbé.","Sildenafil is rapidly absorbed.",4,5
"2914","fr","en","Le solvant est limpide et incolore.","The solvent is clear and colourless.",6,6
"2915","fr","en","Le sorafénib n’ a eu aucun effet sur la pharmacocinétique de la gemcitabine ou de l’ oxaliplatine.","Sorafenib had no effect on the pharmacokinetics of gemcitabine or oxaliplatin.",11,17
"2916","fr","en","Le stylo contient simplement une cartouche incorporée.","The Pen simply has a built in cartridge.",8,7
"2917","fr","en","Le stylo en cours d'utilisation ne doit pas être conservé au réfrigérateur.","The pen in-use must not be stored in a refrigerator.",10,12
"2918","fr","en","Le stylo injecteur Preotact et les aiguilles ne sont pas inclues dans ces conditionnements.","The Preotact pen and needles are not included.",8,14
"2919","fr","en","Le stylo KwikPen comporte simplement une cartouche intégrée.","The KwikPen simply has a built in cartridge.",8,8
"2920","fr","en","Le sucralfate et les anti-acides peuvent diminuer la biodisponibilité du lansoprazole.","Sucralfate/Antacids may decrease the bioavailability of lansoprazole.",7,11
"2921","fr","en","Le surdosage aigu peut provoquer une hypoglycémie.","Acute overdose could lead to hypoglycaemia.",6,7
"2922","fr","en","Le symptôme isolé de réaction d’ hypersensibilité le plus fréquemment rapporté était un rash.","The most common isolated symptom of a hypersensitivity reaction was a skin rash.",13,14
"2923","fr","en","Le syndrome malin des neuroleptiques (SMN): le SMN est un syndrome potentiellement mortel associé aux traitements antipsychotiques.","NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products.",12,17
"2924","fr","en","Le système ne doit être activé que par le patient et en cas de douleur.","The system should only be activated by the patient in response to pain.",13,15
"2925","fr","en","Le Tableau 2 présente les résultats à 24 semaines pour les trois échelles d’ évaluation.","The 24-week results for the three assessment tools are summarised in Table 2.",13,15
"2926","fr","en","Le tableau 3 résume les résultats obtenus à la posologie de 40 mg toutes les deux semaines.","The results for the 40 mg every other week dose are summarised in Table 3.",15,17
"2927","fr","en","Le tableau 5 présente les résultats obtenus dans la population de l’ étude 1.","Table 5 includes results in the study 1 population.",9,14
"2928","fr","en","Le tableau ci-dessous décrit les analyses réalisées conformément au protocole de l’ étude.","The table below illustrates the pre- specified protocol analyses.",9,13
"2929","fr","en","Le tableau suivant peut servir de guide pour les posologies en cas d'accidents hémorragiques et en chirurgie.","The following table can be used to guide dosing in bleeding episodes and surgery:",14,17
"2930","fr","en","Le tacrolimus circulant est métabolisé par le cytochrome P450 3A4 (CYP3A4) au niveau hépatique.","Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4 (CYP3A4).",12,14
"2931","fr","en","Le tacrolimus, principe actif d’ Advagraf, est un agent immunosuppresseur.","Tacrolimus, the active substance in Advagraf, is an immunosuppressive agent.",10,10
"2932","fr","en","Le taux d’ incorporation de l’ aliment médicamenteux dépend de l’ état clinique de l’ animal.","The uptake of medicated feed depends on the clinical condition of the animal.",13,16
"2933","fr","en","Le taux de ciprofloxacine dans le sang peut augmenter. • phénytoïne (utilisée pour traiter l'épilepsie).","The ciprofloxacin level in the blood can be increased. • phenytoin (used to treat epilepsy).",15,15
"2934","fr","en","Le taux de réponse objective (TRO), défini par des IRM, était de 8%.","The objective response rate (ORR) based on MRI scans was 8%.",11,13
"2935","fr","en","Le taux estimé de liaison protéique du paclitaxel suite à l’ administration d’ Abraxane est d’ environ 90%.","The protein binding of paclitaxel following Abraxane administration is estimated at about 90%.",13,18
"2936","fr","en","Le taux global des anticorps neutralisants était de 11/ 108 patients (10%).","The overall neutralizing antibody rate was 11/ 108 patients (10%).",10,12
"2937","fr","en","Le TCA au pic ne devra pas être supérieur à deux fois la valeur du témoin.","Peak aPTT should not exceed twice the control value.",9,16
"2938","fr","en","Le telmisartan n’ est pas éliminé par hémodialyse.","Telmisartan is not removed from blood by haemodialysis.",8,8
"2939","fr","en","Le temps d’ attente pour ce produit est de zéro jour.","The withdrawal period is zero days.",6,11
"2940","fr","en","Le temps médian d’apparition de l’éruption cutanée était de 10 jours.","The median time to onset of rash was 10 days.",10,11
"2941","fr","en","Le tepoxalin et ses métabolites sont éliminés dans les fèces (99%).","Tepoxalin and its metabolites are excreted in the faeces (99%).",10,11
"2942","fr","en","Le tériparatide n'a pas augmenté l'incidence des autres types de tumeurs malignes chez le rat.","Teriparatide did not increase the incidence of any other type of neoplasia in rats.",14,15
"2943","fr","en","Le test dure environ 40 minutes.","The test procedure lasts approximately 40 minutes.",7,6
"2944","fr","en","Le texte intégral de l’ EPAR est disponible: ici.","The full EPAR for Actos is available here",8,9
"2945","fr","en","Le thalidomide ne doit en aucun cas être utilisé chez la femme enceinte ou susceptible de l’ être.","Thalidomide must never be used by women who are pregnant or could become pregnant.",14,18
"2946","fr","en","Le timolol abaisse la PIO en réduisant la formation d’ humeur aqueuse.","Timolol lowers IOP by reducing aqueous humour formation.",8,12
"2947","fr","en","Le timolol par voie oculaire n’ est associé à aucun effet indésirable connu sur la fonction hépatique.","There are no known adverse reactions of ocular timolol on liver function.",12,17
"2948","fr","en","Le titulaire de l'autorisation de mise sur le marché continuera à fournir des PSURs annuels.","The holder of marketing authorisation will continue to submit annual PSURs.",11,15
"2949","fr","en","Le titulaire de l’ autorisation de mise sur le marché est Eisai Ltd.","The marketing authorisation holder is Eisai Ltd.",7,13
"2950","fr","en","Le titulaire de l’ Autorisation de Mise sur le Marché est Pfizer Limited, Sandwich, Kent CT13 9NJ, Royaume-Uni.","The marketing authorisation holder of VIAGRA is Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom.",15,18
"2951","fr","en","Le topotécan n'inhibe pas chez l'homme les enzymes P450 (voir rubrique 5.2).","Topotecan does not inhibit human P450 enzymes (see section 5.2).",10,12
"2952","fr","en","Le torémifène n’ a aucun effet sur l’ aptitude à conduire des véhicules et à utiliser des machines","Toremifene has no influence on the ability to drive and use machines.",12,18
"2953","fr","en","Le traitement a été interrompu en raison d’ effets indésirables chez 0,5% des patients.","Treatment was discontinued due to adverse reactions in 0.5% of patients.",11,14
"2954","fr","en","Le traitement avec Copalia n’ est pas recommandé durant l’ allaitement.","Treatment with Copalia is not recommended during breast- feeding.",9,11
"2955","fr","en","Le traitement des enfants de moins de 1 an n’ a pas été étudié:","Treatment of paediatric patients younger than 1 year of age has not been studied:",14,14
"2956","fr","en","Le traitement diurétique sera si possible interrompu 2 à 3 jours avant l’ initiation du traitement par Zestril.","If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with Zestril.",16,18
"2957","fr","en","Le traitement doit débuter 12 à 18 heures environ après la transplantation.","Administration should commence approximately 12-18 hours after the completion of surgery.",11,12
"2958","fr","en","Le traitement doit être instauré sous la surveillance d'un médecin expérimenté dans le traitement de l'hémophilie.","Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia.",16,16
"2959","fr","en","Le traitement doit être poursuivi","Treatment of infections or",4,5
"2960","fr","en","Le traitement doit être suspendu lorsqu’ une intervention chirurgicale est planifiée.","Therapy should be withheld for elective surgery.",7,11
"2961","fr","en","Le traitement est poursuivi tant qu’ il reste avantageux pour le patient.","Treatment should continue as long as the patient gets a benefit from it.",13,12
"2962","fr","en","Le traitement évite une nouvelle infestation pendant 4 semaines.","One application prevents flea infestation for 4 weeks.",8,9
"2963","fr","en","Le traitement laser induit un effet chimique et non thermique.","The laser treatment induces a photochemical, not a thermal, effect.",10,10
"2964","fr","en","Le traitement par le mitratapide devrait être limité à un seul cycle de traitement par chien.","Mitratapide therapy should be restricted to one treatment course for an individual dog.",13,16
"2965","fr","en","Le traitement par NeoRecormon est divisé en deux périodes:","Treatment with NeoRecormon is divided into two stages:",8,9
"2966","fr","en","Le traitement par Nespo doit être interrompu environ quatre semaines après la fin de la C","Nespo therapy should be discontinued approximately four weeks after the end of chemotherapy. ro",14,16
"2967","fr","en","Le traitement par Orfadin, en plus du régime, augmente le taux de survie de 82%.","With additional Orfadin treatment, the survival rate increases to 82%.",10,15
"2968","fr","en","Le traitement par Paxene a permis d’ améliorer le taux de réponse de différentes tumeurs.","Treatment with Paxene has been shown to improve the response rate of various tumours.",14,15
"2969","fr","en","Le traitement par SOMAVERT doit être instauré par un médecin expérimenté dans le traitement de l’ acromégalie.","SOMAVERT treatment should be initiated by a doctor who has experience in the treatment of acromegaly.",16,17
"2970","fr","en","Le traitement par Tarceva doit être supervisé par un médecin expérimenté dans l’utilisation des traitements anticancéreux.","Treatment with Tarceva should be supervised by a doctor who has experience of the use of anticancer medicines.",18,16
"2971","fr","en","Le traitement par VELCADE est très souvent associé à une toxicité hématologique (thrombocytopénie, neutropénie et anémie).","Haematological toxicity VELCADE treatment is very commonly associated with haematological toxicities (thrombocytopenia, neutropenia and anaemia).",15,16
"2972","fr","en","Le traitement peut alors être interrompu ou la dose réduite, selon les recommandations de la rubrique 4.2.","Treatment with Glivec may be interrupted or the dose may be reduced, as",13,17
"2973","fr","en","Le traitement peut être renouvelé si une rechute survient.","The treatment can be repeated if relapse occurs.",8,9
"2974","fr","en","Le traitement peut être répété pendant 2 jours consécutifs au maximum.","Treatment may be repeated for a maximum of two consecutive days.",11,11
"2975","fr","en","Le traitement requis dépend de la nature et de la sévérité des effets indésirables.","The treatment required depends on the nature and severity of the side effect.",13,14
"2976","fr","en","Le traitement se déroule en deux phases:","The treatment is divided into two stages:",7,7
"2977","fr","en","Le traitement sera reconsidéré si après 5 jours aucune amélioration clinique n’ a été constatée.","The treatment should be reconsidered if at 5 days no improvement in the clinical condition is observed.",17,15
"2978","fr","en","Le trastuzumab se lie sélectivement à un antigène appelé facteur de croissance épidermique humain 2 (HER2).","Trastuzumab binds selectively to an antigen called human epidermal growth factor 2 (HER2).",13,16
"2979","fr","en","Le vaccin contribue à réduire les symptômes des maladies.","The vaccine helps to reduce the symptoms of the diseases.",10,9
"2980","fr","en","Le vaccin est destiné à une administration orale uniquement.","This vaccine is for oral administration only.",7,9
"2981","fr","en","Le vaccin est prêt à l’ emploi (aucune reconstitution ou dilution n’ est requise).","The vaccine is ready to use (no reconstitution or dilution is required).",12,14
"2982","fr","en","Le vaccin était bien toléré par les poules, sans effet sur la production d’œ ufs ou de poussins.","The vaccine was well tolerated by the chickens, with no effect on the production of eggs or chicks.",18,18
"2983","fr","en","Le vaccin ne doit en aucun cas être injecté dans une veine.","The vaccine should never be injected into a vein.",9,12
"2984","fr","en","Le vaccin peut ne pas protéger ces sujets contre l'hépatite B.","The vaccine may not prevent hepatitis B in these individuals.",10,11
"2985","fr","en","Le vaccin reconstitué est une émulsion blanche et homogène.","The reconstituted vaccine is a homogeneous white emulsion.",8,9
"2986","fr","en","Le vaccin se présente sous la forme d'une suspension blanchâtre, opalescente et translucide.","The vaccine is an off-white, opalescent, translucent suspension.",8,13
"2987","fr","en","Le valsartan, en administration orale, est un antagoniste puissant et spécifique du récepteur de l’angiotensine II.","Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist.",14,16
"2988","fr","en","Le verre doseur fourni est spécialement conçu pour vous don ner la dose exacte de Norvir solution buvable.","The measuring cup provided has been especially designed to give you the right dose of Norvir oral solution.",18,18
"2989","fr","en","Le vigabatrin est excrété dans le lait maternel.","Vigabatrin is excreted into breast milk.",6,8
"2990","fr","en","Le virus utilisé dans ce vaccin est porteur des antigènes H7 (hémagglutinine 7) et N1 (neuraminidase 1).","The virus used for the vaccine carries the H7 (haemagglutinin 7) and N1 (neuramidase 1) antigens.",16,17
"2991","fr","en","Le volume apparent de distribution est en moyenne de 200 ml/ kg (62 à 350 selon les études).","The apparent volume of distribution is on average 200 ml/ kg (62 to 350 according to various studies).",18,18
"2992","fr","en","Le volume de distribution à l’ état d’ équilibre (Vss) est approximativement de 2 l/ kg.","The steady-state volume of distribution (Vss) is approximately 2 l/ kg.",11,16
"2993","fr","en","Le volume de distribution du maraviroc est d’ environ 194 L.","The volume of distribution of maraviroc is approximately 194 L.",10,11
"2994","fr","en","Le volume de distribution est de 0,3 l/ kg.","The volume of distribution is 0.3 l/ kg.",8,9
"2995","fr","en","Le volume de distribution moyen à l’ équilibre est d’ au moins 28 l chez l’ homme.","The mean steady-state volume of distribution, exclusive of bone, is at least 28 litres in humans.",16,17
"2996","fr","en","Leedu Tel: + 370 45 507 400","Leedu Tel: + 370 45 507 400",7,7
"2997","fr","en","Lekkerkerker (Pays-Bas) en tant que rapporteur et le Dr Hudson (Royaume-Uni) en tant que co-rapporteur.","Hudson (United Kingdom) as Co-rapporteur.",5,15
"2998","fr","en","Les 60% restants du produit sont vraisemblablement éliminés par des voies métaboliques endogènes.","The remaining 60% of the drug is presumably eliminated by endogenous pathways.",12,13
"2999","fr","en","Les activités administratives et budgétaires sont abordées au chapitre 5.","Administration and accounting matters are described in Chapter 5.",9,10
"3000","fr","en","Les administrations sous-cutanée et intradermique n’ ont pas été évaluées.","Neither subcutaneous nor intradermal administration has been studied.",8,10
"3001","fr","en","Les aiguilles provenant d’ autres régions ou pays peuvent ne pas être adaptées à votre stylo NutropinAq Pen.","Needles from other countries may not fit on your NutropinAq Pen.",11,18
"3002","fr","en","Les aiguilles suivantes sont des exemples d’ aiguilles jetables qui peuvent être utilisées avec le stylo BYETTA:","The following are examples of disposable needles that can be used with the BYETTA pen:",15,17
"3003","fr","en","Les AINS peuvent réduire les effets des médicaments diurétiques et anti-hypertenseurs.","NSAIDs may reduce the effect of diuretics and antihypertensive medicinal products.",11,11
"3004","fr","en","Les ampoules sont destinées à un usage unique et toute partie de la solution inutilisée doit être éliminée.","Ampoules are intended for single use only, any unused portions must be discarded.",13,18
"3005","fr","en","Les animaux ne doivent pas être abattus moins de 64 jours après la dernière administration de Zactran.","After the last administration of Zactran, cattle should not be slaughtered for 64 days.",14,17
"3006","fr","en","Les animaux peuvent également présenter des signes de douleur légère pendant une journée.","The animals may also show some signs of slight pain for one day.",13,13
"3007","fr","en","Les anti-acides peuvent interférer avec l’ absorption gastro- intestinale des quinolones.","Anti-acids can interfere with gastro-intestinal absorption of quinolones.",8,11
"3008","fr","en","Les anti-rhumatismaux non stéroïdiens ou les œ strogènes peuvent réduire les effets anti-hypertenseurs de la doxazosine.","Non-steroidal antirheumatics or estrogens may reduce the antihypertensive effect of doxazosin.",11,16
"3009","fr","en","Les antiacides et le sucralfate peuvent réduire la biodisponibilité du lansoprazole.","Antacids and sucralfate may reduce the bioavailability of lansoprazole.",9,11
"3010","fr","en","Les anticorps aideront à protéger contre les maladies dues à ces virus ou bactéries.","The antibodies will help to protect against the diseases caused by these viruses or bacteria.",15,14
"3011","fr","en","Les anticorps monoclonaux sont des protéines qui reconnaissent et se lient à d’ autres protéines spécifiques.","Monoclonal antibodies are proteins that recognise and bind to other unique proteins.",12,16
"3012","fr","en","Les anticorps peuvent réduire l’ efficacité thérapeutique du produit.","Antibodies may reduce the therapeutic effectiveness of the product.",9,9
"3013","fr","en","Les autorités compétentes des États membres continueront à procéder à un réexamen régulier du produit.","The Member States competent authorities will continue to keep the product under regular review.",14,15
"3014","fr","en","Les autres composants sont:","The other ingredients are:",4,4
"3015","fr","en","Les autres constituants sont: bicarbonate de sodium (E500) et hydroxyde de sodium (E524).","The other ingredients are: sodium bicarbonate (E500) and sodium hydroxide (E524).",11,13
"3016","fr","en","Les autres effets indésirables feront l’ objet d’ un traitement symptomatique si nécessaire.","Symptomatic treatment for other adverse reactions should be given as necessary.",11,13
"3017","fr","en","Les autres effets indésirables pouvant survenir avec l’association PegIntron et ribavirine gélules incluent:","Other side effects that may occur with the combination of PegIntron and ribavirin capsules include:",15,13
"3018","fr","en","Les autres effets indésirables rapportés avec Plavix sont:","Other side effects reported with Plavix are:",7,8
"3019","fr","en","Les autres effets indésirables sont peu fréquents, voire rares.","Other side effects are uncommon or rare.",7,9
"3020","fr","en","Les bêta-bloquants peuvent majorer l'effet hypoglycémiant des antidiabétiques.","Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents.",9,8
"3021","fr","en","Les bêta-bloquants peuvent masquer les symptômes d'une hypoglycémie.","ed Beta-blocking agents may mask the symptoms of hypoglycaemia.",9,8
"3022","fr","en","Les bouteilles de gaz vides seront collectées par le fournisseur.","Empty gas cylinders will be collected by the supplier.",9,10
"3023","fr","en","Les bulles d’ air doivent être retirées de la cartouche avant injection (cf.","Air bubbles must be removed from the cartridge before injection (see instructions for using the pen).",16,13
"3024","fr","en","Les capsules doivent toujours être prises par voie orale et avalées entières, sans être mâchées.","The capsules should always be taken by mouth, and swallowed whole and not chewed.",14,15
"3025","fr","en","Les capsules sont orange avec une impression en encre noire du [logo ABBOTT] et de « PK ».","The capsules are orange with a black ink imprint of [Abbott logo] and “ PK”.",15,18
"3026","fr","en","Les caractéristiques pharmacocinétiques du sildénafil n’ ont pas été étudiées chez les insuffisants hépatiques sévères.","The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.",15,15
"3027","fr","en","Les cartouches vides ne peuvent être réutilisées.","Cartridges are not designed to be refilled.",7,7
"3028","fr","en","Les cas spontanés isolés sont considérés comme très rares (< 1/ 10 000), y compris les cas isolés.","Isolated spontaneous cases are presented as very rare defined as (< 1/ 10,000), including isolated reports.",16,18
"3029","fr","en","Les chiens doivent être attentivement surveillés après l’ administration pour s’ assurer que chaque comprimé est avalé.","Dogs should be carefully observed following administration to ensure that each tablet is swallowed.",14,17
"3030","fr","en","Les complications principales d'un surdosage pourraient être une myélodépression et une inflammation des muqueuses.","The primary complications of overdose are anticipated to be bone marrow suppression and mucositis.",14,14
"3031","fr","en","Les comprimés à croquer sont conditionnés en:","The chewable tablets are packed in:",6,7
"3032","fr","en","Les comprimés d’ Avandia existent en différents dosages.","Avandia tablets come in different strengths.",6,8
"3033","fr","en","Les comprimés d’ Onsior pour chiens sont disponibles en boîtes contenant 1, 2, 4 ou 10 plaquettes thermoformées.","Onsior tablets for dogs are available in cardboard boxes containing 1, 2, 4 or 10 blisters.",16,18
"3034","fr","en","Les comprimés de Profender sont aromatisés au boeuf, et habituellement les chiens les acceptent sans nourriture.","Profender tablets are meat flavoured and usually dogs will accept them without any food.",14,16
"3035","fr","en","Les comprimés doivent être avalés avec une boisson.","Tablets need to be swallowed with a glass of liquid.",10,8
"3036","fr","en","Les comprimés doivent être avalés entiers sans être croqués, mâchés ou écrasés.","The tablets should be swallowed whole and should not be bitten, chewed or crushed.",14,12
"3037","fr","en","Les comprimés Nifedipine Pharmamatch retard ne doivent pas etre prescrits à ces patients.","Nifedipine Pharmamatch retard tablets must not be prescribed for these patients.",11,13
"3038","fr","en","Les comprimés pelliculés de Remeron 45 mg contiennent 45 mg de mirtazapine chacun. • Les autres composants sont:","Remeron 45 mg film-coated tablets contain 45 mg mirtazapine per film-coated tablet. • The other ingredients are:",17,18
"3039","fr","en","Les comprimés sont à croquer et peuvent être donnés pendant ou en dehors des repas.","The tablets are chewable and may be given either with or without food.",13,15
"3040","fr","en","Les comprimés sont à prendre par voie orale avec de l'eau, au cours ou en dehors des repas.","The tablets should be taken orally, swallowed with water, and can be taken either with or without food.",18,18
"3041","fr","en","Les comprimés sont jaunes en forme d'amande, avec l’ inscription “ C 20” sur l’ une des faces.","Yellow and almond shaped tablets, marked ""C 20"" on one side.",11,18
"3042","fr","en","Les comprimés sont présentés en étuis de plaquettes aluminium thermoformées dans des boîtes aux formats suivants:","The tablets are supplied in wallets with sealed aluminium blisters in cartons in the following pack sizes",17,16
"3043","fr","en","Les comprimés sont sécables le long de la ligne de sécabilité.","Tablets are breakable along the score line on the tablet.",10,11
"3044","fr","en","Les concentrations de ces médicaments peuvent être augmentées lorsqu’ ils sont co-administrés avec Invirase/ ritonavir.","Concentrations of these medicinal products may be increased when co- administered with Invirase/ ritonavir.",14,15
"3045","fr","en","les concentrations de médicament","The clinical effect of this dose adjustment has not been adequately evaluated.",12,4
"3046","fr","en","Les concentrations les plus élevées sont retrouvées dans la graisse.","Highest concentration levels are found in the fat.",8,10
"3047","fr","en","Les concentrations plasmatiques du métabolite acide sont plus élevées que celles du composé parental chez le chien.","Plasma concentrations of the acid metabolite are higher than those of the parent compound in the dog.",17,17
"3048","fr","en","Les conclusions scientifiques sont fournies à l’ annexe II.","The scientific conclusions are provided in the Annex II.",9,9
"3049","fr","en","Les conditionnements portent la mention « Semaine 1, (2, 3 ou 4). ».","The packages are marked with ‘ week 1 (2, 3 or 4 )’.",13,13
"3050","fr","en","Les conditions d’ Autorisation de Mise sur le Marché sont définies à l’ annexe IV.","The conditions of the Marketing Authorisation are set out in Annex IV.",12,15
"3051","fr","en","Les critères principaux d’ efficacité étaient l’ amélioration de la sévérité des symptômes ou la guérison des fistules.","The main measures of effectiveness were the improvement in the severity of symptoms or the healing of fistulae.",18,18
"3052","fr","en","Les demandes sont soumises directement à l'EMEA.","It provides for the extension of marketing authorisations granted by one",11,7
"3053","fr","en","Les demi-vies d’ élimination étaient respectivement d’ environ deux à trois heures et six à sept heures.","The trials compared the efficacy of IntronA used alone or in combination with ribavirin.",14,17
"3054","fr","en","Les demi-vies longues observées chez les patients insuffisants hépatiques retardent l’ atteinte de l’ état d’ équilibre.","The longer half-lives observed in hepatically impaired patients delay reaching steady state.",12,17
"3055","fr","en","Les dérivés thiazidique passent dans le lait maternel et peuvent inhiber la lactation.","Thiazides appear in human milk and may inhibit lactation.",9,13
"3056","fr","en","Les dérivés, sulfone, sulfite et 5-hydroxyle du lansoprazole ont été identifiés dans le plasma.","Sulphone, sulphide and 5-hydroxyl derivatives of lansoprazole have been identified in plasma.",12,14
"3057","fr","en","Les deux composés sont des antagonistes NMDA chimiquement proches.","Both compounds are chemically related NMDA-antagonists.",6,9
"3058","fr","en","Les deux études ont mis en évidence la supériorité significative d'Oracea en comparaison avec le placebo.","Both studies showed significant superiority of Oracea compared with placebo.",10,16
"3059","fr","en","Les deux impuretés prévisibles sont désignées sous les noms suivants:","The two foreseeable impurities are referred to by the names:",10,10
"3060","fr","en","Les domaines d'actions prioritaires du PERF II sont les suivants:","The priority action areas in PERF II are:",8,10
"3061","fr","en","Les données actuellement disponibles chez les sujets âgés de 65 ans et plus sont limitées.","There are limited data of the use of lapatinib in patients aged 65 years and older.",16,15
"3062","fr","en","Les données chez l’animal ont montré une toxicité sur la reproduction (voir 5.3).","Animal data have shown reproductive toxicity (see 5.3).",8,13
"3063","fr","en","Les données ci-dessus sont données pour un profil pharmacocinétique normal.","The above data are valid in normal pharmacokinetic behaviour.",9,10
"3064","fr","en","Les données cliniques étant limitées, la signification clinique n’ est pas connue.","As only limited data are available the clinical significance of this is not known.",14,12
"3065","fr","en","Les données d'efficacité suivantes concernent l’ utilisation de Savene dans le traitement de l'extravasation d'anthracycline.","The following efficacy data relate to Savene used as treatment of anthracycline extravasation.",13,15
"3066","fr","en","Les données de sécurité d’ emploi sur des durées de traitement supérieures à 4 semaines sont limitées.","The safety information on treatment durations longer than 4 weeks is limited.",12,17
"3067","fr","en","Les données disponibles montrent la possibilité d’ une augmentation du risque d’ avortement spontané.","Available data indicates that there may be an increased risk of spontaneous abortion.",13,14
"3068","fr","en","Les données disponibles sur les patients d’ origine africaine sont limitées.","There is limited data available on patients of African origin.",10,11
"3069","fr","en","Les données issues des études cliniques soutiennent le traitement intermittent par {Nom de fantaisie} jusqu’à 12 mois.","Data from clinical studies support intermittent treatment with < Invented Name > for up to 12 months.",17,17
"3070","fr","en","Les données pharmacocinétiques obtenues après administration intrarachidienne et intraveineuse sont résumées ci-dessous.","IT and intravenous pharmacokinetics data are summarised below.",8,12
"3071","fr","en","Les données présentées ci-après proviennent d'études réalisées soit avec la rosiglitazone seule soit avec la metformine seule.","The following data are findings in studies performed with rosiglitazone or metformin individually.",13,17
"3072","fr","en","Les données résultant de cette étude doivent être fournies aux autorités compétentes nationales pour évaluation.","The data resulting from this study should be provided to the relevant national competent authorities for assessment.",17,15
"3073","fr","en","Les données soutenant l’ utilisation de Wilzin ont été obtenues à partir de 255 patients.","Data to support the use of Wilzin come from 255 patients.",11,15
"3074","fr","en","Les données sur l'acide lactique plasmatique n'étaient pas collectées.","Data on lactic acid in serum were not collected.",9,9
"3075","fr","en","Les doses étant établies pour chaque patient, aucune adaptation posologique supplémentaire n’ est nécessaire en fonction du sexe.","Because doses are titrated for each subject, no additional dose adjustment is necessary based on gender.",16,18
"3076","fr","en","Les doses sont calculées en fonction du poids du patient.","Doses are calculated based on the patient’ s weight.",9,10
"3077","fr","en","Les doses sont ensuite ajustées selon la manière dont le patient répond au traitement.","The doses are then adjusted according to how the patient responds to the treatment.",14,14
"3078","fr","en","Les effets de Baraclude ont été observés sur des modèles expérimentaux avant d’ être étudiés chez l’ homme.","The effects of Baraclude were first tested in experimental models before being studied in humans.",15,18
"3079","fr","en","Les effets de Stalevo peuvent être atténués par certains médicaments.","The effects of Stalevo may be weakened by certain medicines.",10,10
"3080","fr","en","Les effets indésirables de fréquence indéterminée peuvent inclure:","Side effects of unknown frequency may include:",7,8
"3081","fr","en","Les effets indésirables les","The most common side effects with Neupopeg (seen in more than 1 in 10 patients)",15,4
"3082","fr","en","Les effets indésirables observés avec Crestor sont généralement légers et transitoires.","The adverse events seen with Crestor are generally mild and transient.",11,11
"3083","fr","en","Les effets indésirables observés avec une différence supérieure d'au moins 2% par rapport au placebo figurent en italique.","Adverse reactions with at least 2% difference over placebo are marked in italics.",13,18
"3084","fr","en","Les effets indésirables peu fréquents peuvent inclure:","Uncommon side effects may include:",5,7
"3085","fr","en","Les effets indésirables rapportés au cours des essais cliniques en pédiatrie sont décrits dans le Tableau 2 ci-dessous.","Vertigo, tinnitus Hearing loss, hearing disorder",6,18
"3086","fr","en","Les effets indésirables sont similaires chez les enfants.","The side effects are similar in children.",7,8
"3087","fr","en","Les effets indésirables suivants concernent les réactions inattendues observées lors des essais cliniques","The following undesirable effects cover adverse reactions from clinical trials:",10,13
"3088","fr","en","Les effets indésirables suivants ont été rapportés chez certains patients recevant Nespo:","The following side effects have been experienced by some patients taking Nespo:",12,12
"3089","fr","en","Les effets indésirables suivants peuvent se produire avec Thalidomide Celgene:","The following side effects may happen with this medicine:",9,10
"3090","fr","en","Les effets peuvent s’ aggraver, conduisant à une confusion et une perte de connaissance.","The severity can increase, leading to confusion and loss of consciousness.",11,14
"3091","fr","en","Les effets secondaires peuvent survenir au moins encore 5 mois après le dernier traitement.","Side effects may occur at least up to 5 months after the last treatment.",14,14
"3092","fr","en","Les effets sur l'aptitude à conduire des véhicules et à utiliser des machines n'ont pas été étudiés.","No studies on the effects on the ability to drive and use machines have been performed.",16,17
"3093","fr","en","Les enfants de moins de 18 ans ne doivent pas prendre Sonata.","Children under 18 years of age must not take Sonata.",10,12
"3094","fr","en","Les enfants et les adolescents âgés de moins de 18 ans ne recevront pas de Dynastat.","Children and adolescents under the age of 18 will not be given Dynastat.",13,16
"3095","fr","en","Les enseignements: délégation et partenariat","Lessons learned: devolution and partnership",5,5
"3096","fr","en","Les épisodes d’ hypoglycémie légère seront traités par ingestion de glucose ou de produits sucrés.","Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products.",14,15
"3097","fr","en","Les études animales ont montré que la sitagliptine est retrouvée dans le lait maternel.","Animal studies have shown excretion of sitagliptin in breast milk.",10,14
"3098","fr","en","Les études chez l’animal n’ont pas montré d’effets nocifs directs ou indirects sur la grossesse.","Studies in animals do not indicate direct or indirect harmful effects in pregnancy.",13,15
"3099","fr","en","Les études d’ interaction n’ ont été réalisées que chez l’ adulte.","Interaction studies have only been performed in adults.",8,12
"3100","fr","en","Les études de laboratoires ont montré que le maropitant peut être irritant pour les yeux.","In laboratory studies, maropitant has been shown to be a potential eye irritant.",13,15
"3101","fr","en","Les excipients du solvant sont croscarmellose sodique, mannitol, polysorbate 80, eau pour injection, acide chlrohydrique, hydroxide de sodium.","The solvent excipients are croscarmellose sodium, mannitol, polysorbate 80, water for injections, hydrochloric acid, sodium hydroxide.",16,18
"3102","fr","en","Les femmes en âge de procréer doivent éviter une grossesse au cours d’ un traitement par dabigatran etexilate.","Women of child-bearing potential should avoid pregnancy during treatment with dabigatran etexilate.",12,18
"3103","fr","en","Les femmes recevant CANCIDAS ne doivent pas allaiter.","Women receiving CANCIDAS should not breast-feed.",6,8
"3104","fr","en","Les flacons contiennent 20 mg de clofarabine et sont conditionnés dans une","The vials contain 20 mg of clofarabine and are packaged in a box.",13,12
"3105","fr","en","Les flacons partiellement utilisés doivent être éliminés.","Partially used vials should be discarded.",6,7
"3106","fr","en","Les flacons reconstitués doivent être utilisés dans les 4 heures.","Reconstituted vials should be used within 4 hours.",8,10
"3107","fr","en","Les fréquences des effets indésirables issus des études cliniques, et considérés comme imputables à Actrapid, sont répertoriées ci-dessous.","Frequencies of adverse drug reactions from clinical trials that are considered related to Actrapid, are listed below.",17,18
"3108","fr","en","Les gélules d’ Onsenal 200 mg contiennent du lactose (49,8 mg).","Onsenal 200 mg capsules contain lactose (49.8 mg).",8,11
"3109","fr","en","Les gélules d’Emtriva sont composées d’un corps blanc opaque avec une extrémité bleu clair opaque.","Emtriva hard capsules have a white opaque body with a light blue opaque cap.",14,15
"3110","fr","en","Les globules blancs sont importants car ils aident votre en","White blood cells are tn",5,10
"3111","fr","en","Les groupes plus importants devront être traités à l’ aide d’ aliments médicamenteux contenant le mélange.","Larger groups should be treated with medicated feeding stuff containing the premix.",12,16
"3112","fr","en","Les hallucinations sont un effet indésirable connu du traitement par les agonistes dopaminergiques et la lévodopa.","Hallucinations are known as an adverse event of treatment with dopamine agonists and levodopa.",14,16
"3113","fr","en","Les infections fongiques invasives les plus fréquemment rapportées étaient dues à Pneumocystis et Aspergillus.","The most commonly reported invasive fungal infections were Pneumocystis and Aspergillus.",11,14
"3114","fr","en","Les informations ci-après concernent les propriétés pharmacocinétiques de chacune des substances actives de Tandemact","The following statements reflect the pharmacokinetic properties of the individual active substances of Tandemact",14,14
"3115","fr","en","Les informations concernant Volibris destinées aux professionnels de santé devront contenir les informations suivantes:","The healthcare professional information regarding Volibris should contain the following key elements:",12,14
"3116","fr","en","Les informations disponibles chez l'homme montrent qu’ après administration systémique, le tacrolimus est excrété dans le lait maternel.","Human data demonstrate that, after systemic administration, tacrolimus is excreted into breast milk.",13,18
"3117","fr","en","les inhibiteurs de protéase: darunavir, indinavir, lopinavir/ ritonavir, ritonavir, atazanavir associé au ritonavir, saquinavir ou fosamprénavir/ saquinavir.","protease inhibitors: darunavir, indinavir, lopinavir/ ritonavir, ritonavir, ritonavir-boosted atazanavir, saquinavir or fosamprenavir/ saquinavir.",13,17
"3118","fr","en","Les injections se font de préférence dans la cuisse ou le ventre.","The injections are given preferably in the thigh or the front part of the abdominal wall.",16,12
"3119","fr","en","Les Instructions d’ Utilisation mentionnées dans la notice doivent être lues avec attention avant toute utilisation d’ OptiSet","Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully",16,18
"3120","fr","en","Les instructions d’ utilisation sont également décrites dans la partie de la notice destinée aux professionnels de santé.","The instructions for use are also described in the healthcare professionals package leaflet part.",14,18
"3121","fr","en","Les instructions détaillées sur le mode d’ injection figurant à la fin de cette notice doivent être suivies.","The detailed instructions on injection procedure",6,18
"3122","fr","en","Les instructions suivantes expliquent comment injecter Omnitrope 1,3 mg/ ml vous- même.","The following instructions explain how to inject Omnitrope 1.3 mg/ ml yourself.",12,12
"3123","fr","en","Les interférons sont produits par le corps humain et jouent un rôle essentiel dans le système immunitaire.","Interferons are produced by the body and play an essential role in the immune system.",15,17
"3124","fr","en","Les isoenzymes du cytochrome P450 ne participent pas au métabolisme du telmisartan.","The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.",12,12
"3125","fr","en","Les isolats cliniques du VIH-2 ont montré des valeurs de CE50 comprises dans l’ intervalle de 0,3-2,4 nM.","Clinical isolates of HIV-2 demonstrated EC50 values in the range of 0.3-2.4 nM.",13,18
"3126","fr","en","Les lésions cutanées du diabète sont des complications fréquentes du diabète.","Diabetic skin lesions are a common complication of diabetes.",9,11
"3127","fr","en","Les mécanismes impliqués dans la clairance des interférons chez l’ homme n’ ont pas encore été complètement élucidés.","The mechanisms involved in clearance of interferons in man have not yet been fully elucidated.",15,18
"3128","fr","en","Les médicaments contenant du lithium ne doivent pas être pris avec CoAprovel sans la surveillance de votre médecin.","Preparations containing lithium should not be taken with CoAprovel without close supervision by your doctor.",15,18
"3129","fr","en","Les médicaments ne doivent pas être jetés au tout à l'égout ou avec les ordures ménagères.","Medicines should not be disposed of via wastewater or household waste.",11,16
"3130","fr","en","Les médicaments ne doivent pas être jetés au tout à l’ égout ou avec les ordures ménagères.","Medicines should not be disposed of in wastewater or household waste.",11,17
"3131","fr","en","Les meilleurs sites d’ injection sont","The best sites for injection are tissues",7,6
"3132","fr","en","Les mesures efficaces nécessaires doivent être prises pour éviter toute grossesse (voir rubriques 4.4 et 4.6).","Effective measures to avoid pregnancy must be taken (see sections 4.4 and 4.6).",13,16
"3133","fr","en","Les métastases osseuses fixent donc plus fortement le QUADRAMET que l’ os sain environnant.","Thus, areas of metastatic involvement can accumulate significantly greater amounts of QUADRAMET than surrounding normal bone.",16,14
"3134","fr","en","Les modalités de traitement sont présentées séparément pour les adultes et les enfants.","Guidance is given separately for adult and paediatric patients.",9,13
"3135","fr","en","Les modifications exprimant l'opinion du CHMP ont été apportées au RCP.","The SPC was amended to reflect the CHMP position.",9,11
"3136","fr","en","Les observations de surdosage de SPRYCEL dans les études cliniques se limitent à des cas isolés.","Experience with overdose of SPRYCEL in clinical studies is limited to isolated cases.",13,16
"3137","fr","en","Les oedèmes étaient en général légers à modérés, ne nécessitant pas l’ arrêt du traitement.","The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.",17,15
"3138","fr","en","Les patientes ne doivent pas s’ allonger pendant l’ heure qui suit la prise de Bonviva.","Patients should not lie down for 1 hour after taking Bonviva.",11,16
"3139","fr","en","Les patients à risque élevé devront faire l’ objet d’ une étroite surveillance.","Patients at increased risk should be followed closely.",8,13
"3140","fr","en","Les patients adultes ayant des antécédents d'infarctus du myocarde ou d'insuffisance cardiaque","It is recommended that",4,12
"3141","fr","en","Les patients atteints du syndrome de Hunter ne produisent pas l’ enzyme iduronate-2-sulfatase.","Patients with Hunter syndrome do not produce an enzyme called iduronate-2-sulfatase.",11,13
"3142","fr","en","Les patients ayant une intolérance héréditaire au fructose ne doivent pas prendre cétirizine 1 mg/ ml, solution buvable.","Patients with rare hereditary problems of fructose intolerance should not take cetirizine 1 mg/ ml oral solution.",17,18
"3143","fr","en","Les patients de chaque groupe de traitement ont été maintenus à leur dose optimale pendant 6 mois.","Patients in each treatment group were maintained at their optimal dose for 6 months.",14,17
"3144","fr","en","Les patients dépressifs présentent un certain nombre de symptômes associés à la pathologie elle- même.","Depressed patients display a number of symptoms that are associated with the illness itself.",14,15
"3145","fr","en","Les patients devront dès lors être surveillés régulièrement (contrôle ECG et calcémie).","Patients should be monitored with regard to electrocardiogram (ECG) and serum calcium levels.",13,12
"3146","fr","en","Les patients devront être informés qu'en cas de soulagement symptomatique insuffisant, ils ne doivent pas:","Patients should be advised, in case of insufficient symptom relief",10,15
"3147","fr","en","Les patients doivent commencer un régime hypocholestérolémiant avant le traitement et le poursuivre tout au long du traitement.","Patients should start a cholesterol-lowering diet before treatment and continue it through treatment.",13,18
"3148","fr","en","Les patients doivent être informés des signes précoces des réactions d’ hypersensibilité.","Patients should be informed of the early signs of hypersensitivity reactions.",11,12
"3149","fr","en","Les patients doivent se brosser soigneusement les dents deux fois par jour et avoir des consultations dentaires régulières.","Patients should brush their teeth thoroughly twice daily and have regular dental examinations.",13,18
"3150","fr","en","Les patients hémophiles doivent, par conséquent, être informés de la possibilité d'une augmentation des saignements.","Haemophiliac patients should therefore be made aware of the possibility of increased bleeding.",13,15
"3151","fr","en","Les patients impliqués doivent, de préférence, être naïfs de tout traitement par thalidomide.","Patients involved should be preferably naïve to the history of thalidomide.",11,13
"3152","fr","en","Les patients peuvent s’ injecter Rebif eux-mêmes, à condition d’ y avoir été adéquatement formés.","The patients can inject Rebif themselves if they have been trained appropriately.",12,15
"3153","fr","en","Les patients présentant des effets indésirables dose- dépendants, notamment ceux affectant le système nerveux, doivent être surveillés attentivement.","Patients should be monitored carefully for dose-related adverse reactions, especially nervous system symptoms.",13,18
"3154","fr","en","Les patients présentant une insuffisance hépatique doivent être attentivement surveillés afin de détecter tout signe de toxicité médicamenteuse.","Patients with hepatic impairment should be monitored carefully for evidence of drug induced toxicity.",14,18
"3155","fr","en","Les patients présentent habituellement un souffle court et de la toux.","Patients usually present with shortness of breath and cough.",9,11
"3156","fr","en","Les patients qui n'avaient pas répondu ont interrompu le traitement suivant le protocole après 4 semaines.","Patients who achieved a response (defined as clearing of the CSF of malignant cells in the",16,16
"3157","fr","en","Les patients qui ne répondent pas au glucagon doivent recevoir une solution de sérum glucosé par voie intraveineuse.","Patients who fail to respond to glucagon must be given glucose solution intravenously.",13,18
"3158","fr","en","Les patients qui reçoivent Myozyme peuvent développer des anticorps (protéines produites en réponse à Myozyme).","Patients who receive Myozyme may develop antibodies (proteins that are produced in response to Myozyme).",15,15
"3159","fr","en","Les patients souffrant de dermatite atopique sont susceptibles de développer des infections cutanées m","Patients with atopic dermatitis are predisposed to superficial skin ro",10,14
"3160","fr","en","Les patients traités par méthotrexate doivent donc être attentivement surveillés quand l’ administration concomitante de ciprofloxacine est indiquée.","Therefore, patients receiving methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.",15,18
"3161","fr","en","Les personnes de plus de 60 ans ont un risque plus élevé de","Persons aged over 60 years appear to run an increased risk of",12,13
"3162","fr","en","Les personnes présentant une hypersensibilité (allergie) aux AINS doivent éviter tout contact avec Rheumocam.","People who are hypersensitive (allergic) to NSAIDs should avoid contact with Rheumocam.",12,14
"3163","fr","en","Les personnes présentant une hypersensibilité connue à ce type de produits doivent manipuler le produit avec précaution.","People with sensitive skin or known allergy to products of this type should handle the product with caution.",18,17
"3164","fr","en","Les personnes sujettes à une hypersensibilité connue à la clomipramine devront manipuler le produit avec précaution.","People with known hypersensitivity to clomipramine should administer the product with caution.",12,16
"3165","fr","en","Les poils excédentaires doivent être coupés.","Excess hair around the treatment area should be cut.",9,6
"3166","fr","en","Les porcelets nouveaux- nés sont immunisés passivement via l’ ingestion du colostrum des truies/ cochettes vaccinées.","Neonatal piglets derive passive immunity via ingestion of colostrum from vaccinated sows/ gilts.",13,16
"3167","fr","en","Les posologies exprimées en administration 3 fois par semaine sont à prendre de préférence un jour sur deux.","Dosages that are to be administered 3 times a week are best given every other day.",16,18
"3168","fr","en","Les posologies seront ajustées individuellement et le traitement poursuivi aussi longtemps que nécessaire cliniquement.","Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated.",17,14
"3169","fr","en","Les posologies usuelles d’Agopton pour les adultes figurent ci-dessous.","The usual doses of Agopton for adults are given below.",10,9
"3170","fr","en","Les précautions adaptées doivent être prises.","They must continue to use appropriate precautions.",7,6
"3171","fr","en","Les préparations d 'insuline qui ont été congelées ne doivent pas être utilisées.","Insulin preparations which have been frozen must not be used.",10,13
"3172","fr","en","Les prescripteurs doivent alors envisager d’ autres alternatives thérapeutiques lorsqu'un patient prend VIRACEPT (voir rubriques 4.3 et 4.5).","Physicians should consider using alternatives when a patient is taking VIRACEPT (see sections 4.3 and 4.5).",16,18
"3173","fr","en","Les prescripteurs doivent s'assurer que les patients ont pleinement connaissance des informations suivantes concernant la réaction d'hypersensibilité:","Prescribers must ensure that patients are fully informed regarding the following information on the hypersensitivity reaction:",16,17
"3174","fr","en","Les présentations de RELISTOR sont:","The presentations of RELISTOR are:",5,5
"3175","fr","en","Les principaux principes de la comptabilité de l’EMEA sont les suivants:","The main EMEA accounting principles are as follows:",8,11
"3176","fr","en","Les principes actifs et les autres composants d’ Infanrix hexa sont listés à la fin de cette notice.","The active substances and other ingredients in Infanrix hexa are listed at the end of the leaflet.",17,18
"3177","fr","en","Les procédures ci-dessous définissent les modalités de reconstitution et d’administration de BeneFIX.","The procedures below are provided as guidelines for the reconstitution and administration of BeneFIX.",14,12
"3178","fr","en","Les pyodermites superficielles peuvent nécessiter un traitement jusqu’ à au maximum 21 jours.","Superficial pyoderma may require treatment for up to a maximum of 21 days.",13,13
"3179","fr","en","Les réactions au point d'injection n'ont généralement pas nécessité l'arrêt du médicament.","Injection site reactions generally did not necessitate discontinuation of the medicinal product.",12,12
"3180","fr","en","Les réactions d’ hypersensibilité généralisée peuvent menacer le pronostic vital.","Generalised hypersensitivity reactions are potentially life threatening.",7,10
"3181","fr","en","Les réactions d’ hypersensibilité immédiate à l’ insuline ou aux excipients peuvent menacer le pronostic vital.","Immediate type allergic reactions to insulin or to the excipients may be life-threatening.",13,16
"3182","fr","en","Les réactions disparaissent normalement au bout de quelques heures après retrait du dispositif transdermique.","The reactions normally disappear after a few hours when you remove the patch.",13,14
"3183","fr","en","Les réactions indésirables de ces deux essais pivots sont résumées dans le tableau 2.","Adverse reactions in these two pivotal studies are summarised in Table 2.",12,14
"3184","fr","en","Les réactions indésirables sont énumérées ci-après, par classe anatomico-fonctionnelle et par fréquence.","Adverse reactions are listed below by system organ class and frequency.",11,12
"3185","fr","en","Les réactions indésirables suivantes ont été signalées:","The following adverse reactions have been report:",7,7
"3186","fr","en","Les réactions se sont avérées légères et n’ ont généralement pas nécessité de traitement spécifique.","Reactions have been mild and have not generally required specific therapy.",11,15
"3187","fr","en","Les recommandations en vigueur liées au traitement doivent être suivies.","Reference should be made to current treatment guidelines.",8,10
"3188","fr","en","Les résultats d’ efficacité sont présentés dans le tableau ci-dessous.","Efficacy results are presented in the table below:",8,10
"3189","fr","en","Les résultats de l’ étude P907 ont montré une efficacité supérieure à celle du placebo.","Results of P907 showed efficacy over placebo.",7,15
"3190","fr","en","Les résultats de l’ étude sont présentés dans le Tableau 5:","Study results are summarized in Table 5.",7,11
"3191","fr","en","Les résultats des données poolées ont montré que le pourcentage de rejets aigus prouvés par biopsie en","s difference in biopsy-proven acute rejection remained statistically different at one-year posttransplant",12,17
"3192","fr","en","Les résultats devront être transmis à l’ EMR et aux ANC où le bicalutamide 150 mg est autorisé.","The results should be reported to the RMS and the NCAs where bicalutamide 150 mg is authorised.",17,18
"3193","fr","en","Les résultats principaux des études 2,3 et 4 sont présentés ci-dessous.","Key results of studies 2, 3 and 4 are shown below.",11,11
"3194","fr","en","Les résultats sont résumés dans le tableau ci-après.","Results are summarised in the Table below.",7,8
"3195","fr","en","Les risques de surdosage sont liés à l’ administration par erreur d’ une activité excessive.","The risks to be expected are associated with the inadvertent administration of excess radioactivity.",14,15
"3196","fr","en","Les risques peuvent être majorés chez les patients ayant des antécédents récents d’ infiltration pulmonaire ou de pneumonie.","Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk.",15,18
"3197","fr","en","Les saignements (par exemple, hématome au point d’ injection) constituent l’ effet indésirable principal associé à Rapilysin.","The main side effect of Rapilysin is bleeding (such as a bruise at the site of injection).",17,17
"3198","fr","en","Les sept cycles suivants sont constitués de 3 semaines de traitement suivies de six semaines sans traitement.","The following seven cycles consist of three weeks of treatment, followed by a six-week rest period.",16,17
"3199","fr","en","Les seringues sont en verre de type I.","The syringes are type I glass.",6,8
"3200","fr","en","Les seringues sont préremplies avec la dose exacte qui C","For step-by-step instructions please see over the page. na",9,10
"3201","fr","en","Les seuls effets cliniquement pertinents étaient une diminution du nombre de globules rouges et une neutropénie.","The clinically relevant effects noted were a reduction in red blood cell count and neutropenia.",15,16
"3202","fr","en","Les signes de scoliose devront être recherchés au cours du traitement.","Signs of scoliosis should be monitored during treatment.",8,11
"3203","fr","en","Les signes peuvent être un léger jaunissement de la peau ou des yeux.","The signs may be a mild yellowing of the skin or eyes.",12,13
"3204","fr","en","Les solutions doivent être utilisées dans les 4 heures après avoir été sorties du réfrigérateur.","Solutions should be used within 4 hours of their removal from the refrigerator.",13,15
"3205","fr","en","Les spasmes musculaires peuvent être suffisamment violents pour entraîner des fractures osseuses de la colonne vertébrale. 'es","ge muscle spasms can be strong enough to cause bone fractures of the spine.",14,17
"3206","fr","en","Les substances actives sont le losartan potassium et l'hydrochlorothiazide.","The active substances are losartan potassium and hydrochlorothiazide.",8,9
"3207","fr","en","Les substances suivantes peuvent accroître les besoins en insuline: am","lon The following substances may increase insulin requirement:",8,10
"3208","fr","en","Les sujets (n = 215, 54,7%) qui n'étaient pas répondeurs à l'ASAS 20 aux semaines","The blinded period was followed by an open− label period no",11,15
"3209","fr","en","Les symptômes annonciateurs d’une hypoglycémie","Warning symptoms of hypoglycaemia",4,5
"3210","fr","en","Les symptômes d’ hypersensibilité apparaissent habituellement au cours des six premières semaines de traitement par l’ abacavir.","The symptoms related to this hypersensitivity reaction worsen with continued therapy and can be life- threatening.",16,17
"3211","fr","en","Les symptômes de l’ hépatite A débutent 3 à 6 semaines après le contact avec le virus.","Symptoms of hepatitis A begin 3 to 6 weeks after coming into contact with the virus.",16,17
"3212","fr","en","Les tailles de conditionnement suivantes sont disponibles: boîte contenant 1 ou 3 flacons de 3 ml.","The following pack sizes are available: cartons containing 1 or 3 bottles of 3 ml.",15,16
"3213","fr","en","Les TAMM ont présenté des explications orales au CHMP le 22 et le 23 mai 2007.","The MAHs presented oral explanations to the CHMP on 22 and 23 May 2007.",14,16
"3214","fr","en","Les taux d'induction d'une rémission et de réponse enregistrés dans les études CLASSIC I et GAIN 'es","CLASSIC I and GAIN induction of remission and response rates are presented in Table 9. lP Me",17,17
"3215","fr","en","Les taux d’ acide urique dans le sang ont été mesurés tous les mois.","Blood uric acid levels were measured every month.",8,14
"3216","fr","en","Les taux de maintien de la rémission et de réponse sont présentés dans le tableau 12.","Maintenance of remission and response rates are presented in Table 12.",11,16
"3217","fr","en","Les taux de réponse dans ces études augmentent avec l’ observance.","Recombinant interferon alfa-2b also inhibits viral replication in vitro and in vivo.",12,11
"3218","fr","en","Les taux de réponse mesurés par les 5 scores cutanés étaient respectivement de 36% et de 27%.","The response rates according to the 5 skin scores were 36% and 27%, respectively.",14,17
"3219","fr","en","Les taux de succès chez les patients présentant une EI du coeur droit figurent dans le tableau ci-dessous.","The success rates in RIE patients are shown in the table below.",12,18
"3220","fr","en","Les taux plasmatiques de desloratadine peuvent être détectés dans les 30 minutes qui suivent l’ administration.","Desloratadine plasma concentrations can be detected within 30 minutes of administration.",11,16
"3221","fr","en","Les toxines provoquent une défaillance des organes chez les patients (cœ ur, poumons, reins, etc.).","The toxins cause the patient ’ s organs to fail (heart, lungs, kidneys, etc).",14,15
"3222","fr","en","Les traitements hormonaux substitutifs inhibent, de manière générale, la résorption osseuse excessive.","Replacement therapies generally reverse the excessive resorption of bone.",9,12
"3223","fr","en","Les traitements médicaux antidiabétiques peuvent nécessiter une surveillance étroite lors de l’ association à orlistat.","Antidiabetic medicinal product treatment may have to be closely monitored when taking orlistat.",13,15
"3224","fr","en","Les troubles lipidiques devront être pris en charge en clinique de manière appropriée (voir rubrique 4.8).","Lipid disorders should be managed as clinically appropriate (see section 4.8).",11,16
"3225","fr","en","Les vaccins agissent en « apprenant » au système immunitaire à se défendre contre les maladies.","Vaccines work by ‘ teaching’ the immune system how to defend itself against diseases.",14,16
"3226","fr","en","Les valeurs de l'ASC du fosamprénavir représentent moins de 1% à celles observées avec l'amprénavir.","Fosamprenavir AUC values are, in general, less than 1% of those observed for amprenavir.",14,15
"3227","fr","en","Les valeurs limites des tests dynamiques doivent être strictement définies.","The cut-off point of the dynamic test should be strict.",10,10
"3228","fr","en","Les valeurs se sont normalisées à l'arrêt du traitement.","All values returned to baseline levels upon therapy discontinuation.",9,9
"3229","fr","en","Les volumes à injecter supérieurs à 1 ml doivent être fractionnés en doses divisées.","Injection volumes over 1 ml should be given as a divided dose.",12,14
"3230","fr","en","Lésions, intoxications et complications liées aux procédures †","Injury, poisoning and procedural complications †",6,8
"3231","fr","en","Leur différence vient du fait qu’ ils portent différents antigènes.","They vary in that they may carry different antigens.",9,10
"3232","fr","en","Leur fréquence de survenue n’ est pas connue (voir rubrique 4.4).","The frequency of this is unknown (see section 4.4).",9,11
"3233","fr","en","Leur fréquence, observée dans une étude clinique, était de 8%.","The frequency as reported in clinical trials was 8.0%.",9,10
"3234","fr","en","Leur respiration devra être surveillée pendant 3 jours au plus après la vaccination.","Their breathing should be monitored for up to three days after vaccination.",12,13
"3235","fr","en","Levemir 100 U/ml solution injectable en cartouche Penfill insuline détémir","Levemir 100 U/ ml solution for injection in a cartridge Penfill insulin detemir",13,10
"3236","fr","en","Levemir ne doit pas être utilisé s’il a été congelé.","Levemir which has been frozen must not be used.",9,10
"3237","fr","en","Levitra est un médicament contenant le principe actif vardénafil.","Levitra is a medicine that contains the active substance vardenafil.",10,9
"3238","fr","en","Libération transdermique de fentanyl (microgrammes/ h)","Transdermal fentanyl release (micrograms/ h)",5,6
"3239","fr","en","Libérer lentement le piston afin que la gaine protectrice de l’ aiguille recouvre automatiquement l’ aiguille exposée.","Slowly release the plunger and allow the needle guard to automatically cover the exposed needle.",15,17
"3240","fr","en","Lietuva BioMarin Europe Limited biomarinlt@bmrn. com","Lietuva BioMarin Europe Limited biomarinlt@bmrn. com",6,6
"3241","fr","en","Lietuva Gilead Sciences International Ltd Tel: + 44 (0) 20 7136 8820","Lietuva Gilead Sciences International Ltd Tel: + 44 (0) 20 7136 8820",12,12
"3242","fr","en","Lietuva GlaxoSmithKline Lietuva UAB Tel. +370 5 264 90 00 info. lt@gsk. com","Lietuva GlaxoSmithKline Lietuva UAB Tel. +370 5 264 90 00 info.lt@gsk.com",11,13
"3243","fr","en","Lietuva Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.","Lietuva Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.",9,9
"3244","fr","en","Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel. +3705 2514000","Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel. +3705 2514000",9,9
"3245","fr","en","Lietuva UAB ""SERVIER PHARMA"" Tel: +370 (5) 2 63 86 28","Lietuva UAB ""SERVIER PHARMA"" Tel: +370 (5) 2 63 86 28",11,11
"3246","fr","en","Lietuva UAB “Merck Sharp & Dohme”.","Lietuva UAB “Merck Sharp & Dohme”.",6,6
"3247","fr","en","Lietuva UAB Bayer, Bayer Schering Pharma Tel.: +370 5 2336868","Lietuva UAB Bayer, Bayer Schering Pharma Tel.: +370 5 2336868",10,10
"3248","fr","en","Lietuva UAB sanofi-aventis Lietuva Tel: +370 5 2755224","Lietuva UAB sanofi-aventis Lietuva Tel: +370 5 2755224",8,8
"3249","fr","en","Lietuva Valeant Pharmaceuticals Switzerland GmbH Representative Office in Lithuania Tel: +370 37 330 509","Lietuva Valeant Pharmaceuticals Switzerland GmbH Representative Office in Lithuania Tel: +370 37 330 509",14,14
"3250","fr","en","Lignes directrices et mises à jour de l’ harmonisation internationale","Guidelines and updates on international harmonisation",6,10
"3251","fr","en","Lilly Pharma Fertigung und Distribution GmbH & Co.","Lilly Pharma Fertigung und Distribution GmbH & Co.",8,8
"3252","fr","en","Liprolog BASAL 100 UI/ ml Pen, suspension injectable","Liprolog Basal 100 U/ ml Pen, suspension for injection",9,8
"3253","fr","en","Liprolog est une solution aqueuse stérile, limpide et incolore.","Liprolog is a sterile, clear, colourless, aqueous solution.",8,9
"3254","fr","en","Liprolog Mix25 100 UI/ ml KwikPen, suspension injectable","Liprolog Mix25 100 U/ ml KwikPen, suspension for injection",9,8
"3255","fr","en","Liprolog Mix50 100 UI/ml suspension injectable en cartouche (insuline lispro)","Liprolog Mix50 100 U/ml suspension for injection in cartridge (insulin lispro)",11,10
"3256","fr","en","LIRE ATTENTIVEMENT LA NOTICE INTERIEURE","READ ENCLOSED PACKAGE LEAFLET",4,5
"3257","fr","en","Lire la notice avant utilisation","Read the package leaflet before use.",6,5
"3258","fr","en","Lire la notice avant utilisation pour les instructions de reconstitution et de dilution.","Read the package leaflet before use for directions on reconstitution and dilution.",12,13
"3259","fr","en","Lire la notice avant utilisation.","For local use Read the package leaflet before use.",9,5
"3260","fr","en","Lire la notice de l’emballage avant utilisation.","Intraosseuous use Read the package leaflet before use.",8,7
"3261","fr","en","Lire la notice et le manuel d’ utilisation du stylo avant utilisation.","Read the package leaflet and pen user manual before use.",10,12
"3262","fr","en","Lire la notice pour l'élimination des médicaments inutilisés.","Read the package leaflet for disposal of medicines no longer required.",11,8
"3263","fr","en","Lisez attentivement les instructions et suivez -les étape par étape.","Please read the instructions carefully and follow them step by step.",11,10
"3264","fr","en","Liste A Liste B","List A List B",4,4
"3265","fr","en","LISTE DE LA (DES) SUBSTANCE(S) ACTIVE(S) ET AUTRE(S) INGRÉDIENT(S)","STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)",8,9
"3266","fr","en","LISTE DES PRINCIPES ACTIFS ET D’ AUTRES SUBSTANCES","STATEMENT OF ACTIVE AND OTHER SUBSTANCES",6,8
"3267","fr","en","LISTE DU (DES) SUBSTANCE(S) ACTIVE(S) ET AUTRE(S) INGRÉDIENT(S)","STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS",8,8
"3268","fr","en","LITAK est administré par injection sous la peau.","LITAK is given as an injection under the skin.",9,8
"3269","fr","en","Ljubljana Knezov stradon 90 1000 Ljubljana Slovénie","Ljubljana Knezov stradon 90 1000 Ljubljana Slovenia",7,7
"3270","fr","en","Località Valcanello 03012 Anagni (FR) Italie","Località Valcanello 03012 Anagni (FR) Italy",6,6
"3271","fr","en","Londres, le 14 août 2008 EMEA/ CHMP/ 524288/ 2008","London, 14 August 2008 EMEA/ CHMP/ 524284/ 2008",8,9
"3272","fr","en","Londres, le 21 août 2008 Réf.","London, 21 August 2008 Doc.",5,6
"3273","fr","en","Londres, le 3 avril 20 EMEA/ CHMP/ 416317/ 2005","London, 3 April 2006 EMEA/ CHMP/ 416317/ 2005",8,9
"3274","fr","en","Lopid et dénominations associées (voir annexe I)","Lopid and associated names (See Annex I)",7,7
"3275","fr","en","loratadine pendant la grossesse augmente le risque d’ hypospadias.","during pregnancy increases the risk of hypospadia.",7,9
"3276","fr","en","Lors d’ un traitement antipsychotique, l’ amélioration clinique du patient peut nécessiter plusieurs jours voire plusieurs semaines.","During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks.",16,17
"3277","fr","en","Lors des études cliniques conduites dans de nombreuses indications et sur un intervalle de doses très","with ribavirin in patients with chronic hepatitis C.",8,16
"3278","fr","en","Lorsqu'elles ont été observées, des concentrations supérieures à 1,0 ng/ ml ont été transitoires.","Systemic exposure increases with increasing treatment areas.",7,14
"3279","fr","en","Lorsqu’ IntronA est utilisé avec l’ hydroxyurée, la fréquence et la sévérité des vascularites cutanées peuvent être augmentées.","When IntronA is used with hydroxyurea, the frequency and severity of cutaneous vasculitis may be increased.",16,18
"3280","fr","en","Lorsque l'enzyme est bloquée, le virus ne peut","When the enzyme is blocked, the virus does not reproduce normally, slowing down the spread of infection.",17,8
"3281","fr","en","Lorsque l’ administration concomitante est indiquée, une surveillance clinique est nécessaire.","When concomitant administration is warranted, patients should be monitored clinically.",10,11
"3282","fr","en","Lorsque PhotoBarr est injecté, le porfimère est absorbé dans les cellules de tout le corps.","When PhotoBarr is injected, porfimer is absorbed into cells throughout the body.",12,15
"3283","fr","en","Lorsque vous commencez un traitement à la glucosamine, vous devez","When starting on glucosamine, you should be aware of potential",10,10
"3284","fr","en","Lucentis doit être administré par un ophtalmologiste expérimenté ayant l'expérience des injections intravitréennes.","Lucentis must be administered by a qualified ophthalmologist experienced in intravitreal injections.",12,13
"3285","fr","en","Luminity 150 microlitres/ ml, solution pour suspension injectable ou perfusable Perflutren Voie intraveineuse","Luminity 150 microlitres/ ml solution for dispersion for injection or infusion Perflutren Intravenous use",14,13
"3286","fr","en","LUN MAR MER JEU VEN SAM DIM","MON TUE WED THU FRI SAT SUN",7,7
"3287","fr","en","Lundbeck A/ S Ottiliavej 9 DK-2500 Valby Danija Tel: + 45 36301311","Lundbeck A/S Ottiliavej 9 DK-2500 Valby Danija Tel: + 45 36301311",11,12
"3288","fr","en","Lundi Mardi Mercredi Jeudi Vendredi Samedi Dimanche","Monday Tuesday Wednesday Thursday Friday Saturday Sunday",7,7
"3289","fr","en","lus éventuelle et/ ou toute altération de l'aspect physique.","suspension and should be inspected visually for any foreign particulate matter and/ or abnormal physical appearance.",16,9
"3290","fr","en","lus Hypercalcémie de malignité.","r Hypercalcaemia of malignancy.",4,4
"3291","fr","en","lus Retirez la seringue de son enveloppe.","Remove the syringe from the wrapping.",6,7
"3292","fr","en","Luveris 75 UI poudre et solvant pour solution injectable.","Luveris 75 IU, powder and solvent for solution for injection.",10,9
"3293","fr","en","Luxembourg/ Luxemburg Eli Lilly Benelux S. A/ N. V.","Luxembourg/ Luxemburg Eli Lilly Benelux S. A/ N. V.",9,9
"3294","fr","en","Luxembourg/ Luxemburg MEDA Pharma S. A. / N. V.","Luxembourg/ Luxemburg MEDA Pharma S. A. / N. V.",9,9
"3295","fr","en","Luxembourg/ Luxemburg Novartis Pharma GmbH Tél/ Tel: +49 911 273 0","Luxembourg/ Luxemburg Novartis Pharma GmbH Tel: +49 911 273 0",10,11
"3296","fr","en","Luxembourg/ Luxemburg S. A.","Luxembourg/ Luxemburg S. A.",4,4
"3297","fr","en","Luxembourg/ Luxemburg SCS Boehringer Ingelheim Comm. V Tél/ Tel: +32 2 773 33 11","Boehringer Ingelheim Comm. V Tél/ Tel: +32 2 773 33 11",11,14
"3298","fr","en","Luxembourg/ Luxemburg Takeda Global Research and Development Centre (Europe) Ltd., Royaume-Uni Tél/ Tel: +44 (0)20 3116 8000","Luxembourg/ Luxemburg Takeda Global Research and Development Centre (Europe) Ltd., Royaume-Uni Tél/ Tel: +44 (0)20 3116 8000",17,17
"3299","fr","en","Luxembourg/ Luxemburg UCB Pharma SA/ NV Tél/ Tel: +32 / (0)2 559 92 00","Luxembourg/Luxemburg UCB Pharma SA/NV Tél/ Tel: +32 / (0)2 559 92 00",12,14
"3300","fr","en","Luxembourg/Luxemburg Eli Lilly Benelux S.A.","Luxembourg/Luxemburg Eli Lilly Benelux S.A.",5,5
"3301","fr","en","Luxembourg/Luxemburg Pfizer Animal Health s.a., Tél.: + 32 (0)2 554 62 11","Luxembourg/Luxemburg Pfizer Animal Health s.a., Tél.: + 32 (0)2 554 62 11",12,12
"3302","fr","en","Lyophilisat (60 000 UI) et solvant pour solution injectable 1 cartouche à 2 compartiments pour Reco-Pen (1 ml)","Lyophilisate (60,000 IU) and solvent for solution for injection 1 two-chamber cartridge for Reco-Pen (1 ml)",16,18
"3303","fr","en","LYRICA 225 mg gélules","LYRICA 225 mg hard capsules",5,4
"3304","fr","en","LYRICA peut être associé à une vision trouble ou à d’autres modifications de la vue.","LYRICA may be associated with blurred vision or other changes in eyesight.",12,15
"3305","fr","en","MabCampath est contre-indiqué durant la grossesse.","MabCampath is contraindicated during pregnancy.",5,6
"3306","fr","en","MabThera est une solution à diluer pour perfusion, limpide et incolore.","MabThera is a clear, colourless solution, supplied as a concentrate for solution for infusion.",14,11
"3307","fr","en","Macrolide immunosuppresseur, code ATC:","Macrolide immunosuppressant, ATC code:",4,4
"3308","fr","en","Macugen doit être jeté s’ il reste à température ambiante plus de deux semaines.","Macugen should be discarded if kept at room temperature for more than two weeks.",14,14
"3309","fr","en","Magyarország Actavis Hungary Kft., Tel.: +36 52 431-313","Magyarország Actavis Hungary Kft., Tel.: +36 52 431-313",8,8
"3310","fr","en","Magyarország Biogal-Teva Pharma Zrt Rákóczi út 70-72.","Magyarország Biogal-Teva Pharma Zrt Rákóczi út 70-72.",7,7
"3311","fr","en","Magyarország Dunavet-B ZRt, 7020 Dunaföldvár, Ady E. u.","Magyarország Dunavet-B ZRt, 7020 Dunaföldvár, Ady E. u.",8,8
"3312","fr","en","Magyarország IVAX Drug Research Institute Ltd Tel.: +36 1399 3343","Magyarország IVAX Drug Research Institute Ltd Tel.: +36 1399 3343",10,10
"3313","fr","en","Magyarország MSD Magyarország Kft.","Magyarország MSD Magyarország Kft.",4,4
"3314","fr","en","Magyarország Tel: +36 75 542 940 Email: dunavet-bp@externet.hu","Magyarország Tel: +36 75 542 940 Email: dunavet-bp@externet.hu",8,8
"3315","fr","en","Maintenir le tube unidose dans l’emballage extérieur à l’abri de la lumière.","Keep the dosing tube in the outer carton in order to protect from light.",14,12
"3316","fr","en","Maladie du foie entraînant une insuffisance hépatique (voir rubrique 5.2).","Liver disease resulting in hepatic impairment (see section 5.2).",9,10
"3317","fr","en","Malta Agrimed Limited Mdina Road Zebbug MT-ZBG 06 +356 21 465797","Malta Agrimed Limited Mdina Road Zebbug MT-ZBG 06 +356 21 465797",11,11
"3318","fr","en","Malta Baxter Healthcare Ltd Wallingford Road Compton Berkshire RG20 7QW United Kingdom Tel.: + 44 1635 206345","Malta Baxter Healthcare Ltd Wallingford Road Compton Berkshire RG20 7QW, United Kingdom Tel.: + 44 1635 206345",17,17
"3319","fr","en","Malta Česká republika MSD Interpharma Merck Sharp & Dohme IDEA, Inc., org. sl.","Č eská republika Merck Sharp & Dohme IDEA, Inc., org. sl.",11,13
"3320","fr","en","Malta Cherubino Ltd Tel.: +356 21 343270","Malta Cherubino Ltd Tel.: +356 21 343270",7,7
"3321","fr","en","Malta Danmark Wyeth Danmark Tlf: +45 44 88 88 05 Fax: +45 44 88 88 06","Danmark Wyeth Danmark Tlf: +45 44 88 88 05 Fax: +45 44 88 88 06",15,16
"3322","fr","en","Malta GlaxoSmithKline Malta Tel: + 356 21 238131","Malta GlaxoSmithKline Malta Tel: + 356 21 238131",8,8
"3323","fr","en","Malta Orion Corporation Tel: +358 10 4261","Malta Orion Corporation Tel: +358 10 4261",7,7
"3324","fr","en","Malta Vivian Corporation Ltd.","Malta Vivian Corporation Ltd.",4,4
"3325","fr","en","Mangez ensuite un aliment qui augmentera durablement votre taux de sucre dans le sang (par exemple du pain).","Then eat something that has a long-acting effect in raising your blood sugar (e.g. bread).",15,18
"3326","fr","en","Mannitol le comprimé orodispersible de ZYPREXA VELOTAB contient du mannitol.","Mannitol ZYPREXA VELOTAB orodispersible tablet contains mannitol.",7,10
"3327","fr","en","Manuel Ribeiro de Pavia, n. º1 - Venda Nova 2700-547 Amadora Portugal","Manuel Ribeiro de Pavia, n. º1 - Venda Nova 2700-547 Amadora Portugal",12,12
"3328","fr","en","marche pour le moment","marketed at the moment",4,4
"3329","fr","en","Marinopoulou Str., 174 56 Alimos, Athens, Grèce. am","Marinopoulou Str., 174 56 Alimos, Athens, Greece. uc",8,8
"3330","fr","en","Marker vaccine against — Classical Swine Fever","M05BA08 Treatment of tumour",4,7
"3331","fr","en","Masivet est un médicament délivré sur ordonnance pour le traitement des tumeurs à mastocytes chez le chien.","Masivet is a prescription medicine used to treat dog mast cell tumours.",12,17
"3332","fr","en","Masser pour faire pénétrer la crème dans la zone à traiter.","The cream should be rubbed into the treatment area until 3 the cream vanishes.",14,11
"3333","fr","en","Maux de tête Etourdissements, somnolence, paresthésies, syncope","Headache Dizziness, somnolence, paraesthesia, syncope",5,7
"3334","fr","en","McNeil Roderveld 1 B – 2600 Berchem Belgique","McNeil Roderveld 1 B – 2600 Berchem Belgium",8,8
"3335","fr","en","Mécanisme d’ action et effets pharmacodynamiques:","Mechanism of action and pharmacodynamic effects:",6,6
"3336","fr","en","Meda AB Box 906 170 09 Solna Suède","Meda AB Box 906 170 09 Solna Sweden",8,8
"3337","fr","en","Médiane Risque relatif (IC 95%)","Time to treatment failure (TTTF – months) Median HR (95% CI)",11,5
"3338","fr","en","Médicament par classe thérapeutique (dose d’ Invirase utilisé dans les études) Médicaments antirétroviraux","Medicinal product by therapeutic area (dose of Invirase used in study) Antiretroviral agents",13,13
"3339","fr","en","Médicament soumis à prescription médicale en","GENERAL CLASSIFICATION FOR SUPPLY ge lon Medicinal product subject to medical prescription. no",13,6
"3340","fr","en","Médicament soumis à prescription médicale restreinte (voir Annexe I:","Medicinal product subject to restricted medical prescription (See Annex I:",10,9
"3341","fr","en","Médicament soumis à prescription médicale restreinte et spéciale.","Medicinal product subject to restricted and special medical prescription.",9,8
"3342","fr","en","Médicament soumis à prescription médicale.","Medicinal product subject to medical prescription",6,5
"3343","fr","en","Médicament vétérinaire soumis à prescription médicale","To be supplied only on veterinary prescription.",7,6
"3344","fr","en","Médicament vétérinaire soumis à prescription.","Veterinary medicinal product subject to prescription.",6,5
"3345","fr","en","médicament, vous avez une plus grande possibilité d'être enceinte.","becoming pregnant because of how your medicine works.",8,9
"3346","fr","en","médicaments (AINS et bisphosphonates) peuvent entraîner une irritation de l’ estomac et de l’ intestin.","medicinal products (NSAIDs and bisphosphonates) may cause irritation to the stomach and intestine.",13,15
"3347","fr","en","Médicaments ayant un effet sur les concentrations de ritonavir","Drugs that affect ritonavir levels",5,9
"3348","fr","en","Médicaments contenant de la norfloxacine","Norfloxacin containing medicinal products",4,5
"3349","fr","en","Medochemie Ltd Pobox 51409, 3505 Lemesos, Chypre","Medochemie Ltd Pobox 51409, 3505 Lemesos, Cyprus",7,7
"3350","fr","en","Mélanger le contenu du sachet avant utilisation en appuyant doucement sur les faces du sachet unidose.","Oral use Shake before use applying slight pressure to the wall.",11,16
"3351","fr","en","Mélanger parfaitement jusqu’ à ce que la poudre Hib soit complètement dissoute.","Mix thoroughly until the Hib powder is completely dissolved.",9,12
"3352","fr","en","même en cas de symptômes identiques, cela pourrait lui être nocif.","if their symptoms are the same as yours.",8,11
"3353","fr","en","Même si vous vous sentez mieux, n’arrêtez pas de prendre INTELENCE ou vos autres médicaments anti-VIH.","Even if you feel better, do not stop taking INTELENCE or your other anti-HIV medicines.",15,16
"3354","fr","en","Menitorix est disponible en boîtes de 1 ou 10 doses, avec 2 aiguilles séparées ou bien sans aiguille.","Menitorix is available in packs of 1 or 10 with 2 separate needles or without needles.",16,18
"3355","fr","en","MENTION SUR LES LIMITES MAXIMALES DE RÉSIDUS","STATEMENT OF THE MRLs",4,7
"3356","fr","en","mentionné dans cette notice, parlez -en à votre médecin, votre infirmière ou à votre pharmacien.","please tell your doctor, nurse or pharmacist.",7,15
"3357","fr","en","mentionné dans cette notice, parlez en à votre médecin ou votre pharmacien.","your doctor or pharmacist.",4,12
"3358","fr","en","MENTIONS DEVANT FIGURER SUR L’ EMBALLAGE EXTERIEUR","PARTICULARS TO APPEAR ON THE OUTER PACKAGING",7,7
"3359","fr","en","MENTIONS DEVANT FIGURER SUR L’ EMBALLAGE EXTERIEUR (Nom de fantaisie)® 20 mg/ 5 ml, solution buvable en flacon","CARTONS FOR (Invented name)® 20 mg per 5 ml oral liquid",11,18
"3360","fr","en","Merci de les lire attentivement.","Please read it carefully.",4,5
"3361","fr","en","Merck AB S-195 87 Stockholm Tel: +46-8-562 445 00","Merck AB S-195 87 Stockholm Tel: +46-8-562 445 00",9,9
"3362","fr","en","Merck Serono S. A.","Merck Serono S. A.",4,4
"3363","fr","en","Merck Sharp & Dohme (Middle East) Limited., Tel: +357 22866700 Nederland:","Merck Sharp & Dohme (Middle East) Limited., Tel: +357 22866700Nederland:",10,11
"3364","fr","en","Merck Sharp & Dohme B. V.","Merck Sharp & Dohme B. V.",6,6
"3365","fr","en","Merck Sharp & Dohme BV PO Box 581 NL-2003 PC Haarlem The Netherlands Merck Sharpe & Dohme Limited,","Merck Sharp & Dohme BV PO Box 581 NL-2003 PC Haarlem The Netherlands",13,18
"3366","fr","en","Merck Sharp & Dohme IDEA, Inc., Tel: +421.2.58282010 Suomi/ Finland:","Merck Sharp & Dohme IDEA, Inc., Tel: +421.2.58282010 Suomi/ Finland:",10,10
"3367","fr","en","Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Herts EN11 9BU, Royaume Uni","Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Herts EN11 9BU, United Kingdom",13,13
"3368","fr","en","Merck Sharp & Dohme Ltd., Hertfordshire Road, Hoddesdon, Hertfordshire, EN11 9BU, Royaume Uni","Merck Sharp & Dohme Ltd., Hertfordshire Road, Hoddesdon,",8,13
"3369","fr","en","MERCK SHARP & DOHME ROMANIA S. R. L.","MERCK SHARP & DOHME ROMANIA S. R. L.",8,8
"3370","fr","en","Merck Sharp & Dohme, Smartinska 140, SI-1000 Ljubljana Slovénie","Merck Sharp & Dohme, Smartinska 140, SI-1000 Ljubljana Slovenia",9,9
"3371","fr","en","MERIAL 29 avenue Tony Garnier F - 69007 Lyon France","MERIAL 29 avenue Tony Garnier F - 69007 Lyon France",10,10
"3372","fr","en","MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France","Merial, Laboratoire Porte des Alpes Rue de l'Aviation, F-69800 Saint Priest, France",12,12
"3373","fr","en","MERIAL Merial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest France","Mérial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest France",12,13
"3374","fr","en","Métabolisme 95% de la dose sont excrétés dans l’ urine sous forme inchangée et sous forme de métabolites.","Metabolism 95% of the dose is excreted in the urine as drug and metabolites.",14,18
"3375","fr","en","Metacam 1 mg comprimés à croquer pour chiens Flacon:","Metacam 1 mg chewable tablets for dogs Bottle:",8,9
"3376","fr","en","Metacam 5 mg/ ml solution injectable pour bovins et porcins","Metacam 5 mg/ ml solution for injection for cattle and pigs",11,10
"3377","fr","en","Metalyse 10 000 unités, poudre et solvant pour solution injectable","Powder and solvent for solution for injection",7,10
"3378","fr","en","METALYSE ne vous sera ni prescrit ni administré par votre médecin si:","METALYSE will not be prescribed and given by your doctor",10,12
"3379","fr","en","Metformine La metformine est un biguanide possédant des effets antihyperglycémiants, réduisant la glycémie basale et postprandiale.","Metformin Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.",15,16
"3380","fr","en","Méthadone/ Fumarate de ténofovir disoproxil (40-110 q. d. / 300 q. d.)","Methadone/ Tenofovir disoproxil fumarate (40-110 q. d. / 300 q. d.)",11,12
"3381","fr","en","Mexilétine L’ administration simultanée de ciprofloxacine et de mexilétine peut provoquer une augmentation des concentrations plasmatiques de mexilétine.","Mexiletine Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma concentrations of mexiletine.",15,18
"3382","fr","en","MicardisPlus 80 mg/12,5 mg comprimés telmisartan/hydrochlorothiazide","MicardisPlus 80 mg/ 12.5 mg tablets telmisartan/ hydrochlorothiazide",8,6
"3383","fr","en","Microcapsule à libération prolongée et solvant pour suspension injectable","Prolonged-release microcapsule and solvent for suspension for injection",8,9
"3384","fr","en","Migdał owa 4 PL-02-796 Warszawa +48 22 645 11 20","Migdał owa 4 PL-02-796 Warszawa +48 22 645 11 20",10,10
"3385","fr","en","Mimpara 60 mg comprimés Cinacalcet","Mimpara 60 mg tablet Cinacalcet",5,5
"3386","fr","en","Minervum 7061 4817 ZK Breda Pays-Bas","Minervum 7061 4817 ZK Breda The Netherlands",7,6
"3387","fr","en","Mineure, 30-60 y compris les extractions dentaires.","Minor, including tooth extraction",4,7
"3388","fr","en","Minimum de 7 jours et jusqu’ à 4 semaines","minimum of 7 days and",5,9
"3389","fr","en","Mirapexin est indiqué lorsque la cause précise de ce trouble ne peut être identifiée.","Mirapexin is used when a specific cause for the disorder cannot be identified.",13,14
"3390","fr","en","MIRCERA 200 µg/ ml, solution injectable méthoxy polyéthylène glycol-epoetin beta SC/ IV","MIRCERA 200 µg/ml solution for injection methoxy polyethylene glycol-epoetin beta SC/IV",11,12
"3391","fr","en","MIRCERA 50 microgrammes/ 0,3 ml, solution injectable en seringue préremplie méthoxy polyéthylène glycol-epoetin beta","MIRCERA 50 micrograms/0.3 ml solution for injection in pre-filled syringe methoxy polyethylene glycol-epoetin beta",14,14
"3392","fr","en","MIRCERA est destiné à une utilisation à long terme.","MIRCERA is intended for long-term use.",6,9
"3393","fr","en","Mirtazapine 15mg/ ml Oral Solution","The amount of phenylalanine is low in Remeron orodispersible tablets.",10,5
"3394","fr","en","MISE EN GARDE SPECIALE INDIQUANT QUE LE MEDICAMENT DOIT ETRE tn","SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT no",11,11
"3395","fr","en","MISE(S) EN GARDE ÉVENTUELLE(S)","SPECIAL WARNING(S), IF NECESSARY",4,4
"3396","fr","en","Mixtard 10 NovoLet 100 UI/ ml suspension injectable Insuline humaine, (ADNr) Voie SC","Mixtard 10 NovoLet 100 IU/ ml suspension for injection Insulin human (rDNA) SC use",14,13
"3397","fr","en","Mixtard 30 40 UI/ ml suspension injectable en flacon Insuline humaine, (ADNr)","Mixtard 30 40 IU/ ml suspension for injection in a vial Insulin human (rDNA)",14,12
"3398","fr","en","Mixtard 30 Penfill 100 UI/ ml suspension injectable en cartouche Insuline humaine (ADNr)","Mixtard 30 Penfill 100 IU/ ml suspension for injection in a cartridge Insulin human (rDNA)",15,13
"3399","fr","en","Mixtard 50 NovoLet 100 UI/ ml suspension injectable Insuline humaine, (ADNr) Voie SC","Mixtard 50 NovoLet 100 IU/ ml suspension for injection Insulin human (rDNA) SC use",14,13
"3400","fr","en","Mixtard doit être injecté sous la peau (voie sous-cutanée).","Mixtard is for injection under the skin (subcutaneously).",8,9
"3401","fr","en","Mobilisation des CSP Injection sous-cutanée.","Mobilisation of PBPC Subcutaneous injection.",5,5
"3402","fr","en","Mobilité de personnel entre les Communautés et les secteurs publics et privés, visite d' experts","Staff exchanges between community institutions and the public and private sectors, visiting experts",13,15
"3403","fr","en","Mode d’ administration Voie oculaire.","Method of administration For ocular use.",6,5
"3404","fr","en","Mode d’ emploi – reconstitution, dilution et administration","Instructions for use – reconstitution, dilution and administration",8,8
"3405","fr","en","Mode de reconstitution et de dilution d’ INVANZ:","Instructions of how to reconstitute and dilute INVANZ:",8,8
"3406","fr","en","Mode et voie d’ administration","Method and route of administration",5,5
"3407","fr","en","Mode et voie d’ administration Avalez les gélules entières avec un verre d'eau.","Method and route of administration Swallow your capsules whole with a glass of water.",14,13
"3408","fr","en","Modification ou report de dose","VELCADE therapy should be withheld",5,5
"3409","fr","en","modifiée, pour des médicaments contenant de la loratadine;","amended, for loratadine containing medicinal products;",6,8
"3410","fr","en","Moins de 0,0005% de la dose administrée se retrouvait dans le sperme des sujets sains.","Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.",14,15
"3411","fr","en","Mois 12 Mois 24","Month 12 Month 24",4,4
"3412","fr","en","Mois/ année Après ouverture, utiliser dans les 3 heures.","EXP {month/ year} Once broached, use within 3 hours.",9,9
"3413","fr","en","Moisés ABASCAL ALONSO Yann LE CAM, vice-président Alastair KENT Eric ABADIE3 Gianmartino BENZI David LYONS4","Moisés ABASCAL ALONSO, Yann LE CAM, Vice-chairman, Alastair KENT",9,15
"3414","fr","en","Monotard contient du p-hydroxybenzoate de méthyle qui pourrait entraîner des réactions allergiques (éventuellement retardées).","Monotard contains methyl parahydroxybenzoate, which may cause allergic reactions (possibly",10,14
"3415","fr","en","MOTIFS DE LA MODIFICATION DES RESUMES DES CARACTERISTIQUES DU PRODUIT","SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET",8,10
"3416","fr","en","MOTIFS DE LA MODIFICATION DU RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT","GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS",9,10
"3417","fr","en","MOTIFS POUR UN RENOUVELLEMENT SUPPLÉMENTAIRE","GROUNDS FOR ONE ADDITIONAL RENEWAL",5,5
"3418","fr","en","Moyenne Semaine 4 Valeur de p*","Mean at Week 4 P-Value*",5,6
"3419","fr","en","MSD Polska Sp. z o. o.","MSD Polska Sp. z o. o.",6,6
"3420","fr","en","Muscles et os: douleurs dorsales, musculaires et articulaires.","Muscle and bone: back, muscle and joint pain.",8,8
"3421","fr","en","myalgie, douleurs musculo- squelettiques hématurie","Musculoskeletal, and connective tissue disorders",5,5
"3422","fr","en","Mycamine ne contient aucun conservateur.","Mycamine contains no preservatives.",4,5
"3423","fr","en","Myfenax comprimés pelliculés doit être manipulé avec précaution.","Myfenax film-coated tablets should be handled with care.",8,8
"3424","fr","en","Myocet est fourni sous forme d’un ensemble de trois flacons:","Myocet is supplied as a three-vial system:",7,10
"3425","fr","en","Myozyme peut être administré aux enfants, adolescents, adultes ou patients âgés.","Myozyme may be given to children, adolescents, adults or elderly patients.",11,11
"3426","fr","en","n EU/ 1/ 99/ 128/ 020","er EU/ 1/ 99/ 128/ 020",6,6
"3427","fr","en","N, N-Diéthyl-m-toluamide 1-Méthoxy-2-propyl-acétate Dimethyl sulfoxide 1, 8-Cinéole Gamma-hexalactone","N, N-Diethyl-m-toluamide 1-Methoxy-2-propyl-acetate Dimethyl sulfoxide 1, 8-Cineole Gamma-hexalactone",8,8
"3428","fr","en","N'arrêtez pas votre médicament sans l’avis de votre médecin.","Do not stop taking your medicine unless you have discussed this with your doctor first.",15,9
"3429","fr","en","n'ayant pas rattrapé leur retard de croissance à l'âge de 4 ans ou plus.","who failed to show catch-up growth by 4 years of age or later.",13,14
"3430","fr","en","N'injectez pas directement dans une veine.","Do not inject directly into a vein.",7,6
"3431","fr","en","N'ouvrez pas les gélules.","Do not open the capsules.",5,4
"3432","fr","en","N'utilisez aucun produit dont l'emballage a été ouvert.","Do not use opened materials.",5,8
"3433","fr","en","N’ allaitez pas si vous prenez Enviage.","Do not breast-feed if you are taking Enviage.",8,7
"3434","fr","en","n’ ayant pas montré de signes de la maladie peuvent rester infectés.","have shown signs of the disease can remain infected.",9,12
"3435","fr","en","N’ injectez jamais votre insuline directement dans une veine ou dans un muscle.","Never inject your insulin directly into a vein or muscle.",10,13
"3436","fr","en","N’ utilisez jamais Cetrotide","Do not use Cetrotide:",4,4
"3437","fr","en","N’ utilisez jamais NeuroBloc:","You should not receive / be given NeuroBloc:",8,4
"3438","fr","en","N’ utilisez jamais Rebetol","Do not take Rebetol",4,4
"3439","fr","en","N’ utilisez jamais une dose double.","If you forget to use Fentanyl-ratiopharm Do not under any circumstances use a double dose.",15,6
"3440","fr","en","N’ utilisez pas Actraphane","Do not use Actraphane",4,4
"3441","fr","en","N’ utilisez pas d’ eau, essuyez avec un mouchoir propre et sec.","Don ’ t use water to do this, wipe with a clean, dry tissue.",14,12
"3442","fr","en","N’ utilisez pas la solution si elle est opaque ou contient des particules.","not use if the solution is cloudy or contains particles.",10,13
"3443","fr","en","N’ utilisez pas Mixtard","Do not use Mixtard",4,4
"3444","fr","en","N’ utilisez que des aiguilles dont la compatibilité avec OptiSet a été démontrée.","Only use needles that have been approved for use with OptiSet.",11,13
"3445","fr","en","N’administrez jamais Humalog Mix25 par voie intraveineuse.","Under no circumstances should Humalog Mix25 be given intravenously.",9,7
"3446","fr","en","N’appliquez pas la crème plus d’une fois par jour.","Do not apply the cream more than once per day.",10,9
"3447","fr","en","N’arrêtez pas le traitement par Zeffix sans l’avis de votre médecin.","Do not stop treatment with Zeffix without your doctor’s advice.",10,11
"3448","fr","en","N’utilisez jamais {Nom de fantaisie} crème","Do not use < Invented Name > cream",8,6
"3449","fr","en","N’utilisez jamais Liprolog Pen","Do not use Liprolog Pen",5,4
"3450","fr","en","N’utilisez pas de Neupopeg restant dans une seringue préremplie.","Do not use any Neupopeg that is left in the syringe. o tn",13,9
"3451","fr","en","N’utilisez pas votre stylo si ce n’est pas le cas.","If it is not, do not use.",7,10
"3452","fr","en","Naglazyme est un traitement de substitution enzymatique.","Naglazyme is an enzyme replacement therapy.",6,7
"3453","fr","en","Nature et contenu de l’ emballage extérieur Plaquette thermoformée (PVC/ PCTFE/ Aluminium).","PVC/ PCTFE/ Aluminium blister.",4,12
"3454","fr","en","Nausées L’ effet indésirable rapporté le plus fréquemment était des nausées.","Nausea The most frequently reported adverse reaction was nausea.",9,11
"3455","fr","en","Nausées, vomissements, anorexie Diarrhée, constipation, douleurs abdominales, dyspepsie, stomatite, bouche sèche","Nausea, vomiting, anorexia Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth",11,11
"3456","fr","en","nausées/ vomissements diarrhée, dyspepsie/ brûlure d’ estomac","Uncommon: diarrhoea, dyspepsia/ heartburn",4,7
"3457","fr","en","Ne forcez pas car vous pourriez détacher l’aiguille.","Do not use too much force as the needle may loosen.",11,8
"3458","fr","en","Ne frottez pas le site d’ injection.","Do not rub the injection site.",6,7
"3459","fr","en","Ne l'administrez jamais par voie intraveineuse.","You should not administer it using a different administration route.",10,6
"3460","fr","en","Ne le donner jamais à quelqu’ un d'autre,","It may harm them, even if their",7,8
"3461","fr","en","Ne le donnez jamais à quelqu'un d'autre","It may harm them, even",5,7
"3462","fr","en","Ne le donnez jamais à quelqu’ un d'autre,","Do not pass it on to others.",7,8
"3463","fr","en","Ne le donnez jamais à quelqu’ un d’ autre,","It may harm them,",4,9
"3464","fr","en","Ne le trempez jamais, ne le lavez pas et ne le graissez pas.","Do not soak it, wash or lubricate it.",8,13
"3465","fr","en","Ne mélangez Lantus à aucune autre insuline ou à aucun autre médicament.","Do not mix Lantus with any other insulins or medicines.",10,12
"3466","fr","en","Ne modifiez pas votre régime alimentaire sans contacter votre médecin.","Do not change your diet without contacting your doctor.",9,10
"3467","fr","en","Ne pas administrer aux chevaux âgés de moins de 6 semaines.","Do not use in horses less than 6 weeks of age.",11,11
"3468","fr","en","Ne pas administrer aux prématurés ni aux nouveau-nés à terme.","Must not be given to premature babies or neonates.",9,10
"3469","fr","en","Ne pas administrer avec des substances oxydantes.","Do not administer with oxidant substances.",6,7
"3470","fr","en","Ne pas administrer en bolus intraveineux.","Do not use as an intravenous bolus.",7,6
"3471","fr","en","Ne pas administrer par voie orale ou aucune autre voie d’ administration.","Do not administer orally or via any other route.",9,12
"3472","fr","en","Ne pas agiter de façon excessive. e C","Read the package leaflet before use. al in",8,8
"3473","fr","en","Ne pas agiter la solution.","Do not shake the solution.",5,5
"3474","fr","en","Ne pas avaler le dessicant contenu dans le suremballage en aluminium.","Do not swallow the desiccant contained in the foil wrapper.",10,11
"3475","fr","en","Ne pas combiner avec d'autres médicaments vétérinaires.","Do not combine with other veterinary medicinal products.",8,7
"3476","fr","en","Ne pas congeler. en","Do not freeze. na",4,4
"3477","fr","en","NE PAS CONSERVER LE FLACON APRES RECONSTITUTION CAR LA SUSPENSION POURRAIT SEDIMENTER.","DO NOT STORE THE VIAL AFTER RECONSTITUTION OR THE SUSPENSION MAY SETTLE.",12,12
"3478","fr","en","Ne pas dépasser la dose prescrite par votre vétérinaire.","Do not exceed the stated dose prescribed by your veterinarian.",10,9
"3479","fr","en","Ne pas diluer dans des solutions de glucose, car elles entraînent l’ agrégation de la protéine.","Do not dilute with glucose solutions since these cause aggregation of the protein.",13,16
"3480","fr","en","NE PAS enlever le col blanc qui reste sur la seringue.","DO NOT remove the white collar that remains on the syringe.",11,11
"3481","fr","en","Ne pas fumer pendant la manipulation du médicament vétérinaire.","Do not smoke while handling the product.",7,9
"3482","fr","en","Ne pas fumer, manger ou boire durant la manipulation du produit.","This product is highly flammable; keep away from heat, sparks, open flame or other sources of ignition.",17,11
"3483","fr","en","Ne pas injecter par voie intravasculaire!","Do not inject intravascularly!",4,6
"3484","fr","en","Ne pas l'administrer par voie intramusculaire.","Do not administer intramuscularly.",4,6
"3485","fr","en","Ne pas l'utiliser, si la solution contient des particules ou si la solution n'est pas limpide.","Do not use if the solution contains particles or if the solution is not clear.",15,16
"3486","fr","en","Ne pas l’ utiliser si le dernier jour du mois indiqué est dépassé.","Do not use it if the date has passed the last day of the month shown.",16,13
"3487","fr","en","Ne pas manger, boire ou fumer lors de la manipulation du produit.","Do not eat, drink, or smoke when handling the product.",10,12
"3488","fr","en","Ne pas mélanger avec d'autres produits immunologiques.","Do not mix with any other medicinal product.",8,7
"3489","fr","en","Ne pas mélanger avec d’ autres médicaments.","Do not mix with any other vaccine.",7,7
"3490","fr","en","Ne pas mélanger de l'insuline en flacon avec de l'insuline en cartouche.","Do not mix insulin in vials with insulin in cartridges.",10,12
"3491","fr","en","Ne pas mettre au réfrigérateur.","Do not refrigerate or freeze.",5,5
"3492","fr","en","Ne pas mettre Insuman Comb 25 à côté du compartiment congélateur ou d’ une poche de congélation.","Do not put Insuman Comb 25 next to the freezer compartment or a freezer pack.",15,17
"3493","fr","en","Ne pas mettre Lantus à côté du compartiment congélateur ou d’ une poche de congélation.","Do not put Lantus next to the freezer compartment or a freezer pack.",13,15
"3494","fr","en","Ne pas placer Insulin Human Winthrop Comb 15 près du compartiment à glaçons ou d'une poche de congélation.","Do not put Insulin Human Winthrop Comb 15 next to the freezer compartment or a freezer pack.",17,18
"3495","fr","en","Ne pas placer les","Do not purge air through the needle.",7,4
"3496","fr","en","Ne pas placer les doigts sur la fenêtre.","cap from the Micro-Injection System.",5,8
"3497","fr","en","Ne pas prendre plus de 3 gélules à 60 mg par 24 heures.","No more than three 60 mg capsules should be taken in 24 hours.",13,13
"3498","fr","en","Ne pas réfrigérer la solution après reconstitution.","Do not refrigerate the solution after reconstitution.",7,7
"3499","fr","en","Ne pas retirer le dispositif de l’ emballage.","Do not remove the device from the package.",8,8
"3500","fr","en","Ne pas retourner, faire tourner, ni secouer le flacon.","Do not invert, swirl or shake the vial.",8,9
"3501","fr","en","Ne pas secouer le flacon.","Do not shake vial.",4,5
"3502","fr","en","Ne pas toucher le bout exposé de l’ aiguille.","Do not touch the exposed needle.",6,9
"3503","fr","en","Ne pas utiliser Aldurazyme après la date de péremption mentionnée sur l’ étiquette après EXP.","Do not use Aldurazyme after the expiry date which is stated on the label after the letters EXP.",18,15
"3504","fr","en","Ne pas utiliser après ce délai.","Do not use the cartridge after this time period.",9,6
"3505","fr","en","Ne pas utiliser après la date de péremption figurant sur l’ étiquette.","Do not use after the expiry date stated on the label.",11,12
"3506","fr","en","Ne pas utiliser après la date de péremption figurant sur la boîte et le flacon.","Do not use after the expiry date stated on the cardboard box and bottle after EXP:.",16,15
"3507","fr","en","Ne pas utiliser après la date de péremption figurant sur le flacon et la boîte.","Do not use after the expiry date stated on the vial and carton box after EXP:",16,15
"3508","fr","en","Ne pas utiliser après la date de péremption mentionnée sur l’étiquette et la boîte.","Do not use after the expiry date stated on the label and carton.",13,14
"3509","fr","en","Ne pas utiliser Bondronat si vous remarquez que la solution n'est pas limpide ou contient des particules.","Do not use Bondronat if you notice that the solution is not clear or contains particles.",16,17
"3510","fr","en","Ne pas utiliser CEFUROXIME AXETIL après la date de péremption mentionnée sur la boîte.","Do not use this medicine after the expiry date which is stated on the label and carton.",17,14
"3511","fr","en","Ne pas utiliser chez le lapin, le cochon d’ inde, le hamster ou la gerbille.","Do not use in rabbits, guinea pigs, hamsters or gerbils.",10,15
"3512","fr","en","Ne pas utiliser chez les animaux présentant une affection systémique sévère ou chez les animaux mourants.","Do not use in animals with severe systemic disease or in animals that are moribund.",15,16
"3513","fr","en","Ne pas utiliser chez les chiennes gestantes ou en lactation.","Do not use in pregnant or lactating bitches.",8,10
"3514","fr","en","Ne pas utiliser chez les chiennes gravides ou allaitantes.","Do not use in pregnant and lactating bitches.",8,9
"3515","fr","en","Ne pas utiliser chez les chiens pesant moins de 4 kg.","Do not use in dogs weighing less than 4 kg.",10,11
"3516","fr","en","Ne pas utiliser CRIXIVAN après la date de péremption mentionnée sur le flacon ou la boîte.","Do not use CRIXIVAN after the expiry date stated on the bottle or carton.",14,16
"3517","fr","en","Ne pas utiliser dans des pompes péristaltiques avec des sondes en silicone.","Do not use Insulin Human Winthrop Infusat in peristaltic pumps with silicone tubing.",13,12
"3518","fr","en","Ne pas utiliser Elaprase après la date de péremption mentionnée sur l’ étiquette après les lettres EXP.","Do not use Elaprase after the expiry date which is stated on the label after the letters EXP.",18,17
"3519","fr","en","Ne pas utiliser en cas d’ hypersensibilité au principe actif ou à l’ un des excipients.","Do not use in case of hypersensitivity to the active substance or to any of the excipients.",17,16
"3520","fr","en","Ne pas utiliser en cas de présence de particules ou de coloration.","Do not use if it is discoloured or if foreign particles are seen.",13,12
"3521","fr","en","Ne pas utiliser EVRA après la date de péremption mentionnée sur l’étiquette.","Do not use EVRA after the expiry date, which is stated on the label.",14,12
"3522","fr","en","Ne pas utiliser FORSTEO s’il est ou s'il a été congelé.","Do not use FORSTEO if it is, or has been, frozen.",11,11
"3523","fr","en","Ne pas utiliser Helixate NexGen 2000 UI si vous observez des particules ou si la solution est trouble.","Do not use Helixate NexGen 2000 IU if you notice any particles or the solution is cloudy.",17,18
"3524","fr","en","Ne pas utiliser Hycamtin après la date de péremption mentionnée sur la boîte.","Do not use Hycamtin after the expiry date which is stated on the carton.",14,13
"3525","fr","en","Ne pas utiliser IntronA après la date de péremption mentionée sur la boîte.","Do not use IntronA after the expiry date which is stated on the package.",14,13
"3526","fr","en","Ne pas utiliser la solution reconstituée si elle contient des particules ou si elle n’ est pas limpide.","Do not use the reconstituted solution if particle formation or discolouration is noticed.",13,18
"3527","fr","en","Ne pas utiliser la solution si vous constatez qu'elle est trouble ou qu'elle contient des particules.","Do not use if you notice that the solution is not clear or contains particles.",15,16
"3528","fr","en","Ne pas utiliser Lamictal après la date de péremption mentionnée sur la plaquette, la boîte ou le flacon.","Do not use Lamictal after the expiry date shown on the blisters, carton or bottle.",15,18
"3529","fr","en","Ne pas utiliser Nespo si vous pensez qu’il a été congelé.","Do not use Nespo if you think it has been frozen. a",12,11
"3530","fr","en","Ne pas utiliser NovoRapid après la date de péremption mentionnée sur l'étiquette et sur la boîte.","Do not use NovoRapid after the expiry date which is stated on the label and carton.",16,16
"3531","fr","en","Ne pas utiliser Posaconazole SP après la date de péremption mentionnée sur l’étiquette.","Do not use Posaconazole SP after the expiry date which is stated on the label.",15,13
"3532","fr","en","Ne pas utiliser Protaphane après la date de péremption mentionnée sur l’étiquette et sur la boîte.","Do not use Protaphane after the expiry date which is stated on the label and the carton.",17,16
"3533","fr","en","Ne pas utiliser Rasilez HCT après la date de péremption mentionnée sur la boîte.","Do not use Rasilez HCT after the expiry date which is stated on the carton.",15,14
"3534","fr","en","Ne pas utiliser REYATAZ après la date de péremption mentionnée sur l’ étiquette, l’ étuiou la plaquette thermoformée.","Do not use REYATAZ after the expiry date which is stated on the label, carton or blister.",17,18
"3535","fr","en","Ne pas utiliser simultanément avec des anti-inflammatoires non stéroïdiens (AINS) chez les chiens épileptiques.","Do not use in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) in dogs with a history of seizures.",17,14
"3536","fr","en","Ne pas utiliser Soliris après la date de péremption mentionnée sur l’ étiquette après « EXP ».","Do not use Soliris after the expiry date which is stated on the label after “EXP”.",16,17
"3537","fr","en","Ne pas utiliser Synagis après la date de péremption mentionnée sur l’ étiquette.","Do not use Synagis after the expiry date which is stated on the label.",14,13
"3538","fr","en","Ne pas utiliser Viraferon après la date de péremption mentionnée sur la boîte.","uth Do not use Viraferon after the expiry date which is stated on the package.",15,13
"3539","fr","en","Ne pas utiliser Xyrem après la date de péremption mentionnée sur le flacon.","Do not use Xyrem after the expiry date stated on the bottle.",12,13
"3540","fr","en","Ne pas utiliser ZYPREXA Injectable après la date de péremption indiquée sur l'emballage.","Do not use ZYPREXA Injection after the expiry date, which is stated on the carton.",15,13
"3541","fr","en","Ne pas utiliser, si vous remarquez un changement dans l’apparence de Viraferon.","Do not use Viraferon if you notice changes in the appearance of Viraferon.",13,12
"3542","fr","en","Ne passez pas la seringue au lave-vaisselle.","Do not put the syringe in a dishwasher.",8,7
"3543","fr","en","Ne prenez jamais {NOM DU PRODUIT} 20 mg","BEFORE YOU TAKE {PRODUCT NAME} 20 mg",7,8
"3544","fr","en","Ne prenez jamais AMMONAPS","Do not take AMMONAPS",4,4
"3545","fr","en","Ne prenez jamais Cystadane Si vous ou votre enfant êtes allergique (hypersensible) à la bétaïne.","Do not take Cystadane If you or your child are allergic (hypersensitive) to betaine.",14,15
"3546","fr","en","Ne prenez jamais Glivec:","Do not take Glivec:",4,4
"3547","fr","en","Ne prenez jamais Kinzalmono","Do not take Kinzalmono",4,4
"3548","fr","en","Ne prenez jamais Oprymea comprimés:","DO NOT take Oprymea",4,5
"3549","fr","en","Ne prenez jamais Vectibix","Do not use Vectibix",4,4
"3550","fr","en","Ne prenez jamais Zonegran:","Do not take Zonegran:",4,4
"3551","fr","en","Ne prenez jamais ZYPREXA VELOTAB:","BEFORE YOU TAKE ZYPREXA VELOTAB",5,5
"3552","fr","en","Ne prenez pas Avaglim.","Don’ t take Avaglim.",4,4
"3553","fr","en","Ne prenez pas Bonviva","Do not take Bonviva",4,4
"3554","fr","en","Ne prenez pas de dose double pour compenser la dose que vous avez oublié de prendre.","Do not take a double dose to make up for a forgotten dose.",13,16
"3555","fr","en","Ne prenez pas de dose double pour compenser la dose que vous avez oubliée de prendre..","Do not take a double dose to make up for forgotten individual doses.",13,16
"3556","fr","en","Ne prenez pas de double dose pour compenser la dose que vous auriez oublié de prendre.","Do not take a double dose to make up for the forgotten individual doses.",14,16
"3557","fr","en","Ne prenez pas de double dose pour compenser la dose que vous avez oublié de prendre.","Do not take a double dose to make up for a forgotten tablet.",13,16
"3558","fr","en","Ne prenez pas plus d’ un comprimé par jour.","Do not take more than one tablet each day.",9,9
"3559","fr","en","Ne prenez pas Tarceva en même temps que des aliments.","Do not take Tarceva with food.",6,10
"3560","fr","en","Ne prenez pas TRITAZIDE si l’ un ou l’ autre des cas ci-dessus vous concerne.","Do not take TRITAZIDE if any of the above apply to you.",12,15
"3561","fr","en","Ne prenez pas VIAGRA en même temps que d’ autres médicaments sauf si votre médecin vous l’ indique.","Do not take VIAGRA with other medicines unless your doctor tells you that you can.",15,18
"3562","fr","en","Ne prenez simplement pas cette dose puis reprenez le cours habituel de votre traitement.","Simply leave out that dose completely and then take your next dose at the right time.",16,14
"3563","fr","en","Ne préparer que la quantité d’ eau de boisson médicamenteuse nécessaire pour couvrir les besoins journaliers.","Only a sufficient amount of medicated drinking water should be prepared to cover the daily requirements.",16,16
"3564","fr","en","Ne reremplissez pas Actraphane 40 Penfill.","Do not refill Actraphane 40 Penfill.",6,6
"3565","fr","en","Ne reremplissez pas NovoRapid InnoLet.","Do not refill NovoRapid InnoLet.",5,5
"3566","fr","en","Ne retirez pas le stylo de son site d’injection e C","th pen from the injection site.",6,11
"3567","fr","en","Ne secouez pas le stylo et ne le laissez pas tomber.","Do not shake or drop the pre-filled pen. i dic",10,11
"3568","fr","en","Ne tentez pas de rattraper une dose oubliée en injectant deux doses la fois suivante.","Do not make up the missed dose by giving two doses the next time.",14,15
"3569","fr","en","Ne touchez pas l’extrémité de la seringue ou l’intérieur de l’embout.","Do not touch the syringe tip or the inside of the cap.",12,11
"3570","fr","en","Ne vous alarmez pas à la lecture de ces effets éventuels.","Do not be alarmed by this list of possible side effects.",11,11
"3571","fr","en","Ne vous injectez pas d’ insuline.","Do not inject insulin.",4,6
"3572","fr","en","Néanmoins, de nombreuses modifications ont été apportées au RCP.","However, several amendments to the SPC were introduced.",8,9
"3573","fr","en","Néanmoins, en dépit d'un éventuel effet sur les concentrations plasmatiques, ces interactions ne sont pas cliniquement significatives.","However, despite a possible effect on plasma levels, these interactions have not demonstrated clinical significance.",15,17
"3574","fr","en","Néanmoins, il n’ existe aucune indication d’ un impact significatif de ces variations sur le résultat clinique.","However, there is no indication of a relevant impact on the clinical outcome.",13,17
"3575","fr","en","Néanmoins, la stabilité chimique et physique en cours d’ utilisation a été démontrée pendant 24 heures à 25°C.","However, the chemical and physical in-use stability has been demonstrated for 24 hours at 25ºC.",15,18
"3576","fr","en","Nécrose au site d’ injection, tuméfaction au site d’ injection","Injection site necrosis, injection site mass",6,10
"3577","fr","en","Nederland Abbott BV Siriusdreef 51 NL-2132 WT Hoofddorp Tel: + 31 (0) 888 222 688","Siriusdreef 51 NL-2132 WT Hoofddorp Tel: + 31 (0) 888 222 688",12,15
"3578","fr","en","Nederland Allergan n. v.","Nederland Allergan n. v.",4,4
"3579","fr","en","Nederland Boehringer Ingelheim b. v.","Nederland Boehringer Ingelheim b. v.",5,5
"3580","fr","en","Nederland GlaxoSmithKline BV Tel: + 31 (0)30 69 38 100 nlinfo@gsk.com","Nederland GlaxoSmithKline BV Tel: + 31 (0)30 69 38 100 nlinfo@gsk.com",11,11
"3581","fr","en","Nederland GlaxoSmithKline BV Tel: + 31 (0)30 6938100","Tel: + 31 (0)30 6938100 nlinfo@gsk.com",6,8
"3582","fr","en","Nederland Lundbeck B. V.","Nederland Lundbeck B. V.",4,4
"3583","fr","en","Nederland Merck Sharp & Dohme BV Tel: +31 (0) 23 5153153 msdbvnl@merck.com","Nederland Merck Sharp & Dohme BV Tel: +31 (0) 23 5153153 msdbvnl@merck.com",12,12
"3584","fr","en","Nederland Pfizer bv Tel: +31 (0)10 406 4301","Nederland Pfizer bv Tel: +31 (0)10 406 43 01",9,8
"3585","fr","en","Nederland Sandoz B. V.","Nederland Sandoz B. V.",4,4
"3586","fr","en","Nederland UCB Pharma B. V.","Nederland UCB Pharma B. V.",5,5
"3587","fr","en","NEL (IC à 95%)","CHR (95% CI) NEL (95% CI)",6,4
"3588","fr","en","Neoclarityn 5 mg comprimés pelliculés","Neoclarityn 5 mg film-coated tablets",5,5
"3589","fr","en","Neoclarityn lyophilisat oral est indiqué chez l’ adulte et l’ adolescent (12 ans et plus).","Neoclarityn oral lyophilisate is indicated for adults and adolescents (12 years of age and older).",15,15
"3590","fr","en","NeoRecormon 2000 UI solution injectable en seringue préremplie","NeoRecormon 2000 IU solution for injection in pre-filled syringe",9,8
"3591","fr","en","NeoRecormon en cartouche ne doit être utilisé qu'avec le dispositif Reco-Pen.","NeoRecormon cartridge should only be used with Reco-Pen.",8,11
"3592","fr","en","NeoRecormon Multidose contient jusqu’ à 5,0 mg de phénylalanine/ flacon comme excipient.","NeoRecormon Multidose contains up to 5.0 mg phenylalanine/ vial as an excipient.",12,12
"3593","fr","en","NeoSpect est un médicament radiopharmaceutique utilisé dans un but diagnostic.","Product type NeoSpect is a radiopharmaceutical product used for diagnostic purposes.",11,10
"3594","fr","en","Néphrite interstitielle, altération de la fonction rénale, glycosurie","Nephritis interstitial, renal dysfunction, glycosuria",5,8
"3595","fr","en","Nerin House 26 Bridgeway Street Douglas IM1 1EL – Isle of Man Royaume-Uni","Rockspring Healthcare Ltd Nerin House 26 Bridgeway Street Douglas IM1 1EL – Isle of Man UK",16,13
"3596","fr","en","Nespo 40 µg injectable Darbepoetin alfa am","Darbepoetin alfa SC lp",4,7
"3597","fr","en","Nespo 60 microgrammes solution injectable en stylo prérempli Darbepoetin alfa","Nespo 60 micrograms solution for injection in a pre-filled pen Darbepoetin alfa",12,10
"3598","fr","en","Nespo est une solution stérile mais sans conservateur.","Nespo is a sterile but unpreserved product.",7,8
"3599","fr","en","Nettoyer le site d’ injection.","Clean the injection site.",4,5
"3600","fr","en","Nettoyez et désinfectez la peau où l’injection doit être faite.","Cleanse and disinfect the skin where the injection is to be made.",12,10
"3601","fr","en","Netvax est un vaccin.","Netvax is a vaccine.",4,4
"3602","fr","en","Neuf de ces 31 patients n'avaient pas obtenu de réponse au traitement d'induction antérieur (patients réfractaires).","Nine of these 31 patients failed to respond to prior induction (refractory patients).",13,16
"3603","fr","en","Neulasta est administré en une injection unique de 6 mg sous la e","Neupopeg is given as a single 6 mg injection under the skin in",13,13
"3604","fr","en","Neulasta est destiné aux adultes à partir de 18 ans.","Neulasta is for use in adults aged 18 and over.",10,10
"3605","fr","en","Neupro 2 mg/ 24 h dispositif transdermique Rotigotine","Neupro 2 mg/24 h transdermal patch Rotigotine",7,8
"3606","fr","en","Neupro 8 mg/ 24 h","Neupro 8 mg/24 h",4,5
"3607","fr","en","neutropénie/ agranulocytose, anémie hémolytique, leucopénie, thrombopénie.","cardiac arrhythmias aplastic anaemia, bone marrow depression, neutropenia/ agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia",13,6
"3608","fr","en","NEVANAC 1 mg/ ml collyre en suspension","NEVANAC 1 mg/ ml eye drops, suspension",7,7
"3609","fr","en","nevirapine) (utilisés pour le traitement du VIH);","Polska Pfizer Polska Sp. z o. o., Tel.: +48 22 335 61 00",13,7
"3610","fr","en","Névralgie, paresthésie, convulsions, thrombocytopénie transitoire.","Neuralgia, paraesthesia, convulsions, transient thrombocytopenia.",5,5
"3611","fr","en","Newbury Berkshire RG14 1JA Royaume-Uni","Ciproxin Ciproxin Ciproxin Ciproxin Ciproxin",5,5
"3612","fr","en","Nieremberg 10 ES-28002 Madrid, Espagne","Nieremberg 10 ES-28002 Madrid, Spain",5,5
"3613","fr","en","niveau des muscles et du foie, et améliore l'utilisation du pyruvate.","and the liver, and improves pyruvate utilisation.",7,11
"3614","fr","en","Nobilis Influenza H5N2 émulsion pour injection pour les poules.","Nobilis Influenza H5N2 emulsion for injection for chickens",8,9
"3615","fr","en","Nobivac Bb pour chats.","Nobivac Bb for cats",4,4
"3616","fr","en","Nom de fantaisie Hepsera Hepsera","Invented name Hepsera Hepsera",4,5
"3617","fr","en","NOM DU TITULAIRE DE L'AUTORISATION DE MISE SUR LE MARCHE","NAME OF THE MARKETING AUTHORISATION HOLDER",6,10
"3618","fr","en","Nom et adresse d fabricant responsable de la libération des lots","Name and address of the manufacturer responsible for batch release",10,11
"3619","fr","en","Nom et adresse des fabricants de la substance active d'origine biologique","Name and address of the manufacturer of the biological active substance",11,11
"3620","fr","en","Nom et adresse du (des) fabricant(s) responsable(s) de la libération des lots","and address of the manufacturer responsible for batch release",9,12
"3621","fr","en","Nom et adresse du fabricant du(es) principe(s) actif(s) d'origine biologique","Name and address of the manufacturer of the biological active substance(s)",11,10
"3622","fr","en","Nom et adresse du fabricant du(es) principe(s) actif(s) d’ origine biologique","Name and address of the manufacturers of the biological active substance(s)",11,11
"3623","fr","en","Nom et adresse du(des) fabricant(s) des principes actifs d'origine biologique","Name and address of the manufacturer(s) of the biological active substance(s)",11,10
"3624","fr","en","Nombre d’ épisodes d’ incontinence par impériosité par 24 heures","Number of urge incontinence episodes per 24 hours",8,10
"3625","fr","en","Nombre de journées de réunion 2000-2002","Number of meeting days 2000-2002",5,6
"3626","fr","en","Nombre de journées de réunion à l'EMEA Nombre de délégués remboursés","Translations of the agreed SPC, labelling",6,11
"3627","fr","en","Nombres de 1 à 14 Symbole « soleil » Symbole « lune »","Numbers 1 to 14 sun as symbol moon as symbol",10,13
"3628","fr","en","non connue (ne pouvant pas être estimée à partir des données disponibles)","Abnormal liver function tests GGTP increased Photosensitivit y reaction Face oedema Rash",12,12
"3629","fr","en","Non connue* Affections gastro-intestinales:","Not known* Gastrointestinal disorders:",4,4
"3630","fr","en","non hémodialysés, afin d’ éviter de ponctionner des veines périphériques.","haemodialysis to avoid puncture of peripheral veins. in",8,10
"3631","fr","en","Norge Alcon Norge AS + 47 23 25 25 50","Norge Alcon Norge AS +47 23 25 25 50",9,10
"3632","fr","en","Norge Biogen Idec Norway AS +47 23 00 52 50","Norge Biogen Idec Norway AS +47 23 00 52 50",10,10
"3633","fr","en","Norge Deutschland Sandoz AS Sandoz Pharmaceuticals GmbH Jernbaneveien 4 Raiffeisenstr.","Deutschland Sandoz Pharmaceuticals GmbH Raiffeisenstr.",5,10
"3634","fr","en","Norge GE Healthcare AS Nycoveien 1-2 NO-0401 Oslo Tlf: + 47 23 18 50 50","Norge GE Healthcare AS Nycoveien 1-2 NO-0401 Oslo Tlf: + 47 23 18 50 50",15,15
"3635","fr","en","Norge JANSSEN-CILAG A. S.","Norge JANSSEN-CILAG A. S.",4,4
"3636","fr","en","Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd. no","Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd. no",12,12
"3637","fr","en","Norge Orion Pharma AS Gjerdrumsvei 8 Pb.","Norge Orion Pharma AS Gjerdrumsvei 8 Pb.",7,7
"3638","fr","en","Norge Sandoz AS Jernbaneveien 4 N-1400 Ski Tlf: +47 64913000","Norge Sandoz AS Jernbaneveien 4 N-1400 Ski Tlf: +47 64913000",10,10
"3639","fr","en","Norge Teva Sweden AB Tlf: +46 42 12 11 00","Norge Teva Sweden AB Tlf: +46 42 12 11 00",10,10
"3640","fr","en","Norma Hellas Ae Menandrou 54 Athens 10431 Grèce","Norma Hellas Ae Menandrou 54 Athens 10431 Greece",8,8
"3641","fr","en","Normalement, l’ organisme produit une protéine qui bloque les effets nocifs de l’ interleukine-1.","Normally, your body produces a protein that blocks the harmful effects of interleukin-1.",13,14
"3642","fr","en","Normalement, vous serez sous observation pendant toute la durée de la perfusion et jusqu’à 20 minutes après.","You will usually be observed during the whole infusion and for at least 20 minutes thereafter.",16,17
"3643","fr","en","Norvir a été étudié lors de deux études principales, ayant suivi 1 446 patients.","Norvir has been studied in two main studies, involving 1,446 patients.",11,14
"3644","fr","en","Note for Guidance on the Clinical investigation of recombinant factor VIII and IX products Adoptée en octobre 2000","Treatment of glycogen storage disease type II",7,18
"3645","fr","en","Note for guidance on the conduct of pharmacovigilance for centrally authorised products","Note for guidance on the conduct of pharmacovigilance for centrally authorised products",12,12
"3646","fr","en","NOTICE 'e st pl us au to ris é NOTICE:","ng er au th or is ed PACKAGE LEAFLET:",9,10
"3647","fr","en","Notifications spontanées Depuis la commercialisation de BYETTA, les effets indésirables supplémentaires suivants ont été rapportés:","Spontaneous reports Since market introduction of BYETTA, the following additional adverse reactions have been reported:",15,15
"3648","fr","en","Nourrissons âgés de plus de 1 an et enfants âgés de 2 à 12 ans:","Infants 1 year of age and older and children 2 to 12 years of age:",15,15
"3649","fr","en","Nouvelles demandes dans le système centralisé et avis scientifiques","New applications under the centralised system and scientific advice",9,9
"3650","fr","en","Nouvelles questions émergentes en 2003 et leurs implications en termes de charge de travail:","Implementation of the EU telematics strategy",6,14
"3651","fr","en","Novartis Animal Health GmbH, Tel: +43-(0)5338 2000","Novartis Animal Health GmbH, Tel: +43-(0)5338 2000",7,7
"3652","fr","en","Novartis Europharm Limited Wimblehurst Road Horsham West Sussex, RH12 5AB Royaume-Uni","Novartis Europharm Limited Wimblehurst Road Horsham West Sussex, RH12 5AB United Kingdom",12,11
"3653","fr","en","Novartis Finland Oy, Metsänneidonkuja 10, 02130 Espoo, Finlande","Novartis Finland Oy, Metsänneidonkuja 10, 02130 Espoo, Finland",8,8
"3654","fr","en","Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Allemagne","Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany",8,8
"3655","fr","en","Novartis Pharma S. A. S.","Novartis Pharma S. A. S.",5,5
"3656","fr","en","Novartis Vaccines and Diagnostics GmbH and Co.","Novartis Vaccines and Diagnostics GmbH and Co.",7,7
"3657","fr","en","Novo Nordisk A/ S Novo Allé DK-2880 Bagsværd Danemark","Novo Nordisk A/ S Novo Allé",6,9
"3658","fr","en","Novo Nordisk Production SAS 45, avenue d’ Orléans F-28002 Chartres France","Novo Nordisk Production SAS 45, Avenue d’ Orléans F-28002 Chartres France",11,11
"3659","fr","en","NovoMix 30 est administré par voie sous-cutanée au niveau de la cuisse ou la paroi abdominale.","NovoMix 30 is administered subcutaneously in the thigh or in the abdominal wall.",13,16
"3660","fr","en","NovoMix 50 ne doit pas être utilisé s’ il a été congelé.","NovoMix 50 which has been frozen must not be used.",10,12
"3661","fr","en","NovoMix 70 doit être administré immédiatement avant ou après un repas.","NovoMix 70 should be administered in immediate relation to a meal.",11,11
"3662","fr","en","NovoNorm n’ a pas été étudié dans ces tranches d’ âge.","It has not been studied in these age groups.",9,11
"3663","fr","en","NovoRapid (insuline asparte) peut être utilisé chez la femme enceinte.","NovoRapid (insulin aspart) can be used in pregnancy.",8,10
"3664","fr","en","NovoRapid InnoLet est réservé à l’ utilisation par un seul patient.","NovoRapid InnoLet is for use by one person only.",9,11
"3665","fr","en","NovoRapid NovoLet est réservé à l’ utilisation par un seul patient.","NovoRapid NovoLet is for use by one person only.",9,11
"3666","fr","en","NovoSeven 2 mg (100 KUI) poudre et solvant pour solution injectable eptacog alfa (activé)","NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection eptacog alfa (activated)",15,14
"3667","fr","en","Nowogrodzka 68 PL-02-014 Warsaw Tel: +48 22 504 06 41","Nowogrodzka 68 PL-02-014 Warsaw Tel: +48 22 504 06 41",10,10
"3668","fr","en","Noyau du comprimé Lactose monohydraté Hyprolose Crospovidone Cellulose microcristalline Stéarate de magnésium","Tablet core Lactose monohydrate Hyprolose Crospovidone Microcrystalline cellulose Magnesium stearate",10,12
"3669","fr","en","Noyau Mannitol, Hydroxypropylcellulose, Hydroxypropylcellulose faiblement substitutée (LH-21), Hydroxypropylcellulose faiblement substitutée (LH-11), Talc, Macrogol 6000, Huile de ricin hydrogénée","Mannitol Hydroxypropylcellulose Low-substituted Hydroxypropyl Cellulose (LH-21) Low-substituted Hydroxypropyl Cellulose (LH-11) Talc Macrogol 6000 Castor oil, hydrogenated",16,18
"3670","fr","en","Nplate est une poudre à reconstituer en solution injectable.","Nplate is a powder that is made up into a solution for injection.",13,9
"3671","fr","en","NUMERO DU LOT DE FABRICATION","MANUFACTURER’ S BATCH NUMBER",4,5
"3672","fr","en","NUMÉRO DU LOT DE FABRICATION 'es","MANUFACTURER’ S BATCH NUMBER no",5,6
"3673","fr","en","Numéro EMEA Nom inventé","EMEA Number Invented Name",4,4
"3674","fr","en","NUMERO(S) AU REGISTRE COMMUNAUTAIRE DES MEDICAMENTS","NUMBER IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS",8,6
"3675","fr","en","NUMERO(S) D’ AUTORISATION DE MISE SUR LE MARCHE","MARKETING AUTHORISATION NUMBER (S)",4,8
"3676","fr","en","NUMÉRO(S) D’ AUTORISATION DE MISE SUR LE MARCHÉ","MARKETING AUTHORISATION NUMBERS no",4,8
"3677","fr","en","Nycomed Danmark ApS Langebjerg 1, 4000 Roskilde Danemark","Nycomed Danmark ApS Langebjerg 1, 4000 Roskilde Denmark",8,8
"3678","fr","en","obstruction Hyperplasie bénigne de la prostate avec obstruction concomitante du flux urinaire, infections","Benign prostatic hyperplasia and concomitant urinary outflow obstruction, chronic urinary tract infections or bladder stones",15,13
"3679","fr","en","OCTEGRA 400 mg, 400 mg comprimé pelliculé","OCTEGRA 400 mg, comprimé pelliculé",5,7
"3680","fr","en","Œ dèmes (excès de liquide dans les tissus, entraînant un gonflement).","Rare (occur in more than 1 in 10000 patients but less than 1 in 1000 patients)",16,11
"3681","fr","en","Oedème / Prurit / Urticaire.","Oedema / Pruritus / Urticaria.",5,5
"3682","fr","en","Oedème périphérique Perte de poids, prise de poids","weight decrease, weight increase",4,8
"3683","fr","en","Oedèmes Cardiovasculaire périphériques, palpitation et douleur thoracique.","peripheral edema, palpitation and chest pain.",6,7
"3684","fr","en","Officina Farmaceutica Fiorentina S. R. L.","Officina Farmaceutica Fiorentina S. R. L.",6,6
"3685","fr","en","OLANZAPINE MYLAN 20 mg, comprimés pelliculés Olanzapine","Olanzapine Mylan 20 mg film-coated tablets Olanzapine",7,7
"3686","fr","en","Olanzapine Neopharma 2,5 mg comprimés enrobés","Olanzapine Neopharma 2.5 mg coated tablets",6,6
"3687","fr","en","Olanzapine Teva est un médicament dont le principe actif est l’ olanzapine.","Olanzapine Teva is a medicine containing the active substance olanzapine.",10,12
"3688","fr","en","Omnipharm Ltd The Spire Egypt Road Nottingham NG7 7GD Royaume-Uni","Omnipharm Ltd The Spire Egypt Road Nottingham NG7 7GD UK",10,10
"3689","fr","en","Omnitrope est une solution injectable limpide et incolore.","Omnitrope is a clear and colourless solution.",7,8
"3690","fr","en","On a montré que Fuzeon n'interagit pas avec vos autres médicaments anti-VIH ni avec la rifampicine (un antibiotique).","Fuzeon has been shown not to interact with your other anti-HIV medicines or rifampicin (an antibiotic).",16,18
"3691","fr","en","On a observé des effets hépatiques chez le rat suite à une administration chronique de clofarabine.","Hepatic effects were observed in rats following chronic administration of clofarabine.",11,16
"3692","fr","en","On a observé une incidence de 12% des sténoses oesophagiennes pendant la première cure de traitement.","An occurrence rate of 12% for oesophageal strictures was observed during the first course of treatment.",16,16
"3693","fr","en","On dispose d’ informations limitées sur la pharmacocinétique de la glucosamine.","The available information on the pharmacokinetics of glucosamine is limited.",10,11
"3694","fr","en","On ignore encore quel est le degré de pertinence clinique de ces observations.","The clinical relevance of these findings is still unknown.",9,13
"3695","fr","en","On ignore si ces effets peuvent également se produire après l’ injection d’ une dose unique.","It is not known whether these effects can also be induced by a single administration.",15,16
"3696","fr","en","On ignore si Intrinsa augmente le risque de cancer du sein.","It is not known whether Intrinsa increases the risk of breast cancer.",12,11
"3697","fr","en","On ne connaît pas les éventuelles interactions entre l’ infliximab et les autres principes actifs.","Nothing is known regarding possible interactions between infliximab and other active substances.",12,15
"3698","fr","en","On ne dispose d’ aucune donnée concernant les patients présentant une insuffisance hépatique sévère (score Child- Pugh C).","No data are available in patients with severe hepatic insufficiency (Child-Pugh Class C).",13,18
"3699","fr","en","On ne sait pas si ADENURIC passe dans le lait maternel.","It is not known if ADENURIC may pass into human breast milk.",12,11
"3700","fr","en","On ne sait pas si l’ abatacept, la substance active, passe dans le lait maternel.","It is not known whether abatacept, the active ingredient, passes into human milk.",13,15
"3701","fr","en","On ne sait pas si la sitagliptine est dialysable par dialyse péritonéale.","It is not known if sitagliptin is dialyzable by peritoneal dialysis.",11,12
"3702","fr","en","On ne sait pas si la sitagliptine est excrétée dans le lait maternel humain.","It is not known whether sitagliptin is excreted in human milk.",11,14
"3703","fr","en","On peut également s’ attendre à une exposition augmentée au nilotinib avec les inhibiteurs modérés du CYP3A4.","Increased exposure to nilotinib might also be expected with moderate CYP3A4 inhibitors.",12,17
"3704","fr","en","On vous a prescrit un dosage à 50 mg d’Enbrel.","You have been prescribed a 50 mg strength of Enbrel.",10,10
"3705","fr","en","ont des non-consolidations résultant de fractures pathologiques, de tumeurs ou maladies osseuses métaboliques;","have a non-union resulting from pathological fractures, metabolic bone disease or tumours;",12,13
"3706","fr","en","OPATANOL a été aussi efficace que le cromolyne de sodium et que la lévocabastine.","OPATANOL was as effective as cromolyn sodium and as levocabastine.",10,14
"3707","fr","en","Opgenra est un médicament contenant le principe actif eptotermine alfa.","Opgenra is a medicine that contains the active substance eptotermin alfa.",11,10
"3708","fr","en","OPi Orphan Pharma International","OPi Orphan Pharma International",4,4
"3709","fr","en","Oprymea 1,1 mg comprimés Pramipexole","Oprymea 1.1 mg tablets Pramipexole",5,5
"3710","fr","en","Optimark peut être utilisé au cours de l’allaitement.","Optimark can be used during breast-feeding.",6,8
"3711","fr","en","OptiSet doit être utilisé tel que recommandé dans ces instructions d’ utilisation (voir rubrique 6.6).","OptiSet has to be used as recommended in these Instructions for Use (see section 6.6).",15,15
"3712","fr","en","Optisulin est une insuline d'effet prolongé.","Optisulin is a long-acting insulin.",5,6
"3713","fr","en","OPTRUMA reproduit certains des effets bénéfiques des œ strogènes après la ménopause.","OPTRUMA mimics some of the helpful effects of oestrogen after the menopause.",12,12
"3714","fr","en","ORACEA 40 mg (N = 142)","ORACEA 40 mg (N = 142)",6,6
"3715","fr","en","ORENCIA 250 mg, poudre pour solution à diluer pour perfusion.","ORENCIA 250 mg powder for concentrate for solution for infusion.",10,10
"3716","fr","en","ORENCIA si vous présentez une","if you have severe infection. - You should be screened for certain infections prior to treatment with",17,5
"3717","fr","en","Orfadin est utilisé pour traiter la tyrosinémie de type 1 (HT-1), une maladie rare de l’ enfance.","Orfadin is used to treat hereditary tyrosinemia type 1 (HT-1), a rare childhood disease.",14,17
"3718","fr","en","Organigramme de l’ EMEA","Organigram of the EMEA",4,4
"3719","fr","en","Organisation de formations pour jeunes diplômés","Cost of organising graduate traineeships with the Agency",8,6
"3720","fr","en","Organisme en général: frissons, sensibilité à la lumière du soleil, perte de poids.","Most of these side effects are likely to go away with continued treatment.",13,13
"3721","fr","en","Organon Kloosterstraat 6 P. O.","Organon Kloosterstraat 6 P. O.",5,5
"3722","fr","en","Organon, Kloosterstraat 6, Postbus 20, 5340 BH Oss, Pays-Bas","Organon, Kloosterstraat 6, Postbus 20, 5340 BH Oss, The Netherlands",10,9
"3723","fr","en","Origine ethnique - Les différences de pharmacocinétique liées à l’ ethnie n’ ont pas été étudiées","ris Gender - No gender differences were observed after adjustment for body weight.",13,16
"3724","fr","en","Orion Corporation Tel: +358 10 4261","Portugal Orion Corporation Tel: +358 10 4261",7,6
"3725","fr","en","Orion Oyj ORION PHARMA ELÄINLÄÄKKEET","Suomi/Finland Orion Oyj ORION PHARMA ELÄINLÄÄKKEET Tengströminkatu 8, PL/PB 425",10,5
"3726","fr","en","Orionintie 1 FIN-02200 Espoo Finlande","Orion Corporation Orionintie 1 FIN-02200 Espoo Finland",7,5
"3727","fr","en","Oseltamivir 75 mg deux fois par jour","Oseltamivir 75 mg bid",4,7
"3728","fr","en","OSSEOR contient de l’ aspartam, pouvant être nocif pour les patientes atteintes de phénylcétonurie.","OSSEOR contains a source of phenylalanine, which may be harmful for people with phenylketonuria.",14,14
"3729","fr","en","Österreich Am Euro Platz 2 A-1120 Wien Tel: + 43-(0)1 813 12 31","Österreich Am Euro Platz 2 A-1120 Wien Tel: + 43-(0) 1 813 12 31",14,13
"3730","fr","en","Österreich Badener Strasse 23 A-2514 Traiskirchen Tel: + 43-(0)2252 502-0","Badener S trasse 23 A-2514 Traiskirchen lon",7,10
"3731","fr","en","Österreich Eesti Magnum Veterinaaria AS Vae 16 EE-76401 Laagri Tel: +372 650 1920","Eesti Magnum Veterinaaria AS Vae 16 EE-76401 Laagri Tel: +372 650 1920",12,13
"3732","fr","en","Österreich Eesti Novartis Pharma GmbH Novartis Pharma Services Inc.","Eesti Novartis Pharma Services Inc.",5,9
"3733","fr","en","Österreich Eli Lilly Ges. m.b.H.","Österreich Eli Lilly Ges. m.b.H.",5,5
"3734","fr","en","Österreich MERCK Gesellschaft mbH Tel: +43 1 57 6000","MERCK Gesellschaft mbH Tel: +43 1 57 6000",8,9
"3735","fr","en","Österreich Merck Sharp & Dohme G.m.b.H.","Merck Sharp & Dohme G.m.b.H.",5,6
"3736","fr","en","Österreich Nycomed Austria GmbH Lemböckgasse 49 A-1230 Wien Tel: +43 1601 340","Österreich Nycomed Austria GmbH Lemböckgasse 49 A-1230 Wien Tel: +43 1601 340",12,12
"3737","fr","en","Österreich Roche Austria GmbH Tel: +43 (0) 1 27739","Österreich Roche Austria GmbH Tel: +43 (0) 1 27739",9,9
"3738","fr","en","Österreich Servier Austria GmbH Tel: +43 (1) 524 39 99","Tel: +43 (1) 524 39 99",6,10
"3739","fr","en","Österreich Takeda Pharma Ges m. b. H.","Österreich Takeda Pharma Ges m. b. H.",7,7
"3740","fr","en","Österreich UCB Pharma GmbH Tel: +43 / (0) 129180-0","UCB Pharma GmbH Tel: +43 / (0) 129180-0",8,9
"3741","fr","en","Otite, infection mycosique (les","Ear infection, fungal infection (fungal infections were primarily nonsystemic)",9,4
"3742","fr","en","ou chirurgie majeure du genou.","d Phase II and III clinical studies.",7,5
"3743","fr","en","Ouverture de l’ ampoule de solvant:","Opening the ampoule of solvent:",5,6
"3744","fr","en","OVITRELLE 250 MICROGRAMMES, AMPOULE ET FLACON DE SOLVANT","OVITRELLE 250 MICROGRAMS s, SOLVENT VIALS AND AMPOULES",8,8
"3745","fr","en","Oxyde de fer (noir) (E172) Propylène glycol Hypromellose","Iron oxide (black) (E172) Propylene glycol Hypromellose",7,8
"3746","fr","en","Oxyde de fer noir synthétique (E 172) Oxyde de fer jaune synthétique (E172) Propylène glycol Shellac.","Black Iron Oxide-Synthetic (E172) Yellow Iron Oxide- Synthetic (E172) Propylene glycol Shellac.",12,16
"3747","fr","en","Oxyglobin doit être administré en conditions d'asepsie par perfusion intraveineuse à l’ aide d’ un cathéter standard.","Oxyglobin should be administered using aseptic technique via a standard intravenous infusion set and catheter.",15,17
"3748","fr","en","p. m. p. m.","p. m. p. m.",4,4
"3749","fr","en","Pack de 6 flacon","Pack of 6 bottles",4,4
"3750","fr","en","Paclitaxel/ Avastin Paclitaxel (n=229) (n=243)","Paclitaxel/ Avastin Paclitaxel (n=229) (n=243)",5,5
"3751","fr","en","Page 2/ 2 ©EMEA 2008","Page 2/ 2 ©EMEA 2008",5,5
"3752","fr","en","Page 2/ 3 © EMEA 2008 Pourquoi Masivet a -t-il été approuvé?","Why has Masivet been approved?",5,12
"3753","fr","en","Pallagi Street 13 H-4042 Debrecen Hongrie","Pallagi Street 13 H-4042 Debrecen Hungary",6,6
"3754","fr","en","Palonosétron (sous forme de chlorhydrate).","Aloxi 250 micrograms solution for injection Palonosetron (as hydrochloride) IV use",11,5
"3755","fr","en","Pancréatite* Colite ischémique*, colite ulcéreuse* Trouble parodontique, trouble dentaire","Pancreatitis* Ischaemic colitus*, ulcerative colitus* Periodontal disorder, dental disorder",9,9
"3756","fr","en","Pandemrix se présente en deux flacons:","Pandemrix consists of two containers:",5,6
"3757","fr","en","Par ailleurs, il vous faudra un collecteur réservé à l’élimination des seringues et aiguilles usagées.","In addition you will need a disposal unit for used syringes and needles.",13,15
"3758","fr","en","Par ailleurs, les propriétés suivantes ont été mises en évidence.","In addition, the following actions have been demonstrated.",8,10
"3759","fr","en","Par conséquent le traitement par < RENITEC > n’ est pas recommandé.","Treatment with< Renitec > is therefore not recommended.",8,12
"3760","fr","en","Par conséquent, aucun ajustement posologique n’ est nécessaire chez les patients âgés.","Therefore no adjustment of the dose is necessary for elderly patients.",11,12
"3761","fr","en","Par conséquent, aucune adaptation posologique n’ est nécessaire en fonction du sexe.","Therefore, no dosage adjustment based on gender is necessary.",9,12
"3762","fr","en","Par conséquent, aucune recommandation particulière sur la posologie n’ est requise pour ces patients.","No specific dose recommendation is necessary in the elderly.",9,14
"3763","fr","en","Par conséquent, ce médicament ne doit pas être utilisé chez la femme enceinte.","This medicinal product should, therefore, not be administered to pregnant women.",11,13
"3764","fr","en","Par conséquent, ce produit est contre-indiqué pendant la grossesse.","Therefore, this medicinal product should not be used during pregnancy.",10,9
"3765","fr","en","Par conséquent, des précautions appropriées devront continuer à être utilisées.","Appropriate precautions should continue to be employed.",7,10
"3766","fr","en","Par conséquent, il est recommandé de ne pas administrer d’ autres vaccins en même temps que celui -ci.","It is therefore recommended that no other vaccines should be administered concurrently or simultaneously.",14,18
"3767","fr","en","Par conséquent, l'administration de XERISTAR est déconseillée chez les enfants et les adolescents (voir rubrique 4.4).","Therefore, administration of XERISTAR to children and adolescents is not recommended (see section 4.4).",14,16
"3768","fr","en","Par conséquent, l'administration simultanée de ces deux produits devra être entreprise avec prudence (voir rubrique 4.4).","Therefore, concomitant use should be undertaken with caution (see section 4.4).",11,16
"3769","fr","en","Par conséquent, l’ administration à ces patients n’ est pas recommandée.","Therefore use in these patients is not recommended.",8,11
"3770","fr","en","Par conséquent, l’ association de valsartan et d’ un IEC est déconseillée.","Therefore, the combination of valsartan with an ACE inhibitor is not recommended.",12,12
"3771","fr","en","Par conséquent, l’ utilisation d’ ECALTA pendant la grossesse est déconseillée.","Therefore Ecalta is not recommended during pregnancy.",7,11
"3772","fr","en","Par conséquent, la bonne adaptation de la dose d’ hormone somatotrope devra être contrôlée tous les 6 mois.","The accuracy of the growth hormone dose should therefore be controlled every 6 months.",14,18
"3773","fr","en","Par conséquent, le risque potentiel pour l’ espèce humaine n’ est pas connu.","Therefore, the potential risk for humans is unknown.",8,13
"3774","fr","en","Par conséquent, un niveau d’activité similaire à celui de 1999 est proposé.","Therefore a similar level of activity to 1999 is proposed.",10,12
"3775","fr","en","Par contre, la constipation ne disparaît pas si le traitement est poursuivi.","Constipation, on the other hand, does not stop if treatment continues.",11,12
"3776","fr","en","Par dose de 2 ml:","e sp Per dose of 2 ml:",7,5
"3777","fr","en","Par exemple, si vous pesez 60 kg, votre dose journalière sera de 60 MU.","For example, if you weigh 60 kg, your daily dose will be 60 MU.",14,14
"3778","fr","en","Par mesure de précaution, l'allaitement devra être interrompu au cours d'un traitement par le lacosamide.","For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.",11,15
"3779","fr","en","par RoActemra, votre médecin vérifiera si vous présentez les signes et les symptômes de la tuberculose.","of tuberculosis before starting RoActemra.",5,16
"3780","fr","en","Paramètres biologiques chez les patients co-infectés VHC-VIH:","Laboratory values for HCV/ HIV co-infected patients:",7,7
"3781","fr","en","Parareg 30 mg, comprimé pelliculé.","Parareg 30 mg film-coated tablets.",5,5
"3782","fr","en","parentérale; sans ou avec 1 seringue, 2 aiguilles et 1 tampon nettoyant.","syringe, 2 injection needles and 1 cleansing swab;",8,12
"3783","fr","en","Paresthésie, insomnie, dépression, confusion, hypoesthésie, nervosité, bouche sèche, amnésie","Dizziness Paraesthesia, insomnia, depression, confusion, hypoaesthesia, nervousness, dry mouth, amnesia",10,9
"3784","fr","en","Parfois il n’y aucun symptômes et le problème est révélé seulement par les tests sanguins.","Sometimes there are no symptoms of this and the problem appears only in blood tests.",15,15
"3785","fr","en","Parfois, les symptômes débutent plus de 6 heures après le début de la perfusion.","Occasionally, symptoms start later than six hours after the infusion begins.",11,14
"3786","fr","en","Parke-Davis GmbH Pfizerstrasse 1","Parke-Davis GmbH Pfizerstrasse 1",4,4
"3787","fr","en","Parkvägen 2A, 14tr S-169 26 Solna Tel: + 46 8 51 49 43 30","Sverige GE Healthcare AB Parkvägen 2A, 14tr S-169 26 Solna Tel: + 46 8 51 49 43 30",18,14
"3788","fr","en","Parlez -en avec votre médecin.","Please discuss this with your doctor.",6,5
"3789","fr","en","Parmi ces 7 patients, 3 présentaient une infection oculaire, 1 une infection sinusale et 3 une infection disséminée.","Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection.",15,18
"3790","fr","en","Parmi les 492 patients inclus avec une réponse prolongée, seuls 12 patients ont rechuté pendant cette étude.","These three main classes are themselves not homogeneous and may contain several different molecular species of interferon.",17,17
"3791","fr","en","Parocetan 20 mg –","Parocetan 20 mg – Filmtabletten",5,4
"3792","fr","en","Partie A Partie B Avis formulés pour un médicament","Part A Part B Opinions adopted by product",8,9
"3793","fr","en","Pas de condition particulière de conservation.","The veterinary medicinal product does not require any special storage conditions.",11,6
"3794","fr","en","Pas de nausées significatives (VAS** max < 25 mm sur une échelle de 0 à 100 mm)","No Significant Nausea (maximum VAS < 25 mm on a scale of 0-100 mm)",14,17
"3795","fr","en","Pas de précautions particulières de conservation","There are no special storage instructions.",6,6
"3796","fr","en","Pas de précautions particulières de conservation.","No special precautions for storage.",5,6
"3797","fr","en","pas listé dans cette notice, appelez votre médecin ou votre pharmacien.","please tell your doctor or pharmacist.",6,11
"3798","fr","en","Paseo del Club Deportivo n° 1 Bloque 14-2a E-28223 Pozuelo de Alarcón, Madrid Tel: +34 91 4952700","Paseo del Club Deportivo n° 1 Bloque 14-2a E-28223 Pozuelo de Alarcón, Madrid Tel: +34 91 4952700",17,17
"3799","fr","en","Passage à Insulin Human Winthrop Rapid","Transfer to Insulin Human Winthrop Rapid",6,6
"3800","fr","en","Passez immédiatement aux étapes suivantes de l 'injection.","Complete the other stages of injection without delay.",8,8
"3801","fr","en","Patientes qui n’ ovulent pas et qui n’ ont pas de règles ou des règles irrégulières.","Women who are not ovulating and are having irregular periods or no periods at all.",15,16
"3802","fr","en","Patients < 60 kg","Patients < 60 kg",4,4
"3803","fr","en","Patients adultes avec un glioblastome multiforme nouvellement diagnostiqué","Adult patients with newly -diagnosed glioblastoma multiforme",7,8
"3804","fr","en","Patients adultes et enfants âgés de 3 ans ou plus atteints de gliome malin en progression ou récidive:","Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma:",16,18
"3805","fr","en","Patients âgés (≥ 65 ans):","Elderly patients ( 65 years):",5,5
"3806","fr","en","Patients atteints d’ insuffisance rénale:","Patients with renal insufficiency:",4,5
"3807","fr","en","Patients atteints de LLC-B précédemment traités:","Previously treated B-CLL Patients:",4,6
"3808","fr","en","Patients atteints de LLC-B traités en première ligne","First Line B-CLL Patients",4,8
"3809","fr","en","Patients ayant une clairance de la créatinine comprise entre 30 et 49 ml/ min:","Patients with creatinine clearance between 30 and 49 ml/ min:",10,14
"3810","fr","en","Patients cancéreux recevant une chimiothérapie","Cancer patients receiving chemotherapy in",5,5
"3811","fr","en","Patients donnant leur propre sang avant une intervention chirurgicale","Patients donating their own blood before surgery",7,9
"3812","fr","en","Patients en phase accélérée: la posologie recommandée est de 600 mg/ j.","The recommended dosage of Glivec is 600 mg/ day for patients in accelerated phase.",14,12
"3813","fr","en","Patients insuffisants rénaux chroniques","Chronic renal failure patients",4,4
"3814","fr","en","Patients présentant un risque connu de glaucome à angle fermé.","Patients with known risk of narrow-angle glaucoma.",7,10
"3815","fr","en","patients, il n’ est pas possible de faire de recommandation posologique.","dose recommendations cannot be given.",5,11
"3816","fr","en","Paxene a été étudié sur 107 patients atteints d’ un sarcome de Karposi.","Paxene has been studied in 107 patients with Karposi’ s sarcoma.",11,13
"3817","fr","en","Peau et tissus-sous cutanées Fréquent: eczéma, éruptions.","Skin and appendages disorders Common: eczema, rash.",7,7
"3818","fr","en","Peau: démangeaison, éruption cutanée, sensation cutanée anormale ou diminuée, perte de cheveux","Skin: itching, rash, abnormal or decreased skin sensation, loss of hair",11,12
"3819","fr","en","Pedea se présente sous la forme d’ une solution injectable, en boîte de quatre ampoules de 2 ml.","Pedea is a solution for injection available in cartons of four 2 ml ampoules.",14,18
"3820","fr","en","Pegasys 135 microgrammes solution injectable en seringue pré-remplie Peginterféron alfa-2a","Pegasys 135 micrograms solution for injection in pre-filled syringe Peginterferon alfa-2a",11,10
"3821","fr","en","Pegasys est utilisé seul uniquement si, pour une raison quelconque, vous ne pouvez pas prendre la ribavirine.","Pegasys is used alone only if you cannot take ribavirin for any reason.",13,17
"3822","fr","en","pegfilgrastim ne devrait pas être modifiée par une insuffisance rénale ou hépatique.","au expected to be affected by renal or hepatic impairment.",10,12
"3823","fr","en","PegIntron 100 microgrammes poudre et solvant pour solution injectable S. C.","PegIntron 100 micrograms powder and solvent for injection SC",9,11
"3824","fr","en","PegIntron 150 microgrammes poudre et solvant pour solution injectable","PegIntron 150 micrograms powder and solvent for solution for injection",10,9
"3825","fr","en","PegIntron 80 microgrammes poudre et solvant pour solution injectable stylo prérempli peginterféron alfa-2b","PegIntron 80 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b",14,13
"3826","fr","en","PegIntron est utilisé seul en cas d’ intolérance ou de contre-indication à la ribavirine.","PegIntron is used alone in case of intolerance or contraindication to ribavirin.",12,14
"3827","fr","en","Pekka JÄRVINEN, Hannes WAHLROOS Birgitta BRATTHALL, Anders BROSTRÖM Roy ALDER, Steve DEAN12","Birgitta BRATTHALL, Anders BROSTRÖM",4,12
"3828","fr","en","Pelliculage du comprimé: hypromellose, hydroxypropyl cellulose, dioxyde de titane, macrogol.","Tablet coat: hypromellose, hydroxypropyl cellulose, titanium dioxide, macrogol.",8,10
"3829","fr","en","Pelliculage: macrogol 400, hypromellose, dioxyde de titane (E171), oxyde de fer jaune (E172), oxyde de fer rouge (E172).","Film coat: macrogol 400, hypromellose, titanium dioxide (E171), ferric oxide yellow (E172), ferric oxide red (E172).",16,18
"3830","fr","en","Pelzont 1000 mg/ 20 mg, comprimé à libération modifiée.","Pelzont 1000 mg/ 20 mg modified-release tablets.",7,9
"3831","fr","en","Pendant cette période, le lait maternel doit être tiré régulièrement et éliminé.","During this time, breast milk should be expressed at regular intervals and the expressed feeds should be discarded.",18,12
"3832","fr","en","Pendant le traitement, vous devez informer le personnel médical si vous ne vous sentez pas bien.","During treatment, you should tell the medical staff if you feel unwell.",12,16
"3833","fr","en","Pénicillines à large spectre Code ATCvet:","Penicillins with extended spectrum ATCVet code:",6,6
"3834","fr","en","Pentagon Park Boundary Way Hemel Hempstead Herts., HP2 7UD Royaume Uni.","Alcon Laboratories (UK) Ltd Pentagon Park Boundary Way Hemel Hempstead Herts., HP2 7UD United Kingdom",15,11
"3835","fr","en","Perfusion sous-cutanée continue par pompe","Continuous subcutaneous infusion pump",4,5
"3836","fr","en","perpendiculairement dans le pli cutané (figure E).","e fold (picture E).",4,7
"3837","fr","en","Peu fréquent (> 1/ 1000, < 1/ 100)","Uncommon (> 1/ 1,000, < 1/ 100)",7,8
"3838","fr","en","Peu fréquent ≥ 0,1 à < 1% des","Uncommon adverse reactions ≥ 0.1 to < 1% of patients",10,8
"3839","fr","en","Peu fréquent Fatigue, œ dème, symptômes pseudo-grippaux Rare","Uncommon Fatigue, oedema, influenza like symptoms Rare Asthenia, thirst",9,8
"3840","fr","en","Peu fréquent Septicémie Pneumonie Herpès zoster","Uncommon Sepsis Pneumonia Herpes zoster",5,6
"3841","fr","en","Peu fréquent: • réactions cutanées généralisées, telles que démangeaisons, urticaire ou éruptions cutanées non spécifiques","Uncommon: • generalised skin reactions such as itching, bumps on the skin or non-specific rash",15,15
"3842","fr","en","Peu fréquent: asthénie (sensation généralisée de faiblesse, fatigue), réactions au site de perfusion.","Uncommon: asthenia (general sensation of weakness, fatigue), injection site reactions.",10,13
"3843","fr","en","Peu fréquent: dysurie, pollakiurie, hématurie, nocturie, polyurie, incontinence urinaire Très fréquent: alopécie, éruption cutanée","Dysuria, pollakiuria, haematuria, nocturia, polyuria, urinary incontinence",7,14
"3844","fr","en","Peu fréquent: élévation sévère de la bilirubine","Uncommon: severe elevation in bilirubin",5,7
"3845","fr","en","Peu fréquent: gastro-entérite, infection des voies respiratoires supérieures, infection des voies urinaires.","Uncommon: gastroenteritis, upper respiratory infection, urinary tract infection.",8,12
"3846","fr","en","Peu fréquent: palpitations, angor","Uncommon: palpitations, angina pectoris",4,4
"3847","fr","en","Peu fréquents (≥ 1/ 1 000, < 1/ 100):","Uncommon (≥ 1/ 1,000 to < 1/ 100):",8,9
"3848","fr","en","Peu fréquents: malaise, neuropathie périphérique, bouche sèche, paresthésie, transpiration accrue.","Malaise, peripheral neuropathy, dry mouth, paraesthesia, increased sweating.",8,10
"3849","fr","en","Peut être nocif pour les patients présentant une phénylcétonurie.","May be harmful for people with phenylketonuria.",7,9
"3850","fr","en","Peut être utilisé au cours de la gestation et de la lactation.","Can be used during pregnancy and lactation.",7,12
"3851","fr","en","Peuvent s'ajouter des signes tels qu’ élévation des CPK, myoglobinurie (rhabdomyolyse) et insuffisance rénale aiguë.","Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",13,15
"3852","fr","en","Pfizer 23-25, Avenue Du Docteur Lannelongue 75668 Paris Cedex 14 France","Pfizer 23-25, Avenue Du Docteur Lannelongue 75668 Paris Cedex 14 France",11,11
"3853","fr","en","Pfizer Aps Lautrupvang 8 Dk-2750 Ballerup Danemark","Pfizer Aps Lautrupvang 8 Dk-2750 Ballerup Denmark",7,7
"3854","fr","en","Pfizer ApS Tlf: +45 44 20 11 00","Danmark Pfizer ApS Tlf: +45 44 20 11 00",9,8
"3855","fr","en","Pfizer Corporation Austria Ges. m. b. H.","Pfizer Corporation Austria Ges. m. b. H.",7,7
"3856","fr","en","Pfizer Healthcare Ireland 9 Riverwalk, National Digital Pk,","Pfizer Healthcare Ireland 9 Riverwalk, National Digital Pk, Citywest Business Campus, Dublin 24, Ireland c/ o Pfizer Ltd.",18,8
"3857","fr","en","Pfizer Italia s. r. l.","Pfizer Italia s. r. l.",5,5
"3858","fr","en","Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ Royaume-Uni","Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom",10,9
"3859","fr","en","Pfizer Limited, Sandwich, Kent, CT13 9NJ, Royaume-Uni.","Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom.",8,7
"3860","fr","en","Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgique","Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium",9,9
"3861","fr","en","Pfizer PGM, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, France.","Pfizer PGM, Zone Industrielle, 29 route des Industries, 37530 Poce-sur-Cisse, France.",11,11
"3862","fr","en","Pharbita Ronde Tocht 11 1507 CC Zaandam","Pharbita Ronde Tocht 11 1507 CC Zaandam",7,7
"3863","fr","en","Pharmacia Ireland Limited Airways Industrial Estate Dublin 17 Irlande","Pharmacia Ireland Limited Airways Industrial Estate Dublin 17 Ireland",9,9
"3864","fr","en","Pharmacocinétique dans des groupes de patients particuliers:","Pharmacokinetics in special patient groups",5,7
"3865","fr","en","Phase chronique, échec de l'interféron:","Chronic phase, Interferon failure:",4,5
"3866","fr","en","phénytoïne carbamazépine phénobarbital primidone rifampicine lopinavir/ ritonavir","phenytoin carbamazepine phenobarbitone primidone rifampicin lopinavir/ ritonavir",7,7
"3867","fr","en","Phosphate monosodique anhydre Phosphate disodique anhydre Chlorure de sodium Polysorbate 80 Eau pour préparations injectables","Sodium phosphate monobasic Sodium phosphate dibasic Sodium chloride Polysorbate 80 Water for injections",13,15
"3868","fr","en","phosphokinase Augmentation de la bilirubine totale","High creatine phosphokinase Increased total bilirubin",6,6
"3869","fr","en","PhotoBarr 75 mg poudre pour solution injectable Porfimère sodique Voie intraveineuse","PhotoBarr 75 mg powder for solution for injection Porfimer sodium Intravenous use",12,11
"3870","fr","en","Photosensibilité, urticaire, éruption cutanée, prurit Angioedèmes Alopécie","Photosensitivity, urticaria, rash, pruritus Angioedema Alopecia",6,7
"3871","fr","en","Pierre Fabre Medicament 45, Place Abel Gance 92654 Boulogne Cedex France","Pierre Fabre Medicament 45, Place Abel Gance 92654 Boulogne Cedex France",11,11
"3872","fr","en","Pimozide (saquinavir/ ritonavir) Contraceptifs oraux","Pimozide (saquinavir/ ritonavir) Oral contraceptives",5,5
"3873","fr","en","pincée, jusqu’à ce que la seringue soit vide.","Push the plunger with a slow constant pressure, always keeping your skin pinched, until the syringe is empty.",18,8
"3874","fr","en","Pincer doucement la peau au site d’ injection et insérer l’ aiguille.","Gently pinch the skin at the injection site and insert the needle.",12,12
"3875","fr","en","PIOGLITAZONE EN ASSOCIATION TRIPLE AVEC LA METFORMINE ET UN SULFAMIDE HYPOGLYCEMIANT","PIOGLITAZONE IN TRIPLE ORAL COMBINATION THERAPY WITH METFORMIN AND SULPHONYLUREA",10,11
"3876","fr","en","Pirox-CT 20mg/ 1ml Ampullen 6061697.00.00","Pirox-CT 20mg/ 1ml Ampullen 6061697.00.00",5,5
"3877","fr","en","Piroxicam Beral Dispersible 20 Mg,","Piroxicam Beral Dispersible 20 Mg, Comprimé",6,5
"3878","fr","en","Piroxicam Hexal 20mg Tabletten 3000886.01.00","Piroxicam Hexal 20mg Tabletten 3000886.01.00",5,5
"3879","fr","en","Piroxicam Ratiopharm Dispergeerbaar 20 Mg","Piroxicam Ratiopharm Dispergeerbaar 20 Mg",5,5
"3880","fr","en","Piroxicam- Ratiopharm 20 Mg Tabs 6013244.00.00","Piroxicam- Ratiopharm 20 Mg Tabs 6013244.00.00",6,6
"3881","fr","en","pl autres études, ce taux cible était de 12-14 g/ dl.","ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.",13,11
"3882","fr","en","Placebo 44% 32% 51% 17% 76%","Placebo 44% 32% 51% 17% 76%",6,6
"3883","fr","en","Placebo/ MTX- HUMIRA/ MTX","Placebo/ MTX- HUMIRA/ MTX",4,4
"3884","fr","en","Placer le comprimé dans la bouche.","Put the tablet in your mouth.",6,6
"3885","fr","en","Placer le flacon sur une surface rigide et antidérapante et le tenir fermement avec une main.","Place the vial on a rigid, non-slip surface and hold it firmly with one hand.",15,16
"3886","fr","en","Plan de Pharmacovigilance ou les activités de minimisation du risque est connue.","Pharmacovigilance Plan or risk minimisation activities,",6,12
"3887","fr","en","plaquette alvéolaire (PVC/ Aclar/ alu)","blister (PVC/ Aclar/ alu) blister (PVC/ Aclar/ alu) blister (PVC/ Aclar/ alu) blister (PVC/ Aclar/ alu) bottle (HDPE)",18,5
"3888","fr","en","Plaquette thermoformée (PVC-Al-Polyamide/ film thermoscellé 4511/ Al-Papier polyester) Plaquette thermoformée (PVC-PE-PCTFE/ Aluminium)","Foil/ Foil blister (PVC-Al-Polyamide/ 4511 heat seal coating/ A1-polyester paper) Film/ Foil Blister (PVC-PE-PCTFE/ Al blister)",16,12
"3889","fr","en","Plaquette thermoformée (PVC/ PE/ PVDC/ alu)","Film-coated tablets Film-coated tablets Film-coated tablets Film-coated tablets Film-coated tablets Film-coated tablets",12,6
"3890","fr","en","Plaquette thermoformée de 7 comprimés","Blister of 7 tablets",4,5
"3891","fr","en","Plaquette thermoformée pour TESAVEL 100 mg, comprimés pelliculés","Blister for TESAVEL 100 mg film-coated tablets",7,8
"3892","fr","en","Plaquettes thermoformées [PVC/ PVDC/ Aluminium] de 10 comprimés.","PVC/ PVDC/ Aluminium blisters of 10 tablets per blister card.",10,8
"3893","fr","en","Plaquettes thermoformées aluminium/ aluminium.","Aluminium / Aluminium blister.",4,4
"3894","fr","en","Plaquettes thermoformées contenant chacune 7, 10, 14 ou 20 comprimés.","Blister packs containing either 7, 10, 14 or 20 tablets per blister strip.",13,10
"3895","fr","en","Plaquettes thermoformées d'aluminium dans des étuis de 28, 35, 56 ou 70 comprimés par boîte.","Cold-formed aluminium blister strips in cartons of 28, 35, 56 or 70 tablets per carton.",15,15
"3896","fr","en","Plaquettes thermoformées en aluminium/ PVC/ PE/ PCTFE dans des boîtes de 14 ou 28 comprimés pelliculés.","Aluminium/ PVC/ PE/ PCTFE blisters in cartons of 14 or 28 film-coated tablets.",13,16
"3897","fr","en","Plaquettes thermoformées PVDC/ PE/ PVC/ AL","PVDC/ PE/ P VC/ AL blisters",6,6
"3898","fr","en","Pliva Pharma Limited Vision House, Bedford Road Petersfield, Hampsire GU32 3QB Royaume-Uni","Pliva Pharma Limited Vision House, Bedford Road Petersfield, Hampsire GU32 3QB United Kingdom",13,12
"3899","fr","en","Plus de 14 interférons alpha humains génétiquement différents ont été identifiés.","Arthralgia, myalgia, musculoskeletal pain",4,11
"3900","fr","en","Plus de 19.000 patients ont été suivi pendant une durée médiane de 4,8 à 5,9 ans.","Over 19000 patients were followed for a median of 4.8-5.9 years.",11,16
"3901","fr","en","Plus de 90% de ces manifestations ont été considérées d’ intensité légère.","More than 90% of these reports were considered mild.",9,12
"3902","fr","en","Plusieurs personnes peuvent se sentir plutôt normales.","Many may feel quite normal.",5,7
"3903","fr","en","Plusieurs révisions de diverses sections du RCP ont été intégrées.","Several amendments to various sections of the SPC were introduced.",10,10
"3904","fr","en","Points de contact et documents de référence de l’EMEA","EMEA contact points and reference documents",6,9
"3905","fr","en","Points de contact Rolf BASS Téléphone direct (44-20) 74 18 84 11 E-mail: rolf.bass@emea.eudra.org","Contact points Rolf BASS Direct telephone (44-20) 74 18 84 11 E-mail: rolf.bass@emea.eudra.org",13,14
"3906","fr","en","Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome.","Note for Guidance on evaluation of anticancer medicinal Released for consultation products in man (CPMP/EWP/205/95 rev.",16,16
"3907","fr","en","Poleczki 21 PL – 02-822 Warszawa Tel.: + 48 (0) 225451 111","Poleczki 21 PL – 02-822 Warszawa Tel.: + 48 (0) 225451 111",12,12
"3908","fr","en","Polska Abbott Laboratories Poland Sp. z o.o. ul.","Polska Abbott Laboratories Poland Sp. z o.o. ul.",8,8
"3909","fr","en","Polska Amgen Sp. z o.o.","Amgen Sp. z o.o.",4,5
"3910","fr","en","Polska Bayer Sp. z o. o.","Polska Bayer Sp. z o. o.",6,6
"3911","fr","en","Polska Eli Lilly Regional Operations GmbH Elanco Animal Health Kölblgasse 8-10 A-1030 Wien Tel.: +43 1 71178-0","Polska Eli Lilly Regional Operations GmbH Elanco Animal Health Kölblgasse 8-10 A-1030 Wien Tel.: +43 1 71178-0",17,17
"3912","fr","en","Polska GSK Commercial Sp. z o.o.","Polska GSK Commercial Sp. z o.o.",6,6
"3913","fr","en","Polska Lundbeck Poland Sp. z o. o. ul.","Polska Lundbeck Poland Sp. z o. o. ul.",8,8
"3914","fr","en","Polska Mylan Sp. z o. o.","Polska Mylan Sp. z o. o.",6,6
"3915","fr","en","Polska sanofi-aventis Sp. z o.o.","Polska sanofi-aventis Sp. z o.o.",5,5
"3916","fr","en","Polska VIRBAC S. A.","Polska VIRBAC S. A.",4,4
"3917","fr","en","Polyarthrite rhumatoïde La dose recommandée est de 90 mg une fois par jour.","Rheumatoid arthritis The recommended dose is 90 mg once a day.",11,13
"3918","fr","en","Polyester / éthylène vinyle acétate (PET/ EVA), transparent","Polyethylene/ ethyl vinyl acetate (PET/ EVA), clear",7,8
"3919","fr","en","Population ITT + RDO","ITT + RDO population",4,4
"3920","fr","en","Porcilis Pesti, émulsion injectable.","Porcilis Pesti emulsion for injection",5,4
"3921","fr","en","Porcs (truies et cochettes)","Pigs (sows and gilts)",4,4
"3922","fr","en","Porter des gants imperméables et éponger le liquide à l'aide d'un produit absorbant approprié.","Wear waterproof gloves and soak up the liquid with an appropriate absorbent.",12,14
"3923","fr","en","Portez une attention particulière à l'heure à laquelle vous prenez vos repas, à la","You must also keep a close watch on your blood sugar levels by testing your blood glucose often.",18,14
"3924","fr","en","Portugal Abbott Laboratórios, Lda.","Portugal Abbott Laboratórios, Lda.",4,4
"3925","fr","en","Portugal Bayer Portugal S. A.","Portugal Bayer Portugal S. A.",5,5
"3926","fr","en","Portugal EF-Eisai Farmacêutica, Unipessoal Lda Tel: + 351 21 421 7399","Portugal EF-Eisai Farmacêutica, Unipessoal Lda Tel: +351 21 421 7399",10,11
"3927","fr","en","Portugal GlaxoSmithKline – Produtos Farmacêuticos, Lda.","Portugal GlaxoSmithKline – Produtos Farmacêuticos, Lda.",6,6
"3928","fr","en","Portugal Laboratórios Pfizer, Lda Tel: + 351 214 235 500","Portugal Laboratórios Pfizer, Lda Tel: + 351 214 235 500",10,10
"3929","fr","en","Portugal Merck Sharp & Dohme, Lda Tel: + 351 214 465 700 informacao_doente@merck.com","Portugal Merck Sharp & Dohme, Lda Tel: + 351 214 465 700 informacao_doente@merck. com",14,13
"3930","fr","en","Portugal Sanofi Pasteur MSD, SA Tel: +351 21 470 45 50","Portugal Sanofi Pasteur MSD, SA Tel: +351 21 470 45 50",11,11
"3931","fr","en","Portugal Smith Kline & French Portuguesa, Produtos Farmacêuticos, Lda.","Portugal Smith Kline & French Portuguesa, Produtos Farmacêuticos, Lda.",9,9
"3932","fr","en","Portugal Wyeth Lederle Portugal (Farma), Lda.","Portugal Wyeth Lederle Portugal (Farma) Lda.",6,6
"3933","fr","en","Posologie de l'acide acétylsalicylique","Dosage of Acetylsalicylic Acid",4,4
"3934","fr","en","Posologie de Rebetol chez l’ enfant et adolescent en fonction du poids","Rebetol paediatric dose based on body weight",7,12
"3935","fr","en","Posologie de Rebetol en fonction du poids","Rebetol dose based on body weight",6,7
"3936","fr","en","Posologie de titration La dose journalière maximale est de 20 mg.","Dose titration The maximum daily dose is 20 mg per day.",11,11
"3937","fr","en","Posologie et mode d' administration","Posology and method of administration",5,5
"3938","fr","en","Posologie habituelle chez l’adulte et l’adolescent de 12 ans et plus","The usual dose for adults and adolescents aged 12 years and over",12,11
"3939","fr","en","POSOLOGIE POUR CHAQUE ESPÈCE, VOIE ET MODE D’ ADMINISTRATION","DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION",9,9
"3940","fr","en","POSOLOGIE POUR CHAQUE ESPÈCE, VOIE(S) ET MODE D’ ADMINISTRATION","DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION",9,9
"3941","fr","en","Posologie pour les patients présentant une insuffisance rénale","Dosage in patients with impaired kidney function",7,8
"3942","fr","en","Posologie: • Vous devez normalement injecter Humalog Mix25 dans les 15 minutes précédant un repas.","Dosage • You should normally inject Humalog Mix25 within 15 minutes of a meal.",14,15
"3943","fr","en","Postbus 2043 2800 Bd Gouda Pays-Bas","Postbus 2043 2800 Bd Gouda The Netherlands",7,6
"3944","fr","en","Postępu 18A PL-02-676 Warszawa Tel.: + 48 22 606-10-50","Postępu 18A PL-02-676 Warszawa Tel.: + 48 22 606-10-50",9,9
"3945","fr","en","Poudre et solvant pour dispersion injectable.","Powder and solvent for dispersion for injection.",7,6
"3946","fr","en","Poudre et solvant pour solution injectable en stylo prérempli Poudre blanche.","Powder and solvent for solution for injection in pre-filled pen White powder.",12,11
"3947","fr","en","Poudre et solvant pour suspension injectable","Powder and solvent for Intramuscular use suspension for injection",9,6
"3948","fr","en","Poudre et solvant pour suspension injectable à libération prolongée","Powder and solvent for prolonged-release suspension for injection",8,9
"3949","fr","en","Poudre pour InductOs 12 mg kit pour implant, Dibotermine alpha","Powder for InductOs 12 mg kit for implant, dibotermin alfa",10,10
"3950","fr","en","poudre pour solution à diluer pour perfusion","Powder for concentrate for solution for infusion",7,7
"3951","fr","en","Poudre pour solution buvable","Powder for oral solution Powder for oral solution Powder for oral solution",12,4
"3952","fr","en","poudre pour solution injectable","powder for solution for injection",5,4
"3953","fr","en","Poudre pour solution pour perfusion","Powder for solution for infusion",5,5
"3954","fr","en","Poudre pour suspension pour implantation.","Powder for suspension for implantation.",5,5
"3955","fr","en","Poudre: flacon (verre) Solvant: flacon (verre)","Powder: vial (glass) Solvent: vial (glass)",6,6
"3956","fr","en","poudre: flacon (verre) solvant: seringue pré-remplie (verre)","powder: vial (glass); solvent: pre-filled syringe (glass)",7,7
"3957","fr","en","Pour 1 000 doses de NovoSeven, on a rapporté moins d’ un effet indésirable.","For every 1,000 NovoSeven doses less than one side effect has been reported.",13,14
"3958","fr","en","Pour 30 mg de pâte:","Per 30 mg paste:",4,5
"3959","fr","en","Pour administration intraveineuse ou sous-cutanée Lire la notice avant utilisation","For intravenous or subcutaneous use Read the package leaflet before use.",11,10
"3960","fr","en","Pour avoir le détail de tous les effets indésirables observés lors de l'utilisation de TRISENOX, voir la notice.","For the full list of all side effects reported with TRISENOX, see the Package Leaflet.",15,18
"3961","fr","en","Pour calculer le volume requis, procéder comme suit:","The required volume should be calculated as follows:",8,8
"3962","fr","en","Pour ce faire, il vous faut donc des seringues pour injection et des aiguilles.","Therefore, keep injection syringes and needles as well.",8,14
"3963","fr","en","Pour cela, tapotez légèrement sur la moitié supérieure de la seringue, cela fera remonter les bulles d'air éventuelles.","This will cause any air bubbles to rise to the top.",11,18
"3964","fr","en","Pour chacun des termes, le niveau de fréquence est celui des effets indésirables de tous grades.","For each term, the frequency count was based on ADRs of all grades.",13,16
"3965","fr","en","Pour chaque classe de système d’organes, les effets indésirables sont présentés suivant un ordre décroissant de gravité.","Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness.",15,17
"3966","fr","en","Pour chaque fréquence, les effets indésirables sont présentés par ordre de gravité décroissante.","Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.",13,13
"3967","fr","en","Pour chats moyens > 2,5 kg - 5 kg.","For medium cats > 2.5 kg – 5 kg",9,9
"3968","fr","en","Pour connaître la liste complète des restrictions, veuillez vous reporter à la notice.","For the full list of restrictions, please see the Package Leaflet.",11,13
"3969","fr","en","Pour connaître les adaptations posologiques recommandées en fonction du nombre de neutrophiles et de plaquettes, voir rubrique 4.2.","For recommended dose modifications based on ANC and platelet counts, see section 4.2.",13,18
"3970","fr","en","Pour des instructions sur la reconstitution, voir rubrique 6.6.","For instructions on reconstitution, see section 6.6",7,9
"3971","fr","en","Pour éliminer un dispositif IONSYS usagé:","To segregate a used IONSYS system:",6,6
"3972","fr","en","Pour l’ usage ambulatoire, Nespo peut être sorti de ces conditions de conservation une seule fois, en","For the purpose of ambulatory use, Nespo may be removed from storage once for a maximum single in",18,17
"3973","fr","en","Pour la dépression et la douleur neuropathique diabétique:","For depression and diabetic neuropathic pain:",6,8
"3974","fr","en","Pour la liste complète de tous les effets indésirables observés sous ATryn, voir la notice.","For the full list of all side effects reported with ATryn, see the Package Leaflet.",15,15
"3975","fr","en","Pour la liste complète de tous les effets indésirables observés sous Eucreas, veuillez vous reporter à la notice.","For the full list of all side effects reported with Eucreas, see the Package Leaflet.",15,18
"3976","fr","en","Pour la liste complète de tous les effets indésirables observés sous ProQuad, veuillez vous reporter à la notice.","For the full list of all side effects reported with ProQuad, see the Package Leaflet.",15,18
"3977","fr","en","Pour la liste complète, voir la notice.","The full list is available in the Package Leaflet.",9,7
"3978","fr","en","Pour la reconstitution d’ AVONEX, utiliser la seringue préremplie de solvant fournie.","Use the supplied pre-filled syringe of solvent to reconstitute AVONEX for injection.",12,12
"3979","fr","en","Pour la rosiglitazone, les valeurs de Cmax ont diminué d’ environ 32% avec la nourriture.","For rosiglitazone, Cmax values were decreased by approximately 32% with food.",11,15
"3980","fr","en","Pour le comprimé à 12 mg:","For the 12 mg tablet:",5,6
"3981","fr","en","Pour le diagnostic in vivo de l’ infection gastro-intestinale induite par Helicobacter pylori (H. pylori).","For in vivo diagnosis of gastroduodenal Helicobacter pylori (H. pylori) infection.",11,15
"3982","fr","en","Pour les adultes, aspirez la totalité du volume.","For adult patients, withdraw the entire volume.",7,8
"3983","fr","en","Pour les chiens de plus de 25 kg:","For dogs of more than 25 kg:",7,8
"3984","fr","en","Pour les conditions de conservation du médicament en cours d'utilisation, voir rubrique 6.3..","For storage conditions of the in-use medicinal product, see section 6.3.",11,13
"3985","fr","en","Pour les conditions de conservation du médicament reconstitué, voir rubrique 6.3.","For storage conditions of the reconstituted medicinal product, see section 6.3.",11,11
"3986","fr","en","Pour les doses hebdomadaires ultérieures, la durée de perfusion recommandée est de 60 minutes.","For the subsequent weekly doses, the recommended infusion period is 60 minutes.",12,14
"3987","fr","en","Pour les excipients, voir 6.1","For excipients, see 6.1.",4,5
"3988","fr","en","Pour les instructions pour l'utilisation et la manipulation, voir rubrique 6.6.","For instructions for use and handling, see section 6.6.",9,11
"3989","fr","en","Pour les patients mal contrôlés par le glimépiride en monothérapie (habituellement 4 mg).","For patients inadequately controlled on glimepiride monotherapy (typically 4 mg).",10,13
"3990","fr","en","Pour les précautions de conservation, voir rubrique 6.3..","For storage precautions, see section 6.3.",6,8
"3991","fr","en","Pour obtenir davantage d’ informations, voir le résumé des caractéristiques du produit (également compris dans l’ EPAR).","See the Summary of Product Characteristics (also part of the EPAR) for more information.",14,17
"3992","fr","en","Pour plus d'informations, voir le résumé des caractéristiques du produit (également inclus dans l'EPAR).","For more information, see the Summary of Product Characteristics (also part of the EPAR).",14,14
"3993","fr","en","Pour plus d’ informations sur l'état ou le traitement de votre animal, veuillez contacter votre vétérinaire.","If you need more information about your animal’ s medical condition or treatment, contact your veterinarian.",16,16
"3994","fr","en","Pour plus d’ informations sur le traitement de l'hypoglycémie, voir l’ encadré à la fin de cette notice.","For information on the treatment of hypoglycaemia, see box at the end of this leaflet.",15,18
"3995","fr","en","Pour plus d’ informations sur les interactions avec d’ autres médicaments voir rubrique 4.5.","For further information on interactions with medicinal products see section 4.5.",11,14
"3996","fr","en","Pour plus d’ informations sur les médicaments génériques, voir le document sous forme de questions/ réponses disponible ici.","For more information on generic medicines, see the question-and-answer document here.",11,18
"3997","fr","en","Pour plus d’ informations, voir la notice.","For more information, see the Package Leaflet.",7,7
"3998","fr","en","Pour plus d’informations, les médecins doivent se reporter au Résumé des Caractéristiques du Produit de Prezista.","For further information, refer to the Summary of Product Characteristics for Prezista.",12,16
"3999","fr","en","Pour prévenir de telles modifications cutanées, il faut changer de site d’ injection à chaque fois.","Changing the injection site with each injection may help to prevent such skin changes.",14,16
"4000","fr","en","Pour reconstituer et préparer le vaccin, utiliser une eau propre et froide.","To reconstitute and prepare the vaccine, use clean cold water.",10,12
"4001","fr","en","Pour se débarrasser du patch usagé:","To dispose of used patch:",5,6
"4002","fr","en","Pour toute information concernant ce médicament, veuillez contacter le Titulaire de l’autorisation de mise sur le marché.","For any information about this medicine, please contact the Marketing Authorisation Holder.",12,17
"4003","fr","en","Pour toute information concernant la préparation de Lucentis, voir rubrique 6.6.","For information on preparation of Lucentis, see section 6.6.",9,11
"4004","fr","en","Pour une description complète des effets indésirables observés avec Humalog, veuillez vous reporter à la notice.","For the full description of the side effects reported with Humalog, please see the Package Leaflet.",16,16
"4005","fr","en","Pour une description complète des effets indésirables observés sous Coaprovel, voir la notice.","For the full list of all side effects reported with Coaprovel, see the Package Leaflet.",15,13
"4006","fr","en","Pour une description complète des effets indésirables observés sous Herceptin, voir la notice.","For the full list of all side effects reported with Herceptin, see the Package Leaflet.",15,13
"4007","fr","en","Pour une description complète des effets indésirables observés sous Karvezide, voir la notice.","For the full list of all side effects reported with Karvezide, see the Package Leaflet.",15,13
"4008","fr","en","Pour une description complète des effets indésirables observés sous Neoclarityn, voir la notice.","For the full list of all side effects reported with Neoclarityn, see the Package Leaflet.",15,13
"4009","fr","en","Pour une description complète des effets indésirables observés sous PhotoBarr, voir la notice.","For a more complete list of the side effects reported with PhotoBarr, see the Package Leaflet.",16,13
"4010","fr","en","Pour une description complète des effets indésirables observés sous Sprycel, voir la notice.","For the full list of all side effects reported with Sprycel, see the Package Leaflet.",15,13
"4011","fr","en","Pour une description complète des effets indésirables observés sous Viread, veuillez vous reporter à la notice.","For the full list of side effects reported with Viread, see the Package Leaflet.",14,16
"4012","fr","en","Pour une description complète des effets indésirables observés sous Xyrem, veuillez vous reporter à la notice.","For the full list of all side effects reported with Xyrem, see the Package Leaflet.",15,16
"4013","fr","en","Pour une information complète sur les interactions avec les autres médicaments, voir rubrique 4.5.","For full information on interactions with other medicinal products see section 4.5.",12,14
"4014","fr","en","Pour une liste complète des effets indésirables observés lors de l’ utilisation de SevoFlo, voir la notice.","For a full list of all side-effects reported with SevoFlo, see the Package Leaflet.",14,17
"4015","fr","en","Pour une liste complète des excipients, voir point 6.1","For a full list of excipients, see section 6.1",9,9
"4016","fr","en","Pour une liste complète des restrictions, voir la notice.","For the full list of restrictions, see the Package Leaflet.",10,9
"4017","fr","en","Pour une liste exhaustive des restrictions, veuillez vous reporter à la notice.","See the Package Leaflet for the full list of restrictions.",10,12
"4018","fr","en","Pour usage sous-cutané après reconstitution.","For subcutaneous use after reconstitution.",5,5
"4019","fr","en","Pour usage unique seulement","For single use only",4,4
"4020","fr","en","Pour votre confort, collez un sticker sur votre calendrier chaque semaine pour vous rappeler de prendre ADROVANCE.","For your convenience, place a sticker on your calendar each week as a reminder to take your ADROVANCE.",18,17
"4021","fr","en","Pour vous administrer une injection sous-cutanée, vous aurez besoin du matériel suivant:","To give yourself a subcutaneous injection you will need:",9,12
"4022","fr","en","Pourcentage de patientes présentant une nouvelle fracture Nouvelles fractures vertébrales radiologiques chez les","Percentage of patients with new fracture New radiographic vertebral fracture in patients without any",14,13
"4023","fr","en","Pourquoi ACOMPLIA a -t-il été approuvé? am","Why has ACOMPLIA been approved?",5,7
"4024","fr","en","Pourquoi Aprovel a -t-il été approuvé?","Why has Aprovel been approved?",5,6
"4025","fr","en","Pourquoi Biograstim a -t-il été approuvé?","Why has Biograstim been approved?",5,6
"4026","fr","en","Pourquoi Circovac a -t-il été approuvé?","Why has Circovac been approved?",5,6
"4027","fr","en","Pourquoi Doribax a -t-il été approuvé?","Why has Doribax been approved?",5,6
"4028","fr","en","Pourquoi Equilis Te a -t-il été approuvé?","Why has Equilis Te been approved?",6,7
"4029","fr","en","Pourquoi Filgrastim ratiopharm a -t-il été approuvé?","Why has Filgrastim ratiopharm been approved?",6,7
"4030","fr","en","Pourquoi Hepsera a -t-il été approuvé?","Why has Hepsera been approved?",5,6
"4031","fr","en","Pourquoi Intrinsa a -t-il été approuvé?","Why has Intrinsa been approved?",5,6
"4032","fr","en","Pourquoi Kinzalkomb a -t-il été approuvé?","Why has Kinzalkomb been approved?",5,6
"4033","fr","en","Pourquoi Nexavar a -t-il été approuvé?","Why has Nexavar been approved?",5,6
"4034","fr","en","Pourquoi Optaflu a -t-il été approuvé?","Why has Optaflu been approved?",5,6
"4035","fr","en","Pourquoi Posatex a -t-il été approuvé?","Why has Posatex been approved?",5,6
"4036","fr","en","Pourquoi PROTELOS a -t-il été approuvé?","Why has PROTELOS been approved?",5,6
"4037","fr","en","Pourquoi ReFacto AF a -t-il été approuvé?","Why has ReFacto AF been approved?",6,7
"4038","fr","en","Pourquoi Soliris a -t-il été approuvé?","Why has Soliris been approved?",5,6
"4039","fr","en","Pourquoi Tekturna a -t-il été approuvé?","Why has Tekturna been approved?",5,6
"4040","fr","en","Pourquoi Truvada a-t’ il été approuvé?","Why has Truvada been approved?",5,6
"4041","fr","en","Pourquoi une hyperglycémie survient?","Why does hyperglycaemia occur?",4,4
"4042","fr","en","Pourquoi Vistide a -t-il été approuvé?","Why has Vistide been approved?",5,6
"4043","fr","en","Pourquoi Zenapax a -t-il été approuvé? am","Why has Zenapax been approved?",5,7
"4044","fr","en","Poursuivez le traitement comme prescrit.","Continue with the treatment as prescribed.",6,5
"4045","fr","en","Poursuivre cette posologie pendant trois semaines.","This dosage should be continued for three weeks.",8,6
"4046","fr","en","poursuivre l’harmonisation des pratiques réglementaires entre les pays candidats et l’Union européenne.","continue harmonisation of regulatory practices between candidate countries and the European Union.",12,12
"4047","fr","en","Poussez la base dans la chambre en st position intiale pour le rangement. 'e tn en","Push the base n ge lo back into the chamber to store. o tn uc",15,16
"4048","fr","en","Powder and solvent for — solution for injection — 250 µg —","Suspension for injection Monodose preparation of 1 ml contains Hepatitis B surface antigen S, pre -S1 and",17,12
"4049","fr","en","Pradaxa 75 mg, gélules","Pradaxa 75 mg hard capsules",5,4
"4050","fr","en","Pramipexole Teva peut avoir une influence majeure sur la capacité à conduire et à utiliser des machines.","Pramipexole Teva can have a major influence on the ability to drive an use machines.",15,17
"4051","fr","en","Prandin est un médicament contenant le principe actif répaglinide.","Prandin is a medicine that contains the active substance repaglinide.",10,9
"4052","fr","en","Précautions particulières à prendre avec GADOVIST","Take special care with GADOVIST",5,6
"4053","fr","en","Précautions particulières à prendre par la personne qui administre le médicament vétérinaire aux animaux","Special precautions to be taken by the person administering the veterinary medicinal product to animals",15,14
"4054","fr","en","Précautions particulières à prendre par la personne qui administre le médicament vétérinaire aux animaux:","Special precautions to be taken by the person administering the veterinary medicinal product to animals:",15,14
"4055","fr","en","PRECAUTIONS PARTICULIERES D'ELIMINATION DES MEDICAMENTS NON UTILISES OU DES DECHETS PROVENANT DE CES MEDICAMENTS S'IL Y A LIEU","SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE",18,18
"4056","fr","en","Précautions particulières d'emploi chez les animaux","Special precautions for use in animals",6,6
"4057","fr","en","PRECAUTIONS PARTICULIERES D’ELIMINATION DES MEDICAMENTS NON UTILISES OU DES DECHETS PROVENANT DE CES MEDICAMENTS S’IL Y A LIEU","SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF",17,18
"4058","fr","en","Précautions particulières de conservation","Special precautions for storage",4,4
"4059","fr","en","PRÉCAUTIONS PARTICULIÈRES POUR L’ ÉLIMINATION DES PRODUITS NON UTILISÉS OU DES DÉCHETS, LE CAS ÉCHÉANT","SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY",13,15
"4060","fr","en","Préface de M. le Professeur Jean-Michel Alexandre président du Comité des spécialités pharmaceutiques (CPMP)","Jean-Michel Alexandre Chairman, Committee for Proprietary Medicinal Products",8,14
"4061","fr","en","Prélever le volume nécessaire d’ Erbitux du flacon.","Draw up the required volume of Erbitux from a vial.",10,8
"4062","fr","en","Prendre Agopton pendant les repas","Taking Agopton with food and drink",6,5
"4063","fr","en","Prendre la seringue préremplie de solvant fournie dans le conditionnement pour préparer le médicament.","Take the pre-filled syringe with solvent supplied in the pack to prepare your medicine.",14,14
"4064","fr","en","Prendre un comprimé une fois par jour.","Take one tablet once a day.",6,7
"4065","fr","en","Prenez alli au moment des repas.","Take alli at mealtimes.",4,6
"4066","fr","en","Prenez Efexor depot chaque jour, à peu près à la même heure, indifféremment le matin ou le soir.","Take Efexor depot at approximately the same time each day, either in the morning or in the evening.",18,18
"4067","fr","en","Prenez garde de ne pas avaler la capsule de dessicant contenue dans le flacon.","Make sure you do not swallow the desiccant capsule contained in the bottle.",13,14
"4068","fr","en","Prenez Glivec quotidiennement jusqu’ à ce que votre médecin vous dise d’ arrêter.","How long to take Glivec Take Glivec daily until your doctor tells you to stop.",15,13
"4069","fr","en","Prenez l’ aiguille possédant une marque grise et enlevez l’ emballage extérieur.","Take the injection needle with the grey mark and remove its wrapping.",12,12
"4070","fr","en","Prenez Tarceva en respectant toujours la posologie indiquée par votre médecin.","Always take Tarceva exactly as your doctor has told you.",10,11
"4071","fr","en","Prenez toujours ADARTREL exactement comme votre médecin vous l’ a dit.","Always take ADARTREL exactly as your doctor has told you.",10,11
"4072","fr","en","Prenez toujours votre médicament avec du ritonavir et de la nourriture.","Always take with ritonavir and food.",6,11
"4073","fr","en","Prenez vos comprimés tant que votre médecin ne vous a pas dit d’ arrêter.","Keep taking your tablets until your doctor tells you to stop.",11,14
"4074","fr","en","Prenez votre inhalateur d’insuline dans la main. éd","Set up your insulin inhaler Hold your insulin inhaler in your hand.",12,8
"4075","fr","en","Preotact est disponible en boîtes de 2 et 6 cartouches.","Preotact is available in packs of 2 and 6 cartridges.",10,10
"4076","fr","en","Prepandrix ne doit en aucun cas être administré par voie intravasculaire ou intradermique.","Prepandrix should under no circumstances be administered intravascularly or intradermally.",10,13
"4077","fr","en","Préparation de la dose","Preparing a dose of medicine",5,4
"4078","fr","en","Préparation de la solution injectable:","Preparing the injection solution:",4,5
"4079","fr","en","PRÉPARATION POUR L'ADMINISTRATION INTRAVEINEUSE","PREPARATION FOR THE INTRAVENOUS ADMINISTRATION",5,4
"4080","fr","en","Présentation: carton de 3 flacons.","Pack size: carton of 3 vials.",6,5
"4081","fr","en","présentez ces symptômes pour la première fois ou s’ ils s’ aggravent, consultez votre médecin immédiatement.","symptoms for the first time or if they get worse tell your doctor as soon as possible.",17,16
"4082","fr","en","Président du COMP Vice-président du COMP","Chairman of the COMP Vice-chairman of the COMP",8,6
"4083","fr","en","Prevenar suspension injectable Vaccin pneumococcique osidique conjugué, adsorbé Voie intramusculaire.","Prevenar suspension for injection Pneumococcal saccharide conjugated vaccine, adsorbed Intramuscular use.",11,10
"4084","fr","en","Prévenez immédiatement votre médecin si vous souffrez d’ un ou plusieurs des effets secondaires listés ci-dessous.","Tell your doctor or nurse immediately, if you notice any of the effects listed below.",15,16
"4085","fr","en","Prévenez t oujours vos proches et vos soignants que vous avez besoin d'insu line.","Always tell people who are caring for you or treating you that you require insulin.",15,14
"4086","fr","en","Prévenez votre médecin en cas d’ allaitement.","Tell your doctor if you are breast-feeding.",7,7
"4087","fr","en","Prévenez votre médecin ou votre infirmière si vous envisagez une grossesse ou si vous êtes enceinte.","Inform your doctor or nurse if you are planning to become pregnant or if you are ed",17,16
"4088","fr","en","Prévenez votre médecin si vous êtes enceinte, si vous pensez l'être ou si vous souhaitez débuter une grossesse.","Tell your doctor if you are pregnant, think you are pregnant or intend to become pregnant.",16,18
"4089","fr","en","Prévenez votre médecin si vous prenez:","Tell your doctor if you take:",6,6
"4090","fr","en","Prévenez votre pharmacien si vous constatez un changement de l’ aspect du sirop.","Tell your pharmacist if you notice any change in the appearance of the syrup.",14,13
"4091","fr","en","Prévention des événements thromboemboliques veineux (ETEV) chez les patients bénéficiant d’une chirurgie programmée pour prothèse totale de genou:","Prevention of Venous Thromboembolism (VTE) in patients following elective knee replacement surgery:",12,18
"4092","fr","en","Prévention des thromboses veineuses profondes après chirurgie orthopédique programmée (prothèse de hanche ou de genou).","Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.",14,15
"4093","fr","en","PREZISTA doit être pris en association avec une faible dose de ritonavir et d’autres médicaments anti- VIH.","PREZISTA must be taken in combination with a low dose of ritonavir and other anti-HIV medicines.",16,17
"4094","fr","en","Prialt est exclusivement destiné à l'usage intrarachidien.","Prialt is for intrathecal use only.",6,7
"4095","fr","en","Principe actif: gène de la thymidine kinase du virus Herpes simplex médié par adénovirus","Active substance: adenovirus-mediated Herpes simplex virus-thymidine kinase gene",8,14
"4096","fr","en","Principe actif: paclitaxel 6 mg/ ml (150 mg/ 25 ml)","Active ingredient: paclitaxel 6 mg/ml (100 mg/16.7 ml)",8,10
"4097","fr","en","Principes statistiques pour les essais cliniques","Clinical evaluation of medicinal products in",6,6
"4098","fr","en","Pris en association avec d’ autres médicaments antirétroviraux, STOCRIN réduit la quantité de virus présente dans le sang.","STOCRIN taken in combination with other antiretroviral medicines reduces the amount of the virus in the blood.",17,18
"4099","fr","en","Prise d’ autres médicaments avec Emselex Certains médicaments peuvent avoir des interactions avec Emselex.","Taking other medicines with Emselex Some medicines may interact with Emselex.",11,14
"4100","fr","en","Prise de RISPERDAL avec des aliments et des boissons Vous pouvez prendre ce médicament avec ou sans nourriture.","Taking RISPERDAL with food and drink You can take this medicine with or without food.",15,18
"4101","fr","en","Prise en charge En cas de surdosage, une prise en charge appropriée est recommandée.","Management In the event of an overdose, supportive management is recommended.",11,14
"4102","fr","en","Pritor 80 mg comprimés telmisartan","Pritor 80 mg tablets telmisartan",5,5
"4103","fr","en","PritorPlus est une association de deux substances actives, le telmisartan et l’ hydrochlorothiazide dans un comprimé.","PritorPlus is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet.",14,16
"4104","fr","en","Pro. Med. Cs Praha A. S.","Pro. Med. Cs Praha A. S.",6,6
"4105","fr","en","Problèmes courants du diabète","Common problems of diabetes",4,4
"4106","fr","en","Profender 50 mg/10 mg comprimés pour chiens moyens","Profender 50 mg/10 mg tablets for medium dogs",8,8
"4107","fr","en","Profil d'action en cas de diabète de type I","Activity Profile in Patients with Type 1 Diabetes",8,9
"4108","fr","en","Programme de travail de","Work Programme for the",4,4
"4109","fr","en","Programme de travail de l’ agence européenne pour l’ évaluation des médicaments pour la période 1997 - 1998","European Agency for the Evaluation of Medicinal Products 1997 - 1998",11,18
"4110","fr","en","ProMeris Duo 799,5 mg + 799,5 mg Spot -on pour chiens de grande taille {25,1 – 40,0 kg}","ProMeris Duo 799.5 mg + 799.5 mg Spot-on for large dogs {25.1 – 40.0 kg}",15,18
"4111","fr","en","Prometax 3,0 mg [uniquement pour la boîte]","Prometax 3.0 mg [folding box only]",6,7
"4112","fr","en","Prometax est utilisé pour le traitement de la démence chez les patients atteints de la maladie de Parkinson.","Prometax is used for the treatment of dementia in patients with Parkinson’ s disease.",14,18
"4113","fr","en","Prophylaxie de l’ ostéoporose induite par glucocorticoïdes.","Prophylaxis of glucocorticoid-induced osteoporosis.",4,7
"4114","fr","en","Propylène glycol Oxyde de fer noir (E172) Acétate phthalate de polyvinyle Macrogol Hydroxyde d'ammonium.","Propylene glycol Black iron oxide (E172) Polyvinyl acetate phthalate Macrogol Ammonium hydroxide.",12,14
"4115","fr","en","ProQuad poudre pour suspension injectable","ProQuad powder for suspension for injection SC",7,5
"4116","fr","en","Protaphane 40 UI/ ml suspension injectable en flacon Insuline humaine (ADNr)","Protaphane 40 IU/ ml suspension for injection in a vial Insulin human (rDNA)",13,11
"4117","fr","en","Protaphane doit être mis à l’abri de la chaleur excessive et de la lumière.","Protaphane must be protected from excessive heat and sunlight.",9,14
"4118","fr","en","Protaphane est une insulinothérapie substitutive utilisant une insuline identique à l’ insuline produite par le pancréas.","Protaphane is a replacement insulin which identical to the insulin made by the pancreas.",14,16
"4119","fr","en","protecteur est aligné avec l’indicateur de dose situé sur le corps du stylo.","indicator on the barrel.",4,13
"4120","fr","en","Protection Capuchon du interne de stylo l’ aiguille","Inner needle cap Cap scale",5,8
"4121","fr","en","ProteqFlu est un vaccin destiné aux chevaux.","ProteqFlu is a vaccine for use in horses.",8,7
"4122","fr","en","Protopic ne doit pas être utilisé de façon continue.","Protopic should not be used continuously.",6,9
"4123","fr","en","Protopy pommade ne doit pas être appliqué sur des lésions considérées comme étant potentiellement malignes ou précancéreuses.","Protopy ointment should not be applied to lesions that",9,17
"4124","fr","en","Proxalyoc 10 Mg, Lyophilisat Oral","Proxalyoc 10 Mg, Lyophilisat Oral",5,5
"4125","fr","en","psychotiques ou psychose, dépression, nervosité, agitation, troubles du sommeil et vertiges.","psychosis, depression, nervousness, agitation, sleep disorders and vertigo",8,11
"4126","fr","en","Puis -je arrêter de prendre Kaletra ou modifier ma dose?","Can I stop taking Kaletra or change my dose?",9,10
"4127","fr","en","Puis consommez des fruits, des biscuits ou un sandwich selon les conseils de votre médecin et reposez-vous.","This will often get you over mild",7,17
"4128","fr","en","Puis, injectez de l'air de la même façon dans le flacon de Liprolog mais ne retirez pas l'aiguille.","Now inject air into the Liprolog vial in the same manner, but do not withdraw the needle.",17,18
"4129","fr","en","Puis, vous commencerez la phase de monothérapie.","Then, you will start the monotherapy phase.",7,7
"4130","fr","en","Puisque Trudexa et administré en sous-cutané, il n'y a pas d'effets des aliments et des boissons.","Since Trudexa is given subcutaneously, food and drink should not affect Trudexa.",12,16
"4131","fr","en","Puregon 150 UI/ 0,18 ml solution injectable est destiné à être utilisé conjointement avec le stylo Puregon Pen.","Puregon 150 IU/ 0.18 ml solution for injection is designed for use in conjunction with the Puregon Pen.",18,18
"4132","fr","en","Puregon 50 UI poudre pour solution injectable follitropine bêta","Puregon 50 IU powder for injection follitropin beta",8,9
"4133","fr","en","Puregon 900 UI/ 1,08 ml solution injectable est destiné à être utilisé conjointement avec le stylo Puregon Pen.","Puregon 900 IU/ 1.08 ml solution for injection is designed for use in conjunction with the Puregon Pen.",18,18
"4134","fr","en","Purevax FeLV ne doit pas être utilisé chez les chattes gravides.","Purevax FeLV should not be used in pregnant cats.",9,11
"4135","fr","en","Purevax RCP Lyophilisat et solvant pour suspension injectable","Purevax RCP lyophilisate and solvent for suspension for injection.",9,8
"4136","fr","en","Pyrexie, fatigue (incluant asthénie et malaise).","pyrexia, fatigue (including asthenia and malaise)",6,6
"4137","fr","en","Qu'est -ce qu'Infanrix hexa et dans quel cas est -il utilisé 2.","What Infanrix hexa is and what it is used for 2.",11,12
"4138","fr","en","Qu'est -ce qu'Irbesartan Hydrochlorothiazide BMS?","What is Irbesartan Hydrochlorothiazide BMS?",5,5
"4139","fr","en","Qu'est -ce qu'ISENTRESS et dans quel cas est -il utilisé 2.","What ISENTRESS is and what it is used for 2.",10,11
"4140","fr","en","Qu'est -ce que {NOM DU PRODUIT} 80 mg et dans quel cas est -il utilisé 2.","What {PRODUCT NAME} 80 mg is and what it is used for 2.",13,16
"4141","fr","en","Qu'est -ce que Cervarix et dans quel cas est -il utilisé 2.","What Cervarix is and what it is used for 2.",10,12
"4142","fr","en","Qu'est -ce que DULOXETINE BOEHRINGER INGELHEIM et dans quel cas est -il utilisé 2.","What DULOXETINE BOEHRINGER INGELHEIM is and what it is used for 2.",12,14
"4143","fr","en","Qu'est -ce que Myozyme et dans quel cas est -il utilisé?","What Myozyme is and what it is used for 2.",10,11
"4144","fr","en","Qu'est -ce que Tamiflu et dans quel cas est -il utilisé 2.","What Tamiflu is and what it is used for 2.",10,12
"4145","fr","en","Qu'est -ce que VIRAMUNE et dans quel cas est -il utilisé 2.","What VIRAMUNE is and what it is used for 2.",10,12
"4146","fr","en","Qu'est -ce que Xeloda et dans quel cas est -il utilisé 2.","What Xeloda is and what it is used for 2.",10,12
"4147","fr","en","QU'EST-CE QU'ERBITUX ET DANS QUEL CAS EST-IL UTILISE","WHAT ERBITUX IS AND WHAT IT IS USED FOR",9,8
"4148","fr","en","QU'EST-CE QU’ ALIMTA ET DANS QUEL CAS EST-IL UTILISE","WHAT ALIMTA IS AND WHAT IT IS USED FOR",9,9
"4149","fr","en","QU'EST-CE QUE APROVEL ET DANS QUEL CAS EST-IL UTILISE","WHAT APROVEL IS AND WHAT IT IS USED FOR",9,9
"4150","fr","en","QU'EST-CE QUE Biograstim ET DANS QUEL CAS EST-IL UTILISE","WHAT Biograstim IS AND WHAT IT IS USED FOR",9,9
"4151","fr","en","QU'EST-CE QUE BYETTA ET DANS QUEL CAS EST-IL UTILISE","WHAT BYETTA IS AND WHAT IT IS USED FOR",9,9
"4152","fr","en","QU'EST-CE QUE FLEBOGAMMADIF ET DANS QUEL CAS EST-IL UTILISE","WHAT FLEBOGAMMADIF IS AND WHAT IT IS USED FOR",9,9
"4153","fr","en","QU'EST-CE QUE GLUSTIN ET DANS QUELS CAS EST-IL UTILISE?","WHAT GLUSTIN IS AND WHAT IT IS USED FOR",9,9
"4154","fr","en","QU'EST-CE QUE HBVAXPRO 5 microgrammes/0,5 ml ET DANS QUEL CAS EST-IL UTILISÉ","WHAT HBVAXPRO 5 micrograms/ 0.5 ml IS AND WHAT IT IS USED FOR",13,12
"4155","fr","en","QU'EST-CE QUE INSULIN HUMAN WINTHROP COMB 15 ET DANS QUEL CAS EST-IL UTILISE","WHAT INSULIN HUMAN WINTHROP COMB 15 IS AND WHAT IT IS USED FOR",13,13
"4156","fr","en","QU'EST-CE QUE INSUMAN COMB 15 ET DANS QUEL CAS EST-IL UTILISE","WHAT INSUMAN COMB 15 IS AND WHAT IT IS USED FOR",11,11
"4157","fr","en","Qu'est-ce que Pegasys et dans quel cas est-il utilisé 2.","What Pegasys is and what it is used for 2.",10,10
"4158","fr","en","QU'EST-CE QUE PROMETAX ET DANS QUEL CAS EST-IL UTILISE","WHAT PROMETAX IS AND WHAT IT IS USED FOR",9,9
"4159","fr","en","QU'EST-CE QUE SONATA ET DANS QUEL CAS EST-IL UTILISÉ","WHAT SONATA IS AND WHAT IT IS USED FOR",9,9
"4160","fr","en","QU'EST-CE QUE STOCRIN ET DANS QUEL CAS EST-IL UTILISE","WHAT STOCRIN IS AND WHAT IT IS USED FOR",9,9
"4161","fr","en","Qu'est-ce que Telzir et dans quel cas est-il utilisé 2.","What Telzir is and what it is used for 2.",10,10
"4162","fr","en","Qu’ en est -il de l’ utilisation d’ Evoltra dans le traitement de la LAL chez l’ enfant?","What is happening for Evoltra for treatment of ALL in children?",11,18
"4163","fr","en","Qu’ est -ce qu’ Emtriva et dans quel cas est -il utilisé 2.","What Emtriva is and what it is used for 2.",10,13
"4164","fr","en","Qu’ est -ce qu’ Hepsera Hepsera appartient à un groupe de médicaments appelés médicaments antiviraux.","What Hepsera is Hepsera belongs to a group of medicines called antiviral medicines.",13,15
"4165","fr","en","Qu’ est -ce qu’ INVEGA et contenu de l’ emballage extérieur?","What INVEGA looks like and contents of the pack",9,11
"4166","fr","en","Qu’ est -ce qu’ Osigraft et dans quel cas est -il utilisé 2.","What Osigraft is and what it is used for 2.",10,13
"4167","fr","en","Qu’ est -ce que CRIXIVAN et dans quel cas est -il utilisé 2.","What CRIXIVAN is and what it is used for 2.",10,13
"4168","fr","en","Qu’ est -ce que Eurican Herpes 205?","What is Eurican Herpes 205?",5,7
"4169","fr","en","Qu’ est -ce que Fendrix et contenu de l’ emballage extérieur","What Fendrix looks like and contents of the pack",9,11
"4170","fr","en","Qu’ est -ce que ProMeris Duo?","What is ProMeris Duo?",4,6
"4171","fr","en","Qu’ est -ce que Renagel et contenu de l’ emballage extérieur","What Renagel looks like and contents of the pack",9,11
"4172","fr","en","Qu’ est -ce que Trazec et dans quel cas est -il utilisé 2.","What Trazec is and what it is used for 2.",10,13
"4173","fr","en","Qu’ est -ce que Valdoxan et dans quel cas est -il utilisé 2.","What Valdoxan is and what it is used for 2.",10,13
"4174","fr","en","Qu’ est -ce que Yondelis et dans quel cas est -il utilisé 2.","What Yondelis is and what it is used for 2.",10,13
"4175","fr","en","QU’ EST CE PYLOBACTELL ET DANS QUEL CAS EST-IL UTILISE","WHAT PYLOBACTELL IS AND WHAT IT IS USED FOR",9,10
"4176","fr","en","Qu’ est ce que CEFUROXIME AXETIL et contenu de l’ emballage extérieur","What Cefuroxime axetil looks like and contents of the pack",10,12
"4177","fr","en","Qu’ est ce que OPTISON et contenu de l’ emballage extérieur OPTISON est une dispersion injectable.","OPTISON is a dispersion for injection.",6,16
"4178","fr","en","QU’ EST-CE QU’ EFEXOR ET DANS QUEL CAS EST-IL UTILISE","WHAT EFEXOR IS AND WHAT IT IS USED FOR",9,10
"4179","fr","en","QU’ EST-CE QUE BARACLUDE ET DANS QUEL CAS EST-IL UTILISE","WHAT BARACLUDE IS AND WHAT IT IS USED FOR",9,10
"4180","fr","en","QU’ EST-CE QUE GADOVIST 1,0 mmol/ ml, solution injectable ET DANS QUEL CAS EST-IL UTILISÉ","WHAT GADOVIST IS AND WHAT IT IS USED FOR",9,15
"4181","fr","en","QU’ EST-CE QUE NOVOMIX 50 ET DANS QUEL CAS EST-IL UTILISE","WHAT NOVOMIX 50 IS AND WHAT IT IS USED FOR",10,11
"4182","fr","en","QU’ EST-CE QUE OLANZAPINE NEOPHARMA ET DANS QUEL CAS EST-IL UTILISE","WHAT OLANZAPINE NEOPHARMA IS AND WHAT IT IS USED FOR",10,11
"4183","fr","en","QU’ EST-CE QUE POSACONAZOLE SP ET DANS QUEL CAS EST-IL UTILISE","WHAT POSACONAZOLE SP IS AND WHAT IT IS USED FOR",10,11
"4184","fr","en","QU’ EST-CE QUE SIKLOS ET POUR QUOI L’ UTILISE-T-ON","WHAT SIKLOS IS AND WHAT IT IS USED FOR",9,9
"4185","fr","en","QU’EST-CE QU’AZARGA ET DANS QUEL CAS EST-IL UTILISE","WHAT AZARGA IS AND WHAT IT IS USED FOR",9,8
"4186","fr","en","QU’EST-CE QU’HUMIRA ET DANS QUEL CAS EST-IL UTILISE?","WHAT HUMIRA IS AND WHAT IT IS USED FOR",9,8
"4187","fr","en","QU’EST-CE QU’OPTIMARK ET DANS QUEL CAS EST-IL UTILISÉ","WHAT Optimark IS AND WHAT IT IS USED FOR",9,8
"4188","fr","en","Qu’est-ce que Ciprofloxacine Bayer et dans quels cas est-il utilisé?","What Ciprofloxacin Bayer is and what it is used for 2.",11,10
"4189","fr","en","QU’EST-CE QUE LEVEMIR ET DANS QUEL CAS EST-IL UTILISE","WHAT LEVEMIR IS AND WHAT IT IS USED FOR",9,9
"4190","fr","en","Qu’est-ce que MicardisPlus et contenu de l’emballage extérieur","What MicardisPlus looks like and contents of the pack",9,8
"4191","fr","en","QU’EST-CE QUE PREZISTA ET DANS QUEL CAS EST-IL UTILISE","WHAT PREZISTA IS AND WHAT IT IS USED FOR",9,9
"4192","fr","en","Qu’est-ce que Rapamune et contenu de l’emballage extérieur","What Rapamune looks like and contents of the pack",9,8
"4193","fr","en","Qu’est-ce que Rebif et contenu de l’emballage extérieur","What Rebif looks like and contents of the pack",9,8
"4194","fr","en","Qu’est-ce que Ribavirine Teva et contenu de l’emballage extérieur","What Ribavirin Teva looks like and contents of the pack",10,9
"4195","fr","en","Qu’est-ce que Trudexa et dans quel cas est-il utilisé?","What Trudexa is and what it is used for",9,9
"4196","fr","en","Qu’est-ce que Zeffix et dans quel cas est-il utilisé 2.","What Zeffix is and what it is used for 2.",10,10
"4197","fr","en","Qu’il ne doit pas partager le traitement avec une autre personne quelconque","Treatment initiation forms for female patients with no childbearing potential should also include:",13,12
"4198","fr","en","Quadrisol 100 mg/ ml peut être utilisé pendant la gestation.","Quadrisol 100 mg/ ml can be used during pregnancy.",9,10
"4199","fr","en","Qualité des formes à libération prolongée destinées à un usage vétérinaire","Additional quality requirements for products intended for incorporation into animal feeding-stuffs (medicated pre-mixes)",13,11
"4200","fr","en","Qualité et cohérence des documents réglementaires","Head of Sector for personnel and budget Frances NUTTALL",9,6
"4201","fr","en","Qualité, Non-clinique, Clinique, Pharmacovigilance 2.","Quality, Non-clinical, Clinical, Pharmacovigilance 2.",5,5
"4202","fr","en","Quand ce schéma est appliqué, une quatrième dose est recommandée 12 mois après la première dose.","When this schedule is applied, a fourth dose is recommended 12 months after the first dose.",16,16
"4203","fr","en","Quand votre corps a une infection sévère, des caillots peuvent se former dans votre sang.","When your body has a severe infection, clots can form in your blood.",13,15
"4204","fr","en","Quantité de calories par jour","Amount of calories you can eat per day",8,5
"4205","fr","en","QUANTITÉ DE(S) PRINCIPE(S) ACTIF(S)","QUANTITY OF THE ACTIVE SUBSTANCE(S)",5,4
"4206","fr","en","Quatorze voies principales ont été identifiées, parmi lesquelles la O-déméthylation et la N-désalkylation principalement.","Fourteen primary pathways have been identified of which O-demethylation and N-dealkylation are the most important.",15,14
"4207","fr","en","Que contient Avamys La substance active est le furoate de fluticasone.","What Avamys contains The active substance is fluticasone furoate.",9,11
"4208","fr","en","Que contient CRIXIVAN • La substance active est le sulfate d’ indinavir.","Each hard capsule contains indinavir sulphate",6,12
"4209","fr","en","Que contient Extavia? − La substance active est l’interféron bêta 1-b.","What Extavia conta ins − The active substance is interferon beta-1b.",11,11
"4210","fr","en","Que contient Humalog Mix25 100 UI/ml Pen, suspension injectable","What Humalog Mix25 100 U/ml Pen, suspension for injection contains",10,9
"4211","fr","en","Que contient Imprida − Les substances actives d'Imprida sont l'amlodipine (sous forme de bésylate d'amlodipine) et le valsartan.","Each tablet contains 5 mg amlodipine and 80 mg valsartan.",10,18
"4212","fr","en","Que contient Karvea La substance active est l'irbésartan.","What Karvea contains The active substance is irbesartan.",8,8
"4213","fr","en","Que contient KOGENATE Bayer 250 UI","What KOGENATE Bayer 250 IU contains",6,6
"4214","fr","en","Que contient Liprolog Mix25 100 UI/ml Pen, suspension injectable","What Liprolog Mix25 100 U/ml Pen, suspension for injection contains",10,9
"4215","fr","en","Que contient Savene La substance active est le dexrazoxane.","What Savene contains The active substance is dexrazoxane.",8,9
"4216","fr","en","Que contient SUSTIVA Chaque gélule de SUSTIVA contient 50 mg de principe actif éfavirenz.","Each SUSTIVA hard capsule contains 50 mg of the active substance efavirenz.",12,14
"4217","fr","en","QUE FAIRE EN CAS D’URGENCE","WHAT TO DO IN AN EMERGENCY",6,5
"4218","fr","en","que, si possible, une mesure des concentrations","John’ s wort, check viral levels and if possible",9,7
"4219","fr","en","Quel est le bénéfice démontré par Altargo au cours des études?","What benefit has Altargo shown during the studies?",8,11
"4220","fr","en","Quel est le risque associé à l’ utilisation de Temodal?","What is the risk associated with Temodal?",7,10
"4221","fr","en","Quel est le risque associé à l’ utilisation de Zevalin?","What is the risk associated with Zevalin?",7,10
"4222","fr","en","Quel est le risque associé à MIRCERA?","What is the risk associated with MIRCERA?",7,7
"4223","fr","en","Quelle a été la documentation présentée par la société pour justifier sa demande auprès du CHMP?","What documentation did the company present to support its application to the CHMP?",13,16
"4224","fr","en","Quelle était la recommandation du CHMP à ce stade?","What was the recommendation of the CHMP at that time?",10,9
"4225","fr","en","Quelles études ont été menées avec Advagraf?","How has Advagraf been studied?",5,7
"4226","fr","en","Quelles études ont été menées avec Clomicalm?","How has Clomicalm been studied?",5,7
"4227","fr","en","Quelles études ont été menées avec Pandemrix?","How has Pandemrix been studied?",5,7
"4228","fr","en","Quelles études ont été menées avec PROCOMVAX?","How has PROCOMVAX been studied?",5,7
"4229","fr","en","Quelles études ont été menées sur Axura?","How has Axura been studied?",5,7
"4230","fr","en","Quelles études ont été menées sur Easotic?","How has Easotic been studied?",5,7
"4231","fr","en","Quelles études ont été menées sur Exjade?","How has Exjade been studied?",5,7
"4232","fr","en","Quelles études ont été menées sur Hepsera?","How has Hepsera been studied?",5,7
"4233","fr","en","Quelles études ont été menées sur Irbesartan Krka?","How has Irbesartan Krka been studied?",6,8
"4234","fr","en","Quelles études ont été menées sur Luveris?","How has Luveris been studied?",5,7
"4235","fr","en","Quelles études ont été menées sur Neupro?","How has Neupro been studied?",5,7
"4236","fr","en","Quelles études ont été menées sur Stalevo?","How has Stalevo been studied?",5,7
"4237","fr","en","Quelles études ont été menées sur Tysabri?","How has Tysabri been studied?",5,7
"4238","fr","en","Quelles études ont été menées sur Xiliarx?","How has Xiliarx been studied?",5,7
"4239","fr","en","Quelles informations sont encore en attente au sujet de Pandemrix?","What information is still awaited for Pandemrix?",7,10
"4240","fr","en","QUELLES SO NT LES INFORMATIONS A CONNAITRE AVANT D'UTILISER INSUMAN RAPID","BEFORE YOU USE INSUMAN RAPID",5,11
"4241","fr","en","Quelles sont les informations à connaître avant de prendre Inovelon 3.","Before you take Inovelon 3.",5,11
"4242","fr","en","Quelles sont les informations à connaître avant de prendre ISENTRESS 3.","Before you take ISENTRESS 3.",5,11
"4243","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE KUVAN","BEFORE YOU TAKE KUVAN",4,10
"4244","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE MYFENAX?","BEFORE YOU TAKE MYFENAX",4,10
"4245","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE OLANZAPINE TEVA","BEFORE YOU TAKE Olanzapine Teva",5,11
"4246","fr","en","Quelles sont les informations à connaître avant de prendre Pradaxa 3.","Before you take Pradaxa 3.",5,11
"4247","fr","en","Quelles sont les informations à connaître avant de prendre Rapamune 3.","Before you take Rapamune 3.",5,11
"4248","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE RILUTEK","BEFORE YOU TAKE RILUTEK",4,10
"4249","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE STOCRIN","BEFORE YOU TAKE STOCRIN",4,10
"4250","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE TELZIR","BEFORE YOU TAKE TELZIR",4,10
"4251","fr","en","Quelles sont les informations à connaître avant de prendre TRITAZIDE 3.","Before you take TRITAZIDE 3.",5,11
"4252","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE VIRACEPT","BEFORE YOU TAKE VIRACEPT",4,10
"4253","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE YENTREVE?","BEFORE YOU TAKE YENTREVE",4,10
"4254","fr","en","QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT QUE VOTRE ENFANT NE RECOIVE ROTARIX","BEFORE YOUR CHILD RECEIVES ROTARIX",5,13
"4255","fr","en","Quelles sont les mesures prises pour assurer la sécurité d'emploi de Cubicin?","Which measures are being taken to ensure the safe use of Cubicin?",12,12
"4256","fr","en","Quelles sont les mesures prises pour assurer la sécurité d’ emploi de Neupro?","Which measures are being taken to ensure the safe use of Neupro?",12,13
"4257","fr","en","Quelles sont les mesures prises pour assurer la sécurité de Volibris?","Which measures are being taken to ensure the safe use of Volibris?",12,11
"4258","fr","en","quelques heures ou quelques jours.","au Usually, the first symptoms of hyperglycaemia set in gradually, over a period of hours or days.",17,5
"4259","fr","en","Quelques patients inclus dans les études cliniques de phase III étaient co-infectés par les hépatites B et C.","Few patients included in the phase III trials were co-infected with hepatitis B/ C.",14,18
"4260","fr","en","Quelques patients ont fait des tentatives de suicide.","Some patients have actually committed suicide.",6,8
"4261","fr","en","Quelques patients ont ressenti des picotements ou un engourdissement des mains et des pieds.","Some patients have had tingling or numbness in the hands and feet.",12,14
"4262","fr","en","Quels ont été les bénéfices démontrés par Paxene au cours des études?","What benefit has Paxene shown during the studies?",8,12
"4263","fr","en","Quels ont été les effets bénéfiques démontrés par Kiovig au cours des études?","What benefit has Kiovig shown during the studies?",8,13
"4264","fr","en","Quels ont été les motifs invoqués par le laboratoire pour le retrait de la demande?","What were the reasons given by the company to withdraw the application?",12,15
"4265","fr","en","Quels sont les effets indésirables éventuels 5.","Possible side effects 5.",4,7
"4266","fr","en","Quels sont les risques associés à Flebogammadif?","What is the risk associated with Flebogammadif?",7,7
"4267","fr","en","Quels sont les risques associés à Lantus?","What is the risk associated with Lantus?",7,7
"4268","fr","en","Quels sont les risques associés à OSSEOR?","What is the risk associated with OSSEOR?",7,7
"4269","fr","en","Quels sont les risques associés à Tygacil?","What is the risk associated with Tygacil?",7,7
"4270","fr","en","QUESTIONS ET RÉPONSES RELATIVES AU RETRAIT DE LA DEMANDE D’ AUTORISATION DE MISE SUR LE MARCHÉ pour SYNORDIA","QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for SYNORDIA",12,18
"4271","fr","en","qui reçoivent des inducteurs du CYP3A4, par exemple phénytoïne, carbamazépine et phénobarbital.","CYP3A4-inducing agents such as phenytoin, carbamazepine, and phenobarbitone.",8,12
"4272","fr","en","Quinta da Fonte - Edifício Vasco da Gama, 19 - Porto Salvo","Quinta da Fonte - Edifício Vasco da Gama, 19 - Porto Salvo P. O.",14,12
"4273","fr","en","Quintanrix doit être utilisé selon les recommandations officielles.","The use of Quintanrix should be determined on the basis of official recommendations. i dic",15,8
"4274","fr","en","Quixidar 10 mg/ 0,8 ml solution injectable, en seringue pré-remplie.","Quixidar 10 mg/ 0.8 ml solution for injection, pre-filled syringe.",10,10
"4275","fr","en","R > 1 mg/l","R > 1 mg/L R > 1 mg/L R > 1 mg/L R > 1 mg/L",16,4
"4276","fr","en","R, Tel: + 420 (0) 221 115 150","R, Tel: + 420 (0) 221 115 150",8,8
"4277","fr","en","R06AX27 Relief of symptoms associated with seasonal allergic rhinitis","Therapeutic area - ATC - Indication",6,9
"4278","fr","en","Raheen Business Park Limerick Irlande","Raheen Business Park Limerick",4,5
"4279","fr","en","RAMIPRIL HCT – ZENTIVA","RAMIPRIL HCT – ZENTIVA 2.5mg/ 12.5mg",6,4
"4280","fr","en","Ranexa 750 mg comprimés à libération prolongée Ranolazine","Ranexa 750 mg prolonged-release tablets Ranolazine",6,8
"4281","fr","en","Rapamune 1 mg comprimés Sirolimus","Rapamune 1 mg tablets Sirolimus",5,5
"4282","fr","en","Rapilysin 10 U, poudre et solvant pour solution injectable.","Rapilysin 10 U powder and solvent for solution for injection.",10,9
"4283","fr","en","Rapport européen public d’ évaluation (EPAR)","EPAR summary for the public",5,6
"4284","fr","en","Rapportez la cartouche à votre pharmacien ou à votre médecin traitant.","Return the cartridge to your pharmacist or prescribing doctor.",9,11
"4285","fr","en","Rapports non-UE Rapports UE","Non-EU reports EU reports",4,4
"4286","fr","en","raptiva 100 mg/ ml","raptiva 100 mg/ ml",4,4
"4287","fr","en","Rare Hémorragie rétinienne, atrophie optique, crise oculogyre, opacité cornéenne","Retinal haemorrhage, optic atrophy, oculogyration, corneal opacity",7,9
"4288","fr","en","Rare: acouphène, hypoacousie transitoire (particulièrement des hautes fréquences).","Rare: tinnitus, transient hearing loss (particularly high frequencies).",8,8
"4289","fr","en","Rare: ataxie, convulsion, céphalées, cris persistants, hyperkinésie, hypersomnie, léthargie, tremblement.","Rare: ataxia, convulsion, headache, high pitched crying, hyperkinesia, hypersomnia, lethargy, tremor.",11,10
"4290","fr","en","Rare: hypersensibilité Très rare: choc anaphylactique","Rare: hypersensitivity Very rare: anaphylactic shock",6,6
"4291","fr","en","Rare: pancréatite, appendicite aiguë.","Rare: pancreatitis, acute appendicitis.",4,4
"4292","fr","en","Rares (> 1/ 10 000, < 1/ 1 000):","Rare (> 1/ 10,000, < 1/ 1,000):",7,9
"4293","fr","en","rash, acné, photosensibilité, hyperhydrose, peau grasse, prurit, lésions cutanées","polyuria, dysuria, pollakiuria rash, acne, photosensitivity, hyperhidrosis, oily skin, pruritus, skin lesion",12,9
"4294","fr","en","Rasilez 150 mg comprimés pelliculés Aliskiren","Rasilez 150 mg film-coated tablets Aliskiren",6,6
"4295","fr","en","Rasilez HCT est utilisé pour traiter une tension artérielle élevée.","Rasilez HCT is used to treat high blood pressure.",9,10
"4296","fr","en","Ratiograstim 48 MUI/ 0,8 ml solution injectable ou pour perfusion","Ratiograstim 48 MIU/ 0.8 ml solution for injection or infusion",10,10
"4297","fr","en","ration pharmaceutique cible administration","Package size Withdrawal Period",4,4
"4298","fr","en","ratiopharm Arzneimittel Vertriebs- GmbH Albert-Schweitzer-","ratiopharm Arzneimittel Vertriebs- GmbH Albert-Schweitzer-",5,5
"4299","fr","en","ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm, Germany","ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm, Germany",7,7
"4300","fr","en","Réaction allergique Réactions anaphylactiques sévères et autres réactions d’ hypersensibilité","Allergic reaction Severe anaphylactic and other hypersensitivity reactions",8,10
"4301","fr","en","Réaction de photosensibilité Œ dème de la face Rash","Gastrointestinal Disorders incl. related Investigations",5,9
"4302","fr","en","Réactions allergiques cutanées, anaphylactiques, Hypersensibilité Diabète, Hyperuricémie Dépression","Allergic skin reaction, Anaphylactic reactions, Hypersensitivity",6,8
"4303","fr","en","Réactions allergiques Soliris contient une protéine et les protéines peuvent provoquer des réactions allergiques chez certaines personnes.","Allergic reactions Soliris contains a protein and proteins can cause allergic reactions in some people.",15,17
"4304","fr","en","réactions anaphylactiques/ anaphylactoïdes graves, vascularite, y compris vascularite cutanée nécrosante","severe anaphylactic/ anaphylactoid reactions, vasculitis, including cutaneous necrotizing vasculitis",9,10
"4305","fr","en","Réactions au site d’ injection et réactions d’ hypersensibilité locale.","Skin and subcutaneous tissue disorders Common: injection site reactions and local hypersensitivity reactions.",13,10
"4306","fr","en","Réactions au site d’injection Des réactions au site d’injection peuvent se produire au cours du traitement par Extavia.","During Extavia treatment you are likely to experience injection site reactions.",11,18
"4307","fr","en","Réactions au site d’injection.","Changes at the injection site.",5,4
"4308","fr","en","Réactions graves inattendues (PTs), 4.","Serious unexpected reactions (PTs) 4.",5,5
"4309","fr","en","Rebif 8,8 microgrammes/ 0,1 ml Rebif 22 microgrammes/ 0,25 ml Solution injectable Interféron beta 1-a Voie SC","Rebif 8.8 micrograms/ 0.1 ml Rebif 22 micrograms/ 0.25 ml Solution for injection Interferon beta-1a SC use",17,17
"4310","fr","en","Recommandations d'emploi lorsque le relais par un traitement anticoagulant oral est envisagé","Recommendations for use in patients scheduled for a switch to oral anticoagulation",12,12
"4311","fr","en","Recommandations posologiques pour l'association chez les patients infectés par le VHC Génotype","Dosing Recommendations for Combination Therapy for HCV Patients Genotype",9,12
"4312","fr","en","recommandée du traitement par la lamotrigine (voir rubrique 4.2)","high initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine therapy (see section 4.2)",17,9
"4313","fr","en","Reconcile est un comprimé à croquer rond tacheté de couleur ocre à bruni qui contient:","Reconcile is a speckled tan to brown round chewable tablet containing:",11,15
"4314","fr","en","Reconstituer ZYPREXA, Poudre pour Solution Injectable uniquement avec de l’ eau pour préparation injectable.","Reconstitute ZYPREXA Powder for Solution for Injection only with water for injections",12,14
"4315","fr","en","Recueillir des échantillons obtenus après ingestion de l’ urée (“ post-urée”) d’ air","Collect post-urea (red top) breath samples.",6,13
"4316","fr","en","Redresser l'ensemble du dispositif.","Turn the entire unit upright.",5,4
"4317","fr","en","Réduction de l’ inflammation et diminution de la fièvre chez des animaux individuels.","Alleviation of inflammation and reduction of fever in individual animals",10,13
"4318","fr","en","Réduction du risque relatif de fracture vertébrale clinique","Relative risk reduction of clinical",5,8
"4319","fr","en","ReFacto AF 500 UI, poudre pour solution injectable Moroctocog alfa Utilisation IV","ReFacto AF 500 IU powder for solution for injection Moroctocog alfa IV use",13,12
"4320","fr","en","Refermer le flacon correctement après utilisation en suivant les instructions figurant sur le bouchon.","Reclose the bottle properly after use according to the instructions on the cap.",13,14
"4321","fr","en","Refludan ne doit pas être administré aux femmes enceintes ou qui allaitent.","Refludan should not be administered to pregnant women or nursing mothers.",11,12
"4322","fr","en","Réglage du stylo Pen (vérification du débit d'insuline).","Priming the Pen (check Insulin Flow).",6,8
"4323","fr","en","Regranex a été étudié dans le cadre de 4 essais cliniques d’ une durée de 20 semaines.","How has Regranex been studied?",5,17
"4324","fr","en","Regroupez tout ce dont vous avez besoin.","Assemble everything you need.",4,7
"4325","fr","en","Rehablit Lösung 1 1 mg mg/ ml","Rehablit Lösung 1 1 mg mg/ ml",7,7
"4326","fr","en","RELISTOR est administré par voie sous-cutanée.","RELISTOR is given as a subcutaneous injection.",7,6
"4327","fr","en","Remicade est un flacon contenant une poudre à diluer permettant d’ obtenir une solution pour perfusion.","Remicade is a vial containing a powder to be made up into a solution for infusion.",16,16
"4328","fr","en","Renagel 400 mg comprimés pelliculés sevelamer","Renagel 400 mg film-coated tablets sevelamer",6,6
"4329","fr","en","Renards roux Voie orale (Vulpes vulpes) et chiens viverrins (Nyctereutes procyonoides)","Red foxes (vulpes vulpes), raccoon dogs (Nyctereutes procyonoides)",8,11
"4330","fr","en","Répéter la perfusion toutes les 8 à 24 heures, jusqu’ à disparition de la","Repeat infusion every 8 to 24 hours until threat is resolved.",11,14
"4331","fr","en","Réponse ACR (% de patients)","ACR response (% of patients)",5,5
"4332","fr","en","Réponse virale à la 12ème semaine","Predictability of sustained response by viral response at week 12 and genotype*",12,6
"4333","fr","en","Report on selection of influenza vaccines strains for 1998/ 99","Report on selection of influenza vaccines strains for 1998/ 99",10,10
"4334","fr","en","Reportez -vous aux conseils de la section 4 Que faire en cas d’ urgence.","See the advice in 4 What to do in an emergency.",11,14
"4335","fr","en","reproduction et du sein Troubles généraux et anomalies au site d’ administration","Reproductive and breast General and administrative site",7,12
"4336","fr","en","Reproduction is authorised provided the source is acknowledged Comment Tysabri agit -il?","Reproduction is authorised provided the source is acknowledged.",8,12
"4337","fr","en","Reproduction is authorised provided the source is acknowledged Quelles études ont été menées sur Viagra?","Reproduction is authorised provided the source is acknowledged. studies in patients with spinal cord injury and with diabetes.",18,15
"4338","fr","en","Réservé à l’ usage externe.","For external use only.",4,5
"4339","fr","en","Respecter les instructions détaillées qui accompagnent le système d’ administration.","Detailed instruction accompanying the delivery system must be followed.",9,10
"4340","fr","en","Respecter les précautions usuelles concernant la stérilité et la radioprotection.","Usual precautions regarding sterility and radioprotection should be respected.",9,10
"4341","fr","en","Respectez toujours l’utilisation de l’HumalogBASAL KwikPen selon les indications de votre médecin.","Always use Humalog BASAL KwikPen exactly as your doctor has told you.",12,12
"4342","fr","en","Respectez toujours la posologie indiquée par votre médecin.","Always take Cardoreg 4 mg prolonged release tablets and associated names exactly as your doctor has told you.",18,8
"4343","fr","en","Respectez toujours les indications de votre médecin et ne changez pas la posologie de votre propre initiative.","Follow your doctor’ s instructions and do not change the dose yourself.",12,17
"4344","fr","en","Résultats concernant les critères secondaires d’ efficacité (patientes atteintes de cancer du sein avec métastase osseuse)","Secondary Efficacy Results (Breast Disease)",5,16
"4345","fr","en","Résultats globaux (quel que soit le traitement antérieur) 1","Pooled results across the 3 treatment levels",7,9
"4346","fr","en","Résultats issus des essais contrôlés contre placebo","Integrated findings from placebo-controlled trials",5,7
"4347","fr","en","Résumé des Caractéristiques du 'e Produit, rubrique 4.2). tn","Summary of Product Characteristics, section 4.2) no",7,9
"4348","fr","en","RESUME DES CARACTERISTIQUES DU PRODUIT","SUMMARY OF THE PRODUCT CHARACTERISTICS",5,5
"4349","fr","en","RESUME DES CARACTÉRISTIQUES DU PRODUIT","SUMMARY OF PRODUCT CHARACTERISTICS",4,5
"4350","fr","en","RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT","ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS",6,5
"4351","fr","en","RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT 'es n nt e am dic mé Ce","SUMMARY OF PRODUCT CHARACTERISTICS t no uc rod lP nai dic Me",12,13
"4352","fr","en","Résumé des Caractéristiques du Produit, 4.2).","Summary of Product od",4,6
"4353","fr","en","Résumé des Caractéristiques du Produit, rubrique 4.2).","Summary of Product Characteristics, section 4.2)",6,7
"4354","fr","en","RÉSUMÉ GÉNÉRAL DE L’ ÉVALUATION SCIENTIFIQUE D’ ALENDRONATE HEXAL ET DES DÉNOMINATIONS ASSOCIÉES (voir Annexe I)","OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF ALENDRONATE HEXAL AND ASSOCIATED NAMES (see Annex I)",15,16
"4355","fr","en","RÉSUMÉ GÉNÉRAL DE L’ ÉVALUATION SCIENTIFIQUE D’ EFEXOR DEPOT ET DES DÉNOMINATIONS ASSOCIÉES (VOIR ANNEXE I)","OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF EFEXOR DEPOT AND ASSOCIATED NAMES (SEE ANNEX I)",15,16
"4356","fr","en","RÉSUMÉ GÉNÉRAL DE L’ ÉVALUATION SCIENTIFIQUE DE RAPINYL ET DES DÉNOMINATIONS ASSOCIÉES (voir annexe I)","OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF RAPINYL AND ASSOCIATED NAMES (see Annex I)",14,15
"4357","fr","en","RÉSUMÉ GÉNÉRAL DE L’ ÉVALUATION SCIENTIFIQUE DE ZYRTEC ET DENOMINATIONS ASSOCIEES (VOIR ANNEXE I)","OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF ZYRTEC AND ASSOCIATED NAMES (SEE ANNEX I)",14,14
"4358","fr","en","Retacrit 1 000 UI/ 0,3 ml solution injectable en seringue préremplie","Retacrit 1000 IU/ 0.3ml solution for injection in pre-filled syringe",10,11
"4359","fr","en","Retacrit 5 000 UI/ 0,5 ml solution injectable en seringue préremplie","Retacrit 5000 IU/ 0.5ml solution for injection in pre-filled syringe",10,11
"4360","fr","en","Retacrit doit être administré au patient après sa séance de dialyse.","Retacrit should be given after the patient has received a dialysis session.",12,11
"4361","fr","en","Retard de croissance lié à une insuffisance rénale chronique:","Growth failure associated with chronic renal insufficiency:",7,9
"4362","fr","en","Rétention aqueuse Oedème, perte de poids Prise de poids","Fluid retention Oedema, weight loss Weight gain",7,9
"4363","fr","en","Retirer avec précaution le capuchon de l’ aiguille pour injection sans séparer l’ aiguille de la seringue.","Carefully remove the cap from the injection needle without disconnecting the injection needle from the syringe.",16,17
"4364","fr","en","Retirer complètement le couvercle.","Peel back the paper lid completely.",6,4
"4365","fr","en","Retirer l'aiguille du flacon de Liprolog et l'insérer dans le flacon d'insuline à action plus prolongée.","Remove the needle from the vial of Liprolog and insert it into the vial of the longer-acting insulin.",18,16
"4366","fr","en","Retirer l'aiguille et appliquer une pression doucement sur le point d'injection pendant quelques secondes.","Pull the needle out and apply gentle pressure over the injection site for several seconds.",15,14
"4367","fr","en","Retirer la capsule colorée en plastique du flacon.","Flip off the plastic colored cap from the vial",9,8
"4368","fr","en","Retirer le bouchon de la bouteille.","Remove the bottle cap.",4,6
"4369","fr","en","Retirer les capuchons extérieur et intérieur de l’ aiguille.","The outer and inner needle caps should be removed.",9,9
"4370","fr","en","Retirer les opercules des flacons de poudre et de solvant.","Remove caps from powder and solvent vials.",7,10
"4371","fr","en","Retirez l’ aiguille en conservant le même angle que celui utilisé lorsque vous l'avez enfoncée.","Withdraw the needle at the same angle as it was inserted.",11,15
"4372","fr","en","Retirez l’opercule du flacon et nettoyez le bouchon en caoutchouc avec un tampon alcoolisé.","Take off the cap from the vial and clean the rubber stopper with an alcohol wipe.",16,14
"4373","fr","en","Retirez la seringue du flacon.","Remove the oral syringe from the bottle.",7,5
"4374","fr","en","Retirez le bouchon plastique du récipient en verre contenant la poudre.","Remove the plastic cover from the glass container containing the powder.",11,11
"4375","fr","en","Retirez le cache intérieur de l'aiguille et jetez-le.","Remove the inner needle cover and discard.",7,8
"4376","fr","en","Retirez le capuchon du stylo (comme indiqué par la flèche).","Take off the pen cap (as shown by the arrow).",10,10
"4377","fr","en","Retirez le capuchon gris de l’aiguille en","Pull off the grey needle cap",6,7
"4378","fr","en","Retournez le flacon la tête en bas et aspirez doucement la solution obtenue dans la seringue.","Turn the vial upside down and gently draw the solution back into the syringe.",14,16
"4379","fr","en","Réunions de groupes de travail ad hoc","Break-out meetings (Co-)Rapporteur meetings Working party meetings Ad hoc working party meetings Total",13,7
"4380","fr","en","Réunions de présoumission Obligations spécifiques","Pre-submission meetings Specific obligations and",5,5
"4381","fr","en","Réunions du COMP en 2001","Orphan medicinal procedures 2000-2002",4,5
"4382","fr","en","Réunions du CPMP en 2001 (à confirmer)","CPMP meetings in 2001 (to be confirmed)",7,7
"4383","fr","en","Réunions du CVMP en 2001","CVMP meetings in 2001",4,5
"4384","fr","en","Revasc peut entraîner de graves malformations pour votre enfant.","Revasc can cause serious harm to your baby.",8,9
"4385","fr","en","REVENUS PROVENANT DU FONCTIONNEMENT ADMINISTRATIF","REVENUE FROM ADMINISTRATIVE OPERATIONS",4,5
"4386","fr","en","Revisser le capuchon après utilisation.","Replace screw cap after use.",5,5
"4387","fr","en","Revlimid 10 mg gélules","Revlimid 10 mg hard capsules",5,4
"4388","fr","en","REYATAZ 100 mg gélules","REYATAZ 100 mg hard capsules",5,4
"4389","fr","en","REYATAZ 50 mg/ 1,5 g poudre orale","REYATAZ 50 mg/ 1.5 g oral powder",7,7
"4390","fr","en","Ribavirine Teva est un médicament qui peut inhiber la multiplication de certains virus.","Ribavirin Teva is a medicine that can inhibit the multiplication of some viruses.",13,13
"4391","fr","en","Ribavirine TEVA ne doit pas être utilisé en monothérapie.","Ribavirin monotherapy must not be used.",6,9
"4392","fr","en","Ribofen 50 microgram/ hr Transdermal patch (pending)","Ribofen 50 microgram/ hr Transdermal patch (pending)",7,7
"4393","fr","en","Rifabutine/ Efavirenz (300 mg une fois par jour/ 600 mg une fois par jour)","Rifabutin/ Efavirenz (300 mg once daily/ 600 mg once daily)",10,14
"4394","fr","en","Rifampicine/ Efavirenz (600 mg une fois par jour/ 600 mg une fois par jour)","Rifampicin/ Efavirenz (600 mg once daily/ 600 mg once daily)",10,14
"4395","fr","en","RILUTEK est contre-indiqué (voir rubrique 4.3) en cas de grossesse (voir rubrique 5.3).","RILUTEK is contraindicated (see section 4.3) in pregnancy (see section 5.3).",11,13
"4396","fr","en","rimonabant, celui-ci doit être arrêté.","If psychiatric illness is diagnosed during rimonabant therapy, treatment must be stopped. du",13,5
"4397","fr","en","Riprazo est disponible en boîtes contenant 7, 14, 28, 30, 50, 56, 84, 90, 98 ou 280 comprimés.","Riprazo is available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.",18,18
"4398","fr","en","ris base des études réalisées, a conduit aux recommandations relatives aux conditions d’ utilisation du médicament.","or If you need more information about your medical condition or your treatment, read the Package",16,16
"4399","fr","en","ris Chaque seringue préremplie de 0,3 ml contient 60 microgrammes de darbepoetin alfa (200 microgrammes/ ml).","Each 0.3 ml pre-filled syringe contains 60 micrograms darbepoetin alfa (200 micrograms/ ml).",13,16
"4400","fr","en","ris Chaque seringue préremplie de 0,6 ml contient 300 microgrammes de darbepoetin alfa (500 microgrammes/ ml).","Each 0.6 ml pre-filled syringe contains 300 micrograms darbepoetin alfa (500 micrograms/ ml).",13,16
"4401","fr","en","ris majorité des évènements étaient des thromboses veineuses profondes distales asymptomatiques.","The majority of events were asymptomatic distal DVT.",8,11
"4402","fr","en","ris Nespo n’est pas affecté par la prise d’aliments et de boissons.","Food and drink do not affect Nespo.",7,12
"4403","fr","en","ris significative de l’ augmentation du taux d’ hémoglobine ont été observées (p < 0,001).","Erythropoetin is a growth factor that primarily stimulates red blood cell production.",12,15
"4404","fr","en","Risperdal Risperdal omhulde tabletten 4 mg","Risperdal Risperdal omhulde tabletten 4 mg",6,6
"4405","fr","en","RISPERDAL solution buvable La solution est fournie avec une seringue (pipette).","RISPERDAL oral solution The solution comes with a syringe (pipette).",10,11
"4406","fr","en","RISPERDALet dénominations associées (Voir Annexe I) 6 mg comprimé pelliculé","RISPERDAL and associated names (see Annex I) 6 mg film-coated tablets",11,10
"4407","fr","en","Rispolin 2 mg - 2 mg Filmtabletten","Rispolin 2 mg - 2 mg Filmtabletten",7,7
"4408","fr","en","Risque de syndrome sérotoninergique.","MAOI-B (selegeline): risk of serotonin syndrome.",6,4
"4409","fr","en","risques éventuels pour votre santé dans les pays visités,","In the following situations, the management of your diabetes may require a lot of care:",15,9
"4410","fr","en","RISQUES LIES A L’ UTILISATION DES CONTRACEPTIFS OESTROPROGESTATIFS","Risks of using combined hormonal contraceptives",6,8
"4411","fr","en","Ritonavir 400 mg, deux fois/ jour (Indinavir 400 mg, deux fois/ jour)","Recommendations concerning co- administration",4,12
"4412","fr","en","Ritonavir administré comme potentialisateur pharmacocinétique","Ritonavir dosed as a pharmacokinetic enhancer",6,5
"4413","fr","en","RoActemra se présente sous la forme d’ une solution à diluer stérile qui ne comporte pas de conservateur.","RoActemra is supplied as a sterile concentrate that does not contain preservatives.",12,18
"4414","fr","en","Roche Diagnostics GmbH Nonnenwald 2 82377 Penzberg Allemagne","Roche Diagnostics GmbH Nonnenwald 2 82377 Penzberg Germany",8,8
"4415","fr","en","Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Wyhlen Allemagne","Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Wyhlen Germany",8,8
"4416","fr","en","Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW Royaume-Uni","Marketing Authorisation Holder Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom",18,14
"4417","fr","en","România Abbott Laboratories S. A.","România Abbott Laboratories S. A.",5,5
"4418","fr","en","România CSC Pharmaceuticals SA Reprezentanta pentru Romania Drumea Ră dulescu nr.52, sector 4, Bucuresti, Tel: +40213316767","România CSC Pharmaceuticals SA Reprezentanta pentru Romania Drumea Ră dulescu nr.52, sector 4, Bucuresti, Tel: +40213316767",16,16
"4419","fr","en","România Eli Lilly România S. R. L.","Nederland Eli Lilly Nederland B.V.",5,7
"4420","fr","en","România Geneva Romfarm Internacional Tel: + 40 (021) 231 3561","România Geneva Romfarm Internacional Tel: + 40 (021) 231 3561",10,10
"4421","fr","en","România GlaxoSmithKline (GSK) SRL Tel: +40 (0)21 3028 208","România GlaxoSmithKline (GSK) SRL Tel: +40 (0)21 3028 208",9,9
"4422","fr","en","România MEDISON PHARMA SRL + 40 31 7104035","România MEDISON PHARMA SRL + 40 31 7104035",8,8
"4423","fr","en","România Novartis Pharma Services Inc.","România Novartis Pharma Services Inc.",5,5
"4424","fr","en","România Roche România S. R. L.","România Roche România S.R.L.",4,6
"4425","fr","en","România Teva Pharmaceuticals S. R. L.","România Teva Pharmaceuticals S. R. L.",6,6
"4426","fr","en","Roskildevej 22 DK-2620 Albertslund Danemark","AstraZeneca A/ S Roskildevej 22 DK-2620 Albertslund Denmark",8,5
"4427","fr","en","Rotateq, solution buvable Vaccin rotavirus (vivant, oral)","RotaTeq, oral solution Rotavirus vaccine (live oral)",7,7
"4428","fr","en","Rotavirus humain, souche RIX4414 (vivante, atténuée)*................................................ ≥ 10 6.0 DICC50","Human rotavirus RIX4414 strain (live, attenuated)*",6,10
"4429","fr","en","RP ≥ 1 en accord avec la Pharmacopée Européenne","RP > 1 in accordance with the EP",8,9
"4430","fr","en","Rua da Quinta do Pinheiro, 5 P-2794-003 Carnaxide Tel: +351 21 4172121","Divisão de Saúde Animal Rua da Quinta do Pinheiro, 5 P-2794-003 Carnaxide Tel: +351 21 4172121",16,12
"4431","fr","en","Rua da Quinta dos Grilos, 30 P-2790-476 Carnaxide Tel: + 351 21 425 3242 E-mail: uk_medinfo@allergan.com","Rua da Quinta dos Grilos, 30 P-2790-476 Carnaxide Tel: + 351 21 425 3242 E-mail: uk_medinfo@allergan. com",17,16
"4432","fr","en","Rue de l'Institut, 89 1330 Rixensart, Belgique Téléphone: +32 (0)2 656 8111 dic","Rue de l'Institut 89 B-1330 Rixensart, Belgium",7,13
"4433","fr","en","Rue de l'Institut, 89 B-1330 Rixensart Belgique","Rue de l’ Institut 89 B-1330 Rixensart, Belgium",8,7
"4434","fr","en","Rue de Lyons 27460 Igoville France","Rue de Lyons 27460 Igoville France",6,6
"4435","fr","en","S ≤ 1 mg/l","S ≤ 1 mg/L S ≤ 1 mg/L",8,4
"4436","fr","en","s Douleurs gastro- intestinales et abdominales Dyspepsie Flatulences","Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening) Toxic epidermal necrolysis (potentially life- threatening)",17,8
"4437","fr","en","s La dose devra être augmentée de 25% - 50% si:","th Dose should be increased by 25% – 50% if:",10,11
"4438","fr","en","s Que dois -je faire avant de m’ auto-administrer une injection sous-cutanée de Dynepo?","is What should I do before I give myself a subcutaneous injection of Dynepo?",14,14
"4439","fr","en","s Très rares (observés chez moins d’une personne sur 10 000)","Very rare (seen in less than 1 in 10,000 people)",10,11
"4440","fr","en","S-P Veterinary Shire Park Welwyn Garden City Hertfordshire AL7 1TW Royaume-Uni","S-P Veterinary Shire Park Welwyn Garden City Hertfordshire AL7 1TW United Kingdom",12,11
"4441","fr","en","S’assurer que l’extrémité ne touche rien.","Make sure that the tip does not touch anything.",9,6
"4442","fr","en","S’assurer que la pointe de l’aiguille se trouve dans la solution.","Ensure that the tip of the needle is in the solution.",11,11
"4443","fr","en","S’ils surviennent, le traitement par Ciprofloxacine Bayer doit être arrêté; informez alors immédiatement votre médecin.","If this happens, stop taking Ciprofloxacin Bayer and contact your doctor immediately.",12,15
"4444","fr","en","Sachet dose (papier/ LDPE/ aluminium/ copolymère ET PET/ aluminium/ copolymère ET/ papier)","sachet (paper/ LDPE/ alu/ ET copolymer PE/ Alu/ ET copolymer/ paper)",11,12
"4445","fr","en","Sachet en aluminium scellé, dans une boîte en carton","Sealed foil pouch in cardboard carton",6,9
"4446","fr","en","Saignements rectaux, gastrite, vomissements, Peu fréquent dyspepsie, ballonnements, constipation.","rectal haemorrhage, gastritis, vomiting, dyspepsia, abdominal bloating, constipation,",8,9
"4447","fr","en","Sandoz GmbH Biochemiestrasse 10 A-6250 Kundl Autriche","Sandoz GmbH Biochemiestrasse 10 A-6250 Kundl Austria",7,7
"4448","fr","en","Sandwich Kent, CT13 9NJ Royaume Uni","Sandwich Kent, CT13 9NJ",4,6
"4449","fr","en","Sang dans les selles, urticaire.","Side effects that have been reported during marketed use include: blood in stool, hives.",14,5
"4450","fr","en","sanofi -aventis Tel: +44 (0) 1483 505 515","United Kingdom sanofi-aventis Tel: +44 (0) 1483 505 515",9,8
"4451","fr","en","Sanofi Pasteur MSD Ltd, Tel: +44.1.628.785.291","Sanofi Pasteur MSD Ltd, Tel: +44.1.628.785.291",6,6
"4452","fr","en","Sanofi Pasteur MSD SNC 8, rue Jonas Salk 69007 Lyon, France Tel:","Sanofi Pasteur MSD SNC 8, rue Jonas Salk 69007 Lyon, France Tel:",12,12
"4453","fr","en","Sanofi Pasteur MSD SNC, 8, rue Jonas Salk, F-69007 Lyon, France","Sanofi Pasteur MSD SNC, 8, rue Jonas Salk, F-69007 Lyon, France",11,11
"4454","fr","en","Sanofi Pasteur MSD, Tél: +32.2.726.95.84 Magyarország:","Sanofi Pasteur MSD, Tél: +32.2.726.95.84 Magyarország:",6,6
"4455","fr","en","Sanofi Pasteur SA, 2 avenue Pont Pasteur, F-69007 Lyon, France.","Sanofi Pasteur SA, 2, avenue Pont Pasteur, F-69007 Lyon, France.",10,10
"4456","fr","en","Sanofi Winthrop Industrie 1, Rue de la Vierge Ambarès & Lagrave F-33565 Carbon Blanc cedex France","Sanofi Winthrop Industrie 1, rue de la Vierge Ambarès & Lagrave F-33565 Carbon Blanc cedex France",16,16
"4457","fr","en","sanofi-av entis Sp. z o.o.","sanofi-aventis Sp. z o.o.",4,5
"4458","fr","en","Sanofi-aventis Belgium Culliganlaan 1C 1831 Diegem Belgique","Sanofi-aventis Belgium Culliganlaan 1C 1831 Diegem Belgium",7,7
"4459","fr","en","Sanofi-Aventis Deutschland GmbH Industriepark Höchst Brüningstraße 50 D-65926 Frankfurt / Main Allemagne","Sanofi-Aventis Deutschland GmbH Industriepark Höchst Brüningstraße 50 D-65926 Frankfurt / Main Germany",12,12
"4460","fr","en","Sanofi-Aventis France 1-13 Boulevard Anatole France France","Sanofi-Aventis France 1-13 Boulevard Anatole France France",7,7
"4461","fr","en","sanofi-aventis Norge AS Tlf: +47 67 10 71 00","Tlf: +47 67 10 71 00",6,9
"4462","fr","en","Sans Objet Sans Objet","Not Applicable Not Applicable",4,4
"4463","fr","en","Saquinavir 1200 mg trois fois par jour","Saquinavir 1200 mg TID",4,7
"4464","fr","en","Saquinavir/ ritonavir/ Efavirenz Antagoniste du CCR5","Saquinavir/ ritonavir/ Efavirenz CCR5 antagonist",5,6
"4465","fr","en","Sauf indication contraire, les études présentées ont été conduites chez des sujets sains.","Studies were conducted in healthy subjects unless otherwise noted.",9,13
"4466","fr","en","Saunderton, High Wycombe Buckinghamshire HP14 4HJ Tel: +44 1 494 567 567","Saunderton, High Wycombe Buckinghamshire HP14 4HJ Tel: +44 1 494 567 567",12,12
"4467","fr","en","SBL Vaccin AB S-105 21 Stockholm Suède","SBL Vaccin AB S-105 21 Stockholm Sweden",7,7
"4468","fr","en","Schaliënhoevedreef 20H 2800 Mechelen Belgique/ Belgien Tél: +32 (0) 15 45 11 80","Schaliënhoevedreef 20H 2800 Mechelen Belgique/ Belgien Tél: +32 (0) 15 45 11 80",13,13
"4469","fr","en","Schering Lusitana, Lda Estrada Nacional 249, km","Schering Lusitana, Lda Estrada Nacional 249, km",7,7
"4470","fr","en","Schering SA, Z. I.","Schering SA, Z. I.",4,4
"4471","fr","en","Sclérose en plaques, myélite, paralysie faciale, polynévrite telle que syndrome de Guillain-Barré (avec paralysie ascendante), névrite optique","Nervous system disorders Multiple sclerosis, myelitis, facial palsy, polyneuritis such as Guillain-Barré syndrome (with ascending paralysis), optic neuritis",18,17
"4472","fr","en","Score 3,7 (2,7-4,7) d' érosion","Erosion score JSN score a",5,5
"4473","fr","en","Score EVAASPI moyen à la fin du titrage de doses initial, en mm (ET)","Mean VASPI score at end of initial titration in mm (SD)",11,14
"4474","fr","en","Se laver les mains après avoir manipulé le produit.","Wash hands after handling the product",6,9
"4475","fr","en","Se laver les mains après l'application.","Wash your hands after applying it.",6,6
"4476","fr","en","Se laver les mains après utilisation","Wash hands after use.",4,6
"4477","fr","en","Se laver les mains au savon et les désinfecter après la vaccination.","Hands should be washed and disinfected after vaccinating.",8,12
"4478","fr","en","Se laver soigneusement les mains à l’eau et au savon avant la préparation du médicament.","Wash your hands thoroughly with soap and water before preparing the medicine.",12,15
"4479","fr","en","Se référer à la rubrique ci- dessous relative au ritonavir.","See also ritonavir row below.",5,10
"4480","fr","en","Se référer au Résumé des Caractéristiques des Produits contenant du maraviroc.","Refer to the Summary of Product Characteristics for the medicinal product containing maraviroc.",13,11
"4481","fr","en","Se reporter à la rubrique 4.6.","Refer to section 4.6.",4,6
"4482","fr","en","Sédation (dont hypersomnie, léthargie, somnolence) Affections gastro-intestinales Fréquent:","Sedation (including: hypersomnia, lethargy, somnolence).",5,8
"4483","fr","en","Sélectionnez votre dose requise en tournant le sélecteur de dose dans le sens des aiguilles d’ une montre.","Select your required dose by turning the dose selector forward.",10,18
"4484","fr","en","Selon la réponse individuelle, la dose pourra être augmentée à 8 mg une fois par jour.","Based upon individual response, the dose may be increased to 8 mg once daily.",14,16
"4485","fr","en","Selon les cas, seuls certains de ces symptômes et/ ou anomalies biologiques peuvent apparaître.","In individual cases, only some of these symptoms and/ or findings may be evident.",14,14
"4486","fr","en","sem 12 sem 12","wk 12 wk 12 wk",5,4
"4487","fr","en","Semaine 2 (Jour 8 à 14):","Week 2 (day 8-14):",4,6
"4488","fr","en","Semaine 3 (Jour 15 à 21):","Week 3 (day 15-21):",4,6
"4489","fr","en","Sensation de tête vide Paresthésies Céphalées Anxiété","Light-headedness Paraesthesia Headache Anxiety",4,7
"4490","fr","en","Sensation vertigineuse, céphalées, somnolence Accès de sommeil d’ apparition brutale, syncope Amnésie, Dyskinésie, hyperkinésie","dizziness, headache, somnolence sudden onset of sleep, syncope amnesia, dyskinesia, hyperkinesia",11,14
"4491","fr","en","Seretide contient du salmétérol et du propionate de fluticasone, dont les effets indésirables sont connus.","Infections & Candidiasis of the mouth Infestations",7,15
"4492","fr","en","Seretide Evohaler et noms associés (voir Annexe I) 50/ 25 microgrammes/ dose, suspension pour inhalation en flacon pressurisé","Seretide Evohaler and associated names (see Annex I) 25/ 50 microgram/ dose pressurised inhalation, suspension.",15,18
"4493","fr","en","serin g u e-fla c o n à","Turn the bottle right way",5,8
"4494","fr","en","Seringue d’ administration (5 ml) en polypropylène munie d’ un piston en silicone.","Clear polypropylene 5 ml dispensing syringe with silicone rubber piston seal.",11,13
"4495","fr","en","Seringue pré-remplie 0,4 ml (verre) avec système de sécurité automatique","pre-filled syringe (glass) with an automatic safety system",8,10
"4496","fr","en","SERINGUE PRE-REMPLIE AVEC 5,0 ml D'EAU POUR PREPARATIONS INJECTABLES","PRE-FILLED SYRINGE WITH 5.0 ML WATER FOR INJECTIONS",8,9
"4497","fr","en","Serono Europe Limited, 56 Marsh Wall, Londres E14 9TP, Royaume-Uni","Serono Europe Limited, 56 Marsh Wall, London E14 9TP, United Kingdom",11,10
"4498","fr","en","Service Client local EXUBERA/ EXUBERA-","ho Klanteninformatiedienst voor EXUBERA/ EXUBERA- Service-Center/Service Client local EXUBERA",9,5
"4499","fr","en","Servier (Ireland) Industries Ltd","Servier (Ireland) Industries Ltd",4,4
"4500","fr","en","Set n°1 1er palier posologique (0,25 ml) pour les jours 1, 3 et 5 du traitement","Triple pack 1 1st dosage step (0.25 ml) for treatment days 1, 3, 5",14,16
"4501","fr","en","Seule une quantité minime est éliminée par voie urinaire.","Only minute amounts were found in urine.",7,9
"4502","fr","en","Seulement deux événements indésirables graves ont été rapportés (sepsis et cellulite chez le même patient).","Only two serious adverse reactions were reported (sepsis and cellulitis in the same patient).",14,15
"4503","fr","en","seulement du méthotrexate, à 6 et 12 mois (voir tableau 5).","patients receiving methotrexate alone at 6 and 12 months (see Table 5).",12,11
"4504","fr","en","Seules les seringues d’ injection prévues pour cette concentration d'insuline (100 UI/ ml) doivent être utilisées.","Only injection syringes designed for this strength of insulin (100 IU per ml) are to be used.",17,16
"4505","fr","en","Seules les solutions limpides et dépourvues de particules peuvent être utilisées.","Only clear solutions without particles should be used.",8,11
"4506","fr","en","Seuls les chiens en bonne santé doivent être vaccinés.","Only healthy dogs should be vaccinated.",6,9
"4507","fr","en","Sexe: aucune adaptation posologique n’ est requise chez la femme par rapport à l'homme (voir rubrique 5.2).","Gender: no dosage adjustment is required for female patients as compared to male patients (see section 5.2).",17,17
"4508","fr","en","Shellac Dioxyde de titane (E171) Indigotine (E132)","Shellac Titanium dioxide (E171) FD and C Blue 2 (indigo carmine, E132)",12,7
"4509","fr","en","Shire réalisera une étude pharmacocinétique chez des patients jeunes et âgés atteints de TE.","Shire will conduct a pharmacokinetic study in young and elderly patients with ET.",13,14
"4510","fr","en","Shotton Lane Cramlington Northumberland NE23 3JU United Kingdom","Shotton Lane Cramlington Northumberland NE23 3JU United Kingdom",8,8
"4511","fr","en","Si ce n’est pas le cas, changez l’aiguille et répétez l’opération pas plus de 6 fois.","If not, change the needle and repeat the procedure no more than 6 times.",14,16
"4512","fr","en","Si ces symptômes apparaissent, l’ administration doit être interrompue immédiatement.","If these symptoms occur, the administration has to be discontinued immediately.",11,10
"4513","fr","en","Si d’ autres doses ou “ rappel” sont nécessaires, votre médecin vous en informera.","If additional injections or “ booster” are necessary, the doctor will tell you.",13,14
"4514","fr","en","Si de faibles taux de potassium sont décelés, une correction est requise.","If low potassium levels are detected, correction is required.",9,12
"4515","fr","en","Si des anticorps se développent, Advate n’ agira pas efficacement.","If antibodies develop, Advate will not work effectively.",8,10
"4516","fr","en","Si des bulles d' air","If air bubbles appear in the syringe, keep the bottle upside down and slowly",14,5
"4517","fr","en","Si des crises se produisent, la prise de ciprofloxacine doit être interrompue (voir rubrique 4.8).","If seizures occur ciprofloxacin should be discontinued (see section 4.8).",10,15
"4518","fr","en","Si des signes de réactions graves ou d’ hypersensibilité apparaissent, le traitement doit être arrêté.","If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.",14,15
"4519","fr","en","Si elle se produit, une adaptation posologique appropriée doit être instaurée.","If it occurs, appropriate dose adjustment should be made as provided.",11,11
"4520","fr","en","Si indiquée, l'élimination de l'atazanavir non-absorbé doit se faire par vomissements provoqués ou lavage gastrique.","If indicated, elimination of unabsorbed atazanavir should be achieved by emesis or gastric lavage.",14,15
"4521","fr","en","Si l'instauration du traitement par ziconotide s'accompagne d'un arrêt des opiacés, le sevrage doit être progressif.","If discontinuing opiates when initiating ziconotide therapy, opiate withdrawal should be gradual.",12,16
"4522","fr","en","Si l’ un de ces effets indésirables persiste ou devient gênant, informez -en votre médecin.","If any of these side effects persist or are troublesome, please tell your doctor.",14,15
"4523","fr","en","Si l’ un ou l’ autre cas est observé, jetez le vaccin.","In the event of either being observed, discard the vaccine.",10,12
"4524","fr","en","Si l’ utilisation de la ranitidine est envisagée, elle doit l’ être de façon espacée; par ex.","If the use of ranitidine is considered, it should be used in a staggered manner; i. e.",17,17
"4525","fr","en","Si l’une de ces situations s’applique à vous, informez-en votre médecin.","Tell your doctor if any of these applies to you.",10,11
"4526","fr","en","Si la coadministration est","Co- administration of posaconazole with sirolimus is not recommended and should be avoided whenever possible.",15,4
"4527","fr","en","Si la douleur persiste au-delà de 12 heures après l’ examen médical, consultez de nouveau le médecin.","If pain persists for more than 12 hours after examination, seek medical advice again.",14,17
"4528","fr","en","Si la perfusion est ralentie, la durée totale de perfusion ne peut dépasser deux heures.","If the infusion is slowed, the total infusion time may not exceed two hours.",14,15
"4529","fr","en","Si la perfusion était tolérée sans réaction, la vitesse de perfusion était doublée pour les 15 minutes suivantes.","If tolerated without reaction, the infusion rate was doubled for the next 15 minutes.",14,18
"4530","fr","en","Si la posologie journalière requise dépasse 120 mg, elle de- vra être donnée en deux prises.","If the required daily dose exceeds 120 mg, it should be given in two divided doses.",16,16
"4531","fr","en","Si la pression artérielle ne peut pas être stabilisée, le traitement par Epoetin alfa HEXAL devra être interrompu.","If blood pressure cannot be controlled, Epoetin alfa HEXAL treatment should be discontinued.",13,18
"4532","fr","en","Si la solution est froide, réchauffer la seringue entre les paumes.","If the solution is cold, warm the syringe between your palms.",11,11
"4533","fr","en","Si le goutte-à-goutte de Caelyx vous provoque une brûlure ou une douleur locale, avertissez immédiatement votre médecin.","If the drip stings or hurts while you are receiving a dose of Caelyx, tell your doctor immediately.",18,17
"4534","fr","en","Si le médicament est pris à jeun, la substance active est absorbée plus rapidement.","If taken on an empty stomach, the active substance is absorbed more rapidly.",13,14
"4535","fr","en","Si le produit est projeté accidentellement dans les yeux, laver les yeux à grande eau.","If the product accidentally gets into eyes, they should be thoroughly flushed with water.",14,15
"4536","fr","en","Si le volume n'est pas suffisant pour répondre à vos besoins, changez la cartouche.","If there is not enough for your dose, change the cartridge.",11,14
"4537","fr","en","Si moins de 2 ans se sont écoulées depuis la dernière vaccination, une seule dose est suffisante.","If up to 2 years have passed since the last vaccination a single dose is sufficient.",16,17
"4538","fr","en","Si nécessaire, cette dose pourra être modifiée en cours de traitement.","If necessary, the dose may be changed during treatment.",9,11
"4539","fr","en","Si nécessaire, la dose peut être augmentée progressivement jusqu’ à une dose maximale de 60 mg/ jour.","When appropriate the dosage can be gradually increases up to a maximum of 60 mg.",15,17
"4540","fr","en","Si nécessaire, NovoMix 70 peut être injecté peu après le début d’ un repas.","When necessary, NovoMix 70 can be given soon after start of a meal.",13,14
"4541","fr","en","Si nécessaire, recouvrez le site avec un pansement.","If needed, you may cover the injection site with a bandage.",11,8
"4542","fr","en","Si possible, accomplir les gestes chirurgicaux sur le site avant l’ implantation du produit.","Where practical, surgical manipulations to the site should be completed prior to product implantation.",14,14
"4543","fr","en","Si tel est votre cas, consultez immédiatement votre médecin.","Should this happen to you, seek immediate advice from your doctor.",11,9
"4544","fr","en","Si tel est votre cas, vous devez le signaler à votre médecin.","If you experience these, you should consult your doctor before attempting such activities.",13,12
"4545","fr","en","Si un enfant avale des comprimés, prévenez immédiatemnt votre médecin.","If a child swallows some tablets, contact your doctor immediately.",10,10
"4546","fr","en","Si un saignement gastro-intestinal est suspecté, administrer des pansements gastriques.","If gastrointestinal bleeding is suspected, administer gastric protectants.",8,10
"4547","fr","en","Si une administration concomitante est jugée nécessaire, des précautions devront être prises.","If co-medication is considered necessary, caution is advisable.",8,12
"4548","fr","en","Si une dose supplémentaire est nécessaire, utiliser une nouvelle seringue contenant le produit reconstitué suivant les étapes ci-dessus.","If a further dose needs to be administered, use a new syringe with product reconstituted as described above.",18,18
"4549","fr","en","Si une hypotension symptomatique apparaît, un traitement approprié sera initié.","If symptomatic hypotension should occur, supportive treatment should be instituted.",10,10
"4550","fr","en","Si une réaction de photosensibilité survient au cours du traitement, il est recommandé d’ arrêter le traitement.","If a photosensitivity reaction occurs during treatment, it is recommended to stop the treatment.",14,17
"4551","fr","en","Si votre enfant présente un de ces symptômes contactez un médecin en urgence.","However, if your child gets any of these symptoms you should contact a doctor urgently.",15,13
"4552","fr","en","Si votre état s'aggrave, votre médecin vous administrera de nouveau Lucentis dans l 'œ il atteint.","If your condition is found to be worsening, your doctor will administer Lucentis to your affected eye again.",18,16
"4553","fr","en","Si votre foie ne fonctionne pas correctement, la dose usuelle ne doit pas dépasser 40 mg par jour.","If your liver is not working properly, the usual dose should not exceed 40 mg once daily.",17,18
"4554","fr","en","Si vous -même ou une personne de votre famille souffrez de cette maladie, vous devez consulter votre médecin.","If you or someone in your family suffers from this disease, you should consult your doctor.",16,18
"4555","fr","en","Si vous allaitez, n’utilisez pas AZOPT; il peut passer dans votre lait.","If you are breast-feeding, don’ t use AZOPT; it may get into your milk.",14,12
"4556","fr","en","Si vous arrêtez d’ utiliser LeukoScan?","If you stop using LeukoScan",5,6
"4557","fr","en","Si vous arrêtez de prendre votre médicament, vous risquez de perdre votre greffon.","If you stop taking your medicine, you risk losing your transplant.",11,13
"4558","fr","en","Si vous arrêtez votre traitement par les estrogènes, vous devez arrêter également de prendre Intrinsa.","If you stop estrogen therapy you must also stop using Intrinsa.",11,15
"4559","fr","en","Si vous avez arrêté ou souhaitez arrêter le traitement, parlez-en à votre médecin.","Talk to your doctor if you stop or wish to stop treatment.",12,13
"4560","fr","en","si vous avez bénéficié d'une greffe de moelle osseuse ou avez reçu des cellules souches.","If you have had a bone marrow transplant or have received blood stem cells in the past.",17,15
"4561","fr","en","Si vous avez d’autres questions, demandez p lus d’informations à votre médecin ou votre pharmacien.","If you have any further questions, after reading it, please ask your doctor or your pharmacist.",16,15
"4562","fr","en","Si vous avez des doutes sur l'identité des médicaments que vous utilisez, consultez votre médecin ou votre pharmacien.","If you are not sure whether you are taking one of those medicines ask your doctor or pharmacist.",18,18
"4563","fr","en","Si vous avez des questions sur l’utilisation de ce produit, posez les à votre médecin ou pharmacien.","If you have any further questions on the use of this product, ask your doctor or pharmacist.",17,17
"4564","fr","en","Si vous avez injecté plus de SOMAVERT que vous n’ auriez dû","If you inject more SOMAVERT than you should",8,12
"4565","fr","en","Si vous avez ou développez des problèmes rénaux ou hépatiques sévères, ce traitement sera arrêté.","If you have or develop severe kidney or liver problems, the treatment will be stopped.",15,15
"4566","fr","en","Si vous avez pris plus d’Hepsera que vous n’auriez dû","If you take more Hepsera than you should",8,10
"4567","fr","en","Si vous avez pris plus de Cholestagel que vous n’ auriez dû Veuillez contacter votre médecin.","If you take more Cholestagel than you should Please contact your doctor.",12,16
"4568","fr","en","Si vous avez pris plus de MIRAPEXIN comprimés que vous n’ auriez dû:","If you take more MIRAPEXIN than you should If you accidentally take too many tablets,",15,13
"4569","fr","en","Si vous avez pris plus de Truvada que vous n’auriez dû","If you take more Truvada than you should",8,11
"4570","fr","en","Si vous avez une infection quelle qu’elle soit.","If you have an infection of any kind.",8,8
"4571","fr","en","Si vous avez utilisé plus d’ Apidra que vous n’ auriez dû","If you use more Apidra than you should",8,12
"4572","fr","en","Si vous avez utilisé plus d’Insuman Comb 15 que vous n’auriez dû","If you use more Insuman Comb 15 than you should",10,12
"4573","fr","en","Si vous avez utilisé plus de GONAL-f que vous n’auriez dû","If you use more GONAL-f than you should",8,11
"4574","fr","en","Si vous conduisez un véhicule ou utilisez des machines: faites attention aux signes d’ hypoglycémie.","If you drive or use tools or machines: watch out for signs of a hypo.",15,15
"4575","fr","en","Si vous développez une nouvelle infection","If you develop a new infection or notice any new or",11,6
"4576","fr","en","Si vous devez mélanger deux types d’ insuline","If you have to mix two types of insulin",9,8
"4577","fr","en","Si vous doutez de la composition de vos médicaments, demandez à votre médecin ou à votre pharmacien.","If you are uncertain if your medicines contain these substances, you should check with your doctor or pharmacist.",18,17
"4578","fr","en","Si vous êtes admis à l’ hôpital, informez votre médecin que vous prenez Ebixa.","If you go into hospital, let your doctor know that you are taking Ebixa.",14,14
"4579","fr","en","Si vous êtes âgé de plus de 65 ans, vous recevrez la même dose que les autres adultes.","If you are older than 65, you will be given the same dose as other adults.",16,18
"4580","fr","en","Si vous êtes allergique (hypersensible) à l'insuline ou à tout autre composant contenu dans Insulin Human Winthrop Rapid.","If you are allergic (hypersensitive) to insulin or any of the other ingredients of Insulin Human Winthrop Rapid.",18,18
"4581","fr","en","Si vous êtes atteint de la maladie de Crohn, on vous prescrira d’abord d'autres médicaments.","If you have Crohn’ s disease you will first be given other medicines.",13,15
"4582","fr","en","Si vous êtes au moment de la prise suivante, ne prenez pas le comprimé oublié.","If it is close to your next dose, don't take the missed tablet anymore.",14,15
"4583","fr","en","Si vous êtes dans l'une des situations ci-dessus, veuillez en parler à votre médecin avant de prendre Dafiro.","If any of these apply to you, tell your doctor before taking Dafiro.",13,18
"4584","fr","en","Si vous êtes enceinte ou si vous allaitez, l'utilisation d'Aerius sirop n'est pas recommandée.","If you are pregnant or nursing a baby, taking Aerius syrup is not recommended.",14,14
"4585","fr","en","Si vous êtes enceinte, si vous prévoyez une grossesse ou si vous allaitez: demandez conseil à votre médecin","If you are pregnant, planning a pregnancy or breast-feeding: please contact your doctor for advice.",15,18
"4586","fr","en","Si vous n’obtenez toujours pas un jet d’insuline, NE PAS UTILISER le stylo.","If you are still unable to get insulin flowing out of the needle, do NOT use the pen.",18,13
"4587","fr","en","Si vous ne répondez pas au traitement par Valtropin, le médecin procédera à un dosage des anticorps.","If you are failing to respond to therapy with Valtropin, your doctor will test for antibodies.",16,17
"4588","fr","en","Si vous ne tolérez pas certains sucres, consultez votre médecin avant de prendre PritorPlus.","If you are intolerant to some sugars, consult your doctor before taking PritorPlus.",13,14
"4589","fr","en","Si vous ne voyez aucun résultat après 4 mois, contactez votre médecin.","If you do not see any benefit after using it f or 4 months contact your doctor.",17,12
"4590","fr","en","Si vous ou votre enfant voyez apparaître des problèmes d’audition, prévenez votre médecin.","Hypoacusis (hearing loss) Tell the doctor if you/your child develop hearing problems.",12,13
"4591","fr","en","Si vous oubliez d’utiliser Insuman Infusat","If you forget to use Insuman Infusat",7,6
"4592","fr","en","Si vous oubliez de prendre Actos 45 mg, comprimé:","If you forget to take Actos 45mg tablets:",8,9
"4593","fr","en","Si vous oubliez de prendre CEPROTIN","If you forgot to take CEPROTIN",6,6
"4594","fr","en","Si vous oubliez de prendre Ebixa","If you forget to take Ebixa",6,6
"4595","fr","en","Si vous oubliez de prendre Kinzalmono","If you forget to take Kinzalmono",6,6
"4596","fr","en","Si vous oubliez de prendre Orfadin:","If you forget to take Orfadin:",6,6
"4597","fr","en","Si vous oubliez de prendre Silgard","If you forget to take Silgard:",6,6
"4598","fr","en","Si vous oubliez de prendre Zerene:","If you forget to take Zerene",6,6
"4599","fr","en","Si vous pensez correspondre à l’un de ces cas, ne prenez pas les comprimés.","If you think any of these apply to you, do not take the tablets.",14,14
"4600","fr","en","Si vous pensez que vous avez un problème avec Apidra, parlez -en à votre médecin ou votre pharmacien.","If you think you may have a problem with Apidra, have it checked by your doctor or pharmacist.",18,18
"4601","fr","en","Si vous prenez Humira ce risque peut augmenter.","If you take Humira your risk may increase.",8,8
"4602","fr","en","Si vous présentez une telle réaction, contactez immédiatement votre médecin.","When you experience such a reaction, you should immediately contact your doctor.",12,10
"4603","fr","en","Si vous recevez l'association Pegasys-ribavirine, vous devez lire également la notice d'information de la ribavirine.","If you receive combination therapy of Pegasys and ribavirin, you should also read the ribavirin package leaflet.",17,15
"4604","fr","en","Si vous remarquez des particules en suspension, n’utilisez pas la solution.","If you notice any particles in the solution, do not use it.",12,11
"4605","fr","en","Si vous remarquez des problèmes musculaires Parlez -en à votre médecin.","If you notice any muscle problems: → Tell your doctor.",10,11
"4606","fr","en","Si vous remarquez des symptômes d’ infection, veuillez en informer immédiatement votre médecin.","If you notice any symptoms of infection, please tell your doctor immediately.",12,13
"4607","fr","en","Si vous ressentez ces symptômes, vous devez éviter de conduire un véhicule ou d'utiliser des machines.","Do not drive or operate machines if you experience these symptoms.",11,16
"4608","fr","en","Si vous ressentez des symptômes évoquant une atteinte du foie comme","If you experience symptoms suggesting a damage of the liver, such as",12,11
"4609","fr","en","Si vous ressentez l’ un de ces troubles, prévenez votre médecin.","If you experience any of these you should tell your doctor.",11,11
"4610","fr","en","Si vous ressentez l’un de ces symptômes, veuillez en informer votre médecin.","If you notice any of these symptoms please inform your doctor.",11,12
"4611","fr","en","Si vous ressentez plusieurs de ces symptômes, consultez immédiatement votre médecin.","Round, white, standard bevelled-edge, coded with ‘ TZ/ 4’ on one side.",12,11
"4612","fr","en","Si vous souffrez d'un ou de plusieurs symptômes, informez votre médecin.","If you are concerned about any side effects, talk to your doctor.",12,11
"4613","fr","en","Si vous souffrez d’une maladie du foie, vous pouvez également présenter un risque accru d’acidose lactique.","If you have liver disease you may also be more at risk of getting this condition.",16,16
"4614","fr","en","Si vous souffrez de l'une des maladies suivantes, veuillez en informer votre médecin le plus tôt possible:","If you suffer from any of the following illnesses tell your doctor as soon as possible:",16,17
"4615","fr","en","Si vous vous sentez fatigué ou faible, ne conduisez pas et n'utilisez pas de machines.","If you feel tired or weak do not drive and do not use machines.",14,15
"4616","fr","en","Siemens & Co Heilwasser Und Quellenprodukte Des Staatsbades Bad Ems Gmbh & Co. KgArzbacher Str.","Siemens & Co Heilwasser Und Quellenprodukte Des Staatsbades Bad Ems Gmbh & Co. KgArzbacher Str.",15,15
"4617","fr","en","Sifrol est indiqué lorsque la cause précise de ce trouble ne peut être identifiée.","Sifrol is used when a specific cause for the disorder cannot be identified.",13,14
"4618","fr","en","Silapo 10 000 UI/ 1,0 ml solution injectable en seringue préremplie","Silapo 10000 IU/1.0ml solution for injection in pre-filled syringe",9,11
"4619","fr","en","Silapo 6 000 UI/ 0,6 ml solution injectable en seringue préremplie","Silapo 6000 IU/0.6ml solution for injection in pre-filled syringe",9,11
"4620","fr","en","Silapo doit être administré au patient après sa séance de dialyse.","Silapo should be given after the patient has received a dialysis session.",12,11
"4621","fr","en","Sími: + 354 535 7000","Sími: + 354 535 7000",5,5
"4622","fr","en","Simi: +354 535 7000","Sími: +354 535 7000",4,4
"4623","fr","en","Simí: +354 540 8000 ISmail@merck. com","Simí: +354 540 8000 ISmail@merck.com",5,6
"4624","fr","en","Simvastatine ↑↑ Lovastatine ↑↑ Les concentrations plasmatiques dépendent fortement du métabolisme du CYP3A4.","Simvastatin ↑↑ Lovastatin ↑↑ Plasma concentrations highly dependent on CYP3A4 metabolism.",11,13
"4625","fr","en","Singulair 4 mg zrnca","Singulair 4 mg zrnca 4 mg",6,4
"4626","fr","en","Sinon le liquide risque de s’ échapper ce qui peut entrainer un dosage inexact.","Otherwise, the liquid may leak out which can cause inaccurate dosing.",11,14
"4627","fr","en","sitagliptine + metformine et sulfamide hypoglycémiant 2","Sitagliptin with Metformin and a Sulphonylurea2",6,7
"4628","fr","en","SK 821 08 Bratislava 2 Tel: + 421 (0) 2 4445 4176","Karadž ič ova 10 SK 821 08 Bratislava 2 Tel: + 421 (0) 2 4445 4176",16,12
"4629","fr","en","Slovenija BRISTOL-MYERS SQUIBB SPOL.","Slovenija BRISTOL-MYERS SQUIBB SPOL.",4,4
"4630","fr","en","Slovenija Ewopharma d. o. o.","Slovenija Ewopharma d. o. o.",5,5
"4631","fr","en","Slovenija Ireland sanofi-aventis d. o. o. sanofi-aventis Ireland Ltd.","Ireland sanofi-aventis Ireland Ltd.",4,9
"4632","fr","en","Slovenija Lek farmacevtska druž ba d. d.","Slovenija Lek farmacevtska druž ba d. d.",7,7
"4633","fr","en","Slovenija Merck Sharp & Dohme, inovativna zdravila d. o. o.","Slovenija Merck Sharp & Dohme, inovativna zdravila d. o. o.",10,10
"4634","fr","en","Slovenija Takeda Global Research and Development Centre (Europe) Ltd., Velika Britanija Tel: + 44 (0)203 116 8000","Slovenija Takeda Global Research and Development Centre (Europe) Ltd., Velika Britanija Tel: + 44 (0)203 116 8000",17,17
"4635","fr","en","Slovenská republika A LLMEDICAL s.r.o.","Slovenská republika ALLMEDICAL s.r.o.",4,5
"4636","fr","en","Slovenská republika Boehringer Ingelheim Pharma organizač ná zlož ka Tel: +421 2 5810 1211","Slovenská republika Boehringer Ingelheim RCV GmbH & Co KG organizač ná zlož ka Tel: +421 2 5810 1211",18,14
"4637","fr","en","Slovenská republika GlaxoSmithKline Slovakia s.r.o.","Slovenská republika GlaxoSmithKline Slovakia s. r. o.",7,5
"4638","fr","en","Slovenská republika Ísland Pfizer Luxembourg SARL, organizačná zložka Vistor hf Tel: +421–2–3355 5500 Sími: +354 535 7000","Slovenská republika Pfizer Luxembourg SARL, organizačná zložka Tel: +421-2-3355 5500",10,17
"4639","fr","en","Slovenská republika IVAX Pharmaceuticals s. r. o Tel: +420 553 641 111","Slovenská republika IVAX Pharmaceuticals s.r.o Tel: +420 553 641 111",10,12
"4640","fr","en","Slovenská republika Merck Sharp & Dohme IDEA, Inc.","Slovenská republika Merck Sharp & Dohme IDEA, Inc.",8,8
"4641","fr","en","Slovenská republika Nycomed s.r.o.","Slovenská republika Nycomed s. r. o.",6,4
"4642","fr","en","Slovenská republika Servier Slovensko spol. s r. o.","Slovenská republika Servier Slovensko spol. s r. o.",8,8
"4643","fr","en","Slovenská republika UCB s.r.o.","Slovenská republika UCB s.r.o.",4,4
"4644","fr","en","SmithKline Beecham Pharmaceuticals Manor Royal, Crawley West Sussex RH10 9QJ Royaume-Uni","SmithKline Beecham Pharmaceuticals, Manor Royal, Crawley, West Sussex RH10 9QJ, United Kingdom",12,11
"4645","fr","en","SN027512) et le bicarbonate de sodium.","SN027512) and sodium hydrogen carbonate.",5,6
"4646","fr","en","Socitété Teva Classics Le Palatin 1 1, cours du Triangle 92936 Paris la Défense Cedex France","Socitété Teva Classics Le Palatin 1 1, cours du Triangle 92936 Paris la Défense Cedex France",16,16
"4647","fr","en","sodique, cellulose microcristalline, silice colloïdale anhydre, stéarate de magnésium.","cellulose, colloidal anhydrous silica and magnesium stearate.",7,9
"4648","fr","en","Soixante-sept pourcent (67%) des patients ont eu au moins une réaction associée à la perfusion.","Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction.",13,15
"4649","fr","en","SOLACYL 100%, Poudre pour solution orale destinée aux veaux et aux porcs","SOLACYL 100%, powder for oral solution for calves and pigs",10,12
"4650","fr","en","SoloStar délivre des doses d’ insuline allant de 1 à 80 unités, par intervalle de 1 unité.","SoloStar delivers insulin in doses from 1 to 80 units in steps of 1 unit.",15,17
"4651","fr","en","Solution à diluer pour perfusion","Concentrate for solution for infusion",5,5
"4652","fr","en","Solution à diluer pour perfusion 100 mg 1 flacon de 4 ml","Concentrate for solution for infusion 100 mg 1 vial of 4 ml",12,12
"4653","fr","en","Solution buvable limpide, incolore à jaune clair","Clear, colourless to pale or light yellow oral solution",9,7
"4654","fr","en","Solution incolore ou légèrement jaune à diluer pour perfusion.","Colourless to slightly yellow concentrate.",5,9
"4655","fr","en","Solution inject able 40 IU/ml, 100 IU/m flacons + cartouches 3 Présentations","Solution for injection 40 IU/ml vi als, 100 IU/m vials + Cartridges 3 Presentations",14,12
"4656","fr","en","Solution injectable 1 cartouche 1 boîte de 3 aiguilles","Solution for injection 1 cartridge 1 pack with 3 needles",10,9
"4657","fr","en","Solution injectable dans une cartouche (1,5 ml).","Solution for injection in a cartridge (1.5 ml).",8,7
"4658","fr","en","Solution injectable en seringue pré- remplie","Solution for Injection in prefilled",5,6
"4659","fr","en","Solution injectable ou pour","Solution for injection or infusion Subcutaneous and intravenous vial (glass)",10,4
"4660","fr","en","Solution injectable ou pour perfusion.","ra Solution for injection Solution is clear and colourless.",9,5
"4661","fr","en","Solution injectable, 20 seringues pré-remplies avec système de sécurité automatique en","Solution for injection, 20 pre-filled syringes with an automatic safety system ct",12,11
"4662","fr","en","Solvant pour Enbrel 1 ml d’ eau bactériostatique pour préparations injectables","Solvent for Enbrel 1ml bacteriostatic water for injections",8,11
"4663","fr","en","Solvant pour solution Eau pour préparations injectables","Solvent for solution Water for Injections",6,7
"4664","fr","en","Solvant: eau pour injections","Powder: glycine, disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate dihydrate Solvent: water for injections",14,4
"4665","fr","en","Solvant: poloxamer 188, eau pour préparations injectables.","Solvent: poloxamer 188, water for injection",6,7
"4666","fr","en","Solvant: solution claire incolore à légèrement jaune.","Powder: yellow solid Solvent: clear, colourless to slightly yellow solution.",10,7
"4667","fr","en","Somatropine 6,7 mg (20 UI)/ ml.","Somatropin 6.7 mg (20 IU)/ ml.",6,6
"4668","fr","en","somnolence, sensation de brûlure Érythème de la","sensation Erythema of eyelid,",4,7
"4669","fr","en","Son effet est plus puissant sur la PDE5 que sur les autres phosphodiestérases connues.","Its effect is more potent on PDE5 than on other known phosphodiesterases.",12,14
"4670","fr","en","Son effet maximum apparaît 1 à 4 heures après l’ injection.","The maximum effect is exerted between 1 and 4 hours after injection.",12,11
"4671","fr","en","Son efficacité a été démontrée au cours d’ études contrôlées chez des patients traités jusqu’ à 29 semaines.","Efficacy was demonstrated in controlled trials in patients treated for up to 29 weeks.",14,18
"4672","fr","en","Son principe actif est l'insuline lispro.","Its active substance is insulin lispro.",6,6
"4673","fr","en","Son utilisation au cours des trois premiers mois de la grossesse n’ est pas recommandée.","Its use during the first three months of pregnancy is not recommended.",12,15
"4674","fr","en","Sonata appartient à la classe des substances apparentées aux benzodiazépines, qui consiste en des préparations à action hypnotique.","Sonata belongs to a class of substances called benzodiazepine-related medicinal products, which consists of preparations with hypnotic actions.",18,18
"4675","fr","en","sont la fatigue, infections répétées, contusion ou saignement inexpliqué.","unexplained bruising or bleeding.",4,9
"4676","fr","en","Sortir une pipette de l’ emballage.","Remove one pipette from the package.",6,6
"4677","fr","en","Soyez particulièrement vigilant(e) en début de traitement ou après une augmentation de la dose.","Be particularly careful at the start of treatment or after your dose is increased.",14,14
"4678","fr","en","Soyez prudent pendant la conduite des véhicules et l’ utilisation de machine(s).","Be careful when driving a car or using machinery.",9,12
"4679","fr","en","SP Europe 73, rue de Stalle Ce","SP Europe 73, rue de Stalle",6,7
"4680","fr","en","SP Europe Rue de Stalle 73 B-1180 Bruxelles, Belgique","SP Europe Rue de Stalle 73 B-1180 Bruxelles, Belgium",9,9
"4681","fr","en","SP Europe, Rue de Stalle 73, B-1180 Bruxelles, Belgique.","SP Europe, Rue de Stalle 73, B-1180 Bruxelles, Belgium.",9,9
"4682","fr","en","Spécialisé en médecine interne et en pharmacologie clinique.","Specialist in internal medicine and clinical pharmacology.",7,8
"4683","fr","en","Sphères de sucre (contenant du saccharose) et aspartam (E951)","Sugar spheres (containing sucrose) and aspartame (E951)",7,9
"4684","fr","en","SPID60 moyen (+/ - ET) EFFENTORA=9,7(5,58) p < 0,0001 Placebo=4,9 (4,38)","SPID60 mean (+/ - SD) EFFENTORA=9.7(5.58) p < 0.0001 Placebo=4.9(4.38)",10,11
"4685","fr","en","Sprimeo a un effet négligeable sur l’ aptitude à conduire des véhicules et à utiliser des machines.","Sprimeo has negligible influence on the ability to drive and use machines.",12,17
"4686","fr","en","SPRYCEL permet de lutter contre la prolifération de ces cellules leucémiques.","SPRYCEL inhibits the growth of these leukaemic cells.",8,11
"4687","fr","en","st EU/ 1/ 99/ 128/ 005","g on EU/ 1/ 99/ 128/ 005",7,6
"4688","fr","en","St Mary’s Pharmaceutical Unit Quadrant Centre Cardiff Business Park Llanishan Cardiff Wales CF14 5RA Royaume-Uni.","St Mary’s Pharmaceutical Unit Quadrant Centre Cardiff Business Park Llanishan Cardiff Wales CF14 5RA United Kingdom.",16,15
"4689","fr","en","STADA Arzneimittel AG Stadastr.","STADA Arzneimittel AG Stadastr.",4,4
"4690","fr","en","Stalevo 50 mg/ 12,5 mg/ 200 mg comprimés pelliculés lévodopa/ carbidopa/ entacapone","Stalevo 50 mg/ 12.5 mg/ 200 mg film-coated tablets levodopa/ carbidopa/ entacapone",12,12
"4691","fr","en","Stalevo et les préparations martiales doivent donc être pris à 2-3 heures d'intervalle au moins (voir rubrique 4.8).","Therefore, Stalevo and iron preparations should be taken at least 2-3 hours apart (see section 4.8).",16,18
"4692","fr","en","STAMARIL (ou nom de marque local) Poudre et solvant pour suspension injectable.","STAMARIL (or local trade name) Powder and solvent for suspension for injection.",12,12
"4693","fr","en","Starlix 60 mg, comprimés pelliculés Natéglinide","Starlix 60 mg film-coated tablets Nateglinide",6,6
"4694","fr","en","STARTVAC Émulsion injectable pour bovins","STARTVAC Emulsion for injection for cattle",6,5
"4695","fr","en","Stelara est administré sous la surveillance d’ un médecin expérimenté dans le diagnostic et le traitement du psoriasis.","Stelara is given under the supervision of a doctor who has experience in diagnosing and treating psoriasis.",17,18
"4696","fr","en","Steve DEAN Chief Executive Veterinary Medicines Directorate Woodham Lane New Haw, Addlestone Surrey KT15 3LS Royaume-Uni Tel.","Steve DEAN Chief Executive Veterinary Medicines Directorate Woodham Lane New Haw, Addlestone Surrey KT15 3LS United Kingdom Tel.",18,17
"4697","fr","en","Stichting Sanquin Bloedvoorziening, Plesmanlaan 125 1066 CX Amsterdam Pays-Bas","Stichting Sanquin Bloedvoorziening, Plesmanlaan 125 1066 CX Amsterdam The Netherlands",10,9
"4698","fr","en","STOCRIN 200 mg, gélules éfavirenz","STOCRIN 200 mg capsules efavirenz",5,5
"4699","fr","en","STOCRIN peut réduire la quantité de l'anticonvulsivant dans votre sang.","STOCRIN can reduce or increase the amount of anticonvulsant in your blood.",12,10
"4700","fr","en","Stomatite Vomissements Dyspepsie Douleur abdominalec","Vomiting Stomatitis Dyspepsia Abdominal pain C / distension",8,5
"4701","fr","en","Strada Statale No 17, km22 67019 Scoppito (L’ Aquila) Italie","Strada Statale No 17, km22 67019 Scoppito (L’ Aquila) Italy",10,10
"4702","fr","en","Streptoococus agalactiae Streptococcus pneumoniae S. pneumoniae résistant à la pénicilline Streptococcus pyogenes Aérobies à Gram négatif Acinetobacter spp.","Streptoococus agalactiae Streptococcus pneumoniae S. pneumoniae PEN-R Streptococcus pyogenes Gram-negative aerobes Acinetobacter spp.",13,18
"4703","fr","en","STRONGHOLD 30 mg solution pour spot -on","STRONGHOLD 30 mg spot-on solution",5,7
"4704","fr","en","Stryker Biotech 9 Technology Drive West Lebanon NH 03784 U.S.A.","Stryker Biotech 9 Technology Drive West Lebanon NH 03784 USA",10,10
"4705","fr","en","Stylo pré-rempli (verre) (SureClick)","pre-filled pen (glass) (SureClick)",4,4
"4706","fr","en","Stylos avant utilisation A conserver au réfrigérateur (2°C - 8°C).","Not in -use pens Store in a refrigerator (2°C – 8°C).",11,10
"4707","fr","en","SUBSTITUTIFS AUX OPIACES Méthadone ASC ↓ 0,40 (0,31-0,51) Méthadone (dose individualisée)","DRUG ABUSE Methadone Individual Patient Dosing",6,11
"4708","fr","en","Succursale belge Tél/ Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck. com","Succursale belge Tél/Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck.com",10,12
"4709","fr","en","suintement de la plaie retard de cicatrisation des plaies","Wound secretion Impaired wound healing",5,9
"4710","fr","en","Suite à des injections annuelles répétées, le profil de tolérance d'IDflu est similaire à celui des injections précédentes.","After repetitive yearly injections the safety profile of IDflu is similar to the previous injections.",15,18
"4711","fr","en","Suivez attentivement leurs conseils.","ris Talk about your insulin needs with your doctor and diabetes nurse.",12,4
"4712","fr","en","Suivez attentivement toutes les instructions qui vous sont données par votre médecin.","Follow carefully all instructions given to you by your doctor.",10,12
"4713","fr","en","Suivez les indications de votre médecin.","Please follow your doctor’s instructions for taking your medicine.",9,6
"4714","fr","en","Sujet âgé Aucun ajustement posologique n’ est nécessaire chez le sujet âgé.","Elderly No dose adjustment is necessary for the elderly.",9,12
"4715","fr","en","Sujets âgés (≥ 65 ans):","Elderly patients (≥ 65 years old):",6,5
"4716","fr","en","Sujets âgés (plus de 65 ans) Comme pour les adultes","Elderly (over 65 years old) As for adults",8,10
"4717","fr","en","Sujets âgés La dermatite atopique (eczéma) est rarement observée chez les patients âgés de 65 ans et plus.","Atopic dermatitis (eczema) is rarely observed in patients aged 65 and over.",12,18
"4718","fr","en","Sujets âgés: aucune adaptation posologique de Irbesartan Hydrochlorothiazide Winthrop n'est nécessaire chez le sujet âgé.","Elderly patients: no dosage adjustment of Irbesartan Hydrochlorothiazide Winthrop is necessary in elderly patients.",14,15
"4719","fr","en","Suomen Astra OY PL 6 02431 Masala","Suomen Astra OY PL 6",5,7
"4720","fr","en","Suomi/ Finland GlaxoSmithKline Oy Puh/ Tel: + 358 10 30 30 30 Finland. tuoteinfo@gsk. com","Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 Finland.tuoteinfo@gsk.com",11,15
"4721","fr","en","Suomi/ Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30","GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 Finland.tuoteinfo@gsk.com",10,11
"4722","fr","en","Suomi/ Finland JANSSEN-CILAG OY Puh/ Tel: +358 9 4155 5300","Suomi/ Finland JANSSEN-CILAG OY Puh/ Tel: +358 9 4155 5300",10,10
"4723","fr","en","Suomi/ Finland Orion Corporation Orionintie 1 FIN-02200 Espoo/ Esbo Tel: +358 10 4261","Suomi/ Finland Orion Corporation Orionintie 1 FIN-02200 Espoo/ Esbo Tel: +358 10 4261",13,13
"4724","fr","en","Suomi/ Finland Pfizer Oy Puh/ Tel: + 358 (0)9 43 00 40","Suomi/ Finland Pfizer Oy Puh/ Tel: + 358 (0)9 43 00 40",12,12
"4725","fr","en","Suomi/ Finland Sanofi Pasteur MSD, Puh/ Tel: +358.9.565.88.30","Suomi/Finland Sanofi Pasteur MSD, Puh/Tel: +358.9.565.88.30",6,8
"4726","fr","en","Suomi/ Finland Serono Nordic Rajatorpantie 41B FIN-01640 Vantaa Puh/ Tel: +358-9-85 20 20 20","Suomi/ Finland Serono Nordic Rajatorpantie 41B FIN-01640 Vantaa Puh/ Tel: +358-9-85 20 20 20",14,14
"4727","fr","en","Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102 800","Suomi/ Finland Boehringer Ingelheim Finland Ky Puh/ Tel: +358 10 3102 800",12,10
"4728","fr","en","Suomi/Finland PL 3/PB 3 FIN-02201 Espoo/Esbo","Suomi/Finland PL 3/PB 3 FIN-02201 Espoo/Esbo",6,6
"4729","fr","en","Suomi/Finland PL 86/PB 86 FIN-02151 Espoo/Esbo Puh/Tel: + 358-(0)20-7570 300","Puh/Tel: + 358-(0)20-7570 300",4,10
"4730","fr","en","Sur demande de l’EMEA","At the request of the EMEA.",6,4
"4731","fr","en","Sur la base d’une comparaison croisée avec l’amprénavir 1200 mg deux fois","Based on cross-study comparison to 1200 mg amprenavir twice daily alone.",11,12
"4732","fr","en","Sur la base des données disponibles, une relation de causalité ne peut être ni confirmée, ni exclue.","Based on the available data, a causal relationship can neither be confirmed nor excluded.",14,17
"4733","fr","en","SUR LE MARCHE e am dic mé Ce","CONDITIONS OF THE MARKETING AUTHORISATION t uc rod lp ina dic Me",12,8
"4734","fr","en","Sur les 278 patients randomisés, 277 patients ont reçu au moins 1 dose du médicament de l’ étude.","Of the 278 patients randomised, 277 patients received at least 1 dose of study drug.",15,18
"4735","fr","en","Suramox 15% LA, suspension injectable Amoxicilline","Suramox 15% LA, suspension for injection Amoxicillin",7,6
"4736","fr","en","Surveillance de la fonction hépatique:","Monitoring of hepatic function:",4,5
"4737","fr","en","Surveillance de la formation de dioxyde d' azote","Monitoring formation of Nitrogen Dioxide",5,8
"4738","fr","en","Surveillance des patients La protéinurie semble être un indicateur précoce et sensible de néphrotoxicité induite par le cidofovir.","Patient Monitoring Proteinuria appears to be an early and sensitive indicator of cidofovir-induced nephrotoxicity.",14,18
"4739","fr","en","surveiller si vous prenez en même temps de la digoxine et Kaletra.","taking digoxin and Kaletra.",4,12
"4740","fr","en","Survie (mois) Médiane (mois) IC 95% pour la médiane Risque relatif","Survival Time (months) Median (m) 95% CI for median HR",10,11
"4741","fr","en","Suspension injectable 10 seringues 10 aiguilles 10 x 1 dose 1 dose (1 ml)","Suspension for injection 10 syringes 10 needles 10 x 1 dose 1 dose (1 ml)",15,14
"4742","fr","en","Suspension injectable en cartouche.","Suspension for injection in a cartridge.",6,4
"4743","fr","en","Suspension virale congelée Sulfoxyde de diméthyle Milieu de dilution","Dimethyl sulfoxide Dilution medium",4,9
"4744","fr","en","SUSTIVA 600 mg, comprimés pelliculés","SUSTIVA 600 mg film-coated tablets",5,5
"4745","fr","en","SUSTIVA doit être pris tous les jours.","SUSTIVA must be taken every day.",6,7
"4746","fr","en","SUTENT agit contre ces cancers en inhibant la croissance cellulaire tumorale.","SUTENT inhibits the growth of these cells.",7,11
"4747","fr","en","Sverige Actelion Pharmaceuticals Sverige AB Tel: +46 8 544 982 50","Sverige Actelion Pharmaceuticals Sverige AB Tel: +46 8 544 982 50",11,11
"4748","fr","en","Sverige Bayer AB Tel: +46 (0)8 580 223 00","Sverige Bayer AB Tel: +46 (0)8 580 223 00",9,9
"4749","fr","en","Sverige Box 6185 S-102 33 Stockholm Tel: + 46-(0)8 522 21 500","Sverige Box 6185 S-102 33 Stockholm Tel: + 46-(0)8 522 21 500",12,12
"4750","fr","en","Sverige Ceva Vetpharma AB Tel: + 46 (0)46 12 81 00","Sverige Ceva Vetpharma AB Tel: + 46 (0)46 12 81 00",11,11
"4751","fr","en","Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com","Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com",11,11
"4752","fr","en","Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 (0) 8 626 1400 medicinskinfo@merck. com","Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 (0) 8 626 1400 medicinskinfo@merck.com",14,15
"4753","fr","en","Sverige Orion Pharma Animal Health Box 334 S-192 30Tel:","Sverige Orion Pharma Animal Health Box 334 S-192 30Tel:",9,9
"4754","fr","en","Sverige Roche AB Tel: +46 (0) 8 726 1200","Sverige Roche AB Tel: +46 (0) 8 726 1200",9,9
"4755","fr","en","Sverige Serono Nordic AB S-195 87 Stockholm Tel: +46-8-562 445 00","Sverige Serono Nordic AB S-195 87 Stockholm Tel: +46-8-562 445 00",11,11
"4756","fr","en","Swensweg 5, Postbus 552, 2003 RN Haarlem Pays-Bas","Swensweg 5, Postbus 552, 2003 RN Haarlem The Netherlands",9,8
"4757","fr","en","Symptômes Il n'y a pas de données concernant le surdosage avec Copalia.","Symptoms There is no experience of overdose with Copalia.",9,12
"4758","fr","en","Syncope Etourdissement Tremblement Paresthésie Hypoesthésie Céphalée","Syncope Dizziness Tremor Paraesthesia Hypoesthesia Headache",6,6
"4759","fr","en","Syndrome coronarien aigu (SCA)","Acute coronary syndromes (ACS)",4,4
"4760","fr","en","Syndrome de détresse respiratoire aiguë, œ dème pulmonaire, détresse respiratoire, douleurs thoraciques","Patients must avoid potentially hazardous tasks, such as driving or operating machinery while experiencing these symptoms.",16,12
"4761","fr","en","Syndrome de Lyell, érythème polymorphe, lupus érythémateux discoïde","Electrocardiogram QT corrected interval prolonged, blood urea increased, blood cholesterol increased",11,8
"4762","fr","en","syndrome de Stevens-Johnson, syndrome de Lyell, érythème polymorphe","toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme",7,8
"4763","fr","en","Syndrome malin des neuroleptiques (SMN)","Neuroleptic malignant syndrome (NMS)",4,5
"4764","fr","en","systématique à une baisse de réponse ou à tout autre phénomène auto-immun.","ra all cases and have not been regularly associated with loss of response or any other autoimmune phenomenon.",18,12
"4765","fr","en","Système corporel Système cardiovasculaire (voir information détaillée ci- dessous)","Body system Cardiovascular system (see detailed information below)",8,9
"4766","fr","en","T4/ T1 à 0,7","T4/ T1 to 0.7",4,4
"4767","fr","en","TachoSil est présenté dans un double emballage:","TachoSil is packed in a double packaging:",7,7
"4768","fr","en","Tachycardie Insuffisance cardiaque, épanchement péricardique","Cardiac failure, pericardial effusion Vascular disorders Common:",7,5
"4769","fr","en","Tadalafil Lilly appartient à un groupe de médicaments appelés inhibiteurs de la phosphodiestérase de type 5.","Tadalafil Lilly belongs to a group of medicines called phosphodiesterase type 5 inhibitors.",13,16
"4770","fr","en","Taille de l’ emballage 1 seringue pré-remplie avec piston préfixé, sans aiguille","Package size 1 pre-filled syringe with pre-attached plunger rod, without a needle",12,12
"4771","fr","en","Takeda Ireland Limited Bray Business Park Kilruddery County Wicklow Irlande","Takeda Ireland Limited Bray Business Park Kilruddery County Wicklow Ireland",10,10
"4772","fr","en","Tamiflu 12 mg/ ml poudre pour suspension buvable Oseltamivir","Tamiflu 12 mg/ml powder for oral suspension Oseltamivir",8,9
"4773","fr","en","Tamiflu n'est pas une alternative à la vaccination antigrippale.","Tamiflu is not a substitute for influenza vaccination.",8,9
"4774","fr","en","Tandemact 45 mg/ 4 mg, comprimés","Tandemact 45 mg/ 4 mg tablets",6,6
"4775","fr","en","Tapotez délicatement la seringue afin d’ amener toute bulle vers le haut.","Tap the syringe gently to bring any bubbles to the top.",11,12
"4776","fr","en","Tarceva est disponible en dosages de 25 mg, 100 mg et 150 mg.","Tarceva is available in strengths of 25 mg, 100 mg and 150 mg.",13,13
"4777","fr","en","Tasmar 200 mg comprimés:","Tasmar 200 mg tablets:",4,4
"4778","fr","en","Taux d’ HbA1c dans les études versus placebo de l’ association de la sitagliptine et de la metformine*","HbA1c results in placebo-controlled combination therapy studies of sitagliptin and metformin*",11,18
"4779","fr","en","Taux de répondeurs (réponse au traitement) #","Responder rate (treatment response)#",4,7
"4780","fr","en","Taux de Réponse ACR 20","Response Rate ACR 20",4,5
"4781","fr","en","Taux de réponse prolongée avec ViraferonPeg + ribavirine","Sustained response rates with Viraferon Peg + ribavirin (by ribavirin dose, genotype and viral load)",15,8
"4782","fr","en","TAXOTERE 20 mg solution à diluer pour perfusion docétaxel Voie intraveineuse.","TAXOTERE 20 mg concentrate for solution for infusion docetaxel intravenous use",11,11
"4783","fr","en","Tekturna est un médicament dont le principe actif est l’ aliskiren.","Tekturna is a medicine containing the active substance aliskiren.",9,11
"4784","fr","en","Telzir comprimé peut être pris au cours ou en dehors des repas.","Telzir tablet can be taken with or without food.",9,12
"4785","fr","en","Temodal 2,5 mg/ml poudre pour solution pour perfusion témozolomide","Temodal 2.5 mg/ml powder for solution for infusion temozolomide",9,9
"4786","fr","en","Temodal est un médicament anticancéreux.","Temodal is an anticancer medicine.",5,5
"4787","fr","en","Temps d’ attente - Viande et abats (poules et dindes):","Withdrawal periods - Meat and offal (chickens and turkeys):",9,10
"4788","fr","en","Tenez fermement la seringue par les ailettes appui- doigts.","Hold the syringe firmly by the finger grip.",8,9
"4789","fr","en","Tenez un verre ou une tasse sous l’embout du bec verseur (voir l’illustration).","Hold a glass or cup under the nozzle (see picture).",10,13
"4790","fr","en","Tenez votre stylo et les aiguilles hors de la vue et de la portée des enfants.","Keep your pen and needles out of the reach and sight of children.",13,16
"4791","fr","en","Tenez votre stylo verticalement, l’aiguille dirigée vers le haut.","Hold your pen with the needle pointing up.",8,9
"4792","fr","en","Tenir hors de la portée et de la vue des enfants","Keep out of the reach and sight of children",9,11
"4793","fr","en","Tenir hors de la portée et de la vue des enfants.","Do not store above 30oC.",5,11
"4794","fr","en","Tenir hors de la portée et de la vue des enfants. uth","Keep out of the reach and sight of children. isa",10,12
"4795","fr","en","Tenir le stylo, l'aiguille dirigée vers le haut et ôter le capuchon extérieur et le cache de l'aiguille.","Hold the pen with needle pointing up and remove the outer needle cap and inner needle cover.",17,18
"4796","fr","en","ténofovir disoproxil (Truvada ou Atripla).","disoproxil fumarate (Truvada or Atripla).",5,5
"4797","fr","en","Tentative de suicide, idées suicidaires","Attempted suicide, suicidal ideation",4,5
"4798","fr","en","Terfenadin akut von ct","Terfenadin akut von ct",4,4
"4799","fr","en","TESAVEL peut être pris au cours ou en dehors des repas.","TESAVEL can be taken with or without food.",8,11
"4800","fr","en","Tester le dispositif avant d'ouvrir le sachet - voir notice jointe.","Test system before opening sachet – see enclosed leaflet.",9,11
"4801","fr","en","TEVA Pharmaceutical Works Private Limited Company H-2100 Gödöllő Táncsics Mihály út 82 Hongrie","TEVA Pharmaceutical Works Private Limited Company H-2100 Gödöllő Táncsics Mihály út 82 Hungary",13,13
"4802","fr","en","Teva UK limited Brampton Road BN22 9AG East Sussex Royaume-Uni","Denmark Teva UK Limited Brampton Road BN22 9AG East Sussex United Kingdom",12,10
"4803","fr","en","Teva UK Limited Tel: +44 1323 501 111","United Kingdom Teva UK Limited Tel: +44 1323 501 111",10,8
"4804","fr","en","TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex BN22 9AG UK","TEVA UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG UK",13,13
"4805","fr","en","Tevagrastim est une solution injectable ou pour perfusion (goutte-à-goutte dans une veine).","Tevagrastim is a solution for injection or for infusion (drip into a vein).",13,12
"4806","fr","en","TEXTE DE L'EMBALLAGE EXTERIEUR Fertavid 150 UI/ 0,5 ml 10 flacons","OUTER CARTON TEXT Fertavid 150 IU/ 0.5 ml 10 vials",10,11
"4807","fr","en","TEXTE DE L'ETUI Puregon 150 UI 3 ampoules","OUTER CARTON TEXT Puregon 150 IU 3 ampoules",8,8
"4808","fr","en","TEXTE DE L'ETUI Puregon 75 UI 1 flacon","OUTER CARTON TEXT Puregon 75 IU 1 vial",8,8
"4809","fr","en","TEXTE DU FLACON Fertavid 200 UI/ 0,5 ml","VIAL TEXT Fertavid 200 IU/ 0.5 ml",7,8
"4810","fr","en","Thomas Lönngren, en qualité de nouveau directeur exécutif de l'EMEA, le 3 janvier 2001.","Details of membership of the Management Board are given in",10,14
"4811","fr","en","thoracique, malaise, œ dème périphérique","Chills, chest pain, malaise, peripheral oedema",6,5
"4812","fr","en","Thrombocytopénie, lymphadénopathie, lymphopénie Fréquent:","Hypothyroidism§, hyperthyroidism§ Diabetes, aggravated diabetes",5,4
"4813","fr","en","Thrombocytopénie, purpura thrombocytopénique, lymphadénopathie","Blood and lymphatic system disorders thrombocytopenia, thrombocytopenic purpura, lymphadenopathy",9,4
"4814","fr","en","thrombotique thrombocytopéniqu e/ syndrome hémolytique et urémique Leucopénie Neutropénie","Thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome Leukopenia Neutropenia",8,9
"4815","fr","en","Thyrogen 0,9 mg de poudre pour solution injectable","Thyrogen 0.9 mg powder for solution for injection",8,8
"4816","fr","en","Tietgens Boulevard 40 5220 Odense SØ, Danemark","Tietgens Boulevard 40 5220 Odense SØ, Denmark",7,7
"4817","fr","en","Tirer la languette rouge pour séparer la partie inférieure du boîtier de la partie supérieure.","Pull the red tab to separate the bottom housing from the top housing.",13,15
"4818","fr","en","Tirez à fond le bouton d’ injection afin de charger la dose.","Pull out the injection button completely in order to load the dose.",12,12
"4819","fr","en","Titre du document Revision of Note for guidance on carcinogenic potential (3BS7a, Volume 3B, 1998, p.","Document title Revision of Note for guidance on carcinogenic potential (3BS7a, Volume 3B, 1998, p.",15,16
"4820","fr","en","TITULAIRE DE L'AUTORISATION DE FABRICATION RESPONSABLE DE LA LIBERATION DES LOTS","MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE",7,11
"4821","fr","en","Titulaire de l'autorisation de mise sur le marché et fabricant","Marketing Authorisation Holder and Manufacturer",5,10
"4822","fr","en","Titulaire de l'Autorisation de Mise sur le Marché et Fabricant Titulaire de l'autorisation de mise sur le marché:","Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder:",8,18
"4823","fr","en","Titulaire de l’ autorisation de mise sur le marché","Member State EU/ EEA",4,9
"4824","fr","en","Titulaire de l’ Autorisation de mise sur le marché et fabricant:","The marketing authorisation holder and manufacturer:",6,11
"4825","fr","en","Titulaire de l’ autorisation de mise sur le marché:","Marketing Authorisation Holder Orion Corporation",5,9
"4826","fr","en","Titulaire de l’Autorisation de mise sur le marché Eli Lilly Nederland BV, Grootslag 1-5, NL-3991 RA Houten, Pays-Bas.","Marketing Authorisation Holder Eli Lilly Nederland BV, Grootslag 1-5, NL-3991 RA Houten, The Netherlands.",14,18
"4827","fr","en","Titulaire de L’autorisation de mise sur le marché et fabricant Sanofi-Aventis Deutschland GmbH, D-69526 Frankfurt am Main Allemagne.","Marketing Authorisation Holder and Manufacturer Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main Germany",13,18
"4828","fr","en","Titulaire de l’autorisation de mise sur le marché Wyeth Europa Ltd.","Marketing Authorisation Holder Wyeth Europa Ltd.",6,11
"4829","fr","en","Titulaire de l’Autorisation de Mise sur le Marché: éd","ra Marketing Authorisation Holder and Manufacturer",6,9
"4830","fr","en","TITULAIRES DE L’ AUTORISATION DE FABRICATION RESPONSABLES DE LA LIBERATION DES LOTS","MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE",7,12
"4831","fr","en","TK3 205 Alewife Brook Parkway Cambridge, MA 02138 USA","TK3 205 Alewife Brook Parkway Cambridge, MA 02138 USA",9,9
"4832","fr","en","to du bouton gris.","ho ut ra n ge lo",6,4
"4833","fr","en","to Maladie de Paget.","Paget's disease of bone.",4,4
"4834","fr","en","to observés chez 1 patient (0,2%) de chaque groupe.","Major bleedings were observed in 1 patient (0.2%) of each group.",11,9
"4835","fr","en","to Solution injectable en seringue préremplie.","Solution for injection in a pre-filled syringe.",7,6
"4836","fr","en","to Titulaire de l’ Autorisation de mise sur le marché et fabricant","Marketing Authorisation Holder and Manufacturer a",6,12
"4837","fr","en","tor 1 aiguille à injection et 1 tampon nettoyant.","needle and 1 cleansing swab.",5,9
"4838","fr","en","tor Berkshire SL6 4XE - UK Tel: + 44 (0) 1628 773355","Maidenhead Berkshire SL6 4XE - UK Tel: + 44 (0) 1628 773355 Me",13,12
"4839","fr","en","tor Insuline humaine, ADNr","tho Insulin human, rDNA",4,4
"4840","fr","en","tor Le présent document est un résumé du rapport européen public d’ évaluation (EPAR).","tho This document is a summary of the European Public Assessment Report (EPAR).",13,14
"4841","fr","en","tor prolongée est de 47%.","In adult patients receiving interferon in combination with ribavirin, the achieved sustained response rate is 47%.",16,5
"4842","fr","en","tor Roche Registration Limited 6 Falcon Way","s ori Roche Registration Limited 6 Falcon Way",8,7
"4843","fr","en","tor Viraferon est disponible sous trois présentations différentes:","Viraferon is available in three different pack sizes:",8,8
"4844","fr","en","total titre 1 Bâtiment/ équipement","total title 1 1",4,5
"4845","fr","en","Totalité des inhibiteurs de l'HMG CoA- simvastatine).","AUC: ↓ 69% (↓ 62 to ↓ 73) Cmax: ↓ 76% (↓ 63 to ↓ 79) Simvastatin acid:",18,7
"4846","fr","en","Toujours utiliser des techniques respectant les conditions d'asepsie.","Always use an aseptic technique",5,8
"4847","fr","en","tous grades grade 3","grade 4 all grades grade 3",6,4
"4848","fr","en","Tous les 6 mois, avec une dose unique.","Every 6 months, using a single dose.",7,8
"4849","fr","en","Tous les autres patients devront être surveillés pendant au moins 20 minutes après la perfusion.","All other patients should be observed for at least 20 minutes after administration.",13,15
"4850","fr","en","Tous les déchets doivent être éliminés conformément aux exigences locales.","Waste materials should be disposed of in accordance with local requirements.",11,10
"4851","fr","en","Tous les événements rapportés dans les groupes d’ âge suivants:","All events occurring in the following age groups:",8,10
"4852","fr","en","Tous les patients doivent être soumis à un examen ophtalmologique initial.","All patients should have a baseline eye examination.",8,11
"4853","fr","en","Tous les patients étaient éligibles à une autogreffe.","All of the patients were eligible for an autograft.",9,8
"4854","fr","en","Tout changement de dose doit être prescrit et contrôlé par votre médecin.","Any change in dosage must be prescribed and monitored by your doctor.",12,12
"4855","fr","en","Tout es les présentations peuvent ne pas être commercialisées.","Not all pack sizes may be marketed.",7,9
"4856","fr","en","Tout produit non utilisé doit être éliminé conformément à la réglementation en vigueur.","Any unused product should be disposed of in accordance with local requirements.",12,13
"4857","fr","en","Tout produit non utilisé ou déchet doit être éliminé conformément à la réglementation en vigueur.","Any unused product or waste material should be disposed in accordance with local requirements.",14,15
"4858","fr","en","Tout symptôme inflammatoire doit être évalué et un traitement doit être instauré si nécessaire.","Any inflammatory symptoms should be evaluated and treatment instituted when necessary.",11,14
"4859","fr","en","Toute anomalie thyroïdienne détectée doit être traitée de manière conventionnelle.","Any thyroid abnormality detected at that time must be treated with conventional therapy.",13,10
"4860","fr","en","Toute personne recevant Foscan deviendra sensible à la lumière pendant environ 15 jours après l’ injection.","Everyone who takes Foscan will become sensitive to light for about 15 days after injection.",15,16
"4861","fr","en","Toute solution inutilisée doit être jetée.","Any unused solution should be discarded.",6,6
"4862","fr","en","Toute solution non utilisée doit être jetée.","Any unused solution must be discarded.",6,7
"4863","fr","en","Toute suspension restante doit être éliminée 14 jours après reconstitution.","Any remaining suspension should be discarded 14 days after constitution.",10,10
"4864","fr","en","Toutefois, aucune explication particulière de ces résultats chez la femme n'a été identifiée.","However, no proper explanation for these findings in women has been identified.",12,13
"4865","fr","en","Toutefois, ces effets indésirables peuvent éventuellement être réduits en diminuant le débit de perfusion.","However, possible side effects may be reduced by slowing the infusion rate.",12,14
"4866","fr","en","Toutefois, contactez votre m édecin, l'infirmier(ère) ou le pharmacien, si cela vous arrive.","However, you should contact your doctor, nurse or pharmacist if this does happen.",13,13
"4867","fr","en","Toutefois, il faut toujours veiller à suivre exactement les instructions d'utilisation.","However, always try to exactly follow the instructions for use.",10,11
"4868","fr","en","Toutefois, l’ indication comportant le soulagement des symptômes dans cette population n’ est pas suffisamment étayée.","An indication that includes relief of symptoms in this population, however, is not sufficiently supported.",15,16
"4869","fr","en","Toutefois, la prudence s’ impose chez les patients présentant une insuffisance rénale sévère (voir rubrique 4.2)","However, caution should be used in patients with severe renal impairment (see section 4.2).",14,16
"4870","fr","en","Toutefois, ne prenez pas la dose oubliée si le moment de votre prochaine prise est proche.","However, if it is almost time for your next dose, skip the dose you missed.",15,16
"4871","fr","en","Toutefois, si la taille des bulles est trop importante, la dose injectée pourrait être moins précise.","But if the air bubbles are too large it may affect the insulin dose.",14,16
"4872","fr","en","Toutes deux étaient des études en double aveugle, randomisées, en groupes parallèles.","Both were of double- blind, randomised, parallel-group type.",8,12
"4873","fr","en","Toutes les études ont mesuré l’ évolution de la pression oculaire pendant l’ étude.","All the studies measured how the intraocular pressure changed during the study.",12,14
"4874","fr","en","Toutes les observations histologiques ont été bénignes.","All histology findings were benign.",5,7
"4875","fr","en","Toutes les patientes doivent recevoir des apports adéquats en calcium et en vitamine D.","All patients must receive adequate supplemental calcium and vitamin D.",10,14
"4876","fr","en","Toutes les présentations et tous les dosages ne sont pas adaptés à toutes les indications.","Not all dosage forms and strengths are appropriate for some indications.",11,15
"4877","fr","en","Toutes les présentations ne sont pas commercialisées.","Not all pack sizes may be marketed",7,7
"4878","fr","en","Toutes les présentations peuvent ne pas être commercialisées.","Not all pack sizes are marketed.",6,8
"4879","fr","en","Toutes les règles concernant la manipulation des appareils à pression doivent être suivies.","All regulations concerning handling of pressure vessels must be followed.",10,13
"4880","fr","en","tp 1 Qu’ est -ce qu’ Ultratard","r ge 1 What Ultratard is",6,7
"4881","fr","en","tp Hypocalcémie, déshydratation, hyperuricémie, soif Fréquent:","Very rarely: § Psychiatric disorders",5,6
"4882","fr","en","tp Ultratard contient du p-hydroxybenzoate de méthyle qui pourrait entraîner des réactions allergiques (éventuellement retardées).","Ultratard contains methyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed).",11,15
"4883","fr","en","Tracleer réduit le nombre de nouveaux ulcères des doigts qui apparaissent.","Tracleer reduces the number of new finger ulcers that appear.",10,11
"4884","fr","en","Traitement à dose unique des infections urinaires (IU) non compliquées:","Single-dose treatment of uncomplicated UTI:",5,10
"4885","fr","en","Traitement combiné avec la ribavirine:","Combination therapy with ribavirin:",4,5
"4886","fr","en","traitement de consolidation dans ce cas.","patients with fewer than 150,000 platelets per mm³ should not receive Zevalin consolidation treatment.",14,6
"4887","fr","en","Traitement de l’entéropathie proliférative porcine (iléite).","Treatment of Porcine proliferative Enteropathy (ileitis).",6,6
"4888","fr","en","Traitement de la gale sarcoptique (due à Sarcoptes scabiei var. canis)","Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis)",10,11
"4889","fr","en","Traitement de la maladie de Paget.","Treatment of Paget’ s disease of the bone.",8,6
"4890","fr","en","Traitement des candidémies chez les patients non neutropéniques.","Treatment of candidemia in non-neutropenic patients",6,8
"4891","fr","en","Traitement du diabète. am","Treatment of diabetes mellitus. uc",5,4
"4892","fr","en","Traitement et prévention des infestations par les puces et les tiques chez le chien.","Treatment and prevention of infestations with fleas and ticks.",9,14
"4893","fr","en","Traitement et prophylaxie des épisodes hémorragiques chez les patients atteints d’ hémophilie B (déficit congénital en facteur IX).","Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).",14,18
"4894","fr","en","Traitement immunosuppresseur en cours (y compris de fortes doses de corticostéroïdes).","Current immunosuppressive therapy (including high doses of corticosteroids).",8,11
"4895","fr","en","traitement jusqu'à retour au grade 0-1","Interrupt until resolved to grade 0-1",6,6
"4896","fr","en","Traitement symptomatique des mammites aiguës, en association avec une antibiothérapie.","For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.",14,10
"4897","fr","en","Traitement symptomatique des troubles locomoteurs non infectieux: réduction de la boiterie et de l’ inflammation.","For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.",14,15
"4898","fr","en","Transmise pour consultation en août 1998","Development pharmaceutics for Released for consultation in veterinary medicinal products August 1998",12,6
"4899","fr","en","Transmise pour consultation en juin 96","Released for consultation in June 96",6,6
"4900","fr","en","Transmise pour consultation en novembre 96 (nouvelle)","Released for consultation by CPMP in November 96 (new)",9,7
"4901","fr","en","Treatment of acute lymphoblastic leukaemia","Treatment of acute lymphoblastic leukaemia",5,5
"4902","fr","en","Treatment of malignant gastrointestinal stromal tumours","Treatment of malignant gastrointestinal stromal tumours",6,6
"4903","fr","en","Treatment of ovarian cancer","Treatment of ovarian cancer",4,4
"4904","fr","en","Treatment of visceral leishmaniasis","Treatment of visceral leishmaniasis",4,4
"4905","fr","en","Trente-huit pour cent des patients présentaient en prétraitement des mutations connues pour induire des résistances à imatinib.","Thirty-eight percent of patients had baseline mutations known to confer imatinib resistance.",12,17
"4906","fr","en","Très fréquent (≥ 1/ 10) Fréquent (≥ 1/ 100, < 1/ 10)","Very Common (≥ 1/ 10) Common (≥ 1/ 100 to < 1/ 10)",13,12
"4907","fr","en","Très fréquent ≥ 10% des patients","MedDRA System Organ classes Investigations",5,6
"4908","fr","en","Très fréquent Fréquent Fréquent Fréquent","Common Common Uncommon Uncommon Very rare system disorders Very common Common Common Common Uncommon Rare Very rare",17,5
"4909","fr","en","Très fréquent: éruption, exanthème localisé, diaphorèse Fréquent: prurit, douleur cutanée, érythème, urticaire Peu fréquent: phlébite","Very common: rash, localised exanthema, diaphoresis Common: pruritus, skin pain, erythema, urticaria Uncommon: phlebitis",14,15
"4910","fr","en","Très fréquent: fièvre Très fréquent: frissons, douleur au site de perfusion","Very Common: fever Common: chills, catheter site pain",8,11
"4911","fr","en","Très fréquents (Grade 3 ou 4)","Very common (Grade 3 or 4)",6,6
"4912","fr","en","Très rare (< 1/ 10.000)","Very rare (< 1/ 10,000)",5,5
"4913","fr","en","Très rare Érythème polymorphe, syndrome de Stevens-Johnson, syndrome de Lyell","Very rare Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis",10,10
"4914","fr","en","Très rare Très rare","Very rare Very rare",4,4
"4915","fr","en","Très rare: confusion, hallucinations.","Very rare: confusion, hallucinations.",4,4
"4916","fr","en","Très rare: insuffisance rénale, y compris altération rénale, généralement réversible après l’ arrêt du traitement (voir rubrique 4.4).","Very rare: renal insufficiency, including renal failure, usually reversible upon discontinuation of treatment (see section 4.4).",16,18
"4917","fr","en","Très rarement: réactions thromboemboliques telle que infarctus du myocarde, accident vasculaire cérébral, embolie pulmonaire et thrombose veineuse profonde.","Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism and deep vein thromboses.",13,18
"4918","fr","en","Tritace 1,25 mg tablete, Tritace 2,5 mg tablete, Tritace 5 mg tablete, Tritace 10 mg tablete","If you have any questions or are not sure about anything, ask your doctor or pharmacist.",16,16
"4919","fr","en","Tritace 1,25 mg tablety, Tritace 2,5 mg tablety, Tritace 5 mg tablety, Tritace 10 mg tablety","Tritace 1.25 mg tablety, Tritace 2.5 mg tablety, Tritace 5 mg tablety, Tritace 10 mg tablety",16,16
"4920","fr","en","Tritanrix HepB peut être mélangé avec le vaccin lyophilisé Hib (Hiberix).","Tritanrix HepB can be mixed with the lyophilised Hib vaccine (Hiberix).",11,11
"4921","fr","en","Tritazide a été autorisé dans l’ UE en 1993, d’ abord en Allemagne, puis dans les pays suivants:","Tritazide has been authorised in the EU since 1993, first in Germany and then in the following countries:",18,18
"4922","fr","en","Trizivir est contre-indiqué chez les patients ayant une insuffisance rénale au stade terminal.","Trizivir is contraindicated in patients with end-stage renal disease.",9,13
"4923","fr","en","Trocoxil doit être donné immédiatement avant ou pendant le repas principal du chien.","Trocoxil should be given immediately before or during the animal’ s main meal.",13,13
"4924","fr","en","Trois classes majeures d'interférons ont été identifiées: alpha, bêta et gamma.","Three major classes of interferons have been identified: alpha, beta and gamma.",12,11
"4925","fr","en","Trois des six métabolites identifiés sont actifs (M-II, M-III et M-IV).","Three of the six identified metabolites are active (M-II, M-III, and M-IV).",12,11
"4926","fr","en","Trouble de l’ audition (G3/ 4:","Hearing impaired (G3/ 4:",4,6
"4927","fr","en","Troubles cutanés (craquelures, croûtes, escarres, excoriation, écoulement, exsudation), rash (érythème, rougeur, desquamation, irritation, dermatite), prurit (démangeaisons, prurit) Fréquent:","Skin disorder (cracking, scab, crusting, excoriation, drainage, oozing), Rash (erythema, redness, scaling, irritation, dermatitis), Pruritus (itching, pruritus) Common:",18,18
"4928","fr","en","Troubles cutanés et des tissus sous-cutanés Peu fréquent: œ dème (facial, périphérique et généralisé).","Skin and subcutaneous tissue disorders Uncommon: oedema (face oedema, oedema peripheral and ansarca)",13,14
"4929","fr","en","Troubles cutanés et des tissus sous-cutanés:","Skin and subcutaneous tissue disorders: - Rare:",7,6
"4930","fr","en","Troubles cutanés et sous-cutanés:","Skin and subcutaneous tissue disorders:",5,4
"4931","fr","en","Troubles de l'humeur, épisodes dépressifs","Mood disorders, depressive disorders",4,5
"4932","fr","en","Troubles de la nutrition et du métabolisme Très fréquent: anorexie (qui peut être sévère).","Metabolism and nutrition disorders Very common: anorexia (which may be severe).",11,14
"4933","fr","en","Troubles de la peau et des tissus sous cutanés","Adverse Drug Reaction Rash/ Erythema",5,9
"4934","fr","en","Troubles de la reproduction et mammaires","Blood creatine phosphokinase increased Myalgia Back Pain",7,6
"4935","fr","en","Troubles digestifs: diarrhée, sécheresse de la bouche, dyspepsie, nausées, vomissements.","Gastrointestinal disorders: diarrhoea, dry mouth, dyspepsia, nausea, vomiting.",8,10
"4936","fr","en","Troubles du métabolisme et de la nutrition 'es","ris Metabolism and nutrition disorders",5,8
"4937","fr","en","Troubles du métabolisme et de la nutrition Baisse de la glycémie (< 55 mg/dL) × Affections psychiatriques","Metabolism and nutrition disorders Blood glucose decreased (< 55 mg/ dl) × Psychiatric disorders",14,17
"4938","fr","en","Troubles du métabolisme et de la nutrition:","Metabolism and nutrition disorders:",4,7
"4939","fr","en","Troubles du métabolisme et de la nutrition: diminution de la tolérance au glucose, goutte.","Impaired glucose tolerance, gout.",4,14
"4940","fr","en","Troubles gastro- intestinaux incluant examens complémentaire s","Hypertension Hypotension Orthostatic Hypotension",4,7
"4941","fr","en","Troubles généraux et anomalie au site d'administration: asthénie","General disorders and administration site conditions: asthenia",7,8
"4942","fr","en","Troubles généraux et anomalies au site d'administration Très fréquent","Pain in extremity, back pain administrative site conditions Mucosal inflammation",10,9
"4943","fr","en","Troubles généraux et anomalies au site d’ administration Fatigue, œ dème (le plus fréquemment périphérique)","General disorders and administration site conditions Fatigue, oedema (most commonly peripheral)",11,15
"4944","fr","en","Troubles généraux et anomalies au site d’ administration Fréquent:","General disorders and administration site conditions Common:",7,9
"4945","fr","en","Troubles généraux et anomalies au site d’ administration Peu fréquent","General disorders and administration site conditions Uncommon",7,10
"4946","fr","en","Troubles généraux et anomalies au site d’ administration Très fréquents:","General disorders and administration site conditions Very common:",8,10
"4947","fr","en","Troubles généraux et anomalies au site d’ administration:","General disorders and administration site conditions:",6,8
"4948","fr","en","Troubles généraux et anomalies Bouffées de chaleur au site d’ administration","Vascular disorders General disorders and administration site conditions",8,11
"4949","fr","en","Troubles hématologiques et du système lymphatique:","Blood and lymphatic system disorders:",5,6
"4950","fr","en","Troubles hématologiques et lymphatiques: augmentation du risque de saignements.","Blood and lymphatic system disorders: increased bleeding tendency.",8,9
"4951","fr","en","Troubles oculaires Troubles vasculaires","Eye disorders Vascular Disorders",4,4
"4952","fr","en","Troubles psychiatriques Fréquents Peu fréquents Troubles du système nerveux","Psychiatric disorders Common Uncommon Nervous system disorders",7,9
"4953","fr","en","Troubles respiratoires, thoraciques et médiastinaaux Fréquent: bâillements","Respiratory, thoracic and mediastinal disorders Common: yawning.",7,7
"4954","fr","en","Trousse pour préparation radio- pharmaceutique pour perfusion","Kit for radiopharmaceutica l preparation for infusion",7,7
"4955","fr","en","Trouvez une surface propre et placez -y tous les accessoires:","Find a clean area and lay out everything:",8,10
"4956","fr","en","Trudexa 40 mg, solution injectable en seringue préremplie.","Trudexa 40 mg solution for injection in pre-filled syringe",9,8
"4957","fr","en","Trudexa est injecté sous la peau (voie sous-cutanée).","Trudexa is injected under the skin (subcutaneous use).",8,8
"4958","fr","en","Trudexa peut être pris en association avec le méthotrexate ou certains traitements de fond de la Ce","Using other medicines rod",4,17
"4959","fr","en","Truvada est fourni en flacon de 30 comprimés.","Truvada comes in bottles of 30 tablets.",7,8
"4960","fr","en","Tubes de 15, 30, 60 et 100 grammes.","Tubes of 15, 30, 60 and 100 grams.",8,8
"4961","fr","en","Tumeurs bénignes, malignes et non précisées (incl kystes et polypes) Fréquent:","ge vaginitis, gastroenteritis Neoplasms benign, malignant and unspecified (including lon cysts and polyps) Common:",14,11
"4962","fr","en","Tumeurs bénignes, malignes et non spécifiées (incluant kystes et polypes) Fréquent:","Neoplasms benign, malignant and unspecified (including cysts and polyps) Common:",10,11
"4963","fr","en","Turnhoutseweg 30, B- 2340 Beerse, Belgique","Turnhoutseweg 30, 2340 Beerse, Belgium",5,6
"4964","fr","en","Twinrix Adulte ne doit pas être administré:","Twinrix Adult should not be given:",6,7
"4965","fr","en","Type 1 (souche Mahoney) 4 Type 2 (souche MEF-1) 4 Type 3 (souche Saukett) 4","type 1 (Mahoney strain) 4 type 2 (MEF-1 strain) 4 type 3 (Saukett strain) 4",15,15
"4966","fr","en","Type ou localisation du saignement mineur:","Type or Location of Minor Bleeding:",6,6
"4967","fr","en","Tysabri est administré en perfusion d’ une durée d’ une heure toutes les quatre semaines.","Tysabri is given as one infusion lasting one hour every four weeks.",12,15
"4968","fr","en","Tηλ: +30 2 10 89 06 300","Tηλ: +30 2 10 89 06 300",7,7
"4969","fr","en","u celui obtenu avec l'insuline humaine d’ action rapide administrée par voie sous-cutanée.","Information on Clinical Trials",4,13
"4970","fr","en","U Nákladového nádraž í 10 130 00 Prague 3","U Nákladového nádraž í 10",5,9
"4971","fr","en","UB6 0NN Royaume-Uni en","UB6 0NN United Kingdom ct",5,4
"4972","fr","en","UCB Pharma SA (BRAINE) Chemin du Foriest Braine-l'Alleud B-1420 Belgique","UCB Pharma SA (BRAINE) Chemin du Foriest Braine-l'Alleud B-1420 Belgium",10,10
"4973","fr","en","UCB-Group Schwarz- Pharma A. G Alfred Nobel – Str.","UCB-Group, Schwarz Pharma AG., Alfred-Nobel-Str.",5,9
"4974","fr","en","Ulcération buccale, constipation, vomissement","Mouth ulceration, constipation, Vomiting",4,4
"4975","fr","en","Ultérieurement, l'insuline doit encore être bien mélangée avant chaque injection.","Later, you must mix the insulin well again immediately before each injection.",12,10
"4976","fr","en","Un ajustement de la posologie de voriconazole pourra être nécessaire:","For the constituted oral suspension:",5,10
"4977","fr","en","Un ajustement posologique du traitement antidiabétique peut être nécessaire (voir rubrique 4.4).","Dosage adjustment of the antidiabetic medicinal products may be required (see section 4.4).",13,12
"4978","fr","en","Un allongement de l’ intervalle QT a été très rarement rapporté après commercialisation.","QT prolongation QT prolongation has very rarely been reported postmarketing.",10,13
"4979","fr","en","Un autre traitement anticonvulsivant devra être envisagé.","An alternative anticonvulsant should be considered.",6,7
"4980","fr","en","Un autre traitement antihypertenseur approprié devra si possible être mis en place avant le début d’ une grossesse.","Appropriate antihypertensive drug must usually replace Karvezide before starting a pregnancy.",11,18
"4981","fr","en","Un comprimé de 500 mg contient:","One tablet of 500 mg contains:",6,6
"4982","fr","en","Un comprimé pelliculé contient","One film-coated tablet contains",4,4
"4983","fr","en","Un contrôle métabolique optimal, incluant la surveillance glycémique, est donc recommandé.","Optimised metabolic control, including glucose monitoring, is therefore recommended.",9,11
"4984","fr","en","Un contrôle périodique de la fonction hépatique est recommandé pendant le traitement.","Periodic monitoring of hepatic function is recommended during treatment.",9,12
"4985","fr","en","Un effet sédatif ainsi que des sensations vertigineuses peuvent néanmoins être associés à l’ utilisation de XERISTAR.","XERISTAR may be associated with sedation and dizziness.",8,17
"4986","fr","en","Un État membre, l’ Allemagne, a soulevé des objections concernant les indications proposées.","Concerns were raised on the proposed indications by an objecting member state, Germany.",13,13
"4987","fr","en","Un examen régulier de vos amygdales ou de celles de votre enfant est à prévoir.","The doctor should regularly examine your/your child’s tonsils.",8,15
"4988","fr","en","Un flacon contient 1 mg d’ agalsidase alpha","One vial contains 1 mg of agalsidase alfa",8,8
"4989","fr","en","Un flacon contient 2,3 mg de ranibizumab.","Vial containing 2.3 mg of ranibizumab.",6,7
"4990","fr","en","Un flacon contient 250 UI de moroctocog alfa.","One vial contains 250 IU moroctocog alfa.",7,8
"4991","fr","en","Un flacon contient 75 mg d’ omalizumab.","One vial contains 75 mg omalizumab.",6,7
"4992","fr","en","Un flacon de 4 ml à usage multiple.","One multi-use vial of 4 ml.",6,8
"4993","fr","en","Un flacon de plastique (HDPE) contient 120 comprimés pelliculés.","One plastic (HDPE) bottle contains 120 tablets.",7,9
"4994","fr","en","Un flacon de poudre contient 5 mg de somatropine (correspondant à 15 UI).","One vial of powder contains 5 mg somatropin (corresponding to 15 IU).",12,13
"4995","fr","en","Un flacon de poudre pour solution injectable contient 1000 UI de nonacog alfa et des excipients.","One vial with powder for solution for injection contains nonacog alfa 1000 IU and excipients..",15,16
"4996","fr","en","Un ml contient 10 mg de mécasermine.","One ml contains 10 mg of mecasermin.",7,7
"4997","fr","en","Un ml d’Insuman Rapid contient 100 UI (Unités","One ml of Insuman Rapid contains 100 IU (International",9,8
"4998","fr","en","Un ml de Caelyx contient 2 mg de chlorhydrate de doxorubicine liposomal pégylé.","One ml of Caelyx contains 2 mg pegylated liposomal doxorubicin hydrochloride.",11,13
"4999","fr","en","Un ml de solution contient 25 microgrammes de","One ml solution contains 25 micrograms ziconotide (as",8,8
"5000","fr","en","Un pot contient 45 mg d’urée 13C","One jar contains 45 mg 13C-urea.",6,7
"5001","fr","en","Un retour à une réponse normale sera observé à l’ arrêt du traitement.","Discontinuation of treatment will result in a complete return to normal adrenal response.",13,13
"5002","fr","en","Un stylo prérempli Nespo (SureClick) délivre la totalité de la dose contenue dans chaque présentation.","The Nespo (SureClick) pre-filled pen delivers the complete dose of each presentation.",12,15
"5003","fr","en","Un suivi attentif de la fonction hépatique est recommandé.","Nevirapine AUC ↑ 1.26 Nevirapine Cmin ↑ 1.28 Nevirapine Cmax ↑ 1.24 compared to historical controls.",16,9
"5004","fr","en","Un suivi des concentrations de l’agent immunosuppresseur doit être réalisé en cas de co- administration.","Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration occurs.",13,15
"5005","fr","en","Un surdosage d'Efient peut entraîner un temps de saignement prolongé et des complications hémorragiques ultérieures.","Overdose of Efient may lead to prolonged bleeding time and subsequent bleeding complications.",13,15
"5006","fr","en","Un surdosage par l’ eptifibatide peut potentiellement conduire à des saignements.","Potentially, an overdose of eptifibatide could result in bleeding.",9,11
"5007","fr","en","Un surdosage pharmacologique est donc improbable.","The possibility of pharmacological overdose is therefore remote.",8,6
"5008","fr","en","Un système intégré pour la création et la dissémination d’EPAR sera mis en place en 1997.","An audit trail for the creation and release of EPARs will be implemented in 1997.",15,16
"5009","fr","en","Un traitement adapté, tel que des transfusions sanguines, pourra être envisagé au besoin.","Appropriate therapy such as blood transfusions may be given to patients when indicated.",13,13
"5010","fr","en","Un traitement antipyrétique doit être instauré conformément aux recommandations thérapeutiques en vigueur.","Antipyretic treatment should be initiated according to local treatment guidelines.",10,12
"5011","fr","en","Un traitement médical peut s’ avérer nécessaire.","Medical treatment may be necessary.",5,7
"5012","fr","en","Un traitement par bêta-bloquants peut masquer les symptômes d'hypoglycémie.","Hypoglycaemia may be difficult to recognise in subjects receiving beta blockers.",11,9
"5013","fr","en","Un traitement préalable par des substances anti-inflammatoires peut entraîner l'apparition ou l'aggravation d'effets indésirables.","The safety of the veterinary medicinal product has not been established during pregnancy and lactation.",15,14
"5014","fr","en","Un usage détourné d’ Aranesp chez des sujets sains peut entraîner une augmentation excessive de l’ hématocrite.","Misuse of Aranesp by healthy persons may lead to an excessive increase in packed cell volume.",16,17
"5015","fr","en","Une accoutumance et une dépendance physique ou psychique peuvent apparaître si vous utilisez Fentanyl-ratiopharm pendant longtemps.","Tolerance, physical or psychological dependence may develop if you use Fentanyl-ratiopharm for a longer period.",15,16
"5016","fr","en","Une accumulation légèrement supérieure à ce qui était attendu est observée après administration d’ une dose unique.","Slightly greater than expected accumulation occurs relative to single dosing.",10,17
"5017","fr","en","Une activité antivirale synergique a été observée avec l’ association de l’ emtricitabine et du ténofovir in vitro.","Synergistic antiviral activity was observed with the combination of emtricitabine and tenofovir in vitro.",14,18
"5018","fr","en","Une adaptation des doses de zidovudine dans ce cas précis n'a pas été évaluée.","Dose modifications of zidovudine in this situation have not been formally evaluated.",12,14
"5019","fr","en","Une administration chez des patients âgés de plus de 80 ans doit être évitée.","The administration to patients older than 80 years should be avoided.",11,14
"5020","fr","en","Une administration correcte minimisera le léchage de la zone d’ application.","Correct application will minimise licking of the application site.",9,11
"5021","fr","en","Une alopécie et un érythème peuvent aussi apparaître occasionnellement.","Alopecia and erythema may also occur occasionally.",7,9
"5022","fr","en","Une augmentation de la concentration sérique en alpha-foetoprotéine peut indiquer que le traitement est inadapté.","Increase in serum alpha- fetoprotein concentration may be a sign of inadequate treatment.",13,15
"5023","fr","en","Une augmentation du nombre de réunions de présoumission devrait permettre de mieux appréhender les questions réglementaires et administratives.","An increase in the number of pre-submission meetings is anticipated to tackle regulatory and administrative questions aspects.",17,18
"5024","fr","en","Une autorisation de mise sur le marché « sous circonstances exceptionnelles » a été délivrée à ce médicament.","This medicinal product has been authorised under “ Exceptional Circumstances”.",10,18
"5025","fr","en","Une boîte contient 1 ou 4 ou 6 seringues préremplies.","One pack contains 1, 4 or 6 pre-filled syringes",9,10
"5026","fr","en","Une cartouche contient 1,5 ml correspondant à 5 mg de somatropine* (15 UI).","One cartridge contains 1.5 ml corresponding to 5 mg Somatropin* (15 IU).",12,13
"5027","fr","en","Une concentration élevée de NO2 peut provoquer des lésions pulmonaires aiguës.","Elevated NO2 may cause acute lung injury.",7,11
"5028","fr","en","Une dose (0,5 ml) contient:","One dose (0.5 ml) contains:",5,5
"5029","fr","en","Une dose d’ IntronA est administrée chaque jour prévu.","One dose of IntronA is given on each scheduled day.",10,9
"5030","fr","en","Une dose de 2-ml selon les modalités suivantes:","One 2 ml dose according to the following schedule:",9,8
"5031","fr","en","Une dose plus forte de Sustiva peut être requise chez les patients sous rifampicine (un antibiotique).","Patients taking rifampicin (an antibiotic) may need to take a higher dose of Sustiva.",14,16
"5032","fr","en","Une douleur, une rougeur, un gonflement ou des plaies au niveau de la bouche (fréquent).","Pain, redness, swelling or sores in your mouth (common).",9,15
"5033","fr","en","Une élévation asymptomatique des Gamma-GT ne nécessite pas l’ arrêt du traitement par VIRAMUNE.","Asymptomatic GGT elevations are not a contraindication to continue therapy.",10,14
"5034","fr","en","Une étude pré clinique de toxicité du daclizumab sur la reproduction réalisée chez des singes Ce","However, the data show considerable",5,16
"5035","fr","en","Une exposition accidentelle à la congélation n'affecte pas la stabilité de Tevagrastim.","Accidental exposure to freezing temperatures does not adversely affect the stability of Tevagrastim.",13,12
"5036","fr","en","Une face a un bord biseauté et marqué “ LTG” au-dessus du chiffre 2.","One side has a bevelled edge and is marked “ LTG” above the number 2.",15,14
"5037","fr","en","Une fièvre > 39°C a été rapportée chez 3,3% des enfants, contre 1,2% dans le groupe témoin.","Fever of > 39 °C was reported in 3.3% of children compared to 1.2% in the control group.",18,17
"5038","fr","en","Une fois par jour","BID or TID BID or TID Once Daily or BID Once Daily",12,4
"5039","fr","en","une fois par jour§ (N = 193) 100 mg de sitagliptine","Monotherapy Studies Sitagliptin 100 mg once daily§",7,11
"5040","fr","en","Une fois préparée, la perfusion doit être administrée immédiatement.","Once the infusion is prepared it should be administered immediately.",10,9
"5041","fr","en","Une fois reconstitué, le vaccin est une émulsion blanchâtre.","The mixed vaccine is a whitish emulsion.",7,9
"5042","fr","en","Une fois sorti du réfrigérateur, le médicament doit être utilisé au cours de cette période.","Once removed from the refrigerator the medicinal product must be used within this period.",14,15
"5043","fr","en","Une hémorragie digestive peut survenir.","Gastrointestinal bleeding can occur.",4,5
"5044","fr","en","Une hydratation adéquate doit être maintenue.","Adequate hydration should be maintained.",5,6
"5045","fr","en","Une hypersensibilité a été décrite.","Hypersensitivity has been reported.",4,5
"5046","fr","en","Une inhalation peut être utile avant tout exercice physique.","Before physical exertion it might be useful to inhale.",9,9
"5047","fr","en","Une lipodystrophie au site d'injection apparaît peu fréquemment (1/ 1 000 à < 1/ 100).","Lipodystrophy at the injection site is uncommon (1/ 1,000 to < 1/ 100).",13,15
"5048","fr","en","Une mydriase peut survenir au cours d’ un traitement par la venlafaxine.","Mydriasis may occur in association with venlafaxine.",7,12
"5049","fr","en","Une mydriase transitoire, de la salivation, des vomissements et une accélération respiratoire passagère ont pu être observés.","Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.",10,17
"5050","fr","en","Une neutropénie de grade 3 et 4 est apparue chez respectivement 26% et 24% des patients.","Grade 3 and 4 neutropenia occurred in 26% and 24% of patients respectively).",13,16
"5051","fr","en","Une neutropénie est survenue chez 77% des patients.","Neutropenia occurred in 77% of patients.",6,8
"5052","fr","en","Une partie de la dose passe dans la circulation générale et subit un métabolisme hépatique important.","Part of the dose is absorbed systemically where it is extensively metabolised in the liver.",15,16
"5053","fr","en","Une petite quantité d’ oxybutynine est éliminée dans le lait maternel.","It is not known whether oxybutynin is excreted in human milk.",11,11
"5054","fr","en","Une pression artérielle basse (hypotension) a aussi été observée chez un très petit nombre de ces patients.","Low blood pressure (hypotension) has also been seen in a very small number of these patients.",16,17
"5055","fr","en","Une quantité inférieure à 2% de la dose est excrétée dans les urines sous forme d’ irbésartan inchangé.","Less than 2% of the dose is excreted in the urine as unchanged irbesartan.",14,18
"5056","fr","en","Une quantité supplémentaire de facteur VIII a été donnée chez certains patients.","In some patients additional factor VIII was given.",8,12
"5057","fr","en","Une récidive de radiodermite liée à une radiothérapie préalable a été rarement observée après l'administration de Caelyx.","Recall of skin reaction due to prior radiotherapy has rarely occurred with Caelyx administration.",14,17
"5058","fr","en","Une réduction de la dose peut être nécessaire chez les patients présentant des troubles rénaux modérés ou sévères.","The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.",18,18
"5059","fr","en","Une résistance croisée entre le tylvalosine et d’autres macrolides ne peut être exclue.","Cross-resistance between tylvalosin and other macrolides cannot be excluded.",9,13
"5060","fr","en","Une réversibilité a été observée après l’ arrêt de l’ administration.","There was evidence of reversibility upon cessation of treatment.",9,11
"5061","fr","en","Une scoliose peut progresser chez les enfants au cours d’ une croissance rapide.","Scoliosis may progress in any child during rapid growth.",9,13
"5062","fr","en","Une seringue contient une dose journalière pour un cheval de 500 kg.","Each division on the",4,12
"5063","fr","en","Une seringue préremplie contient 40 microgrammes de méthoxy polyéthylène glycol-epoetin beta* soit une concentration de 133 microgrammes/ ml.","One pre-filled syringe contains 40 micrograms of methoxy polyethylene glycol-epoetin beta* at a concentration of 133 micrograms/ ml.",18,18
"5064","fr","en","Une surveillance accrue des taux sériques de bicarbonate est donc recommandée.","Closer monitoring of serum bicarbonate levels is therefore recommended.",9,11
"5065","fr","en","Une surveillance accrue du patient et une diminution de la dose du produit co-administré peuvent être nécessaires.","Increased monitoring of the patient and a reduction in the dose of the concomitant agent may be necessary.",18,17
"5066","fr","en","Une surveillance attentive des fonctions rénale et gastro-intestinale est recommandée.","Careful monitoring of both renal and gastrointestinal function is recommended.",10,10
"5067","fr","en","Une surveillance attentive sera donc effectuée.","Busilvex is a potent cytotoxic medicine that results in profound decrease of blood cells.",14,6
"5068","fr","en","Une surveillance étroite du contrôle glycémique doit être envisagée (voir paragraphe 4.4).","Close monitoring of glycaemic control should be considered (see section 4.4).",11,12
"5069","fr","en","Une surveillance étroite du patient doit être instaurée, ainsi qu’ un traitement symptomatique et de soutient.","The patient should be closely monitored, and the treatment should be symptomatic and supportive.",14,16
"5070","fr","en","Une surveillance médicale sera peut-être nécessaire.","Medical attention may be necessary.",5,6
"5071","fr","en","Une surveillance plus fréquente est parfois nécessaire car les taux sanguins de phénylalanine peuvent augmenter.","More frequent monitoring may be required, as blood phenylalanine levels may increase.",12,15
"5072","fr","en","Une surveillance rapprochée des patients à haut risque doit accompagner le traitement antipsychotique.","Close supervision of high-risk patients should accompany antipsychotic therapy.",9,13
"5073","fr","en","Une toxicité maternelle a été observée chez des lapins à plus de 29 fois l'exposition humaine.","Maternal toxicity was seen in rabbits at more than 29 times the human exposure levels.",15,16
"5074","fr","en","Une utilisation immédiate est recommandée.","An immediate use is recommended.",5,5
"5075","fr","en","Unité pour les médicaments à usage vétérinaire et les technologies de l’information","Unit for Veterinary Medicines and Information Technology",7,12
"5076","fr","en","United Kingdom Baxter Healthcare Ltd Wallingford Road, Compton Newbury Berkshire RG20 7QW - UK Tel.: +44 1635 206345","United Kingdom Baxter Healthcare Ltd Wallingford Road, Compton Newbury Berkshire RG20 7QW - UK Tel.: +44 1635 206345",18,18
"5077","fr","en","United Kingdom Dr Michael RUTTER Dr Kevin WOODWARD (1)","United Kingdom Dr Michael RUTTER Dr Kevin WOODWARD (1)",9,9
"5078","fr","en","United Kingdom GlaxoSmithKline UK Tel: + 44 (0)800 221441 customercontactuk@gsk. com","United Kingdom GlaxoSmithKline UK Tel: + 44 (0)800 221441 customercontactuk@gsk. com",11,11
"5079","fr","en","United Kingdom GlaxoSmithKline UK Tel: + 44 (0)808 100 9997 customercontactuk@gsk.com","Tel: + 44 (0)808 100 9997 customercontactuk@gsk. com",8,11
"5080","fr","en","United Kingdom GlaxoSmithKline UK Tel: +44 (0) 800 221441 customercontactuk@gsk. com","United Kingdom GlaxoSmithKline UK Tel: +44 (0) 800 221441 customercontactuk@gsk. com",11,11
"5081","fr","en","United Kingdom Keith JONES Michael RUTTER","MEMBERSHIP OF THE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS",8,6
"5082","fr","en","United Kingdom Merck Serono Ltd.","United Kingdom Merck Serono Ltd.",5,5
"5083","fr","en","United Kingdom Orphan Europe (UK) Ltd.","United Kingdom Orphan Europe (UK) Ltd.",6,6
"5084","fr","en","United Kingdom/ Ireland Genzyme Therapeutics (United Kingdom) Tel: +44 1865 405200","United Kingdom/ Ireland Genzyme Therapeutics (United Kingdom) Tel: +44 1865 405200",11,11
"5085","fr","en","Univ Doz Dr G.","Univ Doz Dr G.",4,4
"5086","fr","en","Urticaire, éruption, prurit, hyperhidrose,","Urticaria, Rash, Pruritis, Hyperhydrosis,",4,4
"5087","fr","en","us Sans objet. pl • AUTRES CONDITIONS st 'e","ra EFFECTIVE USE OF THE MEDICINAL PRODUCT",7,9
"5088","fr","en","Usage vétérinaire - à ne délivrer que sur ordonnance vétérinaire.","For animal treatment only – to be supplied only on veterinary prescription.",12,10
"5089","fr","en","Usine de Huningue 26 rue de la chapelle F-68330 Huningue Cedex France","Novartis Santé Animale S. A. S Usine de Huningue 26 rue de Chapelle F-68330 France",15,12
"5090","fr","en","Utilisation avec d’ autres vaccins","Use with other vaccines",4,5
"5091","fr","en","Utilisation chez le sujet âgé (de plus de 65 ans)","Use in the elderly (over 65 years of age)",9,10
"5092","fr","en","Utilisation chez les patients de moins de 18 ans:","Use in patients under the age of 18 years:",9,9
"5093","fr","en","Utilisation concomitante avec d’ autres médicaments","Concomitant use with other medicinal products",6,6
"5094","fr","en","Utilisation dans une pompe à perfusion e C","Follow the instructions and recommendations from your doctor regarding the use of Velosulin in a du",16,8
"5095","fr","en","Utilisation de contributions communautaires spéciales pour les médicaments orphelins 2001 84%","reductions are allocated from a special contribution voted each year by the European Parliament and Council.",16,11
"5096","fr","en","Utilisation du dispositif transdermique","How to use the patch",5,4
"5097","fr","en","Utilisation en cas d’ insuffisance hépatique:","Use in hepatic impairment:",4,6
"5098","fr","en","Utilisation en transplantation cardiaque:","Use in cardiac transplant:",4,4
"5099","fr","en","Utiliser dans les 6 heures suivant la décongélation.","Use within 6 hours of thawing.",6,8
"5100","fr","en","Utiliser immédiatement après ouverture du flacon.","To be used immediately after the vial is opened.",9,6
"5101","fr","en","Utiliser immédiatement après reconstitution.","Use immediately after reconstitution.",4,4
"5102","fr","en","Utiliser un vaccin inactivé lorsqu’ il existe (poliomyélite) (voir rubrique 4.4).","Use an inactivated vaccine where it exists (poliomyelitis) (see section 4.4).",11,11
"5103","fr","en","Utiliser une méthode de reconstitution aseptique pour reconstituer le parécoxib lyophilisé (sous forme de parécoxib sodium).","Reconstitution process Use aseptic technique to reconstitute lyophilised parecoxib (as parecoxib sodium).",12,16
"5104","fr","en","Utiliser uniquement avec Omnitrope Pen 5.","Use only with Omnitrope Pen 5.",6,6
"5105","fr","en","Utiliser uniquement des solutions limpides et des conditionnements non endommagés.","Use only clear solutions and undamaged containers.",7,10
"5106","fr","en","Utiliser, pour cet échantillon, l’étiquette code-barre intitulée ""valeur 30-minutes"".","Use the bar-code labels marked “30-minute-value” for this sample.",9,9
"5107","fr","en","Utilisés en association avec Remeron, ces médicaments peuvent augmenter la quantité de Remeron dans votre sang.","In combination with Remeron these medicines can increase the amount of Remeron in your blood.",15,16
"5108","fr","en","Utilisez toujours Quixidar exactement comme votre médecin vous l’a dit.","Always use Quixidar exactly as your doctor has told you.",10,10
"5109","fr","en","Utilisez un pansement adhésif si vous le désirez. 'es 4) Elimination du matériel","Use a plaster if you want to.",7,13
"5110","fr","en","Utilisez une nouvelle aiguille pour chaque dose.","Use a new injection needle for each dose.",8,7
"5111","fr","en","V32I+I47V, I50V, I54L/ M et I84V.","V32I+I47V, I50V, I54L/ M and I84V.",6,6
"5112","fr","en","Vaccin contre la Peste Porcine Classique. gA","Vaccine against Classical Swine Fever gA",6,7
"5113","fr","en","VACCIN CONTRE LA RAGE NE PAS TOUCHER","RABIES VACCINE DO NOT TOUCH",5,7
"5114","fr","en","Vaccin du choléra (inactivé, buvable)","DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral)",12,5
"5115","fr","en","Vaccins vivants: les vaccins vivants ne doivent pas être administrés à des patients ayant une réponse immunitaire altérée.","Live vaccines: live vaccines should not be given to patients with an impaired immune response.",15,18
"5116","fr","en","Valdoxan doit être pris par voie orale.","Valdoxan is for oral use.",5,7
"5117","fr","en","Valtropin se présente sous forme de poudre et solvant pour solution injectable.","Valtropin is presented as a powder and solvent for solution for injection.",12,12
"5118","fr","en","Vaniqa est utilisé dans le traitement de l’ hirsutisme facial chez les femmes.","Vaniqa is used for the treatment of facial hirsutism in women.",11,13
"5119","fr","en","Variation de l’ HbA 1c moyenne (%) à la semaine 24 par rapport au placebo (IC à 95%)","change in HbA 1c (%) at week 24 (95%CI)",9,18
"5120","fr","en","Variation moyenne de l'acuité visuelle (lettres) (ET)a a p < 0,01","Mean change in visual acuity (letters) (SD)a a p < 0.01",11,11
"5121","fr","en","Variation moyenne de l’ AV Semaine 54","in VA Week 54 Mean change",6,7
"5122","fr","en","Variation moyenne des taux d'HbA1c par rapport aux valeurs initiales (% )† à la 24ème semaine","ongoing glimepiride therapy (N=102) Sitagliptin 100 mg once daily added to",11,16
"5123","fr","en","Vascularite, éventuellement associée à une atteinte rénale transitoire","Vasculitis, possibly associated with transient renal involvement",7,8
"5124","fr","en","Vasodilatation, hypertension, migraine Hypotension, coup de chaleur","Hypotension, heat stroke Respiratory, thoracic and mediastinal disorders",8,7
"5125","fr","en","Vectibix 20 mg/ ml solution à diluer pour perfusion.","Vectibix 20 mg/ ml concentrate for solution for infusion.",9,9
"5126","fr","en","Vedim Sp. z. o. o.","Vedim Sp. z. o. o.",5,5
"5127","fr","en","Veiller à éviter la dissémination du virus vaccinal des animaux vaccinés aux faisans.","Care should be taken to avoid spread of the vaccine virus from vaccinated chickens to pheasants.",16,13
"5128","fr","en","Veiller soigneusement à l´exactitude de la dose.","Particular care should be taken with regard to the accuracy of dosing.",12,7
"5129","fr","en","Velosulin 100 UI/ ml, solution injectable ou pour perfusion en flacon Insuline humaine (ADNr)","Velosulin 100 IU/ ml Solution for injection or infusion in a vial Insulin human (rDNA)",15,14
"5130","fr","en","Ventavis 10 microgrammes/ ml, solution pour inhalation par nébuliseur Iloprost","Ventavis 10 microgram/ ml, Nebuliser solution Iloprost",7,10
"5131","fr","en","Venus, 26 Can Parellada Industrial 08228 Terrassa Espagne","Venus, 26 Can Parellada Industrial 08228 Terrassa Spain",8,8
"5132","fr","en","Vérifier à nouveau que la dose de Biograstim dans la seringue est correcte.","Check again to make sure the correct dose of Biograstim is in the syringe.",14,13
"5133","fr","en","Vérifier visuellement qu'il n'y ait pas de bulles d'air dans la seringue.","Visually inspect the syringe for air bubbles.",7,12
"5134","fr","en","Vérifiez cela avant chaque injection.","Check each time you inject yourself.",6,5
"5135","fr","en","Vérifiez l’ aspect de Kineret.","Check the appearance of Kineret.",5,5
"5136","fr","en","Vérifiez la date de péremption sur l'étiquette de la seringue préremplie (EXP:).","Check the expiry date on the pre-filled syringe label (EXP:).",10,12
"5137","fr","en","Vérifiez la position de la pointe de l’aiguille à l’intérieur du bouchon.","Look for the needle tip inside the stopper window.",9,12
"5138","fr","en","Vérifiez votre taux de sucre.","Check your blood sugar",4,5
"5139","fr","en","Vers plats (Cestodes) Dipylidium caninum Taenia spp.","Dipylidium caninum Taenia spp.",4,7
"5140","fr","en","Versez les granulés d’un sachet dans un verre 3.","Empty the granules from one sachet into the glass 3.",10,9
"5141","fr","en","versions génériques influencent les informations contenues dans le résumé des caractéristiques du produit (RCP),","versions influence the information in the Summary of Product Characteristics (SPC).",11,14
"5142","fr","en","Veuillez consulter la carte de rappel patient/ soignant jointe à cette notice.","Please refer to the patient/ carer",6,12
"5143","fr","en","Veuillez consulter votre médecin si vous envisagez une grossesse.","Please consult your doctor if you plan to become pregnant.",10,9
"5144","fr","en","Veuillez informer votre médecin si vous avez des antécédents de maladie du foie.","Please speak with your doctor if you have a history of liver disease.",13,13
"5145","fr","en","Veuillez informer votre médecin si vous pensez que l’ un de ces cas vous concerne.","Check with your doctor if you think any of these apply to you.",13,15
"5146","fr","en","Veuillez informer votre médecin si vous prenez l’ un des médicaments de la liste suivante.","Please also inform your doctor if you are taking any of the following medicines:",14,15
"5147","fr","en","Veuillez informer votre médecin si vous prenez l’ un ou l’ autre des médicaments suivants.","Please tell your doctor if you are taking any of the following medicines.",13,15
"5148","fr","en","Veuillez lire attentivement l'intégralité de cette notice avant d’utiliser ce médicament.","Read all of this leaflet carefully before you start using this medicine.",12,11
"5149","fr","en","Veuillez lire attentivement l'intégralité de cette notice avant de prendre ce médicament","Read all of this leaflet carefully before you start taking this medicine.",12,12
"5150","fr","en","Veuillez lire attentivement l'intégralité de cette notice avant de vous faire vacciner ou de faire vacciner votre enfant.","Read all of this leaflet carefully before you start/ your child starts receiving this vaccine.",15,18
"5151","fr","en","Veuillez lire attentivement l'intégralité de cette notice avant de vous faire vacciner.","Read all of this leaflet carefully before you are vaccinated.",10,12
"5152","fr","en","Veuillez lire attentivement l’ intégralité de cette notice avant de prendre ce médicament.","Read all of this leaflet carefully before you start taking this medicine",12,13
"5153","fr","en","Veuillez lire attentivement l’intégralité de cette notice avant de prendre ce médicament.","Read all of this leaflet carefully before you start taking this medicine. − Keep this leaflet.",16,12
"5154","fr","en","Veuillez lire attentivement l’intégralité de cette notice car elle contient des informations impor - tantes.","Read all of this leaflet carefully because it contains important information for you.",13,15
"5155","fr","en","Veuillez lire attentivement les instructions ci-dessous avant d’ utiliser votre Mixtard 30 InnoLet.","Please read the following instructions carefully before using your Mixtard 30 InnoLet.",12,13
"5156","fr","en","VFEND 50 mg comprimés pelliculés Voriconazole","Do not store above 30°C, do not refrigerate or freeze.",10,6
"5157","fr","en","VFEND a également été étudié chez 61 enfants.","VFEND has also been studied in 61 children.",8,8
"5158","fr","en","VFEND suspension contient 0,54 g de saccharose par ml de suspension.","VFEND suspension contains 0.54g sucrose per ml of suspension.",9,11
"5159","fr","en","VHB et traités par un antagoniste du TNF.","conjunction with TNF-antagonist therapy to prevent HBV reactivation are not available.",11,8
"5160","fr","en","Via Cassanese, 224 I-2090 Segrate Milano","Via Cassanese, 224 I-2090 Segrate Milano",6,6
"5161","fr","en","Via delle Industrie 1 I-20061 Carugate (Milano) Tel: +39 (0)2 921381","Via delle Industrie 1 I-20061 Carugate (Milano) Tel: +39 (0)2 921381",11,11
"5162","fr","en","Via Giacomo Chiesi 43100 Parma","Via Giacomo Chiesi 43100 Parma Italy",6,5
"5163","fr","en","Via Palermo 26/ A 43100 Parma Italie","Via Palermo 26/ A 43100 Parma Italy",7,7
"5164","fr","en","Via Robert Koch, 1-2 20152 Milano Italie","Via Robert Koch, 1-2 20152 Milano Italy",7,7
"5165","fr","en","Via San Martino 12","th Via San Martino 12 I-20122 Milan",7,4
"5166","fr","en","Via San Martino 12 I-20122 Milan Italy","Via San Martino 12 I-20122 Milan Italy",7,7
"5167","fr","en","Viagra est un médicament contenant le principe actif sildénafil.","Viagra is a medicine that contains the active substance sildenafil.",10,9
"5168","fr","en","Viani 50/ 250 Diskus","Viani 50/ 250 Diskus",4,4
"5169","fr","en","Vimpat 50 mg 1 comprimé pelliculé contient 50 mg de lacosamide.","Vimpat 50 mg 1 film-coated tablet contains 50 mg lacosamide.",10,11
"5170","fr","en","Vingt-quatre de ces patients (75,0%) ont retrouvé une réponse clinique après cette modification.","Twenty-four of these patients (75.0%) regained clinical response after crossing over.",11,13
"5171","fr","en","VIRACEPT poudre orale contient du potassium.","VIRACEPT oral powder contains potassium.",5,6
"5172","fr","en","Viraferon 30 millions d’ UI solution injectable, stylo multidose","Viraferon 30 million IU solution for injection, multidose pen",9,9
"5173","fr","en","Viraferon doit être donné seul principalement en cas d’ intolérance ou de contre-indication à la ribavirine. dic","Viraferon should be given alone mainly in case of intolerance or contraindication to ribavirin. rod",15,17
"5174","fr","en","ViraferonPeg 100 microgrammes se présente sous forme de:","ViraferonPeg 100 micrograms is supplied as:",6,8
"5175","fr","en","ViraferonPeg 150 microgrammes se présente sous forme de:","ViraferonPeg 150 micrograms is supplied as:",6,8
"5176","fr","en","ViraferonPeg 80 microgrammes se présente sous forme de:","ViraferonPeg 80 micrograms is supplied as:",6,8
"5177","fr","en","ViraferonPeg est destiné à la voie sous-cutanée.","ViraferonPeg is intended for subcutaneous use.",6,7
"5178","fr","en","VIRAMUNE appartient à la classe des inhibiteurs non nucléosidiques de la transcriptase inverse (INNTI).","VIRAMUNE belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs).",11,14
"5179","fr","en","Viread n’ a pas été étudié chez des patients âgés de plus de 65 ans.","Viread has not been studied in patients over 65 years of age.",12,15
"5180","fr","en","vision floue (voir rubriques 4.7), douleur oculaire.","Eye disorders Common: vision blurred (see section 4.7), eye pain.",10,7
"5181","fr","en","Visser doucement la seringue sur le flacon de poudre (B).","Gently screw the syringe on to the powder vial (B).",10,10
"5182","fr","en","VISTIDE peut entraîner des effets indésirables transitoires, tels que fatigue ou faiblesse.","VISTIDE may cause transient side effects such as fatigue or weakness.",11,12
"5183","fr","en","Voie d’ administration Voie intraveineuse","Route of Administration Intravenous use Intravenous use",7,5
"5184","fr","en","Voie intraveineuse après reconstitution et dilution.","Intravenous use after reconstitution and dilution.",6,6
"5185","fr","en","Voie orale Bien agiter avant l’ utilisation.","Shake well before use.",4,7
"5186","fr","en","Voie orale Flacon (HDPE)","Oral use Bottle (HDPE)",4,4
"5187","fr","en","Voie orale Plaquette thermoformée (PVC/ PE/ PVDC)","Blister (PVC/ PE/ PVDC)",4,7
"5188","fr","en","Voie orale Voie orale Voie intraveineuse","oral use oral use intravenous use",6,6
"5189","fr","en","Voie orale Voie orale Voie orale","Oral use Oral use Oral use Oral use Oral use Oral use",12,6
"5190","fr","en","Voie orale Voie orale Voie orale Voie intraveineuse","oral use oral use oral use intravenous use intravenous use",10,8
"5191","fr","en","Voie sous- cutanée ou intramusculaire","Subcutaneous or intramuscular use",4,5
"5192","fr","en","Voie sous-cutanée ou intraveineuse","Subcutaneous or intravenous use",4,4
"5193","fr","en","Voie sous-cutanée Pour des informations sur la reconstitution et l’ utilisation, lire la notice.","Subcutaneous use For information on reconstitution and use read the package leaflet.",12,14
"5194","fr","en","Voie Sous-cutanée Voie Intraveineuse Voie Intra-artérielle Voie Intra-pleurale Voie Intrapéritonéale Voie locale/ Injections intratumorales","Intramuscular injection Subcutaneous injection Intravenous administration Intra-arterial administration Intra-pleural injection Intraperitoneal administration Local/ Intratumoral injections",15,14
"5195","fr","en","Voir aussi la rubrique 4.4.","See also section 4.4.",4,5
"5196","fr","en","Voir aussi les précautions dans la section 2 Quelles sont les informations à connaître avant d’ utiliser Velosulin.","See also warning in 2 Before you use Velosulin. lp",10,18
"5197","fr","en","Voir la notice pour plus d’informations.","See package leaflet for further information.",6,6
"5198","fr","en","Voir la notice pour plus de détails.","See the Package Leaflet for further details.",7,7
"5199","fr","en","Voir les composants cités en rubrique 6.","ingredients in section 6.",4,7
"5200","fr","en","Voir les Tableaux 1 et 2 pour plus d’ informations.","See Tables 1 and 2 for more information.",8,10
"5201","fr","en","Voir pages suivantes pour le mode d’emploi détaillé..","To treat some types of heart attack, a health professional may give the first dose into a ed",18,8
"5202","fr","en","Voir rubrique 2 « Faites attention avec {NOM DU PRODUIT} 10 mg » pour plus de détails","See Section 2 “ Take special care with {PRODUCT NAME} 10 mg” for details",14,17
"5203","fr","en","Voir section 3 Comment utiliser Insulatard.","See 3 How to use Insulatard.",6,6
"5204","fr","en","Voir Si vous avez une hypo pour comprendre ce qu’ est une hypo et comment la traiter.","Please see If you get a hypo on what a hypo is and how to treat it.",17,17
"5205","fr","en","Vomissement Douleur abdominale Hypophénylalaninémie","Vomiting Abdominal pain Hypophenylalaninemia",4,4
"5206","fr","en","Vomissements Haut-le-cœ ur Nausées","Tachypnoea Gastrointestinal disorders Vomiting Retching Nausea Skin and subcutaneous tissue Urticaria disorders",12,4
"5207","fr","en","Vos capacités de concentration et vos réflexes peuvent être diminués en cas d’hypoglycémie.","Your ability to concentrate or to react will be less during a hypo.",13,13
"5208","fr","en","Vos données de patient seront enregistrées sous une forme anonyme (personne ne saura que ces informations vous concernent).","Your patient data will be registered anonymously – nobody will know it is information about you.",16,18
"5209","fr","en","Votre bouche doit être vide avant de placer votre comprimé sur la langue.","Your mouth should be empty before placing the tablet on the tongue.",12,13
"5210","fr","en","Votre diabète pourra empirer.","Your diabetes may get worse.",5,4
"5211","fr","en","Votre fertilité et celle de votre partenaire devront être évaluées avant de commencer le traitement.","You and your partner's fertility should be evaluated before the treatment is started.",13,15
"5212","fr","en","Votre glycémie peut augmenter ou diminuer si vous buvez de l’ alcool.","Your blood sugar levels may either rise or fall if you drink alcohol.",13,12
"5213","fr","en","Votre insuline agira plus rapidement si vous l’ injectez au niveau de l’ abdomen.","Your insulin will work more quickly if you inject it around the waist.",13,14
"5214","fr","en","Votre médecin a déterminé la posologie correcte de Rebetol en fonction de votre poids.","Your doctor has determined the correct dose of Rebetol based on your weight.",13,14
"5215","fr","en","Votre médecin aura l’ expérience nécessaire dans le traitement de l’ insuffisance rénale et l’ utilisation C","Your doctor will be experienced in the treatment of renal failure and the use of erythropoietin.",16,17
"5216","fr","en","Votre médecin calculera votre dose de Temodal.","Your doctor will work out your dose of Temodal.",9,7
"5217","fr","en","Votre médecin contrôlera votre réponse au traitement et votre état pour déterminer la dose nécessaire de CANCIDAS.","Your doctor will monitor your response and condition to determine what CANCIDAS treatment is needed.",15,17
"5218","fr","en","Votre médecin décidera de la dose appropriée à votre cas.","Your doctor will decide the right dose for you.",9,10
"5219","fr","en","Votre médecin décidera si CEPROTIN peut être utilisé au cours de la grossesse et de l’ allaitement.","Your doctor will decide if CEPROTIN may be used during pregnancy and lactation.",13,17
"5220","fr","en","Votre médecin discutera alors avec vous afin de déterminer si vous devez continuer à prendre MIRAPEXIN.","Your doctor will then discuss with you if you should continue to take MIRAPEXIN.",14,16
"5221","fr","en","Votre médecin discutera avec vous des risques et bénéfices possibles de recevoir Twinrix Enfant durant votre grossesse.","Your doctor will discuss with you the possible risks and benefits of having Twinrix Paediatric during pregnancy.",17,17
"5222","fr","en","Votre médecin effectuera des prises de sang régulières afin de contrôler la correction de l’anémie et 'e","Your doctor will take regular blood samples to measure how your anaemia is responding and may",16,17
"5223","fr","en","Votre médecin ou son assistant(e) vous apprendront comment injecter vous-même Viraferon.","Your doctor or his/her assistant will instruct you how to self -inject Vir aferon.",14,11
"5224","fr","en","Votre médecin ou votre infirmière reconstituera le produit sous forme d’ une solution qui sera administrée par injection.","Your doctor or nurse will make it up into a solution that will be given as an injection.",18,18
"5225","fr","en","Votre médecin peut également vous prescrire des tests sanguins pendant le traitement afin de surveiller vos reins.","Your doctor may also order blood tests during treatment to monitor your kidneys.",13,17
"5226","fr","en","Votre médecin peut juger préférable que v ous pratiquiez vous-même les injections de Kineret.","Your doctor may decide that it would be m ore convenient for you to inject Kineret yourself.",17,14
"5227","fr","en","Votre médecin peut prescrire Rasilez en même temps que d’ autres médicaments utilisés pour traiter l’ hypertension.","Your doctor may prescribe Rasilez together with other medicines used to treat high blood pressure.",15,17
"5228","fr","en","Votre médecin peut souhaiter surveiller le traitement par Enbrel au cas où l’ infection s’aggraverait. • Troubles sanguins:","Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.  Blood disorders:",18,18
"5229","fr","en","Votre médecin peut vous prescrire Humalog Mix25 ainsi qu’une insuline d'action plus prolongée.","Your doctor may tell you to use Humalog Mix25 Pen as well as a longer-acting insulin.",16,13
"5230","fr","en","Votre médecin peut vous recommander un autre dosage si nécessaire.","If necessary your doctor may tell you to take a different dose.",12,10
"5231","fr","en","Votre médecin pourra devoir modifier la dose ou prendre d’ autres précautions.","Your doctor may need to change the dose or take other precautions.",12,12
"5232","fr","en","Votre médecin pourra diminuer la dose du sulfamide hypoglycémiant","Your doctor may reduce the dose of your sulphonylurea",9,9
"5233","fr","en","Votre médecin va décider si vous devez utiliser ce médicament.","Your doctor will decide whether you should use this medicine.",10,10
"5234","fr","en","Votre médecin vérifiera votre tension artérielle, la fréquence de votre pouls et la fonction pulmonaire.","Your doctor will check your blood pressure, pulse rate and lung function.",12,15
"5235","fr","en","Votre médecin vous a prescrit Fuzeon pour vous aider à contrôler votre infection à VIH.","Your doctor has prescribed Fuzeon to help control your HIV infection.",11,15
"5236","fr","en","Votre médecin vous dira exactement quand arrêter Nespo.","Your doctor will tell you exactly when to stop taking Nespo. lp",12,8
"5237","fr","en","Votre médecin vous fera faire des examens sanguins régulièrement au cours du traitement par Avaglim.","Your doctor should regularly test your blood while you are taking Avaglim.",12,15
"5238","fr","en","Votre médecin vous indiquera comment effectuer vous-même l’injection.","You will be instructed by your doctor or his/her assistant on the technique of self-injection.",15,8
"5239","fr","en","Votre médecin vous indiquera comment passer de votre précédent traitement à Karvezide.","Your doctor will instruct you how to switch from the previous treatment to Karvezide.",14,12
"5240","fr","en","Votre médecin vous indiquera si votre maladie vous permet de conduire et d’ utiliser des machines sans risque.","Your doctor will tell you whether your illness allows you to drive and to use machines safely.",17,18
"5241","fr","en","Votre médecin vous indiquera si vous devez arrêter de prendre Combivir.","Your doctor will advise you whether you should stop taking Combivir.",11,11
"5242","fr","en","Votre médecin vous informera de la posologie recommandée.","Your doctor will give you instructions for proper dosage.",9,8
"5243","fr","en","Votre médecin vous informera des risques et bénéfices liés à l’administration de Herceptin pendant la grossesse.","Your doctor will advise you of the risks and benefits of taking Herceptin during pregnancy.",15,16
"5244","fr","en","Votre médecin vous précisera si vous aurez à mélanger les insulines humaines Sanofi-Aventis.","Your doctor will tell you if you have to mix Sanofi-Aventis human insulins.",13,13
"5245","fr","en","votre médecin vous précisera si vous pouvez recevoir STAMARIL sur la base de vos examens sanguins.","doctor will advise you if you can have STAMARIL based on the results of laboratory tests.",16,16
"5246","fr","en","Votre médecin vous prescrira Starlix en association avec un autre antidiabétique oral contenant de la metformine.","Your doctor will prescribe Starlix together with another oral anti-diabetic containing metformin.",12,16
"5247","fr","en","Votre posologie sera calculée en fonction de votre poids.","Your dose will be calculated according to your body weight.",10,9
"5248","fr","en","Votre professionnel de santé pourra suggérer d'autres techniques d'injection s'il les juge mieux adaptées pour vous.","Your healthcare provider may suggest different injection techniques that will work best for you.",14,16
"5249","fr","en","Votre traitement peut durer jusqu’ à 14 jours.","Your treatment can last up to 14 days.",8,8
"5250","fr","en","Vous devez avaler la gélule entière, avec un verre d'eau.","You should swallow your capsule whole with a drink of water.",11,10
"5251","fr","en","Vous devez continuer à prendre les précautions appropriées pour prévenir cette transmission.","You should continue to use appropriate precautions to prevent this.",10,12
"5252","fr","en","Vous devez demander conseil à votre médecin sur vos capacités à conduire si:","You should contact your doctor for advice on driving if:",10,13
"5253","fr","en","Vous devez également prévenir votre médecin, si les symptômes s'aggravent ou si la fièvre persiste.","You should also tell your doctor if the influenza symptoms get worse or the fever continues.",16,15
"5254","fr","en","Vous devez essayer de prendre votre dose quotidienne approximativement à la même heure chaque jour.","Try to take your daily dose at about the same time each day.",13,15
"5255","fr","en","Vous devez être informés que ces deux états peuvent être causées par ce type de médicament.","You should be aware that both of these conditions may be caused by this type of medicine.",17,16
"5256","fr","en","Vous devez informer votre médecin le plus rapidement possible si vous allaitez.","Be sure to tell your doctor immediately if you are breast-feeding.",11,12
"5257","fr","en","Vous devez informer votre médecin si cette situation se produit.","You should tell your doctor if this occurs.",8,10
"5258","fr","en","Vous devez informer votre médecin si vos reins ou votre foie ne fonctionnent pas correctement.","You must tell your doctor if you have impaired kidney or liver function.",13,15
"5259","fr","en","Vous devez par conséquent être suivi régulièrement par votre médecin pendant le traitement par Kaletra.","It is therefore important that you remain under the supervision of your doctor while taking Kaletra.",16,15
"5260","fr","en","Vous devez prendre une gélule par jour d’ ORACEA, le matin.","You should take one capsule ORACEA each day in the morning.",11,11
"5261","fr","en","Vous devez prévenir votre médecin:","You must tell your doctor:",5,5
"5262","fr","en","Vous devez suivre ce régime très soigneusement.","You must follow this diet carefully.",6,7
"5263","fr","en","Vous devez toujours respecter les instructions de votre médecin pour la prise de ReFacto AF.","Always take ReFacto AF exactly as your doctor has instructed you.",11,15
"5264","fr","en","Vous devrez avoir recours à une méthode efficace de contraception.","You should use an effective method of contraception.",8,10
"5265","fr","en","Vous devrez tenir compte de cette information si vous suivez un régime sans sel.","You need to allow for this if you are on a controlled sodium diet.",14,14
"5266","fr","en","Vous êtes allergique (hypersensible) à la stavudine ou à l'un des autres composants contenus dans Zerit.","If you are allergic (hypersensitive) to stavudine or any of the other ingredients of Zerit.",15,16
"5267","fr","en","Vous êtes maintenant prêt pour injecter la dose.","You are now ready to inject the dose.",8,8
"5268","fr","en","Vous les recevrez à l’ hôpital, en période péri- transplantation.","These will be given in hospital, around the time of your transplant operation.",13,10
"5269","fr","en","Vous NE DEVEZ PAS allaiter pendant la durée du traitement par TAXOTERE.","You must NOT breast-feed while you are treated with TAXOTERE.",10,12
"5270","fr","en","Vous ne devez pas prendre plus de 2800 mg par jour.","You should not take more than 2800 mg per day.",10,11
"5271","fr","en","Vous ne devez pas prendre Tekturna avec du jus de pamplemousse.","You should not take Tekturna together with grapefruit juice.",9,11
"5272","fr","en","Vous ne devez pas prendre Valdoxan si votre foie ne fonctionne pas correctement.","You must not use Valdoxan if your liver does not work properly.",12,13
"5273","fr","en","Vous ne devez pas utiliser Fertavid si vous allaitez.","You should not use Fertavid if you are breast-feeding.",9,9
"5274","fr","en","Vous ne pouvez les transmettre à quiconque.","You can’t pass it on to anyone else.",8,7
"5275","fr","en","Vous ne pouvez plus utiliser le stylo lorsqu'il est vide.","When the pre-filled pen is empty you cannot use it again.",11,10
"5276","fr","en","Vous pourrez ressentir une sensation de vertige ou d’étourdissement en position debout ou en vous levant rapidement.","You may feel dizzy or light-headed when you stand or sit up quickly.",13,17
"5277","fr","en","Vous pourriez avoir besoin de la relire.","You may need to read it again.",7,7
"5278","fr","en","Vous pouvez conserver le grand capuchon externe de l’aiguille dans le compartiment.","You may want to store the big outer needle cap in the compartment.",13,12
"5279","fr","en","Vous pouvez également dissoudre le comprimé dans l'eau et boire la suspension.","Alternatively, disperse the tablet in water and drink the resulting suspension.",11,12
"5280","fr","en","Vous pouvez en discuter avec votre médecin.","This c an be discussed with your doctor.",8,7
"5281","fr","en","Vous pouvez les retirer grâce à une lingette ou une compresse imbibée d’ alcool.","You may remove them with an alcohol wipe or alcohol swab.",11,14
"5282","fr","en","Vous pouvez nettoyer l'extérieur de votre Mixtard 30 NovoLet à l’ aide d’ une compresse antiseptique.","You can clean the exterior of your Mixtard 30 NovoLet by wiping it with a medicinal swab.",17,16
"5283","fr","en","Vous pouvez nettoyer votre Protaphane InnoLet à l’aide d’une compresse antiseptique.","You can clean your Protaphane InnoLet by wiping it with a medicinal swab.",13,11
"5284","fr","en","Vous pouvez prendre ce médicament au moment ou en dehors des repas.","You can take this medicine with or without food.",9,12
"5285","fr","en","Vous pouvez prendre Kinzalmono avec ou sans aliments.","You can take Kinzalmono with or without food.",8,8
"5286","fr","en","Vous pouvez revenir progressivement à un éclairage intérieur normal.","You can gradually return to normal indoor lighting.",8,9
"5287","fr","en","Vous pouvez sélectionner des doses entre 1 et 60 unités par palier de 1 unité.","You can select doses from 1 to 60 units in increments of 1 unit.",14,15
"5288","fr","en","Vous pouvez vous doucher, vous baigner, nager et faire du sport normalement lorsque vous portez le dispositif transdermique.","You may shower, bath, swim and exercise as normal while wearing the patch.",13,18
"5289","fr","en","Vous recevrez Abseamed pendant les 3 semaines précédant votre intervention chirurgicale.","You will receive Abseamed during the 3 weeks before your surgery.",11,11
"5290","fr","en","Vous recevrez peut-être un « Avostartclip ».","You may be given an Avostartclip.",6,7
"5291","fr","en","Vous trouverez également ces informations sur la carte patient qui vous a été remise par votre médecin.","You will also find this information in the Patient Alert Card you have been given by your doctor.",18,17
"5292","fr","en","Vous utiliserez normalement Humalog Mix25 Pen dans les 15 minutes qui précèdent ou qui suivent le repas.","You should normally use Humalog Mix25 within 15 minutes of a meal.",12,17
"5293","fr","en","voyez du sang dans la seringue, retirez l’aiguille et introduisez-la ailleurs. éd","is blood in the syringe, remove the needle and re-insert it in another place.",14,12
"5294","fr","en","Waarderweg 39 P. O. Box 581 2031 BN Haarlem Pays-Bas","Waarderweg 39 P. O. Box 581 2031 BN Haarlem The Netherlands",11,10
"5295","fr","en","Wicklow, Irlande Przedsiebiorstwo Farmaceutyczne ANPHARM S. A., ul.","Wicklow, Ireland Przedsiebiorstwo Farmaceutyczne ANPHARM S. A., ul.",8,8
"5296","fr","en","Wilzin ne doit pas être administré à des patients allergiques au zinc.","Wilzin should not be given to patients who are allergic to zinc.",12,12
"5297","fr","en","Wim de Körverstraat 35 5831 AN Boxmeer Pays-Bas","Wim de Körverstraat 35 5831 AN BOXMEER The Netherlands",9,8
"5298","fr","en","Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands","Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer n The Netherlands tio B.",15,9
"5299","fr","en","Wim de Körverstraat 35 PO Box 31 NL – 5830 AA Boxmeer Pays-Bas","Wim de Körverstraat 35 PO Box 31 NL - 5830 AA Boxmeer The Netherlands",14,13
"5300","fr","en","Wyeth Europa Ltd Huntercombe Lane South Taplow, Maidenhead Berkshire SL6 0PH","Wyeth Europa Ltd Huntercombe Lane South Taplow, Maidenhead Berkshire, SL6 0PH",11,11
"5301","fr","en","Wyeth Lederle Vaccines S. A.","Wyeth Lederle Vaccines S. A.",5,5
"5302","fr","en","Wyeth Pharmaceuticals SA/ NV Venlax Rue du Bosquet,15 37,5 mg 1348 Louvain-la-Neuve Belgium","Wyeth Pharmaceuticals SA/ NV Rue du Bosquet,15 1348 Louvain-la-Neuve Belgium",10,13
"5303","fr","en","Xagrid 0,5 mg, gélule","Xagrid 0.5mg hard capsule",4,4
"5304","fr","en","Xeloda 500 mg comprimés pelliculés.","Xeloda 500 mg film-coated tablets.",5,5
"5305","fr","en","Xenical 120 mg, gélule Orlistat","Xenical 120 mg hard capsules Orlistat",6,5
"5306","fr","en","Xigris n’ est pas indiqué chez l’ enfant.","Xigris should not be used in children.",7,8
"5307","fr","en","Xolair 75 mg solution injectable Omalizumab","Xolair 75 mg solution for injection Omalizumab",7,6
"5308","fr","en","Xorimax 125 mg bevont tabletta","Xorimax 125 mg bevont tabletta",5,5
"5309","fr","en","Xyrem est une solution buvable contenant la substance active oxybate de sodium (500 mg/ ml).","Xyrem is an oral solution, which contains the active substance sodium oxybate (500 mg/ ml).",15,15
"5310","fr","en","Y a-t-il des précautions particulières à prendre pour mon chien?","What are the special precautions for my dog?",8,10
"5311","fr","en","YENTREVE 40 mg, gélule gastro-résistante.","YENTREVE 40 mg hard gastro-resistant capsules.",6,5
"5312","fr","en","Yondelis est un médicament anticancéreux qui agit en empêchant les cellules tumorales de se multiplier.","Yondelis is an anti-cancer medicine that works by preventing the tumour cells from multiplying.",14,15
"5313","fr","en","Yttriga ne doit pas être administré directement à un patient.","Yttriga must not be given directly to any patient.",9,10
"5314","fr","en","ZALASTA 10 mg comprimés orodispersibles","Zalasta 10 mg orodispersible tablets",5,5
"5315","fr","en","ZALASTA 5 mg comprimés orodispersibles","Zalasta 5 mg orodispersible tablets",5,5
"5316","fr","en","Zalcitabine et/ou zidovudine (saquinavir non « boosté »)","Zalcitabine and/or Zidovudine (unboosted saquinavir)",5,8
"5317","fr","en","Zarzio est administré par injection sous-cutanée ou perfusion intraveineuse.","Zarzio is given by injection under the skin or infusion into a vein.",13,9
"5318","fr","en","Zeffix 5 mg/ml Solution Buvable Lamivudine","Zeffix 5 mg/ml oral solution Lamivudine",6,6
"5319","fr","en","Zenapax sert à empêcher votre organisme de rejeter un rein greffé.","Zenapax is used to prevent your body from rejecting transplanted kidneys.",11,11
"5320","fr","en","Zerit 20 mg gélules Stavudine","Zerit 20 mg hard capsules Stavudine",6,5
"5321","fr","en","Zerit ne doit pas être utilisé pendant la grossesse; sauf en cas de nécessité absolue.","Zerit should not be used during pregnancy unless clearly necessary.",10,15
"5322","fr","en","Zevalin n’ est pas utilisé directement mais doit être radiomarqué avant usage.","Zevalin is not used directly, but it must be radiolabelled before use.",12,12
"5323","fr","en","Zidovudine Cmin: ↑ 51%","Zidovudine Cmin: ↑ 51%",4,4
"5324","fr","en","Zimbagasse 5 A-1147 Wien Tel: +43 1 57600-0","Zimbagasse 5 A-1147 Wien Tel: +43 1 57600-0",8,8
"5325","fr","en","Zirtec 1 mg/ ml soluzione orale Lettonie:","Formistin, Virlix, Zirtec 10mg/ ml gocce orali soluzione Latvia:",9,7
"5326","fr","en","ZOCORD Donau-City Strasse 6 1220 - Wien, Austria","Donau-City Strasse 6 1220 - Wien, Austria",7,8
"5327","fr","en","Zometa 4 mg poudre et solvant pour solution pour perfusion Acide zolédronique","Zometa 4 mg powder and solvent for solution for infusion Zoledronic acid",12,12
"5328","fr","en","Zonegran 25 mg, gélules. zonisamide","Zonegran 25 mg hard capsules zonisamide",6,5
